DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

42 CFR Parts 416 and 419

[CMS–1695–FC]

RIN 0938–AT30

Medicare Program: Changes to Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs

AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.

ACTION: Final rule with comment period.

SUMMARY: This final rule with comment period revises the Medicare hospital outpatient prospective payment system (OPPS) and the Medicare ambulatory surgical center (ASC) payment system for CY 2019 to implement changes arising from our continuing experience with these systems. In this final rule with comment period, we describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment system. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program. In addition, we are updating the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) Survey measure under the Hospital Inpatient Quality Reporting (IQR) Program by removing the Communication about Pain Outcome Measure, in the PPS-Exempt Off-Campus Departments of a Provider, and the ASC Quality Reporting (ASCQR) Program Measures, in the ASC Quality Reporting (ASCQR) Program.

DATES: Effective date: This final rule with comment period is effective on January 1, 2019.

Comment period: To be assured consideration, comments on the payment classifications assigned to the interim APC assignments and/or status indicators of new or replacement Level II HCPCS codes in this final rule with comment period must be received at one of the addresses provided in the

ADDRESSES section no later than 5 p.m. EST on December 3, 2018.

ADDRESSES: In commenting, please refer to file code CMS–1695–FC when commenting on the issues in this final rule with comment period. Because of staff and resource limitations, we cannot accept comments by facsimile (FAX) transmission.

Comments, including mass comment submissions, must be submitted in one of the following three ways (please choose only one of the ways listed):

1. Electronically. You may (and we encourage you to) submit electronic comments on this regulation to http://www.regulations.gov. Follow the instructions under the “submit a comment” tab.

2. By regular mail. You may mail written comments to the following address ONLY:

Centers for Medicare & Medicaid Services, Department of Health and Human Services, Attention: CMS–1695–FC, P.O. Box 8013, Baltimore, MD 21244–1850.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

3. By express or overnight mail. You may send written comments via express or overnight mail to the following address ONLY:


For information on viewing public comments, we refer readers to the SUPPLEMENTARY INFORMATION section.

FOR FURTHER INFORMATION CONTACT:

340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital, contact Juan Cortes via email Juan.Cortes@cms.hhs.gov or at 410–786–4325.

Advisory Panel on Hospital Outpatient Payment (HOP Panel), contact the HOP Panel mailbox at APCPanel@cms.hhs.gov.

Ambulatory Surgical Center (ASC) Payment System, contact Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410–786–4142.

Ambulatory Surgical Center Quality Reporting (ASCQR) Program, contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786–7236.

Centers for Medicare & Medicaid Services, Department of Health and Human Services, 7500 Security Boulevard, Baltimore, MD 21244–1850.

Please allow sufficient time for mailed comments to be received before the close of the comment period.

For information on viewing public comments, we refer readers to the SUPPLEMENTARY INFORMATION section.

FOR FURTHER INFORMATION CONTACT:

340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital, contact Juan Cortes via email Juan.Cortes@cms.hhs.gov or at 410–786–4325.

Advisory Panel on Hospital Outpatient Payment (HOP Panel), contact the HOP Panel mailbox at APCPanel@cms.hhs.gov.

Ambulatory Surgical Center (ASC) Payment System, contact Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410–786–4142.

Ambulatory Surgical Center Quality Reporting (ASCQR) Program, contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786–7236.
SUPPLEMENTARY INFORMATION: Inspection of Public Comments: All comments received before the close of the comment period are available for viewing by the public, including any personally identifiable or confidential business information that is included in a comment. We post all comments received before the close of the comment period on the following website as soon as possible after they have been received: http://www.regulations.gov/. Follow the search instructions on that website to view public comments.

Electronic Access

This Federal Register document is also available from the Federal Register online database through Federal Digital System (FDsys), a service of the U.S. Government Publishing Office. This database can be accessed via the internet at https://www.gpo.gov/fdsys/.

Addenda Available Only through the Internet on the CMS Website

In the past, a majority of the Addenda referred to in our OPPS/ASC proposed and final rules were published in the Federal Register as part of the annual rulemakings. However, beginning with the CY 2012 OPPS/ASC proposed rule, all of the Addenda no longer appear in the Federal Register as part of the annual OPPS/ASC proposed and final rules to decrease administrative burden and reduce costs associated with publishing lengthy tables. Instead, these Addenda are published and available only on the CMS website. The Addenda relating to the OPPS are available at: https://www.cms.gov/Medicare/Medicare-fee-


Throughout this final rule with comment period, we use CPT codes and descriptions to refer to a variety of services. We note that CPT codes and descriptions are copyright 2018 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association (AMA). Applicable Federal Acquisition Regulations (FAR) and Defense Federal Acquisition Regulations (DFAR) apply.

Table of Contents

I. Summary and Background
A. Executive Summary of This Document
B. Legislative and Regulatory Authority for the Hospital OPPS
C. Excluded OPPS Services and Hospitals
D. Prior Rulemaking
E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel)
F. Public Comments Received in Response to the CY 2019 OPPS/ASC Proposed Rule
G. Public Comments Received in Response to the CY 2018 OPPS/ASC Final Rule With Comment Period

II. Updates Affecting OPPS Payments
A. Recalibration of APC Relative Payment Weights
B. Conversion Factor Update
C. Wage Index Changes
D. Statewide Average Default Cost-to-Charge Ratios (CCRs)
E. Adjustment for Rural Sole Community Hospitals (SCHs) and Essential Access Community Hospitals (EACHs) Under Section 1833(i)(13)(B) of the Act
F. Payment Adjustment for Certain Cancer Hospitals for CY 2019
G. Hospital Outpatient Payment Outliers
H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment
I. Beneficiary Copayments

III. OPPS Ambulatory Payment Classification (APC) Group Policies
A. OPPS Treatment of New CPT and Level II HCPCS Codes
B. OPPS Changes—Variations Within APCs
C. New Technology APCs
D. OPPS APC-Specific Policies

IV. OPPS Payment for Devices
A. Pass-Through Payments for Devices
B. Device-Intensive Procedures

V. OPPS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals
A. OPPS Transitional Pass-Through Payment for Additional Costs of Drugs, Biologicals, and Radiopharmaceuticals
B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals Without Pass-

Through Payment Status
VI. Estimate of OPPS Transitional Pass-
Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices

A. Background
B. Estimate of Pass-Through Spending

VII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services

A. Background

VIII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services

A. Background

IX. OPPS Payment for Hospital Outpatient Services
B. PHP APC Update for CY 2019
C. Outlier Policy for CMHCs
D. Proposed Update to PHP Allowable HCPCS Codes

IX. Procedures That Will Be Paid Only as Nonrecurring Policy Changes
A. Collecting Data on Services Furnished at the Departments of a Provider
B. Collecting Data on Services Furnished at the Departments of a Hospital
C. Excluded OPPS Services and Hospitals
D. Prior Rulemaking

X. Nonrecurring Policy Changes
A. Collecting Data on Services Furnished in Off-Campus Provider-Based Emergency Departments
B. Method To Control Unnecessary Increases in the Volume of Outpatient Services
C. Application of the 340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital
D. Expansion of Clinical Families of Devices, contact Twi Jackson via email Twi.Jackson@cms.hhs.gov or at 410–786–1159.
OPPS Brachytherapy, contact Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410–786–4142.
OPPS Data (APC Weights, Conversion Factor, Copayments, Cost-to-Charge Ratios (CCRs), Data Claims, Geometric Mean Calculation, Outlier Payments, and Wage Index), contact Erick Chuang via email Erick.Chuang@cms.hhs.gov or at 410–786–1816, Steven Johnson via email Steven.Johnson@cms.hhs.gov or at 410–786–3332, or Scott Talaga via email Scott.Talaga@cms.hhs.gov or at 410–786–4142.
OPPS Drugs, Radiopharmaceuticals, Biologicals, and Biosimilar Products, contact Josh McFeeters via email joshua.McFeeters@cms.hhs.gov or at 410–786–9732.
OPPS New Technology Procedures/Services, contact the New Technology APC email at NewTechAPCapplications@cms.hhs.gov.
OPPS Exceptions to the 2 Times Rule, contact Marjorie Baldo via email Marjorie.Baldo@cms.hhs.gov or at 410–786–4617.
OPPS Packaged Items/Services, contact Lela Strong-Holloway via email Lela.Strong@cms.hhs.gov or at 410–786–3213.
OPPS Pass-Through Devices, contact the Device Pass-Through email at DevicePTApplications@cms.hhs.gov.
OPPS Status Indicators (SI) and Comment Indicators (CI), contact Marina Kushnirova via email Marina.Kushnirova@cms.hhs.gov or at 410–786–2682.
Partial Hospitalization Program (PHP) and Community Mental Health Center (CMHC) Issues, contact the PHP Payment Policy Mailbox at PHPPaymentPolicy@cms.hhs.gov.
PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program measures, contact Neksheia McInnis via email Neksheia.McInnis@cms.hhs.gov.
Rural Hospital Payments, contact Josh McFeeters via email joshua.McFeeters@cms.hhs.gov or at 410–786–9732.
Skin Substitutes, contact Josh McFeeters via email joshua.McFeeters@cms.hhs.gov or at 410–786–9732.
All Other Issues Related to Hospital Outpatient and Ambulatory Surgical Center Payments Not Previously Identified, contact Marjorie Baldo via email Marjorie.Baldo@cms.hhs.gov or at 410–786–4617.
XI. CY 2019 OPPS Payment Status and Comment Indicators
   A. CY 2019 OPPS Payment Status Indicator Definitions
   B. CY 2019 Comment Indicator Definitions
XII. Updates to the Ambulatory Surgical Center (ASC) Payment System
   A. Background
   B. Treatment of New and Revised Codes
   C. Update to the List of ASC Covered Surgical Procedures and Covered Ancillary Services
   D. ASC Payment for Covered Surgical Procedures and Covered Ancillary Services
   E. New Technology Intravascular Lenses (NTIOLs)
   F. ASC Payment and Comment Indicators
   G. Calculation of the ASC Payment Rates and the ASC Conversion Factor
XIII. Requirements for the Hospital Outpatient Quality Reporting (OQR) Program
   A. Background
   B. Hospital OQR Program Quality Measures
   C. Administrative Requirements
   D. Form, Manner, and Timing of Data Submitted for the Hospital OQR Program
   E. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR Program Requirements for the CY 2019 Payment Determination
XIV. Requirements for the Ambulatory Surgical Center Quality Reporting (ASCQR) Program
   A. Background
   B. ASCQR Program Quality Measures
   C. Administrative Requirements
   D. Form, Manner, and Timing of Data Submitted for the ASCQR Program
   E. Payment Reduction for ASCs That Fail To Meet the ASCQR Program Requirements
XV. Comments Received in Response to Requests for Information (RFIs)
   A. Comments Received in Response to Request for Information on Promoting Interoperability and Electronic Health Care Information Exchange Through Possible Revisions to the CMS Patient Health and Safety Requirements for Hospitals and Other Medicare-Participating and Medicaid-Participating Providers and Suppliers
   B. Comments Received in Response to Request for Information on Price Transparency: Improving Beneficiary Access to Provider and Supplier Charge Information
   C. Comments Received in Response to Request for Information on Leveraging the Authority for the Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals for a Potential CMS Innovation Center Model
XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program Policies
XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Policies
   A. Background
   B. Retention and Removal of Previously Finalized Quality Measures for PCHs Beginning With the FY 2021 Program Year
   C. Public Display Requirements
XVIII. Files Available to the Public via the Internet
   A. Statutory Requirement for Solicitation of Comments
   B. ICRs for the Hospital OQR Program
   C. ICRs for the ASCQR Program
   D. ICRs for the Update to the HCAHPS Survey Measure in the Hospital IQR Program
   E. Total Reduction in Burden Hours and in Costs
XX. Response to Comments
   A. Statement of Need
   B. Overall Impact for the Provisions of This Final Rule With Comment Period
   C. Detailed Economic Analyses
   D. Effects of the Update to the HCAHPS Survey Measure in the Hospital IQR Program
   E. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program
   F. Regulatory Review Costs
   G. Regulatory Flexibility Act (RFA) Analysis
   H. Unfunded Mandates Reform Act Analysis
   I. Reducing Regulation and Controlling Regulatory Costs
   J. Conclusion
XXI. Economic Analyses
   A. Executive Summary of This Document
   1. Purpose
      In this final rule with comment period, we are updating the payment policies and payment rates for services furnished to Medicare beneficiaries in hospital outpatient departments (HOPDs) and ambulatory surgical centers (ASCs), beginning January 1, 2019. Section 1833(t)(1) of the Social Security Act (the Act) requires us to annually review and update the payment rates for services payable under the Hospital Outpatient Prospective Payment System (OPPS). Specifically, section 1833(t)(9)(A) of the Act requires the Secretary to review certain components of the OPPS not less often than annually, and to revise the groups, relative payment weights, and the wage and other adjustments that take into account changes in medical practices, changes in technologies, and the addition of new services, new cost data, and other relevant information and factors. In addition, under section 1833(i) of the Act, we annually review and update the ASC payment rates. This final rule with comment period also includes additional policy changes made in accordance with our experience with the OPPS and the ASC payment system. We describe these and various other statutory authorities in the relevant sections of this final rule with comment period. In addition, this final rule with comment period updates and refines the requirements for the Hospital Outpatient Quality Reporting (OQR) Program and the ASC Quality Reporting (ASCQR) Program.
      In this final rule with comment period, two quality reporting policies that impact inpatient hospitals are updated due to their time sensitivity. In the Hospital IQR Program, we are updating the HCAHPS Survey measure by removing the Communication about Pain questions from the HCAHPS Survey, which are used to assess patients’ experiences of care, effective with October 2019 discharges for the FY 2021 payment determination and subsequent years. This policy addresses public health concerns about opioid overprescribing through patient pain management questions that were recommended for removal in the President’s Commission on Combating Drug Addiction and the Opioid Crisis report. In addition, we are finalizing that we will not publicly report any data collected from the Communication About Pain questions—a modification from what we proposed. We also are retaining two measures that we proposed for removal in the PCHQR Program beginning with the FY 2021 program year, the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure. This policy impacts infection measurement and public reporting for PPS-exempt cancer hospitals and was deferred to this rule from the CY 2019 IPPS/LTCH PPS final rule published in August 2018.
   2. Improving Patient Outcomes and Reducing Burden Through Meaningful Measures
      Regulatory reform and reducing regulatory burden are high priorities for CMS. To reduce the regulatory burden on the healthcare industry, lower health care costs, and enhance patient care, in October 2017, we launched the Meaningful Measures Initiative.1 This initiative is one component of our agency-wide Patients Over Paperwork Initiative,2 which is aimed at evaluating and streamlining regulations with a goal

2 Remarks by Administrator Seema Verma at the Health Care Payment Learning and Action Network (LAN) Fall Summit, as prepared for delivery on October 30, 2017. Available at: https://www.cms.gov/Newsroom/MediaReleaseDatabase/Fact-sheets/2017-Fact-Sheet-items/2017-10-30.html.
to reduce unnecessary cost and burden, increase efficiencies, and improve beneficiary experience. The Meaningful Measures Initiative is aimed at identifying the highest priority areas for quality measurement and quality improvement in order to assess the core quality of care issues that are most vital to advancing our work to improve patient outcomes. The Meaningful Measures Initiative represents a new approach to quality measures that fosters operational efficiencies, and will reduce costs including, collection and reporting burden, while producing quality measurement that is more focused on meaningful outcomes.

The Meaningful Measures framework has the following objectives:

• Address high-impact measure areas that safeguard public health;
• Patient-centered and meaningful to patients;
• Outcome-based where possible;
• Fulfill each program’s statutory requirements;
• Minimize the level of burden for health care providers;
• Significant opportunity for improvement;
• Address measure needs for population based payment through alternative payment models; and
• Align across programs and/or with other payers.

In order to achieve these objectives, we have identified 19 Meaningful Measures areas and mapped them to six overarching quality priorities, as shown in the table below.

<table>
<thead>
<tr>
<th>Quality Priority</th>
<th>Meaningful Measure Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Making Care Safer by Reducing Harm Caused in the Delivery of Care</td>
<td>Healthcare-Associated Infections</td>
</tr>
<tr>
<td></td>
<td>Preventable Healthcare Harm</td>
</tr>
<tr>
<td>Strengthen Person and Family Engagement as Partners in Their Care</td>
<td>Care is Personalized and Aligned with Patient’s Goals</td>
</tr>
<tr>
<td></td>
<td>End of Life Care According to Preferences</td>
</tr>
<tr>
<td></td>
<td>Patient’s Experience of Care</td>
</tr>
<tr>
<td></td>
<td>Patient Reported Functional Outcomes</td>
</tr>
<tr>
<td>Promote Effective Communication and Coordination of Care</td>
<td>Medication Management</td>
</tr>
<tr>
<td></td>
<td>Admissions and Readmissions to Hospitals</td>
</tr>
<tr>
<td></td>
<td>Transfer of Health Information and Interoperability</td>
</tr>
<tr>
<td></td>
<td>Preventive Care</td>
</tr>
<tr>
<td>Promote Effective Prevention and Treatment of Chronic Disease</td>
<td>Management of Chronic Conditions</td>
</tr>
<tr>
<td></td>
<td>Prevention, Treatment, and Management of Mental Health</td>
</tr>
<tr>
<td></td>
<td>Prevention and Treatment of Opioid and Substance Use Disorders</td>
</tr>
<tr>
<td></td>
<td>Risk Adjusted Mortality</td>
</tr>
<tr>
<td>Work with Communities to Promote Best Practices of Healthy Living</td>
<td>Equity of Care</td>
</tr>
<tr>
<td></td>
<td>Community Engagement</td>
</tr>
<tr>
<td>Make Care Affordable</td>
<td>Appropriate Use of Healthcare</td>
</tr>
<tr>
<td></td>
<td>Patient-Focused Episode of Care</td>
</tr>
<tr>
<td></td>
<td>Risk Adjusted Total Cost of Care</td>
</tr>
</tbody>
</table>

By including Meaningful Measures in our programs, we believe that we can also address the following cross-cutting measure criteria:

• Eliminating disparities;
• Tracking measurable outcomes and impact;
• Safeguarding public health;
• Achieving cost savings;
• Improving access for rural communities; and
• Reducing burden.

We believe that the Meaningful Measures Initiative will improve outcomes for patients, their families, and health care providers while reducing burden and costs for clinicians and providers as well as promoting operational efficiencies.

We received numerous comments from stakeholders regarding the Meaningful Measures Initiative and the impact of its implementation in CMS’ quality programs. Many of these comments pertained to specific program proposals, and are discussed in the appropriate program-specific sections of this final rule with comment period. However, commenters also provided insights and recommendations for the ongoing development of the Meaningful Measures Initiative generally, including: ensuring transparency in public reporting and usability of publicly reported data; evaluating the benefit of individual measures to patients via use in quality programs weighted against the burden to providers of collecting and
reporting that measure data; and identifying additional opportunities for alignment across CMS quality programs. We look forward to continuing to work with stakeholders to refine and further implement the Meaningful Measures Initiative, and will take commenters’ insights and recommendations into account moving forward.


• OPPS Update: For CY 2019, we are increasing the payment rates under the OPPS by an outpatient department (OPD) fee schedule increase factor of 1.35 percent. This increase factor is based on the final hospital inpatient market basket percentage increase of 2.9 percent for inpatient services paid under the hospital inpatient prospective payment system (IPPS), minus the multifactor productivity (MFP) adjustment of 0.8 percentage point, and minus a 0.75 percentage point adjustment required by the Affordable Care Act. Based on this update, we estimate that total payments to OPPS providers (including beneficiary cost-sharing and estimated changes in enrollment, utilization, and case-mix) for CY 2019 will be approximately $74.1 billion, an increase of approximately $5.8 billion compared to estimated CY 2018 OPPS payments.

We are continuing to implement the statutory 2.0 percentage point reduction in payments for hospitals failing to meet the hospital outpatient quality reporting requirements, by applying a reporting factor of 0.980 to the OPPS payments and copayments for all applicable services.

• Comprehensive APCs: For CY 2019, we are creating three new comprehensive APCs (C–APCs). These new C–APCs include ears, nose, and throat (ENT) and vascular procedures. This increases the total number of C–APCs to 65.

• Changes to the Inpatient Only List: For CY 2019, we are removing four procedures from the inpatient only list and adding one procedure to the list.

• Method to Control Unnecessary Increases in Volume of Outpatient Services: To the extent that similar services are safely provided in more than one setting, it is not prudent for the OPPS to pay more for such services because that leads to an unnecessary increase in the number of those services provided in the OPPS setting. We believe that capping the OPPS payment at the Physician Fee Schedule (PFS)-equivalent rate is an effective method to control the volume of the unnecessary increases in services because the payment differential that is driving the site-of-service decision will be removed.

In particular, we believe this method of capping payment will control unnecessary volume increases both in terms of numbers of covered outpatient department services furnished and costs of those services. Therefore, as we proposed, we are using our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexempted items and services furnished by a nonexempted off-campus provider-based department (PBD) of a hospital (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act. We will be phasing in the application of the reduction in payment for code G0463 in this setting over 2 years. In CY 2019, the payment reduction will be transitioned by applying 50 percent of the total reduction in payment that would apply if these departments were paid the site-specific PFS rate for the clinic visit service. In other words, these departments will be paid 70 percent of the OPPS rate for the clinic visit service in CY 2019. In CY 2020 and subsequent years, these departments will be paid 80 percent of the OPPS rate for the clinic visit service. That is, these departments will be paid 40 percent of the OPPS rate for the clinic visit in CY 2020 and subsequent years. In addition to this proposal, we solicited public comments on how to expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in OPD utilization. The public comment we received will be considered for future rulemaking.

• Expansion of Clinical Families of Services atExcepted Off-Campus Provider-Based Departments (PBDs) of a Hospital: For CY 2019, we proposed that if an excepted off-campus PBD furnished items and services from a clinical family of services from which it did not furnish items and services (and subsequently billed for those items and services) during a baseline period, services from the new clinical family of services would not be covered OPD services. Instead, services in the new clinical family of services would be paid under the PFS. While we are not finalizing this proposal at this time, we intend to monitor the expansion of services in excepted off-campus PBDs.

• Application of 340B Drug Payment Policy to Nonexcepted Off-Campus Provider-Based Departments of a Hospital: For CY 2019, as we proposed, we are paying the average sales price (ASP) minus 22.5 percent under the PFS for separately payable 340B-acquired drugs furnished by nonexcepted, off-campus provider-based departments (PBDs) of a hospital. This is consistent with the payment methodology adopted in CY 2018 for 340B-acquired drugs furnished in hospital departments paid under the OPPS.

• Payment Policy for Biosimilar Biological Products without Pass-Through Status That Are Acquired under the 340B Program: For CY 2019, we are making payment for nonpass-through biosimilars acquired under the 340B program at the acquisition cost (WAC)+3 percent instead of WAC+6 percent if ASP data are not available. If WAC data are not available for a drug or biological product, we are continuing our policy to pay for separately payable drugs and biologicals at 95 percent of the average wholesale price (AWP). Drugs and biologicals that are acquired under the 340B Program will continue to be paid at ASP minus 22.5 percent, WAC minus 22.5 percent, or 69.46 percent of AWP, as applicable.

• Device-Intensive Procedure Criteria: For CY 2019, we are modifying the device-intensive criteria to allow procedures that involve single-use devices, regardless of whether or not they remain in the body after the conclusion of the procedure, to qualify as device-intensive procedures. We also are allowing procedures with a device offset percentage of greater than 30 percent to qualify as device-intensive procedures.

• Device Pass-Through Payment Applications: For CY 2019, we evaluated seven applications for device pass-through payments and based on public comments received, we are approving one of these applications for device pass-through payment status.

• New Technology APC Payment for Extremely Low-Volume Procedures: For CY 2019 and future years, we are establishing a different payment methodology for services assigned to New Technology APCs with fewer than 100 claims using our equitable adjustment authority under section 1833(t)(2)(E) or 1833(t)(2)(F) of the Act. We will use a “smoothing methodology” based on multiple years of claims data to
establish a more stable rate for services assigned to New Technology APCs with fewer than 100 claims per year under the OPPS. Under this policy, we will calculate the geometric mean costs, the median costs, and the arithmetic mean costs for these procedures and adopt through our annual rulemaking the most appropriate payment rate for the service using one of these methodologies. We will use this approach to establish a payment rate for each low-volume service both for purposes of assigning the service to a New Technology APC and to a clinical APC at the conclusion of payment for the service through a New Technology APC. In addition, we are excluding services assigned to New Technology APCs from bundling into C–APC procedures.

- **Cancer Hospital Payment Adjustment:** For CY 2019, we are continuing to provide additional payments to cancer hospitals so that the cancer hospital’s payment-to-cost ratio (PCR) after the additional payments is equal to the weighted average PCR for the other OPPS hospitals using the most recently submitted or settled cost report data. However, section 16062(b) of the 21st Century Cures Act requires that this weighted average PCR be reduced by 1.0 percentage point. Based on the data and the required 1.0 percentage point reduction, we are providing that a target PCR of 0.88 will be used to determine the CY 2019 cancer hospital payment adjustment to be paid at cost report settlement. That is, the payment adjustments will be the additional payments divided by the target PCR equal to 0.88 for each cancer hospital.

- **Rural Adjustment:** For CY 2019 and subsequent years, we are continuing the 7.1 percent adjustment to OPPS payments for certain rural SCHs, including essential access community hospitals (EACHs). We intend to continue the 7.1 percent adjustment for future years in the absence of data to suggest a different percentage adjustment should apply.

- **Ambulatory Surgical Center (ASC) Payment Update:** For CYs 2019 through 2023, we are updating the ASC payment system using the hospital market basket update instead of the CPI–U. However, during this 5-year period, we intend to examine whether such adjustment leads to a migration of services from other settings to the ASC setting. Using the hospital market basket methodology, for CY 2019, we are increasing payment rates under the ASC payment system by 2.1 percent for ASCs that meet the quality reporting requirements under the ASCQR Program. This increase is based on a hospital market basket percentage increase of 2.9 percent minus a MFP adjustment required by the Affordable Care Act of 0.8 percentage point.

Based on this update, we estimate that total payments to ASCs (including beneficiary cost-sharing and estimated changes in enrollment, utilization, and case-mix) for CY 2019 will be approximately $4.85 billion, an increase of approximately $200 million compared to estimated CY 2018 Medicare payments to ASCs. We note that the CY 2019 ASC payment update, under our prior policy, would have been 1.8 percent, based on a projected CPI–U update of 2.6 percent minus a MFP adjustment required by the Affordable Care Act of 0.8 percentage point. In addition, we will continue to assess the feasibility of collaborating with stakeholders to collect ASC cost data in a minimally burdensome manner for future policy development.

- **Changes to the List of ASC Covered Surgical Procedures:** For CY 2019, we are revising our definition of “surgery” to include the ASC component to account for certain “surgery-like” procedures that are assigned codes outside the Current Procedural Terminology (CPT) surgical range. In addition, as we proposed, we are adding 12 catheterization procedures, and, in response to public comments, an additional 5 related procedures to the ASC covered procedures list. At this time, we are not finalizing our proposal to establish an additional review of recently added procedures to the ASC covered procedures list. From what we proposed, we are adding 12 cardiac catheterization procedures, and, in response to public comments, an additional 5 related procedures to the ASC covered procedures list. At this time, we are not finalizing our proposal to establish an additional review of recently added procedures to the ASC covered procedures list.

- **Payment for Non-Opioid Pain Management Therapy:** For CY 2019, in response to the recommendation from the President’s Commission on Combating Drug Addiction and the Opioid Crisis, we are changing the packaging policy for certain drugs when administered in the ASC setting and providing separate payment for non-opioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in an ASC.

- **Hospital Outpatient Quality Reporting (OQR) Program:** For CY 2019, we are making changes effective with this final rule with comment period and for the CY 2019, CY 2020, and CY 2021 payment determinations and subsequent years. Effective on the effective date of this final rule with comment period, we are codifying several previously established policies: to retain measures from a previous year’s Hospital OQR Program measure set for subsequent years’ measure sets at 42 CFR 419.46(h)(1); to use the rulemaking process to remove a measure for circumstances for which we do not believe that continued use of a measure raises specific patient safety concerns at 42 CFR 419.46(h)(3); and to immediately remove measures as a result of patient safety concerns at 42 CFR 419.46(h)(2). Effective on the effective date of this final rule with comment period, we are also updating measure removal Factor 7; adding a new removal Factor 8; and codifying our measure removal policies and factors. We are also providing clarification of our criteria for “topped-out” measures. These changes align the Hospital OQR Program measure removal factors with those used in the ASCQR Program.

Beginning with CY 2019, we are updating the frequency with which we will release a Hospital OQR Program Specifications Manual, such that it will occur every 12 months—a modification from what we proposed.

For the CY 2020 payment determination and subsequent years, we are updating the participation status requirements by removing the Notice of Participation (NOP) requirement for facility reporting period for the OP–32: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy measure to 3 years; and removing the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel measure.

Beginning with the CY 2021 payment determination and subsequent years, we are removing the following seven measures: OP–5: Median Time to ECG; OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; OP–17: Tracking Clinical Results between Visits; and OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyp—Avoidance of Inappropriate Use. We are not finalizing our proposals to remove the OP–29 or OP–31 measures.

- **Ambulatory Surgical Center Quality Reporting (ASCQR) Program:** For the ASCQR Program, we are making changes in policies effective with this final rule with comment period and for the CY 2019, CY 2020, and CY 2021 payment determinations and subsequent years. Effective on the effective date of this final rule with comment period, we are removing one measure removal factor; adding two new measure removal factors; and updating the regulations to better reflect our measure removal policies. We are also making one clarification to measure removal Factor...
1. These changes align the ASCQR Program measure removal factors with those used in the Hospital OQR Program.

Beginning with the CY 2020 payment determination and subsequent years, we are extending the reporting period for the ASC–12: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy measure to 3 years; and removing the ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel measure.

Beginning with the CY 2021 payment determination and subsequent years, we are removing the ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Measure. We are not finalizing our proposals to remove the following measures: ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. We also are not finalizing our proposals to remove the following measures: ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are retaining these measures in the ASCQR Program and suspending data collection for them until further action in rulemaking with the goal of revising the measures.

• Hospital Inpatient Quality Reporting (IQR) Program Update: In this final rule with comment period, we are finalizing a modification of our proposals to update the HCAHPS Survey measure by finalizing the removal of the Communication About Pain questions from the HCAHPS Survey for the Hospital IQR Program, effective with October 2019 discharges for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data from October 2020 until October 2022 and then subsequently discontinuing reporting as proposed, we are finalizing that we will not publicly report any data collected from the Communication About Pain questions.

4. Summary of Costs and Benefits

In sections XXI. and XXII. of this CY 2019 OPPS/ASC final rule with comment period, we set forth a detailed analysis of the regulatory and Federalism impacts that the changes will have on affected entities and beneficiaries. Key estimated impacts are described below.

a. Impacts of All OPPS Changes

Table 62 in section XXI. of this final rule with comment period displays the distributional impact of all the OPPS changes on various groups of hospitals and CMHCs for CY 2019 compared to all estimated OPPS payments in CY 2018. We estimate that the policies in this final rule with comment period will result in a 0.6 percent overall increase in OPPS payments to providers. We estimate that total OPPS payments for CY 2019, including beneficiary cost-sharing, to the approximately 3,840 facilities paid under the OPPS (including general acute care hospitals, children’s hospitals, cancer hospitals, and CMHCs) will increase by approximately $360 million compared to CY 2018 payments, excluding our estimated changes in enrollment, utilization, and case-mix.

We estimated the isolated impact of our OPPS policies on CMHCs because CMHCs are only paid for partial hospitalization services under the OPPS. Continuing the provider-specific structure we adopted beginning in CY 2011, and basing payment fully on the type of provider furnishing the service, we estimate a 15.1 percent decrease in CY 2019 payments to CMHCs relative to their CY 2018 payments.

b. Impacts of the Updated Wage Indexes

We estimate that our update of the wage indexes based on the FY 2019 IPPS final rule wage indexes will result in no estimated payment change for urban hospitals under the OPPS and an estimated decrease of 0.2 percent for rural hospitals. These wage indexes include the continued implementation of the OMB labor market area delineations based on 2010 Decennial Census data, with updates, as discussed in section II.C. of this final rule with comment period.

c. Impacts of the Rural Adjustment and the Cancer Hospital Payment Adjustment

There are no significant impacts of our CY 2019 payment policies for hospitals that are eligible for the rural adjustment or for the cancer hospital payment adjustment. We are not making any change in policies for determining the rural hospital payment adjustments. While we are implementing the required reduction to the cancer hospital payment adjustment required by section 16002 of the 21st Century Cures Act for CY 2019, the target payment-to-cost ratio (PCR) for CY 2019 remains the same as in CY 2018 and therefore does not impact the budget neutrality adjustments.

d. Impacts of the OPD Fee Schedule Increase Factor

For the CY 2019 OPPS/ASC, we are establishing an OPD fee schedule increase factor of 1.35 percent and applying that increase factor to the conversion factor for CY 2019. As a result of the OPD fee schedule increase factor and other budget neutrality adjustments, we estimate that rural and urban hospitals will experience an increase of approximately 1.4 percent for urban hospitals and 1.3 percent for rural hospitals. Classifying hospitals by teaching status, we estimate nonteaching hospitals will experience an increase of 1.4 percent, minor teaching hospitals will experience an increase of 1.3 percent, and major teaching hospitals will experience an increase of 1.5 percent. We also classified hospitals by the type of ownership. We estimate that hospitals with voluntary ownership, hospitals with proprietary ownership, and hospitals with government ownership will all experience an increase of 1.4 percent in payments.

e. Impacts of the Policy To Control for Unnecessary Increases in the Volume of Outpatient Services

In section X.B. of this CY 2019 OPPS/ASC final rule with comment period, we discuss our CY 2019 proposal and finalized policies to control for unnecessary increases in the volume of outpatient service by paying for clinic visits furnished at an off-campus PBD of a hospital at a PFS-equivalent rate under the OPPS rather than at the standard OPPS rate. As a result of this finalized policy, we estimated decreases of 0.6 percent to urban hospitals, and estimated decreases of 0.6 percent to rural hospitals, with the estimated effect for individual groups of hospitals depending on the volume of clinic visits provided at the hospitals’ off-campus PBDs.

f. Impacts of the ASC Payment Update

For impact purposes, the surgical procedures on the ASC list of covered procedures are aggregated into surgical specialty groups using CPT and HCPCS code range definitions. The percentage change in estimated total payments by specialty groups under the CY 2019 payment rates, compared to estimated CY 2018 payment rates, generally ranges between an increase of 1 and 3 percent, depending on the service, with some exceptions. We estimate the impact of applying the hospital market basket update to ASC payment rates will increase payments by $80 million under the ASC payment system in CY 2019,
compared to an increase of $60 million if we had applied an update based on CPI–U.

c. Impact of the Changes to the Hospital OQR Program

Across 3,300 hospitals participating in the Hospital OQR Program, we estimate that our requirements will result in the following changes to costs and burdens related to information collection for the Hospital OQR Program compared to previously adopted requirements: (1) No change in the total collection of information burden or costs for the CY 2020 payment determination; (2) a total collection of information burden reduction of approximately $24.9 million for the CY 2021 payment determination due to the removal of four measures: OP–5, OP–12, OP–17, and OP–30.

Further, we anticipate that the removal of a total of eight measures will result in a reduction in costs unrelated to information collection. For example, it may be costly for health care providers to track the confidential feedback, preview reports, and publicly reported information on a measure where we use the measure in more than one program. Also, when measures are in multiple programs, maintaining the specifications for those measures as well as the tools we need to collect, analyze, and publicly report the measure data may result in costs to CMS. In addition, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

B. Legislative and Regulatory Authority for the Hospital OPPS

When Title XVIII of the Social Security Act was enacted, Medicare payment for hospital outpatient services was based on hospital-specific costs. In an effort to ensure that Medicare and its beneficiaries pay appropriately for services and to encourage more efficient delivery of care, the Congress mandated replacement of the reasonable cost-based payment methodology with a prospective payment system (PPS). The Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33) added section 1833(t) to the Act, authorizing implementation of a PPS for hospital outpatient services. The OPPS was first implemented for services furnished on or after August 1, 2000. Implementing regulations for the OPPS are located at 42 CFR parts 410 and 419.


Under the OPPS, we generally pay for hospital Part B services on a rate-per-service basis that varies according to the APC group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) (which includes certain Current Procedural Terminology (CPT) codes) to identify and group the services within each APC. The OPPS includes payment for most hospital outpatient services, except those identified in section I.C. of this final rule with comment period, Section 1833(h)(1)(B) of the Act provides for payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by CMHCs), and certain inpatient hospital services that are paid under Medicare Part B.

The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The labor-related amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located. All services and items within an APC group are comparable clinically and with respect to resource use (section 1833(h)(2)(B) of the Act). In accordance with section 1833(h)(2)(B) of the Act, services to certain inpatient arrangements and services within an APC group cannot be considered comparable with respect to


Under the OPPS, we generally pay for hospital Part B services on a rate-per-service basis that varies according to the APC group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) (which includes certain Current Procedural Terminology (CPT) codes) to identify and group the services within each APC. The OPPS includes payment for most hospital outpatient services, except those identified in section I.C. of this final rule with comment period, Section 1833(h)(1)(B) of the Act provides for payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by CMHCs), and certain inpatient hospital services that are paid under Medicare Part B.

The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The labor-related amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located. All services and items within an APC group are comparable clinically and with respect to resource use (section 1833(h)(2)(B) of the Act). In accordance with section 1833(h)(2)(B) of the Act, services to certain inpatient arrangements and services within an APC group cannot be considered comparable with respect to


Under the OPPS, we generally pay for hospital Part B services on a rate-per-service basis that varies according to the APC group to which the service is assigned. We use the Healthcare Common Procedure Coding System (HCPCS) (which includes certain Current Procedural Terminology (CPT) codes) to identify and group the services within each APC. The OPPS includes payment for most hospital outpatient services, except those identified in section I.C. of this final rule with comment period, Section 1833(h)(1)(B) of the Act provides for payment under the OPPS for hospital outpatient services designated by the Secretary (which includes partial hospitalization services furnished by CMHCs), and certain inpatient hospital services that are paid under Medicare Part B.

The OPPS rate is an unadjusted national payment amount that includes the Medicare payment and the beneficiary copayment. This rate is divided into a labor-related amount and a nonlabor-related amount. The labor-related amount is adjusted for area wage differences using the hospital inpatient wage index value for the locality in which the hospital or CMHC is located. All services and items within an APC group are comparable clinically and with respect to resource use (section 1833(h)(2)(B) of the Act). In accordance with section 1833(h)(2)(B) of the Act, services to certain inpatient arrangements and services within an APC group cannot be considered comparable with respect to
the use of resources if the highest median cost (or mean cost, if elected by the Secretary) for an item or service in the APC group is more than 2 times greater than the lowest median cost (or mean cost, if elected by the Secretary) for an item or service within the same APC group (referred to as the “2 times rule”). In implementing this provision, we generally use the cost of the item or service assigned to an APC group.

For new technology items and services, special payments under the OPPS may be made in one of two ways. Section 1833(i)(16) of the Act provides for temporary additional payments, which we refer to as “transitional pass-through payments,” for at least 2 but not more than 3 years for certain drugs, biological agents, brachytherapy devices used for the treatment of cancer, and categories of other medical devices. For new technology services that are not eligible for transitional pass-through payments, and for which we lack sufficient clinical information and cost data to appropriately assign them to a clinical APC group, we have established special APC groups based on costs, which we refer to as New Technology APCs. These New Technology APCs are designated by cost bands which allow us to provide appropriate and consistent payment for designated new procedures that are not yet reflected in our claims data. Similar to pass-through payments, an assignment to a New Technology APC is temporary; that is, we retain a service within a New Technology APC until we acquire sufficient data to assign it to a clinically appropriate APC group.

C. Excluded OPPS Services and Hospitals

Section 1833(i)(1)(B)(i) of the Act authorizes the Secretary to designate the hospital outpatient services that are paid under the OPPS. While most hospital outpatient services are payable under the OPPS, section 1833(i)(1)(B)(iv) of the Act excludes payment for ambulance, physical and occupational therapy, and speech-language pathology services, for which payment is made under a fee schedule. It also excludes screening mammography, diagnostic mammography, and effective January 1, 2011, an annual wellness visit providing personalized prevention plan services. The Secretary exercises the authority granted under the statute to also exclude from the OPPS certain services that are paid under fee schedules or other payment systems. Such excluded services include, for example, the professional services of physicians and nonphysician practitioners paid under the Medicare Physician Fee Schedule (MPFS); certain laboratory services paid under the Clinical Laboratory Fee Schedule (CLFS); services for beneficiaries with end-stage renal disease (ESRD) that are paid under the ESRD prospective payment system; and services and procedures that require an inpatient stay that are paid under the hospital IPPS. In addition, section 1833(i)(1)(B)(v) of the Act does not include applicable items and services (as defined in subparagraph (A) of paragraph (21)) that are furnished on or after January 1, 2017 by an off-campus outpatient department of a provider (as defined in subparagraph (B) of paragraph (21)). We set forth the services that are excluded from payment under the OPPS in regulations at 42 CFR 419.22.

Under § 419.20(b) of the regulations, we specify the types of hospitals that are excluded from payment under the OPPS. These excluded hospitals include:

- Critical access hospitals (CAHs);
- Hospitals located in Maryland and paid under the Maryland All-Payer Model;
- Hospitals located outside of the 50 States, the District of Columbia, and Puerto Rico; and
- Indian Health Service (IHS) hospitals.

D. Prior Rulemaking

On April 7, 2000, we published in the Federal Register a final rule with comment period (65 FR 18434) to implement a prospective payment system for hospital outpatient services. The hospital OPPS was first implemented for services furnished on or after August 1, 2000. Section 1833(i)(9)(A) of the Act requires the Secretary to review certain components of the OPPS, not less often than annually, and to revise the groups, relative payment weights, and the wage and other adjustments that take into account changes in medical practices, changes in technologies, and the addition of new services, new cost data, and other relevant information and factors.

Since initially implementing the OPPS, we have published final rules in the Federal Register annually to implement statutory requirements and changes arising from our continuing experience with this system. These rules can be viewed on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html.

E. Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel)

1. Authority of the Panel

Section 1833(i)(9)(A) of the Act, as amended by section 201(h) of Pub. L. 106–113, and redesignated by section 202(a)(2) of Pub. L. 106–113, requires that we consult with an external advisory panel of experts to annually review the clinical integrity of the payment groups and their weights under the OPPS. In CY 2000, based on section 1833(i)(9)(A) of the Act, the Secretary established the Advisory Panel on Ambulatory Payment Classification Groups (APC Panel) to fulfill this requirement. In CY 2011, based on section 222 of the Public Health Service Act, which gives discretionary authority to the Secretary to convene advisory councils and committees, the Secretary expanded the panel’s scope to include the supervision of hospital outpatient therapeutic services in addition to the APC groups and weights. To reflect this new role of the panel, the Secretary changed the panel’s name to the Advisory Panel on Hospital Outpatient Payment (the HOP Panel or the Panel). The HOP Panel is not restricted to using data compiled by CMS, and in conducting its review, it may use data collected or developed by organizations outside the Department.

2. Establishment of the Panel

On November 21, 2000, the Secretary signed the initial charter establishing the Panel, and, at that time, named the Panel the APC Panel. This expert panel is composed of appropriate representatives of providers (currently employed full-time, not as consultants, in their respective areas of expertise) who review clinical data and advise CMS about the clinical integrity of the APC groups and their payment weights. Since CY 2012, the Panel also is charged with advising the Secretary on the appropriate level of supervision for individual hospital outpatient therapeutic services. The Panel is technical in nature, and it is governed by the provisions of the Federal Advisory Committee Act (FACA). The current charter specifies, among other requirements, that the Panel—

- May advise on the clinical integrity of Ambulatory Payment Classification (APC) groups and their associated weights;
- May advise on the appropriate supervision level for hospital outpatient services;
- Continues to be technical in nature; and
- Is governed by the provisions of the FACA.
• Has a Designated Federal Official (DFO); and
• Is chaired by a Federal Official designated by the Secretary.

The Panel’s charter was amended on November 15, 2011, renaming the Panel and expanding the Panel’s authority to include supervision of hospital outpatient therapeutic services and to add critical access hospital (CAH) representation to its membership. The Panel’s charter was also amended on November 6, 2014 (80 FR 23009), and the number of members was revised from up to 19 to up to 15 members. The Panel’s current charter was approved on November 21, 2016, for a 2-year period (81 FR 94378).

The current Panel membership and other information pertaining to the Panel, including its charter, Federal Register notices, membership, meeting dates, agenda topics, and meeting reports, can be viewed on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/FACA/AdvisoryPanelonAmbulatoryPaymentClassificationGroups.html.

3. Panel Meetings and Organizational Structure

The Panel has held many meetings, with the last meeting taking place on August 20, 2018. Prior to each meeting, we publish a notice in the Federal Register to announce the meeting and, when necessary, to solicit nominations for Panel membership, to announce new members and to announce any other changes of which the public should be aware. Beginning in CY 2017, we have transitioned to one meeting per year (81 FR 31941). Further information on the 2018 summer meeting can be found in the meeting notice titled “Medicare Program: Announcement of the Advisory Panel on Hospital Outpatient Payment (the Panel) Meeting on August 20–21, 2018” (83 FR 19785).

In addition, the Panel has established an operational structure that, in part, currently includes the use of three subcommittees to facilitate its required review process. The three current subcommittees include the following:
• APC Groups and Status Indicator Assignments Subcommittee, which advises the Panel on the appropriate status indicators to be assigned to HCPCS codes, including but not limited to whether a HCPCS code or a category of codes should be packaged or separately paid, as well as the appropriate APC assignment of HCPCS codes regarding services for which separate payment is made;
• Data Subcommittee, which is responsible for studying the data issues confronting the Panel and for recommending options for resolving them; and
• Visits and Observation Subcommittee, which reviews and makes recommendations to the Panel on all technical issues pertaining to observation services and hospital outpatient visits paid under the OPPS.

Each of these subcommittees was established by a majority vote from the full Panel during a scheduled Panel meeting, and the Panel recommended at the August 20, 2018 meeting that the subcommittees continue. We accepted this recommendation.

Discussions of the other recommendations made by the Panel at the August 20, 2018 Panel meeting, namely CPT codes and a comprehensive APC for autologous hematopoietic stem cell transplantation, OPPS payment for outpatient clinic visits and restrictions to service line expansions, and packaging policies, were discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37138 through 37143) or are included in the sections of this final rule with comment period that are specific to each recommendation. For discussions of earlier Panel meetings and recommendations, we refer readers to previously published OPPS/ASC proposed and final rules, the CMS website mentioned earlier in this section, and the FACA database at http://facadatabase.gov.

F. Public Comments Received in Response to the CY 2019 OPPS/ASC Proposed Rule

We received over 2,990 timely pieces of correspondence on the CY 2019 OPPS/ASC proposed rule that appeared in the Federal Register on July 31, 2018 (83 FR 37046). We note that we received some public comments that were outside the scope of the CY 2019 OPPS/ASC proposed rule. Out-of-scope public comments are not addressed in this CY 2019 OPPS/ASC final rule with comment period. Summaries of those public comments that are within the scope of the proposed rule and our responses are set forth in the various sections of this final rule with comment period under the appropriate headings.

G. Public Comments Received on the CY 2018 OPPS/ASC Final Rule With Comment Period

We received over 125 timely pieces of correspondence on the CY 2018 OPPS/ASC final rule with comment period that appeared in the Federal Register on December 14, 2017 (82 FR 59216), some of which contain comments on the interim APC assignments and/or status indicators of new or replacement Level II HCPCS codes (identified with comment indicator “NI” in OPPS Addendum B, ASC Addendum AA, and ASC Addendum BB to that final rule). Summaries of the public comments are set forth in the CY 2019 proposed rule and this final rule with comment period under the appropriate subject matter headings.

II. Updates Affecting OPPS Payments

A. Recalibration of APC Relative Payment Weights

1. Database Construction

a. Database Source and Methodology

Section 1833(t)(9)(A) of the Act requires that the Secretary review not less often than annually and revise the relative payment weights for APCs. In the April 7, 2000 OPPS final rule with comment period (65 FR 18482), we explained in detail how we calculated the relative payment weights that were implemented on August 1, 2000 for each APC group.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37055), for CY 2019, we proposed to recalibrate the APC relative payment weights for services furnished on or after January 1, 2019, and before January 1, 2020 (CY 2019), using the same basic methodology that we described in the CY 2018 OPPS/ASC final rule with comment period (82 FR 52367 through 52370), using updated CY 2017 claims data. That is, as we proposed, we recalibrate the relative payment weights for each APC based on claims and cost report data for hospital outpatient department (HOPD) services, using the most recent available data to construct a database for calculating APC group weights.

For the purpose of recalibrating the APC relative payment weights for CY 2019, we began with approximately 163 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2017, and before January 1, 2018, before applying our exclusionary criteria and other methodological adjustments. After the application of those data processing changes, we used approximately 86 million final action claims to develop the proposed CY 2019 OPPS payment weights. For exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for the CY 2019 OPPS/ASC proposed rule on the CMS website at: http://www.cms.gov/Medicare/
In the CY 2014 OPPS/ASC proposed rule, we did not propose to remove any codes from the CY 2019 bypass list.

We did not receive any public comments on our general proposal to recalibrate the relative payment weights for each APC based on claims and cost report data for HOPD services or on our proposed bypass code process. Therefore, as proposed in the final rule, we identified the proposed "pseudo" single claims process and the final CY 2019 bypass list of 169 HCPCS codes, as displayed in Addendum N to this final rule with comment period (which is available via the internet on the CMS website). For this final rule with comment period, for purposes of recalibrating the final APC relative payment weights for CY 2019, we used approximately 91 million final action claims (claims for which all disputes and adjustments have been resolved and payment has been made) for HOPD services furnished on or after January 1, 2017 and before January 1, 2018. For exact numbers of claims used and additional details on the claims accounting process, we refer readers to the claims accounting narrative under supporting documentation for this CY 2019 OPPS/ASC final rule with comment period on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

b. Calculation and Use of Cost-to-Charge Ratios (CCRs)

For CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37055), we proposed to continue to use the hospital-specific overall ancillary and departmental cost-to-charge ratios (CCRs) to convert charges to estimated costs through application of a revenue code-to-cost center crosswalk. To calculate the APC costs on which the CY 2019 APC payment rates are based, we calculated hospital-specific overall ancillary CCRs and hospital-specific departmental CCRs for each hospital for which we had CY 2017 claims data by comparing these claims data to the most recently available hospital cost reports, which, in most cases, are from CY 2016. For the proposed CY 2019 OPPS payment rates, we used the set of claims processed during CY 2017. We applied the hospital-specific CCR to the hospital's charges at the most detailed level possible, based on a revenue code-to-cost center crosswalk that contains a hierarchy of CCRs used to estimate costs from charges for each revenue code. That crosswalk is available for review and comment on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

To ensure the completeness of the revenue code-to-cost center crosswalk, we reviewed changes to the list of revenue codes for CY 2017 (the year of claims data we used to calculate the proposed CY 2019 OPPS payment rates) and found that the National Uniform Billing Committee (NUBC) did not add any new revenue codes to the NUBC 2017 Data Specifications Manual.

In accordance with our longstanding policy, we calculate CCRs for the standard and nonstandard cost centers accepted by the electronic cost report database. In general, the most detailed level at which we calculate CCRs is the hospital-specific departmental level. For a discussion of the hospital-specific overall ancillary CCR calculation, we refer readers to the CY 2007 OPPS/ASC final rule with comment period (71 FR 67983 through 67985). The calculation of blood costs is a longstanding exception (since the CY 2005 OPPS) to this general methodology for calculation of CCRs used for converting charges to costs on each claim. This exception is discussed in detail in the CY 2007 OPPS/ASC final rule with comment period and discussed further in section II.A.2.a.(1) of the proposed rule and this final rule with comment period.

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74840 through 74847), we finalized our policy of creating new cost centers and distinct CCRs for implantable devices, magnetic resonance imaging (MRIs), computed tomography (CT) scans, and cardiac catheterization. However, in response to the CY 2014 OPPS/ASC proposed rule, commenters reported that some hospitals currently use an imprecise "square feet" allocation methodology for the costs of large moveable equipment like CT scan and MRI machines. They indicated that while CMS recommended using two alternative allocation methods, "direct assignment" or "dollar value," as a more accurate methodology for directly assigning equipment costs, industry analysis suggested that approximately only half of the reported cost centers for CT scans and MRIs rely on these preferred methodologies. In response to concerns from commenters, we finalized a policy for the CY 2014 OPPS to remove claims from providers that use a cost allocation method of "square feet" to calculate CCRs used to estimate costs associated with the APCs for CT and MRI (78 FR 74847). Further, we finalized a transitional policy to estimate the imaging APC relative payment weights using only CT and MRI cost data from providers that do not use "square feet" as the cost allocation statistic. We provided that this finalized policy would sunset in 4 years to provide a sufficient time for hospitals to transition to a more accurate cost allocation method and for the related data to be available for ratessetting purposes (78 FR 74847). Therefore, beginning CY 2018, with the sunset of the transition policy, we would estimate the imaging APC relative payment weights using cost data from all providers, regardless of the cost allocation statistic employed. However, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59228 and 59229), we finalized a policy to extend the transition policy for 1 additional year and continued to remove claims from providers that use a cost allocation method of "square feet" to calculate CT and MRI CCRs for the CY 2018 OPPS.

As we discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59228), some stakeholders have raised concerns regarding using claims from all providers to calculate CT and MRI CCRs, regardless of the cost allocations statistic employed (78 FR 74840 through 74847). Stakeholders noted that providers continue to use the "square feet" cost allocation method and that including claims from such providers would cause significant
reductions in the imaging APC payment rates.

Table 1 below demonstrates the relative effect on imaging APC payments after removing cost data for providers that report CT and MRI standard cost centers using “square feet” as the cost allocation method by extracting HCRIS data on Worksheet B–1. Table 2 below provides statistical values based on the CT and MRI standard cost center CCRs using the different cost allocation methods.

TABLE 1.—PERCENTAGE CHANGE IN ESTIMATE COST FOR CT AND MRI APCs WHEN EXCLUDING CLAIMS FROM PROVIDER USING “SQUARE FEET” AS THE COST ALLOCATION METHOD

<table>
<thead>
<tr>
<th>APC</th>
<th>APC Descriptor</th>
<th>Percentage Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>5521</td>
<td>Level 1 Imaging without Contrast</td>
<td>-4.0%</td>
</tr>
<tr>
<td>5522</td>
<td>Level 2 Imaging without Contrast</td>
<td>5.6%</td>
</tr>
<tr>
<td>5523</td>
<td>Level 3 Imaging without Contrast</td>
<td>4.2%</td>
</tr>
<tr>
<td>5524</td>
<td>Level 4 Imaging without Contrast</td>
<td>5.3%</td>
</tr>
<tr>
<td>5571</td>
<td>Level 1 Imaging with Contrast</td>
<td>7.8%</td>
</tr>
<tr>
<td>5572</td>
<td>Level 2 Imaging with Contrast</td>
<td>8.3%</td>
</tr>
<tr>
<td>5573</td>
<td>Level 3 Imaging with Contrast</td>
<td>2.8%</td>
</tr>
<tr>
<td>8005</td>
<td>CT and CTA without Contrast Composite</td>
<td>14.1%</td>
</tr>
<tr>
<td>8006</td>
<td>CT and CTA with Contrast Composite</td>
<td>11.5%</td>
</tr>
<tr>
<td>8007</td>
<td>MRI and MRA without Contrast Composite</td>
<td>6.5%</td>
</tr>
<tr>
<td>8008</td>
<td>MRI and MRA with Contrast Composite</td>
<td>6.8%</td>
</tr>
</tbody>
</table>

TABLE 2.—CCR STATISTICAL VALUES BASED ON USE OF DIFFERENT COST ALLOCATION METHODS

<table>
<thead>
<tr>
<th>Cost Allocation Method</th>
<th>CT</th>
<th>MRI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median CCR</td>
<td>Mean CCR</td>
</tr>
<tr>
<td>All Providers</td>
<td>0.0370</td>
<td>0.0512</td>
</tr>
<tr>
<td>Square Feet Only</td>
<td>0.0300</td>
<td>0.0453</td>
</tr>
<tr>
<td>Direct Assign</td>
<td>0.0554</td>
<td>0.0642</td>
</tr>
<tr>
<td>Dollar Value</td>
<td>0.0435</td>
<td>0.0588</td>
</tr>
<tr>
<td>Direct Assign and Dollar Value</td>
<td>0.0438</td>
<td>0.0589</td>
</tr>
</tbody>
</table>

Our analysis shows that since the CY 2014 OPPS in which we established the transition policy, the number of valid MRI CCRs has increased by 17.5 percent to 2,177 providers and the number of valid CT CCRs has increased by 15.1 percent to 2,251 providers. However, as shown in Table 1 above, nearly all imaging APCs would see an increase in payment rates for CY 2019 if claims from providers that report using the “square feet” cost allocation method were removed. This can be attributed to the generally lower CCR values from providers that use a cost allocation method of “square feet” as shown in Table 2 above.

In response to provider concerns and to provide added flexibility for hospitals to improve their cost allocation methods, for the CY 2019 OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37056), we proposed to extend our transition policy and remove claims from providers that use a cost allocation method of “square feet” to calculate CCRs used to estimate costs with the APCs for CT and MRI identified in Table 2 above. We stated in the proposed rule that this proposed extension would mean that CMS would now be providing 6 years for providers to transition from a “square feet” cost allocation method to another cost allocation method. We stated in the proposed rule that we do not believe
another extension in CY 2020 will be warranted and expect to determine the imaging APC relative payment weights for CY 2020 using cost data from all providers, regardless of the cost allocation method employed.

Comment: Some commenters supported CMS’ proposal to extend its transition policy an additional year and determine imaging APC relative payment weights for CY 2020 using cost data from all providers.

Response: We thank the commenters for their support.

Comment: Some commenters recommended that CMS discontinue the use of CT and MRI cost centers for developing CT and MRI CCRs and use a single diagnostic radiology CCR instead. One commenter suggested that CCRs for CT and MRI are inaccurate, too low, and equalize the payment rates for advanced and nonadvanced imaging. This commenter also noted that if CMS were to use CCRs from all cost allocation methods, including “square feet,” such a change would impact technical payments under the Medicare Physician Fee Schedule because OPPS payments for imaging services would fall below the technical payments for such services under the Medicare Physician Fee Schedule and would require a reduction as required by section 1848(b)(4) of the Act.

Further, the commenter noted that a significant number of CT and MRI CCRs are close to zero. The commenter suggested that this probably reflects that the costs of the equipment and dedicated space for these services are likely spread across to other departments of hospitals. The commenter also suggested that hospitals have standard accounting practices for high-cost moveable equipment and that it would be burdensome and inconsistent to apply a different standard for costs associated with CT and MRI.

Response: We appreciate the comments regarding the use of standard CT and MRI cost center CCRs. As we stated in prior rulemaking, we recognize the concerns with regard to the application of the CT and MRI standard cost center CCRs and their use in OPPS ratesetting in lieu of the previously used single diagnostic radiology CCR. As compared to the IPPS, there is greater sensitivity to the cost allocation method being used on the cost report forms for these relatively new standard imaging cost centers under the OPPS due to the limited size of the OPPS payment bundles and because the OPPS applies the CCRs at the departmental level for cost estimation purposes. However, we note that since the time we initially established the transition policy in the OPPS, we have made changes toward making the OPPS more of a prospective payment system, including greater packaging and the development of the comprehensive APCs. As we have made changes to package a greater number of items and services with imaging payments under the OPPS, and CT and MRI procedures are not solely based on the CCR applied to each procedure, we believe there is less sensitivity to imaging payments that is attributable to the cost allocation method being used on the cost report forms.

Table 3 and Table 4 below display the largest and smallest CT and MRI CCRs based on the cost allocation method, respectively. Specifically, Tables 3 and 4 display the minimum, 5th percentile, 10th percentile, 90th percentile, 95th percentile, and maximum CCRs based on the cost allocation method. While we note that there are differences in CT and MRI CCR values by the cost allocation method, we also note that the CT CCR distributions and MRI CCR distributions are largely similar across the cost allocation method. As stated in past rulemaking, we also note that our current trimming methodology excludes CCRs that are +/− 3 standard deviations from the geometric mean. While we acknowledge the commenter’s concern that a number of CCRs, particular those CT CCRs from hospitals that use a cost allocation method of “square feet,” are below 0.0100, we do not believe it would be appropriate to modify our standard trimming methodology because it is not our general policy to judge the accuracy of hospital charging and hospital cost reporting practices for purposes of ratesetting.

![Table 3](image)

**TABLE 3.—SELECTED DISTRIBUTION OF CT CCR STATISTICAL VALUES BASED ON USE OF DIFFERENT COST ALLOCATION METHODS**

<table>
<thead>
<tr>
<th>Cost Allocation Method</th>
<th>Minimum</th>
<th>5th Percentile</th>
<th>10th Percentile</th>
<th>90th Percentile</th>
<th>95th Percentile</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Providers</td>
<td>0.0036</td>
<td>0.0115</td>
<td>0.0147</td>
<td>0.1010</td>
<td>0.1399</td>
<td>0.4052</td>
</tr>
<tr>
<td>Square Feet Only</td>
<td>0.0036</td>
<td>0.0099</td>
<td>0.0121</td>
<td>0.0922</td>
<td>0.1379</td>
<td>0.4052</td>
</tr>
<tr>
<td>Direct Assign</td>
<td>0.0055</td>
<td>0.0222</td>
<td>0.0259</td>
<td>0.1223</td>
<td>0.1534</td>
<td>0.2282</td>
</tr>
<tr>
<td>Dollar Value</td>
<td>0.0046</td>
<td>0.0180</td>
<td>0.0223</td>
<td>0.1087</td>
<td>0.1458</td>
<td>0.4009</td>
</tr>
<tr>
<td>Direct Assign and Dollar Value</td>
<td>0.0046</td>
<td>0.0179</td>
<td>0.0224</td>
<td>0.1087</td>
<td>0.1493</td>
<td>0.4009</td>
</tr>
</tbody>
</table>
TABLE 4.—SELECTED DISTRIBUTION OF MRI CCR STATISTICAL VALUES BASED ON USE OF DIFFERENT COST ALLOCATION METHODS

<table>
<thead>
<tr>
<th>Cost Allocation Method</th>
<th>Minimum</th>
<th>5th Percentile</th>
<th>10th Percentile</th>
<th>90th Percentile</th>
<th>95th Percentile</th>
<th>Maximum</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Providers</td>
<td>0.0106</td>
<td>0.0292</td>
<td>0.0355</td>
<td>0.1975</td>
<td>0.2653</td>
<td>0.6700</td>
</tr>
<tr>
<td>Square Feet Only</td>
<td>0.0106</td>
<td>0.0247</td>
<td>0.0305</td>
<td>0.1822</td>
<td>0.2469</td>
<td>0.6563</td>
</tr>
<tr>
<td>Direct Assign</td>
<td>0.0271</td>
<td>0.0456</td>
<td>0.0525</td>
<td>0.2119</td>
<td>0.2904</td>
<td>0.6081</td>
</tr>
<tr>
<td>Dollar Value</td>
<td>0.0175</td>
<td>0.0365</td>
<td>0.0446</td>
<td>0.2187</td>
<td>0.2920</td>
<td>0.6700</td>
</tr>
</tbody>
</table>

In addition, as we stated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74845), we have noted the potential impact the CT and MRI CCRs may have on other payment systems. We understand that payment reductions for imaging services under the OPPS could have significant payment impacts under the Physician Fee Schedule where the technical component payment for many imaging services is capped at the OPPS payment amount. We will continue to monitor OPPS imaging payments in the future and consider the potential impacts of payment changes to other payment systems.

Over the past several years, we have encouraged hospitals to use more precise cost reporting methods through cost reporting instructions and communication with Medicare contractors regarding the approval of hospitals’ request to switch from the square feet statistical allocation method. While we have not seen a substantial decline in the number of hospitals that use the square feet cost allocation method, and we acknowledge that there are costs and challenges with transitioning to a different accounting method for CT and MRI costs, we continue to believe that adopting CT and MRI cost center CCRs fosters more specific cost reporting and improves the data contained in the electronic cost report data files and, therefore, the accuracy of our cost estimation process for the OPPS relative weights. Therefore, for CY 2019, after consideration of the public comments we received, for CY 2019, we are finalizing our proposal to extend our transition policy for 1 additional year and continue to remove claims from providers that use a “square feet” cost allocation method to calculate CT and MRI CCRs for the CY 2019 OPPS.

2. Data Development Process and Calculation of Costs Used for Rate Setting

In this section of this final rule with comment period, we discuss the use of claims to calculate the OPPS payment rates for CY 2019. The Hospital OPPS page on the CMS website on which this final rule is posted (http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html) provides an accounting of claims used in the development of the final payment rates. That accounting provides additional detail regarding the number of claims derived at each stage of the process. In addition, below in this section we discuss the file of claims that comprises the data set that is available upon payment of an administrative fee under a CMS data use agreement. The CMS website, http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html, includes information about obtaining the “OPPS Limited Data Set,” which now includes the additional variables previously available only in the OPPS Identifiable Data Set, including ICD–10-CM diagnosis codes and revenue code payment amounts. This file is derived from the CY 2017 claims that were used to calculate the final payment rates for this CY 2019 OPPS/ASC final rule with comment period.

Previously, the OPPS established the scaled relative weights, on which payments are based using APC median costs, a process described in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74188). However, as discussed in more detail in section II.A.2.f. of the CY 2013 OPPS/ASC final rule with comment period (77 FR 68259 through 68271), we finalized the use of geometric mean costs to calculate the relative weights on which the CY 2013 OPPS payment rates were based. While this policy changed the cost metric on which the relative payments are based, the data process in general remained the same, under the methodologies that we used to obtain appropriate claims data and accurate cost information in determining estimated service cost. In the CY 2019 OPPS/ASC proposed rule (83 FR 37037), we proposed to continue to use geometric mean costs to calculate the relative weights on which the CY 2019 OPPS payment rates are based.

Comment: One commenter believed that revenue code 0815 (Allogeneic Stem Cell Acquisition Services) was inadvertently excluded from the packaged revenue code list for use in the OPPS ratesetting. The commenter stated that this would primarily have an impact on APC 5244 (Level 4 Blood Product Exchange and Related Services) which would potentially include those packaged costs. The commenter requested that CMS include revenue code 0815 on the packaged revenue code list in order to be consistent with the C–APC ratesetting approach from prior years.

Response: We thank the commenter for bringing this omission to our attention. As discussed in the CY 2018 OPPS/ASC final rule with comment period (81 FR 79856), beginning in CY 2017, we would include the revenue code for purposes of identifying costs associated with stem cell transplants. We agree that the revenue code was inadvertently not included on the packaged revenue code list and therefore have included it in this final rule with comment period for the CY 2019 OPPS ratesetting.

After consideration of the public comment on the proposed process we received, we are adding revenue code 0815 to the packaged revenue code list and are finalizing our proposed methodology for calculating geometric mean costs for purposes of creating relative payment weights and subsequent APC payment rates for the CY 2019 OPPS. For more information
We note that this is the first year in which claims data containing lines with the modifier “PN” are available, which indicate nonexempted items and services furnished and billed by off-campus provider-based departments (PBDs) of hospitals. Because nonexempted services are not paid under the OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37057), we proposed to remove those claim lines reported with modifier “PN” from the claims data used in ratesetting for the CY 2019 OPPS and subsequent years.

Comment: One commenter requested that CMS not finalize the removal of claims with modifier “PN” from the CY 2019 OPPS and future ratesetting. The commenter believed that this could result in unfair adjustments against hospital outpatient departments with large off-campus PBD presence and that CMS should perform ratesetting with and without modifier “PN” in CY 2020 and continue to gather stakeholder input until the impact of removing those lines is fully understood.

Response: While we generally attempt to obtain more information from the claims and cost data available to us, we do so to obtain accurate cost information for OPPS services. As discussed in the proposed rule, we do not believe that lines with modifier “PN” should be included as part of the OPPS ratesetting process because they are paid under the otherwise applicable payment system, rather than the OPPS (83 FR 37056 and 37057). We note that the impact of removing these modifier “PN” lines has only a nominal effect on the APC geometric mean costs due to the relatively low number of claims reported with modifier “PN”.

After consideration of the public comment we received, we are finalizing the policy of removing lines with the “PN” modifier as proposed.

For details of the claims process used in this final rule with comment period, we refer readers to the claims accounting narrative under supporting documentation for this CY 2019 OPPS/ASC final rule with comment period on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

a. Calculation of Single Procedure APC Criteria-Based Costs

(1) Blood and Blood Products

(a) Methodology

Since the implementation of the OPPS in August 2000, we have made separate payments for blood and blood products through APCs rather than packaging payment for them into payments for the procedures with which they are administered. Hospital payments for the costs of blood and blood products, as well as for the costs of collecting, processing, and storing blood and blood products, are made through the OPPS payments for specific blood product APCs.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37057 through 37058), we proposed to continue to establish payment rates for blood and blood products using our blood-specific CCR methodology, which utilizes actual or simulated CCRs from the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. This methodology has been our standard ratesetting methodology for blood and blood products since CY 2005. It was developed in response to data analysis indicating that there was a significant difference in CCRs for those hospitals with and without blood-specific cost centers, and past public comments indicating that the former OPPS policy of defaulting to the overall hospital CCR for hospitals not reporting a blood-specific cost center often resulted in an underestimation of the true hospital costs for blood and blood products. Specifically, in order to address the differences in CCRs and to better reflect hospitals’ costs, we proposed to continue to simulate blood CCRs for each hospital that does not report a blood cost center by calculating the ratio of the blood-specific CCRs to hospitals’ overall CCRs for those hospitals that do report costs and charges for blood cost centers. We also proposed to apply this mean ratio to the overall CCRs of hospitals not reporting costs and charges for blood cost centers on their cost reports in order to simulate blood-specific CCRs for those hospitals. We proposed to calculate the costs upon which the proposed CY 2019 payment rates for blood and blood products are based using the actual blood-specific CCR for hospitals that reported costs and charges for a blood cost center and a hospital-specific, simulated blood-specific CCR for hospitals that did not report costs and charges for a blood cost center.

We continue to believe that the hospital-specific, simulated blood-specific, CCR methodology better responds to the absence of a blood-specific CCR for a hospital than alternative methodologies, such as defaulting to the overall hospital CCR or applying an average blood-specific CCR across hospitals. Because this methodology takes into account the unique charging and cost accounting structure of each hospital, we believe that it yields more accurate estimated costs for these products. We stated in the proposed rule that we continue to believe that this methodology in CY 2019 would result in costs for blood and blood products that appropriately reflect the relative estimated costs of these products for hospitals without blood cost centers and, therefore, for these blood products in general.

We note that, as discussed in section IA.2.b. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59234 through 59239), we defined a comprehensive APC (C–APC) as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. Under this policy, we include the costs of blood and blood products when calculating the overall costs of these C–APCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37057 through 37058), we proposed to continue to apply the blood-specific CCR methodology described in this section when calculating the costs of the blood and blood products that appear on claims with services assigned to the C–APCs. Because the costs of blood and blood products would be reflected in the overall costs of the C–APCs (and, as a result, in the payment rates of the C–APCs), we proposed to not make separate payments for blood and blood products when they appear on the same claims as services assigned to the C–APCs (we refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66796)).

We also referred readers to Addendum B to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website) for the proposed CY 2019 payment rates for blood and blood products (which are identified with status indicator “R”). For a more detailed discussion of the blood-specific CCR methodology, we refer readers to the CY 2005 OPPS proposed rule (69 FR 50524 through...
50525). For a full history of OPPS payment for blood and blood products, we refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66807 through 66810).

We did not receive any public comments for these proposals. Therefore, we are finalizing our proposals, without modification, to continue to apply the blood-specific CCR methodology described in this section when calculating the costs of the blood and blood products that appear on claims with services assigned to the C–APCs and to not make separate payments for blood and blood products when they appear on the same claims as services assigned to the C–APCs for CY 2019.

(b) Pathogen-Reduced Platelets Payment Rate

In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70322 through 70323), we reiterated that we calculated payment rates for blood and blood products using our blood-specific CCR methodology, which utilizes actual or simulated CCRs from the most recently available hospital cost reports to convert hospital charges for blood and blood products to costs. Because HCPCS code P9072 (Platelets, pheresis, pathogen reduced or rapid bacterial tested, each unit), the predecessor code to HCPCS code P9073 (Platelets, pheresis, pathogen-reduced, each unit), was new for CY 2016, there were no claims data available on the charges and costs for this blood product upon which to apply our blood-specific CCR methodology. Therefore, we established an interim payment rate for HCPCS code P9072 based on a crosswalk to existing blood product HCPCS code P9037 (Platelets, pheresis, leukocytes reduced, irradiated, each unit), which we believed provided the best proxy for the costs of the new blood product. In addition, we stated that once we had claims data for HCPCS code P9072, we would calculate its payment rate using the claims data that should be available for the code beginning in CY 2018, which is our practice for other blood product HCPCS codes for which claims data have been available for 2 years.

We stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59232) that, although our standard practice for new codes involves using claims data to set payment rates once claims data become available, we were concerned that there may have been confusion among the provider community about the services that HCPCS code P9072 described. That is, as early as 2016, there were discussions about changing the descriptor for HCPCS code P9072 to include the phrase “or rapid bacterial tested”, which is a less costly technology than pathogen reduction. In addition, effective January 2017, the code descriptor for HCPCS code P9072 was changed to describe rapid bacterial testing of platelets and, effective July 1, 2017, the descriptor for the temporary successor code for HCPCS code P9072 (HCPCS code Q9988) was changed again back to the original descriptor for HCPCS code P9072 that was in place for 2016.

Based on the ongoing discussions involving changes to the original HCPCS code P9072 established in CY 2016, we believed that claims from CY 2016 for pathogen reduced platelets may have potentially reflected certain claims for rapid bacterial testing of platelets. Therefore, we decided to continue to crosswalk the payment amount for services described by HCPCS code P9073 to the payment amount for services described by HCPCS code P9037 for CY 2018 (82 FR 50323), as had been done previously, to determine the payment rate for services described by HCPCS code P9072. In the CY 2019 OPPS/ASC proposed rule (83 FR 37058), for CY 2019, we discussed that we had reviewed the CY 2017 claims data for the two predecessor codes to HCPCS code P9073 (HCPCS codes P9072 and Q9988), along with the claims data for the CY 2017 temporary code for pathogen test for platelets (HCPCS code Q9987), which describes rapid bacterial testing of platelets.

We found that there were over 2,200 claims billed with either HCPCS code P9072 or Q9988. Accordingly, we believe that there are a sufficient number of claims to use to calculate a payment rate for HCPCS code P9073 for CY 2019. We also performed checks to estimate the share of claims that may have been billed for rapid bacterial testing of platelets as compared to the share of claims that may have been billed for pathogen-reduced, pheresis platelets (based on when HCPCS code P9072 was an active procedure code from January 1, 2017 to June 30, 2017). First, we found that the geometric mean cost for pathogen-reduced, pheresis platelets, as reported by HCPCS code Q9988 when billed separately from rapid bacterial testing of platelets, was $453.87, and that over 1,200 claims were billed for services described by HCPCS code Q9988. Next, we found that the geometric mean cost for rapid bacterial testing of platelets, as reported by HCPCS code P9072, was $33.44, and there were 59 claims reported for services described by HCPCS code Q9987, of which 3 were separately paid.

These findings imply that almost all of the claims billed for services reported with HCPCS code P9072 were for pathogen-reduced, pheresis platelets. In addition, the geometric mean cost for services described by HCPCS code P9072, which may contain rapid bacterial testing of platelets claims, was $468.11, which is higher than the geometric mean cost for services described by HCPCS code Q9988 of $453.87, which should not have contained claims for rapid bacterial testing of platelets. Because the geometric mean for services described by HCPCS code Q9987 is only $33.44, it would be expected that if a significant share of claims billed for services described by HCPCS code P9072 were for the rapid bacterial testing of platelets, the geometric mean cost for services described by HCPCS code P9072 would be lower than the geometric mean cost for services described by HCPCS code Q9988. Instead, we found that the geometric mean cost for services described by HCPCS code Q9988 is higher than the geometric mean cost for services described by HCPCS code P9072.

Based on our analysis of claims data, we stated in the CY 2019 OPPS/ASC proposed rule that we believed there were sufficient claims available to establish a payment rate for pathogen-reduced pheresis platelets without using a crosswalk. Therefore, we proposed to calculate the payment rate for services described by HCPCS code P9073 in CY 2019 and in subsequent years using claims payment history, which is the standard methodology used by the OPPS for HCPCS and CPT codes with at least 2 years of claims history. We referred readers to Addendum B of the proposed rule for the proposed payment rate for services described by HCPCS code P9073 reportable under the OPPS. Addendum B is available via the internet on the CMS website.

Comment: Several commenters opposed the proposal to use claims history to calculate the payment rate for services described by HCPCS code P9073. Instead, the commenters requested that CMS calculate the payment rate for services described by HCPCS code P9072 based on a crosswalk to existing blood product HCPCS code P9037 through either CY 2019 or CY 2020. The commenters stated that the acquisition cost for pathogen-reduced platelets is over $600, which is substantially higher than the proposed payment rate for services described by HCPCS code P9073 found in Addendum B to the proposed rule.
and closer to the payment rate for services described by HCPCS code P9073. Some commenters indicated that the cost for pathogen-reduced platelets is higher than the cost of leukocytes reduced and irradiated platelets, the product covered by HCPCS code P9073, the crosswalked code. Several of the commenters believed the claim costs for pathogen-reduced platelets were lower than actual costs because of coding errors by providers, providers who did not use pathogen-reduced platelets billing the service, and confusion over whether to use the hospital CCR or the blood center CCR to report charges for pathogen-reduced platelets. One commenter also stated that a provider that billed several claims for pathogen-reduced platelets believed that CMS assigned an unusually low OCR to its claims, leading the provider to report lower than actual costs for the service.

Response: We appreciate the concerns of the commenters. Pathogen-reduced platelets (HCPCS code P9073) are a relatively new service. As we noted in the CY 2009 OPPS/ASC proposed rule (83 FR 37058), there were many changes to the procedure code billed for pathogen-reduced platelets, as well as with the services covered by the procedure codes for pathogen-reduced platelets and the code descriptors. We had concerns that all of these coding changes could lead to billing confusion. The comments we received from providers, stakeholder groups, and the developer of the pathogen-reduced technology support that there indeed may have been confusion about billing that has led to aberrancies in the data we have available for ratesetting.

After consideration of the public comments we received, we are not finalizing our proposal to calculate the payment rate for services described by HCPCS code P9073 in CY 2019 using claims payment history. Instead, for CY 2019 (that is, for one more year), we are establishing the payment rate for services described by HCPCS code P9073 by performing a crosswalk from the payment amount for services described by HCPCS code P9073 to the payment amount for services described by HCPCS code P9037. We refer readers to Addendum B to the final rule with comment period for the final payment rate for services described by HCPCS code P9073 reportable under the OPPS. Addendum B is available via the internet on the CMS website.

(2) Brachytherapy Sources

Section 1833(t)(2)(H) of the Act mandates the creation of additional groups of covered OPD services that classify devices of brachytherapy consisting of a seed or seeds (or radioactive source) (“brachytherapy sources”) separately from other services or groups of services. The statute provides certain criteria for the additional groups. For the history of OPPS payment for brachytherapy services, we refer readers to prior OPPS final rules, such as the CY 2012 OPPS/ASC final rule with comment period (77 FR 66240 through 66241). As we have stated in prior OPPS updates, we believe that adopting the general OPPS prospective payment methodology for brachytherapy services is appropriate for a number of reasons (77 FR 66240). The general OPPS methodology uses costs based on claims data to set the relative payment weights for hospital outpatient services. This payment methodology results in more consistent, predictable, and equitable payment amounts per source across hospitals by averaging the extremely high and low values, in contrast to payment based on hospitals’ charges adjusted to costs. We believe that the OPPS methodology, as opposed to payment based on hospitals’ charges adjusted to cost, also would provide hospitals with incentives for efficiency in the provision of brachytherapy services to Medicare beneficiaries. Moreover, this approach is consistent with our payment methodology for the vast majority of items and services paid under the OPPS. We refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70323 through 70325) for further discussion of the history of OPPS payment for brachytherapy sources.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37059), for CY 2019, we proposed to use the costs derived from CY 2017 claims data to set the proposed CY 2019 payment rates for brachytherapy sources because CY 2017 is the same year of data we proposed to use to set the proposed payment rates for most other items and services that would be paid under the CY 2019 OPPS. We proposed to base the payment rates for brachytherapy sources on the geometric mean unit costs for each source, consistent with the methodology that we proposed for other items and services paid under the OPPS, as discussed in section II.A.2. of the proposed rule. We also proposed to continue the other payment policies for brachytherapy sources that we finalized and first implemented in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60537). We proposed to pay for the stranded and nonstranded not otherwise specified (NOS) codes, HCPCS codes C2698 (Brachytherapy source, stranded, not otherwise specified, per source) and C2699 (Brachytherapy source, non-stranded, not otherwise specified, per source), at a rate equal to the lowest stranded or nonstranded prospective payment rate for such sources, respectively, on a per source basis (as opposed to, for example, a per mCi), which is based on the policy we established in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66786; which was delayed until January 1, 2010 by section 142 of Pub. L. 110–275). Specifically, this policy is intended to enable us to assign new HCPCS codes for new brachytherapy sources to their own APCs, with prospective payment rates set based on our consideration of external data and other relevant information regarding the expected costs of the sources to hospitals. The proposed CY 2019 payment rates for brachytherapy sources were included in Addendum B to the proposed rule (which is available via the internet on the CMS website) and were identified with status indicator “U”. For CY 2019, we proposed to continue to assign status indicator “U” (Brachytherapy Sources, Paid under OPPS; separate APC payment) to HCPCS code C2645 (Brachytherapy planar source, palladium-103, per square millimeter) and to use external data (invoice prices) and other relevant information to establish the proposed APC payment rate for HCPCS code C2645.

Specifically, we proposed to set the payment rate at $4.69 per mm², the same rate that was in effect for CYs 2017 and 2018.

We note that, for CY 2019, we proposed to assign status indicator “E2” (Items and Services for Which Pricing Information and Claims Data Are Not Available) to HCPCS code C2644 (Brachytherapy cesium-131 chloride) because this code was not reported on CY 2017 claims. Therefore, we were unable to calculate a proposed payment rate based on the general OPPS ratesetting methodology described earlier. Although HCPCS code C2644 became effective July 1, 2014, there are no CY 2017 claims reporting this code. Therefore, we proposed to assign new proposed status indicator “E2” to HCPCS code C2644 in the CY 2019 OPPS.
Comment: One commenter expressed concern regarding CMS’ policy to establish prospective payment rates for brachytherapy sources using the general OPPS methodology, which uses costs based on claims data to set the relative payment weights for hospital outpatient services. The commenter stated that, as a result of use of these cost data from claims, payments for low-volume brachytherapy sources have fluctuated significantly under the OPPS.

Response: As we stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74161) when we established a prospective payment for brachytherapy sources, the OPPS relies on the concept of averaging, where the payment may be more or less than the estimated cost of providing a service for a particular patient; however, with the exception of outlier cases, we believe that such a prospective payment is adequate to ensure access to appropriate care. We acknowledge that payment for brachytherapy sources based on geometric mean costs from a small set of claims may be more variable on a year-to-year basis when compared to geometric mean costs for brachytherapy sources from a larger claims set. However, as illustrated in Table 5 below, we believe that payment for currently payable brachytherapy sources has been relatively consistent over the years and that a prospective payment for brachytherapy sources based on geometric mean costs is appropriate and provides hospitals with the greatest incentives for efficiency in furnishing brachytherapy treatment. For CY 2019 OPPS payment rates for the brachytherapy sources listed in Table 5, we refer readers to Addendum B of this final rule with comment period (which is available via the internet on the CMS website).
After consideration of the public comments we received, we are finalizing our proposal to continue to set the payment rates for brachytherapy sources using our established prospective payment methodology. We also are finalizing our proposal to assign status indicator “U” (Brachytherapy Sources, Paid under OPPS; separate APC payment) to HCPCS code C2644 (Brachytherapy cesium-131 chloride) based on the general OPPS ratesetting methodology, we are finalizing our proposal to assign HCPCS code C2644 status indicator “E2” (Items and Services for Which Pricing Information and Claims Data Are Not Available) for CY 2019.

The final CY 2019 payment rates for brachytherapy sources are included in Addendum B to this final rule with comment period (which is available via the internet on the CMS website) and are identified with status indicator “U”.

We continue to invite hospitals and other parties to submit recommendations to us for new codes to describe new brachytherapy sources. Such recommendations should be

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>Short Descriptor</th>
<th>CY 2015 OPPS Payment Rate</th>
<th>CY 2016 OPPS Payment Rate</th>
<th>CY 2017 OPPS Payment Rate</th>
<th>CY 2018 OPPS Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2616</td>
<td>Brachytx, non-str, Yttrium-90</td>
<td>$15,582.68</td>
<td>$16,021.70</td>
<td>$16,507.73</td>
<td>$16,717.59</td>
</tr>
<tr>
<td>2632</td>
<td>Iodine I-35 sodium iodide</td>
<td>$13.25</td>
<td>$7.14</td>
<td>$29.93</td>
<td>$26.65</td>
</tr>
<tr>
<td>2634</td>
<td>Brachytx, non-str, HA, I-25</td>
<td>$85.81</td>
<td>$85.18</td>
<td>$120.52</td>
<td>$117.66</td>
</tr>
<tr>
<td>2635</td>
<td>Brachytx, non-str, HA, P-103</td>
<td>$25.81</td>
<td>$35.24</td>
<td>$25.70</td>
<td>$25.94</td>
</tr>
<tr>
<td>2636</td>
<td>Brachy linear, non-str P-103</td>
<td>$19.44</td>
<td>$14.24</td>
<td>$18.65</td>
<td>$27.08</td>
</tr>
<tr>
<td>2638</td>
<td>Brachytx, stranded, I-25</td>
<td>$42.42</td>
<td>$38.09</td>
<td>$37.97</td>
<td>$34.73</td>
</tr>
<tr>
<td>2639</td>
<td>Brachytx, non-stranded, I-25</td>
<td>$37.05</td>
<td>$36.64</td>
<td>$35.70</td>
<td>$34.66</td>
</tr>
<tr>
<td>2640</td>
<td>Brachytx, stranded, P-103</td>
<td>$65.50</td>
<td>$68.78</td>
<td>$73.22</td>
<td>$78.72</td>
</tr>
<tr>
<td>2641</td>
<td>Brachytx, non-stranded, P-103</td>
<td>$67.93</td>
<td>$66.23</td>
<td>$65.45</td>
<td>$64.27</td>
</tr>
<tr>
<td>2642</td>
<td>Brachytx, stranded, C-131</td>
<td>$105.39</td>
<td>$86.59</td>
<td>$87.61</td>
<td>$87.89</td>
</tr>
<tr>
<td>2643</td>
<td>Brachytx, non-stranded, C-131</td>
<td>$54.71</td>
<td>$52.18</td>
<td>$59.19</td>
<td>$87.40</td>
</tr>
<tr>
<td>2645</td>
<td>Brachytx, non-str, Gold-198</td>
<td>$37.31</td>
<td>$45.54</td>
<td>$135.30</td>
<td>$122.61</td>
</tr>
<tr>
<td>2646</td>
<td>Brachytx, non-str, HDRiR-192</td>
<td>$272.38</td>
<td>$294.04</td>
<td>$281.58</td>
<td>$294.59</td>
</tr>
<tr>
<td>2647</td>
<td>Brachytx, NS, Non-HDRiR-192</td>
<td>$53.73</td>
<td>$93.11</td>
<td>$33.83</td>
<td>$19.16</td>
</tr>
<tr>
<td>2648</td>
<td>Brachytx planar, p-103</td>
<td>N/A</td>
<td>N/A</td>
<td>$4.69</td>
<td>$4.69</td>
</tr>
<tr>
<td>2698</td>
<td>Brachytx, stranded, NOS</td>
<td>$42.42</td>
<td>$38.09</td>
<td>$37.97</td>
<td>$34.73</td>
</tr>
<tr>
<td>2699</td>
<td>Brachytx, non-stranded, NOS</td>
<td>$19.44</td>
<td>$14.24</td>
<td>$18.65</td>
<td>$19.16</td>
</tr>
</tbody>
</table>

Note: N/A reflects brachytherapy APCs that did not have a payment rate for a payment year because the brachytherapy source did not have an established C-code.
directed to the Division of Outpatient Care, Mail Stop C4–01–25, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244. We will continue to add new brachytherapy source codes and descriptors to our systems for payment on a quarterly basis.

b. Comprehensive APCs (C–APCs) for CY 2019

(1) Background

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74861 through 74910), we finalized a comprehensive payment policy that packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. The policy was finalized in CY 2014, but the effective date was delayed until January 1, 2015, to allow additional time for further analysis, opportunity for public comment, and systems preparation. The comprehensive APC (C–APC) policy was implemented effective January 1, 2015, with modifications and clarifications in response to public comments received regarding specific provisions of the C–APC policy (79 FR 66798 through 66810). A C–APC is defined as a classification for the provision of a primary service and all adjunctive services provided to support the delivery of the primary service. We established C–APCs as a category broadly for OPPS payment and implemented 25 C–APCs beginning in CY 2015 (79 FR 66809 through 66810). In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70332), we finalized 10 additional C–APCs to be paid under the existing C–APC payment policy and added one additional level to both the Orthopedic Surgery and Vascular Procedures clinical families, which increased the total number of C–APCs to 37 for CY 2016. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79584 through 79585), we finalized another 25 C–APCs for a total of 62 C–APCs. In the CY 2018 OPPS/ASC final rule with comment period, we did not change the total number of C–APCs from 62.

Under this policy, we designate a service described by a HCPCS code assigned to a C–APC as the primary service when the service is identified by OPPS status indicator “J1”. When such a primary service is reported on a hospital outpatient claim, taking into consideration the few exceptions that are discussed below, we make payment for all other items and services reported on the hospital outpatient claim as being integral, ancillary, supportive, dependent, and adjunctive to the primary service (hereinafter collectively referred to as “adjunctive services”) and representing components of a complete comprehensive service (78 FR 74865 and 79 FR 66799). Payments for adjunctive services are packaged into the payments for the primary services. This results in a single prospective payment for each of the primary, comprehensive services based on the costs of all reported services at the claim level.

Services excluded from the C–APC policy under the OPPS include services that are not covered OPD services, services that cannot by statute be paid for under the OPPS, and services that are required by statute to be separately paid. This includes certain mammography and ambulance services that are not covered OPD services in accordance with section 1833(i)(1)(B)(iv) of the Act; brachytherapy seeds, which also are required by statute to receive separate payment under section 1833(i)(2)(H) of the Act; pass-through payment drugs and devices, which also require separate payment under section 1833(i)(6) of the Act; self-administered drugs (SADs) that are not otherwise packaged as supplies because they are not covered under Medicare Part B under section 1861(s)(2)(B) of the Act; and certain preventive services (78 FR 74865 and 79 FR 66800 through 66801). A list of services excluded from the C–APC policy is included in Addendum J to this final rule with comment period (which is available via the internet on the CMS website).

The C–APC policy payment methodology set forth in the CY 2014 OPPS/ASC final rule with comment period for the C–APCs and modified and implemented beginning in CY 2015 is summarized as follows (78 FR 74887 and 79 FR 66800):

**Basic Methodology.** As stated in the CY 2015 OPPS/ASC final rule with comment period, we define the C–APC payment policy as including all covered OPD services on a hospital outpatient claim reporting a primary service that is assigned to status indicator “J1”, excluding services that are not covered OPD services or that cannot by statute be paid for under the OPPS. Services and procedures described by HCPCS codes assigned to status indicator “J1” are assigned to C–APCs based on our usual APC assignment methodology by evaluating the geometric mean costs of the primary service and the establishment of resource similarity and the clinical characteristics of each procedure to establish clinical similarity within each APC.

In the CY 2016 OPPS/ASC final rule with comment period, we expanded the C–APC payment methodology to qualifying extended assessment and management encounters through the “Comprehensive Observation Services” C–APC (C–APC 8011). Services within this APC are assigned status indicator “J2”. Specifically, we make a payment through C–APC 8011 for a claim that:

- Does not contain a procedure described by a HCPCS code to which we have assigned status indicator “J2” that is reported with a date of service on the same day or 1 day earlier than the date of service associated with services described by HCPCS code G0378;
- Contains 8 or more units of services described by HCPCS code G0378 (Hospital observation services, per hour);
- Contains services provided on the same date of service or 1 day before the date of service for HCPCS code G0378 that are described by one of the following codes: HCPCS code G0379 (Direct admission of patient for hospital observation care) on the same date of service as HCPCS code G0378; CPT code 99281 (Emergency department visit for the evaluation and management of a patient (Level 1)); CPT code 99282 (Emergency department visit for the evaluation and management of a patient (Level 2)); CPT code 99283 (Emergency department visit for the evaluation and management of a patient (Level 3)); CPT code 99284 (Emergency department visit for the evaluation and management of a patient (Level 4)); CPT code 99285 (Emergency department visit for the evaluation and management of a patient (Level 5)) or HCPCS code G0380 (Type B emergency department visit (Level 1)); HCPCS code G0381 (Type B emergency department visit (Level 2)); HCPCS code G0382 (Type B emergency department visit (Level 3)); HCPCS code G0383 (Type B emergency department visit (Level 4)); HCPCS code G0384 (Type B emergency department visit (Level 5)); CPT code 99231 (Critical care, evaluation and management of the critically ill or critically injured patient; first 30–74 minutes); or HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient); and
- Does not contain services described by a HCPCS code to which we have assigned status indicator “J1”.

The assignment of status indicator “J2” to a specific combination of services performed in combination with each other allows for all other OPPS payable services and items reported on the claim (excluding services that are
not covered OPD services or that cannot by statute be paid for under the OPPS) to be deemed adjunctive services representing components of a comprehensive service and resulting in a single prospective payment for the comprehensive service based on the costs of all reported services on the claim (80 FR 70333 through 70336).

Services included under the C–APC payment packaging policy, that is, services that are typically adjunctive to the primary service and provided during the delivery of the comprehensive service, include diagnostic procedures, laboratory tests, and other diagnostic tests and treatments that assist in the delivery of the primary procedure; visits and evaluations performed in association with the procedure; uncoded services and supplies used during the service; durable medical equipment as well as prosthetic and orthotic items and supplies when provided as part of the outpatient service; and any other components reported by HCPCS codes that represent services that are provided during the complete comprehensive service (78 FR 74865 and 79 FR 66800).

In addition, payment for hospital outpatient department services that are similar to therapy services and delivered either by therapists or nontherapists is included as part of the payment for the packaged complete comprehensive service. These services that are provided during the perioperative period are adjunctive services and are deemed not to be therapy services as described in section 1834(k) of the Act, regardless of whether the services are delivered by therapists or other nontherapist health care workers. We have previously noted that therapy services are those provided by therapists under a plan of care in accordance with section 1835(a)(2)(C) and section 1835(a)(2)(D) of the Act and are paid for under section 1834(k) of the Act, subject to annual therapy caps as applicable (78 FR 74867 and 79 FR 66800). However, certain other services similar to therapy services are considered and paid for as hospital outpatient department services.

Payment for these nontherapy outpatient department services that are reported with therapy codes and provided with a comprehensive service is included in the payment for the packaged complete comprehensive service. We note that these services, even though they are reported with therapy codes, are hospital outpatient department services and not therapy services. Therefore, the requirement for functional reporting under the regulations at 42 CFR 410.59(a)(4) and 42 CFR 410.60(a)(4) does not apply. We refer readers to the July 2016 OPPS Change Request 9658 (Transmittal 3523) for further instructions on reporting these services in the context of a C–APC service.

Items included in the packaged payment provided in conjunction with the primary service also include all drugs, biologicals, and radiopharmaceuticals, regardless of cost, except those drugs with pass-through payment status and SADs, unless they function as packaged supplies (78 FR 74868 through 74869 and 74909 and 79 FR 66800). We refer readers to Section 50.2M, Chapter 15, of the Medicare Benefit Policy Manual for a description of our policy on SADs treated as hospital outpatient supplies, including lists of SADs that function as supplies and those that do not function as supplies.

We define each hospital outpatient claim reporting a single unit of a single primary service assigned to status indicator “J1” as a single “J1” unit procedure claim (78 FR 74871 and 79 FR 66801). Line item charges for services included on the C–APC claim are converted to line item costs, which are then summed to develop the estimated APC costs. These claims are then assigned one unit of the service with status indicator “J1” and later used to develop the geometric mean costs for the C–APC relative payment weights. (We note that we use the term “comprehensive” to describe the geometric mean cost of a claim reporting “J1” service(s) or the geometric mean cost of a C–APC, inclusive of all of the items and services included in the C–APC service payment bundle.) Charges for services that would otherwise be separately payable are added to the charges for the primary service. This process differs from our traditional cost accounting methodology only in that all such services on the claim are packaged (except certain services as described above). We apply our standard data trims, which exclude claims with extremely high primary units or extreme costs.

The comprehensive geometric mean costs are used to establish resource similarity and, along with clinical similarity, dictate the assignment of the primary services to the C–APCs. We establish a ranking of each primary service (single unit only) to be assigned to status indicator “J1” according to its comprehensive geometric mean costs. For the minority of claims reporting more than one primary service assigned to status indicator “J1”, we use a revision to the complexity adjustment policy to determine if the paired code combinations or paired code combinations of “J1” services and certain add-on codes (as described further below) from the originating C–APC (the C–APC to which the designated primary service is first assigned) to the next higher paying C–APC in the same clinical family of C–APCs. We apply this type of complexity adjustment when the paired code combination represents a complex, costly form or version of the primary service according to the following criteria:

- Frequency of 25 or more claims reporting the code combination (frequency threshold); and
- Violation of the 2 times rule in the originating C–APC (cost threshold).

These criteria identify paired code combinations that occur commonly and exhibit materially greater resource requirements than the primary service. The CY 2017 OPPS/ASC final rule with comment period (81 FR 79582) included a revision to the complexity adjustment eligibility criteria. Specifically, we finalized a policy to discontinue the requirement that a code combination (that qualifies for a complexity adjustment by satisfying the frequency and cost criteria thresholds described above) also not create a 2 times rule violation in the higher level or receiving APC.

After designating a single primary service for a claim, we evaluate that service in combination with each of the other services reported to the claim assigned to status indicator “J1” (or certain add-on codes) to determine if
there are paired code combinations that meet the complexity adjustment criteria. For a new HCPCS code, we determine initial C–APC assignment and qualification for a complexity adjustment using the best available information, crosswalking the new HCPCS code to a predecessor code(s) when appropriate.

Once we have determined that a particular code combination of “J1” services (or combinations of “J1” services reported in conjunction with certain add-on codes) represents a complex version of the primary service because it is sufficiently costly, frequent, and a subset of the primary comprehensive service overall according to the criteria described above, we promote the claim including the complex version of the primary service as described by the code combination to the next higher cost C–APC within the clinical family, unless the primary service is already assigned to the highest cost APC within the C–APC clinical family or assigned to the only C–APC in a clinical family. We do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C–APC in a clinical family just to accommodate potential complexity adjustments. Therefore, the highest payment for any claim including a code combination for services assigned to a C–APC would be the highest paying C–APC in the clinical family (79 FR 66802).

We package payment for all add-on codes into the payment for the C–APC. However, certain primary service add-on combinations may qualify for a complexity adjustment. As noted in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70331), all add-on codes that can be appropriately reported in combination with a base code that describes a primary “J1” service are evaluated for a complexity adjustment.

To determine which combinations of primary service codes reported in conjunction with an add-on code may qualify for a complexity adjustment for CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37061), we proposed to apply the frequency and cost criteria thresholds discussed above, testing claims reporting one unit of a single primary service assigned to status indicator “J1” and any number of units of a single add-on code for the primary “J1” service. If the frequency and cost criteria thresholds for a complexity adjustment are met and reassignment to the next higher cost APC in the clinical family is appropriate (based on meeting the criteria outlined above), we make a complexity adjustment for the code combination; that is, we reassign the primary service code reported in conjunction with the add-on code to the next higher cost C–APC within the same clinical family of C–APCs. As previously stated, we package payment for add-on codes into the C–APC payment rate. If any add-on code reported in conjunction with the “J1” primary service code does not qualify for a complexity adjustment, payment for the add-on service continues to be packaged into the payment for the primary service and is not reassigned to the next higher cost C–APC. We listed the complexity adjustments proposed for “J1” and add-on code combinations for CY 2019, along with all of the other proposed complexity adjustments, in Addendum J to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website).

Addendum J to the proposed rule included the cost statistics for each code combination that would qualify for a complexity adjustment (including primary code and add-on code combinations). Addendum J to the proposed rule also contained summary cost statistics for each of the paired code combinations that describe a complex code combination that would qualify for a complexity adjustment and were proposed to be reassigned to the next higher cost C–APC within the clinical family. The combined statistics for all proposed reassigned complex code combinations were represented by an alphanumeric code with the first 4 digits of the designated primary service followed by a letter. For example, the proposed geometric mean cost listed in Addendum J for the code combination described by complexity adjustment assignment 3320R, which is assigned to C–APC 5224 (Level 4 Pacemaker and Similar Procedures), includes all paired code combinations that were proposed to be reassigned to C–APC 5224 when CPT code 33208 is the primary code. Providing the information contained in Addendum J to the proposed rule allowed stakeholders the opportunity to better assess the impact associated with the proposed reassignment of claims with each of the paired code combinations eligible for a complexity adjustment.

Comment: Several commenters requested that CMS alter the C–APC eligibility criteria to allow additional code combinations to qualify for complexity adjustments. The commenters requested that CMS consider clusters of “J1” and add-on codes, rather than only code pairs, and also consider code combinations of “J1” codes and devices such as drug-coated balloons and drug-eluting stents. The commenters also requested that CMS eliminate the 25-claim frequency threshold. Another commenter requested that CMS consider patient complexity and procedures assigned to status indicator “S“ or “T” when evaluating procedures for a complexity adjustment. One commenter suggested that procedures initially eligible for a complexity adjustment by meeting the applicable requirements in a year maintain that complexity adjustment for a total period of 3 years, regardless of whether they continue to meet the criteria after the first year.

In terms of payment for complexity adjustments, one commenter requested that CMS promote the qualifying code combination to two APC levels higher than the originating APC rather than to the next higher paying C–APC. Another commenter suggested that CMS pay the geometric mean cost of the highest ranking procedure in the qualifying code combination at 100 percent, and then each secondary procedure at 50 percent of the geometric mean cost of the secondary procedure.

Other commenters also requested an explanation of how the geometric mean costs of the code combinations evaluated for complexity adjustments are calculated, stating that the geometric mean cost of certain code combinations represented in Addendum J were lower than the geometric mean costs of the primary service when the service is billed without an additional “J1” or “J1” add-on procedure. Commenters also requested that CMS establish complexity adjustments for the specific code combinations listed in Table 6 below.

BILLING CODE 4120–01–P
### TABLE 6.—C–APC COMPLEXITY ADJUSTMENTS REQUESTED BY COMMENTERS

<table>
<thead>
<tr>
<th>Primary “J1” HCPCS Code</th>
<th>Secondary “J1” or Add-on HCPCS Code</th>
<th>Primary APC Assignment</th>
<th>Requested Complexity Adjusted APC Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>22551 (Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2)</td>
<td>22552 (Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2, each additional interspace (list separately in addition to code for separate procedure))</td>
<td>5115</td>
<td>5116</td>
</tr>
<tr>
<td>28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method)</td>
<td>20900 (Bone graft, any donor area; minor or small (eg, dowel or button))</td>
<td>5114</td>
<td>5115</td>
</tr>
<tr>
<td>28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method)</td>
<td>28285 (Correction, hammertoe (eg, interphalangeal fusion, partial or total phalanectomy))</td>
<td>5114</td>
<td>5115</td>
</tr>
<tr>
<td>28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint)</td>
<td>20900 ((Bone graft, any donor area; minor or small (eg, dowel or button))</td>
<td>5114</td>
<td>5115</td>
</tr>
<tr>
<td>28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint)</td>
<td>28292 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with resection of proximal phalanx base, when performed, any method)</td>
<td>5114</td>
<td>5115</td>
</tr>
<tr>
<td>Primary “J1” HCPCS Code</td>
<td>Secondary “J1” or Add-on HCPCS Code</td>
<td>Primary APC Assignment</td>
<td>Requested Complexity Adjusted APC Assignment</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------------------------------------</td>
<td>------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint)</td>
<td>38220 (Diagnostic bone marrow; aspiration(s))</td>
<td>5114</td>
<td>5115</td>
</tr>
<tr>
<td>31276 (Nasal/sinus endoscopy, surgical, with frontal sinus exploration, including removal of tissue from frontal sinus, when performed)</td>
<td>31255 (Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior))</td>
<td>5155</td>
<td>N/A</td>
</tr>
<tr>
<td>31288 (Nasal/sinus endoscopy, surgical, with sphenoidotomy; with removal of tissue from the sphenoid sinus)</td>
<td>31255 (Nasal/sinus endoscopy, surgical with ethmoidectomy; total (anterior and posterior))</td>
<td>5155</td>
<td>N/A</td>
</tr>
<tr>
<td>31296 (Nasal/sinus endoscopy, surgical; with dilation of frontal sinus ostium (eg, balloon dilation)</td>
<td>31297 (Nasal/sinus endoscopy, surgical; with dilation of sphenoid sinus ostium (eg, balloon dilation)</td>
<td>5155</td>
<td>N/A</td>
</tr>
<tr>
<td>52214 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) of trigone, bladder neck, prostatic fossa, urethra, or periurethral glands)</td>
<td>C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure))</td>
<td>5373</td>
<td>5374</td>
</tr>
<tr>
<td>52234 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; small bladder tumor(s) (0.5 up to 2.0 cm))</td>
<td>C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure))</td>
<td>5374</td>
<td>5375</td>
</tr>
</tbody>
</table>
Response: We appreciate these comments. However, at this time, we do not believe changes to the C–APC complexity adjustment criteria are necessary or that we should make exceptions to the criteria to allow claims with the code combinations suggested by the commenters to receive complexity adjustments. As stated previously (81 FR 79582), we continue to believe that the complexity adjustment criteria, which require a frequency of 25 or more claims reporting a code combination and a violation of the 2 times rule in the originating C–APC within the clinical family, are adequate to determine if a combination of procedures represents a complex, costly subset of the primary service. If a code combination meets these criteria, the combination receives payment at the next higher cost C–APC within the clinical family, and the geometric mean costs attributed to the primary procedure could be skewed.

With regard to the specific complexity adjustments requested by commenters listed in Table 6 above, we note that we did not propose that claims with these code combinations would receive complexity adjustments because they did not meet the cost and frequency criteria for the adjustment. Therefore, we do not believe it is appropriate to change the complexity adjustment criteria at this time, and because the suggested code combinations do not meet the existing criteria, we do not believe it is appropriate to establish complexity adjustments for these code combinations at this time.

Regarding the request for a code combination that qualified for a complexity adjustment in a year to continue to qualify for the adjustment for the next 2 years for a total period of 3 years, we note that we evaluate code combinations each year against our complexity adjustment criteria using the latest available data. At this time, we do not believe it is necessary to expand the ability for code combinations to meet the complexity adjustment criteria at this time, and because the suggested code combinations do not meet the existing criteria, we do not believe it is appropriate to establish complexity adjustments for these code combinations at this time.

The complexity adjustment cost threshold compares the code combinations to the lowest cost-significant procedure assigned to the APC. If the cost of the code combination does not exceed twice the cost of the lowest cost-significant procedure within the APC, no complexity adjustment is made. Lowering or eliminating this threshold could remove so many claims from the accounting for the primary “J1” service that the geometric mean costs attributed to the primary procedure could be skewed.

With regard to the specific complexity adjustments requested by commenters listed in Table 6 above, we note that we did not propose that claims with these code combinations would receive complexity adjustments because they did not meet the cost and frequency criteria for the adjustment. Therefore, we do not believe it is appropriate to change the complexity adjustment criteria at this time, and because the suggested code combinations do not meet the existing criteria, we do not believe it is appropriate to establish complexity adjustments for these code combinations at this time.

Regarding the request for a code combination that qualified for a complexity adjustment in a year to continue to qualify for the adjustment for the next 2 years for a total period of 3 years, we note that we evaluate code combinations each year against our complexity adjustment criteria using the latest available data. At this time, we do not believe it is necessary to expand the ability for code combinations to meet the complexity adjustment criteria in this manner because we believe that the existing criteria that were already established sufficiently reflect those combinations of procedures that are commonly billed together and are costly enough to merit a complexity adjustment. Further, we believe that code combinations should be evaluated each year to determine if they meet the criteria based on the latest hospital billing and utilization data. We also do not believe that it is necessary to provide payment for claims including qualifying code combinations at two APC levels higher than the originating APC or for CMS to pay based on the geometric mean cost of the highest ranking procedure in the qualifying code combination at 100 percent, and then each secondary procedure based on 50 percent of the geometric mean cost of the secondary procedure. We believe that payment at the next higher paying C–APC is adequate for code combinations that exhibit materially greater resource requirements than the primary service and that, in many cases, paying the rate assigned to two levels higher may lead to a significant overpayment. As mentioned previously, we do not create new APCs with a comprehensive geometric mean cost that is higher than the highest geometric mean cost (or only) C–APC in a clinical family just to accommodate potential complexity adjustments. The highest payment for any claim including a code combination for services assigned to a C–APC would be the highest paying C–APC in the clinical family (79 FR 66802). Therefore, a policy to pay for claims with qualifying code combinations at two C–APC levels higher than the originating APC is not always feasible. Likewise, while paying 100 percent of the highest ranking procedure and paying 50 percent of the

<table>
<thead>
<tr>
<th>Primary “J1” HCPCS Code</th>
<th>Secondary “J1” or Add-on HCPCS Code</th>
<th>Primary APC Assignment</th>
<th>Requested Complexity Adjusted APC Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>52235 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; medium bladder tumor(s) (2.0 to 5.0 cm))</td>
<td>C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure))</td>
<td>5374</td>
<td>5375</td>
</tr>
<tr>
<td>52240 (Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; large bladder tumor(s))</td>
<td>C9738 (Adjunctive blue light cystoscopy with fluorescent imaging agent (list separately in addition to code for primary procedure))</td>
<td>5375</td>
<td>5376</td>
</tr>
</tbody>
</table>
proposed to add three C–APCs under the existing C–APC payment policy beginning in CY 2019: Proposed C–APC 5163 (Level 3 ENT Procedures); proposed C–APC 5183 (Level 3 Vascular Procedures); and proposed C–APC 5184 (Level 4 Vascular Procedures). These APCs were selected to be included in this proposal because, similar to other C–APCs, these APCs include primary, comprehensive services, such as major surgical procedures, that are typically reported with other ancillary and adhesive services. Also, similar to other APCs that have been converted to C–APCs, there are higher APC levels within the clinical family or related clinical family of these APCs that have previously been assigned to a C–APC.

Table 3 of the proposed rule listed the proposed C–APCs for CY 2019. All C–APCs were displayed in Addendum J to the proposed rule (which is available via the internet on the CMS website). Addendum J to the proposed rule also contained all of the data related to the C–APC payment policy methodology, including the list of proposed complexity adjustments and other information.

Comment: Several commenters supported the proposals. Other commenters, including device manufacturer associations, expressed ongoing concerns that the C–APC payment rates may not adequately reflect the costs associated with the services and requested that CMS not establish any additional C–APCs. These commenters also requested that CMS provide an analysis of the impact of the C–APC policy on affected procedures.

Response: We appreciate the commenters’ responses. We continue to believe that the proposed C–APCs for CY 2019 are appropriate to be added to the existing C–APC payment policy. We also note that, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59246), we conducted an analysis of the effects of the C–APC policy. The analysis looked at data from CY 2016 OPPS/ASC final rule with comment period, the CY 2017 OPPS/ASC final rule with comment period, and the CY 2018 OPPS/ASC proposed rule, which involved claims data from CY 2014 (before C–APCs became effective) to CY 2016. We looked at separately payable codes that were then assigned to C–APCs and, overall, we observed an increase in claim line frequency, units billed, and Medicare payment for those procedures, which suggest that the C–APC payment policy did not adversely affect access to care or reduce payments to hospitals.

Comment: Several commenters requested that CMS discontinue the C–APC payment policy for several brachytherapy insertion procedures and single session stereotactic radiosurgery procedures, stating concerns that the C–APC methodology does not account for the complexity of delivering radiation therapy and fails to capture appropriately coded claims. The commenters also requested that CMS continue to make separate payments for the 10 planning and preparation codes related to stereotactic radiosurgery (SRS) and include the HCPCS code for IMRT planning (77301) on the list of planning and preparation codes, stating that the service has become more common in single fraction radiosurgery treatment planning.

Response: At this time, we do not believe that it is necessary to discontinue the C–APCs that include brachytherapy insertion procedures and single session SRS procedures. We continue to believe that the C–APC policy is appropriately applied to these surgical procedures for the reasons cited when this policy was first adopted and note that the commenters did not provide any empirical evidence to support their claims that the existing C–APC policy does not adequately pay for these procedures. Also, we will continue in CY 2019 to pay separately for the 10 planning and preparation services (HCPCS codes 70551, 70552, 70553, 77011, 77014, 77280, 77285, 77290, 77295, and 77336) adjacent to the delivery of the SRS treatment using either the Cobalt-60-based or LINAC based technology when furnished to a beneficiary within 3 months of the SRT service for CY 2019 (82 FR 59242 and 59243).

Comment: Several commenters representing stem cell transplant organizations requested that CMS also establish a new C–APC for autologous stem cell transplants for CY 2019. These commenters stated that the C–APC methodology will allow CMS to better capture the costs of additional services, such as laboratory tests, provided with the autologous transplant. The Advisory Panel on Hospital Outpatient Payment (HOP Panel) also recommended that CMS study the appropriateness of creating a comprehensive APC for autologous hematopoietic stem cell transplantation.

Response: We appreciate these comments and may consider the creation of a C–APC for autologous stem cell transplants for future rulemaking as recommended by the HOP Panel. 

Comment: Two manufacturers of drugs used in ocular procedures requested that CMS discontinue the C–APC payment policy for existing C–APCs that include procedures involving
their drugs and instead provide separate payment for the drugs. The manufacturer commenters, as well as several physicians, believed that the C–APC packaging policy, which packages payment for certain drugs that are adjunctive to the primary service, results in underpayment for the drugs.

Response: We continue to believe that the procedures assigned to the proposed C–APCs, including the procedures involving the drugs used in ocular procedures mentioned by the commenters, are appropriately paid through a comprehensive APC and the costs of drugs (as well as other items or services furnished with the procedures) are reflected in hospital billing, and therefore the rates that are established for the ocular procedures. As stated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79584), procedures assigned to C–APCs are primary services (mostly major surgical procedures) that are typically the focus of the hospital outpatient stay. In addition, with regard to the packaging of the drugs based on the C–APC policy, as stated in previous rules (78 FR 74868 through 74869 and 74909 and 79 FR 66800), items included in the packaged payment provided with the primary “J1” service include all drugs, biologicals, and radiopharmaceuticals payable under the OPPS, regardless of cost, except those drugs with pass-through payment status.

After consideration of the public comments we received, we are finalizing the proposed C–APCs for CY 2019. Table 7 below lists the final C–APCs for CY 2019. All C–APCs are displayed in Addendum J to this final rule with comment period (which is available via the internet on the CMS website). Addendum J to this final rule with comment period also contains all of the data related to the C–APC payment policy methodology, including the list of complexity adjustments and other information for CY 2019.

BILLING CODE 4120–01–P
TABLE 7.—CY 2019 C-APCs

<table>
<thead>
<tr>
<th>C-APC</th>
<th>CY 2019 APC Group Title</th>
<th>Clinical Family</th>
<th>New C-APC</th>
</tr>
</thead>
<tbody>
<tr>
<td>5072</td>
<td>Level 2 Excision/Biopsy/Incision and Drainage</td>
<td>EBIDX</td>
<td></td>
</tr>
<tr>
<td>5073</td>
<td>Level 3 Excision/Biopsy/Incision and Drainage</td>
<td>EBIDX</td>
<td></td>
</tr>
<tr>
<td>5091</td>
<td>Level 1 Breast/Lymphatic Surgery and Related Procedures</td>
<td>BREAS</td>
<td></td>
</tr>
<tr>
<td>5092</td>
<td>Level 2 Breast/Lymphatic Surgery and Related Procedures</td>
<td>BREAS</td>
<td></td>
</tr>
<tr>
<td>5093</td>
<td>Level 3 Breast/Lymphatic Surgery and Related Procedures</td>
<td>BREAS</td>
<td></td>
</tr>
<tr>
<td>5094</td>
<td>Level 4 Breast/Lymphatic Surgery and Related Procedures</td>
<td>BREAS</td>
<td></td>
</tr>
<tr>
<td>5112</td>
<td>Level 2 Musculoskeletal Procedures</td>
<td>ORTHO</td>
<td></td>
</tr>
<tr>
<td>5113</td>
<td>Level 3 Musculoskeletal Procedures</td>
<td>ORTHO</td>
<td></td>
</tr>
<tr>
<td>5114</td>
<td>Level 4 Musculoskeletal Procedures</td>
<td>ORTHO</td>
<td></td>
</tr>
<tr>
<td>5115</td>
<td>Level 5 Musculoskeletal Procedures</td>
<td>ORTHO</td>
<td></td>
</tr>
<tr>
<td>5116</td>
<td>Level 6 Musculoskeletal Procedures</td>
<td>ORTHO</td>
<td></td>
</tr>
<tr>
<td>5153</td>
<td>Level 3 Airway Endoscopy</td>
<td>AENDO</td>
<td></td>
</tr>
<tr>
<td>5154</td>
<td>Level 4 Airway Endoscopy</td>
<td>AENDO</td>
<td></td>
</tr>
<tr>
<td>5155</td>
<td>Level 5 Airway Endoscopy</td>
<td>AENDO</td>
<td></td>
</tr>
<tr>
<td>5163</td>
<td>Level 3 ENT Procedures</td>
<td>ENTXX</td>
<td></td>
</tr>
<tr>
<td>5164</td>
<td>Level 4 ENT Procedures</td>
<td>ENTXX</td>
<td></td>
</tr>
<tr>
<td>5165</td>
<td>Level 5 ENT Procedures</td>
<td>ENTXX</td>
<td></td>
</tr>
<tr>
<td>5166</td>
<td>Cochlear Implant Procedure</td>
<td>COCHL</td>
<td></td>
</tr>
<tr>
<td>5183</td>
<td>Level 3 Vascular Procedures</td>
<td>VASCX</td>
<td></td>
</tr>
<tr>
<td>5184</td>
<td>Level 4 Vascular Procedures</td>
<td>VASCX</td>
<td></td>
</tr>
<tr>
<td>5191</td>
<td>Level 1 Endovascular Procedures</td>
<td>EVASC</td>
<td></td>
</tr>
<tr>
<td>5192</td>
<td>Level 2 Endovascular Procedures</td>
<td>EVASC</td>
<td></td>
</tr>
<tr>
<td>5193</td>
<td>Level 3 Endovascular Procedures</td>
<td>EVASC</td>
<td></td>
</tr>
<tr>
<td>5194</td>
<td>Level 4 Endovascular Procedures</td>
<td>EVASC</td>
<td></td>
</tr>
<tr>
<td>5200</td>
<td>Implantation Wireless PA Pressure Monitor</td>
<td>WPMXX</td>
<td></td>
</tr>
<tr>
<td>5211</td>
<td>Level 1 Electrophysiologic Procedures</td>
<td>EPHYS</td>
<td></td>
</tr>
<tr>
<td>5212</td>
<td>Level 2 Electrophysiologic Procedures</td>
<td>EPHYS</td>
<td></td>
</tr>
<tr>
<td>5213</td>
<td>Level 3 Electrophysiologic Procedures</td>
<td>EPHYS</td>
<td></td>
</tr>
<tr>
<td>5222</td>
<td>Level 2 Pacemaker and Similar Procedures</td>
<td>AICDP</td>
<td></td>
</tr>
<tr>
<td>5223</td>
<td>Level 3 Pacemaker and Similar Procedures</td>
<td>AICDP</td>
<td></td>
</tr>
<tr>
<td>5224</td>
<td>Level 4 Pacemaker and Similar Procedures</td>
<td>AICDP</td>
<td></td>
</tr>
<tr>
<td>5231</td>
<td>Level 1 ICD and Similar Procedures</td>
<td>AICDP</td>
<td></td>
</tr>
<tr>
<td>C-APC</td>
<td>CY 2019 APC Group Title</td>
<td>Clinical Family</td>
<td>New C-APC</td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------</td>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>5232</td>
<td>Level 2 ICD and Similar Procedures</td>
<td>AICDP</td>
<td></td>
</tr>
<tr>
<td>5244</td>
<td>Level 4 Blood Product Exchange and Related Services</td>
<td>SCTXX</td>
<td></td>
</tr>
<tr>
<td>5302</td>
<td>Level 2 Upper GI Procedures</td>
<td>GIXXX</td>
<td></td>
</tr>
<tr>
<td>5303</td>
<td>Level 3 Upper GI Procedures</td>
<td>GIXXX</td>
<td></td>
</tr>
<tr>
<td>5313</td>
<td>Level 3 Lower GI Procedures</td>
<td>GIXXX</td>
<td></td>
</tr>
<tr>
<td>5331</td>
<td>Complex GI Procedures</td>
<td>GIXXX</td>
<td></td>
</tr>
<tr>
<td>5341</td>
<td>Abdominal/Peritoneal/Biliary and Related Procedures</td>
<td>GIXXX</td>
<td></td>
</tr>
<tr>
<td>5361</td>
<td>Level 1 Laparoscopy and Related Services</td>
<td>LAPXX</td>
<td></td>
</tr>
<tr>
<td>5362</td>
<td>Level 2 Laparoscopy and Related Services</td>
<td>LAPXX</td>
<td></td>
</tr>
<tr>
<td>5373</td>
<td>Level 3 Urology and Related Services</td>
<td>UROXX</td>
<td></td>
</tr>
<tr>
<td>5374</td>
<td>Level 4 Urology and Related Services</td>
<td>UROXX</td>
<td></td>
</tr>
<tr>
<td>5375</td>
<td>Level 5 Urology and Related Services</td>
<td>UROXX</td>
<td></td>
</tr>
<tr>
<td>5376</td>
<td>Level 6 Urology and Related Services</td>
<td>UROXX</td>
<td></td>
</tr>
<tr>
<td>5377</td>
<td>Level 7 Urology and Related Services</td>
<td>UROXX</td>
<td></td>
</tr>
<tr>
<td>5382</td>
<td>Level 2 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5383</td>
<td>Level 3 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5384</td>
<td>Level 4 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5385</td>
<td>Level 5 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5386</td>
<td>Level 6 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5387</td>
<td>Level 7 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5414</td>
<td>Level 4 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5415</td>
<td>Level 5 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5416</td>
<td>Level 6 Gynecologic Procedures</td>
<td>GYNXX</td>
<td></td>
</tr>
<tr>
<td>5431</td>
<td>Level 1 Nerve Procedures</td>
<td>NERVE</td>
<td></td>
</tr>
<tr>
<td>5432</td>
<td>Level 2 Nerve Procedures</td>
<td>NERVE</td>
<td></td>
</tr>
<tr>
<td>5462</td>
<td>Level 2 Neurostimulator and Related Procedures</td>
<td>NSTIM</td>
<td></td>
</tr>
<tr>
<td>5463</td>
<td>Level 3 Neurostimulator and Related Procedures</td>
<td>NSTIM</td>
<td></td>
</tr>
<tr>
<td>5464</td>
<td>Level 4 Neurostimulator and Related Procedures</td>
<td>NSTIM</td>
<td></td>
</tr>
<tr>
<td>5471</td>
<td>Implantation of Drug Infusion Device</td>
<td>PUMPS</td>
<td></td>
</tr>
<tr>
<td>5491</td>
<td>Level 1 Intraocular Procedures</td>
<td>INEYE</td>
<td></td>
</tr>
<tr>
<td>5492</td>
<td>Level 2 Intraocular Procedures</td>
<td>INEYE</td>
<td></td>
</tr>
<tr>
<td>5493</td>
<td>Level 3 Intraocular Procedures</td>
<td>INEYE</td>
<td></td>
</tr>
<tr>
<td>5494</td>
<td>Level 4 Intraocular Procedures</td>
<td>INEYE</td>
<td></td>
</tr>
<tr>
<td>5495</td>
<td>Level 5 Intraocular Procedures</td>
<td>INEYE</td>
<td></td>
</tr>
<tr>
<td>5503</td>
<td>Level 3 Extraocular, Repair, and Plastic Eye Procedures</td>
<td>EXEYE</td>
<td></td>
</tr>
<tr>
<td>5504</td>
<td>Level 4 Extraocular, Repair, and Plastic Eye Procedures</td>
<td>EXEYE</td>
<td></td>
</tr>
<tr>
<td>5627</td>
<td>Level 7 Radiation Therapy</td>
<td>RADTX</td>
<td></td>
</tr>
<tr>
<td>5881</td>
<td>Ancillary Outpatient Services When Patient Dies</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>8011</td>
<td>Comprehensive Observation Services</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>

**C-APC Clinical Family Descriptor Key:**

AENDO = Airway Endoscopy
AICDP = Automatic Implantable Cardiac Defibrillators, Pacemakers, and Related Devices.
BREAS = Breast Surgery  
COCHL = Cochlear Implant  
EBIDX = Excision/ Biopsy/Incision and Drainage  
ENTXX = ENT Procedures  
EPHYS = Cardiac Electrophysiology  
EVASC = Endovascular Procedures  
EXEYE = Extraocular Ophthalmic Surgery  
GIXXX = Gastrointestinal Procedures  
GYNXX = Gynecologic Procedures  
INEYE = Intraocular Surgery  
LAPXX = Laparoscopic Procedures  
NERVE = Nerve Procedures  
NSTM = Neurostimulators  
ORTHO = Orthopedic Surgery  
PUMPS = Implantable Drug Delivery Systems  
RADTX = Radiation Oncology  
SCTXX = Stem Cell Transplant  
UROXX = Urologic Procedures  
VASCX = Vascular Procedures  
WPMXX = Wireless PA Pressure Monitor  

BILLING CODE 4120–01–C

(3) Exclusion of Procedures Assigned to New Technology APCs From the C–APC Policy

Services that are assigned to New Technology APCs are typically new procedures that do not have sufficient claims history to establish an accurate payment for the procedures. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected (82 FR 59277).

The C–APC payment policy packages payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level. When a procedure assigned to a New Technology APC is included on the claim with a primary procedure, identified by OPPS status indicator “J1”, payment for the new technology service is typically packaged into the payment for the primary procedure. Because the new technology service is not separately paid in this scenario, the overall number of single claims available to determine an appropriate clinical APC for the new service is reduced. This is contrary to the objective of the New Technology APC payment policy, which is to gather sufficient claims data to enable us to assign the service to an appropriate clinical APC.

For example, for CY 2017, there were seven claims generated for HCPCS code 0100T (Placement of a subconjunctival retinal prostheses receiver and pulse generator, and implantation of an intraocular retinal electrode array, with vitrectomy), which involves the use of the Argus II Retinal Prosthesis System. However, several of these claims were not available for ratesetting because HCPCS code 0100T was reported with a “J1” procedure and, therefore, payment was packaged into the associated C–APC payment. If these services had been separately paid under the OPPS, there would be at least two additional single claims available for ratesetting.

As mentioned previously, the purpose of the new technology APC policy is to ensure that there are sufficient claims data for new services, which is particularly important for services with a low volume such as procedures described by HCPCS code 0100T. Another concern is the costs reported for the claims when payment is not packaged for a new technology procedure may not be representative of all of the services included on a claim that is generated, which may also affect our ability to assign the new service to the most appropriate clinical APC.

To address this issue and help ensure that there is sufficient claims data for services assigned to New Technology APCs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37063), we proposed to exclude payment for any procedure that is assigned to a New Technology APC (APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged when included on a claim with a “J1” service assigned to a C–APC. This issue is also addressed in section III.C.3.b. of the proposed rule and this final rule with comment period.

Comment: Numerous commenters supported the proposal.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing the proposal, without modification, to exclude payment for any procedure that is assigned to a New Technology APC (APCs 1491 through 1599 and APCs 1901 through 1908) from being packaged when included on a claim with a “J1” service assigned to a C–APC.

c. Calculation of Composite APC Criteria-Based Costs

As discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66613), we believe it is important that the OPPS enhance incentives for hospitals to provide necessary, high quality care as efficiently as possible. For CY 2008, we developed composite APCs to provide a single payment for groups of services that are typically performed together during a single clinical encounter and that result in the provision of a complete service. Combining payment for multiple, independent services into a single OPPS payment in this way enables hospitals to manage their resources with maximum flexibility by monitoring and adjusting the volume and efficiency of services themselves. An additional advantage to the composite APC model is that we can use data from correctly coded multiple procedure claims to...
calculate payment rates for the specified combinations of services, rather than relying upon single procedure claims which may be low in volume and/or incorrectly coded. Under the OPPS, we currently have composite policies for mental health services and multiple imaging services. (We note that, in the CY 2018 OPPS/ASC final rule with comment period, we finalized a policy to delete the composite APC 8001 (LDR Prostate Brachytherapy Composite) for CY 2018 and subsequent years.) We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 through 66614 and 66650 through 66652) for a full discussion of the development of the composite APC methodology, and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74163) and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59241 through 59244 and 59246 through 52950) for more recent background.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), for CY 2019 and subsequent years, we proposed to continue our composite APC payment policies for mental health services and multiple imaging services, as discussed below. In addition, as discussed in section II.A.2.b.(3) and II.A.2.c. of the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33577 through 33578 and 59241 through 59242 and 59246, respectively), in the CY 2019 proposed rule, we proposed to continue to assign CPT code 55875 (Transperineal placement of needles or catheters into prostate for interstitial radiotherapy application, with or without cystoscopy) to status indicator “J1” and to continue to assign the services described by CPT code 55875 to C–APC 5375 (Level 5 Urology and Related Services) for CY 2019. We did not receive any public comments on these proposed assignments. Therefore, for CY 2019, we are continuing to assign CPT code 55875 to status indicator “J1” and to assign services described by CPT code 55875 to C–APC 5375.

(1) Mental Health Services Composite APC

In the CY 2019 OPPS/ASC proposed rule (83 FR 37064), we proposed to continue our longstanding policy of limiting the aggregate payment for specified less resource-intensive mental health services furnished on the same date to the payment for a day of partial hospitalization services provided by a hospital, which we consider to be the most resource intensive of all outpatient mental health services. We refer readers to the April 7, 2000 OPPS final rule with comment period (65 FR 18452 through 18455) for the initial discussion of this longstanding policy and the CY 2012 OPPS/ASC final rule with comment period (76 FR 74168) for more recent background.

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79588 through 79589), we finalized a policy to combine the existing Level 1 and Level 2 hospital-based PHP APCs into a single hospital-based PHP APC, and thereby discontinue APCs 5861 (Level 1 Partial Hospitalization (3 services) for Hospital-Based PHPs) and 5862 (Level 2 Partial Hospitalization (4 or more services) for Hospital-Based PHPs) and replace them with APC 5863 (Partial Hospitalization (3 or more services per day)).

In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33580 through 33581 and 59246 through 59247, respectively), we proposed and finalized the policy for CY 2018 and subsequent years that, when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services will be paid through composite APC 8010 (Mental Health Services Composite). In addition, we set the payment rate for composite APC 8010 for CY 2018 at the same payment rate that will be paid for APC 5863, which is the maximum per diem payment rate for a hospital, and finalized a policy that the hospital will continue to be paid the payment rate for composite APC 8010.

Comment: One commenter supported equalizing payments between the outpatient APC rate and the PHP per diem rate. The commenter also supported the increase in the proposed CY 2019 payment rates from the CY 2018 payment rates.

Response: We appreciate the commenter’s support.

After consideration of the public comment we received, we are finalizing our CY 2019 proposal, without modification, that when the aggregate payment for specified mental health services provided by one hospital to a single beneficiary on a single date of service, based on the payment rates associated with the APCs for the individual services, exceeds the maximum per diem payment rate for partial hospitalization services provided by a hospital, those specified mental health services will be paid through composite APC 8010 for CY 2019. In addition, we are finalizing our CY 2019 proposal, without modification, to set the payment rate for composite APC 8010 at the same payment rate as APC 5863, which is the maximum partial hospitalization per diem payment rate for a hospital, and that the hospital continue to be paid the proposed payment rate for composite APC 8010.

(2) Multiple Imaging Composite APCs

Among the most resource intensive of all outpatient services is the related services to diagnostic imaging procedures performed for a hospital, those specified mental health services would be paid through composite APC 8010 for CY 2019. In addition, we proposed to set the proposed payment rate for composite APC 8010 at the same payment rate that we proposed for APC 5863, which is the maximum partial hospitalization per diem payment rate for a hospital, and that the hospital continue to be paid the proposed payment rate for composite APC 8010.

Effective January 1, 2009, we provide a single payment each time a hospital submits a claim for more than one imaging procedure within an imaging family on the same date of service, in order to reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session (73 FR 41448 through 41450). We utilize three imaging families based on imaging modality for purposes of this methodology: (1) Ultrasound; (2) computed tomographic angiography (CTA); and (3) magnetic resonance imaging.
imaging (MRI) and magnetic resonance angiography (MRA). The HCPCS codes subject to the multiple imaging composite policy and their respective families are listed in Table 12 of the CY 2014 OPPS/ASC final rule with comment period (78 FR 74920 through 74924).

While there are three imaging families, there are five multiple imaging composite APCs due to the statutory requirement under section 1833(t)(2)(G) of the Act that we differentiate payment for OPPS imaging services provided with and without contrast. While the ultrasound procedures included under the policy do not involve contrast, both CT/CTA and MRI/MRA scans can be provided with or without contrast. The five multiple imaging composite APCs established in CY 2009 are:

- APC 8004 (Ultrasound Composite);
- APC 8005 (CT and CTA without Contrast Composite);
- APC 8006 (CT and CTA with Contrast Composite);
- APC 8007 (MRI and MRA without Contrast Composite); and
- APC 8008 (MRI and MRA with Contrast Composite).

We define the single imaging session for the “with contrast” composite APCs as having at least one or more imaging procedures from the same family performed with contrast on the same date of service. For example, if the hospital performs an MRI without contrast during the same session as at least one other MRI with contrast, the hospital will receive payment based on the payment rate for APC 8008, the “with contrast” composite APC.

We make a single payment for those imaging procedures that qualify for payment based on the composite APC payment rate, which includes any packaged services furnished on the same date of service. The standard (noncomposite) APC assignments continue to apply for single imaging procedures and multiple imaging procedures performed across families. For a full discussion of the development of the multiple imaging composite APC methodology, we refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68559 through 68569).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we proposed, for CY 2019 and subsequent years, to continue to pay for all multiple imaging procedures within an imaging family performed on the same date of service using the multiple imaging composite APC payment methodology. We stated that we continue to believe that this policy would reflect and promote the efficiencies hospitals can achieve when performing multiple imaging procedures during a single session.

The proposed CY 2019 payment rates for the five multiple imaging composite APCs (APCs 8004, 8005, 8006, 8007, and 8008) were based on proposed geometric mean costs calculated from a partial year of CY 2017 claims available for the CY 2019 OPPS/ASC proposed rule that qualified for composite payment under the current policy (that is, those claims reporting more than one procedure within the same family on a single date of service). To calculate the proposed geometric mean costs, we used the same methodology that we have used to calculate the geometric mean costs for these composite APCs since CY 2014, as described in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918). The imaging HCPCS codes referred to as “overlap bypass codes” that we removed from the bypass list for purposes of calculating the proposed multiple imaging composite APC geometric mean costs, in accordance with our established methodology as stated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74918), were identified by asterisks in Addendum N to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website) and were discussed in more detail in section II.A.1.b. of the CY 2019 OPPS/ASC proposed rule.

For the CY 2019 OPPS/ASC proposed rule, we were able to identify approximately 638,902 “single session” claims out of an estimated 1.7 million potential claims for payment through composite APCs from our ratesetting claims data, which represents approximately 37 percent of all eligible claims, to calculate the proposed CY 2019 geometric mean costs for the multiple imaging composite APCs. Table 4 of the CY 2019 OPPS/ASC proposed rule listed the proposed HCPCS codes that would be subject to the multiple imaging composite APC policy and their respective families and approximate composite APC proposed geometric mean costs for CY 2019.

We did not receive any public comments on these proposals. However, in the CY 2019 OPPS/ASC proposed rule (83 FR 37065), we inadvertently omitted the new CPT codes that will be effective January 1, 2019 from Table 4. We did include these codes in Addendum M to the proposed rule (which was available via the internet on the CMS website). Therefore, new Category I CPT codes that will be effective January 1, 2019 are flagged with comment indicator “NI” in Addendum M to this CY 2019 OPPS/ASC final rule with comment period to indicate that we have assigned the codes an interim APC assignment for CY 2019. We are inviting public comments in this CY 2019 OPPS/ASC final rule with comment period on the interim APC assignments and payment rates for the new codes in Addendum M that will be finalized in the CY 2020 OPPS/ASC final rule with comment period.

Table 8 below lists the HCPCS codes that will be subject to the multiple imaging composite APC policy and their respective families and approximate composite APC final geometric mean costs for CY 2019.
## TABLE 8.—OPPS IMAGING FAMILIES AND MULTIPLE IMAGING PROCEDURE COMPOSITE APCs

<table>
<thead>
<tr>
<th>Family 1 – Ultrasound</th>
<th>CY 2019 APC 8004 (Ultrasound Composite)</th>
<th>CY 2019 Approximate APC Geometric Mean Cost = $302</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>76700</td>
<td>Us exam, abdom, complete</td>
</tr>
<tr>
<td></td>
<td>76705</td>
<td>Echo exam of abdomen</td>
</tr>
<tr>
<td></td>
<td>76770</td>
<td>Us exam abdo back wall, comp</td>
</tr>
<tr>
<td></td>
<td>76776</td>
<td>Us exam k transpl w/Doppler</td>
</tr>
<tr>
<td></td>
<td>76831</td>
<td>Echo exam, uterus</td>
</tr>
<tr>
<td></td>
<td>76856</td>
<td>Us exam, pelvic, complete</td>
</tr>
<tr>
<td></td>
<td>76857</td>
<td>Us exam, pelvic, limited</td>
</tr>
<tr>
<td></td>
<td>76981</td>
<td>Us parenchyma</td>
</tr>
<tr>
<td></td>
<td>76982</td>
<td>Use 1st target lesion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Family 2 - CT and CTA with and without Contrast</th>
<th>CY 2019 APC 8005 (CT and CTA without Contrast Composite)*</th>
<th>CY 2019 Approximate APC Geometric Mean Cost = $267</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>70450</td>
<td>Ct head/brain w/o dye</td>
</tr>
<tr>
<td></td>
<td>70480</td>
<td>Ct orbit/ear/fossa w/o dye</td>
</tr>
<tr>
<td></td>
<td>70486</td>
<td>Ct maxillofacial w/o dye</td>
</tr>
<tr>
<td></td>
<td>70490</td>
<td>Ct soft tissue neck w/o dye</td>
</tr>
<tr>
<td></td>
<td>71250</td>
<td>Ct thorax w/o dye</td>
</tr>
<tr>
<td></td>
<td>72125</td>
<td>Ct neck spine w/o dye</td>
</tr>
<tr>
<td></td>
<td>72128</td>
<td>Ct chest spine w/o dye</td>
</tr>
<tr>
<td></td>
<td>72131</td>
<td>Ct lumbar spine w/o dye</td>
</tr>
<tr>
<td></td>
<td>72192</td>
<td>Ct pelvis w/o dye</td>
</tr>
<tr>
<td></td>
<td>73200</td>
<td>Ct upper extremity w/o dye</td>
</tr>
<tr>
<td></td>
<td>73700</td>
<td>Ct lower extremity w/o dye</td>
</tr>
<tr>
<td></td>
<td>74150</td>
<td>Ct abdomen w/o dye</td>
</tr>
<tr>
<td></td>
<td>74261</td>
<td>Ct colonography, w/o dye</td>
</tr>
<tr>
<td></td>
<td>74176</td>
<td>Ct angio abd &amp; pelvis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CY 2019 APC 8006 (CT and CTA with Contrast Composite)</th>
<th>CY 2019 Approximate APC Geometric Mean Cost = $485</th>
</tr>
</thead>
<tbody>
<tr>
<td>70487</td>
<td>Ct maxillofacial w/dye</td>
</tr>
<tr>
<td>70460</td>
<td>Ct head/brain w/dye</td>
</tr>
<tr>
<td>70470</td>
<td>Ct head/brain w/o &amp; w/dye</td>
</tr>
<tr>
<td>70481</td>
<td>Ct orbit/ear/fossa w/dye</td>
</tr>
<tr>
<td>70482</td>
<td>Ct orbit/ear/fossa w/o &amp; w/dye</td>
</tr>
<tr>
<td>Procedure Code</td>
<td>Description</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>70488</td>
<td>Ct maxillofacial w/o &amp; w/dye</td>
</tr>
<tr>
<td>70491</td>
<td>Ct soft tissue neck w/dye</td>
</tr>
<tr>
<td>70492</td>
<td>Ct soft tissue neck w/o &amp; w/dye</td>
</tr>
<tr>
<td>70496</td>
<td>Ct angiography, head</td>
</tr>
<tr>
<td>70498</td>
<td>Ct angiography, neck</td>
</tr>
<tr>
<td>71260</td>
<td>Ct thorax w/dye</td>
</tr>
<tr>
<td>71270</td>
<td>Ct thorax w/o &amp; w/dye</td>
</tr>
<tr>
<td>71275</td>
<td>Ct angiography, chest</td>
</tr>
<tr>
<td>72126</td>
<td>Ct neck spine w/dye</td>
</tr>
<tr>
<td>72127</td>
<td>Ct neck spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72129</td>
<td>Ct chest spine w/dye</td>
</tr>
<tr>
<td>72130</td>
<td>Ct chest spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72132</td>
<td>Ct lumbar spine w/dye</td>
</tr>
<tr>
<td>72133</td>
<td>Ct lumbar spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72191</td>
<td>Ct angiography pelv w/o &amp; w/dye</td>
</tr>
<tr>
<td>72193</td>
<td>Ct pelvis w/dye</td>
</tr>
<tr>
<td>72194</td>
<td>Ct pelvis w/o &amp; w/dye</td>
</tr>
<tr>
<td>73201</td>
<td>Ct upper extremity w/dye</td>
</tr>
<tr>
<td>73202</td>
<td>Ct upper extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>73206</td>
<td>Ct angiography upper extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>73701</td>
<td>Ct lower extremity w/dye</td>
</tr>
<tr>
<td>73702</td>
<td>Ct lower extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>73706</td>
<td>Ct angiography lower extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>74160</td>
<td>Ct abdomen w/dye</td>
</tr>
<tr>
<td>74170</td>
<td>Ct abdomen w/o &amp; w/dye</td>
</tr>
<tr>
<td>74175</td>
<td>Ct angiography abdomen w/o &amp; w/dye</td>
</tr>
<tr>
<td>74262</td>
<td>Ct colonography, w/dye</td>
</tr>
<tr>
<td>75635</td>
<td>Ct angiography abdominal arteries</td>
</tr>
<tr>
<td>74177</td>
<td>Ct angiography abdomen &amp; pelvis w/contrast</td>
</tr>
<tr>
<td>74178</td>
<td>Ct angiography abdomen &amp; pelvis 1+ regions</td>
</tr>
</tbody>
</table>

* If a “without contrast” CT or CTA procedure is performed during the same session as a “with contrast” CT or CTA procedure, the I/OCE assigns the procedure to APC 8006 rather than APC 8005.

**Family 3 - MRI and MRA with and without Contrast**

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>70336</td>
<td>Magnetic image, jaw joint</td>
</tr>
<tr>
<td>70540</td>
<td>MRI orbit/face/neck w/o dye</td>
</tr>
<tr>
<td>70544</td>
<td>Mr angiography head w/o dye</td>
</tr>
</tbody>
</table>

**CY 2019 Approximate APC Geometric Mean Cost = $549**
<table>
<thead>
<tr>
<th>Code</th>
<th>Procedure Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>70547</td>
<td>Mr angiography neck w/o dye</td>
</tr>
<tr>
<td>70551</td>
<td>Mri brain w/o dye</td>
</tr>
<tr>
<td>70554</td>
<td>Fmri brain by tech</td>
</tr>
<tr>
<td>71550</td>
<td>Mri chest w/o dye</td>
</tr>
<tr>
<td>72141</td>
<td>Mri neck spine w/o dye</td>
</tr>
<tr>
<td>72146</td>
<td>Mri chest spine w/o dye</td>
</tr>
<tr>
<td>72148</td>
<td>Mri lumbar spine w/o dye</td>
</tr>
<tr>
<td>72195</td>
<td>Mri pelvis w/o dye</td>
</tr>
<tr>
<td>73218</td>
<td>Mri upper extremity w/o dye</td>
</tr>
<tr>
<td>73221</td>
<td>Mri joint upr extrem w/o dye</td>
</tr>
<tr>
<td>73718</td>
<td>Mri lower extremity w/o dye</td>
</tr>
<tr>
<td>73721</td>
<td>Mri jnt of lwr extre w/o dye</td>
</tr>
<tr>
<td>74181</td>
<td>Mri abdomen w/o dye</td>
</tr>
<tr>
<td>75557</td>
<td>Cardiac mri for morph</td>
</tr>
<tr>
<td>75559</td>
<td>Cardiac mri w/stress img</td>
</tr>
<tr>
<td>76391</td>
<td>Mr elastography</td>
</tr>
<tr>
<td>77046</td>
<td>Mri breast c- unilaterial</td>
</tr>
<tr>
<td>77047</td>
<td>Mri breast c- bilateral</td>
</tr>
<tr>
<td>C8901</td>
<td>MRA w/o cont, abd</td>
</tr>
<tr>
<td>C8910</td>
<td>MRA w/o cont, chest</td>
</tr>
<tr>
<td>C8913</td>
<td>MRA w/o cont, lwr ext</td>
</tr>
<tr>
<td>C8919</td>
<td>MRA w/o cont, pelvis</td>
</tr>
<tr>
<td>C8932</td>
<td>MRA, w/o dye, spinal canal</td>
</tr>
<tr>
<td>C8935</td>
<td>MRA, w/o dye, upper extr</td>
</tr>
</tbody>
</table>

**CY 2019 APC 8008 (MRI and MRA with Contrast Composite)**

**CY 2019 Approximate APC Geometric Mean Cost = $863**

<table>
<thead>
<tr>
<th>Code</th>
<th>Procedure Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>70549</td>
<td>Mr angiograph neck w/o &amp; w/dye</td>
</tr>
<tr>
<td>70542</td>
<td>Mri orbit/face/neck w/dye</td>
</tr>
<tr>
<td>70543</td>
<td>Mri orb/fac/neck w/o &amp; w/dye</td>
</tr>
<tr>
<td>70545</td>
<td>Mr angiography head w/dye</td>
</tr>
<tr>
<td>70546</td>
<td>Mr angiograph head w/o &amp; w/dye</td>
</tr>
<tr>
<td>70547</td>
<td>Mr angiography neck w/o dye</td>
</tr>
<tr>
<td>70548</td>
<td>Mr angiography neck w/dye</td>
</tr>
<tr>
<td>70552</td>
<td>Mri brain w/dye</td>
</tr>
<tr>
<td>70553</td>
<td>Mri brain w/o &amp; w/dye</td>
</tr>
<tr>
<td>71551</td>
<td>Mri chest w/dye</td>
</tr>
<tr>
<td>71552</td>
<td>Mri chest w/o &amp; w/dye</td>
</tr>
<tr>
<td>72142</td>
<td>Mri neck spine w/dye</td>
</tr>
<tr>
<td>72147</td>
<td>Mri chest spine w/dye</td>
</tr>
</tbody>
</table>
3. Changes to Packaged Items and Services
   a. Background and Rationale for Packaging in the OPPS

   Like other prospective payment systems, the OPPS relies on the concept of averaging to establish a payment rate for services. The payment may be more or less than the estimated cost of providing a specific service or a bundle of specific services for a particular patient. The OPPS packages payments

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>72149</td>
<td>MRI lumbar spine w/dye</td>
</tr>
<tr>
<td>72156</td>
<td>MRI neck spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72157</td>
<td>MRI chest spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72158</td>
<td>MRI lumbar spine w/o &amp; w/dye</td>
</tr>
<tr>
<td>72196</td>
<td>MRI pelvis w/dye</td>
</tr>
<tr>
<td>72197</td>
<td>MRI pelvis w/o &amp; w/dye</td>
</tr>
<tr>
<td>73219</td>
<td>MRI upper extremity w/dye</td>
</tr>
<tr>
<td>73220</td>
<td>MRI uppr extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>73222</td>
<td>MRI joint upr extrem w/dye</td>
</tr>
<tr>
<td>73223</td>
<td>MRI joint upr extr w/o &amp; w/dye</td>
</tr>
<tr>
<td>73719</td>
<td>MRI lower extremity w/dye</td>
</tr>
<tr>
<td>73720</td>
<td>MRI lwr extremity w/o &amp; w/dye</td>
</tr>
<tr>
<td>73722</td>
<td>MRI joint of lwr extr w/dye</td>
</tr>
<tr>
<td>73723</td>
<td>MRI joint lwr extr w/o &amp; w/dye</td>
</tr>
<tr>
<td>74182</td>
<td>MRI abdomen w/dye</td>
</tr>
<tr>
<td>74183</td>
<td>MRI abdomen w/o &amp; w/dye</td>
</tr>
<tr>
<td>75561</td>
<td>Cardiac mri for morph w/dye</td>
</tr>
<tr>
<td>75563</td>
<td>Card mri w/stress img &amp; dye</td>
</tr>
<tr>
<td>C8900</td>
<td>MRA w/cont, abd</td>
</tr>
<tr>
<td>C8902</td>
<td>MRA w/o fol w/cont, abd</td>
</tr>
<tr>
<td>C8903</td>
<td>MRI w/cont, breast, uni</td>
</tr>
<tr>
<td>C8905</td>
<td>MRI w/o fol w/cont, brst, un</td>
</tr>
<tr>
<td>C8906</td>
<td>MRI w/cont, breast, bi</td>
</tr>
<tr>
<td>C8908</td>
<td>MRI w/o fol w/cont, breast,</td>
</tr>
<tr>
<td>C8909</td>
<td>MRA w/cont, chest</td>
</tr>
<tr>
<td>C8911</td>
<td>MRA w/o fol w/cont, chest</td>
</tr>
<tr>
<td>C8912</td>
<td>MRA w/cont, lwr ext</td>
</tr>
<tr>
<td>C8914</td>
<td>MRA w/o fol w/cont, lwr ext</td>
</tr>
<tr>
<td>C8918</td>
<td>MRA w/cont, pelvis</td>
</tr>
<tr>
<td>C8920</td>
<td>MRA w/o fol w/cont, pelvis</td>
</tr>
<tr>
<td>C8931</td>
<td>MRA, w/dye, spinal canal</td>
</tr>
<tr>
<td>C8933</td>
<td>MRA, w/o&amp;w/dye, spinal canal</td>
</tr>
<tr>
<td>C8934</td>
<td>MRA, w/dye, upper extremity</td>
</tr>
<tr>
<td>C8936</td>
<td>MRA, w/o&amp;w/dye, upper extr</td>
</tr>
</tbody>
</table>

* If a “without contrast” MRI or MRA procedure is performed during the same session as a “with contrast” MRI or MRA procedure, the I/OCE assigns the procedure to APC 8008 rather than APC 8007.
for multiple interrelated items and services into a single payment to create incentives for hospitals to furnish services most efficiently and to manage their resources with maximum flexibility. Our packaging policies support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. For example, where there are a variety of devices, drugs, items, and supplies that could be used to furnish a service, some of which are more costly than others, packaging encourages hospitals to use the most cost-efficient item that meets the patient’s needs, rather than to routinely use a more expensive item, which often occurs if separate payment is provided for the item.

Packaging also encourages hospitals to effectively negotiate with manufacturers and suppliers to reduce the purchase price of items and services or to explore alternative group purchasing arrangements, thereby encouraging the most economical health care delivery. Similarly, packaging encourages hospitals to establish protocols that ensure that necessary services are furnished, while scrutinizing the services ordered by practitioners to maximize the efficient use of hospital resources. Packaging payments into larger payment bundles promotes the predictability and accuracy of payment for services over time. Finally, packaging may reduce the importance of refining service-specific payment because packaged payments include costs associated with higher cost cases requiring many ancillary items and services and lower cost cases requiring fewer ancillary items and services. Because packaging encourages efficiency and is an essential component of a prospective payment system, packaging payments for items and services that are typically integral, ancillary, supportive, dependent, or adjunctive to a primary service has been a fundamental part of the OPPS since its implementation in August 2000. For an extensive discussion of the history and background of the OPPS packaging policy, we refer readers to the CY 2000 OPPS final rule (65 FR 18434), the CY 2008 OPPS/ASC final rule with comment period (72 FR 66580), the CY 2014 OPPS/ASC final rule with comment period (78 FR 74925), the CY 2015 OPPS/ASC final rule with comment period (79 FR 66817), the CY 2016 OPPS/ASC final rule with comment period (80 FR 70343), the CY 2017 OPPS/ASC final rule with comment period (81 FR 79592), and the CY 2018 OPPS/ASC final rule with comment period (82 FR 59250). As we continue to develop larger payment groups that more broadly reflect services provided in an encounter or episode of care, we have expanded the OPPS packaging policies. Most, but not necessarily all, categories of items and services currently packaged in the OPPS are listed in 42 CFR 419.2(b). Our overarching goal is to make payments for all services under the OPPS more consistent with those of a prospective payment system and less like those of a per-service fee schedule, which pays separately for each coded item. As a part of this effort, we have continued to examine the payment for items and services provided under the OPPS to determine which OPPS services can be packaged to further achieve the objective of advancing the OPPS toward a more prospective payment system.

For CY 2019, we examined the items and services currently provided under the OPPS, reviewing categories of integral, ancillary, supportive, dependent, or adjunctive items and services for which we believe payment would be appropriately packaged into payment of the primary service that they support. Specifically, we examined the HCPCS code definitions (including CPT code descriptors) and outpatient hospital billing patterns to determine whether there were categories of codes for which packaging would be appropriate according to existing OPPS packaging policies or a logical expansion of those existing OPPS packaging policies. In the CY 2019 OPPS/ASC proposed rule (83 37067 through 37071), for CY 2019, we proposed to conditionally package the costs of selected newly identified ancillary services into payment with a primary service where we believe that the packaged item or service is integral, ancillary, supportive, dependent, or adjunctive to the provision of care that was reported by the primary service. HCPSC code. Below we discuss the proposed and finalized changes to the packaging policies beginning in CY 2019.

b. CY 2019 Packaging Policy for Non-Opioid Pain Management Treatments

In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the framework of existing packaging categories, such as drugs that function as supplies in a surgical procedure or diagnostic test or procedure, we requested stakeholder feedback on common clinical scenarios involving currently packaged items and services described by HCPCS codes that stakeholders believe should not be packaged under the OPPS. We also expressed interest in stakeholder feedback on common clinical scenarios involving separately payable HCPCS codes for which payment would be most appropriately packaged under the OPPS. Commenters expressed a variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC final rule with comment period, we summarized the comments received in response to our request (82 FR 59255). The comments ranged from requests to unpackage most items and services that are either conditionally or unconditionally packaged under the OPPS, including drugs and devices, to specific requests for separate payment for a specific drug or device. We stated in the CY 2018 OPPS/ASC final rule with comment period that CMS would continue to explore and evaluate packaging policies under the OPPS and consider these policies in future rulemaking.

In addition to stakeholder feedback regarding OPPS packaging policies, the President’s Commission on Combating Drug Addiction and the Opioid Crisis (the Commission) recently recommended that CMS examine payment policies for certain drugs that function as a supply, specifically non-opioid pain management treatments. The Commission was established in 2017 to study ways to combat and treat drug abuse, addiction, and the opioid crisis. The Commission’s report 3 included a recommendation for CMS to “… review and modify ratesetting policies that discourage the use of non-opioid treatments for pain, such as certain bundled payments that make alternative treatment options cost prohibitive for hospitals and doctors, particularly those options for treating immediate post-surgical pain. …”. 4

With respect to the packaging policy, the Commission’s report states that “… the current CMS payment policy for ‘supplies’ related to surgical procedures creates unintended incentives to prescribe opioid medications to patients for post-surgical pain instead of administering non-opioid pain medications. Under current policies, CMS provides one all-inclusive bundled payment to hospitals for all ‘surgical supplies,’ which includes hospital-administered drug products intended to manage patients’ postsurgical pain. This policy results in the hospitals receiving the same fixed fee from Medicare whether the surgeon

---


In fact, under the OPPS, we observed the opposite effect for several drugs that function as a supply, including Exparel (HCPCS code C9290). Exparel is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In 2011, Exparel was approved by the FDA for administration into the postsurgical site to provide postsurgical analgesia. Exparel had pass-through payment status from CYs 2012 through 2014 and was separately paid under both the OPPS and the ASC payment system during this 3-year period. Beginning in CY 2015, Exparel was packaged as a surgical supply under both the OPPS and the ASC payment system. Exparel is currently the only non-opioid pain management drug that is packaged as a drug that functions as a supply when used in a surgical procedure under the OPPS and the ASC payment system. From CYs 2013 through 2017, there was an overall increase in the OPPS Medicare utilization of Exparel of approximately 158 percent (from 2.3 million units to 7.7 million units) during this 5-year time period. The total number of claims reporting Exparel increased by 222 percent (from 10,609 claims to 34,183 claims) over this time period. This increase in utilization continued, even after the 3-year drug pass-through payment period ended for this product in 2014, with 18 percent overall growth in the total number of units used from CYs 2015 through 2017 (from 6.5 million units to 7.7 million units). The number of claims reporting Exparel increased by 21 percent during this time period (from 28,166 claims to 34,183 claims).

Thus, we have not found evidence to support the notion that the OPPS packaging policy has had an unintended consequence of discouraging the use of non-opioid treatment for postsurgical pain management in the hospital outpatient department. Therefore, based on this data analysis, we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe that changes were necessary under the OPPS for the packaged drug policy for drugs that function as a surgical supply when used in a surgical procedure in this setting at this time.

In terms of Exparel in particular, we have received several requests to pay separately for the drug rather than packaging payment for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66874 and 66875), in response to comments from stakeholders requesting separate payment for Exparel, we stated that we considered Exparel to be a drug that functions as a surgical supply because it is indicated for the alleviation of postsurgical pain. We also stated that we consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59345), we reiterated our position with regard to payment for Exparel, stating that we believed that payment for this drug is appropriately packaged with the primary surgical procedure. In addition, we have reviewed recently available literature with respect to Exparel, including a briefing document submitted for the FDA Advisory Committee Meeting held February 14–15, 2018, by the manufacturer of Exparel that notes that "... Bupivacaine, the active pharmaceutical ingredient in Exparel, is a local anesthetic that has been used for infiltration/field block and peripheral nerve block for decades" and that "since its approval, Exparel has been used extensively, with an estimated 3.5 million patient exposures in the US." On April 6, 2018, the FDA approved Exarel’s new indication for use as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Accordingly, we continue to believe it is appropriate to package payment for Exparel as we do with other postsurgical pain management drugs when it is furnished in a hospital outpatient department. However, we invited public comments on whether separate payment would nonetheless further incentivize appropriate use of Exparel in the hospital outpatient setting and peer-reviewed evidence that such increased utilization would lead to a decrease in

---

5 Ibid.
6 Available at: https://www.hhs.gov/about/leadership/secretary/speeches/2017-speeches/secretary-price-announces-hhs-strategy-for-fighting-opioid-crisis/index.html.
8 Available at: https://www.phe.gov/emergency/news/healthactions/phe/Pages/default.aspx.
opioid use and addiction among Medicare beneficiaries.

Comment: Several commenters, including hospital associations, medical specialty societies, and drug manufacturers, requested that CMS pay separately for Exparel in the hospital outpatient setting. Some of these commenters noted that Exparel is used more frequently in this setting and the use of non-opioid pain management treatments should also be encouraged in the hospital outpatient department. The manufacturer of Exparel, Pacira Pharmaceuticals, stated that since the drug became packaged in 2015, utilization of the drug in the hospital outpatient department has remained flat while the opioid crisis has continued to worsen. The manufacturer suggested that, to address the opioid crisis among Medicare beneficiaries, CMS should promote “increased penetration of non-opioid therapies in the HOPD setting—or in other words, higher rates of usage of non-opioid treatments for the same number of surgical procedures.”

Response: While these commenters advocated paying separately for Exparel in the hospital outpatient setting, we do not believe that there is sufficient evidence that non-opioid pain management drugs should be paid separately in the hospital outpatient setting at this time. The commenters submitted some peer-reviewed studies, discussed in further detail below, that showed that the use of Exparel could lead to a decrease in opioid use in the treatment of acute post-surgical pain among Medicare beneficiaries. However, the commenters did not provide evidence that the OPPS packaging policy for Exparel (or other non-opioid drugs) creates a barrier to use of Exparel in the hospital setting. Further, while we received some public comments suggesting that, as a result of using Exparel in the OPPS setting, providers may prescribe fewer opioids for Medicare beneficiaries, we do not believe that the OPPS packaging policy presents a barrier to use of Exparel or affects the likelihood that providers may prescribe fewer opioids in the HOPD setting. Several drugs are packaged under the OPPS and payment for such drugs is included in the payment for the associated primary procedure. We were not persuaded by the anecdotal information supplied by commenters suggesting that some providers avoid use of non-opioid alternatives (including Exparel) solely because of the OPPS packaged payment policy. Finally, while the rate of growth for Exparel use in the HOPD setting has declined over recent years, such trend might be expected because absolute utilization tends to be smaller in the initial period when a drug first comes available on the U.S. market.

Additionally, we observed that the total number of providers billing for Exparel under the OPPS has increased each year from 2012 to 2017. Therefore, we do not believe that the current OPPS payment methodology for Exparel and other non-opioid pain management drugs presents a barrier to their use.

In addition, higher use in the hospital outpatient setting not only supports the notion that the packaged payment for Exparel is not causing an access to care issue, but also that the payment rate for primary procedures in the HOPD using Exparel adequately reflects the cost of the drug. That is, because Exparel is commonly used and billed under the OPPS, the APC rates for the primary procedures reflect such utilization. Therefore, the higher utilization in the OPPS setting should mitigate the need for separate payment. We remind readers that the OPPS is a prospective payment system, not a cost-based system and, by design, is based on a system of averages whereby payment for certain cases may exceed the costs incurred, while for others, it may not. As stated earlier in this section, the OPPS packages payments for multiple interrelated items and services into a single payment to create incentives for hospitals to furnish services most efficiently and to manage their resources with maximum flexibility. Our packaging policies support our strategic goal of using larger payment bundles in the OPPS for non-opioid pain management drugs that function as surgical supplies may significantly and appropriately impact hospitals’ incentives to provide care in the most efficient manner. We will continue to analyze the evidence and monitor utilization of non-opioid alternatives in the OPD and ASC settings for potential future rulemaking.

We also stated in the proposed rule that, although we found increases in utilization for Exparel when it is paid under the OPPS, we did notice different effects on Exparel utilization when examining the effects of our packaging policy under the ASC payment system. In particular, during the same 5-year period of CYS 2013 through 2017, the total number of units of Exparel used in the ASC setting decreased by 25 percent (from 98,160 total units to 73,595 total units) and the total number of claims reporting Exparel decreased by 16 percent (from 527 claims to 441 claims). In the ASC setting, after the pass-through payment period ended for Exparel at the end of CY 2014, the total number of units of Exparel used decreased by 70 percent (from 244,757 units to 73,595 units) between CYS 2015 and 2017. The total number of claims reporting Exparel also decreased during this time period by 62 percent (from 1,190 claims to 441 claims). However, there was an increase of 238 percent (from 98,160 total units to 331,348 total units) in the total number of units of Exparel used in the ASC setting during the time period of CYS 2013 and 2014 when the drug received pass-through payments, indicating that the payment rate of ASP+6 percent for Exparel may have had an impact on its usage in the ASC setting. The total number of claims while several variables may contribute to this difference in utilization and claims reporting between the hospital outpatient department and the ASC setting, one potential explanation is that, in comparison to hospital outpatient departments, ASCs tend to provide specialized care and a more limited range of services. Also, ASCs are paid, in aggregate, a rate that is approximately 55 percent of the OPPS rate. Therefore, fluctuations in payment rates for specific services may impact these providers more acutely than hospital outpatient departments, and therefore, ASCs may be less likely to choose to furnish non-opioid postsurgical pain management treatments, which are typically more expensive than opioids, as a result. Another possible contributing factor is that ASCs do not typically report packaged items and services and, accordingly, our analysis may be undercounting the number of Exparel units utilized in the ASC setting.

In light of the results of our evaluation of packaging policies under the OPPS and the ASC payment system, which showed decreased utilization for certain drugs that function as a supply in the ASC setting in comparison to the hospital outpatient department setting, as well as the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, we stated in the proposed rule that we believe a change in how we pay for non-opioid pain management drugs that function as surgical supplies may be warranted. In particular, we stated that we believe it may be appropriate to pay separately for evidence-based non-opioid pain management drugs that function as a supply in a surgical procedure in the ASC setting to address the decreased utilization of these drugs and to encourage use of these types of drugs rather than prescription opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 OPPS/ASC
The proposed rule to unpackage and pay separately for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019 (83 FR 37065).

We have stated previously (82 FR 59250) that our packaging policies are designed to support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. The packaging policies established under the OPPS also typically apply when services are provided in the ASC setting, and the policies have the same strategic goals in both settings. While the CY 2019 proposal is a departure from our current ASC packaging policy for drugs (specifically, non-opioid pain management drugs) that function as a supply when used in a surgical procedure, we stated in the proposed rule that we believe that the proposed change will incentivize the use of non-opioid pain management drugs and is responsive to the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, with the overall goal of combating the current opioid addiction crisis. As previously noted, a discussion of the CY 2019 proposal for payment of non-opioid pain management drugs in the ASC setting was presented in further detail in section XII.D.3. of the proposed rule, and we refer readers to section XII.D.3. of this CY 2019 OPPS/ASC final rule with comment period for further discussion of the final rule for CY 2019. We also stated in the CY 2019 OPPS/ASC proposed rule that we were interested in peer-reviewed evidence that demonstrates that use of non-opioid alternatives, such as Exparel, furnished in the outpatient setting actually does lead to a decrease in prescription opioid use and addiction and invited public comments containing evidence that demonstrate whether and how such non-opioid alternatives affect prescription opioid use during or after an outpatient visit or procedure.

Comment: Several commenters, including individual stakeholders, hospital and physician groups, national medical associations, drug rehabilitation specialists, device manufacturers, and groups representing the pharmaceutical industry, supported the proposal to unpackage and pay separately for the cost of non-opioid pain management drugs that function as surgical supplies, such as Exparel, in the ASC setting for CY 2019. These commenters believed that packaged payment for non-opioid alternatives presents a barrier to care and that separate payment for non-opioid pain management drugs would be an appropriate response to the opioid drug abuse epidemic.

Other commenters, including MedPAC, did not support this proposal and stated that the policy was counter to the OPPS packaging policies created to encourage efficiencies and could set a precedent for unpackaging services. One commenter stated that Exparel is more costly, but not more effective than bupivacaine, a less costly non-opioid alternative. Other commenters expressed concerns that the proposal may have the unintended consequence of limiting access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. The commenters noted that some non-opioid pain management treatments may pose other risks for patients and patient safety.

Response: This comment and other comments specific to packaging under the ASC payment system are addressed in section XII.D.3. of this final rule with comment period.

In addition, as noted in section XII.D.3. of the proposed rule (83 FR 37065 through 37068), we sought comments on whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) as well as whether there are other non-opioid pain management alternatives that would have similar effects and may warrant separate payment. For example, we stated we were interested in identifying whether single post-surgical analgesic injections, such as Exparel, or other non-opioid drugs or devices that are used during an outpatient visit or procedure are associated with decreased opioid prescriptions and/or reduced cases of associated opioid addiction following such an outpatient visit or procedure. We also requested comments that provide evidence (such as published peer-reviewed literature) we could use to determine whether these products help to deter or avoid prescription opioid use and addiction as well as evidence that the current packaged payment for such non-opioid alternatives presents a barrier to access to care and, therefore, warrants separate payment under either or both the OPPS and the ASC payment system. We stated that any evidence demonstrating the reduction or avoidance of prescription opioids would be useful to determine whether separate payment is warranted for CY 2019. We also stated that if evidence changes over time, we would consider whether a reexamination of any policy adopted in the final rule would be necessary.

Comment: With regard to whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure and supportive evidence of these reductions, one commenter, the manufacturer of Exparel, submitted studies that claimed that the use of Exparel by Medicare patients undergoing total knee replacement procedures reduced prescription opioid consumption by 90 percent compared to the control group measured at 48 hours post-surgery. The manufacturer submitted additional studies claiming statistically significant reductions in opioid use with the use of Exparel for various surgeries, including laparotomy, shoulder replacement, and breast reconstruction.

Several commenters identified other non-opioid pain management drugs that they believe decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) and may warrant separate payment for CY 2019. Commenters from the makers of other packaged non-opioid pain management drugs, including a non-opioid intrathecal infusion drug indicated for the management of severe chronic pain, submitted supporting studies which claimed that the drug reduced opioid use in patients with chronic pain.

Several commenters, from hospitals, hospital associations, and clinical specialty organizations, requested separate payment for IV acetaminophen, IV ibuprofen, and epidural steroid injections. In addition, one commenter, the manufacturer of a non-opioid analgesic containing bupivacaine hcl not currently approved by FDA, requested clarification regarding whether the proposal would also apply to this drug once it receives FDA approval. Several commenters requested separate payment for a drug that treats postoperative pain after cataract surgery, currently has drug pass-through payment status, and therefore is not packaged under the OPPS or the ASC payment system. The commenters requested that CMS explicitly state that this drug will also be paid for separately in the ASC setting after pass-through other non-opioid alternatives affect prescription opioid use during or after an outpatient visit or procedure. We also requested comments that provide evidence (such as published peer-reviewed literature) we could use to determine whether these products help to deter or avoid prescription opioid use and addiction as well as evidence that the current packaged payment for such non-opioid alternatives presents a barrier to access to care and, therefore, warrants separate payment under either or both the OPPS and the ASC payment system. We stated that any evidence demonstrating the reduction or avoidance of prescription opioids would be useful to determine whether separate payment is warranted for CY 2019. We also stated that if evidence changes over time, we would consider whether a reexamination of any policy adopted in the final rule would be necessary.

Comment: With regard to whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure and supportive evidence of these reductions, one commenter, the manufacturer of Exparel, submitted studies that claimed that the use of Exparel by Medicare patients undergoing total knee replacement procedures reduced prescription opioid consumption by 90 percent compared to the control group measured at 48 hours post-surgery. The manufacturer submitted additional studies claiming statistically significant reductions in opioid use with the use of Exparel for various surgeries, including laparotomy, shoulder replacement, and breast reconstruction.

Several commenters identified other non-opioid pain management drugs that they believe decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) and may warrant separate payment for CY 2019. Commenters from the makers of other packaged non-opioid pain management drugs, including a non-opioid intrathecal infusion drug indicated for the management of severe chronic pain, submitted supporting studies which claimed that the drug reduced opioid use in patients with chronic pain.

Several commenters, from hospitals, hospital associations, and clinical specialty organizations, requested separate payment for IV acetaminophen, IV ibuprofen, and epidural steroid injections. In addition, one commenter, the manufacturer of a non-opioid analgesic containing bupivacaine hcl not currently approved by FDA, requested clarification regarding whether the proposal would also apply to this drug once it receives FDA approval. Several commenters requested separate payment for a drug that treats postoperative pain after cataract surgery, currently has drug pass-through payment status, and therefore is not packaged under the OPPS or the ASC payment system. The commenters requested that CMS explicitly state that this drug will also be paid for separately in the ASC setting after pass-through

13 Michael A. Mont et al., Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J. of Arthroplasty (2018).
payment status ends for the drug in 2020. Lastly, one commenter, the makers of a diagnostic drug that is not a non-opioid, requested separate payment.

Response: We appreciate these comments. After reviewing the studies provided by the commenters, we continue to believe the separate payment is appropriate for Exparel in the ASC setting. At this time, we have not found compelling evidence for other non-opioid pain management drugs described above to warrant separate payment under the ASC payment system for CY 2019. Also, with regard to the requests for CMS to confirm that the proposed policy would also apply in the future to certain non-opioid pain management drugs, we reiterate that the proposed policy is for CY 2019 and is applicable to non-opioid pain management drugs that are currently packaged under the policy for drugs that function as a surgical supply when used in the ASC setting, which currently is only Exparel. To the extent that other non-opioid pain management drugs become available on the U.S. market in 2019, this policy would also apply to those drugs.

As noted above, we stated in the proposed rule that we were interested in comments regarding other non-opioid treatments besides Exparel that might be affected by our OPPS and ASC packaging policies, including alternative, non-opioid pain management treatments, such as devices or therapy services that are not currently separable payable. We stated that we were specifically interested in comments regarding whether CMS should consider separate payment for items and services for which payment is currently packaged under the OPPS and the ASC payment system that are effective non-opioid alternatives as well as evidence that demonstrates such items and services lead to a decrease in prescription opioid use and/or addiction during or after an outpatient visit or procedure in order to determine whether separate payment may be warranted. As previously stated, we intended to examine the evidence submitted to determine whether to adopt a final policy in this final rule with comment period that incentivizes use of non-opioid alternative items and services that have evidence to demonstrate an associated decrease in prescription opioid use and/or addiction following an outpatient visit or procedure. We stated that some examples of evidence that may be relevant could include an indication on the product’s FDA label or studies published in peer-reviewed literature that such product aids in the management of acute or chronic pain and is an evidence-based non-opioid alternative for acute and/or chronic pain management. We indicated in the proposed rule that we also were interested in evidence relating to products that have shown clinical improvement over other alternatives, such as a device that has been shown to provide a substantial clinical benefit over the standard of care for pain management. We stated that this could include, for example, spinal cord stimulators used to treat chronic pain, such as the devices described by HCPCS codes C1822 (Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system), C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system), and C1767 (Generator, neurostimulator (implantable), nonrechargeable) which are primarily assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and Related Procedures) with proposed CY 2019 payment rates of $18,718 and $27,662, respectively, that have received pass-through payment status as well as other similar devices.

Currently, all devices are packaged under the OPPS and the ASC payment system unless they have pass-through payment status. However, we stated in the proposed rule that, in light of the Commission’s recommendation to review and modify rulesetting policies that discourage the use of non-opioid treatments for pain, we were interested in comments from stakeholders regarding whether, similar to the goals of the proposed payment policy for non-opioid pain management drugs that function as a surgical supply when used in a surgical procedure, a policy of providing separate payment (rather than packaged payment) for these products, indefinitely or for a specified period of time, would also incentivize the use of alternative non-opioid pain management treatments and improve access to non-opioid alternatives, particularly for Innovative and low-volume items and services.

We also stated that we were interested in comments regarding whether we should provide separate payment for non-opioid pain management treatments or products using a mechanism such as an equitable payment adjustment under our authority at section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determinative, in so necessary to ensure equitable payments. For example, we stated in the proposed rule that we were considering whether an equitable payment adjustment in the form of an add-on payment for APCs that use a non-opioid pain management drug, device, or service would be appropriate. We indicated that, to the extent that commenters provided evidence to support this approach, we would consider adopting a final policy in this final rule with comment period, which could include regulatory changes that would allow for an exception to the packaging of certain nonpass-through devices that represent non-opioid alternatives for acute or chronic pain that have evidence to demonstrate that their use leads to a decrease in opioid prescriptions and/or opioid abuse or misuse during or after an outpatient visit or procedure to effectuate such change.

Comment: Several commenters, manufacturers of spinal cord stimulators (SCS), stated that separate payment was also warranted for these devices because they provide an alternative treatment option to opioids for patients with chronic, leg, or back pain. One of the manufacturers of a high-frequency SCS device provided supporting studies which claimed that patients treated with their device reported a statistically significant average decrease in opioid use compared to the control group. This commenter also submitted data that showed a decline in the mean daily dosage of opioid medication taken and that fewer patients were relying on opioids at all to manage their pain when they used the manufacturer’s device. Another commenter, a SCS manufacturer, stated that there are few peer-reviewed studies that evaluate opioid elimination and/or reduction following SCS and that there is a need for more population-based research with opioid reduction or elimination as a study endpoint. However, this commenter believed that current studies suggest that opioid use may be reduced following SCS therapy.

Commenters representing various stakeholders requested separate payments for various non-opioid pain management treatments, such as...
continuous nerve blocks (including a disposable elastomeric pump that delivers non-opioid local anesthetic to a surgical site or nerve), cooled thermal radiofrequency ablation for nonsurgical, chronic nerve pain, and physical therapy services. These commenters, including national hospital associations, recommended that while ‘certainly not a solution to the opioid epidemic, unpackaging appropriate non-opioid therapies, like Exparel, is a low-cost tactic that could change long-standing practice patterns without major negative consequences.’ This same commenter suggested that Medicare consider separate payment for Polar ice devices for postoperative pain relief after knee procedures. The commenter also noted that therapeutic massage, topically applied THC oil, acupuncture, and dry needling procedures are very effective therapies for relief of both postoperative pain and long-term and chronic pain.

Commenters suggested various mechanisms through which separate payment or a higher-paying APC assignment for the primary service could be made. Commenters offered reports, studies, and anecdotal evidence of varying degrees to support why the items or services about which they were writing offered an alternative to or reduction of the need for opioid prescriptions.

Response: We appreciate the detailed responses to our solicitation for comments on this topic. We plan to take these comments and suggestions into consideration for future rulemaking. We agree that incentives to avoid and/or reduce opioid prescriptions may be one of several strategies for addressing the opioid epidemic. To the extent that the items and services mentioned by the commenters are effective alternatives to opioid prescriptions, we encourage providers to use them when medically necessary. We note that some of the items and services mentioned by commenters are not covered by Medicare, and we do not intend to establish payment for noncovered items and services. We look forward to working with stakeholders as we further consider suggested refinements to the OPPS and the ASC payment system that will encourage use of medically necessary items and services that have demonstrated efficacy in decreasing opioid prescriptions and/or opioid abuse or misuse during or after an outpatient visit or procedure.

Comment: One commenter suggested that CMS provide separate payment for HCPCS code A4306 (Disposable drug delivery system 4306 rate of less than 50 ml per hour) in the hospital outpatient department setting and the ASC setting following a post-surgery procedure. This commenter explained that if a patient needs additional pain relief 3 to 5 days post-surgery, a facility cannot receive payment for providing a replacement disposable drug delivery system (HCPCS code A4306) unless the entire continuous nerve block procedure is performed. This commenter believed that CMS should allow for HCPCS code A4306 to be dispensed to the patient as long as the patient is in pain, the pump is empty, and the delivery catheters are still in place. The commenter believed that the drug delivery system should incentivize the continued use of non-opioid alternatives when needed. In addition, several commenters stated that CMS should use an equitable payment adjustment under our authority at section 1833(t)(2)(E) of the Act to establish add-on payments for packaged devices used as non-opioid alternatives.

Response: We appreciate the commenter’s suggestion. We acknowledge that use of these items may help in the reduction of opioid use postoperatively. However, we note that packaged payment of such an item does not prevent the use of these items. We remind readers that payment for packaged items is included in the payment for the primary service. We share the commenter’s concern about the need to reduce opioid use and will take the commenter’s suggestion into consideration for future rulemaking.

After reviewing the non-opioid pain management alternatives suggested by the commenters as well as the studies and other data provided to support the request for separate payment, we have not determined that separate payment is warranted at this time for any of the non-opioid pain management alternatives discussed above. We also invited public comments on whether a reorganization of the APC structure for procedures involving non-opioid products or establishing more granular APC groupings for specific procedure and device combinations to ensure that the payment rate for such services is aligned with the resources associated with procedures involving specific devices would better achieve our goal of incentivizing increased use of non-opioid alternatives, with the aim of reducing opioid use and subsequent addiction. For example, we stated that we would consider finalizing a policy to establish new APCs for procedures involving non-opioid pain management packaged items or services if such APCs would better recognize the resources involved in furnishing such items and services to eliminate the need for prescription opioids. In addition, given the general desire to encourage provider efficiency through creating larger bundles of care and packaging items and services that are integral, ancillary, supportive, dependent, or adjunctive to a primary service, we also invited comments on how such alternative payment structures would continue to balance the goals of incentivizing provider efficiencies with encouraging the use of non-opioid alternatives to pain management.

Furthermore, because patients may receive opioid prescriptions following receipt of a non-opioid drug or implantation of a device, we stated that we were interested in identifying any cost implications for the patient and the Medicare program caused by this potential change in policy. We also stated that the implications of incentivizing use of non-opioid pain management alternatives for postsurgical acute pain relief during or after an outpatient visit or procedure are of interest. The goal is to encourage appropriate use of such non-opioid alternatives. As previously stated, this comment solicitation is also discussed in section XII.D.3. of this final rule with comment period relating to the ASC payment system.

Comment: Regarding APC reorganization, one commenter suggested that CMS restructure the two-level Nerve Procedure APCs (5431 and 5432) to provide more payment granularity for the procedures included in the APCs by creating a third level.

Response: This comment is addressed in section III.D.17. of this final rule with comment period. As stated in that section, we believe that the current two-level APCs for the Nerve Procedures provide an appropriate distinction between the resource costs at each level and provide clinical homogeneity. We will continue to review this APC structure to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change.

In addition, in the proposed rule, we invited the public to submit ideas on regulatory, subregulatory, policy, practice, and procedural changes to help prevent opioid use disorders and improve access to treatment under the Medicare program. We stated that we were interested in identifying barriers that may inhibit access to non-opioid alternatives for pain treatment and management or access to opioid use disorder treatment, including those barriers related to payment methodologies or coverage. In addition, consistent with our “Patients Over
Paperwork” Initiative, we stated that we were interested in suggestions to improve existing requirements in order to more effectively address the opioid epidemic.

Comment: Several commenters addressed payment barriers that may inhibit access to non-opioid pain management treatments previously discussed throughout this section. With regard to barriers related to payment methodologies or coverage, one commenter, a clinical specialty society, suggested that CMS support multidisciplinary pain management and enhanced recovery after surgery (ERAS) and encourage patient access to certified registered nurse anesthetist (CRNA) pain management. One commenter also suggested that CMS reduce cost-sharing and eliminate the need for prior authorization for non-opioid pain management strategies.

Response: We appreciate the various insightful comments we received from stakeholders regarding barriers that may inhibit access to non-opioid alternatives for pain treatment and management in order to more effectively address the opioid epidemic. Many of these comments have been previously addressed throughout this section.

After consideration of the public comments that we received, we are finalizing the proposed policy, without modification, to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019. We will continue to analyze the issue of access to non-opioid alternatives in the OPD and the ASC settings as we implement section 6082 of the Substance Use–Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115–271 enacted on October 24, 2018. This policy is also discussed in section X.D.3 of this final rule with comment period.

4. Calculation of OPPS Scaled Payment Weights

We established a policy in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68283) of using geometric mean-based APC costs to calculate relative payment weights under the OPPS. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59255 through 59256), we applied this policy and calculated the relative payment weights for each APC for CY 2018 that were shown in Addenda A and B to that final rule with comment period (which were made available via the internet on the CMS website) using the APC costs discussed in sections II.A.1 and II.A.2, of that final rule with comment period. For CY 2019, as we did for CY 2018, in the CY 2019 OPPS/ASC proposed rule (83 FR 37071), we proposed to continue to apply the policy established in CY 2013 and calculate relative payment weights for each APC for CY 2019 using geometric mean-based APC costs.

For CY 2012 and CY 2013, outpatient clinic visits were assigned to one of five levels of clinic visit APCs, with APC 0600 representing a mid-level clinic visit. In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75036 through 75043), we finalized a policy that created alphanumeric HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient), representing any and all clinic visits under the OPPS. HCPCS code G0463 was assigned to APC 0634 (Hospital Clinic Visits). We also finalized a policy to use CY 2012 claims data to develop the CY 2014 OPPS payment rates for HCPCS code G0463 based on the geometric mean cost of the levels one through five CPT E/M codes for clinic visits previously recognized under the OPPS (CPT codes 99201 through 99205 and 99211 through 99215). In addition, we finalized a policy to no longer recognize a distinction between new and established patient clinic visits.

For CY 2016, we deleted APC 0634 and reassigned the outpatient clinic visit HCPCS code G0463 to APC 5012 (Level 2 Examinations and Related Services) (80 FR 70732). For CY 2019, as we did for CY 2018, we proposed to continue to standardize all of the relative payment weights to APC 5012. We believe that standardizing relative payment weights to the geometric mean of the APC to which HCPCS code G0463 is assigned maintains consistency in calculating unscaled weights that represent the cost of some of the most frequently provided OPPS services. For CY 2019, as we did for CY 2018, we proposed to assign APC 5012 a relative payment weight of 1.00 and to divide the geometric mean cost of each APC by the geometric mean cost for APC 5012 to derive the unscaled relative payment weight for each APC. The choice of the APC on which to standardize the relative payment weights does not affect payments made under the OPPS because we scale the weights for budget neutrality.

We did not receive any public comments on our proposal to continue to use the geometric mean cost of APC 5012 to calculate relative payment weights for CY 2019. Therefore, we are finalizing our proposal and assigning APC 5012 the relative payment weight of 1.00, and using the relative payment weight for APC 5012 to derive the unscaled relative payment weight for each APC for CY 2019.

We note that, in section X.B. of the OPPS/ASC proposed rule (83 FR 37137 through 37138) and of this final rule with comment period, we discuss our CY 2019 proposal and established final policy to control for unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at excepted off-campus provider-based department (PBD) at an amount of 70 percent of the OPPS rate for a clinic visit service in CY 2019, rather than at the standard OPPS rate. While the volume associated with these visits is included in the impact model, and thus used in calculating the weight scalar, the proposal and final policy have only a negligible effect on the scalar. Specifically, under the proposed and final policy, there is no change to the relativity of the OPPS payment weights because the adjustment is made at the payment level rather than in the cost modeling. Further, under our proposed and final policy, the savings that will result from the change in payments for these clinic visits will not be budget neutral. Therefore, the impact of the proposed and final policy will generally not be reflected in the budget neutrality adjustments, whether the adjustment is to the OPPS relative weights or to the OPPS conversion factor. We refer readers to section X.B. of this CY 2019 OPPS/ASC final rule with comment period for further discussion of this final policy.

Section 1833(t)(9)(B) of the Act requires that APC reclassification and recalibration changes, wage index changes, and other adjustments be made in a budget neutral manner. Budget neutrality ensures that the estimated aggregate weight under the OPPS for CY 2019 is neither greater than nor less than the estimated aggregate weight that would have been made without the changes. To comply with this requirement concerning the APC changes, in the CY 2019 OPPS/ASC proposed rule (83 FR 37071 through 37072), we proposed to compare the estimated aggregate weight using the CY 2018 scaled relative payment weights to the estimated aggregate weight using the proposed CY 2019 unscaled relative payment weights.

For CY 2018, we multiplied the CY 2018 scaled APC relative payment weight applicable to a service paid under the OPPS by the volume of that service from CY 2017 to claim the total relative payment weight for
each service. We then added together the total relative payment weight for each of these services in order to calculate an estimated aggregate weight for the year. For CY 2019, we proposed to apply the same process using the estimated CY 2019 unscaled relative payment weights rather than scaled relative payment weights. We proposed to calculate the weight scalar by dividing the CY 2018 estimated aggregate weight by the unscaled CY 2019 estimated aggregate weight.

For a detailed discussion of the weight scalar calculation, we refer readers to the OPPS claims accounting document available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html. Click on the CY 2019 OPPS final rule link and open the claims accounting document link at the bottom of the page.

We proposed to compare the estimated unscaled relative payment weights in CY 2019 to the estimated total relative weights in CY 2018 using CY 2017 claims data, holding all other components of the payment system constant to isolate changes in total weight. Based on this comparison, we proposed to adjust the calculated CY 2019 unscaled relative payment weights for purposes of budget neutrality. We proposed to adjust the estimated CY 2019 unscaled relative payment weights by multiplying them by a proposed weight scalar of 1.4553 to ensure that the proposed CY 2019 relative payment weights are scaled to be budget neutral. The proposed CY 2019 relative payment weights listed in Addenda A and B to the proposed rule (which are available via the internet on the CMS website) were scaled and incorporated the recalibration adjustments discussed in sections II.A.1. and II.A.2. of this final rule with comment period.

**B. Conversion Factor Update**

Section 1833(t)(3)(C)(ii) of the Act requires the Secretary to update the conversion factor used to determine the payment rates under the OPPS on an annual basis by applying the OPD fee schedule increase factor. For purposes of section 1833(t)(3)(C) of the Act, subject to sections 1833(t)(17) and 1833(t)(3)(F) of the Act, the OPD fee schedule increase factor is equal to the hospital inpatient market basket percentage increase applicable to hospital discharges under section 1886(b)(3)(B)(iii) of the Act. As stated in the CY 2019 OPPS/ASC proposed rule, in the FY 2019 IPPS/LTPPS proposed rule (83 FR 20381), consistent with current law, based on IHS Global, Inc.’s fourth quarter 2017 forecast of the FY 2019 market basket increase, the proposed FY 2019 IPPS market basket update was 2.8 percent. However, sections 1833(t)(3)(F) and 1833(t)(3)(G)(v) of the Act, as added by section 3401(i) of the Patient Protection and Affordable Care Act of 2010 (Pub. L. 111–148) and as amended by section 10319(g) of that law and further amended by section 1105(e) of the Health Care and Education Reconciliation Act of 2010 (Pub. L. 111–132), provide adjustments to the OPD fee schedule increase factor for CY 2019. Specifically, section 1833(t)(3)(F)(i) of the Act requires that, for 2012 and subsequent years, the OPD fee schedule increase factor under subparagraph (C)(iv) be reduced by the productivity adjustment described in section 1886(b)(3)(B)(xi)(III) of the Act. Section 1886(b)(3)(B)(xi)(III) of the Act defines the productivity adjustment as equal to the 10-year moving average of changes in annual economy-wide, private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period ending with the OPD fee schedule increase factor for CY 2019 or, in the absence of such an estimate, the MFP adjustment calculation process described in the proposed rule, without modification, for CY 2019. Using updated final rule claims data, we are updating the estimated CY 2019 unscaled relative payment weights by multiplying them by a weight scalar of 1.4574 to ensure that the final CY 2019 relative payment weights are scaled to be budget neutral.

The final CY 2019 relative payment weights listed in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website) were scaled and incorporated the recalibration adjustments discussed in sections II.A.1. and II.A.2. of this final rule with comment period.

**FY 2012 IPPS/LTCH PPS Final Rule**

In the FY 2012 IPPS/LTCH PPS final rule (76 FR 51689 through 51692), we finalized our methodology for calculating and applying the MFP adjustment, and then revised this methodology as discussed in the FY 2016 IPPS/LTCH PPS final rule (80 FR 49509). In the FY 2019 OPPS/ASC proposed rule (83 FR 37072), the proposed MFP adjustment for FY 2019 was 0.8 percentage point.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37072), we proposed that in future years, we would use updated data, if appropriate, to determine the CY 2019 market basket update and the MFP adjustment, which are components in calculating the OPD fee schedule increase factor under sections 1833(t)(3)(C)(iv) and 1833(t)(3)(F) of the Act, in this CY 2019 OPPS/ASC final rule with comment period.

In addition, section 1833(t)(3)(F)(ii) of the Act requires that, for each of years 2010 through 2019, the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act be reduced by the adjustment described in section 1833(t)(3)(G) of the Act. For CY 2019, section 1833(t)(3)(G)(v) of the Act provides a 0.75 percentage point reduction to the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act. Therefore, in accordance with sections 1833(t)(3)(F)(ii) and 1833(t)(3)(G)(v) of the Act, in the CY 2019 OPPS/ASC proposed rule, we proposed to apply a 0.75 percentage point reduction to the OPD fee schedule increase factor for CY 2019.

We note that section 1833(t)(3)(F) of the Act provides that application of this subparagraph may result in the OPD fee schedule increase factor under section 1833(t)(3)(C)(iv) of the Act being less than 0.0 percent for a year, and may result in OPPS payment rates being less than rates for the preceding year. As described in further detail below, we are applying an OPD fee schedule increase factor of 1.35 percent for the CY 2019 OPPS (which is 2.9 percent, the final estimate of the hospital inpatient market basket percentage increase, less the final 0.8 percentage point MFP adjustment, and less the 0.75 percentage point additional adjustment).

Hospitals that fail to meet the Hospital OQR Program reporting requirements are subject to an additional reduction of 2.0 percentage points from the OPD fee schedule increase factor adjustment to the conversion factor that would be used to
calculate the OPPS payment rates for their services, as required by section 1833(l)(17) of the Act. For further discussion of the Hospital OQR Program, we refer readers to section XIII. of this final rule with comment period.

In the CY 2019 OPPS/ASC proposed rule, we proposed to amend 42 CFR 419.32(b)(1)(iv)(B) by adding a new paragraph (10) to reflect the requirement in section 1833(l)(3)(F)(i) of the Act that, for CY 2019, we reduce the OPD fee schedule increase factor by the MFP adjustment as determined by CMS, and to reflect the requirement in section 1833(l)(3)(G)(v) of the Act, as required by section 1833(l)(3)(F)(ii) of the Act, that we reduce the OPD fee schedule increase factor by an additional 0.75 percentage point for CY 2019.

To set the OPPS conversion factor for the CY 2019 OPPS/ASC proposed rule, we proposed to increase the CY 2018 conversion factor of $78.636 by 1.25 percent (63 FR 37073). In accordance with section 1833(l)(9)(B) of the Act, we proposed further to adjust the conversion factor for CY 2019 to ensure that any revisions made to the wage index and rural adjustment were made on a budget neutral basis. We proposed to calculate an overall budget neutrality factor of 1.0004 for wage index changes by comparing proposed total estimated payments from our simulation model using the proposed FY 2019 IPPS wage indexes to those payments using the FY 2018 IPPS wage indexes, as adopted on a calendar year basis for the OPPS.

For the CY 2019 OPPS/ASC proposed rule, we proposed to maintain the current rural adjustment policy, as discussed in section II.E. of the proposed rule and this final rule with comment period. Therefore, the proposed budget neutrality factor for the rural adjustment was 1.0000.

For the CY 2019 OPPS/ASC proposed rule, we proposed to continue previously established policies for implementing the cancer hospital payment adjustment described in section 1833(t)(18) of the Act, as discussed in section II.F. of the proposed rule and this final rule with comment period. We proposed to calculate a CY 2019 budget neutrality adjustment factor for the proposed CY 2019 cancer hospital payment adjustment by comparing estimated total CY 2019 payments under section 1833(l) of the Act, including the proposed CY 2019 cancer hospital payment adjustment, to estimated CY 2019 total payments using the CY 2018 final cancer hospital payment adjustment schedule under section 1833(l)(18)(B) of the Act. The CY 2019 proposed estimated payments applying the proposed CY 2019 cancer hospital payment adjustment were the same as estimated payments applying the CY 2018 final cancer hospital payment adjustment. Therefore, we proposed to apply a budget neutrality adjustment factor of 1.0000 to the conversion factor for the cancer hospital payment adjustment. In accordance with section 16002(b) of the 21st Century Cures Act, we stated in the proposed rule that we are applying a budget neutrality factor calculated as if the proposed cancer hospital adjustment target payment-to-cost ratio was 0.89, not the 0.88 target payment-to-cost ratio we are applying as stated in section II.F. of the proposed rule.

For the CY 2019 OPPS/ASC proposed rule, we estimated that proposed pass-through spending for drugs, biologicals, and devices for CY 2019 would equal approximately $126.7 million, which represented 0.17 percent of total projected CY 2019 OPPS spending. Therefore, the proposed conversion factor would be adjusted by the difference between the 0.17 percent estimate of pass-through spending for CY 2018 and the 0.17 percent estimate of proposed pass-through spending for CY 2019, resulting in a proposed decrease for CY 2019 of 0.13 percent. Proposed estimated payments for outliers would remain at 1.0 percent of total OPPS payments for CY 2019. We estimated for the proposed rule that outlier payments would be 1.02 percent of total OPPS payments in CY 2018; the 1.00 percent for proposed outlier payments in CY 2019 would constitute a 0.02 percent increase in payment in CY 2019 relative to CY 2018.

For the CY 2019 OPPS/ASC proposed rule, we also proposed that hospitals that fail to meet the reporting requirements of the Hospital OQR Program would continue to be subject to a further reduction of 2.0 percentage points to the OPD fee schedule increase factor. For hospitals that fail to meet the requirements of the Hospital OQR Program, we proposed to make all other adjustments discussed above, but use a reduced OPD fee schedule update factor of -0.75 percent (that is, the proposed OPD fee schedule increase factor of 1.25 percent further reduced by 2.0 percentage points). This would result in a proposed reduced conversion factor for CY 2019 of $77.955 for hospitals that fail to meet the Hospital OQR Program requirements (a difference of -1.591 in the conversion factor relative to hospitals that met the requirements).

In summary, for CY 2019, we proposed to increase the CY 2018 IPPS wage indexes, as adopted on a calendar year basis for the OPPS, to those payments using the CY 2018 IPPS wage indexes, as required by section 1833(t)(18) of the Act, as required by section 1833(t)(3)(F) and (t)(3)(G)(v) of the Act. We proposed to use a reduced conversion factor of $79.546 in the calculation of payments for hospitals that fail to meet the Hospital OQR Program requirements (a difference of -1.591 in the conversion factor relative to hospitals that met the requirements).

For CY 2019, we proposed to use a conversion factor of $79.546 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the proposed OPD fee schedule increase factor of 1.25 percent for CY 2019, the required proposed wage index budget neutrality adjustment of approximately 1.0004, the proposed cancer hospital payment adjustment of 1.0000, and the proposed adjustment of -0.13 percentage point of projected OPPS spending for the difference in pass-through spending that resulted in a proposed conversion factor for CY 2019 of $79.546.

We invited public comments on these proposals. However, we did not receive any public comments. Therefore, we are finalizing these proposals without modification. For CY 2019, we proposed to continue previously established policies for implementing the OPPS spending for the difference in pass-through spending that resulted in a proposed conversion factor for CY 2019 of $79.490 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the proposed OPD fee schedule increase factor of 1.25 percent for CY 2019, the required wage index budget neutrality adjustment of 1.0000 to the conversion factor for the hospital payment adjustment described in section 1833(l)(18) of the Act (discussed in section II.F. of this final rule with comment period). Based on the final rule updated data used in calculating the cancer hospital payment adjustment in section II.F. of this final rule with comment period, the target payment-to-cost ratio for the cancer hospital payment adjustment, which was 0.88 for CY 2018, is 0.88 for CY 2019. As a result, we are applying a budget neutrality adjustment factor of 1.0000 to the conversion factor for the cancer hospital payment adjustment.

As a result of these finalized policies, the OPD fee schedule increase factor for the CY 2019 OPPS is 1.35 percent (which reflects the 2.9 percent final estimate of the hospital inpatient market basket percentage increase, less the final 0.8 percentage point MFP adjustment, and less the 0.75 percentage point additional adjustment). For CY 2019, we are using a conversion factor of $79.490 in the calculation of the national unadjusted payment rates for those items and services for which payment rates are calculated using geometric mean costs; that is, the proposed OPD fee schedule increase factor of 1.25 percent for CY 2019, the required wage index budget neutrality adjustment of
approximate 0.9984, and the adjustment of 0.10 percentage point of projected OPPS spending for the difference in pass-through spending that results in a conversion factor for CY 2019 of $79.490.

C. Wage Index Changes

Section 1833(t)(2)(D) of the Act requires the Secretary to determine a wage adjustment factor to adjust the portion of payment and coinsurance attributable to labor-related costs for relative differences in labor and labor-related costs across geographic regions in a budget neutral manner (codified at 42 CFR 419.43(a)). This portion of the OPPS payment rate is called the OPPS labor-related share. Budget neutrality is discussed in section II.B. of this final rule with comment period.

The OPPS labor-related share is 60 percent of the national OPPS payment. This labor-related share is based on a regression analysis that determined that, for all hospitals, approximately 60 percent of the costs of services paid under the OPPS were attributable to wage costs. We confirmed that this labor-related share for outpatient services is appropriate during our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 66553). In the CY 2019 OPPS/ASC proposed rule (83 FR 37073), we proposed to continue this policy for the CY 2019 OPPS. We refer readers to section II.H. of this final rule with comment period for a description and an example of how the wage index for a particular hospital is used to determine payment for the hospital.

We did not receive any public comments on this proposal. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37073), we are finalizing our proposal, without modification, to continue this policy as discussed above for the CY 2019 OPPS.

As discussed in the claims accounting narrative included with the supporting documentation for this final rule with comment period (which is available via the internet on the CMS website), for estimating APC costs, we standardize 60 percent of estimated claims costs for geographic area wage variation using the same FY 2019 pre-reclassified wage index that the IPPS uses to standardize costs. This standardization process removes the effects of differences in area wage levels from the determination of a national unadjusted OPPS payment rate and copayment amount. Under 419.43(c)(1) and 419.43(c) (published in the OPPS April 7, 2000 final rule with comment period (65 FR 18495 and 18545)), the OPPS adopted the final fiscal year IPPS post-reclassified wage index as the calendar year wage index for adjusting the OPPS standard payment amounts for labor market differences. Therefore, the wage index that applies to a particular acute care, short-stay hospital under the IPPS also applies to that hospital under the OPPS. As initially explained in the September 8, 1998 OPPS proposed rule (63 FR 47576), we believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. In accordance with section 1886(d)(3)(E) of the Act, the IPPS wage index is updated annually.

The Affordable Care Act contained several provisions affecting the wage index. These provisions were discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74191). Section 10324 of the Affordable Care Act added section 1886(d)(3)(E)(iii)(II) to the Act, which defines a frontier State and amended section 1833(t) of the Act to add paragraph (19), which requires a frontier State wage index floor of 1.00 in certain cases, and states that the frontier State floor shall not be applied in a budget neutral manner. We codified these requirements at §419.43(c)(2) and (c)(3) of our regulations. For the CY 2019 OPPS, we proposed to implement this provision in the same manner as we have since CY 2011. Under this policy, the frontier State hospitals would receive a wage index of 1.00 if the otherwise applicable wage index (including reclassification, the rural floor, and rural floor budget neutrality) is less than 1.00 (as discussed below and in the CY 2019 OPPS/ASC proposed rule (83 FR 37073)). We referred readers to the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 41362 through 41390) for a detailed discussion of all proposed and final changes to the FY 2019 OPPS wage indexes.

We note that, in the CY 2019 IPPS/LTCH PPS proposed rule (83 FR 20362 through 20363), we proposed not to apply the imputed floor to the OPPS wage index computations for FY 2019 and subsequent fiscal years. Consistent with this, we proposed in the CY 2019 OPPS/ASC proposed rule (83 FR 37074) not to extend the imputed floor policy under the OPPS beyond December 31, 2018 (the date the imputed floor policy is set to expire under the OPPS). In the CY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380), we finalized our proposal to not extend the imputed floor policy under the OPPS. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380) for a detailed discussion of our rationale for discontinuing the imputed floor under the IPPS.

Summarized below are the comments we received regarding our proposal to discontinue the imputed floor under the OPPS, along with our response.

Comment: Several commenters agreed with the proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018.

Response: We appreciate the commenters’ support.
After consideration of the public comments we received, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074), consistent with the FY 2019 IPPS/LTCH PPS final rule, we are finalizing our proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018.

As discussed in the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 through 49963) and in each subsequent IPPS/LTCH PPS final rule, including the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41363), the Office of Management and Budget (OMB) issued revisions to the labor market area delineations on February 28, 2013 (based on 2010 Decennial Census data), that included a number of significant changes such as new Core Based Statistical Areas (CBSAs), urban counties that became rural, rural counties that became urban, and existing CBSAs that were split apart (OMB Bulletin 13–01). This bulletin can be found at: https://obamawhitehouse.archives.gov/sites/default/files/omb/bulletins/2013/b13-01.pdf. In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49950 through 49985), for purposes of the IPPS, we adopted the use of the OMB statistical area delineations contained in OMB Bulletin No. 13–01, effective October 1, 2014. For purposes of the OPPS, in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66826 through 66828), we adopted the use of the OMB statistical area delineations contained in OMB Bulletin No. 13–01, effective January 1, 2015, beginning with the CY 2015 OPPS wage indexes. In the FY 2017 IPPS/LTCH PPS final rule (81 FR 56913), we adopted revisions to statistical areas contained in OMB Bulletin No. 15–01, issued on July 15, 2015, which provided updates to and superseded OMB Bulletin No. 13–01 that was issued on February 28, 2013. For purposes of the OPPS, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79598), we adopted the revisions to the OMB statistical area delineations contained in OMB Bulletin No. 15–01, effective January 1, 2017, beginning with the CY 2017 OPPS wage indexes. We believe that it is important for the OPPS to use the latest labor market area delineations available as soon as is reasonably possible in order to maintain a more accurate and up-to-date payment system that reflects the reality of population shifts and labor market conditions.

On August 15, 2017, OMB issued OMB Bulletin No. 17–01, which provided updates to and superseded OMB Bulletin No. 15–01 that was issued on July 15, 2015. The attachments to OMB Bulletin No. 17–01 provide detailed information on the update to the statistical areas since July 15, 2015, and are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2014 and July 1, 2015. In OMB Bulletin No. 17–01, OMB announced that one Micropolitan Statistical Area now qualifies as a Metropolitan Statistical Area. The new urban CBSA is as follows:

- Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of the principal city of Twin Falls, Idaho in Jerome County, Idaho and Twin Falls County, Idaho.

The OMB Bulletin No. 17–01 is available on the OMB website at https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2017/b-17-01.pdf. In the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20354), we noted that we did not have sufficient time to include this change in the computation of the proposed FY 2019 IPPS wage index, ratesetting, and Tables 2 and 3 associated with the FY 2019 IPPS/LTCH PPS proposed rule. We stated that this new CBSA may affect the IPPS budget neutrality factors and wage indexes, depending on whether the area is eligible for the rural floor and the impact of the overall payments of the hospital located in this new CBSA.

As we stated in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41363), for the FY 2019 IPPS wage indexes, we used the OMB delineations that were adopted beginning with FY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and incorporated the revision from OMB Bulletin No. 17–01 in the final FY 2019 IPPS wage index, ratesetting, and tables. Similarly, in the CY 2019 OPPS/ASC proposed rule (82 FR 37075), for the proposed CY 2019 OPPS wage indexes, we proposed to use the OMB Bulletin No. 17–01.
delineations that were adopted beginning with CY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and stated that we would incorporate the revision from OMB Bulletin No. 17–01 in the final CY 2019 OPPS wage index, ratesetting, and tables. We did not receive any public comments on our proposals. Accordingly, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37074 through 37075), we are finalizing the proposal, without modification, to use the OMB delineations that were adopted beginning with CY 2015 to calculate the area wage indexes, with updates as reflected in OMB Bulletin Nos. 13–01, 15–01, and 17–01, and have incorporated the revision from OMB Bulletin No. 17–01 in the final CY 2019 OPPS wage index, ratesetting, and tables.

CBSAs are made up of one or more constituent counties. Each CBSA and constituent county has its own unique identifying codes. The FY 2018 IPPS/LTCH PPS final rule (82 FR 38130) discussed the two different lists of codes to identify counties: Social Security Administration (SSA) codes and Federal Information Processing Standard (FIPS) codes. Historically, CMS listed and used SSA and FIPS county codes to identify and crosswalk counties to CBSA codes for purposes of the IPPS and OPPS wage indexes. However, the SSA county codes are no longer being maintained and updated, although the FIPS codes continue to be maintained by the U.S. Census Bureau. The Census Bureau’s most current statistical area information is derived from ongoing census data received since 2010; the most recent data are from 2015. In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), for purposes of crosswalking counties to CBSAs for the IPPS wage index, we finalized our proposal to discontinue the use of the SSA county codes and begin using only the FIPS county codes. Similarly, for the purposes of crosswalking counties to CBSAs for the OPPS wage index, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59260), we finalized our proposal to discontinue the use of SSA county codes and begin using only the FIPS county codes for the purposes of crosswalking counties to CBSAs for the OPPS wage index.

The Census Bureau maintains a complete list of changes to counties or county equivalent entities on the website at https://www.census.gov/geo/reference/county-changes.html. In our transition to using only FIPS codes for counties for the IPPS wage index, in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38130), we updated the FIPS codes used for crosswalking counties to CBSAs for the IPPS wage index effective October 1, 2017, to incorporate changes to the counties or county equivalent entities included in the Census Bureau’s most recent list. We included these updates to calculate the area IPPS wage indexes in a manner that is generally consistent with the CBSA-based methodologies finalized in the FY 2005 IPPS final rule and the FY 2015 IPPS/LTCH PPS final rule. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59261), we finalized our proposal to implement these FIPS code updates for the OPPS wage index effective January 1, 2018, beginning with the CY 2018 OPPS wage indexes.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we proposed to use the FY 2019 hospital IPPS post-reclassified wage index for urban and rural areas as the wage index for the OPPS to determine the wage adjustment for both the OPPS payment rate and the copayment standardized amount for CY 2019. Therefore, we stated in the proposed rule that any adjustments for the FY 2019 IPPS post-reclassified wage index would be reflected in the final CY 2019 OPPS wage index. (We refer readers to the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20353 through 20377) and final rule (83 FR 41362 through 41390), and the proposed and final FY 2019 hospital wage index files posted on the CMS website.) We included these updates in the CY 2019 OPPS/ASC proposed rule (83 FR 37075) that we believe that using the IPPS wage index as the source of an adjustment factor for the OPPS is reasonable and logical, given the inseparable, subordinate status of the HOPD within the hospital overall. Summarized below are the comments we received regarding this proposal, along with our response.

Comment: Several commenters opposed applying a budget neutrality adjustment for the rural floor under the OPPS on a national basis. The commenters believed applying budget neutrality under the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment standardized amount for CY 2019. Therefore, any adjustments for the FY 2019 IPPS post-reclassified wage index are reflected in the final CY 2019 OPPS wage index. As stated earlier, we continue to believe that using the final fiscal year IPPS post-reclassified wage index, inclusive of any adjustments, as the wage index for the OPPS to determine the wage adjustments for both the OPPS payment rate and the copayment standardized amount is reasonable and logical, given the
inseparable, subordinate status of the HOPD within the hospital overall.

Hospitals that are paid under the OPPS, but not under the IPPS, do not have an assigned hospital wage index under the IPPS. Therefore, for non-IPPS hospitals paid under the OPPS, it is our longstanding policy to assign the wage index that would be applicable if the hospital were paid under the IPPS, based on its geographic location and any applicable wage index adjustments. In the FY 2019 OPPS/ASC proposed rule (83 FR 37075), we proposed to continue this policy for CY 2019, and included a brief summary of the major proposed FY 2019 IPPS wage index policies and adjustments that we proposed to apply to these hospitals under the OPPS for CY 2019, which we have summarized below. We invited public comments on these proposals. We refer readers to the FY 2019 IPPS/LTCH PPS final rule (83 FR 41362 through 41390) for a detailed discussion of the changes to the FY 2019 IPPS wage indexes.

Applying our longstanding policy to allow non-IPPS hospitals paid under the OPPS to qualify for the out-migration adjustment if they are located in a section 505 out-migration county (section 505 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA)). Applying this adjustment is consistent with our policy of adopting IPPS wage index policies for hospitals paid under the OPPS. We note that, because non-IPPS hospitals cannot reclassify, they are eligible for the out-migration wage adjustment if they are located in a section 505 out-migration county. This is the same out-migration adjustment policy that applies if the hospital were paid under the IPPS. For CY 2019, we proposed to continue our policy of assigning non-IPPS hospitals paid under the OPPS to qualify for the out-migration adjustment if they are located in a section 505 out-migration county (section 505 of the MMA). We did not receive any public comments on these proposals. Therefore, for the reasons discussed above and in the FY 2019 OPPS/ASC proposed rule (83 FR 37075 through 37076), we are finalizing these proposals without modification.

As stated earlier, in the FY 2015 IPPS/LTCH PPS final rule, we adopted the OMB labor market area delineations issued by OMB in OMB Bulletin No. 13–01 on February 28, 2013, based on standards published on June 28, 2010 (75 FR 37246 through 37252) and the 2010 Census data to delineate labor market areas and assign the IPPS wage index. For IPPS wage index purposes, for hospitals that were located in urban CBSAs in FY 2014 but were designated as rural under these revised OMB labor market area delineations, we generally assigned them the urban wage index value of the CBSA in which they were physically located for FY 2014 for a period of 3 fiscal years (79 FR 49957 through 49960). To be consistent, we applied the same policy to hospitals paid under the OPPS but not under the IPPS so that such hospitals maintained the wage index of the CBSA in which they were physically located for FY 2014 for 3 calendar years (until December 31, 2017). Because this 3-year transition ended at the end of CY 2017, it was not applied beginning in CY 2018.

In addition, in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20362 through 20363), we proposed not to extend the imputed floor policy under the IPPS for FY 2019 and subsequent fiscal years, and in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41376 through 41380), we finalized this proposal. Similarly, in the CY 2019 OPPS/ASC proposed rule, we proposed not to extend the imputed floor policy under the OPPS beyond December 31, 2018 (the date the policy is set to expire). The comments we received on this proposal, along with our response, are summarized above. As discussed earlier, consistent with the FY 2019 IPPS/LTCH PPS final rule, in this CY 2019 OPPS/ASC final rule with comment period, we are finalizing our proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018. As discussed earlier, consistent with the FY 2019 IPPS/LTCH PPS final rule, in this CY 2019 OPPS/ASC final rule with comment period, we are finalizing our proposal not to extend the imputed floor policy under the OPPS beyond December 31, 2018.

For CMHCs, for CY 2019, we proposed to continue to calculate the wage index by using the post-recategorization IPPS wage index based on the CBSA where the CMHC is located. As with OPPS hospitals and for the reasons mentioned earlier, for CMHCs located in urban CBSAs that were designated as rural under the revised OMB labor market area delineations in OMB Bulletin No. 13–01, we finalized a policy to maintain the urban wage index value of the CBSA in which they were physically located for FY 2014 for 3 calendar years (until December 31, 2017). Because this 3-year transition ended at the end of CY 2017, it was not applied beginning in CY 2018. We proposed that the wage index that would apply to CMHCs for CY 2019 would include the rural floor adjustment, but would not include the imputed floor adjustment because, as discussed above, we proposed to not extend the imputed floor policy beyond December 31, 2018. If so, we proposed that the wage index that would apply to CMHCs would not include the out-migration adjustment because that adjustment only applies to hospitals.

We did not receive any public comments on these proposals. Therefore, for the reasons discussed above and in the CY 2019 OPPS/ASC proposed rule (83 FR 37076), we are finalizing these proposals without modification.

Table 2 associated with the FY 2019 IPPS/LTCH PPS final rule (available via the internet on the CMS website at: http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovers/index.html) identifies counties eligible for the out-migration adjustment and IPPS hospitals that will receive the adjustment for FY 2019. We are including the out-migration adjustment information from Table 2 associated with the FY 2019 IPPS/LTCH PPS final rule as Addendum L to this final rule with comment period with the addition of non-IPPS hospitals that will receive the section 505 out-migration adjustment under the OPPS. Addendum L is available via the internet on the CMS website. We refer readers to the CMS website for the OPPS at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html. At this link, readers will find a link to the final FY 2019 IPPS wage index tables and Addendum L.

D. Statewide Average Default Cost-to-Charge Ratios (CCRs)

In addition to using CCRs to estimate costs from charges on claims for ratemsetting, CMS uses overall hospital-specific CCRs calculated from the hospital’s most recent cost report to determine outlier payments, payments for pass-through devices, and monthly interim transitional corridor payments under the OPPS during the PFS year. MACs cannot calculate a CCR for some hospitals because there is no cost report available. For these hospitals, CMS uses the statewide average default CCRs to determine the payments mentioned earlier until a hospital’s MAC is able to calculate the hospital’s actual CCR from its most recently submitted Medicare cost report. These hospitals include, but are not limited to, hospitals that are new, hospitals that have not accepted assignment of an existing hospital’s provider agreement, and hospitals that have not yet submitted a cost report.

CMS also uses the statewide average default CCRs to determine payments for hospitals that appear to have a biased CCR (that is, the CCR falls outside the predetermined ceiling threshold for a valid CCR) or for hospitals in which the most recent cost report reflects an all-
inclusive rate status (Medicare Claims Processing Manual (Pub. 100–04), Chapter 4, Section 10.11).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37076), we proposed to update the default ratios for CY 2019 using the most recent cost report data. We discussed our policy for using default CCRs, including setting the ceiling threshold for a valid CCR, in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599) in the context of our adoption of an outlier reconciliation policy for cost reports beginning on or after January 1, 2009. For detail on our process for calculating the statewide average CCRs, we referred readers to the CY 2019 OPPS proposed rule Claims Accounting Narrative that is posted on the CMS website. Table 5 published in the proposed rule (83 FR 37076 through 37078) listed the proposed statewide average default CCRs for OPPS services furnished on or after January 1, 2019, based on proposed rule data.

We did not receive any public comments on our proposal to use statewide average default CCRs if a MAC cannot calculate a CCR for a hospital and to use these CCRs to adjust charges to costs on claims data for setting the final CY 2019 OPPS relative payment weights. Therefore, we are finalizing our proposal without modification.

Table 9 below lists the statewide average default CCRs for OPPS services furnished on or after January 1, 2019, based on final rule data.

BILLING CODE 4120–01–P
### TABLE 9.—CY 2019 STATEWIDE AVERAGE CCRs

<table>
<thead>
<tr>
<th>State</th>
<th>Urban/Rural</th>
<th>CY 2019 Default CCR</th>
<th>Previous Default CCR (CY 2018 OPPS Final Rule)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALASKA</td>
<td>RURAL</td>
<td>0.655</td>
<td>0.659</td>
</tr>
<tr>
<td>ALASKA</td>
<td>URBAN</td>
<td>0.219</td>
<td>0.218</td>
</tr>
<tr>
<td>ALABAMA</td>
<td>RURAL</td>
<td>0.185</td>
<td>0.190</td>
</tr>
<tr>
<td>ALABAMA</td>
<td>URBAN</td>
<td>0.153</td>
<td>0.155</td>
</tr>
<tr>
<td>ARKANSAS</td>
<td>RURAL</td>
<td>0.194</td>
<td>0.186</td>
</tr>
<tr>
<td>ARKANSAS</td>
<td>URBAN</td>
<td>0.195</td>
<td>0.200</td>
</tr>
<tr>
<td>ARIZONA</td>
<td>RURAL</td>
<td>0.245</td>
<td>0.232</td>
</tr>
<tr>
<td>ARIZONA</td>
<td>URBAN</td>
<td>0.161</td>
<td>0.160</td>
</tr>
<tr>
<td>CALIFORNIA</td>
<td>RURAL</td>
<td>0.180</td>
<td>0.181</td>
</tr>
<tr>
<td>CALIFORNIA</td>
<td>URBAN</td>
<td>0.188</td>
<td>0.193</td>
</tr>
<tr>
<td>COLORADO</td>
<td>RURAL</td>
<td>0.344</td>
<td>0.346</td>
</tr>
<tr>
<td>COLORADO</td>
<td>URBAN</td>
<td>0.198</td>
<td>0.204</td>
</tr>
<tr>
<td>CONNECTICUT</td>
<td>RURAL</td>
<td>0.323</td>
<td>0.324</td>
</tr>
<tr>
<td>CONNECTICUT</td>
<td>URBAN</td>
<td>0.248</td>
<td>0.249</td>
</tr>
<tr>
<td>DISTRICT OF COLUMBIA</td>
<td>URBAN</td>
<td>0.268</td>
<td>0.279</td>
</tr>
<tr>
<td>DELAWARE</td>
<td>URBAN</td>
<td>0.266</td>
<td>0.295</td>
</tr>
<tr>
<td>FLORIDA</td>
<td>RURAL</td>
<td>0.169</td>
<td>0.158</td>
</tr>
<tr>
<td>FLORIDA</td>
<td>URBAN</td>
<td>0.134</td>
<td>0.138</td>
</tr>
<tr>
<td>GEORGIA</td>
<td>RURAL</td>
<td>0.225</td>
<td>0.222</td>
</tr>
<tr>
<td>GEORGIA</td>
<td>URBAN</td>
<td>0.195</td>
<td>0.198</td>
</tr>
<tr>
<td>HAWAII</td>
<td>RURAL</td>
<td>0.340</td>
<td>0.332</td>
</tr>
<tr>
<td>HAWAII</td>
<td>URBAN</td>
<td>0.320</td>
<td>0.322</td>
</tr>
<tr>
<td>IOWA</td>
<td>RURAL</td>
<td>0.285</td>
<td>0.296</td>
</tr>
<tr>
<td>IOWA</td>
<td>URBAN</td>
<td>0.240</td>
<td>0.254</td>
</tr>
<tr>
<td>IDAHO</td>
<td>RURAL</td>
<td>0.418</td>
<td>0.339</td>
</tr>
<tr>
<td>IDAHO</td>
<td>URBAN</td>
<td>0.344</td>
<td>0.369</td>
</tr>
<tr>
<td>ILLINOIS</td>
<td>RURAL</td>
<td>0.206</td>
<td>0.214</td>
</tr>
<tr>
<td>ILLINOIS</td>
<td>URBAN</td>
<td>0.211</td>
<td>0.208</td>
</tr>
<tr>
<td>INDIANA</td>
<td>RURAL</td>
<td>0.250</td>
<td>0.299</td>
</tr>
<tr>
<td>INDIANA</td>
<td>URBAN</td>
<td>0.209</td>
<td>0.213</td>
</tr>
<tr>
<td>KANSAS</td>
<td>RURAL</td>
<td>0.258</td>
<td>0.264</td>
</tr>
<tr>
<td>State</td>
<td>Urban/Rural</td>
<td>CY 2019 Default CCR</td>
<td>Previous Default CCR (CY 2018 OPPS Final Rule)</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>KANSAS</td>
<td>URBAN</td>
<td>0.187</td>
<td>0.199</td>
</tr>
<tr>
<td>KENTUCKY</td>
<td>RURAL</td>
<td>0.175</td>
<td>0.184</td>
</tr>
<tr>
<td>KENTUCKY</td>
<td>URBAN</td>
<td>0.189</td>
<td>0.187</td>
</tr>
<tr>
<td>LOUISIANA</td>
<td>RURAL</td>
<td>0.212</td>
<td>0.212</td>
</tr>
<tr>
<td>LOUISIANA</td>
<td>URBAN</td>
<td>0.191</td>
<td>0.195</td>
</tr>
<tr>
<td>MASSACHUSETTS</td>
<td>RURAL</td>
<td>0.322</td>
<td>0.322</td>
</tr>
<tr>
<td>MASSACHUSETTS</td>
<td>URBAN</td>
<td>0.336</td>
<td>0.348</td>
</tr>
<tr>
<td>MAINE</td>
<td>RURAL</td>
<td>0.395</td>
<td>0.419</td>
</tr>
<tr>
<td>MAINE</td>
<td>URBAN</td>
<td>0.373</td>
<td>0.422</td>
</tr>
<tr>
<td>MARYLAND</td>
<td>RURAL</td>
<td>0.253</td>
<td>0.258</td>
</tr>
<tr>
<td>MARYLAND</td>
<td>URBAN</td>
<td>0.226</td>
<td>0.227</td>
</tr>
<tr>
<td>MICHIGAN</td>
<td>RURAL</td>
<td>0.297</td>
<td>0.302</td>
</tr>
<tr>
<td>MICHIGAN</td>
<td>URBAN</td>
<td>0.312</td>
<td>0.318</td>
</tr>
<tr>
<td>MINNESOTA</td>
<td>RURAL</td>
<td>0.364</td>
<td>0.379</td>
</tr>
<tr>
<td>MINNESOTA</td>
<td>URBAN</td>
<td>0.306</td>
<td>0.302</td>
</tr>
<tr>
<td>MISSOURI</td>
<td>RURAL</td>
<td>0.213</td>
<td>0.220</td>
</tr>
<tr>
<td>MISSOURI</td>
<td>URBAN</td>
<td>0.244</td>
<td>0.240</td>
</tr>
<tr>
<td>MISSISSIPPI</td>
<td>RURAL</td>
<td>0.209</td>
<td>0.213</td>
</tr>
<tr>
<td>MISSISSIPPI</td>
<td>URBAN</td>
<td>0.160</td>
<td>0.160</td>
</tr>
<tr>
<td>MONTANA</td>
<td>RURAL</td>
<td>0.476</td>
<td>0.486</td>
</tr>
<tr>
<td>MONTANA</td>
<td>URBAN</td>
<td>0.334</td>
<td>0.350</td>
</tr>
<tr>
<td>NORTH CAROLINA</td>
<td>RURAL</td>
<td>0.200</td>
<td>0.206</td>
</tr>
<tr>
<td>NORTH CAROLINA</td>
<td>URBAN</td>
<td>0.211</td>
<td>0.212</td>
</tr>
<tr>
<td>NORTH DAKOTA</td>
<td>RURAL</td>
<td>0.326</td>
<td>0.366</td>
</tr>
<tr>
<td>NORTH DAKOTA</td>
<td>URBAN</td>
<td>0.375</td>
<td>0.369</td>
</tr>
<tr>
<td>NEBRASKA</td>
<td>RURAL</td>
<td>0.293</td>
<td>0.313</td>
</tr>
<tr>
<td>NEBRASKA</td>
<td>URBAN</td>
<td>0.238</td>
<td>0.233</td>
</tr>
<tr>
<td>NEW HAMPSHIRE</td>
<td>RURAL</td>
<td>0.309</td>
<td>0.307</td>
</tr>
<tr>
<td>NEW HAMPSHIRE</td>
<td>URBAN</td>
<td>0.259</td>
<td>0.255</td>
</tr>
<tr>
<td>NEW JERSEY</td>
<td>URBAN</td>
<td>0.198</td>
<td>0.200</td>
</tr>
<tr>
<td>NEW MEXICO</td>
<td>RURAL</td>
<td>0.205</td>
<td>0.224</td>
</tr>
<tr>
<td>NEW MEXICO</td>
<td>URBAN</td>
<td>0.274</td>
<td>0.284</td>
</tr>
<tr>
<td>NEVADA</td>
<td>RURAL</td>
<td>0.163</td>
<td>0.175</td>
</tr>
<tr>
<td>NEVADA</td>
<td>URBAN</td>
<td>0.125</td>
<td>0.114</td>
</tr>
<tr>
<td>NEW YORK</td>
<td>RURAL</td>
<td>0.303</td>
<td>0.299</td>
</tr>
<tr>
<td>NEW YORK</td>
<td>URBAN</td>
<td>0.268</td>
<td>0.303</td>
</tr>
</tbody>
</table>
In the CY 2006 OPPS final rule with comment period (70 FR 68556), we finalized a payment increase for rural sole community hospitals (SCHs) of 7.1 percent for all services and procedures paid under the OPPS, excluding drugs, biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act, as added by section 411 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) (Pub. L. 108–173). Section 1833(t)(13) of the Act provided the Secretary the authority to make an adjustment to OPPS payments for rural hospitals, effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural areas and hospitals in urban areas. Our analysis

<table>
<thead>
<tr>
<th>State</th>
<th>Urban/Rural</th>
<th>CY 2019 Default CCR</th>
<th>Previous Default CCR (CY 2018 OPPS Final Rule)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OHIO</td>
<td>RURAL</td>
<td>0.268</td>
<td>0.280</td>
</tr>
<tr>
<td>OHIO</td>
<td>URBAN</td>
<td>0.250</td>
<td>0.203</td>
</tr>
<tr>
<td>OKLAHOMA</td>
<td>RURAL</td>
<td>0.213</td>
<td>0.215</td>
</tr>
<tr>
<td>OKLAHOMA</td>
<td>URBAN</td>
<td>0.172</td>
<td>0.169</td>
</tr>
<tr>
<td>OREGON</td>
<td>RURAL</td>
<td>0.267</td>
<td>0.290</td>
</tr>
<tr>
<td>OREGON</td>
<td>URBAN</td>
<td>0.326</td>
<td>0.336</td>
</tr>
<tr>
<td>PENNSYLVANIA</td>
<td>RURAL</td>
<td>0.262</td>
<td>0.267</td>
</tr>
<tr>
<td>PENNSYLVANIA</td>
<td>URBAN</td>
<td>0.177</td>
<td>0.173</td>
</tr>
<tr>
<td>PUERTO RICO</td>
<td>URBAN</td>
<td>0.555</td>
<td>0.577</td>
</tr>
<tr>
<td>RHODE ISLAND</td>
<td>URBAN</td>
<td>0.277</td>
<td>0.276</td>
</tr>
<tr>
<td>SOUTH CAROLINA</td>
<td>RURAL</td>
<td>0.167</td>
<td>0.170</td>
</tr>
<tr>
<td>SOUTH CAROLINA</td>
<td>URBAN</td>
<td>0.184</td>
<td>0.191</td>
</tr>
<tr>
<td>SOUTH DAKOTA</td>
<td>RURAL</td>
<td>0.346</td>
<td>0.391</td>
</tr>
<tr>
<td>SOUTH DAKOTA</td>
<td>URBAN</td>
<td>0.237</td>
<td>0.242</td>
</tr>
<tr>
<td>TENNESSEE</td>
<td>RURAL</td>
<td>0.169</td>
<td>0.173</td>
</tr>
<tr>
<td>TENNESSEE</td>
<td>URBAN</td>
<td>0.179</td>
<td>0.174</td>
</tr>
<tr>
<td>TEXAS</td>
<td>RURAL</td>
<td>0.210</td>
<td>0.205</td>
</tr>
<tr>
<td>TEXAS</td>
<td>URBAN</td>
<td>0.167</td>
<td>0.168</td>
</tr>
<tr>
<td>UTAH</td>
<td>RURAL</td>
<td>0.298</td>
<td>0.391</td>
</tr>
<tr>
<td>UTAH</td>
<td>URBAN</td>
<td>0.318</td>
<td>0.304</td>
</tr>
<tr>
<td>VIRGINIA</td>
<td>RURAL</td>
<td>0.183</td>
<td>0.177</td>
</tr>
<tr>
<td>VIRGINIA</td>
<td>URBAN</td>
<td>0.210</td>
<td>0.215</td>
</tr>
<tr>
<td>VERMONT</td>
<td>RURAL</td>
<td>0.414</td>
<td>0.393</td>
</tr>
<tr>
<td>VERMONT</td>
<td>URBAN</td>
<td>0.397</td>
<td>0.378</td>
</tr>
<tr>
<td>WASHINGTON</td>
<td>RURAL</td>
<td>0.261</td>
<td>0.256</td>
</tr>
<tr>
<td>WASHINGTON</td>
<td>URBAN</td>
<td>0.326</td>
<td>0.323</td>
</tr>
<tr>
<td>WISCONSIN</td>
<td>RURAL</td>
<td>0.348</td>
<td>0.348</td>
</tr>
<tr>
<td>WISCONSIN</td>
<td>URBAN</td>
<td>0.314</td>
<td>0.308</td>
</tr>
<tr>
<td>WEST VIRGINIA</td>
<td>RURAL</td>
<td>0.257</td>
<td>0.253</td>
</tr>
<tr>
<td>WEST VIRGINIA</td>
<td>URBAN</td>
<td>0.276</td>
<td>0.297</td>
</tr>
<tr>
<td>WYOMING</td>
<td>RURAL</td>
<td>0.401</td>
<td>0.407</td>
</tr>
<tr>
<td>WYOMING</td>
<td>URBAN</td>
<td>0.325</td>
<td>0.327</td>
</tr>
</tbody>
</table>
showed a difference in costs for rural SCHs. Therefore, for the CY 2006 OPPS, we finalized a payment adjustment for rural SCHs of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act.

In the CY 2007 OPPS/ASC final rule with comment period (71 FR 68010 and 68227), for purposes of receiving this rural adjustment, we revised § 419.43(g) of the regulations to clarify that essential access community hospitals (EACHs) also are eligible to receive the rural SCH adjustment, assuming these entities otherwise meet the rural adjustment criteria. Currently, two hospitals are classified as EACHs, and as of CY 1998, under section 4201(c) of Pub. L. 105–33, a hospital can no longer become newly classified as an EACH.

This adjustment for rural SCHs is budget neutral and applied before calculating outlier payments and copayments. We stated in the CY 2006 OPPS final rule with comment period (70 FR 68560) that we would not reestablish the adjustment amount on an annual basis, but we may review the adjustment in the future and, if appropriate, would revise the adjustment. We provided the same 7.1 percent adjustment to rural SCHs, including EACHs, again in CYs 2008 through 2018. Further, in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68590), we updated the regulations at 419.43(g)(4) to specify, in general terms, that items paid at charges reduced to costs by application of a hospital-specific CCR are excluded from the 7.1 percent payment adjustment.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37078), for the CY 2019 OPPS, we proposed to continue the current policy of a 7.1 percent payment adjustment that is done in a budget neutral manner for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the pass-through payment policy, and items paid at charges reduced to costs. We invited public comment on our proposal.

In addition, we proposed to maintain this 7.1 percent payment adjustment for the years after CY 2019 until we identify data in the future that would support a change to this payment adjustment. We invited public comments on our proposal.

Response: Several commenters supported the proposal to continue the 7.1 percent payment adjustment for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the pass-through payment policy, and items paid at charges reduced to costs. A few commenters explicitly supported the part of the proposal that would allow the adjustment to continue after CY 2019 until CMS identifies data that would cause CMS to reassess the adjustment. These commenters approved of having more certainty about whether the rural SCH adjustment would be in effect on an ongoing basis, because it would help hospitals covered by the adjustment improve their budget forecasting based on expected revenues.

Response: We appreciate the commenters’ support.

Comment: One commenter suggested that CMS further examine whether the payment adjustment for rural SCHs, including EACHs, should continue to be 7.1 percent. The commenter noted the rate of the payment adjustment was based on data analyses that are more than 10 years old.

Response: While the data for the initial analyses are more than 10 years old, we periodically review the calculations used to generate the rural SCHs and EACHs adjustment. For any given year, the level of increased costs experienced by rural SCH and EACH may be higher or lower than the current 7.1 percent adjustment. Since being established in CY 2008, we believe the payment increase of 7.1 percent has continued to reasonably reflect the increased costs that rural SCHs and EACHs face when providing outpatient hospital services based on regression analyses performed on the claims data.

Comment: Some commenters requested that CMS expand the payment adjustment for rural SCHs and EACHs to additional types of hospitals. One commenter requested that the payment adjustment apply to include urban SCHs because, according to the commenter, urban SCHs care for patient populations similar to rural SCHs and EACHs, face similar financial challenges to rural SCHs and EACHs, and act as safety net providers for rural areas despite their designation as urban providers. Another commenter requested that the payment adjustment also apply to Medicare-dependent hospitals (MDHs) because, according to the commenter, these hospitals face similar financial challenges to rural SCHs and EACHs, and MDHs play a similar safety net role to rural SCHs and EACHs, especially for Medicare.

One commenter requested that the payment adjustment for all rural hospitals be increased to reduce financial vulnerability for rural hospitals related to the high share of Medicare and Medicaid beneficiaries they serve.

Response: We thank the commenters for their comments. However, the analysis we did to compare costs of urban providers to those of rural providers did not support an add-on adjustment for providers other than rural SCHs and EACHs, and our follow-up analyses performed in recent years have not shown differences in costs for all services for any of the additional types of providers mentioned by the commenters. Accordingly, we do not believe we currently have a basis to expand the payment adjustment to any other providers other than rural SCHs and EACHs.

After consideration of the public comments we received, we are implementing our proposals, without modification, to continue the current policy of a 7.1 percent payment adjustment that is done in a budget neutral manner for rural SCHs, including EACHs, for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, devices paid under the pass-through payment policy, and items paid at charges reduced to costs. In addition, we will maintain this 7.1 percent payment adjustment for the years after CY 2019 until our data support a change to this payment adjustment.

F. Payment Adjustment for Certain Cancer Hospitals for CY 2019

1. Background

Since the inception of the OPPS, which was authorized by the Balanced Budget Act of 1997 (BBA) (Pub. L. 105–33), Medicare has paid the 11 hospitals that meet the criteria for cancer hospitals identified in section 1886(d)(1)(B)(v) of the Act under the OPPS for covered outpatient hospital services. These cancer hospitals are exempted from payment under the IPPS. With the Medicare, Medicaid and SCHIP Balanced Budget Refinement Act of 1999 (Pub. L. 106–113), Congress established section 1833(t)(7) of the Act, “ Transitional Adjustment to Limit Decline in Payment,” to determine OPPS payments to cancer and children’s hospitals based on their pre-BBA payment amount (often referred to as “held harmless”).

As required under section 1833(t)(7)(D)(ii) of the Act, a cancer hospital receives the full amount of the difference between payments for covered outpatient services under the IPPS and a “pre-BBA amount.” That is, cancer hospitals are permanently held harmless to their “pre-BBA amount.”
and they receive transitional outpatient payments (TOPs) or hold harmless payments to ensure that they do not receive a payment that is lower in amount under the OPPS than the payment amount they would have received before implementation of the OPPS, as set forth in section 1833(t)(7)(F) of the Act. The “pre-BBA amount” is the product of the hospital’s reasonable costs for covered outpatient services occurring in the current year and the base payment-to-cost ratio (PCR) for the hospital defined in section 1833(t)(7)(F)(ii) of the Act. The “pre-BBA amount” and the determination of the base PCR are defined at 42 CFR 419.70(f). TOPs are calculated on Worksheet E, Part B, of the Hospital Cost Report or the Hospital Health Care Complex Cost Report (Form CMS–2552–96 or Form CMS–2552–10, respectively), as applicable each year. Section 1833(t)(7)(H) of the Act exempts TOPs from budget neutrality calculations.

Section 3138 of the Affordable Care Act amended section 1833(t) of the Act by adding a new paragraph (18), which instructs the Secretary to conduct a study to determine if, under the OPPS, outpatient costs incurred by cancer hospitals described in section 1886(d)(1)(B)(v) of the Act with respect to APC groups exceed outpatient costs incurred by other hospitals furnishing services under section 1833(t) of the Act, as determined appropriate by the Secretary. Section 1833(t)(18)(A) of the Act requires the Secretary to take into consideration the cost of drugs and biologicals incurred by cancer hospitals and other hospitals. Section 1833(t)(18)(B) of the Act provides that, if the Secretary determines that cancer hospitals’ costs are higher than those of other hospitals, the Secretary shall provide an appropriate adjustment under section 1833(t)(2)(E) of the Act to reflect these higher costs. In 2011, after conducting the study required by section 1833(t)(18)(A) of the Act, we determined that outpatient costs incurred by the 11 specified cancer hospitals were higher than the costs incurred by other OPPS hospitals. For a complete discussion regarding the cancer hospital cost study, we refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74200 through 74201).

Based on these findings, we finalized a policy to provide a payment adjustment to the 11 specified cancer hospitals that reflects their higher outpatient costs, as discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74202 through 74206). Specifically, we adopted a policy to provide additional payments to the cancer hospitals so that each cancer hospital’s final PCR for services provided in a given calendar year is equal to the weighted average PCR (which we refer to as the “target PCR”) for other hospitals paid under the OPPS. The target PCR is set in advance of the calendar year and is calculated using the most recently submitted or settled cost report data that are available at the time of final rulemaking for the calendar year. The amount of the payment adjustment is made on an aggregate basis at cost report settlement. We note that the changes made by section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs are assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period. For CYs 2012 and 2013, the target PCR for purposes of the cancer hospital payment adjustment was 0.91. For CY 2014, the target PCR for purposes of the cancer hospital payment adjustment was 0.89. For CY 2015, the target PCR was 0.90. For CY 2016, the target PCR was 0.92, as discussed in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70362 through 70363). For CY 2017, the target PCR was 0.91, as discussed in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79603 through 79604). For CY 2018, the target PCR was 0.88, as discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59265 through 59266).

2. Policy for CY 2019

Section 16002(b) of the 21st Century Cures Act (Pub. L. 114–255) amended section 1833(t)(18) of the Act by adding a new subparagraph (C), which requires that in applying 42 CFR 419.43(i) (that is, the payment adjustment for certain cancer hospitals) for services furnished on or after January 1, 2018, the target PCR adjustment be reduced by 1.0 percentage point less than what would otherwise apply. Section 16002(b) also provides that, in addition to the percentage reduction, the Secretary may consider making an additional percentage point reduction to the target PCR that takes into account payment rates for applicable items and services described under section 1833(t)(21)(C) of the Act for hospitals that are not cancer hospitals described under section 1886(d)(1)(B)(v) of the Act. Further, in making any budget neutrality adjustment under section 1833(t)(18) of the Act, the Secretary shall not take into account the reduced expenditures that result from application of section 1833(t)(18)(C) of the Act.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37079), for CY 2019, we proposed to provide additional payments to the 11 specified cancer hospitals so that each cancer hospital’s final PCR is equal to the weighted average PCR (or “target PCR”) for the other OPPS hospitals using the most recent submitted or settled cost report data that were available at the time of the development of the proposed rule, reduced by 1.0 percentage point, to comply with section 16002(b) of the 21st Century Cures Act. We invited public comment on our proposal. We did not propose an additional reduction beyond the 1.0 percentage point reduction required by section 16002(b) for CY 2019. To calculate the proposed CY 2019 target PCR, we used the same extract of cost report data from HCRIS, as discussed in section II.A, of the proposed rule and this final rule with comment period, used to estimate costs for the CY 2019 OPPS. Using these cost report data, we included data from Worksheet E, Part B, for each hospital, using data from each hospital’s most recent cost report, whether as submitted or settled.

We then limited the dataset to the hospitals with CY 2017 claims data that we used to model the impact of the proposed CY 2019 APC relative payment weights (3,676 hospitals) because it is appropriate to use the same set of hospitals that are being used to calibrate the modeled CY 2019 OPPS. The cost report data for the hospitals in this dataset were from cost report periods with fiscal year ends ranging from 2014 to 2017. We then removed the cost report data of the 43 hospitals located in Puerto Rico from our dataset because we did not believe their cost structure reflected the costs of most hospitals paid under the OPPS, and, therefore, their inclusion may bias the calculation of hospital-weighted statistics. We also removed the cost report data of 18 hospitals because these hospitals had cost report data that were not complete (missing aggregate OPPS payments, missing aggregate cost data, or missing both), so that all cost reports in the study would have both the payment and cost data necessary to calculate a PCR for each hospital, leading to a proposed analytic file of 3,615 hospitals with cost report data. Using this smaller dataset of cost report data, we estimated that, on average, the OPPS payments to other hospitals furnishing services under the OPPS were appropriate with respect to the average cost of reasonable cost (weighted average PCR of 0.89). Therefore, after applying the
1.0 percentage point reduction, as required by section 16002(b) of the 21st Century Cures Act, we proposed that the payment amount associated with the cancer hospital payment adjustment to be determined at cost report settlement would be the additional payment needed to result in a proposed target PCR equal to 0.88 for each cancer hospital.

We did not receive any public comments on our proposals. Therefore, we are finalizing our proposed cancer hospital payment adjustment methodology without modification. For this final rule with comment period, we are using the most recent cost report data through June 30, 2018 to update the adjustment. This update yields a target PCR of 0.89. We limited the dataset to the hospitals with CY 2017 claims data that we used to model the impact of the CY 2019 APC relative payment weights (3,696 hospitals) because it is appropriate to use the same set of hospitals that we are using to calibrate the modeled CY 2019 OPPS. The cost report data for the hospitals in the dataset were from cost report periods with fiscal year ends ranging from 2010 to 2018. We then removed the cost report data of the 46 hospitals located in Puerto Rico from our dataset because we do not believe that their cost structure reflects the costs of most hospitals paid under the OPPS and, therefore, their inclusion may bias the calculation of hospital-weighted statistics. We also removed the cost report data of 22 hospitals because these hospitals had cost report data that were not complete (missing aggregate OPPS payments, missing aggregate cost data, or missing both), so that all cost reports in the study would have both the payment and cost data necessary to calculate a PCR for each hospital, leading to an analytic file of 3,628 hospitals with cost report data.

Using this smaller dataset of cost report data, we estimated a target PCR of 0.89. Therefore, after applying the 1.0 percentage point reduction as required by section 16002(b) of the 21st Century Cures Act, we are finalizing that the payment amount associated with the cancer hospital payment adjustment to be determined at cost report settlement will be the additional payment needed to result in a PCR equal to 0.88 for each cancer hospital. Table 10 below shows the estimated percentage increase in OPPS payments to each hospital for CY 2019, due to the cancer hospital payment adjustment policy. The actual amount of the CY 2019 cancer hospital payment adjustment for each hospital will be determined at cost report settlement and will depend on each hospital’s CY 2019 payments and costs. We note that the requirements contained in section 1833(t)(18) of the Act do not affect the existing statutory provisions that provide for TOPs for cancer hospitals. The TOPs will be assessed, as usual, after all payments, including the cancer hospital payment adjustment, have been made for a cost reporting period.

**TABLE 10.—ESTIMATED CY 2019 HOSPITAL-SPECIFIC PAYMENT ADJUSTMENT FOR CANCER HOSPITALS TO BE PROVIDED AT COST REPORT SETTLEMENT**

<table>
<thead>
<tr>
<th>Provider Number</th>
<th>Hospital Name</th>
<th>Estimated Percentage Increase in OPPS Payments for CY 2019 due to Payment Adjustment</th>
</tr>
</thead>
<tbody>
<tr>
<td>050146</td>
<td>City of Hope Comprehensive Cancer Center</td>
<td>37.1%</td>
</tr>
<tr>
<td>050660</td>
<td>USC Norris Cancer Hospital</td>
<td>13.4%</td>
</tr>
<tr>
<td>100079</td>
<td>Sylvester Comprehensive Cancer Center</td>
<td>21.0%</td>
</tr>
<tr>
<td>100271</td>
<td>H. Lee Moffitt Cancer Center &amp; Research Institute</td>
<td>22.3%</td>
</tr>
<tr>
<td>220162</td>
<td>Dana-Farber Cancer Institute</td>
<td>43.7%</td>
</tr>
<tr>
<td>330154</td>
<td>Memorial Sloan-Kettering Cancer Center</td>
<td>46.4%</td>
</tr>
<tr>
<td>330354</td>
<td>Roswell Park Cancer Institute</td>
<td>16.2%</td>
</tr>
<tr>
<td>360242</td>
<td>James Cancer Hospital &amp; Solove Research Institute</td>
<td>22.6%</td>
</tr>
<tr>
<td>390196</td>
<td>Fox Chase Cancer Center</td>
<td>8.4%</td>
</tr>
<tr>
<td>450076</td>
<td>M.D. Anderson Cancer Center</td>
<td>53.6%</td>
</tr>
<tr>
<td>500138</td>
<td>Seattle Cancer Care Alliance</td>
<td>54.3%</td>
</tr>
</tbody>
</table>
G. Hospital Outpatient Outlier Payments

1. Background

The OPPS provides outlier payments to hospitals to help mitigate the financial risk associated with high-cost and complex procedures, where a very costly service could present a hospital with significant financial loss. As explained in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66832 through 66834), we set our projected target for aggregate outlier payments at 1.0 percent of the estimated aggregate total payments under the OPPS for the prospective year. Outlier payments are provided on a service-by-service basis when the cost of a service exceeds the APC payment amount multiplier threshold (the APC payment amount multiplied by a certain amount) as well as the APC payment amount plus a fixed-dollar amount threshold (the APC payment plus a certain amount of dollars). In CY 2018, the outlier threshold was met when the hospital’s cost of furnishing a service exceeded 1.75 times (the multiplier threshold) the APC payment amount and exceeded the APC payment amount plus $4,150 (the fixed-dollar amount threshold) (82 FR 59267 through 59268). If the cost of a service exceeds both the multiplier threshold and the fixed-dollar threshold, the outlier payment is calculated as 50 percent of the amount by which the cost of furnishing the service exceeds 1.75 times the APC payment amount. Beginning with CY 2009 payments, outlier payments are subject to a reconciliation process similar to the IPPS outlier reconciliation process for cost reports, as discussed in the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599).

It has been our policy to report the actual amount of outlier payments as a percent of total spending in the claims being used to model the OPPS. Our estimate of total outlier payments as a percent of total CY 2017 OPPS payments, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

2. Outlier Calculation for CY 2019

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2019 would be approximately 1.02 percent of the total CY 2019 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

For the CY 2019 OPPS/ASC proposed rule, using CY 2017 claims data and CY 2018 payment rates, we estimate that the aggregate outlier payments for CY 2018 would be approximately 1.02 percent of the total CY 2018 OPPS payments. We provided estimated CY 2019 outlier payments for hospitals and CMHCs with claims included in the claims data that we used to model impacts in the Hospital-Specific Impacts—Provider-Specific Data file on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.
constant and assuming that outlier payments would continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payments equaled 1.0 percent of aggregated estimated total CY 2019 OPPS payments. We estimated that a proposed fixed-dollar threshold of $4,600, combined with the proposed multiplier threshold of 1.75 times the APC payment rate, would allocate 1.0 percent of aggregated total OPPS payments to outlier payments. For CMHCs, we proposed that, if a CMHC’s cost for partial hospitalization services, paid under APC 5853, exceeds 3.40 times the payment rate for APC 5853, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.40 times the APC 5853 payment rate.

Section 1833(l)(17)(A) of the Act, which applies to hospitals, as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to report data required for the quality measures selected by the Secretary, in the form and manner required by the Secretary under section 1833(l)(17)(B) of the Act, incur a 2.0 percentage point reduction to their OPD fee schedule increase factor; that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that will apply to certain outpatient items and services furnished by hospitals that are required to report onpatient quality data and that fail to meet the Hospital OQR Program requirements. For hospitals that fail to meet the Hospital OQR Program requirements, as we proposed, we are continuing the policy that we implemented in CY 2010 that the hospitals’ costs will be compared to the reduced payments for purposes of outlier eligibility and payment calculation. For more information on the Hospital OQR Program, we referred readers to section XIII. of this final rule with comment period.

Comment: One commenter expressed concern that, due to the increase in the proposed fixed-dollar threshold to $4,600 relative to the previous CY 2018 fixed-dollar outlier threshold of $4,150, the drastic reduction in outlier payments would have an adverse effect on access to services for Medicare beneficiaries. Therefore, the commenter requested that the threshold be transitioned over a 3-year period.

Response: As indicated earlier, we introduced a fixed-dollar threshold in order to better target outlier payments to those high-cost and complex procedures where a very costly service could present a hospital with significant financial loss. We maintain the target outlier percentage of 1.0 percent of estimated aggregate total payment under the OPPS and have a fixed-dollar threshold so that OPPS outlier payments are made only when the hospital would experience a significant loss for furnishing a particular service. The methodology we use to calculate the fixed-dollar threshold for the prospective payment year factors is based on several data inputs that may change from prior payment years. For instance, updated hospital CCR data and changes to the OPPS payment methodology influence projected outlier payments in the prospective year.

We do not believe that it is appropriate to transition towards implementation of the CY 2019 OPPS fixed-dollar outlier threshold in the manner described by the commenter. The fixed-dollar outlier threshold is specifically developed in order to best estimate aggregate outlier payments of 1 percent of the OPPS. In addition, transitioning in this suggested manner would remove the consideration of updated data, which is critical in best estimating the fixed-dollar threshold that would result in total OPPS outliers being 1 percent of aggregate OPPS payments. Finally, we note that the increase in the fixed-dollar outlier threshold does not necessarily result in a decrease in aggregate OPPS outlier payments. Rather, it ensures that the aggregate pool remains at 1 percent and that outlier payments are directed towards the high cost and complex procedures associated with potential financial risk.

After consideration of the public comment we received, we are finalizing our proposal, without modification, to continue our policy of estimating outlier payments to be 1.0 percent of the estimated aggregate total payments under the OPPS and to use our established methodology to set the OPPS outlier fixed-dollar loss threshold for CY 2019.

3. Final Outlier Calculation

Consistent with historical practice, we used updated data for this final rule with comment period for outlier calculations. For CY 2019, we are applying the overall CCRs from the October 2018 OPPS file after adjustment (using the CCR inflation adjustment factor of 0.9813 to approximate CY 2019 CCRs) to charges on CY 2017 claims that were adjusted using a charge inflation factor of 1.033 to approximate CY 2019 charges. These are the same CCR adjustment and charge inflation factors that were used to set the IPPS fixed-dollar thresholds for the FY 2019 IPPS/LTCH PPS final rule (83 FR 41722). We simulated aggregated CY 2019 hospital outlier payments using these costs for several different fixed-dollar thresholds, holding the 1.75 multiple-threshold constant and assuming that outlier payments will continue to be made at 50 percent of the amount by which the cost of furnishing the service would exceed 1.75 times the APC payment amount, until the total outlier payment equaled 1.0 percent of aggregated estimated total CY 2019 OPPS payments. We estimate that a fixed-dollar threshold of $4,825 combined with the multiple threshold of 1.75 times the APC payment rate, will allocated the 1.0 percent of aggregated total OPPS payments to outlier payments.

For CMHCs, if a CMHC’s cost for partial hospitalization services, paid under PAC 5853, exceeds 3.40 times the payment rate the outlier payment will be calculated as 50 percent of the amount by which the cost exceeds 3.40 times APC 5853.

H. Calculation of an Adjusted Medicare Payment From the National Unadjusted Medicare Payment

The basic methodology for determining prospective payment rates for HOPD services under the OPPS is set forth in existing regulations at 42 CFR part 419, subparts C and D. For this CY 2019 OPPS/ASC final rule with comment period, the payment rate for most services and procedures for which payment is made under the OPPS is the product of the conversion factor calculated in accordance with section II.B. of this final rule with comment period and the relative payment weight determined under section II.A. of this final rule with comment period. Therefore, the national unadjusted payment rate for most APCs contained in Addendum A to this final rule with comment period (which is available via the internet on the CMS website) was calculated by multiplying the CY 2019 scaled weight for the APC by the CY 2019 conversion factor.

We note that section 1833(l)(17) of the Act, which applies to hospitals as defined under section 1886(d)(1)(B) of the Act, requires that hospitals that fail to submit data required to be submitted on quality measures selected by the Secretary, in the format and manner and at a time specified by the Secretary, incur a reduction of 2.0 percentage
points to their OPD fee schedule increase factor, that is, the annual payment update factor. The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that apply to certain outpatient items and services provided by hospitals that are required to report outpatient quality data and that fail to meet the Hospital OQR Program (formerly referred to as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP)) requirements. For further discussion of the payment reduction for hospitals that fail to meet the requirements of the Hospital OQR Program, we refer readers to section XIII. of this final rule with comment period.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37082), we demonstrated the steps to determine the APC payments that will be made in a calendar year under the OPPS to a hospital that fulfills the Hospital OQR Program requirements and to a hospital that fails to meet the Hospital OQR Program requirements for a service that has any of the following status indicator assignments: “J1”, “J2”, “P”, “Q1”, “Q2”, “Q3”, “Q4”, “R”, “S”, “T”, “U”, or “V” (as defined in Addendum D1 to the proposed rule, which is available via the internet on the CMS website), in a circumstance in which the multiple procedure discount does not apply, the procedure is not bilateral, and conditionally packaged services (status indicator of “Q1” and “Q2”) qualify for separate payment. We noted that, although blood and blood products with status indicator “R” and brachytherapy sources with status indicator “U” are not subject to wage adjustment, they are subject to reduced payments when a hospital fails to meet the Hospital OQR Program requirements.

We did not receive any public comments specific to the steps under the methodology that we included in the proposed rule to determine the APC payments for CY 2019. Therefore, we are finalizing use of the steps in the methodology presented below, as we proposed, to demonstrate the calculation of the final CY 2019 OPPS payments using the same parameters.

Individual providers interested in calculating the payment amount that they will receive for a specific service from the national unadjusted payment rates presented in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website) should follow the formulas presented in the following steps. For purposes of the payment calculations below, we refer to the national unadjusted payment rate for hospitals that meet the requirements of the Hospital OQR Program as the “full” national unadjusted payment rate. We refer to the national unadjusted payment rate for hospitals that fail to meet the requirements of the Hospital OQR Program as the “reduced” national unadjusted payment rate. The reduced national unadjusted payment rate is calculated by multiplying the reporting ratio of 0.980 times the “full” national unadjusted payment rate. The national unadjusted payment rate used in the calculations below is either the full national unadjusted payment rate or the reduced national unadjusted payment rate, depending on whether the hospital met its Hospital OQR Program requirements in order to receive the full CY 2019 OPPS fee schedule increase factor.

**Step 1.** Calculate 60 percent (the labor-related portion) of the national unadjusted payment rate. Since the initial implementation of the OPPS, we have used 60 percent to represent our estimate of that portion of costs attributable, on average, to labor. We refer readers to the April 7, 2000 OPPS final rule with comment period (65 FR 18496 through 18497) for a detailed discussion of how we derived this percentage. During our regression analysis for the payment adjustment for rural hospitals in the CY 2006 OPPS final rule with comment period (70 FR 68553), we confirmed that this labor-related share for hospital outpatient services is appropriate.

The formula below is a mathematical representation of Step 1 and identifies the labor-related portion of the national payment rate for a specific service.

\[
X = 0.60 \times \text{(national unadjusted payment rate)}
\]

**Step 2.** Determine the wage index area in which the hospital is located and identify the wage index level that applies to the specific hospital. We note that, under the CY 2019 OPPS policy for continuing to use the OMB labor market area delineations based on the 2010 Decennial Census data for the wage indexes used under the IPPS, a hold harmless policy for the wage index may apply, as discussed in section II.C. of this final rule with comment period. The wage index values assigned to each area reflect the geographic statistical areas (which are based upon OMB standards) to which hospitals are assigned for FY 2019 under the IPPS, reclassification through the Metropolitan Gross Classification Review Board (MGCRB), section 1886(d)(8)(B) “Lugar” hospitals, reclassifications under section 1886(d)(8)(G) of the Act, as defined in §412.103 of the regulations, and hospitals designated as urban under section 601(g) of Public Law 98–21. For further discussion of the changes to the FY 2019 IPPS wage indexes, as applied to the CY 2019 OPPS, we refer readers to section II.C. of this final rule with comment period. We are continuing to apply a wage index floor of 1.00 to frontier States, in accordance with section 10324 of the Affordable Care Act of 2010.

**Step 3.** Adjust the wage index of hospitals located in certain qualifying counties that have a relatively high percentage of hospital employees who reside in the county, but who work in a different county with a higher wage index, in accordance with section 505 of Public Law 108–173. Addendum L to this final rule with comment period (which is available via the internet on the CMS website) contains the qualifying counties and the associated wage index increase developed for the FY 2019 OPPS, which are listed in Table 2 associated with the FY 2019 IPPS/ LTCH PPS final rule available via the internet on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ AcutepatientPPS/index.html. (Click on the link on the left side of the screen titled “FY 2019 IPPS Final Rule Home Page” and select “FY 2019 Final Rule Tables.”) This step is to be followed only if the hospital is not reclassified or redesignated under section 1886(d)(8) or section 1886(d)(10) of the Act.

**Step 4.** Multiply the applicable wage index determined under Steps 2 and 3 by the amount determined under Step 1 that represents the labor-related portion of the national unadjusted payment rate.

The formula below is a mathematical representation of Step 4 and adjusts the labor-related portion of the national unadjusted payment rate for the specific service by the wage index.

\[
x = 0.60 \times \text{(national unadjusted payment rate)}
\]

**Step 5.** Calculate 40 percent (the nonlabor-related portion) of the national unadjusted payment rate and add that amount to the resulting product of Step 4. The result is the wage index adjusted payment rate for the relevant wage index area.

The formula below is a mathematical representation of Step 5 and calculates the remaining portion of the national payment rate, the amount not
attributable to labor, and the adjusted payment for the specific service.

Y is the nonlabor-related portion of the national unadjusted payment rate.

Y = 40 * (national unadjusted payment rate).

Adjusted Medicare Payment = Y + X.

Step 6. If a provider is an SCH, as set forth in the regulations at § 412.92, or an EACH, which is considered to be an SCH under section 1886(d)(5)(D)(ii)(III) of the Act, and located in a rural area, as defined in § 412.64(b), or is treated as being located in a rural area under § 412.103, multiply the wage index adjusted payment rate by 1.071 to calculate the total payment.

The formula below is a mathematical representation of Step 6 and applies the rural adjustment for rural SCHs.

Adjusted Medicare Payment (SCH or EACH) = Adjusted Medicare Payment * 1.071.

We are providing examples below of the calculation of both the full and reduced national unadjusted payment rates that will apply to certain outpatient items and services performed by hospitals that meet and that fail to meet the Hospital OQR Program requirements, using the steps outlined above. For purposes of this example, we used a provider that is located in Brooklyn, New York that is assigned to CBSA 35614. This provider bills one service that is assigned to APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage). The CY 2019 full national unadjusted payment rate for APC 5071 is approximately $579.34. The reduced national unadjusted payment rate for APC 5071 for a hospital that fails to meet the Hospital OQR Program requirements is approximately $567.75. This reduced rate is calculated by multiplying the reporting ratio of 0.980 by the full unadjusted payment rate for APC 5071.

The FY 2019 wage index for a provider located in CBSA 35614 in New York is 1.2853. The labor-related portion of the full national unadjusted payment is approximately $446.77 (60 * $579.34 * 1.2853). The labor-related portion of the reduced national unadjusted payment is approximately $437.84 (60 * $567.75 * 1.2853). The nonlabor-related portion of the full national unadjusted payment is approximately $231.74 (40 * $579.34). The nonlabor-related portion of the reduced national unadjusted payment is approximately $227.10 (40 * $567.75). The sum of the labor-related and nonlabor-related portions of the full national unadjusted payment is approximately $678.51 ($446.77 + $231.74). The sum of the portions of the reduced national adjusted payment is approximately $664.94 ($437.84 + $227.10).

I. Beneficiary Copayments

1. Background

Section 1833(i)(3)(B) of the Act requires the Secretary to set rules for determining the unadjusted copayment amounts to be paid by beneficiaries for covered OPD services. Section 1833(i)(8)(C)(ii) of the Act specifies that the Secretary must reduce the national unadjusted copayment amount for a covered OPD service (or group of such services) furnished in a year in a manner so that the effective copayment rate (determined on a national unadjusted basis) for that service in the year does not exceed a specified percentage. As specified in section 1833(i)(8)(C)(ii)(V) of the Act, the effective copayment rate for a covered OPD service paid under the OPPS in CY 2006, and in calendar years thereafter, shall not exceed 40 percent of the APC payment rate.

Section 1833(i)(3)(B)(ii) of the Act provides that, for a covered OPD service (or group of such services) furnished in a year, the national unadjusted copayment amount cannot be less than 20 percent of the OPD fee schedule amount. However, section 1833(i)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure (including items such as drugs and biologicals) performed in a year to the amount of the inpatient hospital deductible for that year.

Section 4104 of the Affordable Care Act eliminated the Medicare Part B coinsurance for preventive services furnished on and after January 1, 2011, that meet certain requirements, including flexible sigmoidoscopies and screening colonoscopies, and waived the Part B deductible for screening colonoscopies that become diagnostic during the procedure. Our discussion of the changes made by the Affordable Care Act with regard to copayments for preventive services furnished on and after January 1, 2011, may be found in section XII.B. of the CY 2011 OPPS/ASC final rule with comment period (75 FR 72013).

2. OPPS Copayment Policy

In the CY 2019 OPPS/ASC proposed rule (83 FR 37083), for CY 2019, we proposed to determine copayment amounts for new and revised APCs using the same methodology that we implemented in CY 2004. (We refer readers to the November 7, 2003 OPPS final rule with comment period (68 FR 63458).) In addition, we proposed to use the same standard rounding principles that we have historically used in instances where the application of our standard copayment methodology would result in a copayment amount that is less than 20 percent and cannot be rounded, under standard rounding principles, to 20 percent. (We refer readers to the CY 2008 OPPS/ASC final rule with comment period (72 FR 66667) in which we discuss our rationale for applying these rounding principles.) The proposed national unadjusted copayment amounts for services payable under the OPPS that would be effective January 1, 2019 were included in Addenda A and B to the proposed rule (which are available via the internet on the CMS website).

As discussed in section XIII.E. of the proposed rule and this final rule with comment period, for CY 2019, the Medicare beneficiary’s minimum unadjusted copayment and national unadjusted copayment for a service to which a reduced national unadjusted payment rate applies will equal the product of the reporting ratio and the national unadjusted copayment, or the product of the reporting ratio and the minimum unadjusted copayment, respectively, for the service.

We note that OPPS copayments may increase or decrease each year based on changes in the calculated APC payment rates due to updated cost report and claims data, and any changes to the OPPS cost modeling process. However, as described in the CY 2004 OPPS final rule with comment period, the development of the copayment methodology generally moves beneficiary copayments closer to 20 percent of OPPS APC payments (68 FR 63458 through 63459).

In the CY 2004 OPPS final rule with comment period (68 FR 63459), we adopted a new methodology to calculate unadjusted copayment amounts in situations including reorganizing APCs, and we finalized the following rules to determine copayment amounts in CY 2004 and subsequent years.

- When an APC group consists solely of HCPCS codes that were not paid under the OPPS the prior year because they were packaged or excluded or are new codes, the unadjusted copayment amount would be 20 percent of the APC payment rate.
- If a new APC that did not exist during the prior year is created and consists of HCPCS codes previously assigned to other APCs, the copayment amount is calculated as the product of the APC payment rate and the lowest
coinsurance percentage of the codes comprising the new APC.

- If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is equal to or greater than the prior year’s rate, the copayment amount remains constant (unless the resulting coinsurance percentage is less than 20 percent).

- If no codes are added to or removed from an APC and, after recalibration of its relative payment weight, the new payment rate is less than the prior year’s rate, the copayment amount is calculated as the product of the new payment rate and the prior year’s coinsurance percentage.

- If HCPCS codes are added to or deleted from an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in a decrease in the coinsurance percentage for the reconfigured APC, the copayment amount would not change (unless retaining the copayment amount would result in a coinsurance rate less than 20 percent).

- If HCPCS codes are added to an APC and, after recalibrating its relative payment weight, holding its unadjusted copayment amount constant results in an increase in the coinsurance percentage for the reconfigured APC, the copayment amount would be calculated as the product of the payment rate of the reconfigured APC and the lowest coinsurance percentage of the codes being added to the reconfigured APC.

We noted in the CY 2004 OPPS final rule with comment period that we would seek to lower the copayment percentage for a service in an APC from the prior year if the copayment percentage was greater than 20 percent. We noted that this principle was consistent with section 1833(t)(8)(C)(ii) of the Act, which accelerates the reduction in the national unadjusted coinsurance rate to that beneficiary liability will eventually equal 20 percent of the OPPS payment rate for all OPPS services to which a copayment applies, and with section 1833(t)(3)(B) of the Act, which achieves a 20-percent copayment percentage when fully phased in and gives the Secretary the authority to set rules for determining copayment amounts for new services. We further noted that the use of this methodology would, in general, reduce the beneficiary coinsurance rate and copayment amount for APCs for which the payment rate changes as the result of the reconfiguration of APCs and/or recalibration of relative payment weights (68 FR 63459).

Comment: One commenter supported the beneficiary copayment limit that may be collected for certain drugs to the amount of the inpatient hospital deductible for that year.

Response: We appreciate the commenter’s support. We note that section 1833(t)(8)(C)(i) of the Act requires us to limit the amount of beneficiary copayment that may be collected for a procedure (including items such as drugs and biologicals) performed in a year to the amount of the inpatient hospital deductible for that year.

3. Calculation of an Adjusted Copayment Amount for an APC Group

Individuals interested in calculating the national copayment liability for a Medicare beneficiary for a given service provided by a hospital that met or failed to meet its Hospital QRR Program requirements should follow the formulas presented in the following steps.

Step 1. Calculate the beneficiary payment percentage for the APC by dividing the APC’s national unadjusted copayment by its payment rate. For example, using APC 5071, $115.87 is approximately 20 percent of the full national unadjusted payment rate of $579.34. For APCs with only a minimum unadjusted copayment in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website), the beneficiary payment percentage is 20 percent.

The formula below is a mathematical representation of Step 1 and calculates the national copayment as a percentage of national payment for a given service. B is the beneficiary payment percentage. B = National unadjusted copayment for APC/national unadjusted payment rate for APC.

Step 2. Calculate the appropriate wage-adjusted payment rate for the APC for the procedure in question, as indicated in Steps 2 through 4 under section II.H. of this final rule with comment period. Calculate the rural adjustment for eligible providers as indicated in Step 6 under section II.H. of this final rule with comment period.

Step 3. Multiply the percentage calculated in Step 1 by the payment rate calculated in Step 2. The result is the wage-adjusted copayment amount for the APC.

The formula below is a mathematical representation of Step 3 and applies the beneficiary payment percentage to the adjusted payment rate for a service calculated under section II.H. of this final rule with comment period, with and without the rural adjustment, to calculate the adjusted beneficiary copayment for a given service.

Wage-adjusted copayment amount for the APC = Adjusted Medicare Payment * B.

Wage-adjusted copayment amount for the APC (SCH or EACH) = (Adjusted Medicare Payment * 1.071) * B.

Step 4. For a hospital that failed to meet its Hospital QRR Program requirements, multiply the copayment calculated in Step 3 by the reporting ratio of 0.980.

The unadjusted copayments for services payable under the OPPS that will be effective January 1, 2019, are shown in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website). We note that the national unadjusted payment rates and copayment rates shown in Addenda A and B to this final rule with comment period reflect the CY 2019 OPPS fee schedule increase factor discussed in section II.B. of this final rule with comment period.

In addition, as noted earlier, section 1833(t)(8)(C)(i) of the Act limits the amount of beneficiary copayment that may be collected for a procedure performed in a year to the amount of the inpatient hospital deductible for that year.

III. OPPS Ambulatory Payment Classification (APC) Group Policies

A. OPPS Treatment of New CPT and Level II HCPCS Codes

CPT and Level II HCPCS codes are used to report procedures, services, items, and supplies under the hospital OPPS. Specifically, CMS recognizes the following codes on OPPS claims:

- Category I CPT codes, which describe surgical procedures and medical services;
- Category III CPT codes, which describe new and emerging technologies, services, and procedures; and
- Level II HCPCS codes, which are used primarily to identify products, supplies, temporary procedures, and services not described by CPT codes.

CPT codes are established by the American Medical Association (AMA) and the Level II HCPCS codes are established by CMS. These codes are updated and changed throughout the year. CPT and HCPCS code changes that affect the OPPS are published both through the annual rulemaking cycle and through the OPPS Change Requests (CRs). CMS releases new Level II HCPCS codes to the public.
or recognizes the release of new CPT codes by the AMA and makes these codes effective (that is, the codes can be reported on Medicare claims) outside of the formal rulemaking process via OPPS quarterly update CRs. Based on our review, we assign the new CPT and Level II HCPCS codes to interim status indicators (SIs) and APCs. These interim assignments are finalized in the OPPS/ASC final rules. This quarterly process offers hospitals access to codes that may more accurately describe items or services furnished and provides payment or more accurate payment for these items or services in a timelier manner than if we waited for the annual rulemaking process. We solicit public comments on these new codes and finalize our proposals related to these codes through our annual rulemaking process.

We note that, under the OPPS, the APC assignment determines the payment rate for an item, procedure, or service. Those items, procedures, or services not paid separately under the hospital OPPS are assigned to appropriate status indicators. Certain payment status indicators provide separate payment, while other payment status indicators do not. Section XI. of this final rule with comment period discusses the various status indicators used under the OPPS.

In Table 11 below, we summarize our current process for updating codes through our OPPS quarterly update CRs, seeking public comments, and finalizing the treatment of these new codes under the OPPS.

### TABLE 11.—COMMENT TIMEFRAME FOR NEW OR REVISED HCPCS CODES

<table>
<thead>
<tr>
<th>OPPS Quarterly Update CR</th>
<th>Type of Code</th>
<th>Effective Date</th>
<th>Comments Sought</th>
<th>When Finalized</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>April 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td>July 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>July 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td></td>
<td>Category I (certain vaccine codes)</td>
<td>July 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td></td>
<td>CPT Codes, Category III CPT codes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>October 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>October 1, 2018</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
<td>CY 2020 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td>January 1, 2019</td>
<td>Category I and III CPT Codes</td>
<td>January 1, 2019</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td></td>
<td>Level II HCPCS Codes</td>
<td>January 1, 2019</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
<td>CY 2020 OPPS/ASC final rule with comment period</td>
</tr>
</tbody>
</table>
1. Treatment of New HCPCS Codes That Were Effective April 1, 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule

Through the April 2018 OPPS quarterly update CR (Transmittal 4005, Change Request 10515, dated March 20, 2018), we made effective nine new Level II HCPCS codes for separate payment under the OPPS. In the CY 2019 OPPS/ASC proposed rule (83 FR 37085), we solicited public comments on the proposed APC and status indicator assignments for these Level II HCPCS codes, which were listed in Table 8 of the proposed rule.

We received some public comments related to HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)), which we address in section III.D.16. of this final rule with comment period. With the exception of HCPCS code C9749, we did not receive any public comments on the proposed OPPS APC and status indicator assignments for the new Level II HCPCS codes implemented in April 2018. Therefore, we are finalizing the proposed APC and status indicator assignments for these codes, as indicated in Table 12 below. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. Their replacement codes are listed in Table 12. The final payment rates for these codes can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 to this final rule with comment period (which is available via the internet on the CMS website).

In addition, there were several new laboratory CPT Multianalyte Assays with Algorithmic Analyses (MAAA) codes (M-codes) and Proprietary Laboratory Analyses (PLA) codes (U-codes) that were effective April 1, 2018, but were too late to include in the April 2018 OPPS Update. Because these codes were released on the American Medical Association’s (AMA) CPT website in February 2018, they were too late for us to include in the April 2018 OPPS Update CR and in the April 2018 Integrated Outpatient Code Editor (IOCE) and, consequently, were included in the July 2018 OPPS Update with an effective date of April 1, 2018. These CPT codes were listed in Table 9 of the CY 2019 OPPS/ASC proposed rule (83 FR 37086). In the proposed rule, we solicited public comments on the proposed APC and status indicator assignments for these CPT codes. The proposed payment rates for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website).

**Comment:** One commenter stated that the test described by CPT code 0037U (Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden) specifically, FoundationOne CDx™, is a human DNA tumor mutation profiling test that is covered by Medicare and has been designated as an Advanced Diagnostic Laboratory Test (ADLT) under the Clinical Laboratory Fee Schedule (CLFS). The commenter supported the proposed OPPS status indicator assignment of “A” (Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS) for CPT code 0037U.

**Response:** We thank the commenter for the feedback. CPT code 0037U,

### Table 12.—NEW LEVEL II HCPCS CODES EFFECTIVE APRIL 1, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>C9462</td>
<td>C9462</td>
<td>Injection, delafloxacin, 1 mg</td>
<td>G</td>
<td>9462</td>
</tr>
<tr>
<td>C9463</td>
<td>J0185</td>
<td>Injection, aprepitant, 1 mg</td>
<td>G</td>
<td>9463</td>
</tr>
<tr>
<td>C9464</td>
<td>J2797</td>
<td>Injection, rolapitant, 0.5 mg</td>
<td>G</td>
<td>9464</td>
</tr>
<tr>
<td>C9465</td>
<td>J7318</td>
<td>Hyaluronan or derivative, Duolane, for intra-articular injection, per dose</td>
<td>G</td>
<td>9465</td>
</tr>
<tr>
<td>C9466</td>
<td>J0517</td>
<td>Injection, benralizumab, 1 mg</td>
<td>G</td>
<td>9466</td>
</tr>
<tr>
<td>C9467</td>
<td>J9311</td>
<td>Injection, rituximab 10 mg and hyaluronidase</td>
<td>G</td>
<td>9467</td>
</tr>
<tr>
<td>C9468</td>
<td>J7203</td>
<td>Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu</td>
<td>G</td>
<td>9468</td>
</tr>
<tr>
<td>C9469*</td>
<td>J3304*</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
<td>G</td>
<td>9469</td>
</tr>
<tr>
<td>C9749</td>
<td>C9749</td>
<td>Repair of nasal vestibular lateral wall stenosis with implant(s)</td>
<td>J1</td>
<td>5164</td>
</tr>
</tbody>
</table>

*HCPCS code C9469 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), which was effective April 1, 2018, was deleted June 30, 2018 and replaced with HCPCS code Q9993 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg) effective July 1, 2018. HCPCS code Q9993 was deleted December 31, 2018, and replaced with HCPCS code J3304 effective January 1, 2019.
which is covered by Medicare, met the criteria for classification as a new ADLT and received its ADLT status in May 2018. Under the OPPS, codes that receive ADLT status under section 1834A(d)(5)(A) of the Act are assigned to status indicator “A”. Therefore, we are finalizing the OPPS status indicator “A” for CPT code 0037U as proposed. After consideration of the public comment we received, we are finalizing the proposed status indicator assignments for the new MAAA and PLA CPT codes effective April 1, 2018. The final status indicator assignments for the CPT codes are listed in Table 13 below. The status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website).
### TABLE 13.—NEW CPT MAAA AND PROPRIETARY LABORATORY ANALYSES (PLA) CODES EFFECTIVE APRIL 1, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0012M</td>
<td>Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and XCR2), utilizing urine, algorithm reported as a risk score for having urothelial carcinoma</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0013M</td>
<td>Oncology (urothelial), mRNA, gene expression profiling by real-time quantitative PCR of five genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm reported as a risk score for having recurrent urothelial carcinoma</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0035U</td>
<td>Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0036U</td>
<td>Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0037U</td>
<td>Targeted genomic sequence analysis, solid organ neoplasm, DNA analysis of 324 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0038U</td>
<td>Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0039U</td>
<td>Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0040U</td>
<td>BCR/ABL1 (t(9;22)) (eg, chronic myelogenous leukemia) translocation analysis, major breakpoint, quantitative</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0041U</td>
<td>Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM</td>
<td>Q4</td>
<td>N/A</td>
</tr>
</tbody>
</table>
2. Treatment of New HCPCS Codes That Were Effective July 1, 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule

Through the July 2018 OPPS quarterly update CR (Transmittal 4075, Change Request 1078, dated June 15, 2018), we made 4 new Category III CPT codes and 10 Level II HCPCS codes effective July 1, 2018 (14 codes total), and assigned them to appropriate interim OPPS status indicators and APCs. As listed in Table 10 of the CY 2019 OPPS/ASC proposed rule (83 FR 37086 through 37087), 13 of the 14 HCPCS codes are separately payable under the OPPS while 1 HCPCS code is not. Specifically, HCPCS code Q9993 is assigned to status indicator “E1” to indicate that the item is not payable by Medicare. In addition, we note that HCPCS code C9469 was deleted June 30, 2018, and replaced with HCPCS code Q9993 effective July 1, 2018. Because HCPCS code Q9993 describes the same drug as HCPCS code C9469, we proposed to continue the drug’s pass-through payment status and to assign HCPCS code Q9993 to the same APC and status indicators as its predecessor HCPCS code C9469, as shown in Table 10 of the proposed rule.

In the CY 2019 OPPS/ASC proposed rule, we solicited public comments on the proposed APC and status indicator assignments for CY 2019 for the CPT and Level II HCPCS codes implemented on July 1, 2018, all of which were listed in Table 10 of the proposed rule. The proposed payment rates and status indicators for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website).

We did not receive any public comments on the proposed APC and status indicator assignments for the new Category III CPT codes and Level II HCPCS codes implemented in July 2018. Therefore, we are finalizing the proposed APC and status indicator assignments for these codes, as indicated in Table 14 below. We note that several of the HCPCS C and Q-codes have been replaced with HCPCS J-codes effective January 1, 2019. Their replacement codes are listed in Table 14 below. The final payment rates for these codes can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0042U</td>
<td>Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0043U</td>
<td>Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0044U</td>
<td>Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>C9030</td>
<td>J9057</td>
<td>Injection, copanlisib, 1 mg</td>
<td>G</td>
</tr>
<tr>
<td>C9031</td>
<td>A9513</td>
<td>Lutetium Lu 177, dotatate, therapeutic, 1 millicurie</td>
<td>G</td>
</tr>
<tr>
<td>C9032</td>
<td>J3398</td>
<td>Injection, voretigene neparvovec-rzyl, 1 billion vector genome</td>
<td>G</td>
</tr>
<tr>
<td>Q5105</td>
<td>Q5105</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units</td>
<td>G</td>
</tr>
<tr>
<td>Q5106</td>
<td>Q5106</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units</td>
<td>G</td>
</tr>
<tr>
<td>Q9991</td>
<td>Q9991</td>
<td>Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg</td>
<td>G</td>
</tr>
<tr>
<td>Q9992</td>
<td>Q9992</td>
<td>Injection, buprenorphine extended-release (Sublocade), greater than 100 mg</td>
<td>G</td>
</tr>
<tr>
<td>Q9993*</td>
<td>J3304*</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
<td>G</td>
</tr>
<tr>
<td>Q9994</td>
<td>Q9994</td>
<td>In-line cartridge containing digestive enzyme(s) for enteral feeding, each</td>
<td>E1</td>
</tr>
<tr>
<td>Q9995</td>
<td>J7170</td>
<td>Injection, emicizumab-kxwh, 0.5 mg</td>
<td>G</td>
</tr>
<tr>
<td>0505T</td>
<td>0505T</td>
<td>Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion</td>
<td>J1</td>
</tr>
</tbody>
</table>
In addition, there are several new PLA codes (U-codes) that were effective July 1, 2018, but were too late to include in the July 2018 OPPS Update. Consequently, the codes were included in the October 2018 OPPS Update with an effective date of July 1, 2018. The CPT codes were listed in Table 11 of the CY 2019 OPPS/ASC proposed rule along with the proposed APC and status indicator assignments for these CPT codes. In the CY 2019 OPPS/ASC proposed rule (83 FR 37087), we solicited public comments on the proposed APC and status indicator assignments for the CPT codes. The proposed payment rates for these codes, where applicable, were included in Addendum B to the proposed rule (which is available via the internet on the CMS website).

We did not receive any public comments on the proposed status indicator assignments for the PLA codes effective July 1, 2018. Therefore, we are finalizing the proposed status indicator assignments for these codes, as indicated in Table 15 below. We note that the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website).

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0506T</td>
<td>0506T</td>
<td>Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report</td>
<td>Q1</td>
<td>5733</td>
</tr>
<tr>
<td>0507T</td>
<td>0507T</td>
<td>Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report</td>
<td>Q1</td>
<td>5733</td>
</tr>
<tr>
<td>0508T</td>
<td>0508T</td>
<td>Pulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia</td>
<td>S</td>
<td>5522</td>
</tr>
</tbody>
</table>

1HCPCS code C9469 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), which was effective April 1, 2018, was deleted June 30, 2018 and replaced with HCPCS code Q9993 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), effective July 1, 2018. HCPCS code Q9993 was deleted December 31, 2018, and replaced with HCPCS code J3304, effective January 1, 2019.
### TABLE 15.—NEW CPT PROPRIETARY LABORATORY ANALYSES (PLA) CODES EFFECTIVE JULY 1, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0045U</td>
<td>Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0046U</td>
<td>FLT3 (fms-related tyrosine kinase 3) (eg, acute myeloid leukemia) internal tandem duplication (ITD) variants, quantitative</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0047U</td>
<td>Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0048U</td>
<td>Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0049U</td>
<td>NPMI (nucleophosmin) (eg, acute myeloid leukemia) gene analysis, quantitative</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0050U</td>
<td>Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0051U</td>
<td>Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>0052U</td>
<td>Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0053U</td>
<td>Oncology (prostate cancer), FISH analysis of 4 genes (ASAP1, HDAC9, CHD1 and PTEN), needle biopsy specimen, algorithm reported as probability of higher tumor grade</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0054U</td>
<td>Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0055U</td>
<td>Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0056U</td>
<td>Hematology (acute myelogenous leukemia), DNA, whole genome next-generation sequencing to detect gene rearrangement(s), blood or bone marrow, report of specific gene rearrangement(s)</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0057U</td>
<td>Oncology (solid organ neoplasia), mRNA, gene expression profiling by massively parallel sequencing for analysis of 51 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a normalized percentile rank</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0058U</td>
<td>Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative</td>
<td>Q4</td>
<td>N/A</td>
</tr>
<tr>
<td>0059U</td>
<td>Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative</td>
<td>Q4</td>
<td>N/A</td>
</tr>
</tbody>
</table>
In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to continue this process for CY 2019. Specifically, for CY 2019, we proposed to include in Addendum B to the CY 2019 OPPS/ASC final rule with comment period the following new HCPCS codes:

- New Level II HCPCS codes effective October 1, 2018, that would be incorporated in the October 2018 OPPS quarterly update CR and
- HCPCS codes effective January 1, 2019, that would be included in the January 2019 OPPS quarterly update CR.

As stated above, the October 1, 2018 and January 1, 2019 codes are flagged with comment indicator “NI” in Addendum B to this OPPS/ASC final rule with comment period to indicate that we have assigned these codes an interim OPPS payment status for CY 2019. We are inviting public comments on the interim status indicator and APC assignments for these codes, if applicable, that will be finalized in the CY 2020 OPPS/ASC final rule with comment period.

In the CY 2019 OPPS/ASC proposed rule with comment period (79 FR 66841 through 66844), we finalized a revised process of assigning APC and status indicators for codes flagged with comment indicator “NI” in Addendum B to this OPPS/ASC final rule with comment period to indicate that we are assigning them an interim payment status which is subject to public comment. Specifically, the interim status indicator and APC assignments for codes flagged with comment indicator “NI” are open to public comment in this final rule with comment period, and we will respond to those public comments in the OPPS/ASC final rule with comment period for the next year’s OPPS/ASC update.

In the CY 2019 OPPS/ASC final rule with comment period, we finalized a revised process of assigning APC and status indicators for codes flagged with comment indicator “NI.” Specifically, for the new/revised codes that we received in a timely manner from the AMA’s CPT Editorial Panel, we finalized our proposal to include the codes that would be effective January 1. Specifically, for the new/revised CPT codes that we receive in a timely manner from the AMA’s CPT Editorial Panel, we finalized our proposal to include the codes that would be effective January 1 in the OPPS/ASC proposed rules, along with proposed APC and status indicator assignments for them, and to finalize the APC and status indicator assignments in the OPPS/ASC final rules beginning with the CY 2016 OPPS update. For those new/revised CPT codes that were received too late for inclusion in the OPPS/ASC proposed rule, we finalized our proposal to establish and use HCPCS G-codes that mirror the predecessor CPT codes and retain the current APC and status indicator assignments for a year until we can propose APC and status indicator assignments in the following year’s rulemaking cycle. We note that even if we find that we need to create HCPCS G-codes in place of certain CPT codes for the PFS proposed rule, we do not anticipate that these HCPCS G-codes will always be necessary for OPPS purposes. We will make every effort to include proposed APC and status indicator assignments for all new and revised CPT codes that the AMA makes publicly available in time for us to include them in the annual proposed rule, and to avoid the resort to HCPCS G-codes and the resulting delay in utilization of the most current CPT codes. Also, we finalized our proposal to make interim APC and status indicator assignments for CPT codes that are not available in time for the proposed rule and that describe wholly new services (such as new technologies or new surgical procedures), solicit public comments, and finalize the specific APC and status indicator assignments for those codes in the following year’s final rule.

For the CY 2019 OPPS update, we received the CY 2019 CPT codes from the AMA in time for inclusion in the CY 2019 OPPS/ASC proposed rule. The new, revised, and deleted CY 2019 Category I and III CPT codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We noted in the proposed rule that the new and revised codes are assigned to new status indicator “NI” to indicate that the code is new for the next calendar year or the code is an existing

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0060U</td>
<td>Twin zyosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>0061U</td>
<td>Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis</td>
<td>Q4</td>
<td>N/A</td>
</tr>
</tbody>
</table>

ользователь

ась в контексте
code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year with a proposed APC assignment, and that comments will be accepted on the proposed APC and status indicator assignments.

Further, we reminded readers that the CPT code descriptors that appear in Addendum B are short descriptors and do not accurately describe the complete procedure, service, or item described by the CPT code. Therefore, we included the 5-digit placeholder codes and their long descriptors for the new and revised CY 2019 CPT codes in Addendum O to the proposed rule (which is available via the internet on the CMS website) so that the public could adequately comment on the proposed APCs and status indicator assignments. The 5-digit placeholder codes were included in Addendum O, specifically under the column labeled “CY 2019 OPPS/ASC Proposed Rule 5-Digit AMA Placeholder Code,” to the proposed rule. We noted that the final CPT code numbers will be included in this CY 2019 OPPS/ASC final rule with comment period. We also noted that not every code listed in Addendum O is subject to public comment. For the new and revised Category I and III CPT codes, we requested public comments on only those codes that are assigned to comment indicator “NP”.

In summary, in the CY 2019 OPPS/ASC proposed rule, we solicited public comments on the proposed CY 2019 status indicator and APC assignments for the new and revised Category I and III CPT codes that will be effective January 1, 2019. The CPT codes were listed in Addendum B to the proposed rule with short descriptors only. We listed them again in Addendum O to the proposed rule with long descriptors. We also proposed to finalize the status indicator and APC assignments for these codes (with their final CPT code numbers) in the CY 2019 OPPS/ASC final rule with comment period. The proposed status indicator and APC assignments for these codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website).

Commenters addressed several of the new CPT codes that were assigned to comment indicator “NP” in Addendum B to the CY 2019 OPPS/ASC proposed rule. We have responded to those public comments in sections II.A.2.b. (Comprehensive APCs), III.D. (OPPS APC-Specific Policies), IV.B. (Device-Intensive Procedures) and XII. (Updates to the ASC Payment System) of this CY 2019 OPPS/ASC final rule with comment period.

The final status indicators, APC assignments, and payment rates for the new CPT codes that are effective January 1, 2019 can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website). In addition, the status indicator meanings can be found in Addendum D1 (OPPS Payment Status Indicators for CY 2019) to this final rule with comment period (which is available via the internet on the CMS website).

B. OPPS Changes—Variations Within APCs

1. Background

Section 1833(t)(2)(A) of the Act requires the Secretary to develop a classification system for covered hospital outpatient department services. Section 1833(t)(2)(B) of the Act provides that the Secretary may establish groups of covered OPPS services within this classification system, so that services classified within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we developed a grouping classification system, referred to as Ambulatory Payment Classifications (APCs), as set forth in regulations at 42 CFR 419.31. We use Level I and Level II HCPCS codes to identify and group the services within each APC. The APCs are organized such that each group is homogeneous both clinically and in terms of resource use. Using this classification system, we have established distinct groups of similar services. We also have developed separate APC groups for certain medical devices, drugs, biologicals, therapeutic radiopharmaceuticals, and brachytherapy devices that are not packaged into the payment for the procedure.

We have packaged into the payment for each procedure or service within an APC group the costs associated with those items and services that are typically ancillary and supportive to a primary diagnostic or therapeutic modality and, in those cases, are an integral part of the primary service they support. Therefore, we do not make separate payment for these packaged items or services. In general, packaged items and services include, but are not limited to, the items and services listed in regulations at 42 CFR 419.2(b). A further discussion of packaged services is included in section II.A.3. of this final rule with comment period.

Under OPPS, we generally pay for covered hospital outpatient services on a rate-per-service basis, where the service may be reported with one or more HCPCS codes. Payment varies according to the APC group to which the independent service or combination of services is assigned. In the CY 2019 OPPS/ASC proposed rule (83 FR 37089), for CY 2019, we proposed that each APC relative payment weight represents the hospital cost of the services included in that APC, relative to the hospital cost of the services included in APC 5012 (Clinic Visits and Related Services). The APC relative payment weights are scaled to APC 5012 because it is the hospital clinic visit APC and clinic visits are among the most frequently furnished services in the hospital outpatient setting.

2. Application of the 2 Times Rule

Section 1833(t)(9)(A) of the Act requires the Secretary to review, not less often than annually, and revise the APC groups, the relative payment weights, and the wage and other adjustments described in paragraph (2) to take into account changes in medical services, changes in technology, the addition of new services, new cost data, and other relevant information and factors. Section 1833(t)(9)(A) of the Act also requires the Secretary to consult with an expert outside advisory panel composed of an appropriate selection of representatives of providers to review (and advise the Secretary concerning) the clinical integrity of the APC groups and the relative payment weights. We note that the HOP Panel recommendations for specific services for the CY 2019 OPPS update are discussed in the relevant specific sections throughout this CY 2019 OPPS/ASC final rule with comment period.

In addition, section 1833(t)(2) of the Act provides that, subject to certain exceptions, the items and services within an APC group cannot be considered comparable with respect to the use of resources if the highest cost for an item or service in the group is more than 2 times greater than the lowest cost for an item or service within the same group (referred to as the “2 times rule”). The statute authorizes the Secretary to make exceptions to the 2 times rule in unusual cases, such as low-volume items and services (but the Secretary may not make such an exception in the case of a drug or biological that has been designated as an orphan drug under section 526 of the Federal Food, Drug, and Cosmetic Act). In determining the APCs with a 2 times rule violation, we consider only those HCPCS codes that are significant based on claim volume. We note that, for purposes of identifying significant procedure codes for examination under
the 2 times rule, we consider procedure codes that have more than 1,000 single major claims or procedure codes that both have more than 99 single major claims and contribute at least 2 percent of the single major claims used to establish the APC cost to be significant (75 FR 71832). This longstanding definition of when a procedure code is significant for purposes of the 2 times rule was selected because we believe that a subset of 1,000 or fewer claims is negligible within the set of approximately 100 million single procedure or single session claims we use for establishing costs. Similarly, a procedure code for which there are fewer than 99 single claims and that comprises less than 2 percent of the single major claims within an APC will have a negligible impact on the APC cost (75 FR 71832). In the CY 2019 OPPS/ASC proposed rule (83 FR 37089), for CY 2019, we proposed to make exceptions to this limit on the variation of costs within each APC group in unusual cases, such as for certain low-volume items and services.

For the CY 2019 OPPS update, in the CY 2019 OPPS/ASC proposed rule, we identified the APCs with violations of the 2 times rule. Therefore, we proposed changes to the procedure codes assigned to these APCs in Addendum B to the proposed rule. We noted that Addendum B does not appear in the printed version of the Federal Register as part of the CY 2019 OPPS/ASC proposed rule. Rather, it is published and made available via the internet on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html.

1. APCCs Reassigned To APCCs

Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-B-Updates.html).

3. APC Exceptions to the 2 Times Rule

Taking into account the APC changes that we proposed to make for CY 2019 in the CY 2019 OPPS/ASC proposed rule, we reviewed all of the APCs to determine which APCs would not meet the requirements of the 2 times rule. We used the following criteria to evaluate whether to propose exceptions to the 2 times rule for affected APCs:

- Resource homogeneity;
- Clinical homogeneity;
- Hospital outpatient setting utilization;
- Frequency of service (volume); and
- Opportunity for upcoding and code fragments.

Based on the CY 2017 claims data available for the CY 2019 proposed rule, we found 16 APCs with violations of the 2 times rule. We applied the criteria as described above to identify the APCs for which we proposed to make exceptions under the 2 times rule for CY 2019, and found that all of the 16 APCs we identified met the criteria for an exception to the 2 times rule based on the CY 2017 claims data available for the proposed rule. We did not include in that determination those APCs where a 2 times rule violation was not a relevant concept, such as APC 5401 (Dialysis), which only has two HCPCS codes assigned to it that have a similar geometric mean costs and do not create a 2 time rule violation.

We note that, for cases in which a recommendation by the HOP Panel appears to result in or allow a violation of the 2 times rule, we may accept the HOP Panel’s recommendation because those recommendations are based on explicit consideration (that is, a review of the latest OPPS claims data and group discussion of the issue) of resource use, clinical homogeneity, site of service, and the quality of the claims data used to determine the APC payment rates.

Table 12 of the proposed rule listed the 16 APCs that we proposed to make an exception for under the 2 times rule for CY 2019 based on the criteria cited above and claims data submitted between January 1, 2017, and December 31, 2017, and processed on or before December 31, 2017. In the proposed rule, we stated that, for the final rule with comment period, we intend to use claims data for dates of service between January 1, 2017, and December 31, 2017, that were processed on or before June 30, 2018, and updated CCRs, if available.

Based on the updated final rule CY 2017 claims data used for this CY 2019 final rule with comment period, we were able to remedy 1 APC violation out of the 16 APCs that appeared in Table 12 of the CY 2019 OPPS/ASC proposed rule. Specifically, APC 5735 (Level 5 Minor Procedures) no longer met the criteria for exception to the 2 times rule in this final rule with comment period. In addition, based on our analysis of the final rule claims data, we found a total of 17 APCs with violations of the 2 times rule. Of these 17 total APCs, 15 were identified in the proposed rule and 2 are newly identified APCs. Specifically, we found the following 15 APCs that were identified for the proposed rule that continued to have violations of the 2 times rule for this final rule with comment period:

- APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage);
- APC 5113 (Level 3 Musculoskeletal Procedures);
- APC 5521 (Level 1 Imaging without Contrast);
- APC 5522 (Level 2 Imaging without Contrast);
- APC 5523 (Level 3 Imaging without Contrast);
- APC 5571 (Level 1 Imaging with Contrast);
- APC 5612 (Level 2 Therapeutic Radiation Treatment Preparation);
- APC 5691 (Level 1 Drug Administration);
- APC 5692 (Level 2 Drug Administration);
- APC 5721 (Level 1 Diagnostic Tests and Related Services);
- APC 5724 (Level 4 Diagnostic Tests and Related Services);
- APC 5731 (Level 1 Minor Procedures);
- APC 5732 (Level 2 Minor Procedures);
- APC 5822 (Level 2 Health and Behavior Services); and
- APC 5823 (Level 3 Health and Behavior Services).

In addition, we found that the following two additional APCs violated the 2 times rule using the final rule with comment period claims data:

- APC 5193 (Level 3 Endovascular Procedures); and
- APC 5524 (Level 4 Imaging without Contrast).

After considering the public comments we received on proposed APC assignments and our analysis of the CY 2017 costs from hospital claims and cost report data available for this CY 2019 final rule with comment period, we are finalizing our proposals, with some modifications. Specifically, we are
finalizing our proposal to except 15 of the 16 proposed APCs from the 2 times rule for CY 2019 and also excepting 2 additional APCs (APCs 5193 and 5524). As noted above, we were able to remedy one of the proposed rule 2 time rule violations in this final rule with comment period (APC 5735).

Table 16 below lists the 17 APCs that we are excepting from the 2 times rule for CY 2019 based on the criteria described earlier and a review of updated claims data for dates of service between January 1, 2017 and December 31, 2017, that were processed on or before June 30, 2018, and updated CCRs, if available. We note that, for cases in which a recommendation by the HOP Panel appears to result in or allow a violation of the 2 times rule, we generally accept the HOP Panel’s recommendation because those recommendations are based on explicit consideration of resource use, clinical homogeneity, site of service, and the quality of the claims data used to determine the APC payment rates. The geometric mean costs for hospital outpatient services for these and all other APCs that were used in the development of this final rule with comment period can be found on the CMS website at: http://www.cms.gov.

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5071</td>
<td>Level 1 Excision/ Biopsy/ Incision and Drainage</td>
</tr>
<tr>
<td>5113</td>
<td>Level 3 Musculoskeletal Procedures</td>
</tr>
<tr>
<td>5193</td>
<td>Level 3 Endovascular Procedures</td>
</tr>
<tr>
<td>5521</td>
<td>Level 1 Imaging without Contrast</td>
</tr>
<tr>
<td>5522</td>
<td>Level 2 Imaging without Contrast</td>
</tr>
<tr>
<td>5523</td>
<td>Level 3 Imaging without Contrast</td>
</tr>
<tr>
<td>5524</td>
<td>Level 4 Imaging without Contrast</td>
</tr>
<tr>
<td>5571</td>
<td>Level 1 Imaging with Contrast</td>
</tr>
<tr>
<td>5612</td>
<td>Level 2 Therapeutic Radiation Treatment Preparation</td>
</tr>
<tr>
<td>5691</td>
<td>Level 1 Drug Administration</td>
</tr>
<tr>
<td>5692</td>
<td>Level 2 Drug Administration</td>
</tr>
<tr>
<td>5721</td>
<td>Level 1 Diagnostic Tests and Related Services</td>
</tr>
<tr>
<td>5724</td>
<td>Level 4 Diagnostic Tests and Related Services</td>
</tr>
<tr>
<td>5731</td>
<td>Level 1 Minor Procedures</td>
</tr>
<tr>
<td>5732</td>
<td>Level 2 Minor Procedures</td>
</tr>
<tr>
<td>5822</td>
<td>Level 2 Health and Behavior Services</td>
</tr>
<tr>
<td>5823</td>
<td>Level 3 Health and Behavior Services</td>
</tr>
</tbody>
</table>

C. New Technology APCs

1. Background

In the November 30, 2001 final rule (66 FR 59903), we finalized changes to the time period in which a service can be eligible for payment under a New Technology APC. Beginning in CY 2002, we retain services within New Technology APC groups until we gather sufficient claims data to enable us to assign the service to an appropriate clinical APC. This policy allows us to move a service from a New Technology APC in less than 2 years if sufficient data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient data upon which to base a decision for reassignment have not been collected.

In the CY 2004 OPPS final rule with comment period (68 FR 63416), we restructured the New Technology APCs to make the cost intervals more consistent across payment levels and refined the cost bands for these APCs to retain two parallel sets of New Technology APCs, one set with a status indicator of “S” (Significant Procedures, Not Discounted when Multiple. Paid under OPPS; separate APC payment) and the other set with a status indicator of “T” (Significant Procedure, Multiple Reduction Applies. Paid under OPPS; separate APC payment). These current New Technology APC configurations allow us to price new technology services more appropriately and consistently.

For CY 2018, there were 52 New Technology APC levels, ranging from the lowest cost band assigned to APC 1491 (New Technology—Level 1A ($0–$10)) through the highest cost band assigned to APC 1908 (New Technology—Level 52 ($145,001–$160,000)). We note that the cost bands for the New Technology APCs, specifically, APCs 1491 through 1599 and 1901 through 1908, vary with increments ranging from $10 to $14,999. These cost bands identify the APCs to which new technology procedures and services with estimated service costs that fall within those cost bands are assigned under the OPPS. Payment for each APC is made at the mid-point of the APC’s assigned cost band. For example, payment for New Technology APC 1507 (New Technology—Level 7 ($801–$600)) is made at $550.50.

Under the OPPS, one of our goals is to make payments that are appropriate for the services that are necessary for the treatment of Medicare beneficiaries. The OPPS, like other Medicare payment systems, is budget neutral and increases are limited to the annual hospital inpatient market basket increase. We
believe that our payment rates generally reflect the costs that are associated with providing care to Medicare beneficiaries. Furthermore, we believe that our payment rates are adequate to ensure access to services (80 FR 70374).

For many emerging technologies, there is a transitional period during which utilization may be low, often because providers are first learning about the techniques and their clinical utility. Quite often, parties request that Medicare make higher payment amounts under the New Technology APCs for new procedures in that transitional phase. These requests, and their accompanying estimates for expected total patient utilization, often reflect very low rates of patient use of expensive equipment, resulting in high per-use costs for which requesters believe Medicare should make full payment. Medicare does not, and we believe should not, assume responsibility for more than its share of the costs of procedures based on projected utilization for Medicare beneficiaries and does not set its payment rates based on initial projections of low utilization for services that require expensive capital equipment. For the OPPS, we rely on hospitals to make informed business decisions regarding the acquisition of high-cost equipment, taking into consideration their knowledge about their entire patient base (Medicare beneficiaries included) and an understanding of Medicare’s and other payers’ payment policies. (We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68314) for further discussion regarding this payment policy.)

We note that, in a budget neutral system, payments may not fully cover hospitals’ costs in a particular circumstance, including those for the purchase and maintenance of capital equipment. We rely on hospitals to make their decisions regarding the acquisition of high-cost equipment with the understanding that the Medicare program must be careful to establish its initial payment rates, including those made through New Technology APCs, for new services that lack hospital claims data based on realistic utilization projections for all such services delivered in cost-efficient hospital outpatient settings. As the OPPS acquires claims data regarding hospital costs associated with new procedures, we regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures as they transition into mainstream medical practice (77 FR 68314). For CY 2019, we included the proposed payment rates for New Technology APCs 1491 to 1599 and 1901 through 1908 in Addendum A to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website). The final payment rates for these New Technology APCs are included in Addendum A to the CY 2019 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website).

2. Establishing Payment Rates for Low-Volume New Technology Procedures

Procedures that are assigned to New Technology APCs are typically new procedures that do not have sufficient claims history to establish an accurate payment for the procedures. One of the objectives of establishing New Technology APCs is to generate sufficient claims data for a new procedure so that it can be assigned to an appropriate clinical APC. Some procedures that are assigned to New Technology APCs have very low annual volume, which we consider to be fewer than 100 claims. We consider procedures with fewer than 100 claims annually as low-volume procedures because there is a higher probability that the payment data for a procedure may not have a normal statistical distribution, which could affect the quality of our standard cost methodology that is used to assign services to an APC. In addition, services with fewer than 100 claims per year are not generally considered to be a significant contributor to the APC ratesetting calculations and, therefore, are not included in the assessment of the 2 times rule. For these low-volume procedures, we are concerned that the methodology we use to estimate the cost of a procedure under the OPPS by calculating the geometric mean for all separately paid claims for a HCPCS procedure code from the most recent available year of claims data may not generate an accurate estimate of the actual cost of the procedure.

In accordance with section 1833(t)(2)(B) of the Act, services classified within each APC must be comparable clinically and with respect to the use of resources. As described earlier, assigning a procedure to a new technology APC allows us to gather claims data to price the procedure and assign it to the APC with services that use similar resources and are clinically comparable. However, where utilization of services assigned to a New Technology APC is projected to lead to wide variation in payment rates from year to year, resulting in even lower utilization and potential barriers to access to new technologies, which ultimately limits our ability to assign the service to the appropriate clinical APC. To mitigate these issues, we believe that it is appropriate to utilize our equitable adjustment authority at section 1833(t)(2)(E) of the Act to adjust how we determine the costs for low-volume services assigned to New Technology APCs. We have utilized our equitable adjustment authority at section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to estimate an appropriate payment amount for low-volume new technology procedures in the past (82 FR 59281). Although we have used this adjustment authority on a case-by-case basis in the past, we believe that it is appropriate to adopt an adjustment for low-volume services assigned to New Technology APCs in order mitigate the wide payment fluctuations that can occur for new technology services with fewer than 100 claims and to provide more predictable payment for these services.

For purposes of this adjustment, we believe that it is appropriate to use up to 4 years of claims data in calculating the applicable payment rate for the prospective year, rather than using solely the most recent available year of claims data, when a service assigned to a New Technology APC has a low annual volume of claims, which, for purposes of this adjustment, we define as fewer than 100 claims annually. We consider procedures with fewer than 100 claims annually as low-volume procedures because there is a higher probability that the payment data for a procedure may not have a normal statistical distribution, which could affect the quality of our standard cost methodology that is used to assign services to an APC. For these low-volume procedures, we are concerned that the methodology we use to estimate the cost of a procedure under the OPPS by calculating the geometric mean for all separately paid claims for a HCPCS procedure code from the most recent available year of claims data may not generate an accurate estimate of the actual cost of the procedure. Using multiple years of claims data will potentially allow for more than 100 claims to be used to set the payment rate, which would, in turn, create a more statistically reliable payment rate.

In addition, to better approximate the cost of a low-volume service within a New Technology APC, we believe that using the median or arithmetic mean rather than the geometric mean (which
“trims” the costs of certain claims out) may be more appropriate in some circumstances, given the extremely low volume of claims. Low claim volumes increase the impact of “outlier” claims; that is, claims with either a very low or very high payment rate as compared to the average claim, which would have a substantial impact on any statistical methodology used to estimate the most appropriate payment rate for a service. We believe that having the flexibility to utilize an alternative statistical methodology to calculate the payment rate in the case of low-volume new technology services would help to create a more stable payment rate. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37091 through 37092), we proposed that, in each of our annual rulemakings, we would seek public comments on which statistical methodology should be used for each low-volume New Technology APC. In the preamble of each annual rulemaking, we stated that we will present the result of each statistical methodology and solicit public comment on which methodology should be used to establish the payment rate for a low-volume new technology service. In addition, we will use our assessment of the resources used to perform a service and guidance from the developer or manufacturer of the service, as well as other stakeholders, to determine the most appropriate payment rate. Once we identify the most appropriate payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate.

Accordingly, in the CY 2019 OPPS/ASC proposed rule (83 FR 37091 through 37092), for CY 2019, we proposed to establish a different payment methodology for services assigned to New Technology APCs with fewer than 100 claims using our equitable adjustment authority under section 1833(t)(2)(E) of the Act. Under this proposal, we proposed to use up to 4 years of claims data to establish a payment rate for each applicable service both for purposes of assigning a service to a New Technology APC and for assigning a service to a regular APC at the conclusion of payment for the service through a New Technology APC. The goal of such a policy is to promote transparency and stability in the payment rates for these low-volume new technology procedures and to mitigate wide variation from year to year for such services. We also proposed to use the geometric mean, the median, or the arithmetic mean to calculate the cost of furnishing the applicable service, present the result of each statistical methodology in our annual rulemaking, and solicit public comment on which methodology should be used to establish the payment rate. We stated that the geometric mean may not be representative of the actual cost of a service when fewer than 100 claims are present because the payment amounts for the claims may not be distributed normally. We stated that, under this proposal, we would have the option to use the median payment amount or the arithmetic mean to assign a more representative payment for the service. Once we identify the payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate.

Comment: One commenter requested that CMS expand the proposal to cover all low-volume procedures with fewer than 100 claims annually in the OPPS rather than only those procedures assigned to New Technology APCs. The commenter noted the issues cited for establishing the low-volume policy, including data not having a normal statistical distribution, excessive influence of outliers, and the quality of claims data affect all low-volume procedures, and not just those procedure assigned to a New Technology APC.

Response: We disagree with the commenter’s request. The fact that a procedure has been assigned to a clinical APC means we have some idea of the costs involved in performing the procedure and what the cost of the procedure should be. Concerns over the appropriate APC assignment for an individual procedure may be addressed on a case-by-case basis through our annual rulemaking. We remind commenters that they can submit public comments on the appropriate APC assignment for a particular code during that process. We believe reviewing each procedure assigned to a clinical APC annually to determine if the arithmetic mean, geometric mean, or median of the claims data should be used to determine the payment rate is both unnecessary and operationally infeasible. The low-volume policy instead is intended only for those procedures assigned to New Technology APCs with such limited claims data that we are not able to assign them to clinical APCs and need as much available data to determine the payment rate for a procedure.

Comment: One commenter asked that CMS use the equitable adjustment authority under section 1833(t)(2)(E) of the Act in other instances not covered by the proposed low-volume policy, where a procedure that has recently been introduced to the outpatient setting has inconsistent payment data due to small number of claims.

Response: We retain the ability to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act when we determine that it is needed.

Comment: Several commenters supported the proposal to use up to 4 years of claims data and to have flexibility to use the geometric mean, arithmetic mean, or median of claims data to establish a payment rate for low-volume procedures assigned to a New Technology APC.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposed policy to establish payment rates for low-volume procedures with fewer than 100 claims per year that are assigned to New Technology APCs, without modification. We may use up to 4 years of claims data to establish a payment rate for each applicable service both for purposes of assigning a service to a New Technology APC and for assigning a service to a regular APC at the conclusion of payment for the service through a New Technology APC. We will use the geometric mean, the median, or the arithmetic mean to calculate the cost of furnishing the applicable service, present the result of each statistical methodology in our annual rulemaking, and solicit public comment on which methodology should be used to establish the payment rate. Once we identify the payment rate for a service, we would assign the service to the New Technology APC with the cost band that includes its payment rate.

3. Procedures Assigned to New Technology APC Groups for CY 2019

As we explained in the CY 2002 OPPS final rule with comment period (66 FR 59902), we generally retain a procedure in the New Technology APC to which it is initially assigned until we have obtained sufficient claims data to justify reassignment of the procedure to a clinically appropriate APC.

In addition, in cases where we find that our initial New Technology APC assignment was based on inaccurate or inadequate information (although it was the best information available at the time), where we obtain new information that was not available at the time of our initial New Technology APC assignment, or where the New Technology APCs are restructured, we may, based on more recent resource utilization information (including data for each applicable service of refined New Technology APC cost bands), reassign the procedure or service to a
different New Technology APC that more appropriately reflects its cost (66 FR 59063).

Consistent with our current policy, for CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37092), we proposed to retain services within New Technology APC groups until we obtain sufficient claims data to justify reassignment of the service to a clinically appropriate APC. The flexibility associated with this policy allows us to reassign a service from a New Technology APC in less than 2 years if sufficient claims data are available. It also allows us to retain a service in a New Technology APC for more than 2 years if sufficient claims data upon which to base a decision for reassignment have not been obtained (66 FR 59092).

a. Magnetic Resonance-Guided Focused Ultrasound Surgery (MRgFUS) (APCs 1537, 5114, and 5414)

Currently, there are four CPT/HCPCS codes that describe magnetic resonance image-guided, high-intensity focused ultrasound (MRgFUS) procedures, three of which we proposed to continue to assign to standard APCs, and one that we proposed to reassign to a different New Technology APC for CY 2019. These codes include CPT codes 0071T, 0072T, and 0398T, and HCPCS code C9734. CPT codes 0071T and 0072T describe procedures for the treatment of uterine fibroids, CPT code 0398T describes procedures for the treatment of essential tremor, and HCPCS code C9734 to status indicator "J1".

For procedures described by CPT code 0398T, we have only identified one paid claim for a procedure in CY 2016 and two paid claims in CY 2017, for a total of three paid claims. We note that the procedures described by CPT code 0398T were first assigned to a New Technology APC in CY 2016. Accordingly, there are only 2 years of claims data available for the OPPS ratessetting purposes. The payment amounts for the claims varied widely, with a cost of $29,254 for the sole CY 2016 claim and a geometric mean cost of $4,647 for the two CY 2017 claims. In the proposed rule, we expressed concerned that the reported geometric mean cost for CY 2017, which we would normally use to determine the proposed payment rate for the procedures described by CPT code 0398T, was significantly lower than the reported cost of the claim received in CY 2016, as well as the payment rate for the procedures for CY 2017 ($9,750.50) and for CY 2018 ($17,500.50). In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, as mentioned in section III.C.2. of the proposed rule, we proposed to use our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to establish a payment rate that is more likely to be representative of the cost of the procedures described by CPT code 0398T, despite the low geometric mean costs for procedures described by CPT code 0398T. We also proposed to continue to assign the APC to status indicator “J1” (Hospital Part B services paid through a comprehensive APC) to indicate that payment for all covered Part B services reported on the claim are packaged with the payment for the primary “J1” service for the claim, except for services assigned to OPPS status indicator “F”, “G”, “H”, “L”, and “U”; ambulance services; diagnostic and screening mammography; all preventive services; and certain Part B inpatient services. In addition, we proposed to continue to assign the services described by HCPCS code C9734 (Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance) to APC 5115 (Level 5 Musculoskeletal Procedures), with a proposed payment rate of approximately $10,936 for CY 2019. We also proposed to continue to assign HCPCS code C9734 to status indicator “J1”.

Our analysis found that the arithmetic mean of the three claims is $12,849.11, the geometric mean of the three claims is $8,579.01 (compared to $4,647.56 for CY 2017), and the median of the claims is $4,676.77. Consistent with what we stated in section III.C.2. of the proposed rule, we presented the result of each statistical methodology in this preamble, and we sought public comments on which method should be used to establish payment for the procedures described by CPT code 0398T. We believe that the arithmetic mean is the most appropriate representative cost of the procedures described by CPT code 0398T, which gives consideration to the payment rates established for the procedures in CY 2017 and CY 2018, without any trimming. The arithmetic mean also gives consideration to the full range in cost for the three paid claims, which represent 2 years of claims data for the procedures. We proposed to estimate the proposed payment rate for the procedures described by CPT code 0398T by calculating the arithmetic mean of the three paid claims for the procedures in CY 2016 and CY 2017, and assigning the procedures described by CPT code 0398T to the New Technology APC that includes the estimated cost. Accordingly, we proposed to reassign the procedures described by CPT code 0398T from APC 1576 (New Technology—Level 39 ($12,500–$20,000)) to APC 1575 (New Technology—Level 39 ($15,001–$20,000)), with a proposed payment rate of $12,500.50 for CY 2019. We refer readers to Addendum B to the proposed rule for the proposed payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.
Response: Since the proposed rule was issued, there have been several more claims for services described by CPT code 0398T that were paid in CY 2017. Currently, there are 11 paid claims for services described by CPT code 0398T for CY 2017, and these 11 claims have an estimated cost of between $4,186.51 and $5,153.28. We performed our low-volume new technology process for CPT code 0398T for all available claims from CY 2017 and included the one claim of $29,254 from CY 2016. The results of our analysis found that for claims billed with CPT code 0398T, the geometric mean cost was $5,360.99, the arithmetic mean cost was $6,654.68, and the median cost was $4,581.45.

We have concerns about using the claims data available for this final rule with comment period to set the payment rate for CPT code 0398T for CY 2019. The payment rate for CPT code 0398T for CY 2018 was $17,500.50, and in the CY 2019 proposed rule (83 FR 37093), we proposed a payment rate of $12,500.50. However for this final rule with comment period, the highest payment rate using the most recent available claims data and the newly adopted smoothing methodology for low-volume New Technology APCs is $6,750.50, which is the mid-point of New Technology APC 1531. New Technology APC 1531 is the cost band for the arithmetic mean cost of CPT code 0398T. A payment rate of $6,750.50 would be the result of a $10,750 reduction in the payment rate in a period of just 1 year, or a payment rate reduction of over 60 percent. In addition, this payment reduction would be based on a total of 14 claims that have been billed for CPT code 0398T since we first received claims for this procedure in CY 2016. We believe that it is important to mitigate significant payment differences, especially payment differences that result in shifts of over $10,000 in a single year, while also basing payment rates on available costs information and claims data. We are concerned that these large changes in payment could potentially create an access to care issue for services described by CPT code 0398T; especially, when the procedure is starting to receive local coverage determinations from MACs allowing more Medicare beneficiaries to use the procedure. While the proposed payment rate of $12,500.50 is also a decrease from the current payment rate, we believe that it would be appropriate to finalize the proposed rate to mitigate a much sharper decline in payment from one year to the next.

In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Accordingly, we are using our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to maintain the proposed rate for this procedure, despite the lower geometric mean, arithmetic mean, and median costs calculated from the claims data used for this final rule with comment period. As stated earlier, we believe that this situation is unique, given the large reduction in payment this would represent for CPT code 0398T and the very limited number of claims reported for the procedure. Therefore, for CY 2019, we are reassigning CPT code 0398T from APC 1576 to APC 1575 (New Technology—Level 38 ($10,001–$15,000)). This APC assignment will establish a payment rate for CPT code 0398T of $12,500.50, which was the proposed payment rate for the procedure in the CY 2019 OPPS/ASC proposed rule. As we do each year, we acquire claims data regarding hospital costs associated with new procedures. We regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures like CPT code 0398T as they transition into mainstream medical practice (77 FR 68314).

Comment: One commenter supported the proposed increase in Medicare payment for MRI-guided high intensity focused ultrasound procedures described by CPT codes 0071T and 0072T.

Response: We appreciate the commenter’s support.

In summary, after consideration of the public comments we received, we are finalizing our proposal for the APC assignment of CPT code 0398T. Specifically, we are reassigning this code to New Technology APC 1575 (New Technology—Level 38 ($10,001–$15,000)), with a payment rate of $12,500.50, for CY 2019 through use of our equitable adjustment authority. In addition, we are finalizing our proposal, without modification, to assign HCPCS code C9734 to APC 5114. We also are finalizing our proposal to continue to assign CPT codes 0071T and 0072T to APC 5414, without modification. Table 17 below lists the final CY 2018 status indicator and APC assignments for MRgFUS procedures. We refer readers to Addendum B of this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0071T</td>
<td>Focused ultrasound ablation of uterine leiomyomata, including mr guidance; total leiomyomata volume less than 200 cc of tissue.</td>
<td>J1</td>
<td>5414</td>
<td>$2,272.77</td>
<td>J1</td>
<td>5414</td>
<td>Refer to OPPS Addendum B.</td>
</tr>
<tr>
<td>0072T</td>
<td>Focused ultrasound ablation of uterine leiomyomata, including mr guidance; total leiomyomata volume greater or equal to 200 cc of tissue.</td>
<td>J1</td>
<td>5414</td>
<td>$2,272.77</td>
<td>J1</td>
<td>5414</td>
<td>Refer to OPPS Addendum B.</td>
</tr>
<tr>
<td>0398T</td>
<td>Magnetic resonance image guided high intensity focused ultrasound (mrGFUS), stereotactic ablation lesion, intracranial for movement disorder including stereotactic navigation and frame placement when performed.</td>
<td>S</td>
<td>1576</td>
<td>$17,500.50</td>
<td>S</td>
<td>1575</td>
<td>Refer to OPPS Addendum B.</td>
</tr>
</tbody>
</table>
b. Retinal Prosthesis Implant Procedure

CPT code 0100T (Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy) describes the implantation of a retinal prosthesis, specifically, a procedure involving the use of the Argus® II Retinal Prosthesis System. This first retinal prosthesis was approved by the Food and Drug Administration (FDA) in 2013 for adult patients diagnosed with severe to profound retinitis pigmentosa. Pass-through payment status was granted for the Argus® II device under HCPCS code C1841 (Retinal prosthesis, includes all internal and external components) beginning October 1, 2013, and this status expired on December 31, 2015. We note that after pass-through payment status expires for a medical device, the payment for the device is packaged into the payment for the associated surgical procedure. Consequently, for CY 2016, the device described by HCPCS code C1841 was assigned to OPPS status indicator “N” to indicate that payment for the device is packaged and included in the payment rate for the surgical procedure described by CPT code 0100T. For CY 2016, the procedure described by CPT code 0100T was assigned to New Technology APC 1599, with a payment rate of $95,000, which was the highest rate of $95,000.50 for CY 2017. We noted that the CY 2015 OPPS claims data used for the CY 2017 final rule with comment period showed 9 single claims (out of 13 total claims) for the procedure described by CPT code 0100T, with a geometric mean cost of approximately $142,003 based on claims submitted between January 1, 2015, through December 31, 2015, and processed through June 30, 2016. Based on the CY 2015 OPPS claims data available for the final rule with comment period and our understanding of the Argus® II procedure, we reassigned the procedure described by CPT code 0100T from New Technology APC 1599 to New Technology APC 1904, with a final payment rate of $150,000.50 for CY 2017. We noted that this payment rate included the cost of both the surgical procedure (CPT code 0100T) and the retinal prosthesis device (HCPCS code C1841).

For CY 2018, the reported cost of the Argus® II procedure based on CY 2016 hospital outpatient claims data used for the CY 2018 OPPS/ASC final rule with comment period was approximately $94,455, which was more than $55,000 less than the payment rate for the procedure in CY 2017. We noted that the costs of the Argus® II procedure are extraordinarily high compared to many other procedures paid under the OPPS. In addition, the number of claims submitted has been very low and has not exceeded 10 claims within a single year. We believed that it is important to mitigate significant payment differences, especially shifts of several tens of thousands of dollars, while also basing payment rates on available cost information and claims data. In CY 2016, the payment rate for the Argus® II procedure was $95,000.50. The payment rate increased to $150,000.50 in CY 2017. For CY 2018, if we had established the payment rate based on updated final rule claims data, the payment rate would have decreased to $95,000.50 for CY 2018, a decrease of $55,000 relative to CY 2017. We were concerned that these large changes in payment could potentially create an access to care issue for the Argus® II procedure, and we wanted to establish a payment rate to mitigate the potential sharp decline in payment from CY 2017 to CY 2018.

In accordance with section 1833(t)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, we used our equitable adjustment authority under section 1833(t)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to maintain the payment rate for this procedure, despite the lower geometric mean costs available in the claims data used for the final rule with comment period. For CY 2018, we reassigned the Argus® II procedure to APC 1904 (New Technology—Level 50 ($115,001–$130,000)), which established a payment rate for the Argus® II procedure of $122,500.50, which was the arithmetic mean of the payment rates for the procedure for CY 2016 and CY 2017.

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37093 through 37094), for CY 2019, the reported cost of the Argus® II procedure based on CY 2017 hospital outpatient claims data used for the CY 2019 OPPS/ASC proposed rule was approximately $152,021, which was $29,520 more than the payment rate for the procedure for CY 2018. In the proposed rule, we continued to note that the costs of the Argus® II procedure are extraordinarily high compared to many other procedures paid under the OPPS. In
addition, the number of claims submitted has been very low and did not exceed 10 claims for CY 2017. We stated that we continue to believe that it is important to mitigate significant payment differences, especially shifts of several tens of thousands of dollars, while also basing payment rates on available cost information and claims data because we are concerned that large decreases in the payment rate could potentially create an access to care issue for the Argus® II procedure. In addition, we indicated that we wanted to establish a payment rate to mitigate the potential sharp increase in payment from CY 2018 to CY 2019, and potentially ensure a more stable payment rate in future years.

In accordance with section 1833I(i)(2)(B) of the Act, we must establish that services classified within each APC are comparable clinically and with respect to the use of resources. Therefore, as discussed in section III.C.2. of the proposed rule, we proposed to use our equitable adjustment authority under section 1833I(i)(2)(E) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments, to establish a payment rate that is more representative of the likely cost of the service. We stated that we believe the likely cost of the Argus® II procedure is lower than the geometric mean cost calculated from the CY 2017 claims data used for the proposed rule and closer to the CY 2018 payment rate.

We analyzed claims data for the Argus® II procedure using the last 3 years of available data from CY 2015 through CY 2017. These data included claims from the last year (CY 2015) that the Argus® II received transitional device pass-through payments and the first 2 years since device pass-through payment status for the Argus® II expired. We found the geometric mean for the procedure to be $129,891 (compared to $152,021 in CY 2017 alone), the arithmetic mean to be $134,619, and the median to be $133,679. As indicated in our proposal in section III.C.2. of the proposed rule (83 FR 37091 through 37092), we presented the result of each statistical methodology in the preamble of the proposed rule, and requested public comment on which methodology should be used to establish a payment rate. We proposed to use the arithmetic mean, which generates the highest payment rate of the three statistical methodologies, to estimate the cost of the Argus® II procedure as a means to balance the fluctuations in the costs of the procedure that have occurred from CY 2015 through CY 2017, while acknowledging the higher payment rates for the procedure in CY 2015 and CY 2017. Therefore, for CY 2019, we proposed to reassign the Argus® II procedure from APC 1904 (New Technology—Level 50 ($115,001–$130,000)) to APC 1906 (New Technology—Level 51 ($130,001–$145,000)), which resulted in a proposed payment rate for the Argus® II procedure of $137,500.50.

As we do each year, we acquired claims data regarding hospital costs associated with new procedures. We regularly examine the claims data and any available new information regarding the clinical aspects of new procedures to confirm that our OPPS payments remain appropriate for procedures like the Argus® II procedure as they transition into mainstream medical practice (77 FR 68314). We noted that the proposed payment rate included both the surgical procedure (CPT code 0100T) and the use of the Argus® II device (HCPCS code C1841).

Comment: Several commenters requested that CMS realign CPT code 0100T to APC 1908 (New Technology—Level 52 ($145,001–$160,000)) with a payment rate of $152,500.50. The commenters were concerned that the proposed assignment of APC 1906 (New Technology—Level 51 ($130,001–$145,000)) with a payment rate of $137,500.50 will not cover all of the costs of the procedure.

Response: We have updated our payment rate for CPT code 0100T. We analyzed claims data for the Argus® II procedure using the last 3 years of available data from CY 2015 through CY 2017, which was updated with additional claims from CY 2017. These data included claims from the last year (CY 2015) that the Argus® II received transitional device pass-through payments and the first 2 years since device pass-through payment status for the Argus® II expired. We found the updated geometric mean cost for the procedure to be $145,808 (compared to $129,891 in the proposed rule), the arithmetic mean cost to be $151,367, and the median cost to be $151,266. All three of these methods of calculating the cost of the Argus® II procedure map to the cost band associated with APC 1908 (New Technology—Level 52 ($145,001–$160,000)), which has a payment rate of $152,500.50.

After reviewing the comments we received and updating our data analysis, we are proposing to reassign the Argus® II procedure (CPT code 0100T) to APC 1908 (New Technology—Level 52 ($145,001–$160,000)) with a payment rate of $152,500.50 for CY 2019.

We discussed in the CY 2019 OPPS/ASC proposed rule that the most recent claims data available have shown another payment issue with regard to the Argus® II procedure. We have found that payment for the Argus® II procedure is sometimes bundled into the payment for another procedure. We identified two possible instances in the CY 2017 claims data in which this may have occurred. The bundling of payment for the Argus® II procedure occurs when the procedure is reported with other eye procedures assigned to a comprehensive APC (C–APC). A C–APC bundles payment for all services related to the primary service into one payment rate. We stated in the proposed rule that we were concerned that when payment for new technology services is bundled into the payment for comprehensive procedures, there is not complete claims information to estimate accurately the cost of these services to allow their assignment to clinical APCs. Therefore, we proposed to exclude payment for all procedures assigned to New Technology APCs from being bundled into the payment for procedures assigned to a C–APC. This action would allow for separate payment for the Argus® II procedure even when it is performed with another comprehensive service, which would provide more cost information regarding the procedure. This proposal was also discussed in section II.A.2.c. of the proposed rule.

Comment: A number of commenters supported the proposal.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal to exclude payment for all procedures assigned to New Technology APCs from being bundled into the payment for procedures assigned to a C–APC for CY 2019.

c. Bronchoscopy With Transbronchial Ablation of Lesion(s) by Microwave Energy

CMS has established HCPCS code G9751 (Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration(s)/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic
intervention(s)), effective January 1, 2019. This microwave ablation procedure utilizes a flexible catheter to access the lung tumor via a working channel and may be used as an alternative procedure to a percutaneous microwave approach. Based on our review of the New Technology APC application for this service and the service’s clinical similarity to existing services paid under the OPPS, we estimated the likely cost of the procedure to be between $8,001 and $8,500. Therefore, we are assigning the procedure described by HCPCS code C9751 to New Technology APC 1571 (New Technology—Level 34 ($8,001–$8,500)), with a payment rate of $8,250 for CY 2019. Details regarding HCPCS code C9751 are shown in Table 18.

### TABLE 18.—INFORMATION FOR HCPCS CODE C9751 ASSIGNED TO A NEW TECHNOLOGY APC

<table>
<thead>
<tr>
<th>CY 2019 HCPCS Code</th>
<th>Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9751</td>
<td>Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or tranbronchial sampling (eg, aspiration[s]/biopsy[ies])</td>
</tr>
</tbody>
</table>

### D. OPPS APC-Specific Policies

1. Benign Prostatic Hyperplasia Treatments (APCs 5373 and 5374)

For the CY 2019 OPPS update, the CPT Editorial Panel established new CPT code 53854 to describe the Rezum Therapy procedure, which is also known as steam therapy or water vapor therapy, for the treatment of benign prostatic hyperplasia. Prior to January 1, 2019, the Rezum Therapy procedure was described by HCPCS code C9748, which was assigned to APC 5373 (Level 3 Urology and Related Services) when the code was established effective January 1, 2018. HCPCS code C9748 will be deleted on December 31, 2018 because it will be replaced with new CPT code 53854, effective January 1, 2019. We note that Table 19 below lists the long descriptors for both HCPCS code C9748 and CPT code 53854.

As displayed in Table 19 below, and in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to delete HCPCS code C9748 and assign the code to status indicator “D” to indicate that the code would be deleted for the January 2019 OPPS update. We also proposed to assign the new replacement code, CPT code 53854, to APC 5373, with a proposed payment rate of approximately $1,731. We note that the predecessor HCPCS code for CPT code 53854 (HCPCS code C9748) was also assigned to APC 5373. In addition, we note that CPT code 53854 was listed as code 538X3 (the 5-digit CMS placeholder code) in Addendum B, with the assignment of the code to status indicator “D” in Addendum O, with the long descriptor, to the CY 2019 OPPS/ASC proposed rule. We also assigned CPT code 53854 to comment indicator “NP” in Addendum B to indicate that the code is new for CY 2019 with a proposed APC assignment.

**Comment:** Several commenters addressed the proposed APC assignment for the Rezum Therapy procedure (CPT code 53854), as well as the APC assignments for the following other benign prostatic hyperplasia treatment procedures:

- Transurethral microwave therapy (TUMT) procedure, which is described by CPT code 53850, and which we proposed to continue to assign to APC 5374 (Level 4 Urology and Related Services), with a proposed payment rate of approximately $2,756;
- Transurethral needle ablation procedure (TUNA), which is described by CPT code 53852, and which we proposed to continue to assign to APC 5375 (Level 5 Urology and Related Services) with a proposed payment rate of approximately $3,776.

We note that Table 19 lists the long descriptors for the Rezum Therapy, TUMT, and TUNA procedures.

One commenter disagreed with the proposed assignment for the Rezum Therapy procedure described by CPT code 53854 to APC 5373, and indicated that APC 5373 does not contain other procedures that are similar clinically or in resource costs. The commenter stated that the Rezum Therapy procedure is comparable to the TUMT procedure, which is proposed to be assigned to APC 5374, and the TUNA procedure, which is proposed to be assigned to APC 5375. Therefore, the commenter requested that CPT code 53854, which describes the Rezum Therapy procedure, be assigned to APC 5375 instead of APC 5373. In addition, the commenter requested that the TUMT procedure described by CPT code 53850 be reassigned from APC 5374 to APC 5375. The commenter further stated that all three benign prostatic hyperplasia treatment procedures are comparable and suggested that they be assigned to APC 5375 based on clinical homogeneity and resource costs. Another commenter also believed that the Rezum Therapy procedure described by CPT code 53854 should be assigned to APC 5375.

**Response:** Review of our claims data used for this final rule with comment period, which is based on claims submitted between January 1, 2017 and December 31, 2017, and processed through June 30, 2018, reveals that the resource costs for these three benign prostatic hyperplasia treatment procedures are significantly different.

Our analysis shows that the geometric mean cost for CPT code 53850 (the TUMT procedure) is approximately...
$3,272 (based on 107 single claims out of 107 total claims) compared to CPT code 53852 (the TUNA procedure) whose geometric mean cost is approximately $2,989 (based on 408 single claims out of 410 total claims). In addition, in September 2017, CMS received a New Technology APC application requesting a new HCPCS code for the Rezum Therapy procedure because, according to the applicant, the only available CPT code to report the procedure was CPT code 53899 (Unlisted procedure, urinary system). Based on our review of the application, assessment of the procedure, and input from our clinical advisors, we established HCPCS code C9748, effective January 1, 2018, and assigned the code to APC 5373, with a payment rate of approximately $1,696. We announced this new HCPCS C-code and APC assignment in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59320) and stated that we believed the Rezum Therapy procedure shares similar resource costs and clinical homogeneity to the other procedures assigned to APC 5373.

Further, because of the public comments received on the Rezum Therapy procedure, we conducted a preliminary claims review for HCPCS code C9748, and found that, based on 73 claims that were processed on or before July 27, 2018, the geometric mean cost for the procedure is approximately $1,711, which is significantly lower than the geometric mean cost for either CPT code 53850 (TUMT procedure) at approximately $3,272 or CPT code 53852 (TUNA procedure) at approximately $2,989.

In addition, a presenter at the August 20, 2018 HOP Panel meeting requested that the HOP Panel recommend that CMS reassign placeholder CPT code 538X3 (CPT code 53854) to APC 5374 or 5375 based on clinical similarity to the procedures described by CPT codes 53850 and 53852. Based on the information presented at the meeting, the HOP Panel made no recommendation to revise the APC assignment for the Rezum Therapy procedure. However, based on the public comments received for the reassignment for all three benign prostatic hyperplasia treatment procedures, we reviewed the procedures assigned to the family of Urology APCs for this final rule with comment period and made some modifications to more appropriately reflect the resource costs and clinical characteristics of the services within each APC grouping. Specifically, we revised the APC assignment of the procedures assigned to the family of Urology APCs to more appropriately reflect a prospective payment system that is based on payment groupings and not code-specific payment rates, while maintaining clinical and resource homogeneity. Based on our review and modification, we revised the APC assignment for CPT code 53852 (the TUNA procedure) from APC 5375 (Level 5 Urology and Related Services) to APC 5374 (Level 4 Urology and Related Services) based on its clinical and resource homogeneity to the other procedures in the APC 5374.

Specifically, our claims data show that the geometric mean cost for CPT code 53852 is approximately $2,989, which is comparable to the geometric mean cost of approximately $2,952 for APC 5374, rather than the geometric mean cost of approximately $4,055 for APC 5375. We believe that this modification to the proposed assignment of CPT code 53852 to APC 5374 is appropriate.

In addition, based on our latest claims data used for the final rule with comment period, we believe that CPT codes 53850 (the TUMT procedure) and 53852 (the TUNA procedure) are appropriately assigned to APC 5374. We also believe that, based on our assessment of the Rezum Therapy procedure and its cost, as reported in the CMS New Technology application, and based on our preliminary claims review for HCPCS code C9748 (which is the predecessor code for CPT code 53854), the Rezum Therapy procedure continues to be appropriately assigned to APC 5373 based on its clinical and resource homogeneity to the other procedures in the APC.

Comment: One commenter agreed with the proposed continued APC assignment for CPT code 53852 (the TUNA procedure) to APC 5375. The commenter also contended that, while the presenter at the August 20, 2018 HOP Panel meeting recommended an assignment of APC 5374 or APC 5375 for the procedure, the Rezum Therapy procedure is less costly to perform than the TUNA procedure, and also noted that the HOP Panel made no recommendation to CMS to change the APC assignment for either procedure.

Response: Based on our comprehensive review of the procedures assigned to the Urology APCs, and analysis of the latest claims data, we do not agree that that we should continue to assign the procedure described by CPT code 58352 (the TUNA procedure) to APC 5375 because the geometric mean cost of the procedure of approximately $2,989 is significantly less than the geometric mean cost of approximately $4,055 for APC 5375. We believe that the geometric mean cost of approximately $2,989 for the procedure described by CPT code 53852 is more comparable to the geometric mean cost of approximately $2,952 for APC 5374. Therefore, for this final rule with comment period, we are revising the proposed APC assignment for the procedure described by CPT code 58352 and assigning the procedure to APC 5374 for CY 2019.

After consideration of the public comments we received, and based on the information presented above, as well as our evaluation of the latest claims data for the TUMT, TUNA, and Rezum Therapy procedures, we are finalizing the proposed APC assignment for the procedures described by CPT code 53850 and CPT code 53854, and revising the APC assignment for the procedure described by CPT code 53852 to APC 5374 (instead of APC 5375). The final APC and status indicator assignments are listed in Table 19 below. We refer readers to Addendum B to this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.
For CY 2019, we proposed to continue to assign the procedure described by CPT code 0408T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes) to APC 5231 (Level 1 ICD and Similar Procedures) with a proposed payment rate of approximately $22,242. The commenter stated that the proposed payment rate for APC 5231 does not accurately reflect the cost or clinical characteristics of the procedure and technology. The commenter added that, under the IPPS, the procedures describing the insertion of the complete system are assigned to one MS–DRG, and suggested that CMS adopt this same methodology under the OPPS. Specifically, the commenter recommended that CMS assign the procedures describing the insertion of the complete CCM, ICD, and CRT–D systems to APC 5232.

Response: The commenter suggested that we assign the procedures describing the insertion of the complete CCM, ICD, and CRT–D to one APC but did not provide the specific CPT codes associated with the ICD and CRT–D systems. Based on the information provided, we believe that the commenter is requesting that we assign to APC 5232 the following codes:

- **Cardiac contractility modulation (CCM):** CPT code 0408T (which we proposed in APC 5231 (Level 1 ICD and Similar Procedures));
- **Implantable cardioverter-defibrillator (ICD):** CPT code 33249 (which we proposed in APC 5232 (Level 2 ICD and Similar Procedures)); and
- **Cardiac Resynchronization Therapy Defibrillator (CRT–D):** CPT codes 33249 (which we proposed to assign to APC 5232 (Level 2 ICD and Similar Procedures) and 33225 (which we proposed to package payment because this is an add-on code), or CPT code 33270 (which we proposed to assign to APC 5232 (Level 2 ICD and Similar Procedures)).

Based on the latest hospital outpatient claims data used for this final rule with comment period, our analysis does not support the assignment of the procedures describing the insertion of the complete CCM system (described by CPT code 0408T) to APC 5231. We examined the latest hospital outpatient claims data for CPT code 0408T for dates of service between January 1, 2017, and December 31, 2017, that were processed on or before June 30, 2018. Our analysis of the claims data show a geometric mean cost of approximately $15,131 for CPT code 0408T, based on 2 single claims (out of 2 total claims). We do not believe that it is appropriate

### TABLE 19.—PROPOSED AND FINAL CY 2019 APC AND SI ASSIGNMENTS FOR THE TUMT, TUNA, AND REZUM PROCEDURES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A 53850</td>
<td>Transurethral destruction of prostate tissue; by microwave thermoabrasion</td>
<td>J1</td>
<td>5374</td>
<td>J1</td>
<td>5374</td>
</tr>
<tr>
<td>N/A 53852</td>
<td>Transurethral destruction of prostate tissue; by radiofrequency thermoabrasion</td>
<td>J1</td>
<td>5375</td>
<td>J1</td>
<td>5374</td>
</tr>
<tr>
<td>538X3 53854</td>
<td>Transurethral destruction of prostate tissue; by radiofrequency generated water vapor thermoabrasion</td>
<td>J1</td>
<td>5373</td>
<td>J1</td>
<td>5373</td>
</tr>
<tr>
<td>N/A C9748</td>
<td>Transurethral destruction of prostate tissue; by radiofrequency water vapor (steam) thermal therapy</td>
<td>D</td>
<td>N/A</td>
<td>D</td>
<td>N/A</td>
</tr>
</tbody>
</table>
to assign the procedure described by CPT code 0408T to APC 5232 because its geometric mean cost is approximately $30,921, which is significantly higher than the geometric mean cost of approximately $15,131 for CPT code 0408T. Therefore, assigning the procedure described by CPT code 0408T to APC 5232 would result in an overpayment for the procedure. We believe that APC 5231 is the most appropriate APC assignment for the procedure described by CPT code 0408T based on its clinical and resource homogeneity to the other procedures assigned to this APC.

We also analyzed the latest hospital outpatient claims data for the procedure for the insertion of the complete systems for ICD and CRT–D. The insertion of a complete ICD system is described by CPT code 33249, and our analysis reveals that the geometric mean cost of approximately $33,384 for CPT code 33249 based on 29,451 single claims (out of 29,867 total claims) is significantly higher than that of CPT code 0408T whose geometric mean cost is approximately $15,131. The insertion of a complete CRT–D system is described by either CPT code 33249 or 33270. Similar to the procedure described by CPT code 33249, our findings reveal that the geometric mean cost for the procedure described by CPT code 33270 is approximately $35,361 based on 1,011 single claims (out of 1,023 total claims), which is significantly greater than that of CPT code 0408T. Based on our claims data, we do not believe that we should reassign the procedure described by CPT code 0408T (the insertion of the complete CCM systems) to APC 5232, which is the APC assignment for the insertion of the complete ICD and CRT–D systems. We believe that the geometric mean cost of approximately $15,131 for CPT code 0408T is comparable to the geometric mean cost of about $22,187 for APC 5231. We also believe that the geometric mean cost of approximately $33,384 for CPT code 33249, and the geometric mean cost of approximately $35,361 for CPT code 33270 are comparable to the geometric mean cost of approximately $30,921 for APC 5232.

Therefore, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign CPT code 0408T to APC 5231, and to continue to assign CPT code 33249 and 33270 to APC 5232 for CY 2019. The final CY 2019 payment rate for the code can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

As we do every year, we will reevaluate the APC assignment for CPT codes 0408T, 33249, and 33270 for the next rulemaking cycle. We remind hospitals that we review, on an annual basis, the APC assignments for all items and services paid under the OPPS.

3. Cardiac Resynchronization Therapy (APCs 5221, 5222, 5231, 5731, and 5741)

In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign eight new CY 2019 cardiac resynchronization therapy CPT codes to various APCs, which are listed in Table 20 below. The codes were listed as 06X5T, 06X6T, 06X7T, 06X8T, 06X9T, 07X2T, 06X0T, and 07X0T (the 5-digit CMS placeholder codes) in Addendum B with short descriptors and in Addendum O with long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator “NP” in Addendum B to the proposed rule to indicate that the codes are new for CY 2019 with proposed APC assignments and that public comments would be accepted on their proposed APC assignments. We note that these codes will be effective January 1, 2019.

TABLE 20.—PROPOSED CY 2019 OPPS APC AND SI FOR THE CARDIAC RESYNCHRONIZATION THERAPY CPT CODES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>06X5T</td>
<td>0515T</td>
<td>Insj wcs lv compl sys</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>06X6T</td>
<td>0516T</td>
<td>Insj wcs lv eltrd only</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>06X7T</td>
<td>0517T</td>
<td>Insj wcs lv pg</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>06X8T</td>
<td>0518T</td>
<td>Rmvl pg compt wcs</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>06X9T</td>
<td>0519T</td>
<td>Rmvl &amp; rplcnt pg compt wcs</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>07X2T</td>
<td>0520T</td>
<td>Rmvl&amp;rplcnt pg wcs new eltrd</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>06X0T</td>
<td>0521T</td>
<td>Interrog dev eval wcs ip</td>
<td>Q1</td>
<td>5731</td>
</tr>
<tr>
<td>07X0T</td>
<td>0522T</td>
<td>Prgrmg dev eval wcs ip</td>
<td>Q1</td>
<td>5741</td>
</tr>
</tbody>
</table>

Comment: One commenter disagreed with CMS’ proposed APC assignments for certain cardiac resynchronization Category III CPT codes that are new for CY 2019 and therefore do not have associated claims data available. Specifically, the commenter requested that five of the eight new CPT codes be reassigned to the following APCs:

- CPT code 0515T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation
when performed; complete system (includes electrode and generator (transmitter and battery))—from the proposed assignment to APC 5222 (Level 2 Pacemaker and Similar Procedures) to APC 5231 (Level 1 ICD and Similar Procedures);

• CPT code 0516T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation when performed; electrode only)—from the proposed assignment to APC 5221 (Level 1 Pacemaker and Similar Procedures) to APC 5194 (Level 4 Endovascular Procedures);

• CPT code 0517T (Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation when performed; pulse generator component(s) only (battery and/or transmitter))—from the proposed assignment to APC 5221 to APC 5222 (Level 2 Pacemaker and Similar Procedures);

• CPT code 0520T (Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter) including placement of a new electrode)—from the proposed assignment to APC 5221 to APC 5231; and

• CPT code 0521T (Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter; implantable subcutaneous lead defibrillator system). CPT codes 93288 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead pacemaker system), 93289 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements), 93290 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable cardiovascular monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors), and 93292 (Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; wearable defibrillator system), which are all assigned to APC 5741, and, consequently, the procedure described by CPT code 0521T also should be assigned to this same APC.

Response: Based on our clinical review, we agree with the commenter that there is greater homogeneity, both clinically and in terms of resource use, by assigning CPT codes 0515T and 0520T to APC 5231. We also agree with the commenter that CPT code 0517T is more homogenous clinically and in terms of resource use with the procedures assigned to APC 5222.

However, we disagree with the commenter’s recommendation to assign the procedure described by CPT 0516T to APC 5194. Based on our review of the procedure, we believe that CPT code 0516T is appropriately assigned to APC 5222 because of its clinical and resource homogeneity to the other procedures assigned to this APC. We also disagree with the commenter’s suggestion to assign the procedure described by CPT code 0521T to APC 5741 because the resources required in performing this procedure are not as intensive as those required for the procedure described by CPT code 0522T, which we proposed to assign to APC 5741. We believe that the procedure described by CPT code 0521T is appropriately assigned to APC 5731 because of its clinical and resource homogeneity to the other procedures assigned to this APC. Table 21 below summarizes the commenter’s requested APC assignment for each of the codes along with our decision and the final APC and status indicator assignments.

In summary, after consideration of the public comment we received, we are finalizing our proposal to assign the procedures described by CPT codes 0515T, 0516T, 0517T, 0520T, and 0521T to the final APCs listed in Table 21 below. We are modifying our proposed APC assignment of the procedures described by CPT codes 0515T, 0516T, 0517T, and 0520T, and these modifications are reflected in the final APCs listed in Table 21 below. The final CY 2019 payment rate for CPT codes 0515T through 0521T can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).
Chimeric Antigen Receptor (CAR) T-cell therapy is a cell-based gene therapy in which T-cells are collected and genetically engineered to express a chimeric antigen receptor that will bind to a certain protein on a patient's cancerous cells. The CAR T-cells are then administered to the patient to attack certain cancerous cells and the individual is observed for potential serious side effects that would require medical intervention.

Two CAR T-cell therapies received FDA approval in 2017. KYMRIAH® (manufactured by Novartis Pharmaceuticals Corporation) was approved for use in the treatment of adult patients with relapsed or refractory large B-cell lymphoma and who have not responded to or who have relapsed after at least two other kinds of treatment.

As indicated in the CY 2019 OPPS/ASC proposed rule (83 FR 37114), the HCPCS code to describe the use of KYMRIAH® (HCPCS code Q2040) has been active since January 1, 2018 for OPPS, and the HCPCS code to describe the use of YESCARTA® (HCPCS code Q2041) has been active since April 1, 2018 for OPPS. The HCPCS coding for the currently approved CAR T-cell therapies include leukapheresis and dose preparation procedures because these services are included in the manufacturing of these biologicals. Both of these CAR T-cell therapies were approved for transitional pass-through payment status, effective April 1, 2018. The HCPCS codes that describe the use of these CAR T-cell therapies were assigned status indicator “G” in Addenda A and B to the CY 2019 OPPS/ASC proposed rule.

As discussed in section V.A.4. of the CY 2019 OPPS/ASC proposed rule, the HCPCS codes that describe the use of these CAR T-cell therapies were assigned status indicator “G” in Addenda A and B to the CY 2019 OPPS/ASC proposed rule.

As discussed in section V.A.4. of the CY 2019 OPPS/ASC proposed rule, we are finalizing our proposal to continue pass-through payment status for HCPCS code Q2040 (which is being deleted and replaced with HCPCS code Q2042, effective January 1, 2019) and HCPCS code Q2041 for CY 2019. In section V.A.4. of this final rule with comment period, we also are finalizing our proposal to determine the pass-through payment rate following the standard ASP methodology, updating pass-through payment rates on a quarterly basis if applicable information indicates that adjustments to the payment rates are necessary.

The AMA created four Category III CPT codes that are related to CAR T-cell therapy, effective January 1, 2019. As listed in Addendum B of the CY 2019 OPPS/ASC proposed rule, we proposed to assign procedures described by these CPT codes, 0537T, 0538T, 0539T, and 0540T, to status indicator “B” (Codes that are not recognized by OPPS when submitted on an outpatient hospital Part B bill type (12x and 13x)) to indicate that the services are not paid under the OPPS. We note that, these codes were listed as placeholder CPT codes 05X1T, 05X2T, 05X3T, and 05X4T in both Addendum B and O to the CY 2019 OPPS/ASC proposed rule.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0515T</td>
<td>Insj wcs lv compl sys</td>
<td>J1</td>
<td>5222</td>
<td>5231</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5231</td>
</tr>
<tr>
<td>0516T</td>
<td>Insj wcs lv eltrd only</td>
<td>T</td>
<td>5221</td>
<td>5194</td>
<td>Disagree</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0517T</td>
<td>Insj wcs lv pg</td>
<td>T</td>
<td>5221</td>
<td>5222</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0518T</td>
<td>Rmvl pg compt wcs</td>
<td>T</td>
<td>5221</td>
<td>5221</td>
<td>Same as proposal</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>0519T</td>
<td>Rmvl &amp; rplcmnt pg compt wcs</td>
<td>T</td>
<td>5221</td>
<td>5221</td>
<td>Same as proposal</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>0520T</td>
<td>Rmvl &amp; rplcmnt pg wcs new eltrd</td>
<td>T</td>
<td>5221</td>
<td>5231</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5231</td>
</tr>
<tr>
<td>0521T</td>
<td>Interrog dev eval wcs ip</td>
<td>Q1</td>
<td>5731</td>
<td>5741</td>
<td>Disagree</td>
<td>Q1</td>
<td>5731</td>
</tr>
<tr>
<td>0522T</td>
<td>Prgrmg dev eval wcs ip</td>
<td>Q1</td>
<td>5741</td>
<td>5741</td>
<td>Same as proposal</td>
<td>Q1</td>
<td>5741</td>
</tr>
</tbody>
</table>

### Table 21: CARDIAC RESYNCHRONIZATION THERAPY CODES WITH COMMENTER’S RECOMMENDED APCS, FINAL CMS DECISION, AND FINAL CY 2019 APC AND SI ASSIGNMENTS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0515T</td>
<td>Insj wcs lv compl sys</td>
<td>J1</td>
<td>5222</td>
<td>5231</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5231</td>
</tr>
<tr>
<td>0516T</td>
<td>Insj wcs lv eltrd only</td>
<td>T</td>
<td>5221</td>
<td>5194</td>
<td>Disagree</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0517T</td>
<td>Insj wcs lv pg</td>
<td>T</td>
<td>5221</td>
<td>5222</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0518T</td>
<td>Rmvl pg compt wcs</td>
<td>T</td>
<td>5221</td>
<td>5221</td>
<td>Same as proposal</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>0519T</td>
<td>Rmvl &amp; rplcmnt pg compt wcs</td>
<td>T</td>
<td>5221</td>
<td>5221</td>
<td>Same as proposal</td>
<td>T</td>
<td>5221</td>
</tr>
<tr>
<td>0520T</td>
<td>Rmvl &amp; rplcmnt pg wcs new eltrd</td>
<td>T</td>
<td>5221</td>
<td>5231</td>
<td>Agree with commenter</td>
<td>J1</td>
<td>5231</td>
</tr>
<tr>
<td>0521T</td>
<td>Interrog dev eval wcs ip</td>
<td>Q1</td>
<td>5731</td>
<td>5741</td>
<td>Disagree</td>
<td>Q1</td>
<td>5731</td>
</tr>
<tr>
<td>0522T</td>
<td>Prgrmg dev eval wcs ip</td>
<td>Q1</td>
<td>5741</td>
<td>5741</td>
<td>Same as proposal</td>
<td>Q1</td>
<td>5741</td>
</tr>
</tbody>
</table>
OPPS/ASC proposed rule. Addendum B listed the short descriptor, with the proposed status indicator of “B”, while Addendum O listed the complete long descriptors under placeholder CPT codes 05X1T, 05X2T, 05X3T, and 05X4T. The final CPT codes and long descriptors, with their respective proposed OPPS status indicators, are listed in Table 23 at the end of this section.

At the summer 2018 meeting of the HOP Panel, the HOP Panel recommended that CMS assign the status indicator for procedures described by these specific CPT codes from “B” to “S”. The Panel further recommended that CMS assign the procedures described by CPT code 0537T and CPT code 0540T to APC 5242 (Level 2 Blood Product Exchange and Related Services), and the procedures described by CPT code 0538T and CPT code 0539T to APC 5241 (Level 1 Blood Product Exchange and Related Services).

Comment: Some commenters disagreed with the proposed status indicator assignment of “B” for the procedures described by CPT codes 0537T, 0538T, 0539T, and 0540T, and requested that CMS recognize these procedures and the services described by the CPT codes under the OPPS and pay separately for them. Some of these commenters urged CMS to accept and finalize the HOP Panel’s recommendations for assignment of these CPT codes. Commenters stated that providers may currently use the unlisted code (38206) to bill for the services described by the new CPT codes because the currently available CPT codes fail to accurately describe the procedure being rendered. The commenters indicated that these services are similar to stem cell transplant services, and suggested that the similarities between various codes, including similarities between the procedures described by CPT code 05X1T (0537T) and CPT code 38206 (Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous), which is assigned to APC 5242 (Level 2 Blood Product Exchange and Related Services); CPT code 05X2T (0538T) and CPT code 38207 (Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage), which is assigned to APC 5241 (Level 1 Blood Product Exchange and Related Services); CPT code 05X3T (0539T) and CPT code 38208 (Transplant preparation of hematopoietic progenitor cells; cryopreservation and storage; thawing of previously frozen harvest, without washing, per donor), which is assigned to APC 5241 (Level 1 Blood Product Exchange and Related Services), and finally CPT code 05X4T (0540T) and CPT code 38241 (Hematopoietic progenitor cell (hpc); autologous transplantation), which is assigned to APC 5242 (Level 2 Blood Product Exchange and Related Services), be validly recognized and considered when determining applicable policy and assignments.

A few commenters believed that there are possible similarities between the CAR T-cell procedure CPT code 0540T and chemotherapy codes, in general. However, other commenters asserted that CAR T-cell services were distinct from the services associated with chemotherapy and stem cell transplant codes, but noted that the codes suggested were the best available approximations for payment at present and could provide useful benchmarks of resource utilization. Some commenters also supported the creation of a new Autologous HCT C–APC to adequately compensate for CAR T-cell related services. Some commenters requested that the existing Q-codes for CAR T-cell therapies be revised to reference only the CAR T-cell products, and that leukapheresis and other services related to the preparation, collection and treatment be separately coded and paid.

A few commenters referenced the National Coverage Decision (NCD) for apheresis (effective 1992), which provides coverage only under limited conditions for therapeutic apheresis, and asked CMS to clarify whether it applies to harvesting blood-derived T-lymphocytes for development of genetically modified autologous CAR T-cells. Some commenters referenced the ongoing National Coverage Analysis (NCA) for CAR T-cells, and asked CMS to provide guidance in the interim on how to bill for CAR T-cells and its therapies’ administration.

The commenters also suggested additional modifications to HCPCS codes Q2040 and Q2041, such as adopting HCPCS J-codes instead of HCPCS Q-codes. Some commenters requested guidance on how to bill for specific services, inpatient services, or partial services related to CAR T-cell therapy, including but not limited to, billing for pre-infusion steps, billing for services provided a number of days before the infusion, billing if the CAR T-cell product is not infused, and billing if services are provided at different facilities, such as both inpatient and outpatient facilities.

Finally, another commenter supported the proposal not to pay separately for procedures described by CPT codes 0537T, 0538T and 0539T because the commenters maintained that payment for these CPT codes and the performance of the services describe various steps of the manufacturing process and, therefore, are appropriately included and conveyed in the descriptors of and the existence of Q-codes for CAR T-cell therapies. The commenter supported the appropriateness of including these steps in the payment for the drug as a means to ensure the manufacturer can preserve the integrity of the process and to maximize the quality of therapy.

Finally, one commenter believed that separate payments for leukapheresis would increase beneficiary cost-sharing.

Response: We do not believe that separate payment under the OPPS is necessary for procedures described by CPT codes 0537T, 0538T, and 0539T. The existing CAR T-cell therapies on the market were approved as biologics and, therefore, provisions of the Medicare statute providing for payment for biologics apply. The procedures described by CPT codes 0537T, 0538T, and 0539T describe various steps required to collect and prepare the genetically modified T-cells, and Medicare does not generally pay separately for each step used to manufacture a drug or biological. We note that the HCPCS coding for the currently approved CAR T-cell therapy drugs, HCPCS codes Q2040 and Q2041, includes leukapheresis and dose preparation procedures because these services are included in the manufacturing of these biologicals. We also note that, for OPPS billing purposes, the Q-codes are treated in the same manner as J-codes, and a procedure assignment conversion to a J-code for payment classification purposes would not affect payment by Medicare. Q-codes can be updated quarterly, which allows for greater frequency of modifications and, therefore, we believe are appropriate for these new therapies. HOPFs can bill Medicare for reasonable and necessary services that are otherwise payable under the OPPS, and we believe that the comments in reference to payment for services provided in settings not payable under OPPS are outside the scope of the proposed rule.

With respect to NCD 110.14 for apheresis (Therapeutic Pheresis) (https://www.cms.gov/medicare-coverage-database/details/nctdetai...), we note that it refers only to therapeutic treatments where blood is taken from the patient, processed, and returned to the patient as
part of a continuous procedure and is distinguished from situations where a patient is transfused at a later date. With respect to comments referencing the ongoing NCA for CAR T-cells, we remind readers that coverage analysis and determination do not determine what code or payment is assigned a particular item or service, but information on this NCA and process may be found at: https://www.cms.gov/medicare-coverage-database/details/nca-tracking-sheet.aspx?NCAId=291. Accordingly, we are not revising the existing Q-codes for CAR T-cell therapies to remove leukapheresis and dose preparation procedures, and we are not accepting the HOP Panel’s recommendation for procedures described by CPT codes 0537T, 0538T and 0539T.

In regard to comments concerning CPT code 0540T, we were persuaded by commenters that the administration of CAR T-cell services would be more specifically described by CPT code 0540T. Because CPT code 0540T is a new code for CY 2019, we do not have any claims data on which to base our proposed payment rate. In the absence of claims data, we reviewed the clinical characteristics of the procedures to determine whether they are similar to existing procedures. After reviewing information from public commenters and input from our medical advisors, we believe that new CPT code 0540T is clinically similar to the services assigned to APC 5694 (Level IV Drug Administration), with a proposed payment rate of approximately $291, such as the procedure described by CPT code 96413 (Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug). We acknowledge commenters’ supporting data and indications that CAR T-cell service is complex, distinct from chemotherapy, and has the potential for highly adverse reactions. However, we note that CPT’s prefatory language for the “Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration” section in which the procedure described by CPT code 96413, and some other services assigned to APC 5694 are listed, describes these procedures as administration of highly complex drugs or biologic agents with greater incidence of severe adverse patient reaction. We also note that the unique toxicities associated with CAR T-cell therapies tend not to occur at time of infusion, and services to monitor or treat adverse reactions on a subsequent day would not be included in the procedure described by CPT code 0540T. Therefore, we are accepting the HOP Panel’s recommendation and the commenters’ request to assign the status indicator assignment of the procedure described by CPT code 0540T from “B” to “S.” However, we are not accepting the HOP Panel’s recommendation and the commenters’ request to assign the procedure described by CPT code 0540T to APC 5242 (Level 2 Blood Product Exchange and Related Services), but instead are assigning the procedure described by CPT code 0540T to APC 5694 (Level IV Drug Administration) for CY 2019. We remind hospitals that every year, we review the APC assignments for all services and items paid under the OPPS, and we will reevaluate the APC assignment for the procedures described by CPT code 0540T once sufficient claims data for this code become available.

Comment: Some commenters suggested that separately paying for the services described by new CPT codes for CAR T-cell therapy under the OPPS would allow Medicare and others to track utilization and cost data of these specific services. Some commenters also noted that the National Uniform Billing Committee (NUBC) established two new revenue codes and a value code related to CAR T-cell therapy, and expressed support for CMS’ creation of a new CAR T-cell-related cost center (or centers) to assist with tracking CAR T-cell-related costs.

Response: The existing HCPCS codes for CAR T-cell therapies include both leukapheresis and dose-preparation procedures, and for the reasons stated previously, there is no separate payment by Medicare for these steps in the manufacturing process. However, it will be possible for Medicare to track utilization and cost data from hospitals reporting these services, even for codes reported for services in which no separate payment is made. The CAR T-cell related revenue codes and value code established by the NUBC will be reportable on HOPD claims, and will be available for tracking utilization and cost data, effective for claims received on or after April 1, 2019. At this time, we do not believe that the additional creation by CMS of a new cost center is necessary as the currently established methods for tracking CAR T-cell related costs are sufficient. However, we will monitor for this issue to determine if a distinct cost center should be established in the future.

Comment: Some commenters noted that HCPCS code Q2040 describes doses of “up to 250 million” cells, and requested guidance on how to bill for an adult indication that may require doses of “up to 600 million cells.”

Response: HCPCS code Q2040 (which is being replaced by HCPCS code Q2042, effective January 1, 2019) is billed only once per infusion. For CY 2019, we revised the descriptor for HCPCS code Q2042 to describe doses “up to 600 million cells . . . per therapeutic dose.” For CY 2019, we also revised the descriptor for HCPCS code Q2041, in order to maintain consistency in the HCPCS coding for CAR T-cells.

In summary, after consideration of the public comments we received, we are adopting as final, without modification, the proposal to assign status indicator “B” to CPT codes 0537T, 0538T, and 0539T for CY 2019. We are revising our proposal and finalizing the policy to assign status indicator “S” to CPT code 0540T and to assign CPT code 0540T to APC 5694 for CY 2019. Additionally, for CY 2019, we are assigning status indicator “D” to CPT code Q2040, status indicator “G” to HCPCS code Q2041, and status indicator “G” to HCPCS code Q2042, as summarized in Table 22 below. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. In addition, we refer readers to Addendum D1 to this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019.
<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long Descriptors</th>
<th>CY 2018 OPPS SI</th>
<th>CY 2018 OPPS APC</th>
<th>October 2018 OPPS Payment Rate</th>
<th>Final CY 2019 OPPS SI</th>
<th>Final CY 2019 OPPS APC</th>
<th>Final CY 2019 OPPS Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2040</td>
<td>Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion*</td>
<td>G</td>
<td>9081</td>
<td>$500,901.94</td>
<td>D</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Q2041</td>
<td>Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose**</td>
<td>G</td>
<td>9035</td>
<td>$395,380.00</td>
<td>G</td>
<td>9035</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>Q2042</td>
<td>Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose</td>
<td>G</td>
<td>9194</td>
<td>Refer to OPPS Addendum B</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* HCPCS code Q2040: As discussed above in this section, CMS deleted HCPCS Code Q2040, replaced it with HCPCS Code Q2042, and revised the long descriptor to “Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose” effective January 1, 2019.

** HCPCS code Q2041: As discussed above in this section, CMS revised the long descriptor to “Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose” effective January 1, 2019.
5. **Drug-Eluting Implant (APC 5733)**

   For CY 2019, we proposed to continue to assign CPT code 0356T (Insertion of drug-eluting implant (including punctal dilation and implant removal when performed) into lacrimal canaliculus, each) to APC 5733 (Level 3 Minor Procedures) with a proposed payment rate of approximately $57. We also proposed to continue to assign the CPT code to status indicator “Q1” to indicate one of the following with regards to payment:

   - Packaged APC payment if billed on the same claim as a HCPCS code assigned status indicator “S”, “T”, or “V”; or
   - Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria. Payment is packaged into a single payment for specific combinations of services; or
   - In other circumstances, payment is made through a separate APC payment.

   **Comment:** Several commenters disagreed with the proposed continuation of the status indicator assignment of “Q1” for CPT code 0356T and recommended an assignment to a significant procedure status indicator instead of a conditionally packaged status indicator. One commenter indicated that the procedure described by CPT code 0356T represents a nonsurgical, independent procedure that is not based on any other primary procedure, and believed that a status indicator reassignment would ensure proper claims processing for providers.

   **Response:** As indicated above and in OPPS Addendum D1 of the CY 2019 OPPS/ASC proposed rule, status indicator “Q1” represents one of three potential payment assignments. Depending on the claim submitted, and whether the procedure described by CPT code 0356T is performed with any other surgeries or services on the same day, the procedure described by CPT code 0356T may be paid separately through an APC (in this case APC 5733) or paid as part of a payment when included in the more significant procedure that is reported on the claim. Based on the nature of this procedure, which may be performed by itself or with other procedures on the same day, we believe that the continued assignment of status indicator “Q1” is appropriate for the procedure described by CPT code 0356T.

   After consideration of the public comments we received, we are finalizing our proposal, without

---

**TABLE 23.—PROPOSED AND FINAL CY 2019 SI FOR CPT CODES 0537T, 0538T, 0539T, AND 0540T**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>05X1T</td>
<td>0537T</td>
<td>B</td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td>05X2T</td>
<td>0538T</td>
<td>B</td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td>05X3T</td>
<td>0539T</td>
<td>B</td>
<td>B</td>
<td>N/A</td>
</tr>
<tr>
<td>05X4T</td>
<td>0540T</td>
<td>B</td>
<td>S</td>
<td>5694</td>
</tr>
</tbody>
</table>
modification, to assign CPT code 0356T to status indicator “Q1” for CY 2019. The final CY 2019 payment rate for the CPT code can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

6. Endovascular Procedures (APCs 5191 Through 5194)

At the annual meeting for the HOP Panel held on August 21, 2017, the HOP Panel recommended that, for CY 2018, CMS examine the number of APCs for endovascular procedures. The HOP Panel also recommended that the appropriate Panel subcommittee review the APCs for endovascular procedures to determine whether more granularity (that is, more APCs) is warranted.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59293 through 59294), we stated that we believed that the current C–APC levels for the Endovascular Procedures C–APC family provide an appropriate distinction between the resource costs at each level and clinical homogeneity. We also stated that we would continue to review the C–APC structure for endovascular procedures to determine if any additional granularity is necessary for this C–APC family.

Using the most recent data available for the CY 2019 OPPS/ASC proposed rule, we analyzed the four existing levels of the Endovascular Procedures C–APCs. We did not observe any violations of the 2 times rule within the current Endovascular Procedures C–APC structure. Some stakeholders have suggested that for certain procedures, such as angioplasty procedures involving the use of a drug-coated balloon in addition to a nondrug-coated balloon, resource costs are significantly higher than the geometric mean cost (and associated C–APC payment) for all of the angioplasty procedures combined. We stated in the proposed rule that we recognize that the costs of a given procedure, involving additional devices, will be higher than the costs of the procedure when it does not involve such additional devices. However, the OPPS is a prospective payment system based on a system of averages in which the costs of some cases within an APC will be more costly than the APC payment rate, while the costs of other cases will be less costly. While we believe that there is sufficient granularity within the existing Endovascular Procedures C–APC structure and at least one stakeholder agrees, we stated that we have also received input from other stakeholders who have suggested alternative structures for this C–APC family that include a five-level structure and a six-level structure. An illustration of these proposed C–APC structure levels was displayed in Table 15 and Table 16, respectively, of the proposed rule. Because interested stakeholders have suggested a variety of options for the endovascular procedures C–APC structure, including keeping the existing C–APC structure, in the CY 2019 OPPS/ASC proposed rule, we proposed to maintain the existing four-level structure for this C–APC family listed in Table 14 of the proposed rule. However, we invited public comments on our proposal, as well as the stakeholder-requested five-level and six-level structures displayed in the Tables 15 and 16 of the proposed rule. We noted that the approximate geometric mean costs associated with the suggested five-level and six-level C–APC structures shown in Tables 15 and 16 of the proposed rule were only estimates and, if either of the suggested structure levels were adopted, they would be subject to change, depending on the final rule with comment period data and the particular services that are assigned to each C–APC.

Comment: Several commenters supported CMS’ proposal to continue with a four-level APC structure, along with the proposed CPT code assignments to each of the endovascular APCs as described in the CY 2019 OPPS/ASC proposed rule. These commenters stated that adding additional APCs to the endovascular series could result in some APCs containing very few procedures, and further believed that this policy change would also be contrary to the concept of broader APC groupings under the OPPS. Another commenter requested that CMS provide greater detail about future proposals in order for stakeholders to be able to provide fully informed comments and recommendations.

Other commenters also agreed with CMS’ assessment that the four-level APC structure and the assignment of the procedures to these APCs does not result in any 2 times rule violations, and believed that the current granularity within the existing Endovascular Procedures C–APCs’ structure sufficiently represents resource cost and clinical homogeneity.

Response: We appreciate the commenters’ input and support. At this time, we believe that the current APC structure levels for the Endovascular Procedures C–APC family provide an appropriate distinction between resource costs at each level and clinical homogeneity.

Comment: Several commenters believed that the current structure of the Endovascular Procedures APCs violates the 2 times rule when certain code combinations, such as the procedures described by CPT 37224 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty) and HCPCS code C2623 (Catheter, transluminal angioplasty, drug-coated, non-laser), are reported in combination. As a result, the commenters requested that CMS make a complexity adjustment for CY 2019 by assigning cases for the procedures described by CPT code 37224 and HCPCS code C2623 when reported in combination with one another to APC 5193.

Some of these commenters believed that the current structure of the Endovascular Procedures APCs is insufficiently granular, and noted that the current APC structure has significant differentials in payments of over $5,000 between the current procedures assigned to Level 2 (APC 5192) and between the procedures assigned to Level 3 and Level 4 (APC 5194). These commenters further contended that the large numbers of procedures assigned to each level of APC, coupled with the high total volume of procedures assigned to each level within each APC, prevent technology costs from being adequately and accurately reflected in the OPPS payment rates. As a result, these commenters requested that CMS create a six-level structure Endovascular Procedure APC reflecting the following cost bands:
Some of these commenters also specifically suggested that the procedures described by CPT code 37224 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal angioplasty) and HCPCS code C2623 (Catheter, transluminal angioplasty, drug-coated, non-laser); and CPT code 37726 (Revascularization, endovascular, open or percutaneous, femoral, popliteal artery(s), unilateral; with transluminal stent placement(s), includes angioplasty within the same vessel, when performed) and HCPCS code C1874 (Stent, coated/covered, with delivery system) be assigned to the newly created APC 5193, respectively, in order to take into consideration the performance of and utilization of procedures involving drug-coated balloons and drug eluting stents that are required for these procedures.

Several of these same commenters requested that CMS create new HCPCS code modifiers to take into account the performance of the procedures described by CPT code 37724 when reported in combination with HCPCS code C2623, and CPT code 37226 when reported in combination with HCPCS code C1874. The commenters provided that CMS could model the costs for these cases using CY 2017 and CY 2018 claims data when these codes are reported in combination with one another. The commenters further believed that the creation of new HCPCS code modifiers are necessary in order to differentiate drug-coated device procedures from non-drug-coated device procedures, and will provide the granularity in HCPCS and APC coding that will allow CMS to collect data for the CPT/HCPCS codes to appropriately calculate payment rates within the APCs. Another commenter further stated that these procedures should be assigned within the current four-level structure of APC 5193 and APC 5195, respectively.

Response: We appreciate the commenters’ suggestion. As noted in the proposed rule, we understand that some stakeholders have suggested that when certain procedures, such as those described by CPT code 37224 and HCPCS code C2623 are reported in combination, a 2 times rule violation occurs. However, we recognize that the costs of a given procedure, involving additional devices, will be higher than the costs of the procedure when it does not involve such additional devices, and we do not believe that these types of 2 times rule violations are avoidable, given the nature of a prospective payment system (83 FR 37095).

Using the most recent data available for this final rule with comment period, we analyzed the various alternative suggestions for the recommended HCPCS code placements, including maintaining the CY 2018 APC groupings, creating a six-level APC, and reconfiguring significant HCPCS code placements within the current structure. We note that, when we modeled the creation of a six-level structure APC and modeled a reconfiguration of significant HCPCS code placements, we noticed significant downward payment fluctuations for several services, some as high as a $2,500 decrease relative to the payment rate in CY 2018. Furthermore, based on these findings, we are still not convinced that we should pay for a complexity adjustment for the procedure described by CPT code 37224 when reported in combination with HCPCS code C2623 or for the procedure described by CPT code 37226 when reported in combination with HCPCS code C1874. As noted above and as provided in the proposed rule, the OPPS is a prospective payment system based on a system of averages in which the costs of some cases within an APC will be more costly than the APC payment rate, while the costs of other cases will be less costly and in these particular procedures we believe that if a complexity adjustment would be applied it would adversely affect the APC payment (83 FR 37095).

Additionally, at this time, we do not support the creation of any new HCPCS codes for inclusion in the Endovascular Procedures APCs. Specifically, we do not believe that we have the needed evidence and data to support combining payment for either the procedure described by CPT code 37724 when reported in combination with HCPCS code C2623 or the procedure described by CPT code 37226 when reported in combination with HCPCS code C1874 because we believe that payment for these services are currently adequate.

However, we do share similar concerns with the commenters regarding the significant differential payments between the procedures assigned within the current four-level structure of the Endovascular Procedures APCs and intend to revisit this particular issue in future rulemaking. Therefore, after consideration of the public comments and suggestions we received, we are maintaining the CY 2018 APC structure of four levels for the Endovascular Procedures APCs. We understand the importance of payment stability for providers and believe that continuation of the four levels within the Endovascular Procedures APCs will minimize fluctuation in payment rates from CY 2018 to CY 2019. As displayed in the “Two Times Listing” file to this final rule with comment period, which is available via the internet on the CMS website, the APC geometric mean costs for APCs 5521 through 5524 are consistent with the CY 2018 APC geometric mean costs for the same APCs, indicating the relative weights that are used to calculate payment are stable.

We will continue to review this APC structure to determine if additional granularity is necessary for this C–APC family, including if additional HCPCS codes should be created in future rulemaking. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. Additionally, we refer readers to Addendum A to this final rule with comment period for the complete list of APCs and their payment rates under the OPPS. Both Addendum A and Addendum B are available via the internet on the CMS website.

<table>
<thead>
<tr>
<th>APC</th>
<th>Description</th>
<th>Approximate Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>5191</td>
<td>Level 1 Endovascular APC</td>
<td>$2,000-$4,000</td>
</tr>
<tr>
<td>5192</td>
<td>Level 2 Endovascular APC</td>
<td>$4,000 to $6,750</td>
</tr>
<tr>
<td>519X/New 5193</td>
<td>Level 3 Endovascular APC</td>
<td>$6,750 to $9,000</td>
</tr>
<tr>
<td>5193/New 5194</td>
<td>Level 4 Endovascular APC</td>
<td>$9,000-$11,000</td>
</tr>
<tr>
<td>519Y/New 5195</td>
<td>Level 5 Endovascular APC</td>
<td>$11,000 to $14,000</td>
</tr>
<tr>
<td>Current 5194/New 5196</td>
<td>Level 6 Endovascular APC</td>
<td>$14,000+</td>
</tr>
</tbody>
</table>
7. Fine Needle Aspiration Biopsy (APC 5071)

As displayed in Table 25 below and in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign CPT codes 10009 and 10011 to APC 5071 (Level 1 Excision/Biopsy/Incision and Drainage), with a proposed payment rate of approximately $582. The codes were listed as 10X16 and 10X18 (the 5-digit CMS placeholder codes), respectively, in Addendum B with the short descriptors and in Addendum O with the long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator “NP” in Addendum B to indicate that the codes are new for CY 2019, with proposed APC assignments, and that public comments would be accepted on their proposed APC assignments. We note that these codes will be effective January 1, 2019.

Comment: One commenter disagreed with the proposed assignment of the procedure described by CPT code 10009 to APC 5071 and suggested that APC 5072 (Level 2 Excision/Biopsy/Incision and Drainage), with a proposed payment rate of approximately $1,370, is more appropriate because the resource cost of the CT guidance used in the procedure is higher than the resource cost of ultrasound or fluoroscopy. The commenter disagreed with the proposed assignment of the procedure described by CPT code 10011 to APC 5071 and recommended that APC C–5373 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $1,731, is more appropriate because the cost of the MRI guidance used in the procedure is clinically similar to the other services in this APC.

Response: Because CPT codes 10009 and 10011 are new codes for CY 2019, we do not have claims data on which to base the payment rates. However, in the absence of claims data, we reviewed the clinical characteristics of the procedures described by CPT codes 10009 and 10011 to determine whether they are similar to existing procedures. After reviewing information from the public commenter and input from our medical advisors, we believe that the procedures described by new CPT codes 10009 and 10011 are clinically similar to those procedures assigned to APC 5071. We are unclear of the rationale for the commenter’s suggestion of recommending a Urology APC assignment (C–APC 5373) for the procedure described by CPT code 10011 when this procedure describes a fine needle aspiration biopsy, which is not a urology-specific procedure. Therefore, we are not accepting the commenter’s recommendation. In addition, we remind hospitals that, every year, we review the APC assignments for all services and items paid under the OPPS. We will reevaluate the APC assignment for the procedures described by CPT codes 10009 and 10011 once we have claims data for the codes.

After consideration of the public comment received, we are finalizing our proposal, without modification, to assign the procedures described by CPT codes 10009 and 10011 to APC 5071 for CY 2019. The final APC and status indicator assignments are listed in Table 25 below. We refer readers to Addendum B of this final rule with comment period for the final payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.
8. Fluorescence In Situ Hybridization (FISH) Assays (APCs 5672 and 5673)

As displayed in Table 26 below and in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedures described by CPT codes 88364 through 88377 to status indicator “N” to indicate a packaged payment status, or status indicators “Q1” and “Q2” to indicate a conditionally packaged payment status, with APC assignments to either APC 5672 (Level 2 Pathology), with a proposed payment rate of approximately $145, or APC 5673 (Level 3 Pathology), with a proposed payment rate of approximately $273.

Comment: One commenter urged CMS to exclude certain FISH assays from the OPPS packaging policy. Specifically, the commenter stated that the technical component of services that are associated with the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 have unique clinical utilization that is distinct from conventional laboratory tests, and suggested that the services described by these codes be excluded from the OPPS payment packaging policy. The commenter further stated that these tests are utilized in both the hospital outpatient and hospital inpatient setting similar to molecular pathology tests and advanced diagnostic laboratory tests (ADLTs).

Response: As stated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79593), payment for most laboratory tests is packaged under OPPS. Under our current policy, payment for certain clinical diagnostic laboratory tests that are listed on the Clinical Laboratory Fee Schedule (CLFS) is packaged in the OPPS as integral, ancillary, supportive, dependent, or adjunctive to the primary service or services provided in the hospital outpatient setting (81 FR 79593 and 42 CFR 419.2(b)(17)). However, we have established exceptions to the OPPS laboratory test packaging policy for molecular pathology tests, certain ADLTs, and preventive laboratory tests. Specifically, we exclude from packaging the following laboratory tests:

- Molecular pathology tests, because these relatively new tests may have a different pattern of clinical use than more conventional laboratory tests, which may make them generally less tied to a primary service in the hospital outpatient setting than the more common and routine laboratory tests that are packaged (80 FR 70348 through 70350).

- ADLTs, as designated under the CLFS, that meet the criteria of section 1834A(d)(5)(A) of the Act (81 FR 79593 through 79594), and

- Preventive laboratory tests that are listed in Section 1.2, Chapter 18 of the Medicare Claims Processing Manual (Pub. 100–04) (80 FR 70349).

We note that laboratory tests also are paid separately when they are the only services provided to a beneficiary on a claim (81 FR 79593). When payment for laboratory tests is not packaged under the OPPS, and the tests are listed on the CLFS, the payment is made at the CLFS payment rates, outside the OPPS, under Medicare Part B.

With regard to the services described by CPT codes 88364, 88365, and 88373, we proposed to continue to assign these add-on services to status indicator “N” because, under the OPPS, payment for services described by add-on codes are packaged in accordance with the regulations at §419.2(b)(18).

In addition, with regard to the services described by CPT codes 88365, 88366, 88367, and 88377, we proposed to continue to assign these codes to status indicator “Q1” to indicate that these services are separately payable when not billed on the same claim as a HCPCS code assigned status indicator “T”, “S”, or “V”. Further, with regard to the services described by CPT codes 88367 and 88368, we proposed to continue to assign these codes to status indicator “Q2” to indicate that payment for these services will be packaged in the APC payment if billed on the same date of service as a HCPCS code assigned to status indicator “T”, but in all other circumstances, separate APC payment for the services would be made. Based on the nature of these services, we believe the payment for the services described by CPT codes 88365, 88366, 88367, 88368, 88374, and 88377 should continue to be conditionally packaged under the OPPS because these laboratory tests may be performed with other procedures on the same day.

In summary, because the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 are not molecular pathology laboratory tests, ADLTs, or preventive laboratory tests as stated in the above response, we believe that we should continue to package the payment for these services under the OPPS. Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, to assign the services described by CPT codes 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, and 88377 to the final APCs and status indicator assignments listed in Table 26 below. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website. In addition, we refer readers to Addendum D1 of this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019.
TABLE 26.—PROPOSED AND FINAL CY 2019 APC AND SI ASSIGNMENTS FOR CPT CODES 88364, 88365, 88366, 88367, 88368, 88369, 88373, 88374, AND 88377

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>88364</td>
<td>Insitu hybridization (fish)</td>
<td>N</td>
<td></td>
<td></td>
<td>N</td>
<td>N/A</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88365</td>
<td>Insitu hybridization (fish)</td>
<td>Q1</td>
<td>5672</td>
<td>$144.65</td>
<td>Q1</td>
<td>5672</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88366</td>
<td>Insitu hybridization (fish)</td>
<td>Q1</td>
<td>5673</td>
<td>$271.73</td>
<td>Q1</td>
<td>5673</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88367</td>
<td>Insitu hybridization auto</td>
<td>Q2</td>
<td>5673</td>
<td>$271.73</td>
<td>Q2</td>
<td>5673</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88368</td>
<td>Insitu hybridization manual</td>
<td>Q2</td>
<td>5673</td>
<td>$271.73</td>
<td>Q2</td>
<td>5673</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88369</td>
<td>M/phmtrc alysishquant/semiq</td>
<td>N</td>
<td></td>
<td></td>
<td>N</td>
<td>N/A</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88373</td>
<td>M/phmtrc alysishquant/semiq</td>
<td>N</td>
<td></td>
<td></td>
<td>N</td>
<td>N/A</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88374</td>
<td>M/phmtrc alysishquant/semiq</td>
<td>Q1</td>
<td>5672</td>
<td>$144.65</td>
<td>Q1</td>
<td>5672</td>
<td>Refer to OPPS Addendum B</td>
</tr>
<tr>
<td>88377</td>
<td>M/phmtrc alysishquant/semiq</td>
<td>Q1</td>
<td>5672</td>
<td>$144.65</td>
<td>Q1</td>
<td>5672</td>
<td>Refer to OPPS Addendum B</td>
</tr>
</tbody>
</table>

BILLING CODE 4120–01–C

9. Immediate Breast Implant Following Mastopexy/Mastectomy (C–APC 5092)

For CY 2019, we proposed to continue to assign the procedures described by CPT code 19340 (Immediate insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction) to C–APC 5092 (Level 2 Breast/Lymphatic Surgery and Related Procedures), with a proposed payment rate of approximately $4,960.

Comment: Some commenters disagreed with the proposed continued APC assignment for the procedure described by CPT code 19340 to C–APC 5092 and suggested instead a reassignment to C–APC 5093 (Level 3 Breast/Lymphatic Surgery and Related Procedures), with a proposed payment rate of approximately $7,432. One commenter believed that the procedure described by CPT code 19340 shares similar clinical and resource characteristics as the procedures described by CPT codes 19325 (Mammoplasty, augmentation; with prosthetic implant) and 19342 (Delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction), which are assigned to C–APC 5093. Another commenter requested a review and reconfiguration of C–APCs 5092 and 5093, and believed
that the cost of performing the procedure described by CPT code 19340 is similar to the surgical procedures assigned to C–APC 5093.

Response: Analysis of the hospital outpatient claims data used for this final rule with comment period, which is based on claims submitted between January 1, 2017 and December 31, 2017, and processed through June 30, 2018, do not support a reassignment of the procedure described by CPT code 19340 to C–APC 5093. Specifically, our claims data show a geometric mean cost of approximately $5,341 for the procedure described by CPT code 19340 based on 1,187 single claims (out of 1,203 total claims), which is comparable to the geometric mean cost of approximately $4,958 for C–APC 5092. In contrast, our claims data show a higher geometric mean cost for the procedures described by CPT codes 19325 (approximately $6,326 based on 209 single claims out of 210 total claims) and 19342 (approximately $6,232 based on 1,190 single claims out of 1,202 total claims) that is comparable to the geometric mean cost of approximately $7,513 for C–APC 5093. Based on our analysis, we believe that the procedure described by CPT code 19340 is appropriately assigned to C–APC 5092 based on resource and clinical homogeneity to the other procedures in the APC. We note that all of the procedures described by CPT codes assigned to this Breast/ Lymphatic Surgery and Related Procedures C–APC are clinically similar and that the resource similarity is based on the geometric mean costs derived from claims submitted by hospitals performing these procedures.

After consideration of the public comments we received and based on our analysis of the latest hospital outpatient claims data for the procedures described by CPT codes 19340, 19325, and 19342, we are finalizing our proposal, without modification, to continue to assign CPT code 19340 to C–APC 5092. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.

In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign eight new intracardiac ischemia monitoring CPT codes to various APCs, which are listed in Table 27 below. The codes were listed as 00X0T through 00X7T (the 5-digit CMS placeholder codes) in Addendum B with short descriptors and in Addendum O with long descriptors to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator “NP” in Addendum B to the proposed rule to indicate that the codes are new for CY 2019, with proposed APC assignments, and that public comments would be accepted on their proposed APC assignments. We note these codes will be effective January 1, 2019. Although the codes are new for CY 2019, the services associated with intracardiac ischemia monitoring were previously described by CPT codes 0302T through 0307T, which were deleted on December 31, 2017.

**TABLE 27.—PROPOSED CY 2019 OPPS APC AND SI ASSIGNMENTS FOR THE INTRACARDIAC ISCHEMIA MONITORING CPT CODES**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>00X0T</td>
<td>0525T</td>
<td>Insj/emplnt compl imms</td>
<td>J1</td>
<td>5223</td>
</tr>
<tr>
<td>00X1T</td>
<td>0526T</td>
<td>Insj/emplnt imms elrd only</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>00X2T</td>
<td>0527T</td>
<td>Insj/emplnt imms implt mntr</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>00X3T</td>
<td>0528T</td>
<td>Prgrmg dev eval imms ip</td>
<td>Q1</td>
<td>5741</td>
</tr>
<tr>
<td>00X4T</td>
<td>0529T</td>
<td>Interrog dev eval imms ip</td>
<td>Q1</td>
<td>5741</td>
</tr>
<tr>
<td>00X5T</td>
<td>0530T</td>
<td>Removal complete imms</td>
<td>Q2</td>
<td>5221</td>
</tr>
<tr>
<td>00X6T</td>
<td>0531T</td>
<td>Removal imms electrode only</td>
<td>Q2</td>
<td>5221</td>
</tr>
<tr>
<td>00X7T</td>
<td>0532T</td>
<td>Removal imms implt mntr only</td>
<td>Q2</td>
<td>5221</td>
</tr>
</tbody>
</table>

Comment: One commenter disagreed with CMS’ proposed APC assignment for the new intracardiac ischemia monitoring Category III CPT code 0525T (Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)) and requested assignment to APC 5224 (Level 4 Pacemaker and Similar Procedures) instead of APC 5223. The commenter suggested that the procedure described by CPT code 0525T be assigned to APC 5224, which is the same APC that was assigned to its predecessor CPT code 0302T (Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation when performed and intra-operative interrogation and programming when performed; complete system (includes device and electrode)) when the code was active during CY 2017. The commenter also stated that the procedure described by CPT code 0525T is more complex and requires significantly more resources than the other procedures assigned to APC 5223. The commenter further indicated that the cost of the Guardian System alone, which is related to the CPT codes of concern, is between $8,000 to $8,700, while the overall cost for the insertion of the complete system is between $15,700 and $16,400.
Response: For CY 2018, CMS received a New Technology APC application requesting a new HCPCS code for the insertion of an intracardiac ischemia monitoring system because no current CPT code existed to describe the procedure, and because its predecessor CPT code 0302T was deleted on December 31, 2017. Based on our review of the application, evaluation of the procedure, and input from our clinical advisors, we agreed that no existing code appropriately describes the insertion of an intracardiac ischemia monitoring system and, therefore, established HCPCS code C9750 (Insertion or removal and replacement of intracardiac ischemia monitoring system including imaging supervision and interpretation and peri-operative interrogation and programming; complete system (includes device and electrode)), effective July 1, 2018. For the October 2018 OPPS update, we assigned HCPCS code C9750 to APC 5223 (Level 3 Pacemaker and Similar Procedures) with a payment rate of approximately $9,748. We announced this new HCPCS code and APC assignment in the October 2018 OPPS quarterly update CR (Transmittal 4123, Change Request 10923, dated August 24, 2018). Because the procedure described by CPT code 0525T is the same procedure described by HCPCS code C9750, we proposed to assign CPT code 0525T to APC 5223.

In addition, we reviewed our claims data for the predecessor CPT code 0302T that were submitted during CY 2012 through CY 2017. We note that predecessor CPT code 0302T became effective July 1, 2012 and was deleted on December 31, 2017. Our analysis of the claims data for CPT code 0302T revealed no single claim submitted for CY 2012 through CY 2017. Based on input from our medical advisors and our APC assignment for predecessor CPT code 0302T, we believe that APC 5223 is the appropriate APC assignment for the procedure described by CPT code 0525T.

Comment: One commenter also disagreed with the proposed assignment of the service described by CPT code 0525T to APC 5741, and requested that the service be assigned to APC 5743 (Level 3 Electronic Analysis of Devices) instead. The commenter stated that the service generally takes about 60 minutes to perform, which is similar to the following services assigned to APC 5743:

- CPT code 0462T (Programming device evaluation (in person) with iterative adjustment of the implantable mechano-electrical skin interface and/or external driver to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable aortic counterpulsation ventricular assist system, per day);
- CPT code 0463T (Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter, implantable aortic counterpulsation ventricular assist system, per day); and
- CPT code 0472T (Device evaluation, interrogation, and initial programming of intraocular retinal electrode array (e.g., retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional).

Response: Based on our review of the predecessor CPT codes for the intracardiac ischemia monitoring systems that were in existence from July 1, 2012 through December 31, 2017, we found that the service described by CPT code 0528T (Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report) was previously described by predecessor CPT code 0305T (Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report). Similar to predecessor CPT code 0302T, predecessor CPT code 0305T became effective July 1, 2012 and was deleted on December 31, 2017. Our analysis of the claims data for the service described by CPT code 0305T revealed no single claim submitted during CY 2012 through CY 2017. Based on input from our medical advisors and our APC assignment for predecessor CPT code 0305T to APC 5741, we believe that APC 5741 is the appropriate APC assignment for the service described by CPT code 0528T, based on similar programming device evaluation codes assigned to this APC.

In summary, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign the services described by CPT codes 0525T through 0532T to the final APCs listed in Table 28 below. We note that HCPCS code C9750 will be deleted December 31, 2018, because it will be replaced with CPT code 0525T, effective January 1, 2019. The final CY 2019 payment rate for CPT codes 0525T through 0532T can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).
As noted in Table 29 below, for CY 2019, we proposed to continue to assign the procedure described by CPT code 0472T to APC 5743 (Level 3 Electronic Analysis of Devices), with a proposed payment rate of approximately $280. We also proposed to continue to assign the procedure described by CPT code 0473T to APC 5742 (Level 2 Electronic Analysis of Devices), with a proposed payment rate of approximately $115.

### Comment:
One commenter supported CMS’ proposal to continue to assign the programming services for Argus II, which are described by CPT codes 0472T and 0473T, to APCs 5742 and 5743. A commenter also encouraged CMS to continue to assign the reprogramming service of the Argus II retinal prosthesis to APC 5743. We note that CMS’ final rule does not change this coding assignment. In the final rule, we also proposed to assign the initial system programming and imaging services for Argus II to APC 5743. However, the final rule does not change this coding assignment.

### Table 28—Final CY 2019 OPPS APCs and Status Indicators (SI) for the Intracardiac Ischemia Monitoring CPT Codes

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0525T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)</td>
<td>J1</td>
<td>5223</td>
</tr>
<tr>
<td>0526T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0527T</td>
<td>Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only</td>
<td>J1</td>
<td>5222</td>
</tr>
<tr>
<td>0528T</td>
<td>Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report</td>
<td>Q1</td>
<td>5741</td>
</tr>
<tr>
<td>0529T</td>
<td>Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report</td>
<td>Q1</td>
<td>5741</td>
</tr>
<tr>
<td>0530T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)</td>
<td>Q2</td>
<td>5221</td>
</tr>
<tr>
<td>0531T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only</td>
<td>Q2</td>
<td>5221</td>
</tr>
<tr>
<td>0532T</td>
<td>Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only</td>
<td>Q2</td>
<td>5221</td>
</tr>
</tbody>
</table>
Response: We appreciate the commenter’s support. Based on input from our medical advisors, we believe that CPT codes 0472T and 0473T are appropriately assigned to APCs 5743 and 5742, respectively, based on clinical and resource homogeneity to the other services assigned to these APCs. Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, to continue to assign the procedures described by CPT codes 0472T and 0473T to APCs 5743 and 5742, respectively, for CY 2019.

The final APC and status indicator assignments are listed in Table 29 below. The final payment rates for these codes, where applicable, can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

**TABLE 29.—PROPOSED AND FINAL CY 2019 APC AND SI ASSIGNMENTS FOR CPT CODES 0472T AND 0473T**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0472T</td>
<td>Device evaluation, interrogation, and initial programming of intraocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional</td>
<td>Q1</td>
<td>5743</td>
<td>Q1</td>
<td>5743</td>
</tr>
<tr>
<td>0473T</td>
<td>Device evaluation and interrogation of intraocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional</td>
<td>Q1</td>
<td>5742</td>
<td>Q1</td>
<td>5742</td>
</tr>
</tbody>
</table>

**BILLING CODE 4120–01–C**

12. Kidney Dilation of Tract (C–APC 5373)

In Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedure described by CPT code 50436 (Dilation of existing tract, percutaneous, for an endourologic procedure including imaging guidance (e.g., ultrasound and/or fluoroscopy) and all associated radiological supervision and interpretation, with postprocedure tube placement, when performed) to C–APC 5373 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $1,731. This code was listed as 50X39 (the 5-digit CMS placeholder code) in Addendum B, with the short descriptor, and in Addendum O, with the long descriptor, to the CY 2019 OPPS/ASC proposed rule. We also proposed to assign this code to comment indicator “NP” in Addendum B to indicate that public comments would be accepted on the proposed APC assignment. We note that this code will be effective January 1, 2019.

Comment: One commenter disagreed with the proposed assignment of CPT code 50436 to C–APC 5373 and instead recommended assignment to C–APC 5374 (Level 3 Urology and Related Services), with a proposed payment rate of approximately $2,755, because of the higher resource costs associated with the procedure.

Response: Because CPT code 50436 is a new code for CY 2019, we do not have claims data on which to base a payment rate. However, in the absence of claims data, we reviewed the clinical characteristics of the procedure to determine whether the surgical procedure is similar to existing procedures. After review of the procedure and input from our clinical advisors, we believe that the procedure described by new CPT code 50436 is clinically similar to those procedures assigned to C–APC 5373. We will reevaluate the APC assignment for the procedure described by CPT code 50436 once claims data for this procedure become available. We note that as we do every year, we review the APC assignments for all services and items paid under the OPPS.

After consideration of the public comment we received, we are finalizing our proposal to assign the procedure described by CPT code 50436 to C–APC 5373. We refer readers to Addendum B of this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.

13. Intraocular Procedures (APC 5494)

In prior years, the procedure described by CPT code 0308T (Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis) has been assigned to the APC 5495 (Level 5
Intraocular Procedures) based on its estimated costs. In addition, its relative payment weight has been based on its median under our payment policy for low-volume device-intensive procedures established in the CY 2016 OPPS because the APC contained a low volume of claims. The low-volume device-intensive procedures policy is discussed in more detail in section III.C.2. of the proposed rule and this final rule with comment period.

In reviewing the claims data available for the proposed rule for CY 2019 OPPS ratesetting, we found that there were only two claims containing procedures described by CPT code 0308T, with a geometric mean of $5,438.99 and a median of $8,237.56. Based on those two claims, APC 5495 would have had a proposed geometric mean of $5,438.99 and a proposed median of $8,237.56. However, based on its estimated costs in the most recently available claims data, we stated in the proposed rule that we believe that the procedure described by CPT code 0308T is more appropriately placed in the APC 5493, which has a geometric mean cost of $9,821.47, which is more comparable to that of the procedure described by CPT code 0308T. Therefore, for CY 2019, we proposed to reassign the procedure described by CPT code 0308T from APC 5495 to APC 5493 (Level 3 Intraocular Procedures) and to delete APC 5495. We stated that we would continue to monitor the volume of claims reporting a procedure described by CPT code 0308T available to us for future ratesetting.

**Comment:** One commenter requested that the procedure described by CPT code 0308T be assigned to a New Technology APC based on the proposed low-volume New Technology policy, without requesting a specific New Technology APC or cost band. The commenter believed that the reasons for developing the low volume New Technology policy are consistent with issues related to the procedure described by CPT code 0308T, including the quality of claims data, and resulting cost fluctuation. The commenter noted that because those issues facing low-volume procedures would be the same, regardless of whether the procedures are assigned to a New Technology or clinical APC, it would be appropriate to assign the procedure described by CPT code 0308T to a New Technology APC. However, the commenter requested that, if that change were not to be made, CMS instead assign the procedure described by the CPT code to APC 5495, which was previously for “Level 5 Intraocular Procedures” and that the same.

smoothing methodology for low volume New Technology procedures, which includes use of multiple years of claims data, apply to the procedure described by CPT code 0308T, given its low volume.

**Response:** In previous years, the procedure described by CPT code 0308T was assigned to APC 5495 (Level 5 Intraocular Procedures) using a median-based weight under the low-volume device intensive policy. Based on the CY 2017 claims data available for ratesetting, in the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedure described by CPT code 0308T to APC 5493, noting that we would continue to monitor the data. In the CY 2019 OPPS final rule claims data, the estimated cost of the single claim with CPT code 0308T as the primary service is approximately $12,939.75.

While we appreciate the stakeholder’s comments regarding changes in estimated costs based on the claims data available for ratesetting, we have concerns with establishing a New Technology APC methodology for a clinical APC especially in the absence of a New Technology application, which is used to evaluate new technology APC requests. We also note that the procedure described by CPT code 0308T has historically been assigned to a clinical APC beginning with the CY 2013 OPPS.

Recognizing the estimated cost based on the final rule claims data and the commenter’s concerns, we believe that the procedure described by CPT code 0308T is appropriate for assignment to clinical APC 5494 (Level 4 Intraocular Procedures). CPT code 0308T has device-intensive status based on its device offset percentage and the fact that the APC to which the procedure is assigned has fewer than 100 total claims. Therefore, the low-volume device intensive policy of using the median cost for OPPS ratesetting would apply.

After consideration of the public comment we received, we are modifying our proposal to assign the procedure described by CPT code 0308T to APC 5493 and instead are assigning the procedure described by CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) for CY 2019.

14. **Magnetocardiography**

As displayed in Table 30 below and in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign the services described by CPT codes 0541T and 0542T the status indicator “E1” to indicate that these codes are not payable by Medicare when submitted on outpatient claims (any outpatient bill type) because the services associated with these codes are either not covered by any Medicare outpatient benefit category, statutorily excluded by Medicare, or not reasonable and necessary. The codes were listed as 0X01T and 0X02T (the 5-digit CMS placeholder codes), respectively, in Addendum B, with the short descriptors, and in Addendum O, with the long descriptors, to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator “NP” in Addendum B to indicate that the codes are new for CY 2019 and that public comments would be accepted on their proposed status indicator assignments. We note that these codes will be effective January 1, 2019.

**Comment:** One commenter disagreed with the proposed status indicator assignment of “E1” for CPT codes 0541T and 0542T, and stated that the technology was approved by the FDA. The commenter explained that these codes describe magnetocardiography (MCG), which is a “high-fidelity biomagnetic imaging technique that utilizes highly sensitive magnetometers and a compact shield in order to measure, image and analyze the repolarization patterns of the heart.” The commenter also indicated that MCG may be used to replace or avoid the need for additional cardiac stress and related testing, myocardial perfusion imaging, and/or PET procedures, and rapidly triage patients who present to the ED with chest pain or other symptoms of cardiac ischemia.

Because the technology has been approved by the FDA, the commenter requested that CMS assign the procedures described by both CPT codes to APC 5593 (Level 3 Nuclear Medicine) or APC 5724 (Level 4 Diagnostic Tests and Related Services). Although the commenter requested an assignment to either APC 5593 or 5724, the commenter also noted that the services described by CPT codes 0541T and 0542T are clinically comparable to the services that are assigned to the following three APCs:

- **APC 5593** (Level 3 Nuclear Medicine), with a proposed payment rate of approximately $1,228, which includes—
  - CPT code 78451 (Myocardial perfusion imaging); and
  - CPT code 78452 (Myocardial perfusion imaging)

- **APC 5594** (Level 4 Nuclear Medicine), with a proposed payment rate of approximately $1,386, which includes—
  - CPT code 78453 (Myocardial perfusion imaging); and
  - CPT code 78454 (Myocardial perfusion imaging)
• CPT code 78491 (Positron Emission Tomography (PET) myocardial functional imaging); and
• CPT code 78492 (Positron Emission Tomography (PET) myocardial functional imaging)
• APC 5724 (Level 4 Diagnostic Tests and Related Services), with a proposed payment rate of approximately $918, which includes—
  • CPT code 95965 (Magnetoencephalography (MEG)); and
  • CPT code 95966 (Magnetoencephalography (MEG))

In addition to the requested APC assignment, the commenter requested that CMS assign the codes status indicator “S” (Procedure or Service, Not Discounted When Multiple. Paid under OPPS; separate APC payment), instead of status indicator “E1”, similar to the status indicator assignment for the comparable codes in APCs 5593, 5594, and 5724.

Response: Based on our understanding of the procedure, we found that the service associated with these codes are currently in clinical trial (Study Title: “Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients”;
ClinicalTrials.gov Identifier: NCT03255772). Further review of the clinical trial revealed that the clinical study has not yet met CMS’ standards for coverage, nor does it appear on the CMS Approved IDE List, which can be found at this CMS website: https://www.cms.gov/Medicare/Coverage/IDE/Approved-IDE-Studies.html. Moreover, based on our review associated with the technology, we have not found evidence of FDA approval or clearance of the Cardioflux System as it appears that an application is pending with FDA, even though predicate devices have already been approved and are on the market. Because this specific MCG technology has not been approved for Medicare coverage or cleared by the FDA, we believe that we should continue to assign the procedures described by CPT codes 0541T and 0542T to status indicator “E1” for CY 2019. If this technology later meets CMS’ standards for coverage, we will reassess the APC assignment for the codes in a future quarterly update and/or rulemaking cycle.

Therefore, after consideration of the public comment received, we are finalizing our proposal, without modification, for the assignment of status indicator “E1” to the procedures described by CPT codes 0541T and 0542T. The final status indicator assignment for both codes is listed in Table 30 below. We refer readers to Addendum D1 of this final rule with comment period for the complete list of the OPPS payment status indicators and their definitions for CY 2019. Addendum D1 is available via the internet on the CMS website.
Prior to the CY 2016 OPPS, payment for musculoskeletal procedures was primarily divided according to anatomy and the type of musculoskeletal procedure. As part of the CY 2016 reorganization to better structure the OPPS payments towards prospective payment packages, we consolidated those individual APCs so that they became a general Musculoskeletal Procedures APC series (80 FR 70397 through 70398).

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59300), we continued to apply a six-level structure for the Musculoskeletal APCs because doing so provided an appropriate distinction for resource costs at each level and to provide clinical homogeneity. However, we also indicated that we would continue to review the structure of these APCs to determine whether additional granularity would be necessary.

While we did not propose any changes to the 2019 OPPS structure of the Musculoskeletal Procedures APC series in the CY 2019 OPPS/ASC proposed rule, we stated that we recognize that commenters have previously expressed concerns regarding the granularity of the current APC levels and requested establishment of additional APC levels. Therefore, we solicited public comments on the creation of a new APC level between the current Level 5 and Level 6 within the Musculoskeletal Procedures APC series.

### TABLE 30.—PROPOSED AND FINAL CY 2019 SI FOR CPT CODES 0541T AND 0542T

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0X01T</td>
<td>0541T</td>
<td>Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic field time series images, quantitative analysis of magnetic dipoles, machine learning derived clinical scoring, and automated report generation, single study;</td>
<td>E1</td>
<td>N/A</td>
<td>E1</td>
<td>N/A</td>
</tr>
<tr>
<td>0X02T</td>
<td>0542T</td>
<td>Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic field time series images, quantitative analysis of magnetic dipoles, machine learning derived clinical scoring, and automated report generation, single study; interpretation and report</td>
<td>E1</td>
<td>N/A</td>
<td>E1</td>
<td>N/A</td>
</tr>
</tbody>
</table>
Table 18 of the proposed rule listed the Musculoskeletal Procedures APCs, the HCPCS codes assigned to the APCs, and the proposed APC geometric mean cost.

Comment: Many commenters requested that CMS maintain the current six-level APC structure. Some of these commenters stated that the current structure provides sufficient granularity in the APCs, while other commenters suggested that, because Medicare previously made changes to create additional APCs in the Musculoskeletal Procedures APC series in the CY 2016 and CY 2017 OPPS, CMS delay any additional changes. Some commenters requested that CMS create additional levels and assign specific codes to either the new levels or existing levels within the relative structure. One commenter requested CMS maintain the procedure described by CPT code 27279 (Arthrodesis sacroiliac joint) at the highest level APC based on its geometric mean cost, if any additional high cost APC level above the current Level 6 were created. Another commenter requested that CMS create additional intermediate levels between the existing APC Levels 4 and 5 and between Levels 5 and 6, and assign the procedures described by CPT code 28740 (Fusion of foot bones) and CPT code 28297 (Correction hallux valgus) to the new APC level between Levels 4 and 5. One commenter requested that, if a level were to be created between the current Levels 5 and 6, the procedure described by CPT code 27447 (Total knee arthroplasty) be assigned to that APC level. Other commenters requested that total knee arthroplasty be assigned to APC 1575 (New Technology—Level 38 ($10,001–$15,000)) for CY 2019, which has a payment rate at $12,500 based on their analysis of the costs of the procedure for only those claims that reported certain device costs, rather than using all claims to calculate the geometric mean costs of the service.

Response: We appreciate the commenters’ support for maintaining the current APC structure. While we have previously stated that we believe that the six level APC structure for the Musculoskeletal Procedures APC series remains appropriate in providing distinction between resource costs at each level and clinical homogeneity (82 FR 59300), in the CY 2019 proposed rule, we solicited comment on whether additional levels might be appropriate based on stakeholder concerns (83 FR 37096). Based on that stakeholder input, we will maintain the existing six level Musculoskeletal Procedures APC structure for the CY 2019 OPPS. While we are not creating additional APC levels in this final rule with comment period, we reviewed the APC assignment of individual HCPCS codes that commenters requested be reassigned if additional APC levels were created to confirm whether their current assignment was appropriate. We believe that the APC assignment of CPT code 27279 (Arthrodesis sacroiliac joint) to APC 5116, and CPT codes 28740 (Fusion of foot bones) and 28297 (Correction hallux valgus) to APC 5114 remain appropriate based on their geometric mean costs.

With regards to the placement of the total knee arthroplasty procedure in APC 5115 (Level 5 Musculoskeletal Procedures), we continue to believe that C–APC 5115 is an appropriate APC assignment for the procedures described by CPT code 27447, which has an estimated geometric mean cost of $9,997.45. Further, we note that the 50th percentile IPPS payment for total knee arthroplasty procedures without major complications/comorbidities (MS–DRG 470) is approximately $11,550 for FY 2019. We note that the final CY 2019 payment for New Technology APC 1575 is $12,500.50. As previously stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 58394 through 59385), we would expect that beneficiaries selected for outpatient total knee arthroplasty procedures would generally be expected to be less complex than those treated as hospital inpatients. Therefore, we do not believe that it would be appropriate for the OPPS payment rate to exceed the IPPS payment rate for total knee arthroplasty procedures without major complications/comorbidities because IPPS cases would generally be expected to be more complicated and complex than those performed in the hospital outpatient setting.

We note that we rely on hospitals to bill all HCPCS codes accurately in accordance with their code descriptors and CPT and CMS instructions, as applicable, and to report charges on claims and charges and costs on their Medicare hospital cost reports appropriately (77 FR 68324). As we do every year, we will review and evaluate the APC groupings based on the latest available data in the next rulemaking cycle.

After consideration of the public comments we received, we are finalizing the six level Musculoskeletal Procedures APC structure. We also are finalizing the proposed assignments of the procedures described by CPT codes 27279 (Arthrodesis sacroiliac joint) to APC 5116, the procedures described by CPT codes 28740 (Fusion of foot bones) and 28297 (Correction hallux valgus) to APC 5114, and the procedures described by CPT code 27447 (Total knee arthroplasty) to APC 5115.

### Table 31.—CY 2019 Musculoskeletal Procedures APCs

<table>
<thead>
<tr>
<th>APC</th>
<th>Group Title</th>
<th>HCPCS Codes Assigned to APC</th>
<th>APC Geometric Mean Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>5111</td>
<td>Level 1 Musculoskeletal Procedures</td>
<td>102</td>
<td>$227.04</td>
</tr>
<tr>
<td>5112</td>
<td>Level 2 Musculoskeletal Procedures</td>
<td>133</td>
<td>$1,324.69</td>
</tr>
<tr>
<td>5113</td>
<td>Level 3 Musculoskeletal Procedures</td>
<td>442</td>
<td>$2,646.02</td>
</tr>
<tr>
<td>5114</td>
<td>Level 4 Musculoskeletal Procedures</td>
<td>287</td>
<td>$5,748.86</td>
</tr>
<tr>
<td>5115</td>
<td>Level 5 Musculoskeletal Procedures</td>
<td>67</td>
<td>$10,806.47</td>
</tr>
<tr>
<td>5116</td>
<td>Level 6 Musculoskeletal Procedures</td>
<td>15</td>
<td>$15,535.58</td>
</tr>
</tbody>
</table>
16. Nasal Airway Obstruction Treatment (APC 5164)

For CY 2019, we proposed to continue to assign the procedures described by HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)) to APC 5164 (Level 4 ENT Procedures) with a proposed payment rate of approximately $2,241. We note that HCPCS code C9749 describes the Latera absorbable implant procedure for nasal airway obstruction.

Comment: One commenter disagreed with the proposed APC assignment of the procedure described by HCPCS code C9749 to APC 5164 and requested that CMS assign the procedure to New Technology APC 1523 (New Technology—Level 23 ($2,501–$3,000)), which had a proposed payment rate of approximately $2,751. The commenter stated that the cost for a pair of the Latera implants is $1,325, and that the proposed payment rate for APC 5164 does not cover the cost of performing the procedure. The commenter further stated that information from clinical experts and medical directors suggests that the complexity and resources to perform the Latera implant procedure are similar to those associated with procedures assigned to APC 5165 (Level 5 ENT Procedures).

Response: In December 2017, CMS received a New Technology APC application requesting a new HCPCS code for the Latera implant because, according to the applicant, the only available CPT code to report the procedure is CPT code 30990 (Unlisted procedure, nose). Based on our review of the application, assessment of the procedure, and input from our clinical advisors, we established HCPCS code C9749 effective April 1, 2018. For the April 2018 OPPS Update, we assigned HCPCS code C9749 to APC 5164 with a payment rate of approximately $2,199. We announced this new HCPCS code and APC assignment in the April 2018 OPPS quarterly update change request (Transmittal 4005, Change Request 10515, dated March 20, 2018). Based on cost information submitted to CMS in the New Technology APC application, we assigned the procedure to APC 5164 rather than New Technology APC 1523. However, based on further assessment on the nature of the procedure, and input from public commenters and our clinical advisors, we believe that HCPCS code C9749 should be reassigned to APC 5165 (Level 5 ENT Procedures) to more appropriately reflect the resource costs and clinical characteristics associated with the Latera implant procedure.

Therefore, after consideration of the public comment we received, we are finalizing our proposal, without modification, to assign the procedure described by HCPCS code C9749 from APC 5164 to APC 5165. The final payment rate for HCPCS code C9749 can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

17. Nerve Procedures and Services (APCs 5431 Through 5432)

For CY 2019, we proposed to continue the existing two-level structure of the Nerve Procedures APCs (APC 5431 through 5432), as displayed in Table 32 below and in Addendum A to the CY 2019 OPPS/ASC proposed rule (which is available via the internet on the CMS website).

<table>
<thead>
<tr>
<th>APC</th>
<th>Proposed CY 2019 OPPS Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>5431 (Level 1 Nerve Procedures)</td>
<td>$1,643.56</td>
</tr>
<tr>
<td>5432 (Level 2 Nerve Procedures)</td>
<td>$4,613.10</td>
</tr>
</tbody>
</table>

Comment: One commenter requested that CMS create a new modifier to identify the performance of continuous nerve block procedures that are performed as a secondary procedure, and to allow payment for the performance of such procedures, for example, the procedure described by CPT code 64416 (Injection, anesthetic agent; brachial plexus, continuous infusion by catheter (including catheter placement)), not to be packaged if reported in combination with the procedure described by CPT code 29827 (Arthroscopy, shoulder, surgical; with rotator cuff repair). Instead, the commenter suggested a modifier to allow for payment at a full OPPS rate. The commenter noted that continuous nerve block procedure codes are assigned to status indicator “T,” which further provides that payment for the procedures are currently packaged when reported in combination with procedures that are assigned to C–APCs and, therefore, are not separately paid. The commenter stated that packaging payment for the certain procedures discourages hospitals from using non-opioid postsurgical pain alternative approaches, such as a continuous nerve block procedure.

The commenter further believed that CMS should create a new HCPCS code modifier in order to track, research, and identify the use of non-opioid pain management alternatives that are resulting in positive beneficiary health care impacts and outcomes, which are reducing opioid use and combatting the opioid crisis. Additionally, the commenter included a list of applicable continuous nerve block procedure codes (shown in the table below) to which the commenter suggested that a HCPCS modifier could be appended to indicate that the procedure would receive separate payment.
Response: We appreciate the commenter’s suggestion to create a new HCPCS modifier to identify the continuous nerve block procedures when performed as a secondary procedure, as well as recommending the list of CPT codes that should be considered for such inclusion for separate payment. However, payment for these continuous nerve block procedures is currently packaged under the OPPS because they are adjunctive to the primary service rendered and, therefore, represent components of a complete service. Therefore, at this time we will continue to package payment for these services, and consider the creation of a new HCPCS modifier and separate payment for such non-opioid alternatives approaches in future rulemaking.

Comment: One commenter suggested that CMS restructure the two-level Nerve Procedure APCs (APCs 5431 and 5432) to provide more payment granularity for the types of procedures included in the APCs by creating a third level. The commenter believed that there is a substantial payment differential between the procedures assigned to Level 1 Nerve Procedure APC 5431 and Level 2 Nerve Procedure APC 5432, and that the current payment for some of these procedures does not adequately cover the cost of providing the services. The commenter further stated that, as an example, the procedures described by CPT codes 64633 (Destruction by neurolytic agent, paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); cervical or thoracic, single facet joint) and 64635 (destruction by neurolytic agent paravertebral facet joint nerve(s), with imaging guidance (fluoroscopy or CT); lumbar or sacral, single facet joint), which are assigned to APC 5431 with a proposed payment rate of approximately $1,644, while the geometric means for each of the procedures described by CPT codes 64633 and 64635 are $1,482 and $1,729, respectively. The commenter recommended a potential geometric mean cost for a potential three-level APC structure within the Nerve Procedures APCs and submitted a three-level APC structure, along with estimated payment rates, which is shown in the table below.

<table>
<thead>
<tr>
<th>APC Level</th>
<th>Number of Singles Used to Calculate APC Geometric Mean</th>
<th>Total Frequency of Claims</th>
<th>APC Geometric Mean Cost</th>
<th>Estimated Payment Rate</th>
<th>Number of HCPCS Codes</th>
<th>2 Times Rule Violation</th>
</tr>
</thead>
<tbody>
<tr>
<td>5431</td>
<td>113,284</td>
<td>116,158</td>
<td>$1,583</td>
<td>$1,555</td>
<td>15</td>
<td>0</td>
</tr>
<tr>
<td>5432</td>
<td>15,035</td>
<td>17,051</td>
<td>$2,476</td>
<td>$2,431</td>
<td>58</td>
<td>0</td>
</tr>
<tr>
<td>5433</td>
<td>1,757</td>
<td>1,763</td>
<td>$5,373</td>
<td>$5,276</td>
<td>28</td>
<td>0</td>
</tr>
</tbody>
</table>

The commenter also recommended that CMS develop two new HCPCS G-codes to describe the performance of radiofrequency nerve ablation procedures. The commenter suggested that one of the G-codes could be created to describe procedures involving the genicular nerve, and the other G-code could be created to describe procedures...
involving the sacroiliac joint. The commenter further recommended that both of these G-codes be created to describe procedures describing non-opioid treatment alternatives for chronic pain management, and to assign both of these newly created G-codes to Level 2 Nerve Procedures APC 5232 based on its recommended three-level APC structure, with an estimated payment rate of $2,431. The commenter was aware that Category I CPT codes are in development, but will not be ready for release until CY 2020 at the earliest. Therefore, the commenter requested that CMS create such G-codes in order to allow for physicians and hospitals to report the performance of the procedures and use of the approach, and to be paid for utilization of these procedures in the interim. The commenter supplied a suggested descriptor for the G-code for the genicular nerve as: Radiofrequency nerve ablation; genicular nerves, including imaging guidance, when performed. The commenter also supplied a suggested descriptor for the G-code for the sacroiliac joint as: Radiofrequency nerve ablation; sacroiliac joint, including imaging guidance, when performed.

Response: We appreciate the commenter’s suggestions. However, at this time, we believe that the current two-level structure Nerve Procedures APCs provide an appropriate distinction between the resource costs at each level and clinical homogeneity. We will continue to review the APCs’ structure to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change.

With regard to the request to establish new HCPCS G-codes, although new CPT codes are in development for release for the CY 2020 update, we note that it does not appear that a request for new temporary Category III codes was made for CY 2019. Nonetheless, we intend to take the commenter’s request for new HCPCS G-codes under advisement.

Therefore, after consideration of the public comment received, we are finalizing our CY 2019 Nerve Procedures APCs two-level structure, as proposed. We refer readers to Addendum A to this final rule with comment period for the complete list of APCs and their payment rates. In addition, we refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. Both Addendum A and Addendum B are available via the internet on the CMS website.

18. Radiology and Procedures and Services

a. Imaging Procedures and Services

(58924 Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations)

Section 1833(t)(2)(G) of the Act requires the Secretary to create additional groups of covered OPD services that classify separately those procedures that utilize contrast agents from those that do not utilize contrast agents. In CY 2016, as a part of our comprehensive review of the structure of the APCs and procedure code assignments, we restructured the APCs that contain imaging services (80 FR 70392). The purpose of this restructuring was to more appropriately reflect the resource costs and clinical characteristics of the services classified within the Imaging APCs. The restructuring of the Imaging APCs resulted in broader groupings that removed the excessive granularity of grouping imaging services according to organ or physiologic system, which did not necessarily reflect either significant differences in resources or how these services are delivered in the hospital outpatient setting. In CY 2017, in response to public comments on the CY 2017 OPPS/ASC proposed rule, we further consolidated the Imaging APCs from 17 APCs in CY 2016 to 7 APCs in CY 2017 (81 FR 79633). These included four Imaging without Contrast APCs and three Imaging with Contrast APCs.

For CY 2018, we proposed to establish a new Level 5 Imaging without Contrast APC to more appropriately group certain imaging services with higher resource costs and stated that our latest claims data supported splitting the CY 2017 Level 4 Imaging without Contrast APC into two APCs such that the Level 4 Imaging without Contrast APC would include high frequency, low-cost services and the proposed Level 5 Imaging without Contrast APC would include low frequency, high-cost services. Therefore, for CY 2018, we proposed to add a fifth level within the Imaging without Contrast APCs (82 FR 33608). However, based on public comments, we did not finalize this proposal. In general, commenters disagreed with CMS’ proposal to add a fifth level within the Imaging without Contrast APC series because they believed that the addition of a fifth level would reduce payment for several imaging services, including vascular ultrasound procedures (82 FR 59309 through 59311). Commenters also noted that the lower payment rates under the OPPS would lead to fewer patients being referred under the PFS.

For the CY 2019 OPPS/ASC proposed rule (83 FR 37096 through 37097), we reviewed the services assigned to the seven Imaging APCs listed in Table 17 of the proposed rule. Specifically, we evaluated the resource costs and clinical coherence of the procedures associated with the four levels of Imaging without Contrast APCs and the three levels of Imaging with Contrast APCs, as well as identified for correction any 2 times rule violations, to the extent feasible. Based on the geometric mean cost for each APC, which was listed in Table 17 of the proposed rule, for CY 2019, we proposed to maintain the seven Imaging APCs, which consist of four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs, and to make minor reassignments to the HCPCS codes within this series to resolve or mitigate any violations of the 2 times rule, or both.

We invited public comments on our proposal. Moreover, we specifically expressed an interest in receiving public comments and recommendations on the proposed HCPCS code reassignments associated with each of the seven Imaging APCs. We referred readers to Addendum B to the proposed rule (which is available via the internet on the CMS website) for the proposed list of specific codes that would be reassigned to each Imaging APC.

Comment: Commenters generally agreed with CMS’ proposal to maintain the Imaging APCs: Four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs. The commenters stated that maintaining the current Imaging APC structure would provide more stability for these services and would allow for cost trends to be assessed over time. Several of these commenters believed that the cost data for the procedures within these APCs have been consistent for many years and cautioned CMS against changing payment for services assigned to these APCs. Commenters recommended that if CMS believes any revision to the current APCs is necessary, the revisions be considered for future rulemaking and be subject to review and comment from stakeholders, in order to continue to maintain stability and sufficient payment and in order for hospitals to be able to continue to provide these services.

Response: We appreciate the commenters’ support for maintaining the seven Imaging APCs consisting of four levels of Imaging without Contrast APCs and three levels of Imaging with Contrast APCs.

Comment: One commenter supported CMS’ proposal to maintain the Level 3 Imaging without Contrast APC (5573) as proposed for CY 2019. The commenter further stated that the
proposed payment rate for services in this APC appropriately reflects use of contrast agents and that a lower payment rate may lead to lower utilization of medically necessary contrast agents and may lead to use of more costly advanced imaging modalities such as cardiac MRI and nuclear perfusion studies, which will increase overall cost.

Response: As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37096 through 37097), we reviewed the resource costs and clinical coherence of the procedures associated with the four levels of Imaging without Contrast APCs and the three levels of Imaging with Contrast APCs, as well as reviewed any 2 times rule violations. Based on this review, we decided to maintain the seven Imaging APCs structure based on the clinical similarities and resource costs and in light of commenters’ support of this proposal.

Comment: One commenter noted the lack of payment stability for the procedure described by CPT code 93307 (Echocardiography, transthoracic, real-time with image documentation (2d), includes M-mode recording, when performed, complete, without spectral or color Doppler echocardiography). The commenter noted that CMS proposed to reassign the procedure described by CPT code 93307 to APC 5523, and that, in CY 2018, this code was assigned to APC 5524. The commenter stated that the reassigned CPT code 93307 to APC 5523 is inappropriate because it is not similar to the other procedures in that APC in regard to either clinical or resource use, and would result in a 52-percent decrease in payment for CY 2019 compared to the CY 2018 payment rate.

Response: We acknowledge the commenter’s concern. However, we believe that the assignment of the procedure described by CPT code 93307 to APC 5523 is more appropriate based on clinical similarities and resource use. Specifically, we note that, based on the data available for this final rule with comment period, the lowest significant procedure geometric mean cost within APC 5523 is HCPCS code 76000 (Fluoroscopy (separate procedure), up to 1 hour physician or other qualified health care professional time), with a geometric mean of $174.34, and the highest significant procedure cost within APC 5523 is HCPCS code 74455 (Urethrocystography, voiding, radiological supervision and interpretation), with a geometric mean cost of $358.11. The geometric mean cost of CPT code 93307 is $352.15, which is similar to that of other procedures assigned to APC 5523.

Furthermore, the highest significant cost for a procedure within APC 5524 is for the procedure described by HCPCS code 93312 (Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report), which has a geometric mean cost of $854.45. This proposed reassignment would have a greater impact on the 2 times violation by being over the violation limit by approximately $138, compared to the assignment of the CPT code to APC 5523, which also has a 2 times violation, but to a lesser extent (that is, approximately $31). Therefore, based on this information, we are finalizing the proposed structure of APC 5523, with assignment of the CPT codes as proposed in the CY 2019 OPPS/ASC proposed rule. We will continue to monitor clinical homogeneity and resource costs within these APCs to identify any payment changes that may be warranted in future rulemaking.

Comment: One commenter disagreed with the proposal to maintain the procedure described by HCPCS code G0297 (Low dose CT for lung cancer screening) in APC 5521 and believed the calculation of the geometric mean using the CT cost center does not sufficiently estimate costs, although CMS has 61,505 single claims to calculate the geometric mean cost for the procedure described by HCPCS code G0297. Based on its analysis, the commenter believed that using the diagnostic radiology cost center, which won its reassignment proposal, to calculate estimated costs of $96.55 for the service, is more appropriate than the geometric mean cost of using the CT cost center, which is $37.96. The commenter believed that use of the CT cost centers is depressing payment for imaging services and believed all imaging studies should use the diagnostic radiology cost centers instead.

Response: We believe that the procedure described by HCPCS code G0297 is appropriately assigned to APC 5521, based on its estimated cost relative to that of the other procedures in the APC. We believe that the manner in which we establish the geometric mean for estimating service costs for the Imaging APCs is appropriate. As part of changes to establish more accurate cost reporting, we developed the CT, MRI, and Cardiac Catherization cost centers in the CMS 2552–10 form. Since the CY 2014 OPPS, in which we first included those cost centers for rate-setting, we have included a methodology that reduces cost data from providers reporting the standard CT and MRI cost centers using “square feet” as the cost allocation statistic. We continue to believe this is appropriate as discussed in section II.A.1.h. of this final rule with comment period. However, we will continue to monitor payment for these imaging services and will consider the most appropriate methodology for ratersetting for such services in future rulemaking.

Additionally, we refer readers to the Medicare CY 2019 OPPS Final Rule Claims Accounting narrative for additional details regarding the calculation of the geometric mean costs.

Comment: One commenter expressed concern regarding payment stability for cardiac magnetic imaging with contrast services, specifically cardiac magnetic resonance imaging (MRI) for morphology with dye (the procedure described by CPT code 75561 within APC 5572). The commenter was concerned that the proposed payment for this service is set to decline by 15 percent from the CY 2018 payment rate and believed that this would threaten hospitals’ ability to maintain certain equipment, supplies, and agents used for these services. The commenter suggested that CMS study how best to assign low volume procedures to an APC.

Response: Our analysis of the final rule updated claims data revealed a geometric mean cost of approximately $416.84 for CPT code 75561 based on 8,248 single claims out of 15,022 total claims. The geometric mean cost for APC 5572 is approximately $390. After reviewing the procedures assigned to APC 5572, we believe that the geometric mean cost for the procedure described by CPT code 75561 indicates that it is appropriately assigned to APC 5572 based on its clinical homogeneity and resource costs. As we do each year, we will continue to review the APC assignments for all services and items paid under the OPPS.

Comment: One commenter expressed concern regarding the payment amount for the procedure described by CPT code 75574 (Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with contrast material, including 3d image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)) within APC 5571. Specifically, the commenter noted a 20-percent reduction from CY 2018 to CY 2019 within this APC. The commenter stated that the procedure described by
CPT code 75574 should be considered a low-volume service compared to other services within the APC and that high-volume codes within this APC are diluting the effect of the procedure described by CPT code 75574 on the APC payment rate. As a result, the commenter requested that CMS study how the APC structure could be modified to define low volume services and foster payment adequacy for low-volume codes such as CPT code 75574.

Response: We acknowledge the commenter’s concerns regarding payment for CPT code 75574. At this point, we do not believe we have the necessary data to finalize a change based on the lack of information that the payment is insufficient. However, we will take under advisement and consider studying the impact of the APC structures on services that make up lower volume HCPCS and CPT codes in comparison to other services in higher volume HCPCS and CPT codes within an APC in future rulemaking. We remind hospitals that every year, we review the APC assignments for all services and items paid under the OPPS. We will reevaluate the APC assignment for the service described by CPT code 75574 for next year’s rulemaking. After consideration of the public comments we received, we are finalizing our proposal to maintain the existing levels of the Imaging APCs, which consist of four levels of Imaging with Contrast APCs and three levels of Imaging without Contrast APCs. Table 33 below compares the CY 2018 and CY 2019 geometric mean costs for the imaging APCs. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reported under the OPPS. In addition, we refer readers to Addendum D1 to this final rule with comment period for the status indicator meanings for all codes reported under the OPPS. Both Addendum B and Addendum D1 are available via the internet on the CMS website.

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
<th>CY 2018 APC Geometric Mean Cost</th>
<th>CY 2019 APC Geometric Mean Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>5521</td>
<td>Level 1 Imaging without Contrast</td>
<td>$62.08</td>
<td>$62.84</td>
</tr>
<tr>
<td>5522</td>
<td>Level 2 Imaging without Contrast</td>
<td>$114.39</td>
<td>$113.48</td>
</tr>
<tr>
<td>5523</td>
<td>Level 3 Imaging without Contrast</td>
<td>$232.17</td>
<td>$232.56</td>
</tr>
<tr>
<td>5524</td>
<td>Level 4 Imaging without Contrast</td>
<td>$486.38</td>
<td>$501.79</td>
</tr>
<tr>
<td>5571</td>
<td>Level 1 Imaging with Contrast</td>
<td>$252.58</td>
<td>$203.48</td>
</tr>
<tr>
<td>5572</td>
<td>Level 2 Imaging with Contrast</td>
<td>$456.08</td>
<td>$389.22</td>
</tr>
<tr>
<td>5573</td>
<td>Level 3 Imaging with Contrast</td>
<td>$681.45</td>
<td>$697.73</td>
</tr>
</tbody>
</table>

b. Non-Ophthalmic Fluorescent Vascular Angiography (APC 5572)

As listed in Addendum B of the CY 2019 OPPS/ASC proposed rule, we proposed to continue to assign the procedure described by HCPCS code C9733 to APC 5523 (Level 3 Imaging without Contrast) with a proposed payment rate of approximately $232. We also proposed to maintain the status indicator assignment of “Q2” (T-packaged) to indicate that payment for the service is conditionally packaged when performed in conjunction with other procedures on the same day but paid separately when performed as a stand-alone service.

Comment: One commenter stated that HCPCS code C9733 describes a procedure that includes disposable components and a contrast agent (indocyanine green) that cost hospitals approximately $455. Consequently, the commenter disagreed with the proposed APC assignment of this service to APC 5523 because the APC payment rate only covers 50 percent of the hospital costs for the procedure. In addition, the commenter believed that hospitals are underreporting the costs for the procedure described by HCPCS code C9733 based on its review of the CMS cost file which showed a geometric mean cost of $252.43, which is below the cost of the supplies associated with this procedure. The commenter suggested that hospitals may not be reporting this code when performed with an outpatient visit because payment for the service described by HCPCS code C9733 is conditionally packaged. Because of the perceived underreporting, the commenter requested that CMS provide instructions to hospitals in an upcoming MLN Matters article on appropriate billing for the procedure described by HCPCS code C9733.

Response: Based on our review of the CY 2019 final rule claims data, the procedure described by HCPCS code C9733 has a geometric mean cost of approximately $250 based on 173 single claims (out of 982 total claims). Because this procedure involves the use of a contrast agent, we believe that a reassignment to one of the existing levels of the Imaging with Contrast APCs would be more appropriate for HCPCS code C9733. Specifically, we believe that a reassignment to APC 5572 (Level 2 Imaging without Contrast), with a geometric mean cost of approximately $389 is appropriate. We believe this reassignment will improve clinical homogeneity and align the resource costs of the service described by HCPCS code C9733 with those of imaging with contrast procedures assigned to APC 5572.

In addition, with regard to the comment that hospitals underreport the procedure described by HCPCS code C9733, based on our analysis of the CY 2019 hospital outpatient claims data used for this final rule with comment period, we are unable to determine whether hospitals are underreporting the procedure. It is generally not our policy to judge the accuracy of hospital coding and charging for purposes of ratesetting. We rely on hospitals to accurately report the use of HCPCS codes in accordance with their code descriptors and CPT and CMS instructions, and to report services on
claims and charges and costs for the services on their Medicare hospital cost report appropriately. However, we do not specify the methodologies that hospitals use to set charges for this or any other service. In addition, we state in Chapter 4 of the Medicare Claims Processing Manual that “it is extremely important that hospitals report all HCPCS codes consistent with their descriptors; CPT and/or CMS instructions and correct coding principles, and all charges for all services they furnish, whether payment for the services is made separately paid or is packaged” to enable CMS to establish future ratesetting for OPPS services.”

After consideration of the public comment received, we are finalizing our proposal with modification. Specifically, we are reassigning the procedure described by HCPCS code C9733 to APC 5572 instead of APC 5523, based on its clinical and resource homogeneity to the other procedures assigned to APC 5572. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS.

Addendum B is available via the internet on the CMS website.

19. Remote Physiologic Monitoring (APCs 5012 and 5741)

As displayed in Table 34 below and in Addendum B to the CY 2019 OPPS/ASC proposed rule, we proposed to assign the procedure described by CPT code 99453 to APC 5012 (Clinic Visits and Related Services) with a proposed payment rate of approximately $116. We also proposed to assign the procedure described by CPT code 99454 to APC 5741 (Level 1 Electronic Analysis of Devices) with a proposed payment rate of approximately $37. The long descriptors for CPT codes 99453 and 99454 can be found in Table 34 below. The codes were listed as 990X0 and 990X1 (the 5-digit CMS placeholder codes), respectively, in Addendum B, with short descriptors, and in Addendum O, with long descriptors, to the CY 2019 OPPS/ASC proposed rule. We also assigned these codes to comment indicator “NP” in Addendum B to the proposed rule to indicate that the codes are new for CY 2019 with proposed APC assignments, and that public comments would be accepted on their proposed APC assignments. We note that these codes will be effective January 1, 2019.

Comment: One commenter supported the APC assignments for both CPT codes 99453 and 99454 and requested that CMS finalize the APC assignments for CY 2019.

Response: We appreciate the commenter’s support. Based on input from our medical advisors, we believe that procedures described by CPT codes 99453 and 99454 are appropriately assigned in APCs 5012 and 5741, respectively, based on clinical and resource homogeneity to the other services assigned to these APCs.

Therefore, after consideration of the public comment received, we are finalizing our proposal without modification for the procedures described by CPT codes 99453 and 99454. The final APC and status indicator assignments are listed in Table 34 below. The final payment rates for these codes, where applicable, can be found in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

### TABLE 34.—PROPOSED AND FINAL CY 2019 APC AND SI ASSIGNMENTS FOR CPT CODES 99453 AND 99454

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>990X0 99453</td>
<td>V</td>
<td>5012</td>
<td>V</td>
<td>5012</td>
<td></td>
</tr>
<tr>
<td>990X1 99454</td>
<td>Q1</td>
<td>5741</td>
<td>Q1</td>
<td>5741</td>
<td></td>
</tr>
</tbody>
</table>

Remote monitoring of physiologic parameter(s) (e.g., weight, blood pressure, pulse oximetry, respiratory flow rate), initial; set-up and patient education on use of equipment.
20. Sclerotherapy (APC 5054)

As displayed in Table 35 below and in Addendum B of the CY 2019 OPPS/ASC proposed rule, we proposed to continue to assign CPT codes 36465 and 36466 to APC 5054 (Level 4 Skin Procedures), with a proposed payment rate of approximately $1,565.

Comment: One commenter disagreed with the proposed assignment of the procedures described by CPT codes 36465 and 36466 to APC 5054 and requested a reassignment to APC 5183 (Level 3 Vascular Procedures), which had a proposed payment rate of approximately $2,648. The commenter stated that the per-procedure cost for the Varithena foam sclerosant used in the procedure is $1,064. The commenter stated that APC 5183 is more clinically appropriate and reflects the resources required to perform the procedure. Specifically, the commenter indicated that the procedures described by CPT codes 36465 and 36466 share similar clinical and resource characteristics to the following surgical procedures that are assigned to APC 5183:

- CPT code 36473 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechnochemical; first vein treated);
- CPT code 36475 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, radiofrequency; first vein treated); and
- CPT code 36478 (Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, laser; first vein treated).

Response: Based on input from our clinical advisors, we believe that the procedures described by CPT codes 36465 and 36466 are clinically similar to the procedures assigned to APC 5054. We do not believe that the resources used for the procedures described by CPT codes 36465 and 36466 are comparable to the procedures described by CPT codes 36473, 36475, and 36478, which are assigned to C–APC 5183. Consequently, we believe that APC 5054 appropriately reflects the resources and clinical characteristics associated with the procedures described by CPT codes 36465 and 36466. We note that the geometric mean cost for APC 5054 is approximately $1,562, which exceeds the cost of the Varithena foam sclerosant (as reported by the commenter) used in the procedure.

Therefore, after consideration of the public comment received, we are finalizing our proposal without modification for assignment of the procedures described by CPT codes 36465 and 36466 to APC 5054. The final APC and status indicator assignments are listed in Table 35 below. As we do every year, we review the APC assignments for all services and items paid under the OPPS. We will reassess the APC assignment for the procedures described by CPT codes 36465 and 36466 for the CY 2020 rulemaking. We refer readers to Addendum B to this final rule with comment period for the payment rates for all codes reportable under the OPPS. Addendum B is available via the internet on the CMS website.

### TABLE 35.—PROPOSED AND FINAL CY 2019 APCs AND SI FOR CPT CODES 36465 AND 36466

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>36465</td>
<td>Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; single incompetent extremity truncal vein (e.g., great saphenous vein, accessory saphenous vein)</td>
<td>T</td>
<td>5054</td>
<td>T</td>
</tr>
<tr>
<td>36466</td>
<td>Injection of non-compounded foam sclerosant with ultrasound compression maneuvers to guide dispersion of the injectate, inclusive of all imaging guidance and monitoring; multiple incompetent truncal veins (e.g., great saphenous vein, accessory saphenous vein), same leg</td>
<td>T</td>
<td>5054</td>
<td>T</td>
</tr>
</tbody>
</table>
IV. OPPS Payment for Devices

A. Pass-Through Payment for Devices

1. Beginning Eligibility Date for Device Pass-Through Status and Quarterly Expiration of Device Pass-Through Payments

a. Background

Under section 1833(t)(6)(B)(iii) of the Act, the period for which a device category eligible for transitional pass-through payments under the OPPS can be in effect is at least 2 years but not more than 3 years. Prior to CY 2017, our regulation at 42 CFR 419.66(g) provided that this pass-through payment eligibility period began on the date CMS established a particular transitional pass-through category of devices, and we based the pass-through status expiration date for a device category on the date on which pass-through payment was effective for the category. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79654), in accordance with section 1833(t)(6)(B)(iii)(II) of the Act, we amended § 419.66(g) to provide that the pass-through eligibility period for a device category begins on the first date on which pass-through payment is made under the OPPS for any medical device described by such category.

In addition, prior to CY 2017, our policy was to propose and finalize the dates for expiration of pass-through status for device categories as part of the OPPS annual update. This means that device pass-through status would expire at the end of a calendar year when at least 2 years of pass-through payments have been made, regardless of the quarter in which the device was approved. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79655), we changed our policy to allow for quarterly expiration of pass-through payment status for devices, beginning with pass-through devices approved in CY 2017 and subsequent calendar years, to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through payment devices. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79648 through 79661) for a full discussion of the changes to the device pass-through payment policy. We also have an established policy to package the costs of the devices that are no longer eligible for pass-through payments into the costs of the procedures with which the devices are reported in the claims data used to set the payment rates (67 FR 66763).

b. Expiration of Transitional Pass-Through Payments for Certain Devices

As stated earlier, section 1833(t)(6)(B)(iii) of the Act requires that, under the OPPS, a category of devices be eligible for transitional pass-through payments for at least 2 years, but not more than 3 years. There currently are no device categories eligible for pass-through payment.

2. New Device Pass-Through Applications

a. Background

Section 1833(t)(6) of the Act provides for pass-through payments for devices, and section 1833(t)(6)(B) of the Act requires CMS to use categories in determining the eligibility of devices for pass-through payments. As part of implementing the statute through regulations, we have continued to believe that it is important for hospitals to receive pass-through payments for devices that offer substantial clinical improvement in the treatment of Medicare beneficiaries to facilitate access by beneficiaries to the advantages of the new technology. Conversely, we have noted that the need for additional payments for devices that offer little or no clinical improvement over previously existing devices is less apparent. In such cases, these devices can still be used by hospitals, and hospitals will be paid for them through appropriate APC payment. Moreover, a goal is to target pass-through payments for those devices where cost considerations might be most likely to interfere with patient access (66 FR 55852; 67 FR 66782; and 70 FR 68629).

As specified in regulations at 42 CFR 419.66(b)(1) through (3), to be eligible for transitional pass-through payment under the OPPS, a device must meet the following criteria: (1) If required by FDA, the device must have received FDA approval or clearance (except for a device that has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA), or meet another appropriate FDA exemption; and the pass-through payment application must be submitted within 3 years from the date of the initial FDA approval or clearance, if required, unless there is a documented, verifiable delay in U.S. market availability after FDA approval or clearance is granted, in which case CMS will consider the pass-through payment application if it is submitted within 3 years from the date of market availability; (2) the device is determined to be reasonable and necessary for the diagnosis or treatment of an illness or injury or to improve the functioning of a malformed body part, as required by section 1862(a)(1)(A) of the Act; and (3) the device is an integral part of the service furnished, is used for one patient only, comes in contact with human tissue, and is surgically implanted or inserted (either permanently or temporarily), or applied in or on a wound or other skin lesion. In addition, according to § 419.66(b)(4), a device is not eligible to be considered for device pass-through payment if it is any of the following: (1) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciation assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15–1); or (2) a material or supply furnished incident to a service (for example, a suture, customized surgical kit, or clip, other than a radiological site marker).

Separately, we use the following criteria, as set forth under § 419.66(c), to determine whether a new category of pass-through payment devices should be established. The device to be included in the new category must—

- Not be appropriately described by an existing category or by any category previously in effect established for transitional pass-through payments, and was not being paid for as an outpatient service as of December 31, 1996;
- Have an average cost that is not “insignificant” relative to the payment amount for the procedure or service with which the device is associated as determined under § 419.66(d) by demonstrating: (1) The estimated average reasonable costs of devices in the category exceeds 25 percent of the applicable APC payment amount for the service related to the category of devices; (2) the estimated average reasonable cost of the devices in the category exceeds the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent; and (3) the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device exceeds 10 percent of the APC payment amount for the related service (with the exception of brachytherapy and temperature-monitored cryoblation, which are exempt from the cost requirements as specified at § 419.66(c)(3) and (e)); and
- Demonstrate a substantial clinical improvement, that is, substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or
devices in a previously established category or other available treatment. Beginning in CY 2016, we changed our device pass-through evaluation and determination process. Device pass-through applications are still submitted to CMS through the quarterly subregulatory process, but the applications will be subject to notice-and-comment rulemaking in the next applicable OPPS annual rulemaking cycle. Under this process, all applications that are preliminarily approved upon quarterly review will automatically be included in the next applicable OPPS annual rulemaking cycle, while submitters of applications that are not approved upon quarterly review will have the option of being included in the next applicable OPPS annual rulemaking cycle or withdrawing their application from consideration. Under this notice-and-comment process, applicants may submit new evidence, such as clinical trial results published in a peer-reviewed journal or other materials for consideration during the public comment process for the proposed rule. This process allows those applications that we are able to determine meet all the criteria for device pass-through payment under the quarterly review process to receive timely pass-through payment status, while still allowing for a transparent, public review process for all applications (80 FR 70417 through 70418).

More details on the requirements for device pass-through payment applications are included on the CMS website in the application form itself at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/passthrough_payment.html, in the “Downloads” section. In addition, CMS is amenable to meeting with applicants or potential applicants to discuss research trial design in advance of any device pass-through application or to discuss application criteria, including the substantial clinical improvement criterion.

b. Applications Received for Device Pass-Through Payment for CY 2019

We received seven applications by the March 1, 2018 quarterly deadline, which was the last quarterly deadline for applications to be received in time to be included in the CY 2019 OPPS/ASC proposed rule. We received four of the applications in the second quarter of 2017, one of the applications in the third quarter of 2017, and two of the applications in the first quarter of 2018. None of the seven applications were approved for device pass-through payment during the quarterly review process.

Applications received for the later deadlines for the remaining 2018 quarters (June 1, September 1, and December 1), if any, will be presented in the CY 2020 OPPS/ASC proposed rule. We note that the quarterly application process and requirements have not changed in light of the addition of rulemaking review. Detailed instructions on submission of a quarterly device pass-through payment application are included on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/catapp.pdf. A discussion of the seven applications received by the March 1, 2018 deadline is presented below, as detailed in the CY 2019 OPPS/ASC proposed rule (83 FR 37098 through 37107).

(1) AquaBeam System

PROCEPT BioRobotics Corporation submitted an application for a new device category for transitional pass-through status for the AquaBeam System. The AquaBeam System is intended for the resection and removal of prostate tissue in males suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The applicant stated that this is a very common condition typically occurring in elderly men. The clinical symptoms of this condition can include diminished urinary stream and partial urethral obstruction.16 According to the applicant, the AquaBeam system resects the prostate to relieve symptoms of urethral compression. The resection is performed robotically using a high velocity, nonheated sterile saline water jet (in a procedure called Aquablation). The applicant stated that the AquaBeam System utilizes real-time intra-operative ultrasound guidance to allow the surgeon to precisely plan the surgical resection area of the prostate and then the system delivers Aquablation therapy to accurately resect the obstructive prostate tissue without the use of heat. The materials submitted by the applicant state that the AquaBeam System consists of a disposable, single-use handpiece as well as other components that are considered capital equipment.

With respect to the eligibility criterion at §419.66(b)(3), according to the applicant, the AquaBeam System is integral to the service provided, is used for one patient only, comes in contact with human skin, and is surgically implanted or inserted (either permanently or temporarily). The applicant also claimed the AquaBeam System meets the device eligibility requirements of §419.66(b)(4) because it is not an instrument, apparatus, implement, or items for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service. However, in the CY 2000 interim final rule with comment period (65 FR 67804 through 67805), we explained how we interpreted §419.43(o)(4)(iv). We stated that we consider a device to be surgically implanted or inserted if it is surgically inserted or implanted via a natural or surgically created orifice, or inserted or implanted via a surgically created incision. We also stated that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We consider items used to create incisions, such as scalpels, electrocautery units, biopsy apparatuses, or other commonly used operating room instruments, to be supplies or capital equipment, not eligible for transitional pass-through payments. We stated that we believe the function of these items is different and distinct from that of devices that are used for surgical implantation or insertion. Finally, we stated that, generally, we would expect that surgical implantation or insertion of a device occurs after the surgeon uses certain primary tools, supplies, or instruments to create the surgical site for implanting the device. In the CY 2006 final rule with comment period (70 FR 68629 and 68630), we adopted as final our interpretation that surgical insertion or implantation criteria include devices that are surgically inserted or implanted via a natural or surgically created orifice, as well as those devices that are inserted or implanted via a surgically created incision. We reiterated that we maintain all of the other criteria in §419.66 of the regulations, namely, that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted. We invited public comments on whether the AquaBeam System meets the eligibility criteria at §419.66(b).

Comment: Commenters, including the manufacturer of AquaBeam and stakeholders, believed that the AquaBeam System met the eligibility criteria at §419.66(b).

Response: We appreciate the commenters’ input. However, we do not believe that the AquaBeam device meets

---

the eligibility criteria described at § 419.66(b). Specifically, we do not believe that the device is surgically implanted or inserted. As stated earlier, we have described in previous rulemaking (65 FR 67804 through 67805 and 70 FR 68329 through 68630) how we interpret the surgical insertion or implantation criteria, and we do not believe that the use of the Aquabeam device is consistent with that interpretation; namely, that we do not consider an item used to cut or otherwise create a surgical opening to be a device that is surgically implanted or inserted (70 FR 68630). Because we have determined that the Aquabeam device does not meet the basic eligibility criterion for transitional pass-through payment status, we have not evaluated this product to determine whether it meets the other criteria required for transitional pass-through payment for devices; that is the newness criterion, the substantial clinical improvement criterion, and the cost criterion.

After consideration of the public comments we received, we are not approving device pass-through payment status for the Aquabeam System for CY 2019.

(2) BioBag® (Larval Debridement Therapy in a Contained Dressing)

BioMonde US, LLC resubmitted an application for a new device pass-through category for the BioBag® (larval debridement therapy in a contained dressing), hereinafter referred to as the BioBag®. The application submitted contained similar information to the previous application received in March 2016 that was evaluated in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79650). The only new information provided by the applicant were additional studies completed since the original application addressing the substantial clinical improvement criterion.

According to the applicant, the BioBag® is a biosurgical wound treatment (“maggot therapy”) consisting of disinfected, living larvae (Lucilia sericata) in a polyester net bag; the larvae remove dead tissue from wounds. The BioBag® is indicated for debridement of nonhealing necrotic skin and soft tissue wounds, including pressure ulcers, venous stasis ulcers, neuropathic foot ulcers, and nonhealing traumatic or postsurgical wounds. Debridement, which is the action of removing devitalized tissue and bacteria from a wound, is required to treat or prevent infection and to allow the wound to progress through the healing process. This system contains disinfected, living larvae that remove the dead tissue from wounds and leave healthy tissue undisturbed. The larvae are provided in a sterile polyester net bag, available in different sizes. The only other similar product is free-range (that is, uncontained) larvae. Free-range larvae are not widely used in the United States because application is time consuming, there is a fear of larvae escaping from the wound, and there are concerns about proper and safe handling of the larvae. The total number of treatment cycles depends on the characteristics of the wound, the response of the wound, and the aim of the therapy. Most ulcers are completely debrided within 1 to 6 treatment cycles.

With respect to the newness criterion at § 419.66(b)(1), the applicant received FDA clearance for the BioBag® through the premarket notification section 510(k) process on August 28, 2013, and the first U.S. sale of the BioBag® occurred in April 2015. The June 1, 2017 application is more than 3 years after FDA clearance but less than 3 years after its first U.S. sale. We invited public comments on whether the BioBag® meets the newness criterion.

Comment: The manufacturer stated that, although the BioBag® received its 510(k) clearance in 2013, BioBag® was not commercially available in the United States until its American-based production facility was established in 2015 to make the product available on the market.

Response: We appreciate the additional information provided by the manufacturer to demonstrate that the BioBag® is not a material or medical supply. Based on this information, we have determined that the BioBag® meets the eligibility criterion.

The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. With respect to the existence of a previous pass-through device category that describes the BioBag®, the applicant suggested a category descriptor of “Contained medicinal larvae for the debridement of necrotic skin and soft tissue wounds.” We have not identified an existing pass-through payment category that describes the BioBag®.

The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to the substantial clinical improvement criterion, the applicant provided substantial evidence that larval therapy may improve outcomes compared to other methods of wound debridement. However, given the existence of the Medical Maggots®, another form of larval therapy that has been on the market since 2004, the relevant comparison is between the BioBag® and the Medical Maggots®. There are many reasons to suspect that the BioBag® could improve outcomes and be preferable to the Medical Maggots®. In essence, with the latter, the maggots are directly placed on the wound, which may result in escape, leading to infection control issues as well as dosing variability. In addition, there are the issues with patient comfort. With the BioBag®, the maggots are in a sealed container so escape is not an issue. The applicant cited a study showing large decreases in maggot supply, but instead is a treatment for wound debridement, including the specialized nature of the product, that the product is not purchased in bulk, and that it provides a treatment outcome for non-healing wounds.

Response: We appreciate the additional information provided by the manufacturer to demonstrate that the BioBag® is not a material or medical supply. Based on this information, we have determined that the BioBag® meets the eligibility criterion.
not provide any data that clinical outcomes are improved using the BioBag® as opposed to the Medical Maggots®. Based on the studies presented, we believe there are insufficient data to determine whether the BioBag® offers a substantial clinical improvement over other treatments for wound care. We invited public comments on whether the BioBag® meets the substantial clinical improvement criterion.

Comment: The manufacturer identified four items to indicate that the BioBag® may provide substantial clinical improvement over other available treatments. These items include debridement of wounds infected with MRSA, removing more tissue than loose maggots, the ease of use of the BioBag® over loose maggots, and less pain during debridement. The commenter stated that these items were supported by journal citations.

Several other commenters discussed the benefits of the BioBag®, and a few commenters discussed the benefits of larval debridement of wounds more generally. The commenters cited benefits that included that the BioBag® debrides only dead tissue, that BioBag® makes it easier to apply and remove maggots from wounds, and that BioBag® is a lower-cost and less-invasive treatment than surgical debridement. The commenters did not provide any support of these benefits by medical studies.

Response: We have reviewed these public comments and the additional journal citations and believe that most of the information provided by commenters reenforced our discussion in the proposed rule that stated that there are many reasons why the BioBag® may be treatment from loose maggots. However, we have not been provided with sufficient support from clinical studies to determine that the BioBag® meets the substantial clinical improvement criterion. Each of the three clinical studies cited by the manufacturer did identify possible benefits from the use of the BioBag® over treatment from loose maggots, hydrogel, or other surgical debridement methods. However, the findings had only marginal clinical significance, and did not reflect sufficient clinical support to reach the threshold of demonstrating significant clinical improvement.

For example, the study of debridement through containment,17 was done in vitro (that is, in a laboratory setting) and not in vivo (that is, through testing on human subjects). Therefore, we are uncertain how the study findings would extrapolate to a patient receiving treatment. Second, we did not find that the clinical evidence fully supported the commenters’ claimed benefits. For instance, a commenter, the manufacturer provided data comparing the amount of material debrided by the BioBag® at 4 days to free larvae at 3 days from the same study of debridement through containment.18 To help demonstrate substantial clinical improvement, we believe that the commenter should have compared the amount of material debrided by both treatment methods over a similar time period. When similar time periods are compared between both treatment methods, the study found the amount of material debrided by the BioBag® and the free larvae is similar. In another study cited by the commenter discussing the prevalence of pain during maggot debridement therapy,19 the share of study patients experiencing pain was similar for people receiving treatment using a BioBag® device when compared to people receiving maggot debridement therapy from free larvae kept in a cage-like dressing.

After consideration of the public comments we received, we have determined that the BioBag® does not meet the significant clinical improvement criterion.

The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of a device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. With respect to the cost criterion, the applicant stated that the BioBag® would be reported with CPT code 97602 (Removal of devitalized tissue from wound[s], non-selective debridement, without anesthesia (e.g., wet-to-moist dressings, enzymatic, abrasion, larval therapy), including topical application[s], wound assessment, and instruction[s] for ongoing care, per session). CPT code 97602 is assigned to APC 5051 (Level 1 Skin Procedures), with a payment rate of $153.12, and a device offset of $0.02. The price of the BioBag® varies with the size of the bag ($375 to $435 per bag), and bag size selection is based on the size of the wound.

Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated reasonable cost of $435 for the BioBag® exceeds the applicable APC amount for the service related to the category of devices of $153.12 by 284.09 percent ($435/$153.12 × 100 = 284.09 percent). Thus, we determined that the BioBag® appears to meet the first cost significance test.

The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of devices in the category must exceed the cost of the device-related portion of the APC payment amount by at least 25 percent, which means the device cost needs to be at least 125 percent of the device offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $435 for the BioBag® exceeds the proposed device-related portion of the APC amount for the related service of $0.02 by 2,175,000 percent ($435/$0.02 × 100 = 2,175,000 percent). Thus, we determined that the BioBag® appears to meet the second cost significance test.

Section 419.66(d)(3), the third cost significance test, requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount determined to be associated with the device exceeds 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $435 for the BioBag® and the portion of the proposed APC payment for the device of $0.02 exceeds 10 percent at 284.08 percent (($435 − $0.02)/$153.12 × 100 = 284.08 percent). Thus, we determined that the BioBag® appears to meet the third cost significance test and satisfies the cost significance criterion. We invited public comments on whether the BioBag® meets the device pass-through payment criteria discussed in this section, including all three cost criteria.

We did not receive any public comments on the cost criteria for the BioBag®. Therefore, we have determined that the BioBag® does meet all three cost criteria.

After consideration of the public comments we received and our review of the criteria necessary to receive device pass-through payment, we are not approving the application for the BioBag® to receive device pass-through payment status in CY 2019 because the BioBag® does not meet the substantial clinical improvement criterion.

18 Ibid. Blake, F. et al.
(3) BlastXTM Antimicrobial Wound Gel

Next ScienceTM has submitted an application for a new device category for transitional pass-through payment status for BlastXTM. According to the manufacturer, BlastXTM is a PEG-based aqueous hydrogel which contains citric acid, sodium citrate, and benzalkonium chloride, buffered to a pH of 4.0 at 2.33 osmolality. BlastXTM received a 510(k) clearance from the FDA on March 6, 2017. BlastXTM is indicated for the management of wounds such as Stage I–IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, postsurgical wounds, first and second degree burns, and grafted and donor sites.

The manufacturer stated in its application for transitional pass-through payment status BlastXTM works by disrupting the biofilm matrix in a wound and eliminating the bacteria absorbed within the gel. The manufacturer asserted that disrupting and eliminating the biofilm removes a major barrier to wound healing. The manufacturer also asserted that BlastXTM is not harmful to host tissue and stated that BlastXTM is applied to the wound every other day as a thin layer throughout the entire wound healing process. When used as an adjunct to debridement, BlastXTM is applied immediately after debridement to eliminate any remaining biofilm and prevent the growth of new biofilm.

Based on the evidence provided in the manufacturer’s application, BlastXTM is not a skin substitute and cannot be considered for transitional pass-through payment status as a device. To be considered a device for purposes of the medical device pass-through payment process under the OPPS, a skin substitute needs to be applied in or on a wound or other skin lesion based on 42 CFR 419.66(b)(3). It should be a product that is primarily used in conjunction with the skin graft procedures described by CPT codes 15271 through 15278 or HCPCS codes C5271 through C5278 (78 FR 74937). The skin substitute should only be applied a few times during a typical treatment episode. BlastXTM, according to the manufacturer, may be used in many other procedures other than skin graft procedures, including several debridement and active wound care management procedures. The manufacturer also stated that BlastXTM would be used in association with any currently available skin substitute product and that the product should be applied every other day, which is not how skin substitute products for skin graft procedures are used to heal wounds. BlastXTM is not a required component of the skin graft service, and is used as a supply that may assist with the wound healing process that occurs primarily because of the use of a sheet skin substitute product in a skin graft procedure.

Therefore, with respect to the eligibility criterion at § 419.66(b)(3), in the proposed rule, we determined that BlastXTM is not integral to the service provided (which is a skin graft procedure using a sheet skin substitute), is a material or supply furnished incidentally to a service, and is not surgically inserted into a patient. BlastXTM does not meet the eligibility criterion to be considered a device for transitional pass-through payment. Therefore, we did not evaluate the product on the other criteria required for transitional pass-through payment for devices, including the newness criterion, the substantial clinical improvement criterion, and the cost criterion. We invited public comments on the eligibility of BlastXTM for transitional pass-through payment for devices.

We did not receive any public comments regarding the eligibility of BlastXTM for transitional pass-through payment for devices. Therefore, we are not approving BlastXTM for transitional pass-through payment status for CY 2019 because the product does not meet the eligibility criterion to be considered a device.

(4) EpiCord®

MiMedx® submitted an application for a new OPPS device category for transitional pass-through payment status for EpiCord®, a skin substitute product. According to the applicant, EpiCord® is a minimally manipulated, dehydrated, devitalized umbilical cord allograft for homologous use that provides a protective environment for the healing process. According to the applicant, EpiCord® is comprised of the proteoglycan elements of the umbilical cord with a thin amnion layer and a thicker Wharton’s jelly mucopolysaccharides component. The Wharton’s jelly contains collagen, hyaluronic acid, and chondroitin sulfate, which are the components principally responsible for its mechanical properties.

The applicant stated that EpiCord® is packaged as an individual unit in two sizes, 2 cm x 3 cm and 3 cm x 5 cm. The applicant asserted that EpiCord® is clinically superior to other skin substitutes because it is much thicker than dehydrated amnion/chorion allografts, which allows for application over exposed bone, tendon, nerves, muscle, joint capsule and hardware. According to the applicant, due to its unique thicker, stiffer structure, clinicians are able to apply or suture EpiCord® for deep, tunneling wounds where other products cannot fill the entire wound bed or dead spaces.

With respect to the newness criterion at § 419.66(b)(1), EpiCord® was added to the MiMedx® registration for human cells, tissues, and cellular and tissue-based products (HCT/Ps) on December 31, 2015. In adding EpiCord, MiMedx® asserted that EpiCord® conformed to the requirements for HCT/Ps regulated solely under section 361 of the Public Health Service Act and the regulations at 21 CFR part 1271. For these products, FDA requires that the manufacturer register and list its HCT/Ps with the FDA’s Center for Biologics Evaluation and Research (CBER) within 5 days after beginning operations and update its registration annually, and MiMedx® provided documentation verifying that EpiCord® had been registered. However, no documentation regarding an FDA determination that EpiCord® is appropriate for regulation solely under section 361 of the Public Health Service Act had been submitted. According to the applicant, December 31, 2015 was the first date of sale within the United States for EpiCord®. Therefore, it appears that market availability of EpiCord® is within 3 years of this application.

We note that a product that is regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR part 1271, as asserted by the manufacturer of EpiCord®, is not regulated as a device under the Federal Food, Drug, and Cosmetic Act. The regulations at 21 CFR 1271.20 state that “If you are an establishment that manufactures an HCT/P that does not meet the criteria set out in § 1271.10(a) [for regulation solely under section 361 of the Public Health Service Act and the regulations in part 1271], and you do not qualify for any of the exceptions in § 1271.15, your HCT/P will be regulated as a drug, device, and/or biological product. . . .” The Federal Food, Drug, and Cosmetic Act requires that manufacturers of devices that are not exempt obtain marketing approval or clearance for their products from FDA before they may offer them for sale in the United States. We did not receive documentation from the applicant that EpiCord® is regulated as a device by FDA in accordance with Medicare regulations at 42 CFR 419. Therefore, we invited public comments on whether EpiCord® meets the newness criterion.
Comment: The manufacturer believed that EpiCord® meets the newness criterion. The manufacturer stated that HCT/P products are regulated by the FDA through a registration process and have been paid by CMS for many years under the current regulatory structure. The manufacturer believed the newness criterion requirement for FDA approval for a product should only apply when FDA approval is required for that product. The manufacturer stated that FDA approval does not apply to EpiCord® because of its HCT/P status. The manufacturer stated that the pass-through payment application for EpiCord® was submitted within 3 years of EpiCord® being introduced onto the U.S. market. Finally, the manufacturer noted that the Medicare statute requires that biologicals be included in the category of products that can be considered for pass-through payment status and stated that, if HCT/Ps cannot be considered for transitional pass-through payment through the device pathway, the HCT/P products should be returned to the drug and biological transitional pass-through pathway.

Response: To be able to determine whether a product meets the newness criterion, we need to determine a date when a product could first be used in the United States. Generally, we use the FDA clearance or approval date. We also have a provision in the newness criterion to use the date of first United States sale of the product rather than the FDA approval date, to accommodate the rare cases where a device receives FDA approval but the manufacturer experiences a significant delay establishing a manufacturing and distribution capacity for the new device. We agree that FDA approval cannot be required to be used for the newness criterion when there is no requirement for a new product to receive FDA approval. However, we still need some means to determine whether a product has been able for use in the United States for 3 years or less. The best alternative that we can identify to establish the date a product is considered new is to rely on registration to the FDA HCT/P registry, which indicates the existence of a new product.

Comment: One commenter did not believe that EpiCord® meets the newness criterion. The commenter asserted that EpiCord® is considered to be the same product as EpiFix® that was introduced onto the U.S. market in 2011, and that the application for pass-through payment status for EpiCord® was submitted after the 3-year timeframe for a new product to apply for pass-through payment status. The commenter cited a HCPCS Workgroup decision in 2016 that assigned the use of EpiCord® to HCPCS code Q4131, which, until December 31, 2018, was the identifying HCPCS code for the use of EpiFix®. The commenter also asserted that EpiFix® may also receive pass-through payments, which the commenter believed should not occur, because it will be difficult to determine whether HCPCS code Q4131 is being billed for the use of EpiFix® or EpiCord®.

Response: We disagree with the commenter’s assertion that EpiFix® and EpiCord® are the same product. On December 31, 2015, MiMedx, the manufacturer of EpiCord®, submitted a filing to the FDA HCT/P registry representing EpiCord® as a new product that is a separate product from EpiFix®. In addition, the HCPCS Workgroup has made a decision, effective on January 1, 2019, to designate separate HCPCS codes for EpiFix® (Q4186) and EpiCord® (Q4187) that also demonstrates EpiCord® is a separate product from EpiFix®. We believe that EpiCord® is a separate product from EpiFix®.

After consideration of the public comments we received, we have determined that EpiCord® meets the newness criterion.

With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, EpiCord® is a skin substitute product that is integral to the service provided, is used for one patient only, comes in contact with human tissue, and is surgically inserted into the patient. The applicant also claimed EpiCord® meets the device eligibility requirements of § 419.66(b)(4) because EpiCord® is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material. We invited public comments on whether EpiCord® meets these eligibility criteria.

We did not receive any public comments regarding whether EpiCord® meets the eligibility criterion. Based on the information we have received, we have determined that EpiCord® meets the eligibility criterion.

The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously established by CMS. The information we have received, as of December 31, 1996, has not been sufficiently demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With regard to the substantial clinical improvement criterion, the applicant has established that EpiCord® reduces the mortality rate with use of the device; reduces the rate of device-related complications; decreases the rate of subsequent diagnostic or therapeutic interventions; decreases the number of future hospitalizations or physician visits; provides more rapid beneficial resolution of the disease process treated because of the use of the device; decreases pain, bleeding, or other quantifiable symptom; and reduces recovery time.

To determine if the product meets the substantial improvement criterion, we compared EpiCord® to other skin substitute products. Compared to NEOX CORD 1K Wound Allograft, EpiCord® has half the levels of Vascular Endothelial Growth Factor (VEGF) and insulin-like growth factor binding protein-4 (IGFBP–4) and lower levels of Glial Cell Line Derived Neurotrophic Factor (GDNF) and Epidermal Growth Factor (EGF). Despite EpiCord® having higher levels of other growth factors, the cumulative effect of these differences has not been sufficiently demonstrated in the application. Moreover, most professional opinions do not compare EpiCord® to specific alternative skin substitutes; the few that do are, for the most part, of limited specificity (in terms of foci of superiority to other skin substitutes). Studies demonstrated 41 percent higher relative rates (4.1 percent higher absolute rates) of severe complications for EpiCord® compared to standard of care. Additionally, the control group was moist dressings and offloading (instead of another umbilical biologic product). Furthermore, 38 percent of EpiCord® patients in the study were smokers versus 58 percent of
control patients (smoking impairs wound healing; thus, this important dissimilarity between intervention and study populations casts doubt on attributing observed benefit to the intervention).

Based on the evidence submitted with the application, we had insufficient evidence that EpiCord® provides a substantial clinical improvement over other treatments for wound care. We invited public comments on whether EpiCord® meets the substantial clinical improvement criterion.

Comment: The manufacturer responded to several statements regarding EpiCord® and substantial clinical improvement in the CY 2019 OPPS/ASC proposed rule. The analysis in the proposal rule noted that the pass-through application for EpiCord® stated that EpiCord® had higher levels of some growth factors and lower levels of other growth factors than NEOX CORD 1K Allograft. However, the original application did not clarify what the overall effect of differences in growth factors had on the effectiveness of EpiCord® for wound care and the proposed rule text expressed concern regarding comparisons to individual skin substitute products. The manufacturer asserted that the findings in the application, which were updated by the manufacturer, show that the combination of growth factors and proteins working together does improve wound healing in a complex environment. Also, the manufacturer stated that EpiCord® is the only umbilical cord product with a published multi-center, prospective, randomized-controlled, comparative parallel study.

The manufacturer responded to a statement in the proposed rule that noted 41 percent higher relative rates of severe complications for EpiCord® compared to the standard of care, and concerns the control group in the studies were moist dressings and offloading instead of a biologic product. The manufacturer indicated that the studies include adverse events from all causes and a new study in progress will show no adverse events directly related to EpiCord® or alginate dressings. The manufacturer also stated that many wound experts do not attempt to compare new products to each other because of the high variability of the composition of products, how they are applied, and the dynamics of how different products work.

The manufacturer replied to a statement in the CY 2019 OPPS/ASC proposed rule that noted the substantial higher amount of smokers in the control group for the primary study compared to the group of EpiCord® patients. The manufacturer noted that the concern is that smoking impairs wound healing, and the presence of a higher number of smokers in the control group casts doubt on the conclusion that the difference in outcomes between the control group and the EpiCord® group was because of the use of EpiCord®. The manufacturer performed statistical analyses and the manufacturer reported that it found the effect of the higher proportion of smokers in the control group was not statistically significant. Finally, the manufacturer asserted that EpiCord® meets the substantial clinical improvement criterion as a result of the published multi-center randomized controlled study showing an 81-percent healing rate within 12 weeks, which increases to a 96-percent healing rate when adequate debridement is performed.

Response: We appreciate the detailed response to the questions we had regarding the study the manufacturer submitted that shows EpiCord® would have substantial clinical improvement over comparable wound care treatments. However, this study on its own is not sufficient to establish substantial clinical improvement. First, independent replication of the findings of the study has not been performed. The study indicates beneficial effects from the use of EpiCord®; however, it is not clear if the findings can be reproduced. Multiple studies with similar conditions, and a more equitable distribution of smokers in the control and intervention groups, would be a first step to determine if the findings are valid. Second, more comparisons need to be done with different classes of biological skin substitute products. Given the number of skin substitute products on the U.S. market, it is not possible to compare EpiCord® to each product. However, we believe that studies comparing the product against products made with epithelial tissue, other human-sourced products, and animal-sourced products could provide more evidence demonstrating the clinical superiority of EpiCord®.

Comment: Multiple commenters supported granting EpiCord® transitional pass-through payment status. Many of the commenters discussed the strength of the structure of EpiCord®, the high levels of human growth factors found in the product, and its ability to heal complex wounds, but did not provide support by studies or other clinical research.

Response: We appreciate the additional information that the commenters provided on the performance and the benefits of EpiCord®. However, many skin substitute products can be used to heal complex wounds. In addition, none of the commenters provided clinical evidence of how the high levels of human growth factors led to EpiCord® having a superior performance to other skin substitute products.

After consideration of the public comments we received, we have determined that EpiCord® does not meet the substantial clinical improvement criterion.

The third criterion for establishing a device category, at § 419.66(c)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. EpiCord® would be reported with CPT code 15271 or 15275. CPT code 15271 describes the application of skin substitute graft to face, scalp, eyelids, mouth, neck, ears, orbits, genitalia, hands, feet, and/or multiple digits, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area. CPT code 15275 describes the application of skin substitute graft to trunk, arms, legs, total wound surface area up to 100 sq cm; first 25 sq cm or less wound surface area. Both codes are assigned to APC 5054 (Level 4 Skin Procedures). CPT codes 15271 through 15278 are assigned to either APC 5054 (Level 4 Skin Procedures), with a pass-through rate of $1,777 and a device offset of $4.70, or APC 5055 (Level 5 Skin Procedures), with a payment rate of $2,504.69 and a device offset of $35.01. The price of EpiCord® is $1,595 for the 2 cm x 3 cm and $3,695 for the 3 cm x 5 cm product size.

To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product exceeds the applicable APC amount for the service related to the category of devices of $1,427.77 by 258.80 percent ($3,695/$1,427.77 x 100 percent = 258.80 percent). Therefore, it appears that EpiCord® meets the first cost significance test.
devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product exceeds the device-related portion of the APC payment amount for the related service of $4.70 by 78,617.02 percent ($3,695/$4.70 x 100 percent = 78,617.02 percent). Therefore, it appears that EpiCord® meets the second cost significance test.

Section 419.66(d)(3), the third cost significance test, requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $3,695 for the 3 cm x 5 cm product and the portion of the APC payment amount for the device of $4.70 exceeds 10 percent at 258.47 percent (($3,695 − $4.70)/$1,427.77) x 100 percent = 258.47 percent).

Therefore, it appears that EpiCord® meets the third cost significance test. Based on the costs submitted by the applicant and the calculations noted earlier, it appears that EpiCord® meets the cost criterion at § 419.66(c)(3) for new device categories. We invited public comments on whether EpiCord® meets the cost criterion for device pass-through payment.

We did not receive any public comments regarding the cost criteria for EpiCord®. Based on the information that we received, we have determined that EpiCord® meets the cost criteria.

After consideration of the public comments and additional information we have received, we are not approving EpiCord® for transition pass-through payment status in CY 2019 because the product does not meet the substantial clinical improvement criterion.

(5) Remede® System Transvenous Neurostimulator

Respicardia, Inc. submitted an application for a new device category for transitional pass-through payment status for the remede® System Transvenous Neurostimulator. According to the applicant, the remede® System is an implantable phrenic nerve stimulator indicated for the treatment of moderate to severe central sleep apnea (CSA) in adult patients. The applicant stated that the remede® System is the first and only implantable neurostimulator to use transvenous sensing and stimulation technology. The applicant also stated that the remede® System consists of an implantable pulse generator, a transvenous lead to stimulate the phrenic nerve and a transvenous sensing lead to sense respiration via transthoracic impedance. Lastly, the applicant stated that the device stimulates a nerve located in the chest (phrenic nerve) that is responsible for sending signals to the diaphragm to stimulate breathing to restore normal sleep and respiration in patients with moderate to severe central sleep apnea (CSA).

With respect to the newness criterion at § 419.66(b)(1), the applicant received a Category B Investigational Device Exemption (IDE) from FDA on April 18, 2013. Subsequently, the applicant received approval of its premarket approval (PMA) application from FDA on October 6, 2017. The application for a new device category for transitional pass-through payment status for the remede® System was received on May 31, 2017, which is within 3 years of the date of the initial FDA approval or clearance. We invited public comments on whether the remede® System meets the newness criterion.

Comment: The manufacturer believed that the remede® System meets the newness criterion.

Response: We appreciate the commenter’s input.

After consideration of the public comments we received, we believe that the remede® System meets the newness criterion.

With respect to the eligibility criterion at § 419.66(b)(3), according to the applicant, the remede® System is integral to the service provided, is used for one patient only, comes in contact with human skin, and is applied in or on a wound or other skin lesion. The applicant also claimed that the remede® System meets the device eligibility requirements of § 419.66(b)(4) because it is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service.

The criteria for establishing new device categories are specified at § 419.66(c). The first criterion, at § 419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. We have not identified an existing pass-through payment category that describes the remede® System. The applicant proposed a category descriptor for the remede® System of “generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation.”

We invited public comments on this issue.

Comment: The manufacturer of the device indicated that there is no an existing pass-through payment category that describes the remede® System.

Response: We appreciate the manufacturer’s input.

After consideration of the public comments we received, we believe that the remede® System meets the eligibility criterion.

The second criterion for establishing a device category, at § 419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to this criterion, the applicant submitted several journal articles that discussed the health effects of central sleep apnea (CSA) which include fatigue, decreased mental acuity, myocardial ischemia, and dysrhythmias. The applicant stated that patients with CSA may suffer from poor clinical outcomes, including myocardial infarction and congestive heart failure.

The applicant claims that the remede® System has been found to significantly improve apnea-hypopnea index (AHI), which is an index used to indicate the severity of sleep apnea. AHI is represented by the number of apnea and hypopnea events per hour of sleep and was used as the primary effectiveness endpoint in the remede® System pivotal trial. The applicant noted that the remede® System was shown to improve AHI in small, self-controlled studies as well as in larger trials.

The applicant reported that in the pivotal study, a large, multicenter, randomized controlled trial of CSA patients, intention-to-treat analysis found that 51 percent (35/68) of CSA patients using the remede® System had greater than 50 percent reduction of apnea-hypopnea index (AHI) from baseline at 6 months compared to 11 percent (8/73) of the control group (p<0.0001). Per-protocol analysis found that 60 percent (35/58) of remede® System patients had a greater than 50
percent reduction of AHI and in 74 percent (26/35) of these patients AHI dropped to <20.²¹

According to the applicant, an exploratory post-hoc analysis of patients with CSA and congestive heart failure (CHF) in the Pivotal trial found that, at 6 months, the remed® System group had a greater percentage of patients with >=50 percent reduction in AHI compared to control group (63 percent versus 4 percent, p < 0.001).²²

The applicant noted that patient symptoms and quality of life were improved with the remed® System therapy. The mean Epworth Sleepiness Scale (ESS) score significantly decreased in remed® System patients, indicating less daytime sleepiness.²³

Adverse events associated with remed® System insertion and therapy included lead dislodgement/dislocation, hematoma, migraine, atypical chest pain, pocket perforation, pocket infection, extra-respiratory stimulation, concomitant device interaction, and elevated transaminases.²⁴ There were no patient deaths that were related to the device implantation or therapy.

One concern regarding the remed® System is the potential for complications in patients with coexisting cardiac devices, such as pacemakers or ICDs, given that the remed® System device requires lead placement and generation of electric impulses. Another concern with the evidence of substantial clinical improvement is that there is limited long-term data on patients with remed® System implants. The pivotal trial included only 6 months of follow-up. Also, while the applicant reported a reduction in AHI in the treatment group, the applicant did not establish that that level of change was biologically meaningful in the population(s) being studied. The applicant did not conduct a power analysis to determine the necessary size of the study population and the necessary duration of the study to detect both early and late events.

In addition, patients in the pivotal study were not characterized by the use of cardiac devices. Cardiac resynchronization therapy (CRT), in particular, is known to improve chronic sleep apnea in addition to its primary effects on heart failure, and central apnea is a marker of the severity of the congestive heart failure. The applicant did not conduct subset analyses to assess the impact of cardiac resynchronization therapy.

Lastly, while evaluation of AHI and quality of life metrics show improvement with the remed® System, the translation of those effects to mortality benefit is yet to be determined. Further studies of the remed® System are likely needed to determine long-term effects of the device, and as well as its efficacy compared to existing treatments of CPAP or medications.

Based on the evidence submitted with the application, we had insufficient evidence that the remed® System provides a substantial clinical improvement over other similar products and determined that comments on whether the remed® System meets the substantial clinical improvement criterion.

Comment: The manufacturer of the remed® System believed that this device meets the substantial clinical improvement criterion and provided additional data to support this assertion. The manufacturer noted that the primary endpoint of the pivotal study was a reduction of at least 50 percent in the apnea-hypopnea index that is used to classify apnea severity and has been used as a common endpoint in predicate studies testing apnea therapy in sleep literature. The manufacturer further indicated that the remed® System significantly improves secondary endpoints. Patients had improved oxygenation, reduced hypoxia, and 79 percent of treatment group subjects reported improved quality of life as assessed through the Patient Global Assessment. The manufacturer asserted that the study cited was the first randomized study in central sleep apnea to demonstrate improvements in REM sleep and arousals. Further, the manufacturer noted that the treatment group experienced a 3.7 percentage point improvement in the Epworth sleepiness scale, meaning these patients were less sleepy than the control group. The manufacturer indicated, in response to CMS’ questions, that its clinical trials were not designed to establish a clinical improvement in mortality from this device. However, the manufacturer asserted that post-trial analysis indicated improvement in left ventricular ejection fraction, which is associated with reduced mortality, and increased time to first hospitalization for New York Heart Association heart failure patients with reduced ejection fraction. The manufacturer also indicated that reductions in the Apnea Hypopnea Index for trial participants that received the remed® System was now greater at 12 months than it was at 6 months.

In response to CMS’ question regarding why an untreated control group was used in the pivotal trial, as opposed to a direct comparison with CPAP or other treatments, the manufacturer presented several reasons, such as considerable controversy about CPAP in CSA patients with heart failure due to CPAP patients with an ejection fraction less than 40 percent having higher mortality, and a dearth of prospective, randomized clinical data on the safety and efficacy of using CPAP, ASV, or medications to treat patients with non-heart failure CSA.

Regarding CMS’ question of why no power analysis was performed to determine the necessary size of the study population and the necessary duration of the study to detect both early and late events, the manufacturer noted that it worked directly with clinical experts and consulted with the FDA in designing the clinical trial, which the manufacturer maintained was effective and well-rounded. The manufacturer noted that the rationale was that the remed® System would be evaluated on a continuum of efficacy versus safety, but noted that had they determined to power the study for a primary safety endpoint based on the threshold of other implantable cardiac devices, the pivotal trial would have been adequately powered based on the study design (132 patients needed versus 151 enrolled).

In response to CMS’ question regarding potential complications in patients with coexisting cardiac devices, the manufacturer noted that it was understood that many CSA patients would likely have other cardiac devices already implanted and that this led to the design of both implant and testing procedures that accommodated concomitant devices. The manufacturer noted that the remed® System is typically placed on the right side of the chest to leave room for patients to have a cardiac device, which are typically placed on the left side, and that, in the pivotal trial, implantation of the remed® System in patients with a concomitant device did not demonstrate any increased risk. Further, the manufacturer noted that key metrics of implant duration, use of contrast dye, and fluoroscopy time were similar between patients with and without a

---
concomitant cardiac disease. Regarding specific study results, the manufacturer noted that 42 percent (64 of 151) of patients in the pivotal trial had a concomitant device and 98 percent (63 of 64) of patients with a concomitant cardiac device were successfully implanted, as compared to 96 percent (81 of 84) of patients with no concomitant device. The manufacturer believed that there is no increased risk at the time of implant for patients with a coexisting cardiac device. With regard to safety post-procedure, the commenter noted there was no difference in related SAEs between the groups with and without a concomitant cardiac device.

Regarding CMS’ question about whether the impact of cardiac resynchronization therapy (CRT) drove improvement for heart failure patient with a concomitant CRT device, the manufacturer noted limited literature available on this topic, but stated that the literature that does exist suggests that CRT may improve the apnea hypopnea index in some patients, which could lead to an improvement in ejection fraction. However, the manufacturer noted that all CRT patients in the remede® System pivotal trial had their CRT devices for a minimum of nine months and that despite having CRT for a significant duration, still had severe CSA at baseline. Accordingly, the manufacturer believed that it is unlikely that significant CSA improvements were based on CRT rather than the remede® System. The manufacturer noted that statistically significant subgroup analysis on CRT was difficult, but believed that the CRT subgroup did not lead to the overall results on the primary endpoint because the CRT subgroup “underperformed” relative to the non-CRT subgroup.

Finally, with respect to CMS’ question regarding whether the clinical results and patient response were durable and sustainable over time, the manufacturer asserted that it continues to collect effectiveness data beyond the 6-month endpoint of the pivotal IDE trial and that 12-month follow-up results on the pivotal IDE trial were recently published, demonstrating a trend towards increasing benefit for the treatment group at 12 months.

Specifically, the commenter stated that, at 12 months, 91 percent of patients saw a reduction of AHI and with 67 percent achieving a 50 percent or greater reduction in AHI (compared to 60 percent at 6 months).

Several commenters, individual physicians who have treated CSA patients with the remede® System, stated that, for these patients, traditional types of positive pressure ventilation did not work and the remede® System is the only treatment available. Response: We appreciate the commenters’ input. After reviewing the additional information provided during the public comment period, we agree that the remede® System has been shown to improve patients symptoms of central sleep apnea, improve quality of life, requires minimal patient compliance compared to other treatments, and has a low adverse event profile. However, with regard to our questions about impacts on mortality, the applicant did note that its studies were not powered to demonstrate a mortality benefit.

Commenters have adequately addressed the clinical concerns that we outlined in the proposed rule with additional evidence, longer follow-up from the pivotal IDE trial, the interplay of the remede® System and a concomitant cardiac device, and information about power calculations and other data summarized above. Further, we believe that the remede® System offers a treatment option for a patient population unresponsive to, or ineligible for, treatment involving currently available options. That is, those patients who have been diagnosed with moderate to severe CSA have no other available treatment options than the remede® System. Accordingly, we have determined that the remede® System has demonstrated substantial clinical improvement relative to existing treatment options for patients diagnosed with moderate to severe CSA.

The third criterion for establishing a device category, at § 419.66(e)(3), requires us to determine that the cost of the device is not insignificant, as described in § 419.66(d). Section 419.66(d) includes three cost significance criteria that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the remede® System would be reported with CPT code 0424T. CPT code 0424T is assigned to APC 5464 (Level 4 Neurostimulator and Related Procedures). To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. For our calculations, we used APC 5464, which had a CY 2017 payment rate of $27,047.11 at the time the application was received. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 to 86 percent). CPT code 0424T had a device offset amount of $11,089 at the time the application was received. According to the applicant, the cost of the remede® System was $34,500.

Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $34,500 for the remede® System exceeds 127 percent of the applicable APC payment amount for the service related to the category of devices of $27,047.11 ($34,500/$27,047.11 × 100 = 127.5 percent). Therefore, we believe the remede® System meets the first cost significance test.

The second cost significance test, at § 419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $34,500 for the remede® System exceeds the cost of the device-related portion of the proposed APC payment amount for the related service of $11,089 by 311 percent ($34,500 − $11,089) × 100 = 311 percent). Therefore, we believe that the remede® System meets the second cost significance test.

The third cost significance test, at § 419.66(d)(3), requires that the difference between the estimated average reasonable cost of the devices in the category and the portion of the APC payment amount for the service must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $34,500 for the remede® System and the portion of the proposed APC payment amount for the device of $11,089 exceeds the APC payment amount for the related service of $27,047.11 by 87 percent (($34,500/11,089)/$27,047.11 × 100 = 86.6 percent). Therefore, we believe that the remede® System meets the third cost significance test.

We invited public comments on whether the remede® System meets the device pass-through payment criteria discussed in this section, including the cost criteria for device pass-through payment. Comment: The manufacturer of the remede® System believed that the remede® System meets the cost criterion for device pass-through payment status.
Response: We appreciate the manufacturer’s input. After consideration of the public comments we received, we are approving the remedi® System for device pass-through payment status for CY 2019.

(6) Restrata® Wound Matrix

Acera Surgical, Inc. submitted an application for a new device category for transitional pass-through payment status for Restrata® Wound Matrix. Restrata® Wound Matrix is a sterile, single-use product intended for use in local management of wounds. According to the applicant, Restrata® Wound Matrix is a soft, white, conformable, nonfriable, absorbable matrix that works as a wound care management product by acting as a protective covering for wound defects, providing a moist environment for the body’s natural healing process to occur. Restrata® Wound Matrix is made from synthetic biocompatible materials and was designed with a nanoscale nonwoven fibrous structure with high porosity, similar to native extracellular matrix. Restrata® Wound Matrix allows for cellular infiltration, new tissue formation, neovascularization, and wound healing before completely degrading via hydrolysis. The product permits the ingress of cells and soft tissue formation in the defect space/wound bed. Restrata® Wound Matrix can be used to manage wounds, including: Partial and full-thickness wounds, pressure sores/ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (for example, donor site/grafts, post-laser surgery, post-Mohs surgery, podiatric wounds, wound dehiscence), trauma wounds (for example, abrasions, lacerations, partial thickness burns, skin tears), and draining wounds.

With respect to the eligibility criterion at §419.66(b)(3), according to the applicant, Restrata® Wound Matrix is a product that is integral to the service provided, is used for one patient only, comes in contact with human skin, and is surgically inserted into the patient. The description of Restrata® Wound Matrix shows the product meets the device eligibility requirements of §419.66(b)(4) because Restrata® Wound Matrix is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material. We invited public comment on whether Restrata® Wound Matrix meets the eligibility criteria. We did not receive any public comments on whether Restrata® Wound Matrix meets the eligibility criteria. However, after the CY 2019 OPPS/ASC proposed rule was released, CMS determined that Restrata® Wound Matrix is an alginate dressing described with the HCPCS code series A6196 through A6198 (Alginate or other fiber gelling dressing, wound cover, sterile). Alginate dressings are not skin substitute products and are considered to be a supply. According to the eligibility criterion, a supply or material is not eligible to receive device pass-through payment. Based on this determination, we were required to reassess our initial view on whether or not Restrata® Wound Matrix meets the eligibility criterion for device pass-through payment status.

After consideration of all of the information we have received, we have determined that Restrata® Wound Matrix is an alginate dressing and is a supply, and the product does not meet the eligibility criterion for device pass-through payment status. Because we have determined that Restrata® Wound Matrix does not meet the basic eligibility criterion for transitional pass-through payment status, we have not evaluated this product to determine whether it meets the other criteria required for transitional pass-through payment for devices; that is, the newness criterion, the substantial clinical improvement criterion, and the cost criterion.

After consideration of the public comments we received, we are not approving device pass-through payment status for Restrata® Wound Matrix for CY 2019.

(7) SpaceOAR® System

Augmenix, Inc. submitted an application for a new device category for transitional pass-through payment status for SpaceOAR® System. According to the applicant, the SpaceOAR® System is a polyethylene glycol hydrogel spacer that temporarily positions the anterior rectal wall away from the prostate to reduce the radiation delivered to the anterior rectum during prostate cancer radiotherapy treatment. The applicant stated that the SpaceOAR® System reduces some of the side effects associated with radiotherapy, which are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, painful defecation, and erectile dysfunction, among other conditions). The applicant stated that the SpaceOAR® System is implanted several weeks before radiotherapy; the hydrogel maintains space between the prostate and rectum for the entire course of radiotherapy and is completely absorbed by the patient’s body within 6 months.

With respect to the newness criterion at §419.66(b)(1), FDA granted a De Novo request classifying the SpaceOAR® System as a class II device under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act on April 1, 2015. We received the application for a new device category for transitional pass-through payment status for the SpaceOAR® System on June 1, 2017, which is within 3 years of the date of the initial FDA approval or clearance. We invited public comments on whether the SpaceOAR® System meets the newness criterion.

Comment: The manufacturer of SpaceOAR® System believed this device meets the eligibility criteria for device pass-through payment, but did not specifically comment on the newness criterion.

Response: We appreciate the manufacturer’s input.

After consideration of the public comments we received, we believe that the SpaceOAR® System meets the newness criterion for device pass-through payment status.

With respect to the eligibility criterion at §419.66(b)(3), according to the applicant, the SpaceOAR® System is integral to the service provided, is used for one patient only, comes in contact with human skin, and is applied in or on a wound or other skin lesion. The applicant also claimed the SpaceOAR® System meets the device eligibility requirements of §419.66(b)(4) because it is not an instrument, apparatus, implement, or item for which depreciation and financing expenses are recovered, and it is not a supply or material furnished incident to a service.

The criteria for establishing new device categories are specified at §419.66(c). The first criterion, at §419.66(c)(1), provides that CMS determines that a device to be included in the category is not appropriately described by any of the existing categories or by any category previously in effect, and was not being paid for as an outpatient service as of December 31, 1996. We have not identified an existing pass-through payment category that describes the SpaceOAR® System. The applicant suggested a category descriptor for the SpaceOAR® System of “Absorbable perirectal spacer”. We invited public comments on this issue.

Comment: The manufacturer of the SpaceOAR® System believed that this device meets the eligibility criteria for device pass-through payment status, but did not specifically comment on whether a current pass-through payment
category appropriately describes this device.

Response: We appreciate the manufacturer’s input.

After consideration of the public comments we received, we believe that there is no existing pass-through payment category that appropriately describes the SpaceOAR® System and that the SpaceOAR® System meets the eligibility criterion.

The second criterion for establishing a device category, at §419.66(c)(2), provides that CMS determines that a device to be included in the category has demonstrated that it will substantially improve the diagnosis or treatment of an illness or injury or improve the functioning of a malformed body part compared to the benefits of a device or devices in a previously established category or other available treatment. With respect to this criterion, the applicant submitted studies which discussed the techniques for using hydrogel spacers to limit radiation exposure to the rectum in prostate radiotherapy. In support of its assertion that SpaceOAR is a substantial clinical improvement, the applicant submitted several studies that examined the effect that the SpaceOAR® System had on outcomes such as rectal dose, radiation toxicity, and quality of life declines after image guided intensity modulated radiation therapy for prostate cancer. Articles by Mariados et al.25 and Hamstra et al.26 discussed the results of a single-blind phase III trial of image guided intensity modulated radiation therapy with 15 months and 3 years of follow-up, respectively. In the studies, a total of 222 men were randomized 2:1 to the spacer and control group and received 79.2 Gy in 1.8-Gy fractions to total of 222 men were randomized 2:1 follow-up, respectively. In the studies, a total of 222 men were randomized 2:1 to the spacer and control group and received 79.2 Gy in 1.8-Gy fractions to a single-blind phase III trial of image guided intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology, 8, e7–e15.

The results of this study showed that after 3 years, compared with the control group, the participants who received the SpaceOAR® System injection had a statistically significant smaller volume of the rectum receiving a threshold radiation exposure, which was the primary effectiveness endpoint. The results also showed that in an extended follow-up period, the control group experienced larger declines in bowel and urinary quality of life compared to participants who received the SpaceOAR® System treatment. Lastly, in an extended follow-up period, the probability of grade ≥1 rectal toxicity was decreased in the SpaceOAR® System arm (9 percent control group, 2 percent SpaceOAR® System group, p < .03) and no ≥ grade 2 rectal toxicity was observed in the SpaceOAR® System arm. However, the control arm had low rates of rectal toxicity in general. The results of this 3-year follow-up of these participants showed that the differences identified in the 15-month follow-up study were maintained or increased.28

The applicant also included a secondary analysis of the phase III trial data which showed that participants who received lower radiation doses to the penile bulb, associated with the SpaceOAR® System injection, reported similar erectile function compared with the control group based on patient-reported sexual quality of life.29 A 2017 retrospective cohort study by Pinkawa et al.30 evaluated quality of life changes up to 5 years after RT for prostate cancer with the SpaceOAR® System and showed that 5 years after radiation therapy, no patients who received the SpaceOAR® System reported moderate/ big problems with bowel urgency, losing control of stools, or with bowel habits overall. However, there were no statistically significant differences in mean score changes for urinary, bowel, or sexual bother between the percentage of participants in the SpaceOAR® System and control groups at either 1 1/2 years or 5 years postradiation therapy. CMS had concerns regarding the phase III trial inclusion of only low to moderate risk prostate cancer in the study population and failing to use a clinical outcome as a primary endpoint, although the purpose of the spacer is to reduce the side effects of undesired radiation to the rectum including bleeding, diarrhea, fistula, pain, and/or stricture. Notwithstanding acknowledgement that rectal complications may be reduced using biodegradable biomaterials placed to increase the distance between the rectum and the prostate, it is not clear that the SpaceOAR® System is superior to existing alternative biodegradable biomaterials currently utilized for spacing in the context of prostate radiotherapy.

Based on the evidence submitted with the application, we have insufficient evidence that the SpaceOAR® System provides a substantial clinical improvement over other similar products. We invited public comments on whether the SpaceOAR® System meets the substantial clinical improvement criterion.

Comment: The manufacturer of the SpaceOAR® System identified several points which supported this device meeting the substantial clinical improvement criterion. In response to the statement in the proposed rule that the control arm of the phase III trial had low rates of rectal toxicity in general, the manufacturer noted that the low rates of rectal toxicity in the control arm of the study were due to: (1) The radiation plans in both the treatment and control groups were evaluated and approved by an independent core laboratory for compliance to protocol guidelines, which led to low toxicity in the control group relative to standard practice; and (2) all study dose plans used CT and MRI image fusion to improve plan accuracy, while typical plans only use CT imaging. The manufacturer noted that patients in the SpaceOAR® System group still had statistically significant reductions in rectal toxicity and improvements in quality of life in comparison to the control group.

The manufacturer disagreed with a statement in the proposed rule where CMS indicated that the SpaceOAR® System patients “reported similar erectile function compared with the control group based on patient-reported sexual quality of life.” The commenter noted that the patient reported quality of life analysis of baseline potent men at three years found that men treated with the SpaceOAR® System had improved scores on “erectile sufficient for intercourse” as well as better scores on seven of the 13 items regarding sexual function.31

In response to the statement in the proposed rule that the submitted studies included only low to moderate risk prostate cancer in the study population and failed to use a clinical outcome as a primary endpoint, the manufacturer noted that the phase III trial design specifically selected a low and...
intermediate risk prostate cancer population to better allow for a safety
determination. The manufacturer also noted that the significant reductions in
late rectal toxicity and improvements in quality of life at 3 years demonstrate
that the clinical benefits of this device are better than anticipated when the
study was originally developed.

In response to the statement in the proposed rule that it was unclear that the SpaceOAR® System was superior to
existing alternative spacers used for prostate radiotherapy, the manufacturer
noted that the SpaceOAR® System is the only prostate-rectum spacer authorized
for marketing by the FDA for use in prostate radiotherapy. The manufacturer
indicated that the closest comparable product is the endorectal balloon, and
that a study comparing the rectal-spacing capabilities of these two products
during prostate cancer stereotactic body radiation therapy found significantly less rectal radiation
dose in the patients who received the SpaceOAR System.52 The
manufacturer noted a study of these two products during proton radiotherapy
found that, with the SpaceOAR® System, a larger area around the prostate
could be radiated while still significantly reducing the rectum
radiation dose.33 The manufacturer indicated that several studies found that
prostate stability was comparable using these two products.34 35 36
The manufacturer also noted that reductions in placement error and patient comfort
favors the SpaceOAR® System compared to endorectal balloons.37 The
manufacturer asserted that the combined impacts of these results make the SpaceOAR® System a substantial
clinical improvement over endorectal balloons.

Several commenters, representing various oncological and urologic
specialty societies, believed that the SpaceOAR® System meets the
substantial clinical improvement criterion. These commenters noted that
there were no other alternative biodegradable biomaterials with FDA
marketing authorization currently utilized for spacing in the context of
prostate radiotherapy and that this device provided physicians with an
option to help ensure patients are provided with the best clinical outcomes
with the fewest adverse effects.

Response: We appreciate the manufacturer’s and the commenters’ input. We reviewed these comments and the associated literature on this
topic and found that the application did not support that the SpaceOAR® System demonstrated a substantial clinical improvement as a prostate-rectum spacer for prostate
radiotherapy treatment. While the studies provided by the applicant do
indicate that the device provides a dose reduction at the rectum during IMRT for
prostate cancer, we found the clinical results of these studies were equivocal and did not provide definitive evidence of substantial clinical improvement of
radiation toxicity and quality of life scores after radiation therapy.

In response to our concern that the control arm of the study had very low
rates of rectal toxicity (the manufacturers quoted rates of late rectal
toxicity of between 14 and 25 percent for studies without the use of the
SpaceOAR® System), the commenter responded that the low rates of rectal toxicity in the control arm of the study were due to (1) the radiation plans in
both the treatment group and the control group were evaluated and approved by
an independent core laboratory for compliance with protocol guidelines,
which led to low toxicity in the control group relative to standard practice, and (2) all study dose plans used CT and
MRI image fusion to improve plan accuracy, while typical plans only use CT imaging is not supported in the
literature, which states that IMRT is considered the standard of care in RT
treatment centers; in both the United States and Europe, it has largely
replaced older forms of 3D-CRT.34 35
The response that the radiation plans in both the treatment group and the control
group were evaluated and approved by an independent core laboratory for
compliance to protocol guidelines, which led to low toxicity in the control
group relative to standard practice, further calls into question the direct role of the SpaceOAR® System in reducing
toxicity versus more precise planning.

39 40 41 42 43 44 45

40 Ibid.
41 Ibid.

The rates of late grade one or higher rectal toxicity in the control population in the clinical trials submitted by the applicant were 7 percent 38 and 9.2 percent 39 respectively. The rates of late grade one or higher rectal toxicity in the SpaceOAR® System groups in the clinical trials submitted by the applicant were 2 percent in both studies.30-31 We note that image guided radiation therapy has drastically improved radiation dose effects, and conventional radiotherapy is well tolerated by the vast majority of patients.42 It remains unclear if further reduction in radiation dose effects with the SpaceOAR® System translates to a substantial clinical improvement that is maintained over time when compared to patients who did not receive the SpaceOAR® System. The applicant’s explanation that all study dose plans used CT and MRI image fusion to improve plan accuracy, while typical plans only use CT imaging is not supported in the literature, which states that IMRT is considered the standard of care in RT
treatment centers; in both the United States and Europe, it has largely
replaced older forms of 3D-CRT.34 35
The response that the radiation plans in both the treatment group and the control
group were evaluated and approved by an independent core laboratory for
compliance to protocol guidelines, which led to low toxicity in the control
group relative to standard practice, further calls into question the direct role of the SpaceOAR® System in reducing
toxicity versus more precise planning.
protocols and the importance of adhering to guidance protocols.

As discussed further below, we continue to have concerns regarding the applicant’s claims that the statistically significant reduction in late rectal toxicity as well as the improvements in QOL scores tend to substantial clinical improvement, despite the relatively low rates of rectal toxicity in the control group. We note that the data showing reduction in rectal toxicity and improvements in quality are from studies that were not designed with primary clinical outcomes to show superiority, but rather were designed primarily to evaluate the threshold of radiation exposure to the rectum and adverse events related to the procedure. Consequently, the studied clinical outcomes have many differences that did not meet statistical significance or were not sustained over time.

In the pivotal trial, no differences in acute rectal or urinary toxicity from the time of the procedure through the 3-month follow-up were observed between the SpaceOAR® System group and the control group. In this study, there was a statistically significant difference noted between the SpaceOAR® System group and the control group in late rectal toxicity (3 to 15 months after the procedure). In the SpaceOAR® System group, 2 percent of the patients (n=3) experienced late rectal toxicity, while 7 percent of patients in the control group (n=5) experienced late rectal toxicity. There was one incidence of the more clinically serious (grade 3) late rectal toxicity reported in the control group and no incidence of grade 4 rectal toxicity in either group.

Even at 3 years after the procedure, the control arm had very low rates of rectal toxicity. The 3-year incidence of grade ≥1 rectal toxicity was 9.2 percent (approximately 4 patients) in the control group versus 2.0 percent (approximately 2 patients) in the SpaceOAR® System group. The cumulative rate of grade ≥2 rectal bowel toxicity was 6 percent at 3 years in the control arm, with no cases of grade ≥2 rectal toxicity in the SpaceOAR® System group. With regard to improvements in quality of life, the pivotal trial, at 3 months, showed there was no statistically significant difference between the SpaceOAR® System group and the control group in mean changes in bowel and urinary quality of life domains. Although, at 6, 12, and 15 months, a lower percentage of patients in the SpaceOAR® System group reported declines in bowel quality of life compared to those in the control group, at 15 months, 11.6 percent and 21.4 percent of the SpaceOAR® System patients and the control group patients, respectively, experienced 10-point declines in bowel quality of life. However, this difference was not statistically significant. In terms of urinary quality of life at 6 months, a higher percentage of patients in the control group (22.2 percent) had 10-point urinary declines in comparison to the the SpaceOAR® System group (8.8 percent). However, again the durability of these improvements disappeared over time because there was no difference between the SpaceOAR® System group and the control group in urinary quality of life decline at 12 and 15 months follow-ups.

The commenter claimed that when followed up at 3 years, patients in the phase III trial receiving the SpaceOAR® System prior to their prostate cancer radiotherapy demonstrated significant rectal (bowel), urinary, and sexual benefit. However, we found the data to be inconsistent and unreliable to support this claim. Specifically, in the study including 3 years of follow-up data, quality of life was examined using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment. For the average bowel summary score, both the SpaceOAR® System group and the control group had similar acute declines in bowel quality of life between enrollment and 3 months after treatment. Also, at 3 months after treatment, there were no patients in the control group that reported acute bowel pain while 6.8 percent of the SpaceOAR® System patients reported acute bowel pain.

In this study, the proportion of patients with measurable changes in bowel quality of life meeting the minimally important difference (MID) threshold (5 points) or twice that threshold (10 points) was evaluated. According to the authors, these thresholds give an idea of when patient-reported symptoms are likely to be clinically meaningful to prostate cancer patients, with a 10-point decline indicating a more serious clinical effect. From 6 months through 3 years, more men in the control group had a MID in bowel quality of life meeting the threshold of 5 points, but no difference was found for a 10-point decline. At 3 years, the SpaceOAR® System group patients were less likely than the control group patients to have a detectable decline in bowel quality of life for both MID thresholds (5-point: 41 percent (control) versus 14 percent (the SpaceOAR® System); 10-point: 21 percent (control) versus 5 percent (the SpaceOAR® System). However, more than 30 percent of the patients in both the SpaceOAR® System group (n=55) and the control group (n=27) were lost by the 3-year follow-up and the follow-up data were taken from volunteer centers that decided to continue in the study. It is unclear if the differences observed at 3 years are due to the large number of respondents who did not participate at year 3, resulting in a smaller sample size and more unreliable data. For example, regarding urinary quality of life, when averaged over the entire follow-up duration, no significant difference was found in the mean urinary quality of life between the two groups. However, at the 3-year point, a statistically significant difference was found in urinary quality of life favoring the SpaceOAR® System group compared with the control group.

The researchers in this study also assessed the percent of patients with moderate or big problems in quality of life. The researchers found that, at 3 years, only one item showed a statistically significant difference between the treatment groups (moderate to big bother for urinary frequency: The control group of 18 percent versus the SpaceOAR® System group of 5 percent; P <.05). At 3 years after treatment, 2.2 percent of the men in the SpaceOAR® System group evaluated their overall bowel function as a big or moderate bother. This compares to 4.4 percent in the control group, which was not a statistically significant difference. None of the components of rectal bother were statistically significantly better in the men who received the SpaceOAR® System. In contrast, regarding the question of bowel pain, none of the control group patients reported a moderate or big bother after 3 years, while 1.1 percent of the SpaceOAR® System group patients reported that...
bowel pain was a moderate or big bother. The study by Pinkawa et al. looking at 1.5 and 5 year results comparing quality of life of patients pretreated with hydrogel and controls further demonstrates inconsistency in looking at substantial improvements with the SpaceOAR® System. In this study percentages of big problems with bowel urgency, control of stools and bowel habitus overall favored SpaceOAR at 1.5 years. However, only differences in percentage of problems of bowel urgency remained after the 5-year follow-up. Also, no statistically significant difference was shown between the SpaceOAR® System group and the control group in comparing mean bowel bother scores at 1.5 years and 5 years after radiation therapy.

The manufacturer stated that CMS incorrectly stated in the proposed rule that the SpaceOAR® System patients reported similar erectile function compared with the control group based on patient-reported sexual quality of life. The manufacturer is correct; in a study by Hamstra et al., the patient-reported quality of life analysis of baseline potent men found that men in this group treated with the SpaceOAR® System had improved “erections sufficient for intercourse” as well as statistically significant higher scores on 7 of 13 items in the sexual domain in comparison to the control group at 3 years. However, at baseline, sexual functioning in the study was low; only 41 percent of patients had no sexual dysfunction at baseline (EPIC sexual quality of life scores >60, n=88). When comparing men with poor baseline sexual quality of life (EPIC score ≤60, n=125), there was no difference between the SpaceOAR® System group and the control group in function, bother, or sexual summary score at the 3-year follow up. We also note that the Pinkawa study shows that men with the SpaceOAR® System reported erections firm enough for intercourse to be statistically significant. However, again the same study reported the changes in sexual quality of life bother scores were not statistically different between the two groups at 5 years. Again, along with the instability of the 3-year data stated above, the fact that the data are inconsistent and not supported by the long-term quality of life data, we are unable to substantiate substantial clinical improvement. We appreciate the comments received from the urological and the oncological community as well members of the public in support of this technology. The SpaceOAR® System device effectively displaces the anterior wall reducing the dose of radiation the rectum receives during radiation treatment for prostate cancer. However, after consideration of the public comments and the application materials we received, at this time we do not believe that the SpaceOAR® System meets the substantial clinical improvement criterion to receive device pass-through payment. The submitted studies were not designed to show first primary clinical outcomes, and consequently the data on toxicity and quality of life improvement are inconsistent and fail to show enduring improvements. It is difficult to attribute the reductions in late rectal toxicity solely to the device, given improvements in radiation therapy and planning as well as the large number of nonresponders at 3 years postradiation and the 3-year follow-up data were being taken from volunteer centers that decided to continue in the study. We note that many favorable clinical outcomes were not statistically significant but trended in favor of the SpaceOAR® System group. We agree with many authors that it seems to suggest that the greatest utility of the SpaceOAR® System will be its use in populations at greatest risk for radiation toxicity such as hypofractionated treatment or other dose intensifications.

The third criterion for establishing a device category, at §419.66(e)(3), requires us to determine that the cost of the device is not insignificant, as described in §419.66(d). Section 419.66(d) includes three cost significance tests that must each be met. The applicant provided the following information in support of the cost significance requirements. The applicant stated that the SpaceOAR® System would be reported with CPT code 0438T (which was deleted and replaced with CPT code 55874, effective January 1, 2018). CPT code 0438T was assigned to APC 5374 (Level 4 Urology and Related Services). To meet the cost criterion for device pass-through payment, a device must pass all three tests of the cost criterion for at least one APC. For our calculations, we used APC 5374, which had a CY 2017 payment rate of $2,542.56 at the time the application was received. Beginning in CY 2017, we calculate the device offset amount at the HCPCS/CPT code level instead of the APC level (81 FR 79657). CPT code 0438T had a device offset amount of $587.07 at the time the application was received. According to the applicant, the cost of the SpaceOAR® System was $2,850.

Section 419.66(d)(1), the first cost significance requirement, provides that the estimated average reasonable cost of devices in the category must exceed 25 percent of the applicable APC payment amount for the service related to the category of devices. The estimated average reasonable cost of $2,850 for the SpaceOAR® System exceeds 112 percent of the applicable APC payment amount for the service related to the category of devices of $2,542.56 ($2850/$2,542.56 × 100 = 112 percent). Therefore, we believe the SpaceOAR® system meets the first cost significance test.

The second cost significance test, at §419.66(d)(2), provides that the estimated average reasonable cost of the devices in the category must exceed the cost of the device-related portion of the APC payment amount for the related service by at least 25 percent, which means that the device cost needs to be at least 125 percent of the offset amount (the device-related portion of the APC found on the offset list). The estimated average reasonable cost of $2,850 for the SpaceOAR® System exceeds the cost of the device-related portion of the APC payment amount for the related service of $587.07 by 485 percent ($2,850/$587.07 × 100 = 485 percent). Therefore, we believe the SpaceOAR® System meets the second cost significance test.

The third cost significance test, at §419.66(d)(3), requires that the difference between the estimated average reasonable cost of the devices in the category and portion of the APC payment amount for the device must exceed 10 percent of the APC payment amount for the related service. The difference between the estimated average reasonable cost of $2,850 for the SpaceOAR® System and the portion of the APC payment amount for the device of $587.07 exceeds the APC payment amount for the related service of $2,542.56 by 89 percent ($2,850 − $587.07)/$2,542.56 × 100 = 89 percent). Therefore, we believe that the SpaceOAR® System meets the third cost significance test.

We invited public comments on whether the SpaceOAR® System meets the device pass-through payment
criteria discussed in this section, including the cost criteria.

Comment: The manufacturer of the SpaceOAR® System believed this device meets the eligibility criteria for device pass-through payment status, but did not specifically comment on whether this device meets the cost criterion.

Response: We appreciate the manufacturer’s input.

After consideration of the public comments we received, we believe that SpaceOAR® System meets the cost criterion for device pass-through payment status.

After consideration of the public comments we received, we believe that SpaceOAR® System does not qualify for device pass-through payment status because it does not meet the substantial clinical improvement criterion, although it may have clinical benefit for certain patients. As such, we are not approving the application for device pass-through payment status for the SpaceOAR® System for CY 2019.

B. Device-Intensive Procedures

1. Background

Under the OPPS, prior to CY 2017, device-intensive status for procedures was determined at the APC level for APCs with a device offset percentage greater than 40 percent (79 FR 66795). Beginning in CY 2017, CMS began determining device-intensive status at the HCPCS code level. In assigning device-intensive status to an APC prior to CY 2017, the device costs of all the procedures within the APC were calculated and the geometric mean device offset of all of the procedures had to exceed 40 percent. Almost all of the procedures assigned to device-intensive APCs utilized devices, and the device costs for the associated HCPCS codes exceeded the 40-percent threshold. The no cost/full credit and partial credit device policy (79 FR 66672 through 66673) applies to device-intensive APCs and is discussed in detail in section IV.B.4. of this final rule with comment period. A related device policy was the requirement that certain procedures assigned to device-intensive APCs require the reporting of a device code on the claim (80 FR 70422). For further background information on the device-intensive APC policy, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70421 through 70426).

a. HCPCS Code-Level Device-Intensive Determination

As stated earlier, prior to CY 2017, the device-intensive methodology assigned device-intensive status to all procedures requiring the implantation of a device that were assigned to an APC with a device offset greater than 40 percent and, beginning in CY 2015, that met the three criteria listed below. Historically, the device-intensive designation was at the APC level and applied to the applicable procedures within that APC. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658), we changed our methodology to assign device-intensive status at the individual HCPCS code level rather than at the APC level. Under this policy, a procedure could be assigned device-intensive status regardless of its APC assignment, and device-intensive APCs were no longer applied under the OPPS or the ASC payment system.

We believe that a HCPCS code-level device offset is, in most cases, a better representation of a procedure’s device cost than an APC-wide average device offset based on the average device offset of all of the procedures assigned to an APC. Unlike a device offset calculated at the APC level, which is a weighted average offset for all devices used in all of the procedures assigned to an APC, a HCPCS code-level device offset is calculated using only claims for a single HCPCS code. We believe that this methodological change results in a more accurate representation of the cost attributable to implantation of a high-cost device, which ensures consistent device-intensive designation of procedures with a significant device cost.

Further, we believe a HCPCS code-level device offset removes inappropriate device-intensive status for procedures without a significant device cost that are granted such status because of APC assignment.

Under our existing policy, procedures that meet the criteria listed below in section IV.B.1.b. of this final rule with comment period are identified as device-intensive procedures and are subject to all the policies applicable to procedures assigned device-intensive status under our established methodology, including our policies on device edits and no cost/full credit and partial credit, discussed in sections IV.B.3. and IV.B.4. of this final rule with comment period, respectively.

b. Use of the Three Criteria To Designate Device-Intensive Procedures

We clarified our established policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 52474), where we explained that device-intensive procedures require the implantation of a device and additionally are subject to the following criteria:

• All procedures must involve implantable devices that would be reported if device insertion procedures were performed;
  • The required devices must be surgically inserted or implanted devices that remain in the patient’s body after the conclusion of the procedure (at least temporarily); and
  • The device offset amount must be significant, which is defined as exceeding 40 percent of the procedure’s mean cost.

We changed our policy to apply these three criteria to determine whether procedures qualify as device-intensive in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66926), where we stated that we would apply the no cost/full credit and partial credit device policy—which includes the three criteria listed above—to all device-intensive procedures beginning in CY 2015. We reiterated this position in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70424), where we explained that we were finalizing our proposal to continue using the three criteria established in the CY 2007 OPPS/ASC final rule with comment period for determining the APCs to which the CY 2016 device intensive policy will apply. Under the policies we adopted in CYs 2015, 2016, and 2017, all procedures that require the implantation of a device and meet the above criteria are assigned device-intensive status, regardless of their APC placement.

2. Changes to the Device-Intensive Procedure Policy for CY 2019 and Subsequent Years

As part of CMS’ effort to better capture costs for procedures with significant device costs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37108), for CY 2019, we proposed to modify our criteria for device-intensive procedures. We have heard from stakeholders that the current criteria exclude some procedures that stakeholders believe should qualify as device-intensive procedures. Specifically, we were persuaded by stakeholder arguments that procedures requiring expensive surgically inserted or implanted devices that are not capital equipment should qualify as device-intensive procedures, regardless of whether the device remains in the patient’s body after the conclusion of the procedure. We agreed that a broader definition of device-intensive procedures was warranted, and proposed two modifications to the criteria for CY 2019. First, we proposed to allow procedures that involve surgically inserted or implanted single-use devices that meet the device offset percentage threshold to qualify as device-intensive procedures, regardless
of whether the device remains in the patient’s body after the conclusion of the procedure. We proposed this policy because we no longer believed that whether a device remains in the patient’s body should affect its designation as a device-intensive procedure, as such devices could, nonetheless, comprise a large portion of the cost of the applicable procedure. Second, we proposed to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent, to allow a greater number of procedures to qualify as device-intensive. We stated in the proposed rule that we believe allowing these additional procedures to qualify for device-intensive status will help ensure these procedures receive more appropriate payment in the ASC setting, which will help encourage the provision of these services in the ASC setting. In addition, we stated in the proposed rule that this proposed change would help to ensure that more procedures containing relatively high-cost devices are subject to the device edits, which leads to more correctly coded claims and greater accuracy in our claims data.

Specifically, for CY 2019 and subsequent years, we proposed that device-intensive procedures would be subject to the following criteria:

- All procedures must involve implantable devices assigned a CPT or HCPCS code;
- The required devices (including single-use devices) must be surgically inserted or implanted; and
- The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost.

In addition, to further align the device-intensive policy with the criteria used for device pass-through payment status, we proposed to specify, for CY 2019 and subsequent years, that for purposes of satisfying the device-intensive criteria, a device-intensive procedure must involve a device that:

- Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE), and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review;
- Is an integral part of the service furnished;
- Is used for one patient only;
- Comes in contact with human tissue;
- Is surgically implanted or inserted (either permanently or temporarily); and
- Is not any of the following:

(a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15–1); or

(b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker).

As part of this proposal, we solicited public comment on these proposed revised criteria, including whether there are any devices that are not capital equipment that commenters believe should be deemed part of device-intensive procedures that would not meet the proposed definition of single-use devices. In addition, we solicited public comments on the full list of proposed CY 2019 OPPS device-intensive procedures provided in Addendum P to the proposed rule, which is available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html. Specifically, we invited public comment on whether any procedures proposed to receive device-intensive status for CY 2019 should not receive device-intensive status according to the proposed criteria, or if we did not assign device-intensive status for CY 2019 to any procedures commenters believed should receive device-intensive status based on the proposed criteria.

Comment: The majority of commenters supported CMS’ proposal to modify the device-intensive criteria to allow procedures that involve single-use devices, regardless of whether they remain in the body after the conclusion of the procedure, to qualify as device-intensive procedures. The commenters believed that this proposed policy change will better support accurate payment for procedures where an implantable device is a significant proportion of the total cost of the procedure. Some commenters indicated that this proposed change would help to spur innovation in the device industry.

Response: We appreciate the commenters’ support. The majority of commenters supported the proposal to lower the device offset percentage threshold for procedures to qualify as device-intensive from greater than 40 percent to greater than 30 percent. The commenters believed that this proposed policy change will encourage migration of services from the hospital outpatient department into the ASC setting, resulting in cost savings to the Medicare program and Medicare beneficiaries.

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37108 through 37109), in accordance with our proposal stated above to lower the
device offset percentage threshold for procedures to qualify as device-intensive from greater than 40 percent to greater than 30 percent, for CY 2019 and subsequent years, we proposed to modify this policy and apply a 31-percent default device offset to new HCPCS codes describing procedures requiring the implantation of a medical device that do not yet have associated claims data until claims data are available to establish the HCPCS code-level device offset for the procedures. In conjunction with the proposal to lower the default device offset from 41 percent to 31 percent, we proposed to continue our current policy of, in certain rare instances (for example, in the case of a very expensive implantable device), temporarily assigning a higher offset percentage if warranted by additional information such as pricing data from a device manufacturer (81 FR 79658).

Once claims data are available for a new procedure requiring the implantation of a medical device, device-intensive status will be applied to the code if the HCPCS code-level device offset is greater than 30 percent, according to our policy of determining device-intensive status by calculating the HCPCS code-level device offset.

In addition, in the proposed rule, we clarified that since the adoption of our policy in effect as of CY 2018, the associated claims data used for purposes of determining whether or not to apply the default device offset are the associated claims data for either the new HCPCS code or any predecessor code, as described by CPT coding guidance, for the new HCPCS code. Additionally, for CY 2019 and subsequent years, in limited instances where a new HCPCS code does not have a predecessor code as defined by CPT, but describes a procedure that was previously described by an existing code, we proposed to use clinical discretion to identify HCPCS codes that are clinically related or similar to the new HCPCS code but are not officially recognized as a predecessor code by CPT, and to use the claims data of the clinically related or similar code(s) for purposes of determining whether or not to apply the default device offset to the new HCPCS code. Clinically related and similar procedures for purposes of this policy are procedures that have little or no clinical differences and use the same devices as the new HCPCS code. In addition, clinically related and similar codes for purposes of this policy are codes that either currently or previously describe the procedure described by the new HCPCS code. Under this proposal, claims data from clinically related and similar codes would be included as associated claims data for a new code, and where an existing HCPCS code is found to be clinically related or similar to a new HCPCS code, we proposed to apply the device offset percentage derived from the existing clinically related or similar HCPCS code's claims data to the new HCPCS code for determining the device offset percentage. We stated in the proposed rule that we believe that claims data for HCPCS codes describing procedures that have very minor differences from the procedures described by new HCPCS codes would provide an accurate depiction of the cost relationship between the procedure and the device(s) that are used, and would be appropriate to use to set a new code's device offset percentage, in the same way that predecessor codes are used. For instance, for CY 2019, we proposed to use the claims data from existing CPT code 36568 (Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump; younger than 5 years of age), for which the description as of January 1, 2019 is changing to “(Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; younger than 5 years of age)”, to determine the appropriate device offset percentage for new CPT code 36X72 (Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, with imaging guidance; younger than 5 years of age) to determine whether the new HCPCS code qualifies for device-intensive status.

In the CY 2019 OPPS/ASC proposed rule, we indicated that additional information for our consideration of an offset percentage higher than the proposed default of 31 percent for new HCPCS codes describing procedures requiring the implantation (or, in some cases, the insertion) of a medical device that do not yet have associated claims data, such as pricing data or invoices from a device manufacturer, should be directed to the Division of Outpatient Care, Mail Stop C4–01–26, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244–1850, or electronically at outpatientppps@cms.hhs.gov. Additional information can be submitted prior to issuance of an OPPS/ASC proposed rule or as a public comment in response to an issued OPPS/ASC proposed rule. Device offset percentages will be set in each year’s final rule.

The full listing of proposed CY 2019 OPPS device-intensive procedures was included in Addendum P to the proposed rule (which is available via the internet on the CMS website).

Comment: Commenters supported the proposal to apply a default device offset of 31 percent to procedures requiring devices that do not yet have claims data, as well as the proposal to use claims data from clinically similar and related codes to establish device offsets for procedures with new codes that do not have direct predecessor codes according to CPT.

Response: We appreciate the commenters’ support.

Comment: A few commenters suggested that CMS only adjust the non-device portion of the payment by the wage index, consistent with the Agency’s policy for separately payable drugs and biologicals.

Response: While we did not make such a proposal in this year’s proposed rule, we will take this comment into consideration for future rulemaking. We note that such a policy would increase payments to providers with a wage index value of less than 1 and be offset by a budget neutral decrease in payments to other providers.

Comment: A group of commenters urged CMS to calculate the device offset percentage for potential device-intensive procedures using the standard (noncomprehensive APC) ASC ratessetting methodology and to assign device-intensive status in the ASC system based on that device offset percentage, as they believed it is more consistent with the CMS payment system. One commenter requested some clarification in the final
rule about the current methodology for calculating the device offset percentage for device-intensive procedures and specifically asked that CMS:
• Confirm that the ASC device-intensive status as assigned by CMS is based on the offset calculated according to the ASC ratesetting methodology;
• Disclose what offset data (meaning the calculation methodology used) appear in the second spreadsheet of Addendum P titled “2019 NPRM HCPCS Offsets’’;
• Display the device offsets in Addendum P, in future rulemaking, based on the ASC methodology and not the OPPS methodology if the offset data displayed in the second spreadsheet of Addendum P is based on the OPPS methodology and device intensive status is based on the ASC methodology; and
• Modify the second worksheet of Addendum P titled “2019 NPRM HCPCS Offsets’’ to only include the codes for procedures that employ implantable and insertable devices and exclude all of the codes that do not employ implantable or insertable devices, we note that the second worksheet of Addendum P is intended to display the device offsets and device offset percentages for all codes for which we have such data under the OPPS. In addition, the list of services that qualify as device-intensive under the ASC payment system and the services’ device offset percentages for the ASC payment system are included on the CMS website at https://www.cms.gov/Medicare/Medicare-Fee-
for-Service-Payment/ASCPayment/ASC-Policy-Files.html as “CY 2019 Final ASC Device-Intensive Procedures and Procedures to which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies.”

Comment: Commenters supported the proposed device-intensive status for the following CPT codes:
• CPT code 28730 (Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse);
• CPT code 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint);
• CPT code 36903 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis segment);
• CPT code 36904 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s); with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis circuit).

Other commenters requested that CMS assign device-intensive status to:
• HCPCS code C9747 (Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance);
• CPT code 43210 (Esophagogastroduodenoscopy, flexible, transoral; with esophagogastic fundoplasty, partial or complete, includes duodenoscopy when performed);
• CPT code 02757T (Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (e.g., fluoroscopic, ct), single or multiple levels, unilateral or bilateral; lumbar);
• CPT code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed);  
• CPT code 4090T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only);
• CPT code 0410T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only);
• CPT code 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only); and
• CPT code 0414T (Removal and replacement of permanent cardiac contractility modulation system pulse generator only).

Response: We appreciate the commenters’ support. With respect to the commenters’ request that we assign the device-intensive designation to
HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that the device offset percentage for all four of these procedures (as identified by the above mentioned HCPCS codes or predecessor codes) is not above the 30-percent threshold, and therefore these procedures are not eligible to be assigned device-intensive status. CPT codes 0409T, 0410T, 0411T, and 0414T were inadvertently omitted from the listing of proposed device-intensive procedures in the CY 2019 OPPS/ASC proposed rule. However, we have included them as device-intensive procedures in this final rule with comment period.

Comment: One commenter stated that CPT code 86891 (Autologous blood or component, collection processing and storage; intra- or postoperative salvage) was incorrectly proposed to have device-intensive status for CY 2019.

Response: We agree with the commenter. CPT code 86891 was inadvertently included in the listing of device-intensive procedures in Addendum P to the CY 2019 OPPS/ASC proposed rule.

After consideration of the public comments we received, we are finalizing our proposals to allow procedures that involve surgically inserted or implanted, single-use devices that meet the device offset percentage threshold to qualify as device-intensive procedures, regardless of whether the device remains in the patient’s body after the conclusion of the procedure and to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. The full listing of the final CY 2019 device-intensive procedures is included in Addendum P to this final rule with comment period (which is available via the internet on the CMS website).

3. Device Edit Policy

In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66795), we finalized a policy and implemented claims processing edits that require any of the device codes used in the previous device-to-procedure edits to be present on the claim whenever a procedure code assigned to any of the APCs listed in Table 5 of the CY 2015 OPPS/ASC final rule with comment period (the CY 2015 device-dependent APCs) is reported on the claim. In addition, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70422, we modified our previously existing policy and applied the device coding requirements exclusively to procedures that require the implantation of a device that are assigned to a device-intensive APC. In the CY 2016 OPPS/ASC final rule with comment period, we also finalized our policy that the claims processing edits are such that any device code, when reported on a claim with a procedure assigned to a device-intensive APC (listed in Table 42 of the CY 2016 OPPS/ASC final rule with comment period (80 FR 70422)) will satisfy the edit.

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658 through 79659), we changed our policy for CY 2017 and subsequent years to apply the CY 2016 device coding requirements to the newly defined device-intensive procedures. For CY 2017 and subsequent years, we also specified that any device code, when reported on a claim with a device-intensive procedure, will satisfy the edit. In addition, we created HCPCS code C1889 to recognize devices furnished during a device-intensive procedure that are not described by a specific Level II HCPCS Category C-code. Reporting HCPCS code C1889 with a device-intensive procedure will satisfy the edit requiring a device code to be reported on a claim with a device-intensive procedure.

We did not propose any changes to this policy for CY 2019.

Comment: Some commenters expressed concern about a potential claims processing issue that would arise from a number of codes (listed below in Table 36) that were proposed to have device-intensive status, which, in their clinical opinion, do not always require the involvement of implantable or insertable single-use devices and, therefore, could be subject to the claims edit requiring device-intensive procedures to be billed with a device, when the procedure may not require the involvement of a device.

BILLING CODE 4120–01–P
### TABLE 36.—LIST OF CODES PROPOSED TO HAVE DEVICE-INTENSIVE STATUS IDENTIFIED BY COMMENTERS THAT DO NOT ALWAYS REQUIRE THE INVOLVEMENT OF A DEVICE AND THAT INCORRECTLY MAY BE SUBJECT TO CLAIMS DEVICE EDIT

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>23585</td>
<td>Open treatment of scapular fracture (body, glenoid or acromion) includes internal fixation, when performed</td>
</tr>
<tr>
<td>24685</td>
<td>Open treatment of ulnar fracture, proximal end (eg, olecranon or coronoid process[es]), includes internal fixation, when performed</td>
</tr>
<tr>
<td>27784</td>
<td>Open treatment of proximal fibula or shaft fracture, includes internal fixation, when performed</td>
</tr>
<tr>
<td>28485</td>
<td>Open treatment of metatarsal fracture, includes internal fixation, when performed, each</td>
</tr>
<tr>
<td>27792</td>
<td>Open treatment of distal fibular fracture (lateral malleolus), includes internal fixation, when performed</td>
</tr>
<tr>
<td>28555</td>
<td>Open treatment of tarsal bone dislocation, includes internal fixation, when performed</td>
</tr>
<tr>
<td>24575</td>
<td>Open treatment of humeral epicondylar fracture, medial or lateral, includes internal fixation, when performed</td>
</tr>
<tr>
<td>27814</td>
<td>Open treatment of bimalleolar ankle fracture (eg, lateral and medial malleoli, or lateral and posterior malleoli, or medial and posterior malleoli), includes internal fixation, when performed</td>
</tr>
<tr>
<td>28300</td>
<td>Osteotomy; calcaneus (eg, Dwyer or Chambers type procedure), with or without internal fixation</td>
</tr>
<tr>
<td>25525</td>
<td>Open treatment of radial shaft fracture, includes internal fixation, when performed, and closed treatment of distal radioulnar joint dislocation (Galeazzi fracture/dislocation), includes percutaneous skeletal fixation, when performed</td>
</tr>
<tr>
<td>27822</td>
<td>Open treatment of trimalleolar ankle fracture, includes internal fixation, when performed, medial and/or lateral malleolus; without fixation of posterior lip</td>
</tr>
<tr>
<td>25515</td>
<td>Open treatment of radial shaft fracture, includes internal fixation, when performed</td>
</tr>
<tr>
<td>28465</td>
<td>Open treatment of tarsal bone fracture (except talus and calcaneus), includes internal fixation, when performed, each</td>
</tr>
<tr>
<td>24579</td>
<td>Open treatment of humeral condylar fracture, medial or lateral, includes internal fixation, when performed</td>
</tr>
<tr>
<td>28615</td>
<td>Open treatment of tarsometatarsal joint dislocation, includes internal fixation, when performed</td>
</tr>
<tr>
<td>28445</td>
<td>Open treatment of talus fracture, includes internal fixation, when performed</td>
</tr>
<tr>
<td>23515</td>
<td>Open treatment of clavicular fracture, includes internal fixation, when performed</td>
</tr>
<tr>
<td>23680</td>
<td>Open treatment of shoulder dislocation, with surgical or anatomical neck fracture, includes internal fixation, when performed</td>
</tr>
<tr>
<td>HCPCS Code</td>
<td>Long Descriptor</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>27832</td>
<td>Open treatment of proximal tibiofibular joint dislocation, includes internal fixation, when performed, or with excision of proximal fibula</td>
</tr>
<tr>
<td>62350</td>
<td>Implantation, revision or repositioning of tunneled intrathecal or epidural catheter, for long-term medication administration via an external pump or implantable reservoir/infusion pump; without laminectomy</td>
</tr>
</tbody>
</table>

Response: We have noted the commenters’ concern. We have performed a clinical examination of the potential device-intensive procedures and believe the codes listed in Addendum P to this CY 2019 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website) as OPPS device-intensive meet the newly finalized criteria of being a device-intensive procedure. To address any potential claims processing issues pertaining to the device edit policy, we will use subregulatory authority to ensure that the device edit does not improperly prevent correctly coded claims from being paid.

Comment: One commenter requested that CMS either revise the descriptor for HCPCS code C1889 (Implantable/insertable device for device-intensive procedure, not otherwise classified) to remove the specific applicability to device-intensive procedures or establish a new “Not Otherwise Classified” (NOC) HCPCS code for devices that do not have a specific device HCPCS code or are used in a procedure not designated as device-intensive.

Response: We agree with the commenter and have revised the NOC HCPCS code to remove the specific applicability to device-intensive procedures. HCPCS code C1889 now reads “(Implantable/insertable device, not otherwise classified).”

Comment: One commenter requested that CMS restore the device-to-procedure and procedure-to-device edits.

Response: As we stated in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66794), we continue to believe that the elimination of device-to-procedure edits and procedure-to-device edits is appropriate due to the experience hospitals now have in coding and reporting these claims fully. More specifically, for the more costly devices, we believe the C–APCs will reliably reflect the cost of the device if changes for the device are included anywhere on the claim. We note that, under our current policy, hospitals are still expected to adhere to the guidelines of correct coding and append the correct device code to the claim when applicable. We also note that, as with all other items and services recognized under the OPPS, we expect hospitals to code and report their costs appropriately, regardless of whether there are claims processing edits in place.

4. Adjustment to OPPS Payment for No Cost/Full Credit and Partial Credit Devices

a. Background

To ensure equitable OPPS payment when a hospital receives a device without cost or with full credit, in CY 2007, we implemented a policy to reduce the payment for specified device-dependent APCs by the estimated portion of the APC payment attributable to device costs (that is, the device offset) when the hospital receives a specified device at no cost or with full credit (71 FR 68071 through 68077). Hospitals were instructed to report no cost/full credit device cases on the claim using the “FB” modifier on the line with the procedure code in which the no cost/full credit device is used. In cases in which the device is furnished without cost or with full credit, hospitals were instructed to report a token device charge of less than $1.01. In cases in which the device being inserted is an upgrade (either of the same type of device or to a different type of device) with a full credit for the device being replaced, hospitals were instructed to report as the device charge the difference between the hospital’s usual charge for the device being implanted and the hospital’s usual charge for the device for which it received full credit. In CY 2008, we expanded this payment adjustment policy to include cases in which hospitals receive partial credit of 50 percent or more of the cost of a specified device. Hospitals were instructed to append the “FC” modifier to the procedure code that reports the service provided to furnish the device when they receive a partial credit of 50 percent or more of the cost of the new device. We refer readers to the CY 2008 OPPS/ASC final rule with comment period for more background information on the “FB” and “FC” modifiers payment adjustment policies (72 FR 66743 through 66749).

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75005 through 75007), beginning in CY 2014, we modified our policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit. For CY 2013 and prior years, our policy had been to reduce OPPS payment by 100 percent of the device offset amount when a hospital furnishes a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital receives partial credit in the amount of 50 percent or more of the cost for the specified device. For CY 2014, we reduced OPPS payment, for the applicable APCs, by the full or partial credit a hospital receives for a replaced device. Specifically, under this modified policy, hospitals are required to report on the claim the amount of the credit in the amount portion for value code “FD” (Credit Received from the Manufacturer for a Replaced Medical Device) when the hospital receives a credit for a replaced device that is 50 percent or greater than the cost of the device. For CY 2014, we also limited the OPPS payment deduction for the applicable APCs to the total amount of the device offset when the “FD” value code appears on a claim. For CY 2015, we continued our policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit and to use the three criteria established in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68072 through 68077) for determining the APCs to which our CY 2015 policy will apply (79 FR 66872 through 66873).

In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70424), we finalized our policy to no longer specify a list of devices to which the OPPS payment adjustment for no cost/full credit and partial credit devices would...
apply and instead apply this APC payment adjustment to all replaced devices furnished in conjunction with a procedure assigned to a device-intensive APC when the hospital receives a credit for a replaced specified device that is 50 percent or greater than the cost of the device.

b. Policy for No Cost/Full Credit and Partial Credit Devices

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79659 through 79660), CY 2017 and subsequent years, we finalized our policy to reduce OPPS payment for device-intensive procedures, by the full or partial credit a provider receives for a replaced device, when a hospital furnishes a specified device without cost or with a full or partial credit. Under our current policy, hospitals continue to be required to report on the claim the amount of the credit in the amount portion for value code “FD” when the hospital receives a credit for a replaced device that is 50 percent or greater than the cost of the device.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37110), for CY 2019 and subsequent years, we proposed to apply our no cost/full credit and partial credit device policies to all procedures that qualify as device-intensive under our proposed modified criteria discussed in section IV.B.2. of the proposed rule and this final rule with comment period.

We did not receive any public comments on this proposal. Therefore, we are finalizing our proposal to apply our no cost/full credit and partial credit device policies to all procedures that qualify as device-intensive under our finalized modified criteria discussed in section IV.B.2. of this final rule with comment period, for CY 2019 and subsequent years.

5. Payment Policy for Low-Volume Device-Intensive Procedures

In CY 2016, we used our equitable adjustment authority under section 1833(t)(2)(E) of the Act and used the median cost (instead of the geometric mean cost per our standard methodology) to calculate the payment rate for the implantable miniature telescope procedure described by CPT code 0308T (Insertion of ocular telescope prosthesis including removal of crystalline lens or intraocular lens prosthesis), which is the only code assigned to APC 5495 (Level 5 Intraocular Procedures) for CY 2017, but it would be the only procedure code assigned to APC 5495. The payment rates for a procedure described by CPT code 0308T (including the predecessor HCPCS code C0732) were $15,551 in CY 2014, $23,084 in CY 2015, and $17,551 in CY 2016. The procedure described by CPT code 0308T is a high-cost device-intensive surgical procedure that has a very low volume of claims (in part because most of the procedures described by CPT code 0308T are performed in ASCs), and we believe that the median cost is a more appropriate measure of the central tendency for purposes of calculating the cost and the payment rate for this procedure because the median cost is impacted to a lesser degree than the geometric mean cost by more extreme observations. We stated that, in future rulemaking, we would consider proposing a general policy for the payment rate calculation for very low-volume device-intensive APCs (80 FR 70389).

For CY 2017, we proposed and finalized a payment policy for low-volume device-intensive procedures that is similar to the policy applied to the procedure described by CPT code 0308T in CY 2016. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79660 through 79661), we established our current policy that the payment rate for any device-intensive procedure that is assigned to a clinical APC with fewer than 100 total claims for all procedures in the APC be calculated using the median cost instead of the geometric mean cost, for the reasons described above for the policy applied to the procedure described by CPT code 0308T in CY 2016. The CY 2018 final rule geometric mean cost for the procedure described by CPT code 0308T (based on 19 claims containing the device HCPCS C-code, in accordance with the device-intensive edit policy) was approximately $21,302, and the median cost was approximately $19,521. The final CY 2018 payment rate (calculated using the median cost) was approximately $17,560.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37111), for CY 2019, we proposed to continue with our current policy of establishing the payment rate for any device-intensive procedure that is assigned to a clinical APC with fewer than 100 total claims for all procedures in the APC based on calculations using the median cost instead of the geometric mean cost. We stated in the proposed rule that, due to the proposed change in APC assignment for CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) from APC 5495 (Level 5 Intraocular Procedures), our payment policy for low-volume device-intensive procedures would not apply to CPT code 0308T for CY 2019 because there are now more than 100 total claims for the APC to which CPT code 0308T would be assigned. For more information on the proposed and final APC assignment change for CPT code 0308T, we refer readers to section III.D.13. of this final rule with comment period.

Based on the CY 2017 claims data available for ratesetting, in the CY 2019 OPPS/ASC proposed rule, we proposed to assign CPT code 0308T to APC 5493, noting that we would continue to monitor the data. In the CY 2019 OPPS final rule claims data, we found that the estimated cost of the single claim with CPT code 0308T as the primary service is $12,939.75. To recognize the estimated cost based on the final rule claims data, we have assigned CPT code 0308T to APC 5494 (Level 4 Intraocular Procedures) for CY 2019 instead of APC 5493. Due to the assignment of CPT code 0308T to APC 5494 for CY 2019, our payment policy for low-volume device-intensive procedures will apply to CPT code 0308T for CY 2019 because there are less than 100 total claims for the APC to which CPT code 0308T is assigned. For more information on the proposed and final APC assignment change for CPT code 0308T, including a summary of public comments and our responses, we refer readers to section III.D.13. of this final rule with comment period.

V. OPPS Payment Changes for Drugs, Biologicals, and Radiopharmaceuticals

A. OPPS Transitional Pass-Through Payment for Additional Costs of Drugs, Biologicals, and Radiopharmaceuticals

1. Background

Section 1833(t)(6) of the Act provides for temporary additional payments or “transitional pass-through payments” for certain drugs and biologicals. Throughout this final rule with comment period, the term “biological” is used because this is the term that appears in section 1861(t) of the Act. A “biological” as used in this final rule with comment period includes (but is not necessarily limited to) a “biological product” or a “biologic” as defined in the Public Health Service Act. As enacted by the Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999 (BBRA) (Pub. L. 106–113), this pass-through payment provision requires the Secretary to make additional payments to hospitals for: Current orphan drugs, as designated under section 526 of the Federal Food, Drug, and Cosmetic Act; current drugs
and biologicals and brachytherapy sources used in cancer therapy; and current radiopharmaceutical drugs and biologicals. “Current” refers to those types of drugs or biologicals mentioned above that are hospital outpatient services under Medicare Part B for which transitional pass-through payment was made on the first date the hospital OPPS was implemented.

Transitional pass-through payments also are provided for certain “new” drugs and biologicals that were not being paid for as an HOPD service as of December 31, 1996 and whose cost is “not insignificant” in relation to the OPPS payments for the procedures or services associated with the new drug or biological. For pass-through payment purposes, radiopharmaceuticals are included as “drugs.” As required by statute, transitional pass-through payments for a drug or biological described in section 1833(t)(6)(C)(i)(III) of the Act can be made for a period of at least 2 years, but not more than 3 years, after the payment was first made for the product as a hospital outpatient service under Medicare Part B. CY 2019 pass-through drugs and biologicals and their designated APCs are assigned status indicator “G” in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website).

Section 1833(t)(6)(D)(i) of the Act specifies that the pass-through payment amount, in the case of a drug or biological, is the amount by which the amount determined under section 1842(o) of the Act minus the portion of the APC associated with the drug or biological exceeds the portion of the otherwise applicable Medicare OPD fee schedule that the Secretary determines is associated with the drug or biological. The methodology for determining the pass-through payment amount is set forth in regulations at 42 CFR 419.64. These regulations specify that the pass-through payment equals the amount determined under section 1842(o) of the Act minus the portion of the APC payment that CMS determines is associated with the drug or biological.

Section 1847A of the Act establishes the average sales price (ASP) methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the wholesale acquisition cost (WAC), and the average wholesale price (AWP). In this final rule with comment period (83 FR 79662), we described the ASP methodology and “ASP-based” are inclusive of all data sources and methodologies described therein. Additional information on the ASP methodology can be found on the CMS website at: http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Part-B-Drugs/MedicareFee-for-ServicePart-B-Drugs-McPartBDrugAvgSalesPrice/index.html.

The pass-through application and review process for drugs and biologicals is described on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/passthrough_payment.html.

2. Three-Year Transitional Pass-Through Payment Period for All Pass-Through Drugs, Biologicals, and Radiopharmaceuticals and QuarterlyExpiration of Pass-Through Status

As required by statute, transitional pass-through payments for a drug or biological described in section 1833(t)(6)(C)(i)(III) of the Act can be made for a period of at least 2 years, but not more than 3 years, after the payment was first made for the product as a hospital outpatient service under Medicare Part B. Our current policy is to accept pass-through applications on a quarterly basis and to begin pass-through payments for newly approved pass-through drugs and biologicals on a quarterly basis through the next available OPPS quarterly update after the approval of a product’s pass-through status. However, prior to CY 2017, we expired pass-through status for drugs and biologicals on an annual basis through notice-and-comment rulemaking (74 FR 60480). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79662), we finalized a policy change, beginning with pass-through drugs and biologicals newly approved in CY 2017 and subsequent calendar years, to allow for a quarterly expiration of pass-through payment status for drugs, biologicals, and radiopharmaceuticals to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through drugs, biologicals, and radiopharmaceuticals.

This change eliminated the variability of the pass-through payment eligibility period, which previously varied based on when a particular application was initially received. We adopted this change for pass-through approvals beginning on or after CY 2017, to allow, on a prospective basis, for the maximum pass-through payment period for each pass-through drug without exceeding the statutory limit of 3 years.

3. Drugs and Biologicals With Expiring Pass-Through Payment Status in CY 2018

In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed that the pass-through payment status of 23 drugs and biologicals would expire on December 31, 2018, as listed in Table 19 of the proposed rule (83 FR 37112). All of these drugs and biologicals will have received OPPS pass-through payment for at least 2 years and no more than 3 years by December 31, 2018. These drugs and biologicals were approved for pass-through payment status on or before January 1, 2017. In accordance with the policy finalized in CY 2017 and described earlier, pass-through payment status for drugs and biologicals newly approved in CY 2017 and subsequent years will expire on a quarterly basis, with a pass-through payment period as close to 3 years as possible. With the exception of those groups of drugs and biologicals that are always packaged when they do not have pass-through payment status (specifically, anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure (including diagnostic radiopharmaceuticals, contrast agents, and stress agents); and drugs and biologicals that function as supplies when used in a surgical procedure), our standard methodology for providing payment for drugs and biologicals with expiring pass-through payment status in an upcoming calendar year is to determine the product’s estimated per day cost and compare it with the OPPS drug packaging threshold for that calendar year (which is $125 for CY 2019), as discussed further in section V.B.2. of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed that if the estimated per day cost for the drug or biological is less than or equal to the applicable OPPS drug packaging threshold, we would package payment for the drug or biological into the payment for the associated procedure in the upcoming calendar year. If the estimated per day cost of the drug or biological is greater than the OPPS drug packaging threshold, we proposed to provide separate payment at the applicable relative ASP-based payment amount (which was proposed at ASP+6 percent for CY 2019, and is finalized at ASP+6 percent for CY 2019, as discussed further in section V.B.3. of this final rule with comment period).

Comment: A number of commenters requested that pass-through payment status for HCPCS code A9515 (Choline...
c-11, diagnostic, per study dose up to 20 millicuries) be extended until March 2019 to give 3 full years of pass-through payment status for the drug. The drug described by HCPCS code A9515 received pass-through status in April 2016, and in the CY 2019 OPPS/ASC proposed rule, the pass-through payment period for the drug was scheduled to end on December 31, 2018, consistent with the policy in effect in CY 2016 that drugs and biologicals receive at least 2 years but no more than 3 years of pass-through payment status where pass-through payment status for drugs and biologicals was expired on an annual basis through notice-and-comment rulemaking. One commenter requested an extension of pass-through payment status to allow for the collection of more cost data for HCPCS code A9515. Another commenter believed pass-through payment status for HCPCS code A9515 should be extended because of concern that the cost of HCPCS code A9515 exceeds the payment rate for the nuclear medicine services with which HCPCS code A9515 will be packaged. The commenter cited data showing the passing-through payment rate for HCPCS code A9515 was $5,700, while the highest APC payment rate for a nuclear medicine service was $1,377.22 with a drug offset of $248.31. Two commenters also requested that HCPCS codes Q9982 (Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries) and Q9983 (Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries) not be taken off of pass-through payment status due to similar concerns.

Response: As noted in the proposed rule, all three radiopharmaceuticals are covered under the pass-through payment expiration policy in effect in CY 2016 which stated that drugs and biologicals receive at least 2 years and no more than 3 years of pass-through payment status, with the pass-through payment period expiring at the end of a calendar year. Beginning with pass-through drugs and biologicals newly approved in CY 2017 and subsequent calendar years, a new policy is in effect to allow for a quarterly expiration of pass-through payment status for drugs and biologicals to afford a pass-through payment period that is as close to a full 3 years as possible for all pass-through drugs, biologicals, and radiopharmaceuticals (82 FR 59337). HCPCS codes A9515, Q9982, and Q9983 are covered by the policy in effect for CY 2016, and pass-through payment status for these HCPCS codes will end on December 31, 2018. We note that when a radiopharmaceutical or other drug or biological is newly packaged into a related medical procedure, the amount of the payment rate for the related medical procedure does not stay the same. Instead, the payment rate for the medical procedure will be adjusted to reflect the additional cost of the newly packaged radiopharmaceutical in the overall cost of the medical procedure.

Comment: Some commenters recommended that CMS allow products covered by Medicare in the context of a coverage with evidence development (CED) clinical trial to retain their pass-through payment status for the duration of the CED trial. Two of the commenters focused on the packaging of diagnostic radiopharmaceuticals that do not have pass-through payment status. One of the commenters requested that pass-through payment status for Neuraceq™ (Florbetaben F18, HCPCS code Q9982) and Vizamyl™ (Flutemetamol F18, HCPCS code Q9983), which is scheduled to end on December 31, 2018, be extended because of a current CED trial for amyloid positron emission tomography (PET) that will be active through at least CY 2019. (Information on this CED trial can be found on the CMS website at https://www.cms.gov/Medicare/Coverage/Coverage-with-Evidence-Development/Amyloid-PET.html). This commenter also suggested that if pass-through payment status is not extended, these drugs could be paid separately under their own assigned APCs to avoid having the cost of these drugs packaged into the primary procedures for which they are used. Another commenter was more broadly concerned about not receiving payment for a drug or biological when a CED trial is ongoing and a drug or biological used in the trial loses pass-through payment status and becomes packaged. The commenters were concerned that ending pass-through payment for drugs that will no longer be paid separately could negatively impact CED trials as hospitals would be less likely to participate because of the risk of receiving lower payment for the services covered by the CED trial.

Response: We disagree with the commenters’ concern that expiration of pass-through payment status for Neuraceq™ (HCPCS code Q9982) and Vizamyl™ (HCPCS code Q9983) and subsequent packaging of them as “policy-packaged” drugs, will affect trial results. We note that hospitals are not precluded from billing for Neuraceq™ and Vizamyl™ in the context of a CED trial once their pass-through payment status expires. We also note that the payment for both Neuraceq™ and Vizamyl™ will be reflected in the payment rate for the associated procedure. With respect to the request that we create a new APC for Neuraceq™ and Vizamyl™, we do not believe it is appropriate, prudent, or practicable to create unique APCs for specific drugs or biologicals or other individual items that are furnished with a particular procedure or procedures. Finally, with respect to the commenters’ request that we allow drug or biological pass-through payment status for products covered by a CED trial for the duration of the CED trial, we reiterate that the statute limits the period of pass-through payment eligibility to no more than 3 years after the product’s first payment as a hospital outpatient service under Medicare Part B. As such, we are unable to extend pass-through payment status beyond 3 years.

After consideration of the public comments we received, we are finalizing our proposal, without modification, to expire the pass-through payment status of the 23 drugs and biologicals listed in Table 37 below on December 31, 2018.

BILLING CODE 4120-01-P
The final packaged or separately payable status of each of these drugs or biologicals is listed in Addendum B to this final rule with comment period (which is available via the internet on the CMS website).

### TABLE 37.—DRUGS AND BIOLOGICALS FOR WHICH PASS-THROUGH PAYMENT STATUS EXPIRES DECEMBER 31, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A9515</td>
<td>Choline C 11, diagnostic, per study dose</td>
<td>N</td>
<td>N/A</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>C9460</td>
<td>Injection, cangrelor, 1 mg</td>
<td>K</td>
<td>9460</td>
<td>01/01/2016</td>
</tr>
<tr>
<td>C9482</td>
<td>Injection, sotalol hydrochloride, 1 mg</td>
<td>K</td>
<td>9482</td>
<td>10/01/2016</td>
</tr>
<tr>
<td>J1942</td>
<td>Injection, aripiprazole lauroxil, 1 mg</td>
<td>K</td>
<td>9470</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J2182</td>
<td>Injection, mepolizumab, 1 mg</td>
<td>K</td>
<td>9473</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J2786</td>
<td>Injection, reslizumab, 1 mg</td>
<td>K</td>
<td>9481</td>
<td>10/01/2016</td>
</tr>
<tr>
<td>J2840</td>
<td>Injection, sebelipase alfa, 1 mg</td>
<td>K</td>
<td>9478</td>
<td>07/01/2016</td>
</tr>
<tr>
<td>J7202</td>
<td>Injection, Factor IX, albumin fusion protein (recombinant), Idelvion, 1 i.u.</td>
<td>K</td>
<td>9171</td>
<td>10/01/2016</td>
</tr>
<tr>
<td>J7207</td>
<td>Injection, Factor VIII (antihemophilic factor, recombinant) PEGylated, 1 I.U.</td>
<td>K</td>
<td>1844</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J7209</td>
<td>Injection, Factor VIII (antihemophilic factor, recombinant) (Nuwiq), per i.u.</td>
<td>K</td>
<td>1846</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J7322</td>
<td>Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg</td>
<td>K</td>
<td>9471</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J7342</td>
<td>Instillation, ciprofloxacin otic suspension, 6 mg</td>
<td>K</td>
<td>9479</td>
<td>07/01/2016</td>
</tr>
<tr>
<td>J7503</td>
<td>Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg</td>
<td>K</td>
<td>1845</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J9022</td>
<td>Injection, atezolizumab, 10 mg</td>
<td>K</td>
<td>9483</td>
<td>10/01/2016</td>
</tr>
<tr>
<td>J9145</td>
<td>Injection, daratumumab, 10 mg</td>
<td>K</td>
<td>9476</td>
<td>07/01/2016</td>
</tr>
<tr>
<td>J9176</td>
<td>Injection, elotuzumab, 1 mg</td>
<td>K</td>
<td>9477</td>
<td>07/01/2016</td>
</tr>
<tr>
<td>J9205</td>
<td>Injection, irinotecan liposome, 1 mg</td>
<td>K</td>
<td>9474</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J9295</td>
<td>Injection, neucitumumab, 1 mg</td>
<td>K</td>
<td>9475</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J9325</td>
<td>Injection, talimogene laherparepvec, 1 million plaque forming units (PFU)</td>
<td>K</td>
<td>9472</td>
<td>04/01/2016</td>
</tr>
<tr>
<td>J9352</td>
<td>Injection, trabectedin, 0.1 mg</td>
<td>K</td>
<td>9480</td>
<td>07/01/2016</td>
</tr>
<tr>
<td>Q5101</td>
<td>Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram</td>
<td>K</td>
<td>1822</td>
<td>07/01/2015</td>
</tr>
<tr>
<td>Q9982</td>
<td>Flutemetamol F18, diagnostic, per study dose, up to 5 millicuries</td>
<td>N</td>
<td>N/A</td>
<td>01/01/2016</td>
</tr>
<tr>
<td>Q9983</td>
<td>Florbetaben F18, diagnostic, per study dose, up to 8.1 millicuries</td>
<td>N</td>
<td>N/A</td>
<td>01/01/2016</td>
</tr>
</tbody>
</table>

4. Drugs, Biologicals, and Radiopharmaceuticals With New or Continuing Pass-Through Payment Status in CY 2019

In the CY 2019 OPPS/ASC proposed rule (83 FR 37112), we proposed to continue pass-through payment status in CY 2019 for 45 drugs and biologicals. These drugs and biologicals, which were approved for pass-through payment status between January 1, 2017, and July 1, 2018, were listed in Table 20 of the proposed rule (83 FR 37113 through 37114). The APCs and HCPCS codes for these drugs and biologicals approved for pass-through...
payment status through December 31, 2018 were assigned status indicator “G” in Addenda A and B to the proposed rule (which are available via the internet on the CMS website). In addition, as indicated in the proposed rule, there are four drugs and biologicals that have already had 3 years of pass-through payment status but for which pass-through payment status is required to be extended for an additional 2 years under section 1833(f)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141). Because of this requirement, these drugs and biologicals were also included in Table 20 of the proposed rule, which brought the total number of drugs and biologicals with proposed pass-through payment status in CY 2019 to 49. The requirements of section 1301 of Public Law 115–141 are described in further detail in section V.A.5. of this final rule with comment period, and we address public comments that we received related to this topic in that section.

Section 1833(f)(6)(D)(i) of the Act sets the amount of pass-through payment for pass-through drugs and biologicals (the pass-through payment amount) as the difference between the amount authorized under section 1842(o) of the Act and the portion of the otherwise applicable OPD fee schedule that the Secretary determines is associated with the drug or biological. For CY 2019, we proposed to continue to pay for pass-through drugs and biologicals at ASP+6 percent, equivalent to the payment rate these drugs and biologicals would receive in the physician’s office setting in CY 2019. We proposed that a $0 pass-through payment amount would be paid for pass-through drugs and biologicals under the CY 2019 OPPS because the difference between the amount authorized under section 1842(o) of the Act, which was proposed at ASP+6 percent, and the portion of the otherwise applicable OPD fee schedule that the Secretary determines is appropriate, which was proposed at ASP+6 percent, is $0.

In the case of policy-packaged drugs (which include the following: Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure (including contrast agents, diagnostic radiopharmaceuticals, and stress agents); and drugs and biologicals that function as supplies when used in a surgical procedure), we proposed that their pass-through payment amount would be equal to ASP+6 percent for CY 2019 minus a payment offset for any predecessor drug products contributing to the pass-through payment as described in section V.A.6. of the proposed rule. We made this proposal because, if not for the pass-through payment status of these policy-packaged products, payment for these products would be packaged into the associated procedure.

We proposed to continue to update pass-through payment rates on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through payment drugs or biologicals are necessary. For a full description of this policy, we refer readers to the CY 2006 OPPS/ASC final rule with comment period (70 FR 68632 through 68635).

For CY 2019, consistent with our CY 2018 policy for diagnostic and therapeutic radiopharmaceuticals, we proposed to provide payment for both diagnostic and therapeutic radiopharmaceuticals that are granted pass-through payment status based on the ASP methodology. As stated earlier, for purposes of pass-through payment, we consider radiopharmaceuticals to be drugs under the OPPS. Therefore, if a diagnostic or therapeutic radiopharmaceutical receives pass-through payment status during CY 2019, we proposed to follow the standard ASP methodology to determine the pass-through payment rate that drugs receive under section 1842(o) of the Act, which was proposed at ASP+6 percent. If ASP data are not available for a radiopharmaceutical, we proposed to provide pass-through payment at WAC+3 percent (consistent with our proposed policy in section V.B.2.b. of the proposed rule), the equivalent payment provided to pass-through payment drugs and biologicals without ASP information. Additional detail and comments on the WAC+3 percent payment policy can be found in section V.B.2.b. of this final rule. If WAC information also is not available, we proposed to provide payment for the pass-through radiopharmaceutical at 95 percent of its most recent AWP.

We did not receive any public comments regarding our proposals. Therefore, we are implementing these proposals for CY 2019 without modification. We note that public comments pertaining to our proposal to pay WAC+3 percent for drugs and biologicals without ASP information as well as public comments on section 1301 pass-through payment status extensions are addressed elsewhere in this final rule with comment period.

The drugs and biologicals that continue to have pass-through payment status for CY 2019 or have been granted pass-through payment status as of January 2019 are shown in Table 38 below.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A9586</td>
<td>A9586</td>
<td>Florbetapir f18, diagnostic, per study dose, up to 10 millicuries</td>
<td>G</td>
<td>9084</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>A9587</td>
<td>A9587</td>
<td>Gallium ga-68, dotatate, diagnostic, 0.1 millicurie</td>
<td>G</td>
<td>9056</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>A9588</td>
<td>A9588</td>
<td>Fluciclovine f-18, diagnostic, 1 millicurie</td>
<td>G</td>
<td>9052</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>C9014</td>
<td>J0567</td>
<td>Injection, cerliponase alfa, 1 mg</td>
<td>G</td>
<td>9014</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9015</td>
<td>J0599</td>
<td>Injection, c-1 esterase inhibitor (human), (haegarda), 10 units</td>
<td>G</td>
<td>9015</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9016</td>
<td>J3316</td>
<td>Injection, triptorelin, extended-release, 3.75 mg</td>
<td>G</td>
<td>9016</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9024</td>
<td>J9153</td>
<td>Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine</td>
<td>G</td>
<td>9302</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9028</td>
<td>J9229</td>
<td>Injection, inotuzumab ozogamicin, 0.1 mg</td>
<td>G</td>
<td>9028</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9029</td>
<td>J1628</td>
<td>Injection, guselkumab, 1 mg</td>
<td>G</td>
<td>9029</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>C9030</td>
<td>J9057</td>
<td>Injection, copanlisib, 1 mg</td>
<td>G</td>
<td>9030</td>
<td>07/01/2018</td>
</tr>
<tr>
<td>C9031</td>
<td>A9513</td>
<td>Lutetium Lu 177, dotatate, therapeutic, 1 millicurie</td>
<td>G</td>
<td>9067</td>
<td>07/01/2018</td>
</tr>
<tr>
<td>C9032</td>
<td>J3398</td>
<td>Injection, voretigene neparvovec-rzyl, 1 billion vector genomes</td>
<td>G</td>
<td>9070</td>
<td>07/01/2018</td>
</tr>
<tr>
<td>C9033</td>
<td>J1454</td>
<td>Injection, fosnetupitant 235 mg and palonosetron 0.25 mg</td>
<td>G</td>
<td>9099</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>C9034</td>
<td>C9034</td>
<td>Injection, dexamethasone 9%, intraocular, 1 mcg</td>
<td>G</td>
<td>9172</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------</td>
<td>--------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>C9447</td>
<td>C9447</td>
<td>Injection, phenylephrine and ketorolac, 4 ml vial</td>
<td>G</td>
<td>9083</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>C9462</td>
<td>C9462</td>
<td>Injection, delafloxacin, 1 mg</td>
<td>G</td>
<td>9462</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9463</td>
<td>J0185</td>
<td>Injection, aprepitant, 1 mg</td>
<td>G</td>
<td>9463</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9464</td>
<td>J2797</td>
<td>Injection, rolapitant, 0.5 mg</td>
<td>G</td>
<td>9464</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9465</td>
<td>J7318</td>
<td>Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg</td>
<td>G</td>
<td>9174</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9466</td>
<td>J0517</td>
<td>Injection, benralizumab, 1 mg</td>
<td>G</td>
<td>9466</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9467</td>
<td>J9311</td>
<td>Injection, rituximab 10 mg and hyaluronidase</td>
<td>G</td>
<td>9467</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9468</td>
<td>J7203</td>
<td>Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu</td>
<td>G</td>
<td>9468</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>C9488</td>
<td>C9488</td>
<td>Injection, conivaptan hydrochloride, 1 mg</td>
<td>G</td>
<td>9488</td>
<td>04/01/2017</td>
</tr>
<tr>
<td>C9492</td>
<td>J9173</td>
<td>Injection, durvalumab, 10 mg</td>
<td>G</td>
<td>9492</td>
<td>10/01/2017</td>
</tr>
<tr>
<td>C9493</td>
<td>J1301</td>
<td>Injection, edaravone, 1 mg</td>
<td>G</td>
<td>9493</td>
<td>10/01/2017</td>
</tr>
<tr>
<td>J0565</td>
<td>J0565</td>
<td>Injection, bezlotoxumab, 10 mg</td>
<td>G</td>
<td>9490</td>
<td>07/01/2017</td>
</tr>
<tr>
<td>J0570</td>
<td>J0570</td>
<td>Buprenorphine implant, 74.2 mg</td>
<td>G</td>
<td>9058</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>J1428</td>
<td>J1428</td>
<td>Injection, eteplirsen, 10 mg</td>
<td>G</td>
<td>9484</td>
<td>04/01/2017</td>
</tr>
<tr>
<td>J1627</td>
<td>J1627</td>
<td>Injection, granisetron extended release, 0.1 mg</td>
<td>G</td>
<td>9486</td>
<td>04/01/2017</td>
</tr>
<tr>
<td>J2326</td>
<td>J2326</td>
<td>Injection, nusinersen, 0.1 mg</td>
<td>G</td>
<td>9489</td>
<td>07/01/2017</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------------</td>
<td>-------------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>J2350</td>
<td>J2350</td>
<td>Injection, ocrelizumab, 1 mg</td>
<td>G</td>
<td>9494</td>
<td>10/01/2017</td>
</tr>
<tr>
<td>J3358</td>
<td>J3358</td>
<td>Ustekinumab, for Intravenous Injection, 1 mg</td>
<td>G</td>
<td>9487</td>
<td>04/01/2017</td>
</tr>
<tr>
<td>J7179</td>
<td>J7179</td>
<td>Injection, von willebrand factor (recombinant), (Vonvendi), 1 i.u. vwf:rcf</td>
<td>G</td>
<td>9059</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>J7210</td>
<td>J7210</td>
<td>Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u.</td>
<td>G</td>
<td>9043</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>J7328</td>
<td>J7328</td>
<td>Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg</td>
<td>G</td>
<td>1862</td>
<td>01/01/2016</td>
</tr>
<tr>
<td>J7345</td>
<td>J7345</td>
<td>Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg</td>
<td>G</td>
<td>9301</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>J9023</td>
<td>J9023</td>
<td>Injection, avelumab, 10 mg</td>
<td>G</td>
<td>9491</td>
<td>10/01/2017</td>
</tr>
<tr>
<td>J9034</td>
<td>J9034</td>
<td>Injection, bendamustine hcl (Bendeka), 1 mg</td>
<td>G</td>
<td>1861</td>
<td>01/01/2017</td>
</tr>
<tr>
<td>J9203</td>
<td>J9203</td>
<td>Injection, gemtuzumab ozogamicin, 0.1 mg</td>
<td>G</td>
<td>9495</td>
<td>01/01/2018</td>
</tr>
<tr>
<td>J9285</td>
<td>J9285</td>
<td>Injection, olaratumab, 10 mg</td>
<td>G</td>
<td>9485</td>
<td>04/01/2017</td>
</tr>
<tr>
<td>Q2041</td>
<td>Q2041</td>
<td>Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose</td>
<td>G</td>
<td>9035</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------</td>
<td>-------------------------</td>
<td>--------------------------</td>
<td>-------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>N/A</td>
<td>Q2042*</td>
<td>Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose</td>
<td>G</td>
<td>9194</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>Q4172</td>
<td>Q4195</td>
<td>Puraply, per square centimeter</td>
<td>G</td>
<td>9175</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q4172</td>
<td>Q4196</td>
<td>Puraply am, per square centimeter</td>
<td>G</td>
<td>9176</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q5103</td>
<td>Q5103</td>
<td>Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg</td>
<td>G</td>
<td>1847</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>Q5104</td>
<td>Q5104</td>
<td>Injection, infliximab-abda, biosimilar, (renflexis), 10 mg</td>
<td>G</td>
<td>9036</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>Q5105</td>
<td>Q5105</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units</td>
<td>G</td>
<td>9096</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q5106</td>
<td>Q5106</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units</td>
<td>G</td>
<td>9097</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q9950</td>
<td>Q9950</td>
<td>Injection, sulfur hexafluoride lipid microsphere, per ml</td>
<td>G</td>
<td>9085</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q9991</td>
<td>Q9991</td>
<td>Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg</td>
<td>G</td>
<td>9073</td>
<td>07/01/2018</td>
</tr>
<tr>
<td>Q9992</td>
<td>Q9992</td>
<td>Injection, buprenorphine extended-release (Sublocade), greater than 100 mg</td>
<td>G</td>
<td>9239</td>
<td>07/01/2018</td>
</tr>
</tbody>
</table>
### 5. Drugs, Biologicals, and Radiopharmaceuticals With Pass-Through Status as a Result of Section 1301 of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141)

As mentioned earlier, section 1301(a)(1) of the Consolidated Appropriations Act of 2018 (Pub. L. 115–141) amended section 1833(t)(6) of the Act and added a new section 1833(t)(6)(G), which provides that for drugs or biologicals whose period of pass-through payment status ended on December 31, 2017 and for which payment was packaged into a covered hospital outpatient service furnished beginning January 1, 2018, such pass-through payment status shall be extended for a 2-year period beginning on October 1, 2018 through September 30, 2020. There are four products whose period of drug and biological pass-through payment status ended on December 31, 2017. These products were listed in Table 21 of the CY 2019 OPPS/ASC proposed rule (83 FR 37115).

For CY 2019, we proposed to continue pass-through payment status for the drugs and biologicals listed in Table 21 of the proposed rule (we note that these drugs and biologicals were also listed in Table 20 of the proposed rule). The APCs and HCPCS codes for these drugs and biologicals approved for pass-through payment were assigned status indicator “G” in Addenda A and B to the proposed rule (which are available via the internet on the CMS website).

In addition, new section 1833(t)(6)(H) of the Act specifies that the payment amount for such drug or biological under this subsection that is furnished during the period beginning on October 1, 2018, and ending on March 31, 2019, shall be the greater of: (i) The payment amount that would otherwise apply under section 1833(t)(6)(D)(i) of the Act for such drug or biological during such period; or (ii) the payment amount that applied under section 1833(t)(6)(D)(i) of the Act for such drug or biological on December 31, 2017. We stated in the proposed rule that we intended to address pass-through payment for these drugs and biologicals for the last quarter of CY 2018 through program instruction. The program instruction covering pass-through payment for these drugs and biologicals for the last quarter of CY 2018 is Transmittal 4123 titled “October 2018 Update of the Hospital Outpatient Prospective Payment System (OPPS)”, and can be found on the CMS website at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/

### Table: Drugs, Biologicals, and Radiopharmaceuticals With Pass-Through Status

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Q9993</td>
<td>J3304</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
<td>G</td>
<td>9469</td>
<td>04/01/2018</td>
</tr>
<tr>
<td>Q9995</td>
<td>J7170</td>
<td>Injection, emicizumab-kxwh, 0.5 mg</td>
<td>G</td>
<td>9257</td>
<td>07/01/2018</td>
</tr>
<tr>
<td>N/A</td>
<td>C9035</td>
<td>Injection, aripiprazole lauroxil, 1 mg</td>
<td>G</td>
<td>9179</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9036</td>
<td>Injection, patisiran, 0.1 mg</td>
<td>G</td>
<td>9180</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9037</td>
<td>Injection, risperidone (Perseris), 0.5 mg</td>
<td>G</td>
<td>9181</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9038</td>
<td>Injection, mogamulizumab-kpke, 1 mg</td>
<td>G</td>
<td>9182</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9039</td>
<td>Injection, plazomicin, 5 mg</td>
<td>G</td>
<td>9183</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9407</td>
<td>Iodine i-131 iobenguane, diagnostic, 1 millicurie</td>
<td>G</td>
<td>9184</td>
<td>01/01/2019</td>
</tr>
<tr>
<td>N/A</td>
<td>C9408</td>
<td>Iodine i-131 iobenguane, therapeutic, 1 millicurie</td>
<td>G</td>
<td>9185</td>
<td>01/01/2019</td>
</tr>
</tbody>
</table>

* HCPCS code Q2040 (Tisagenlecleucel, up to 250 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion) will be deleted on December 31, 2018 and will be replaced by Q2042 (Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose) on January 1, 2019.
pass-through payment under our proposal for CY 2019.

Comment: Several commenters were opposed to PuraPly and PuraPly AM receiving pass-through payment status for CY 2019. These commenters stated that because PuraPly and PuraPly AM received a 510(k) clearance from the FDA, PuraPly and PuraPly AM should be considered devices rather than drugs or biologicals or that there is at least some ambiguity about whether PuraPly and PuraPly AM are devices. The commenters encouraged CMS to use its discretion and consider PuraPly and PuraPly AM to be devices along the same lines of reasoning as CMS has considered biologicals used as skin substitutes to be considered devices for the purposes of receiving pass-through payment since April 2015. In addition, the commenters noted that PuraPly and PuraPly AM should not have pass-through payment status extended because they are no longer new products. Further, the commenters noted that these products would receive a significant market advantage by being the only graft skin substitute product to receive separate payment. Other commenters noted that extending the pass-through payment status of PuraPly and PuraPly AM would work against the goals CMS has stated in other parts of the proposed rule regarding skin substitute payment. Finally, these commenters maintained that extending pass-through payment status would encourage the use of more high-cost skin substitute products and lead to increased market advantage by increasing the cost thresholds for the high-cost skin substitute group. Another commenter opposed extending pass-through payment status for PuraPly and PuraPly AM based on the belief that the manufacturer of these products may be unfairly increasing the prices for these products when they return to pass-through payment status.

Response: In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66887) that skin substitutes that are approved for pass-through payment status as biologicals effective on or before January 1, 2015 would continue to be paid as pass-through biologicals for the duration of their pass-through payment period. Because PuraPly was approved for pass-through payment status through the drug and biological pass-through payment pathway, we proposed to consider PuraPly to be a drug or biological as described by section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018, and to be eligible for extended pass-through payment under our proposal for CY 2019.

2018Downloads/R4123CP.pdf. For January 1, 2019 through March 31, 2019, we proposed that pass-through payment for these four drugs and biologicals would be the greater of: (1) ASP+6 percent based on current ASP data; or (2) the payment rate for the drug or biological on December 31, 2017. We also proposed for the period of April 1, 2019 through December 31, 2019 that the pass-through payment amount for these drugs and biologicals would be the amount that applies under section 1833(t)(6)(D)(i) of the Act.

We proposed to continue to update pass-through payment rates for these four drugs and biologicals on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through drugs or biologicals are necessary. For a full description of this policy, we refer readers to the CY 2006 OPPS/ASC final rule with comment period (70 FR 68632 through 68635).

The four drugs and biologicals that we proposed would have pass-through payment status for CY 2019 are: (1) Mepilex; (2) Allevyn; (3) PuraPly; and (4) PuraPly AM. Mepilex and Allevyn are drugs (HCPCS code Q4170) that are approved for pass-through payment status in CY 2019 (79 FR 66887); PuraPly and PuraPly AM are biological pass-through substitutes that are approved for pass-through payment status. PuraPly and PuraPly AM were approved for pass-through payment status by CMS on January 1, 2015 under the drug and biological pass-through payment pathway as biologicals. While we acknowledge the comments pointing out that we currently treat skin substitute products as devices for purposes of pass-through payment status, this does not change the fact that PuraPly and PuraPly AM were originally approved for pass-through payments as biologicals. We believe that PuraPly and PuraPly AM’s original approval for pass-through status as biologicals means that they should continue to receive pass-through payments under section 1833(t)(6)(G) of the Act.

We also recognize that the commenters raised important concerns about the impact that extending pass-through payment status for PuraPly and PuraPly AM could have on the payment of wound care services using graft skin substitute products. However, we nonetheless believe that section 1833(t)(6)(G) of the Act requires us to extend the pass-through payment period for PuraPly and PuraPly AM.

Comment: One commenter, the manufacturer of PuraPly and PuraPly AM, urged CMS to implement the proposal to give PuraPly and PuraPly AM pass-through payment status based on the requirements of section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018. The commenter stated that PuraPly and PuraPly AM are biologicals and cited language in OPPS regulations supporting that designation. The commenter also made the point that the pass-through payment status granted to PuraPly and PuraPly AM starting on October 1, 2018 was described in the statute as an extension of the original pass-through payment status and not a new pass-through payment period. The commenter stated that this means the requirements in effect when pass-through payment status for PuraPly and PuraPly AM was established on January 1, 2015 apply to the extended pass-through payment period. The commenter noted that CMS changed how skin substitute products are evaluated for pass-through payment status by evaluating skin substitutes through the medical device pass-through pathway in April of 2015, but emphasized that the change was not retroactive. Therefore, the commenter agreed that PuraPly and PuraPly AM should continue to receive pass-through payment status.

Several members of Congress supported extending pass-through payment status for PuraPly and PuraPly
AM and requested that CMS consider the products to be biologicals that are covered by section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018.

Response: We appreciate the commenters’ support. We are finalizing our proposal to extend pass-through payment status for PuraPly and PuraPly AM based on section 1833(t)(6)(G) of the Act, as added by section 1301(a)(1)(C) of the Consolidated Appropriations Act of 2018.

Comment: One commenter, the manufacturer of Omidria (HCPCS code C9447), supported the extended pass-through payment status for Omidria. Likewise, a second commenter, the manufacturer of Lumason® (HCPCS code Q9950), supported the extended pass-through payment status for Lumason®.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposals, with modification, to accommodate a coding change related to the PuraPly products. Specifically, after the proposed rule was published, we became aware that HCPCS code Q4172 (Puraply, and Puraply AM per square centimeter) will be deleted effective January 1, 2019, and will be replaced by three new HCPCS codes: Q4195 (Puraply, per square centimeter); Q4196 (Puraply am, per square centimeter); and Q4197 (Puraply xt, per square centimeter), effective January 1, 2019. Two of these products, PuraPly (HCPCS code Q4195) and PuraPly AM (HCPCS code Q4196), were products that received original pass-through payment status on January 1, 2015, and will continue to receive pass-through payment status in CY 2019 when our finalized policies are implemented.

For January 1, 2019 through March 31, 2019, we are finalizing our proposal that pass-through payment for the covered drugs and biologicals will be the greater of: (1) ASP+6 percent based on current ASP data; or (2) the payment rate for the drug or biological on December 31, 2017. We also are finalizing our proposal that the pass-through payment amount for these drugs and biologicals will be the amount that applies under section 1833(t)(6)(D)(i) of the Act for the period of April 1, 2019 through December 31, 2019.

We are finalizing our proposal to continue to update pass-through payment rates for these covered drugs and biologicals on a quarterly basis on the CMS website during CY 2019 if later quarter ASP submissions (or more recent WAC or AWP information, as applicable) indicate that adjustments to the payment rates for these pass-through drugs or biologicals are necessary. We refer readers to Table 39 below for the drugs and biologicals covered by the requirements of this section.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A9586</td>
<td>A9586</td>
<td>Florbetapir f18, diagnostic, per study dose, up to 10 millicuries</td>
<td>G</td>
<td>9084</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>C9447</td>
<td>C9447</td>
<td>Injection, phenylephrine and ketorolac, 4 ml vial</td>
<td>G</td>
<td>9083</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q4172</td>
<td>Q4195</td>
<td>Puraply, per square centimeter</td>
<td>G</td>
<td>9175</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q4172</td>
<td>Q4196</td>
<td>Puraply AM, per square centimeter</td>
<td>G</td>
<td>9176</td>
<td>10/01/2018</td>
</tr>
<tr>
<td>Q9950</td>
<td>Q9950</td>
<td>Injection, sulfur hexafluoride lipid microsphere, per ml</td>
<td>G</td>
<td>9085</td>
<td>10/01/2018</td>
</tr>
</tbody>
</table>

6. Provisions for Reducing Transitional Pass-Through Payments for Policy-Packaged Drugs, Biologicals, and Radiopharmaceuticals To Offset Costs Packaged Into APC Groups

Under the regulations at 42 CFR 419.2(b), nonpass-through drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure are packaged in the OPPS. This category includes skin substitutes and other surgical-supply drugs and biologicals. As described earlier, section 1833(t)(6)(D)(i) of the Act specifies that the transitional pass-through payment amount for pass-through drugs and biologicals is the difference between the amount paid under section 1842(e) of the Act and the otherwise applicable OPD fee schedule amount. Because a payment offset is necessary in order to provide an appropriate transitional pass-through payment, we deduct from the pass-through payment for policy-packaged drugs, biologicals, and radiopharmaceuticals an amount reflecting the portion of the APC payment associated with predecessor products in order to ensure no duplicate payment is made. This amount reflecting the portion of the APC payment associated with predecessor products is called the payment offset.

The payment offset policy applies to all policy packaged drugs, biologicals, and radiopharmaceuticals. For a full
description of the payment offset policy as applied to diagnostic radiopharmaceuticals, contrast agents, stress agents, and skin substitutes, we refer readers to the discussion in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70430 through 70432). In the CY 2019 OPPS/ASC proposed rule (83 FR 37115), for CY 2019, as we did in CY 2018, we proposed to continue to apply the same policy packaged offset policy to payment for pass-through diagnostic radiopharmaceuticals, pass-through contrast agents, pass-through stress agents, and pass-through skin substitutes. The proposed APCs to which a payment offset may be applicable for pass-through diagnostic radiopharmaceuticals, pass-through contrast agents, pass-through stress agents, and pass-through skin substitutes were identified in Table 22 of the proposed rule (83 FR 37115).

We did not receive any comments on this proposal. Therefore, we are finalizing this proposal without modification.

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5591</td>
<td>Level 1 Nuclear Medicine and Related Services</td>
</tr>
<tr>
<td>5592</td>
<td>Level 2 Nuclear Medicine and Related Services</td>
</tr>
<tr>
<td>5593</td>
<td>Level 3 Nuclear Medicine and Related Services</td>
</tr>
<tr>
<td>5594</td>
<td>Level 4 Nuclear Medicine and Related Services</td>
</tr>
</tbody>
</table>

**Contrast Agent**

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5571</td>
<td>Level 1 Imaging with Contrast</td>
</tr>
<tr>
<td>5572</td>
<td>Level 2 Imaging with Contrast</td>
</tr>
<tr>
<td>5573</td>
<td>Level 3 Imaging with Contrast</td>
</tr>
</tbody>
</table>

**Stress Agent**

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5722</td>
<td>Level 2 Diagnostic Tests and Related Services</td>
</tr>
<tr>
<td>5593</td>
<td>Level 3 Nuclear Medicine and Related Services</td>
</tr>
</tbody>
</table>

**Skin Substitute**

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>CY 2019 APC Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>5054</td>
<td>Level 4 Skin Procedures</td>
</tr>
<tr>
<td>5055</td>
<td>Level 5 Skin Procedures</td>
</tr>
</tbody>
</table>

In the CY 2019 OPPS/ASC proposed rule, we proposed to continue to post annually on the CMS website at: [https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Annual-Policy-Files.html](https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Annual-Policy-Files.html) a file that contains the APC offset amounts that will be used for that year for purposes of both evaluating cost significance for candidate pass-through payment device categories and drugs and biologicals and establishing any appropriate APC offset amounts. Specifically, the file will continue to provide the amounts and percentages of APC payment associated with packaged implantable devices, policy-packaged drugs, and threshold packaged drugs and biologicals for every OPPS clinical APC. We did not receive any public comments on our proposal, and therefore are finalizing it without modification.

**B. OPPS Payment for Drugs, Biologicals, and Radiopharmaceuticals Without Pass-Through Payment Status**

1. Criteria for Packaging Payment for Drugs, Biologicals, and Radiopharmaceuticals

a. Packaging Threshold

In accordance with section 1833(t)(16)(B) of the Act, the threshold for establishing separate APCs for payment of drugs and biologicals was set to $50 per administration during CYs 2005 and 2006. In CY 2007, we used the four quarter moving average Producer Price Index (PPI) levels for Pharmaceutical Preparations (Prescription) to trend the $50 threshold forward from the third quarter of CY 2005 to the third quarter of CY 2019 and rounded the resulting dollar amount ($127.01) to the nearest $5 increment, which yielded a figure of $125. In performing this calculation, we used the most recent forecast of the quarterly index levels for the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from CMS’ Office of the Actuary. For this CY 2019 OPPS/ASC final rule with comment period, based on these calculations using the CY 2007 OPPS methodology, (which is discussed in more detail in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68085 through 68086)), we set the packaging threshold for establishing separate APCs for drugs and biologicals at $120 for CY 2018 (82 FR 59343).

Following the CY 2007 methodology, for this CY 2019 OPPS/ASC final rule with comment period, we used the most recently available four quarter moving average PPI levels to trend the $50 threshold forward from the third quarter of CY 2005 to the third quarter of CY 2019 and rounded the resulting dollar amount ($127.01) to the nearest $5 increment, which yielded a figure of $125. In performing this calculation, we used the most recent forecast of the quarterly index levels for the PPI for Pharmaceuticals for Human Use (Prescription) (Bureau of Labor Statistics series code WPUSI07003) from CMS’ Office of the Actuary. For this CY 2019 OPPS/ASC final rule with comment period, based on these calculations using the CY 2007 OPPS methodology,
we are finalizing a packaging threshold for CY 2019 of $125.

b. Packaging of Payment for HCPCS Codes That Describe Certain Drugs, Certain Biologicals, and Therapeutic Radiopharmaceuticals Under the Cost Threshold (“Threshold-Packaged Drugs”)

In the CY 2019 OPPS/ASC proposed rule (83 FR 37116), to determine the proposed CY 2019 packaging status for all nonpass-through drugs and biologicals that are not policy packaged, we calculated, on a HCPCS code-specific basis, the per day cost of all drugs, biologicals, and therapeutic radiopharmaceuticals (collectively called “threshold-packaged” drugs) that had a HCPCS code in CY 2017 and were paid (via packaged or separate payment) under the OPPS. We used data from CY 2017 claims processed before January 1, 2018 for this calculation. However, we did not perform this calculation for those drugs and biologicals with multiple HCPCS codes that included different dosages, as described in section V.B.1.d. of the proposed rule, or for the following policy-packaged items that we proposed to continue to package in CY 2019: Anesthesia drugs; drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure; and drugs and biologicals that function as supplies when used in a surgical procedure.

In order to calculate the per day costs for drugs, biologicals, and therapeutic radiopharmaceuticals to determine their proposed packaging status in CY 2019, we used the methodology that was described in detail in the CY 2006 OPPS proposed rule (70 FR 42723 through 42724) and finalized in the CY 2006 OPPS final rule with comment period (70 FR 68636 through 68638). For each drug and biological HCPCS code, we used an estimated payment rate of ASP+6 percent (which is the payment rate we proposed for separately payable drugs and biologicals for CY 2019, as discussed in more detail in section V.B.2.b. of the proposed rule) to calculate the CY 2019 proposed rule per day costs. We used the manufacturer-submitted ASP data from the fourth quarter of CY 2017 (data that were used for payment purposes in the physician’s office setting, effective April 1, 2018) to determine the proposed rule per day cost.

As is our standard methodology, for CY 2019, we proposed to use payment rates based on the ASP data from the first quarter of CY 2018 for budget neutrality packaging determinations, impact analyses, and completion of Addenda A and B to the proposed rule (which are available via the internet on the CMS website) because these were the most recent data available for use at the time of development of the proposed rule.

These data also were the basis for drug payments in the physician’s office setting, effective April 1, 2018. For items that did not have an ASP-based payment rate, such as some therapeutic radiopharmaceuticals, we used their mean unit cost derived from the CY 2017 hospital claims data to determine their per day cost.

We proposed to package items with a per day cost less than or equal to $125, and identify items with a per day cost greater than $125 as separately payable unless they are policy-packaged.

Consistent with our past practice, we cross-walked historical OPPS claims data from the CY 2017 HCPCS codes that were reported to the CY 2018 HCPCS codes that we displayed in Addendum B to the proposed rule (which is available via the internet on the CMS website) for proposed payment in CY 2019.

Comment: A few commenters requested that CMS not finalize the proposed increase in the packaging threshold to $125 and suggested that CMS instead lower the packaging threshold. These commenters expressed concern with the annual increases in the drug packaging threshold, citing that yearly increases have outpaced conversion factor updates and place a financial burden on providers.

Response: We have received and addressed similar comments in prior rules, including most recently in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79666). As we stated in the CY 2007 OPPS/ASC final rule with comment period (71 FR 68086), we believe that packaging certain items is a fundamental component of a prospective payment system, that updating the packaging threshold of $50 for the CY 2005 OPPS is consistent with industry and government practices, and that the PPI for Prescription Drugs is an appropriate mechanism to gauge Part B drug inflation. Therefore, because packaging is a fundamental component of a prospective payment system that continues to provide important flexibility and efficiency in the delivery of high quality hospital outpatient services, we are not adopting the commenters’ recommendation to delay updating the packaging threshold or freeze the packaging threshold at $120.

After consideration of the public comments and consistent with our methodology for establishing the packaging threshold using the most recent PPI forecast data, we are adopting a CY 2019 packaging threshold of $125.

Our policy during previous cycles of the OPPS has been to use updated ASP and claims data to make final determinations of the packaging status of HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals for the OPPS/ASC final rule with comment period. We note that it is also our policy to make an annual packaging determination for a HCPCS code only when we develop the OPPS/ASC final rule with comment period for the update year. Only HCPCS codes that are identified as separately payable in the final rule with comment period are subject to quarterly updates. For our calculation of per day costs of HCPCS codes for drugs and biologicals in this CY 2019 OPPS/ASC final rule with comment period, we used ASP data from the third quarter of CY 2018, which is the basis for calculating payment rates for drugs and biologicals in the physician’s office setting using the ASP methodology, effective July 1, 2018, along with updated hospital claims data from CY 2017. We note that we also used these data for budget neutrality estimates and impact analyses for this CY 2019 OPPS/ASC final rule with comment period.

Payment rates for HCPCS codes for separately payable drugs and biologicals included in Addenda A and B for this final rule with comment period are based on ASP data from the third quarter of CY 2018. These data are the basis for calculating payment rates for drugs and biologicals in the physician’s office setting using the ASP methodology, effective October 1, 2018. These payment rates will then be updated in the January 2019 OPPS update, based on the most recent ASP data to be used for physician’s office and OPPS payment as of January 1, 2019. For items that do not currently have an ASP-based payment rate, we proposed to recalculate their mean unit cost from all of the CY 2017 claims data and updated cost report information available for the CY 2019 final rule with comment period to determine their final per day cost.

Consequently, as stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), the packaging status of some HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals in the proposed rule may be different from the same drug HCPCS code’s packaging status determined based on the data used for this final rule with comment period. Under such circumstances, in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), we proposed to continue to follow the established policies.
radiopharmaceuticals in the proposed biologicals, and therapeutic status of some HCPCS codes for drugs, biologicals, and therapeutic radiopharmaceuticals whose relationship to the drug packaging threshold changes based on the updated drug packaging threshold and on the final updated data:

- HCPCS codes for drugs and biologicals that were paid separately in CY 2018 and that were proposed for separate payment in CY 2019, and that then have per day costs equal to or less than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would remain packaged in CY 2019.
- HCPCS codes for drugs and biologicals for which we proposed packaged payment in CY 2019 but that then have per-day costs greater than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would receive separate payment in CY 2019.
- HCPCS codes for drugs and biologicals that were packaged in CY 2018 and that were proposed for separate payment in CY 2019, and that then have per day costs equal to or less than the CY 2019 final rule drug packaging threshold, based on the updated ASPs and hospital claims data used for this CY 2019 final rule, would continue to receive separate payment in CY 2019.

The category described by § 419.2(b)(16) is broader than that at § 419.2(b)(14). As we stated in the CY 2015 OPPS/ASC final rule with comment period: “We consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including post-surgical Pain Management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy” (79 FR 66875). The category described by § 419.2(b)(15) is large and includes diagnostic radiopharmaceuticals, contrast agents, stress agents, and some other products. The category described by § 419.2(b)(16) includes skin substitutes and some other products. We believe it is important to reiterate that cost consideration is not a factor when determining whether an item is a surgical supply (79 FR 66875).

We did not make any proposals to revise our policy-packaged drug policy. We solicited public comment on the general OPPS packaging policies as discussed in section II.3.a. of this final rule with comment period.

Comment: One commenter recommended that CMS continue to apply the nuclear medicine procedure to radiolabeled product edits to ensure that all packaged costs are included on nuclear medicine claims in order to establish appropriate payment rates in the future. The commenter was concerned that many providers performing nuclear medicine procedures are not including the cost of diagnostic radiopharmaceuticals used for the procedures in their claims submissions. The commenter believed this lack of drug cost reporting is causing the cost of nuclear medicine procedures to be underreported, and that the radiolabeled product edits will ensure providers are reporting the cost of diagnostic radiopharmaceuticals in their claims data.

Response: We do not agree with the commenter that we should reinstate the nuclear medicine procedure to radiolabeled product edits, which required a diagnostic radiopharmaceutical to be present on the same claim as a nuclear medicine procedure for payment under the OPPS to be made. The edits were in place between CY 2008 and CY 2014 (78 FR 75033). We believe the period of time in which the edits were in place was sufficient for hospitals to gain experience reporting procedures involving radiolabeled products and to become accustomed to ensuring that they code and report charges so that their claims fully and appropriately reflect the costs of those radiolabeled products. As with all other items and services recognized under the OPPS, we expect hospitals to code and report their costs appropriately, regardless of whether there are claims processing edits in place.

Comment: Several commenters requested that diagnostic radiopharmaceuticals be paid separately in all cases, not just when the drugs have pass-through payment status. The commenters provided limited data that showed that procedures where diagnostic radiopharmaceuticals are considered to be a surgical supply often are paid at a lower rate than what the payment rate is for the diagnostic radiopharmaceutical itself when the drug is paid separately on pass-through payment status. The commenters stated that diagnostic radiopharmaceuticals are highly complex drugs that undergo a rigorous approval process by the FDA.
The commenters believed that the type of procedure in which a drug or biological is used should not dictate whether that drug or biological is a supply and is packaged.

Response: We continue to believe that diagnostic radiopharmaceuticals are an integral component of many nuclear medicine and imaging procedures and charges associated with radiopharmaceuticals should be reported on hospital claims to the extent they are used. Therefore, payment for the radiopharmaceuticals is reflected within the payment for the primary procedure. While at least one commenter provided limited data showing the proposed cost of the packaged procedure, in CY 2019 is substantially lower than the cost of the separately paid radiopharmaceutical on pass-through payment plus the cost of the procedure associated with the radiopharmaceutical, we note the rates are established in a manner that takes the average (more specifically, the geometric mean) of reported costs to furnish the procedure based on data submitted to us from all hospitals paid under the OPPS. Accordingly, the costs that are calculated by Medicare reflect the average costs of items and services that are packaged into a primary procedure and will not necessarily equal the sum of the cost of the primary procedure and the average sales price of items and services because the billing patterns of hospitals may not reflect that a particular item or service is always billed with the primary procedure.

Further, the costs will be based on the reported costs submitted to Medicare by hospitals, not the list price established by the manufacturer. Claims data that include the radiopharmaceutical packaged with the associate procedure reflect the combined cost of the procedure and the radiopharmaceutical used in the procedure.

d. High Cost/Low Cost Threshold for Packaged Skin Substitutes

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 74938), we uncompartmentioned skin substitute products into their associated surgical procedures as part of a broader policy to package all drugs and biologicals that function as supplies when used in a surgical procedure. As part of the policy to finalize the packaging of skin substitutes, we also finalized a methodology that divides the skin substitutes into a high cost group and a low cost group, in order to ensure adequate resource homogeneity among APC assignments for the skin substitute application procedures (78 FR 74933).

Skin substitutes assigned to the high cost group are described by HCPCS codes 15271 through 15278. Skin substitutes assigned to the low cost group are described by HCPCS codes C5271 through C5278. Geometric mean costs for the various procedures are calculated using only claims for the skin substitutes that are assigned to each group. Specifically, claims billed with HCPCS code 15271, 15273, 15275, or 15277 are used to calculate the geometric mean costs for procedures assigned to the high cost group, and claims billed with HCPCS code C5271, C5273, C5275, or C5277 are used to calculate the geometric mean costs for procedures assigned to the low cost group (78 FR 74935).

Each of the HCPCS codes described above are assigned to one of the following three skin procedure APCs according to the geometric mean cost for the code: APC 5053 (Level 3 Skin Procedures) (HCPCS codes C5271, C5273, and C5277); APC 5054 (Level 4 Skin Procedures) (HCPCS codes C5271, 15273, 15275, and 15277); or APC 5055 (Level 5 Skin Procedures) (HCPCS code 15273). In CY 2018, the payment rate for APC 5053 (Level 3 Skin Procedures) was $488.20, the payment rate for APC 5054 (Level 4 Skin Procedures) was $1,568.43, and the payment rate for APC 5055 (Level 5 Skin Procedures) was $2,710.48. This information also is available in Addenda A and B of the CY 2018 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website).

We have continued the high cost/low cost categories policy since CY 2014, and in the CY 2019 OPPS/ASC proposed rule (83 FR 37117), we proposed to continue it for CY 2019. Under this current policy, skin substitutes in the high cost category are reported with the skin substitute application CPT codes, and skin substitutes in the low cost category are reported with the analogous skin substitute HCPCS C-codes. For a discussion of the CY 2014 and CY 2015 methodologies for assigning skin substitutes to either the high cost group or the low cost group, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 74932 through 74935) and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66882 through 66885).

For a discussion of the high cost/low cost methodology that was adopted in CY 2016 and has been in effect since then, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70434 through 70435). For CY 2019, with our policy since CY 2016, we proposed to continue to determine the high cost/low cost status for each skin substitute product based on either a product’s geometric mean unit cost (MUC) exceeding the geometric MUC threshold or the product’s per day cost (PDC) (the total units of a skin substitute multiplied by the mean unit cost and divided by the total number of days) exceeding the PDC threshold. For CY 2019, as for CY 2018, we proposed to assign each skin substitute that exceeds either the MUC threshold or the PDC threshold to the high cost group. In addition, as described in more detail later in this section, for CY 2019, as for CY 2018, we proposed to assign any skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group. For CY 2019, we proposed that any skin substitute product that was assigned to the high cost group in CY 2018 would be assigned to the high cost group for CY 2019, regardless of whether it exceeds or falls below the CY 2019 MUC or PDC threshold.

For this CY 2019 OPPS/ASC final rule with comment period, consistent with the methodology as established in the CY 2014 through CY 2017 final rules with comment period, we analyzed updated CY 2017 claims data to calculate the MUC threshold (a weighted average of all skin substitutes’ MUCs) and the PDC threshold (a weighted average of all skin substitutes’ PDCs). The final CY 2019 MUC threshold is $49 per cm² (rounded to the nearest $1) (proposed at $49 per cm²) and the final CY 2019 PDC threshold is $872 (rounded to the nearest $1) (proposed at $895).

For CY 2019, we proposed to continue to assign skin substitutes with pass-through payment status to the high cost category. We proposed to assign skin substitutes with pricing information but without claims data to calculate a geometric MUC or PDC to either the high cost or low cost category based on the product’s ASP+6 percent payment rate as compared to the MUC threshold. If ASP is not available, we proposed to use WAC+3 percent to assign a product to either the high cost or low cost category. Finally, if neither ASP nor WAC is available, we stated in the proposed rule that we would use 95 percent of AWP to assign a skin substitute to either the high cost or low cost category. We proposed to use WAC+3 percent instead of WAC+6 percent to conform to our proposed policy described in section V.B.2.b. of the proposed rule to establish a payment rate of WAC+3 percent for separately payable drugs and biologicals that do not have ASP data available. We also
stated in the proposed rule that new skin substitutes without pricing information would be assigned to the low cost category until pricing information is available to compare to the CY 2019 MUC threshold. For a discussion of our existing policy under which we assign skin substitutes without pricing information to the low cost category until pricing information is available, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70436).

Some skin substitute manufacturers have raised concerns about significant fluctuation in both the MUC threshold and the PDC threshold from year to year. The fluctuation in the thresholds may result in the reassignment of several skin substitutes from the high cost group to the low cost group which, under current payment rates, can be a difference of approximately $1,000 in the payment amount for the same procedure. In addition, these stakeholders were concerned that the inclusion of cost data from skin substitutes with pass-through payment status in the MUC and PDC calculations would artificially inflate the thresholds. Skin substitute stakeholders requested that CMS consider alternatives to the current methodology used to calculate the MUC and PDC thresholds and also requested that CMS consider whether it might be appropriate to establish a new cost group in between the low cost group and the high cost group to allow for assignment of moderately priced skin substitutes to a newly created middle group.

We share the goal of promoting payment stability for skin substitute products and their related procedures as price stability allows hospitals using such products to more easily anticipate future payments associated with these products. We have attempted to limit year-to-year shifts for skin substitute products between the high cost and low cost groups through multiple initiatives implemented since CY 2014, including: Establishing separate skin substitute application procedure codes for low-cost skin substitutes (78 FR 74935); using a skin substitute’s MUC calculated from outpatient hospital claims data instead of an average of ASP-6 percent as the primary methodology to assign products to the high cost or low cost group (79 FR 66883); and establishing the PDC threshold as an alternate methodology to assign a skin substitute to the high cost group (80 FR 70434 through 70435).

To allow additional time to evaluate comments and suggestions from stakeholders about the volatility of the MUC and PDC thresholds, in the CY 2018 OPPS/ASC proposed rule (82 FR 33627), for CY 2018, we proposed that a skin substitute that was assigned to the high cost group for CY 2017 would be assigned to the high cost group for CY 2018, even if it does not exceed the CY 2018 MUC or PDC thresholds. We finalized this policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59347). We stated in the CY 2018 OPPS/ASC proposed rule that the goal of our proposal to retain the same skin substitute cost group assignments in CY 2018 as in CY 2017 was to maintain similar levels of payment for skin substitute products for CY 2018 while we study our skin substitute payment methodology to determine whether refinement to the existing policies is consistent with our policy goal of providing payment stability for skin substitutes.

We stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59347) that we would continue to study issues related to the payment of skin substitutes and take these comments into consideration for future rulemaking. We received many responses to our requests for comments in the CY 2018 OPPS/ASC proposed rule about possible refinements to the existing payment methodology for skin substitutes that would be consistent with our policy goal of providing payment stability for these products. In addition, several stakeholders have made us aware of additional concerns and recommendations since the release of the CY 2018 OPPS/ASC final rule with comment period. As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37118 through 37119), we have identified four potential methodologies that have been raised to us that we encouraged the public to review and provide comments on. We stated in the proposed rule that we are especially interested in any specific feedback on policy concerns with any of the options presented as they relate to skin substitutes with differing per day or per episode costs and sizes and other factors that may differ among the dozens of skin substitutes currently on the market. We also specified in the proposed rule that we are interested in any new ideas that are not represented below along with an analysis of how different skin substitute products would fare under such ideas. We stated that we intend to explore the full array of public comments on these ideas for the CY 2020 rulemaking, and we indicated that we will consider the feedback received in response to our requests for comments in the CY 2019 proposed rule in developing proposals for CY 2020.

- Establish a lump-sum “episode-based” payment for a wound care episode. Under this option, a hospital would receive a lump sum payment for all wound care services involving procedures using skin substitutes. The payment would be made for a wound care “episodé” (such as 12 weeks) for one wound. The lump sum payment could be the same for all skin substitutes or could vary based on the estimated number of applications for a given skin substitute during the wound care episode. Under this option, payment to the provider could be made at the start of treatment, or at a different time, and could be made once or split into multiple payments. Quality metrics, such as using the recommended number of treatments for a given skin substitute during a treatment episode, and establishing a plan of care for patients who do not experience 30 percent wound healing after 4 weeks, could be established to ensure the beneficiary receives appropriate care while limiting excessive additional applications of skin substitute products.

- Eliminate the high cost/low cost categories for skin substitutes and only have one payment category and set of procedure codes for all skin substitute products. This option would reduce the financial incentives to use expensive skin substitutes and would provide incentives to use less costly skin substitute products that have been shown to have similar efficacy treating wounds as more expensive skin substitute products. A single payment category would likely have a payment rate that is between the current rates paid for high cost and low cost skin substitute procedures. Initially, a single payment category may lead to substantially higher payment for skin graft procedures performed with cheaper skin substitutes as compared to their costs. However, over time, payment for skin graft procedures using skin substitutes might reflect the lower cost of the procedures.

- Allow for the payment of current add-on codes or create additional procedure codes to pay for skin graft services between 26 cm² and 99 cm² and substantially over 100 cm². Under this option, payment for skin substitutes would be made more granularly based on the size of the skin substitute product being applied. This option also would reduce the risk that hospitals may not use enough of a skin substitute to save money when performing a procedure. However, such granularity in the use of skin substitutes could conflict with the goals of a prospective payment system, which is based on a system of averages. Specifically, it is expected that
some skin graft procedures will be less than 25 cm² or around 100 cm² and will receive higher payments compared to the cost of the services. Conversely, services between 26 cm² and 99 cm² or those that are substantially larger than 100 cm² will receive lower payments compared to the cost of the services, but the payments will average over many skin graft procedures to an appropriate payment rate for the provider.

- **Keep the high cost/low cost skin substitute categories, but change the threshold used to assign skin substitutes in the high cost or low cost group.**

Consider using other benchmarks that would establish more stable thresholds for the high cost and low cost groups. Ideas include, but are not limited to, fixing the MUC or PDC threshold at an amount from a prior year, or setting global payment targets for high cost and low cost skin substitutes and establishing a threshold that meets the payment targets. Establishing different thresholds for the high cost and low cost groups could allow for the use of a mix of lower cost and higher cost skin substitute products that acknowledges that a large share of skin substitutes products used by Medicare providers are higher cost products but still providing substantial cost savings for skin graft procedures. Different thresholds may also reduce the number of skin substitute products that switch between the high cost and low cost groups in a given year to give more payment stability for skin substitute products.

**Comment:** Several commenters supported the four options presented in the CY 2019 OPPS proposed rule (83 FR 37119 through 37119). Other commenters opposed the four options.

**Response:** We appreciate the feedback we received from the commenters. We will continue to study issues related to changing the methodology for paying for skin substitute products, and we will take these comments into consideration for CY 2020 rulemaking.

To allow stakeholders time to analyze and comment on the potential ideas raised above, in the CY 2019 OPPS/ASC proposed rule (83 FR 37119), for CY 2019, we proposed to continue our policy established in CY 2018 to assign skin substitutes to the low cost or high cost group. However, for CY 2020, we stated in the proposed rule that we may revise our policy to reflect one of the potential new methodologies discussed above or a new methodology included in public comments in response to the CY 2019 proposed rule. Specifically, for CY 2020, we proposed to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case we would assign the product to the high cost group.

**Comment:** Two commenters requested that CMS implement a single skin substitute payment category in CY 2019 rather than keeping the current high cost and low cost categories. The commenters believed that the existence of separate categories for high cost and low cost skin substitutes encourages the over-utilization of high cost skin substitutes which increases program costs and copayments for beneficiaries.

**Response:** At this time, we do not believe that establishing one cost category for all skin substitute products is prudent. While several commenters supported a single payment category for skin substitutes as a potential future refinement to the payment policy for these products, several other commenters expressed significant concern about this payment method. Accordingly, we do not believe it would be appropriate to establish such a major payment change in this final rule with comment period without having proposed it.

**Comment:** A number of commenters supported the proposal to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case CMS would assign the product to the high cost group. These commenters also supported the proposal to assign to the high cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and was not assigned to the high cost group in CY 2018. One of the commenters supported the proposal for CY 2019, but requested that CMS establish new skin substitute payment policy for CY 2020. Another commenter requested that CMS maintain the current payment methodologies for up to 5 years until a new skin substitute payment system is implemented.

**Response:** We appreciate the support from the commenters for our proposals and their support for developing a new methodology for paying for skin substitute procedures in future rulemaking.

**Comment:** One commenter expressed appreciation to CMS for assigning HCPCS codes Q4122 (Dermacell, per square centimeter) and Q4150 (Apply wrap ds or dry, per square centimeter) to the high cost group.

**Response:** We appreciate the commenter’s support.

After consideration of the public comments we received, we are finalizing our proposal to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case CMS would assign the product to the high cost group. These commenters also supported the proposal to assign to the high cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and was not assigned to the high cost group in CY 2018. One of the commenters supported the proposal for CY 2019, but requested that CMS establish new skin substitute payment policy for CY 2020. Another commenter requested that CMS maintain the current payment methodologies for up to 5 years until a new skin substitute payment system is implemented.

**Response:** We appreciate the support from the commenters for our proposals and their support for developing a new methodology for paying for skin substitute procedures in future rulemaking.

**Comment:** One commenter expressed appreciation to CMS for assigning HCPCS codes Q4122 (Dermacell, per square centimeter) and Q4150 (Apply wrap ds or dry, per square centimeter) to the high cost group.

**Response:** We appreciate the commenter’s support.

After consideration of the public comments we received, we are finalizing our proposal to assign a skin substitute with a MUC or a PDC that does not exceed either the MUC threshold or the PDC threshold to the low cost group, unless the product was assigned to the high cost group in CY 2018, in which case CMS would assign the product to the high cost group. These commenters also supported the proposal to assign to the high cost group any skin substitute product that does not exceed the CY 2019 MUC or PDC thresholds and assign to the low cost group any skin substitute product that exceeds the CY 2019 MUC or PDC thresholds and was not assigned to the high cost group in CY 2018. One of the commenters supported the proposal for CY 2019, but requested that CMS establish new skin substitute payment policy for CY 2020. Another commenter requested that CMS maintain the current payment methodologies for up to 5 years until a new skin substitute payment system is implemented.

**Response:** We appreciate the support from the commenters for our proposals and their support for developing a new methodology for paying for skin substitute procedures in future rulemaking.
percent for skin substitute products that do not have ASP pricing information or claims data to determine if those products’ costs exceed the CY 2019 MUC. We also are finalizing our proposal to retain our established policy to assign new skin substitute products with pricing information to the low cost group.  

Table 41 below displays the final CY 2019 cost category assignment for each skin substitute product.

<table>
<thead>
<tr>
<th>Skin Substitute Product</th>
<th>Final CY 2019 Cost Category</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BILLING CODE 4120-01-P
### TABLE 41.—SKIN SUBSTITUTE ASSIGNMENTS TO HIGH COST AND LOW COST GROUPS FOR CY 2019

<table>
<thead>
<tr>
<th>CY 2019 HCPCS Code</th>
<th>CY 2019 Short Descriptor</th>
<th>CY 2018 High/Low Assignment</th>
<th>CY 2019 High/Low Assignment</th>
</tr>
</thead>
<tbody>
<tr>
<td>C9363</td>
<td>Integra Meshed Bil Wound Mat</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4100</td>
<td>Skin Substitute, NOS</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4101</td>
<td>Apligraf</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4102</td>
<td>Oasis Wound Matrix</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4103</td>
<td>Oasis Burn Matrix</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4104</td>
<td>Integra BMWD</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4105</td>
<td>Integra DRT</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4106</td>
<td>Dermagraft</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4107</td>
<td>GraftJacket</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4108</td>
<td>Integra Matrix</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4110</td>
<td>Primatrix</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4111</td>
<td>Gammagraft</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4115</td>
<td>Alloskin</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4116</td>
<td>Alloderm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4117</td>
<td>Hyalomatrix</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4121</td>
<td>Theraskin</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4122</td>
<td>Dermacell</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4123</td>
<td>Alloskin</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4124</td>
<td>Oasis Tri-layer Wound Matrix</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4126</td>
<td>Memoderm/derma/tranz/integup</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4127</td>
<td>Talymed</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4128</td>
<td>Flexhd/Allopatchhd/Matrixhd</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4132</td>
<td>Grafix core, grafixpl core</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4133</td>
<td>Grafix stravix prime pl sqcm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4134</td>
<td>hMatrix</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4135</td>
<td>Mediskin</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4136</td>
<td>Ezderm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4137</td>
<td>Amnioexcel biodexcel, 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4138</td>
<td>Biodfence DryFlex, 1cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4140</td>
<td>Biodfence 1cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4141</td>
<td>Alloskin ac, 1cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4143</td>
<td>Repriza, 1cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4146</td>
<td>Tensix, 1CM</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4147</td>
<td>Architect ecm, 1cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4148</td>
<td>Neox neox rt or clarix cord</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4150</td>
<td>Allowrap DS or Dry 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>CY 2019 HCPCS Code</td>
<td>CY 2019 Short Descriptor</td>
<td>CY 2018 High/Low Assignment</td>
<td>CY 2019 High/Low Assignment</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------------------------</td>
<td>----------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Q4151</td>
<td>AmnioBand, Guardian 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4152</td>
<td>Dermapure 1 square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4153</td>
<td>Dermavest 1 square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4154</td>
<td>Biovance 1 square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4156</td>
<td>Neox 100 or clarix 100</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4157</td>
<td>Revitalon 1 square cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4158</td>
<td>Kerecis omega3, per sq cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4159</td>
<td>Affinity 1 square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4160</td>
<td>NuShield 1 square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4161</td>
<td>Bio-Connekt per square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4163</td>
<td>Woundex, bioskin, per sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4164</td>
<td>Helicoll, per square cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4165</td>
<td>Keramatrix, per square cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4166</td>
<td>Cytal, per square cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4167</td>
<td>Truskin, per square cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4169</td>
<td>Artacent wound, per sq cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4170</td>
<td>Cygnus, per square cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4173</td>
<td>Palingen or palingen xplus</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4175</td>
<td>Miroderm, per square cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4176</td>
<td>Neopatch, per square centimeter</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4178</td>
<td>Floweramniopatch, per sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4179</td>
<td>Flowerderm, per sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4180</td>
<td>Revita, per sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4181</td>
<td>Amnio wound, per square cm</td>
<td>High</td>
<td>High*</td>
</tr>
<tr>
<td>Q4182</td>
<td>Transcyte, per sq centimeter</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4183</td>
<td>Surgigraft, 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4184</td>
<td>Cellesta, 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4186</td>
<td>Epifix 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4187</td>
<td>Epicord 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4188</td>
<td>Amnioarmor 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4190</td>
<td>Artacent ac 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4191</td>
<td>Restorigin 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4193</td>
<td>Coll-e-derm 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4194</td>
<td>Novachor 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4195</td>
<td>Puraply 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4196</td>
<td>Puraply am 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4197</td>
<td>Puraply xt 1 sq cm</td>
<td>High</td>
<td>High</td>
</tr>
<tr>
<td>Q4198</td>
<td>Genesis amnio membrane 1sqcm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4200</td>
<td>Skin te 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Q4201</td>
<td>Matrion 1 sq cm</td>
<td>Low</td>
<td>Low</td>
</tr>
</tbody>
</table>
In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60490 through 60491), we finalized a policy to make a single packaging determination for a drug, rather than an individual HCPCS code, when a drug has multiple HCPCS codes describing different dosages because we believed that adopting the standard HCPCS code-specific packaging determinations for these codes could lead to inappropriate payment incentives for hospitals to report certain HCPCS codes instead of others. We continue to believe that making packaging determinations on a drug-specific basis eliminates payment incentives for hospitals to report certain HCPCS codes for drugs and allows hospitals flexibility in choosing to report all HCPCS codes for different dosages of the same drug or only the lowest dosage HCPCS code. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37121), we proposed to continue our policy to make packaging determinations on a drug-specific basis, rather than a HCPCS code-specific basis, for those HCPCS codes that describe the same drug or biological but different dosages in CY 2019.

For CY 2019, in order to propose a packaging determination that is consistent across all HCPCS codes that describe different dosages of the same drug or biological, we aggregated both our CY 2017 claims data and our pricing information at ASP+6 percent across all of the HCPCS codes that describe each distinct drug or biological in order to determine the mean units per day of the drug or biological in terms of the HCPCS code with the lowest dosage descriptor. The following drugs did not have pricing information available for the ASP methodology for the CY 2019 OPPS/ASC proposed rule, and as is our current policy for determining the packaging status of other drugs, we used the mean unit cost available from the CY 2017 claims data to make the proposed packaging determinations for these drugs: HCPCS code J1840 (Injection, kanamycin sulfate, up to 500 mg); HCPCS code J1850 (Injection, kanamycin sulfate, up to 75 mg); HCPCS code J3472 (Injection, hyaluronidase, ovine, preservative free, per 1,000 usp units); HCPCS code J7100 (Infusion, dextran 40, 500 ml); and HCPCS code J7110 (Infusion, dextran 75, 500 ml).

For all other drugs and biologicals that have HCPCS codes describing different doses, we then multiplied the proposed weighted average ASP+6 percent per unit payment amount across all dosage levels of a specific drug or biological by the estimated units per day for all HCPCS codes that describe each drug or biological from our claims data to determine the estimated per day cost of each drug or biological at less than or equal to the proposed CY 2019 drug packaging threshold of $125 (so that all HCPCS codes for the same drug or biological would be packaged) or greater than the proposed CY 2019 drug packaging threshold of $125 (so that all HCPCS codes for the same drug or biological would be separately payable). The proposed packaging status of each drug and biological HCPCS code to which this methodology would apply in CY 2019 was displayed in Table 24 of the CY 2019 OPPS/ASC proposed rule (83 FR 37121).

We did not receive any public comments on this proposal. Therefore, for CY 2019, we are finalizing our CY 2019 proposal, without modification, to continue our policy to make packaging determinations on a drug-specific basis, rather than a HCPCS code-specific basis, for those HCPCS codes that describe the same drug or biological but different dosages. Table 42 below displays the final packaging status of each drug and biological HCPCS code to which the finalized methodology applies for CY 2019.
### TABLE 42.—HCPCS CODES TO WHICH THE CY 2019 DRUG-SPECIFIC PACKAGING DETERMINATION METHODOLOGY APPLIES

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>C9257</td>
<td>Injection, bevacizumab, 0.25 mg</td>
<td>K</td>
</tr>
<tr>
<td>J9035</td>
<td>Injection, bevacizumab, 10 mg</td>
<td>K</td>
</tr>
<tr>
<td>J1020</td>
<td>Injection, methylprednisolone acetate, 20 mg</td>
<td>N</td>
</tr>
<tr>
<td>J1030</td>
<td>Injection, methylprednisolone acetate, 40 mg</td>
<td>N</td>
</tr>
<tr>
<td>J1040</td>
<td>Injection, methylprednisolone acetate, 80 mg</td>
<td>N</td>
</tr>
<tr>
<td>J1460</td>
<td>Injection, gamma globulin, intramuscular, 1 cc</td>
<td>K</td>
</tr>
<tr>
<td>J1560</td>
<td>Injection, gamma globulin, intramuscular over 10 cc</td>
<td>K</td>
</tr>
<tr>
<td>J1642</td>
<td>Injection, heparin sodium, (heparin lock flush), per 10 units</td>
<td>N</td>
</tr>
<tr>
<td>J1644</td>
<td>Injection, heparin sodium, per 1000 units</td>
<td>N</td>
</tr>
<tr>
<td>J1840</td>
<td>Injection, kanamycin sulfate, up to 500 mg</td>
<td>N</td>
</tr>
<tr>
<td>J1850</td>
<td>Injection, kanamycin sulfate, up to 75 mg</td>
<td>N</td>
</tr>
<tr>
<td>J2788</td>
<td>Injection, rho d immune globulin, human, minidose, 50 micrograms (250 i.u.)</td>
<td>N</td>
</tr>
<tr>
<td>J2790</td>
<td>Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.)</td>
<td>N</td>
</tr>
<tr>
<td>J2920</td>
<td>Injection, methylprednisolone sodium succinate, up to 40 mg</td>
<td>N</td>
</tr>
<tr>
<td>J2930</td>
<td>Injection, methylprednisolone sodium succinate, up to 125 mg</td>
<td>N</td>
</tr>
<tr>
<td>J3471</td>
<td>Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units)</td>
<td>N</td>
</tr>
<tr>
<td>J3472</td>
<td>Injection, hyaluronidase, ovine, preservative free, per 1000 usp units</td>
<td>N</td>
</tr>
<tr>
<td>J7030</td>
<td>Infusion, normal saline solution, 1000 cc</td>
<td>N</td>
</tr>
<tr>
<td>J7040</td>
<td>Infusion, normal saline solution, sterile (500 ml=1 unit)</td>
<td>N</td>
</tr>
<tr>
<td>J7050</td>
<td>Infusion, normal saline solution, 250 cc</td>
<td>N</td>
</tr>
<tr>
<td>J7100</td>
<td>Infusion, dextran 40, 500 ml</td>
<td>N</td>
</tr>
<tr>
<td>J7110</td>
<td>Infusion, dextran 75, 500 ml</td>
<td>N</td>
</tr>
<tr>
<td>J7515</td>
<td>Cyclosporine, oral, 25 mg</td>
<td>N</td>
</tr>
<tr>
<td>J7502</td>
<td>Cyclosporine, oral, 100 mg</td>
<td>N</td>
</tr>
<tr>
<td>J8520</td>
<td>Capecitabine, oral, 150 mg</td>
<td>N</td>
</tr>
<tr>
<td>J8521</td>
<td>Capecitabine, oral, 500 mg</td>
<td>N</td>
</tr>
<tr>
<td>J9250</td>
<td>Methotrexate sodium, 5 mg</td>
<td>N</td>
</tr>
<tr>
<td>J9260</td>
<td>Methotrexate sodium, 50 mg</td>
<td>N</td>
</tr>
</tbody>
</table>
2. Payment for Drugs and Biologicals

Without Pass-Through Status That Are Not Packaged

a. Payment for Specified Covered Outpatient Drugs (SCODs) and Other Separately Payable and Packaged Drugs and Biologicals

Section 1833(t)(14) of the Act defines certain separately payable radiopharmaceuticals, drugs, and biologicals and mandates specific payments for these items. Under section 1833(t)(14)(B)(ii) of the Act, a “specified covered outpatient drug” (known as a SCOD) is defined as a covered outpatient drug, as defined in section 1927(k)(2) of the Act, for which a separate APC has been established and that either is a radiopharmaceutical agent or is a drug or biological for which payment was made on a pass-through basis on or before December 31, 2002. Under section 1833(t)(14)(B)(ii) of the Act, certain drugs and biologicals are designated as exceptions and are not included in the definition of SCODs. These exceptions are—

• A drug or biological for which payment is first made on or after January 1, 2003, under the transitional pass-through payment provision in section 1833(t)(6) of the Act.

• A drug or biological for which a temporary HCPCS code has not been assigned.

• During CYs 2004 and 2005, an orphan drug (as designated by the Secretary).

Section 1833(t)(14)(A)(iii) of the Act requires that payment for SCODs in CY 2006 and subsequent years be equal to the average acquisition cost for the drug for that year as determined by the Secretary, subject to any adjustment for overhead costs and taking into account the hospital acquisition cost survey data collected by the Government Accountability Office (GAO) in CYs 2004 and 2005, and later periodic surveys conducted by the Secretary as set forth in the statute. If hospital acquisition cost data are not available, the law requires that payment be equal to payment rates established under the methodology described in section 1842(o), section 1847A, or section 1847B of the Act, as calculated and adjusted by the Secretary as necessary for purposes of paragraph (14). We refer to this alternative methodology as the “statutory default.” Most physician Part B drugs are paid at ASP+6 percent in accordance with section 1842(o) and section 1847A of the Act.

Section 1833(t)(14)(B)(ii) of the Act provides for an adjustment in OPPS payment rates for SCODs to take into account overhead and related expenses, such as pharmacy services and handling costs. Section 1833(t)(14)(E)(ii) of the Act required MedPAC to study pharmacy overhead and related expenses and to make recommendations to the Secretary regarding whether, and if so how, a payment adjustment should be made to compensate hospitals for overhead and related expenses. Section 1833(t)(14)(E)(iii) of the Act authorizes the Secretary to adjust the weights for ambulatory procedure classifications for SCODs to take into account the findings of the MedPAC study. It has been our policy since CY 2006 to apply the same treatment to all separately payable drugs and biologicals, which include SCODs, and drugs and biologicals that are not SCODs. Therefore, we apply the payment methodology in section 1833(t)(14)(A)(iii) of the Act to SCODs, as required by statute, but we also apply it to separately payable drugs and biologicals that are not SCODs, which is a policy determination rather than a statutory requirement. In the CY 2019 OPPS/ASC proposed rule (83 FR 37122), we proposed to apply section 1833(t)(14)(A)(iii)(II) of the Act to all separately payable drugs and biologicals, including SCODs. Although we do not distinguish SCODs in this discussion, we note that we are required to apply section 1833(t)(14)(A)(iii)(II) of the Act to SCODs, but we also are applying this provision to other separately payable drugs and biologicals, consistent with our history of using the same payment methodology for all separately payable drugs and biologicals.

For a detailed discussion of our OPPS drug payment policies from CY 2006 to CY 2012, we refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68383 through 68385). In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68386 through 68389), we first adopted the statutory default policy to pay for separately payable drugs and biologicals at ASP+6 percent based on section 1833(t)(14)(A)(iii)(II) of the Act. We continued this policy of paying for separately payable drugs and biologicals at the statutory default for CYs 2014 through 2018.

Comment: One commenter requested that HCPCS code J0476 (Injection, baclofen, 50 mcg for intrathecal trial) be separately payable in CY 2019 and be assigned status indicator “K” (Paid under OPPS; separate APC payment).

Response: The per day cost of the drug described by HCPCS code J0476 is less than the drug packaging threshold amount of $125. Therefore, the drug described by HCPCS code J0476 will be packaged into the cost of the related services for CY 2019.

Comment: One commenter supported the assignment of GenVisc 850, described by HCPCS code J7320, to a separately payable status with status indicator “K” (Paid under OPPS; separate APC payment) for CY 2019. The commenter also requested that TriVisc, described by HCPCS code J7329, also be assigned to a separately payable status for CY 2019.

Response: We appreciate the commenter’s support. For HCPCS code J7329, we are not able to assign the code to a payable status because no pricing information is available for the code. If pricing information becomes available prior to the next rulemaking cycle, we would expect to assign a payable status in a quarterly update to the OPPS.

b. CY 2019 Payment Policy

In the CY 2019 OPPS/ASC proposed rule (83 FR 37122), for CY 2019, we proposed to continue our payment policy that has been in effect since CY 2013 to pay for separately payable drugs and biologicals at ASP+6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the Act (the statutory default). We proposed to continue to pay for separately payable nonpass-through drugs acquired with a 340B discount at a rate of ASP minus 22.5 percent. We refer readers to section V.A.7. of the proposed rule and this final rule with comment period for more information about how the payment rate for drugs acquired with a 340B discount was established.

In the case of a drug or biological during an initial sales period in which data on the prices for sales for the drug or biological are not sufficiently available from the manufacturer, section 1847A(c)(4) of the Act permits the Secretary to make payments that are based on WAC. Under section 1833(t)(14)(A)(iii)(II), the amount of payment for a separately payable drug equals the average price for the drug for the year established under, among other authorities, section 1847A of the Act. As explained in greater detail in the CY 2019 PFS proposed rule, under section 1847A(c)(4), although payments may be based on WAC, unlike section 1847A(b) of the Act (which specifies that certain payments must be made with a 6 percent add-on), section 1847A(c)(4) of the Act does not require that a particular...
add-on amount be applied to partial quarter WAC-based pricing. Consistent with section 1847A(c)(4) of the Act, in the CY 2019 PFS proposed rule, we proposed that, effective January 1, 2019, WAC-based payments for Part B drugs made under section 1847A(c)(4) of the Act would utilize a 3 percent add-on in place of the 6 percent add-on that is currently being used per our policy in effect as of CY 2018. For the OPPS, in the CY 2019 OPPS/ASC proposed rule (83 FR 37122), we also proposed to utilize a 3 percent add-on instead of a 6 percent add-on for WAC-based drugs pursuant to our authority under section 1833(t)(14)(A)(iii)(II) of the Act, which provides, in part, that the amount of payment for a SCOD is the average price of the drug in the year established under section 1847A of the Act. We also apply this provision to non-SCOD separately payable drugs. Because we proposed to establish the average price for a WAG-based drug under section 1847A of the Act as WAC+3 percent instead of WAC+6 percent, we believe it is appropriate to price separately payable WAG-based drugs at the same amount under the OPPS. We proposed that, if finalized, our proposal to pay for drugs or biologicals at WAC+3 percent, rather than WAC+6 percent, would apply whenever WAC-based pricing is used for a drug or biological. We stated in the proposed rule that for drugs and biologicals that would otherwise be subject to a payment reduction because they were acquired under the 340B Program, the 340B Program rate (in this case, WAC minus 22.5 percent) would continue. We referred readers to the CY 2019 PFS proposed rule for additional background on this anticipated proposal.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), we proposed that payments for separately payable drugs and biologicals are included in the budget neutrality adjustments, under the requirements in section 1833(t)(9)(B) of the Act. We also proposed that the budget neutral weight scalar not be applied in determining payments for these separately paid drugs and biologicals.

We note that separately payable drug and biological payment rates listed in Addenda A and B to this final rule with comment period (available via the internet on the CMS website), which illustrate the final CY 2019 payment of ASP+6 percent for separately payable nonpass-through drugs and biologicals and ASP+6 percent for pass-through drugs and biologicals, reflect either ASP information that is the basis for calculating payment rates for drugs and biologicals in the physician’s office setting effective October 1, 2018, or WAC, AWP, or mean unit cost from CY 2017 claims data and updated cost report information available for this final rule with comment period. In general, these published payment rates are not the same as the actual January 2019 payment rates. This is because payment rates for drugs and biologicals with ASP information for January 2019 will be determined through the standard quarterly process where ASP data submitted by manufacturers for the third quarter of CY 2018 (July 1, 2018 through September 30, 2018) will be used to set the payment rates that are released for the quarter beginning in January 2019 near the end of December 2018. In addition, payment rates for drugs and biologicals in Addenda A and B to this final rule with comment period for which there was no ASP information available for October 2018 are based on mean unit cost in the available CY 2017 claims data. If ASP information becomes available for payment for the quarter beginning in January 2019, we will price payment for these drugs and biologicals based on their newly available ASP information. Finally, there may be drugs and biologicals that have ASP information available for this final rule with comment period (reflecting October 2018 ASP data) that do not have ASP information available for the quarter beginning in January 2019. As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), these drugs and biologicals will then be paid based on mean unit cost data derived from CY 2017 hospital claims. Therefore, the rates listed in Addenda A and B to this final rule with comment period are not for January 2019 payment purposes and are only illustrative of the CY 2019 OPPS payment methodology using the most recently available information at the time of issuance of this final rule with comment period.

Comment: A number of commenters supported CMS’ proposal to continue to pay for separately payable drugs and biologicals based on the statutory default rate of ASP+6 percent.

Response: We appreciate the commenters’ support.

Comment: Several commenters supported the proposal to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act that specify fixed add-on percentages of 6 percent (section 1847A(b) of the Act) or 3 percent (section 1847A(d)(3)(C) of the Act). A fixed percentage is also administratively simple to implement and administer, is predictable, and is easy for manufacturers, providers and the public to understand.

Comment: Many commenters opposed the proposal to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act. Several commenters were concerned that paying less for new drugs may discourage the use of innovative drugs due to concerns about decreased payment, especially with the sequestration cuts decreasing the payment further. These commenters also were concerned that the proposal would only affect payment to the provider, and would not address pricing on the pharmaceutical manufacturer side. The commenters requested additional studies to analyze the appropriateness and accuracy of the 3 percent reduction, and encouraged additional modifications to ASP reporting, such as requiring all Part B drug manufacturers to report pricing information and for all Part B drugs to be included in the ASP quarterly update file.

Response: We appreciate these comments. The implementation of these proposals will improve Medicare payment rates by better aligning payments with drug acquisition costs, which is of great importance to CMS because spending on Part B drugs has grown significantly. A WAC+3 percent add-on is more comparable to an ASP+6 percent add-on, as the WAC pricing does not reflect many of the discounts associated with ASP, such as rebates. The utilization of a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act is consistent with MedPAC’s analysis and recommendations cited in its June 2017 Report to the Congress, and as discussed in the CY 2019 PFS proposed rule (83 FR 35854 through 35855). Overall, this policy still represents a net payment greater than the WAC. In addition, this policy decreases beneficiary cost-sharing for these drugs, which would help Medicare beneficiaries afford to pay for new drugs by reducing out-of-pocket expenses.
Comment: Some commenters did not support the inclusion of radiopharmaceuticals in the proposal to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC. The commenters cited pharmacy overhead and handling costs for radiopharmaceuticals, pointed out that these costs are higher than for any other class of drugs, and suggested an increased payment rate. In addition, the commenters were concerned that this reduction would disproportionately affect the pass-through payments for diagnostic radiopharmaceuticals.

Response: We appreciate these comments. We recognize that radiopharmaceuticals tend to utilize the WAC-based payment methodology more compared to other products. However, no significant evidence has been presented to substantiate that a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC would negatively affect access, including during the pass-through payment status period, if applicable. We received limited current data from commenters to justify the exclusion of radiopharmaceuticals from this proposal.

Comment: Several commenters made recommendations to exclude certain drugs and biologicals from this proposal, including skin substitutes and biosimilar biological products. The commenters were concerned about skin substitutes being assigned to the high- or low-cost category when ASP data are not available based on a WAC+3 percent methodology but paid to a WAC+6 percent methodology. The commenters recommended maintaining payment for biosimilars at WAC+6 percent to encourage the increase in utilization of biosimilars.

Response: We appreciate these comments. However, use of a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act is consistent with MedPAC’s analysis and recommendations cited in its June 2017 Report to the Congress, and as discussed in the CY 2019 PFS proposed rule (83 FR 35854 through 35855). This policy is not meant to give preferential treatment to any drugs or biologicals.

Comment: Commenters were concerned about coverage for drugs that are not included in the ASP Quarterly Update File being paid at WAC+3 percent instead of the current rate of ASP+6 percent. For example, the commenters were concerned that OTIPRIO (HCPCS code J7342), a drug that is not included in the ASP Quarterly Update File, will not be paid at ASP+6 percent, and would be paid at WAC+3 percent. In addition, the commenters requested clarification regarding MAC payment for drugs that fall under sections 1847A(c)(4) and 1847A(b)(1) of the Act.

Response: Drugs that are not included in the ASP Quarterly Update File will continue to be paid at their current rate of ASP+6 percent as long as the manufacturer continues to submit ASP information to CMS on a timely basis and assuming the drug is not packaged. After consideration of the public comments we received, we are finalizing our proposal, without modification, to utilize a 3 percent add-on instead of a 6 percent add-on for drugs that are paid based on WAC under section 1847A(c)(4) of the Act pursuant to our authority under section 1833(t)(14)(A)(iii)(II) of the Act.

c. Biosimilar Biological Products

For CY 2016 and CY 2017, we finalized a policy to pay for biosimilar biological products based on the payment allowance of the product as determined under section 1847A of the Act and to subject nonpass-through biosimilar biological products to our annual threshold-packaged policy (for CY 2016, 80 FR 70445 through 70446; and for CY 2017, 81 FR 79674). In the CY 2018 OPPS/ASC proposed rule (82 FR 33630), for CY 2018, we proposed to continue this same payment policy for biosimilar biological products.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59351), we noted that, with respect to comments we received regarding OPPS payment for biosimilar biological products, in the CY 2018 PFS final rule, CMS finalized a policy to implement separate HCPCS codes for biosimilar biological products. Therefore, consistent with our established OPPS drug, biological, and radiopharmaceutical payment policy, HCPCS coding for biosimilar biological products will be based on policy established under the CY 2018 PFS final rule.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59351), after consideration of the public comments we received, we finalized our proposed payment policy for biosimilar biological products, with the following technical correction: All biosimilar biological products will be eligible for pass-through payment and not just the first biosimilar biological product for a reference product.

In addition, in CY 2018, we adopted a policy that biosimilars without pass-through payment status that were acquired under the 340B Program would be paid the ASP of the biosimilar minus 22.5 percent of the reference product (82 FR 59367). We adopted this policy in the CY 2018 OPPS/ASC final rule with comment period because we believe that biosimilars without pass-through payment status acquired under the 340B Program should be treated in the same manner as other drugs and biologicals acquired through the 340B Program. As noted earlier, biosimilars with pass-through payment status are paid their own ASP+6 percent of the reference product’s ASP. Separately payable biosimilars that do not have pass-through payment status and are not acquired under the 340B Program are also paid their own ASP+6 percent of the reference product’s ASP.

As noted in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), several stakeholders raised concerns to us that the current payment policy for biosimilars acquired under the 340B Program could unfairly lower the OPPS payment for biosimilars not on pass-through payment status because the payment reduction would be based on the reference product’s ASP, which would generally be expected to be priced higher than the biosimilar, thus resulting in a more significant reduction in payment than if the 22.5 percent was calculated based on the biosimilar’s ASP. We agreed with stakeholders that the current payment policy could unfairly lower the price of biosimilars without pass-through payment status that are acquired under the 340B Program. In addition, we believed that these changes would better reflect the resources and production costs that biosimilar manufacturers incur. We also believed this approach is more consistent with the payment methodology for 340B-acquired drugs and biologicals, for which the 22.5 percent reduction is calculated based on the drug or biological’s ASP, rather than the ASP of another product. In addition, we believed that paying for biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP, rather than 22.5 percent of the reference product’s ASP, will more closely approximate hospitals’ acquisition costs for these products.

Accordingly, in the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, we proposed to continue the policy from CY 2018 to make all biosimilar biological products eligible for pass-through payment and
under the 340B Program. Specifically, for CY 2019 and subsequent years, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act, we proposed to pay nonpass-through biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP instead of the biosimilar’s ASP minus 22.5 percent of the reference product’s ASP.

Comment: Many commenters supported CMS’ proposal to pay nonpass-through biosimilars acquired under the 340B Program at ASP minus 22.5 percent of the biosimilar’s ASP, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act. The commenters stated that this proposal would ensure fair access to biosimilar treatments.

Response: We appreciate the commenters’ support. We believe this proposal appropriately reflects the resources and production costs that manufacturers incur, as well as more closely aligns with the hospitals’ acquisition costs of these products.

Comment: Several commenters supported CMS’ proposal to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and not just the first biosimilar biological product for a reference product. The commenters stated that this proposal would continue to lower costs and improve access to treatments.

Response: We appreciate the commenters’ support. We are not convinced that making all biosimilar biological products eligible for pass-through payment would lead to inappropriate treatment changes from a reference product without pass-through payment to a biosimilar product with pass-through payment. Eligibility for pass-through payment status reflects the unique, complex nature of biosimilars and is important as biosimilars become established in the market, just as it is for all other new drugs and biologicals.

After consideration of the public comments we received, we are finalizing our proposed payment policy for biosimilar products, without modification, to continue the policy in place from CY 2018 to make all biosimilar biological products eligible for pass-through payment and not just the first biosimilar biological product for a reference product. We also are finalizing our proposal to pay nonpass-through biosimilars acquired under the 340B Program at the biosimilar’s ASP minus 22.5 percent of the biosimilar’s ASP instead of the biosimilar’s ASP minus 22.5 percent of the reference product’s ASP.

3. Payment Policy for Therapeutic Radiopharmaceuticals

In the CY 2019 OPPS/ASC proposed rule (83 FR 37123), for CY 2019, we proposed to continue the payment policy for therapeutic radiopharmaceuticals that began in CY 2010. We pay for separately payable therapeutic radiopharmaceuticals under the ASP methodology adopted for separately payable drugs and biologicals. If ASP information is unavailable for a therapeutic radiopharmaceutical, we base therapeutic radiopharmaceutical payment on mean unit cost data derived from hospital claims. We believe that the rationale outlined in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60524 through 60525) for applying the principles of separately payable drug pricing to therapeutic radiopharmaceuticals continues to be appropriate for nonpass-through, separately payable therapeutic radiopharmaceuticals in CY 2019.

Therefore, we proposed for CY 2019 to pay all nonpass-through, separately payable therapeutic radiopharmaceuticals at ASP+6 percent, based on the statutory default described in section 1833(t)(14)(A)(iii)(II) of the Act. For a full discussion of ASP-based payment for therapeutic radiopharmaceuticals, we refer readers to the CY 2010 OPPS/ASC final rule with comment period (74 FR 60520 through 60521). We also proposed to rely on CY 2017 mean unit cost data derived from hospital claims data for payment rates for therapeutic radiopharmaceuticals for which ASP data are unavailable and to update the payment rates for separately payable therapeutic radiopharmaceuticals according to our usual process for updating the payment rates for separately payable drugs and biologicals on a quarterly basis if updated ASP information is unavailable. For a complete history of the OPPS payment policy for therapeutic radiopharmaceuticals, we refer readers to the CY 2005 OPPS final rule with comment period (69 FR 65811), the CY 2006 OPPS final rule with comment period (70 FR 68655), and the CY 2010 OPPS/ASC final rule with comment period (74 FR 60524).

The proposed CY 2019 payment rates for nonpass-through, separately payable therapeutic radiopharmaceuticals were included in Addenda A and B to the proposed rule (which are available via the internet on the CMS website).

Comment: Commenters supported continuation of the policy to pay ASP+6 percent for therapeutic radiopharmaceuticals, if available, and to base payment on the mean unit cost derived from hospital claims data when not available. The commenters also requested that CMS examine ways to compensate hospitals for their documented higher overhead and handling costs associated with radiopharmaceuticals.

Response: We appreciate the commenters’ support. However, as we stated earlier in section V.B.1.c. of this final rule with comment period in response to a similar request for additional radiopharmaceutical payment and as previously stated in the CY 2018 OPPS final rule with comment period (82 FR 59352), we continue to believe that a single payment is appropriate for radiopharmaceuticals with pass-through payment status in CY 2019 and that the payment rate of ASP+6 percent is appropriate to provide payment for both the radiopharmaceutical’s acquisition cost and any associated nuclear medicine handling and compounding costs incurred by the hospital pharmacy. Payment for the radiopharmaceutical and radiopharmaceutical processing services is made through the single ASP-based payment. We refer readers to the CMS guidance document available via the internet at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Archives.html for details on submission of ASP data for therapeutic radiopharmaceuticals.

Comment: One commenter asked CMS to clarify the payment rate reported for APC 1675, P32 Na phosphate (HCPCS code A9563), which is based on geometric mean unit cost. The commenter stated that, in the proposed rule, the payment rate for HCPCS code A9563 was reported as $256.00, but the mean unit cost for the radiopharmaceutical as reported in data files accompanying the proposed rule was $519.21.

Response: We thank the commenter for bringing this reporting error to our attention. We are providing a corrected payment rate for APC 1675, P32 Na phosphate (HCPCS code A9563).
phosphate (HCPCS code A9563) in Addenda A and B of this final rule with comment period (which is available via the internet on the CMS website).

After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue to pay all nonpass-through, separately payable therapeutic radiopharmaceuticals at ASP+6 percent. We also are finalizing our proposal to continue to rely on CY 2017 mean unit cost data derived from hospital claims data for payment rates for therapeutic radiopharmaceuticals for which ASP data are unavailable. The CY 2019 final payment rates for nonpass-through separately payable therapeutic radiopharmaceuticals are included in Addenda A and B to this final rule with comment period (which are available via the internet on the CMS website).

4. Payment Adjustment Policy for Radioisotopes Derived From Non-Highly Enriched Uranium Sources

Radioisotopes are widely used in modern medical imaging, particularly for cardiac imaging and predominantly for the Medicare population. Some of the Technetium-99 (Tc-99m), the radioisotope used in the majority of such diagnostic imaging services, is produced in legacy reactors outside of the United States using highly enriched uranium (HEU).

The United States would like to eliminate domestic reliance on these reactors, and is promoting the conversion of all medical radioisotope production to non-HEU sources. Alternative methods for producing Tc-99m without HEU are technologically and economically viable, and conversion to such production has begun. We expect that this change in the supply source for the radioisotope used for modern medical imaging will introduce new costs into the payment system that are not accounted for in the historical claims data.

Therefore, beginning in CY 2013, we finalized a policy to provide an additional payment of $10 for the marginal cost for radioisotopes produced by non-HEU sources (77 FR 68323). Under this policy, hospitals report HCPCS code Q9969 (Tc-99m from non-highly enriched uranium source, report HCPCS code Q9969 (Tc-99m from non-HEU sources) once per dose along with any non-highly enriched uranium source, separate payable procedure of 2019. In addition, one of the manufacturers of Tc-99m generators sent a letter to CMS to support continuing the payment adjustment at the current level because only 30 percent of Tc-99m is produced from non-HEU sources. We also met with a trade group of nuclear pharmacies and cyclotron operators who support an increase in the payment adjustment by the rate of inflation to cover more of the cost of Tc-99m from non-HEU sources.

We appreciate the feedback from stakeholders. However, as stated in the CY 2019 OPPS/ASC proposed rule, we continue to believe that the current adjustment is sufficient for the reasons we have outlined in this and prior rulemakings. The information from stakeholders and the National Academies of Sciences, Engineering, and Medicine indicates that the conversion of the production of Tc-99m from non-HEU sources may take more than 1 year after CY 2018. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37124), for CY 2019 and subsequent years, we proposed to continue to provide an additional $10 payment for radioisotopes produced by non-HEU sources. We noted in the proposed rule our intention to reassess this payment policy once conversion to non-HEU sources is closer to completion or has been completed.

Comment: Several commenters requested that the additional payment for radioisotopes produced by non-HEU sources be increased to either $30 or $10 plus the percentage increase in hospital charge data for APC 1442 for the period of 2014 through 2019, which appears to be a request from the commenter to increase the payment by the rate of hospital inflation. One of the commenters supported this request by supplying provider cost data showing the cost difference between HEU Mo-99 and non-HEU Mo-99 in 2017 per curie was around $30.

One commenter requested that CMS provide an explanation for not applying an annual inflation update to the $10 payment for radioisotopes produced by non-HEU sources, provide details on plans to offset nuclear medicine procedures by the amount of cost paid through the non-HEU policy, and make available to the public data regarding the claims submitted to date under this policy. The commenter also stated that CMS should assess whether the beneficiary copayment policy is adversely impacting patient access.

Response: We appreciate the information we received from stakeholders supporting an increase to the payment rate of $10 for HCPCS code Q9969. As we stated in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68317), “The purpose for the additional payment is limited to mitigating any adverse impact of existing payment policy and is based on the authority set forth at section 1833(t)(2)(E) of the Act.” However, we are open to further study of this issue and are interested in exploring whether a higher add-on payment, such as $30, may be warranted for a future year. We invite stakeholders to continue to submit data and evidence for further consideration as we continue to evaluate this policy. As discussed in the CY 2013 OPPS/ASC final rule with comment period, we did not finalize a policy to use the usual OPPS methodologies to update the non-HEU add-on payment (77 FR 68317). The purpose of the additional payment is limited to mitigating any adverse impact of transitioning to non-HEU sources and is based on the authority set forth at section 1833(t)(2)(E) of the Act. Therefore, we will maintain the current payment rate of $10.

With respect to the comment that we should assess whether the beneficiary copayment amount is adversely affecting patient access, we will consider the commenter’s concern. However, we note that increasing the add-on payment from the current level as the commenter suggested would necessarily increase the beneficiary copayment liability. Finally, the offset for nuclear medicine procedures does not include the cost of the non-HEU add-on payment.

Comment: One commenter requested that CMS provide detailed data on hospital costs associated with radiopharmaceuticals reported with HCPCS code Q9969.

Response: It is not clear what specific data this commenter is seeking that are not already available through public use...
files. We note that, in 2017, HCPCS code Q9969 was billed 34,439 times and is commonly reported with Level II HCPCS codes A9500 (Technetium tcm-99m sestamibi, diagnostic, per study dose) and A9503 (Technetium tcm-99m medronate, diagnostic, per study dose, up to 30 millicuries). The geometric mean costs of this and all Level II HCPCS drug codes, including radiopharmaceutical drug codes, can be found in the cost statistics file that is released with this final rule with comment period.

After consideration of the public comments we received, we are finalizing our proposal, without modification, to continue the policy of providing an additional $10 payment for radioisotopes produced by non-HEU sources for CY 2019 and subsequent years. We will reassess this payment policy once conversion to non-HEU sources is closer to completion or has been completed.

5. Payment for Blood Clotting Factors

For CY 2018, we provided payment for blood clotting factors under the same methodology as other nonpass-through separately payable drugs and biologicals under the OPPS and continued paying an updated furnishing fee (82 FR 59353). That is, for CY 2018, we provided payment for blood clotting factors under the OPPS at ASP+6 percent, plus an additional payment for the furnishing fee. We note that when blood clotting factors are provided in physicians’ offices under Medicare Part B and in other Medicare settings, a furnishing fee is also applied to the payment. The CY 2018 updated furnishing fee was $0.215 per unit.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37124), for CY 2019, we proposed to pay for blood clotting factors at ASP+6 percent, consistent with our proposed payment policy for other nonpass-through, separately payable drugs and biologicals, and to continue our policy for payment of the furnishing fee using an updated amount. Our policy to pay for a furnishing fee for blood clotting factors under the OPPS is consistent with the methodology applied in the physician’s office and in the inpatient hospital setting. These methodologies were first articulated in the CY 2006 OPPS final rule with comment period (70 FR 68661) and later discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66765). The proposed furnishing fee update was based on the percentage increase in the Consumer Price Index (CPI) for medical care for the 12-month period ending with June of the previous year. Because the Bureau of Labor Statistics releases the applicable CPI data after the PFS and OPPS/ASC proposed rules are published, we were not able to include the actual updated furnishing fee in the proposed rules. Therefore, in accordance with our policy, as finalized in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66765), we proposed to announce the actual figure for the percent change in the applicable CPI and the updated furnishing fee calculated based on that figure through applicable program instructions and posting on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html.

Comment: Commenters supported CMS’ proposal to continue to pay for blood clotting factors at ASP+6 percent plus a blood clotting factor furnishing fee in the hospital outpatient department.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are finalizing our proposal, without modification, to provide payment for blood clotting factors under the same methodology as other separately payable drugs and biologicals under the OPPS and to continue payment of an updated furnishing fee. We will announce the actual figure of the percent change in the applicable CPI and the updated furnishing fee calculation based on that figure through the applicable program instructions and posting on the CMS website.

6. Payment for Nonpass-Through Drugs, Biologicals, and Radiopharmaceuticals With HCPCS Codes but Without OPPS Hospital Claims Data

In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, we proposed to continue to use the same payment policy as in CY 2018 for nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data, which describes how we determine the payment rate for drugs, biologicals, or radiopharmaceuticals without an ASP. For a detailed discussion of the payment policy and methodology, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70442 through 70443). The proposed CY 2019 payment status of each of the nonpass-through drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data was listed in Addendum B to the proposed rule, which is available via the internet on the CMS website.

We did not receive any comments on our proposal. Therefore, we are finalizing our CY 2019 proposal without modification, including our proposal to assign drug or biological products status indicator “K” and pay for them separately for the remainder of CY 2019 if pricing information becomes available. The CY 2019 payment status of each of the nonpass-through, drugs, biologicals, and radiopharmaceuticals with HCPCS codes but without OPPS hospital claims data is listed in Addendum B to this final rule with comment period, which is available via the internet on the CMS website.

7. CY 2019 OPPS Payment Methodology for 340B Purchased Drugs

In the CY 2018 OPPS/ASC proposed rule (82 FR 33558 through 33724), we proposed changes to the Medicare Part B drug payment methodology for 340B hospitals. We proposed these changes to better, and more accurately, reflect the resources and acquisition costs that these hospitals incur. We believed that such changes would allow Medicare beneficiaries (and the Medicare program) to pay a more appropriate amount when hospitals participating in the 340B Program furnish drugs to Medicare beneficiaries that are purchased under the 340B Program. Subsequently, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59359 through 59370), we finalized our proposal and adjusted the payment rate for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program from average sales price (ASP)+6 percent to ASP minus 22.5 percent. Our goal is to make Medicare payment for separately payable drugs more aligned with the resources expended by hospitals to acquire such drugs, while recognizing the intent of the 340B Program to allow covered entities, including eligible hospitals, to stretch scarce resources in ways that enable hospitals to continue providing access to care for Medicare beneficiaries and other patients. Critical access hospitals are not included in this 340B policy change because they are paid under section 1834(g) of the Act. We also excepted rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals from the 340B payment adjustment in CY 2018. In addition, as stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs on payment status, which are required to be paid based on the ASP methodology, or
vaccines, which are excluded from the 340B Program.

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37125), another topic that has been brought to our attention since we finalized the payment adjustment for 340B-acquired drugs in the CY 2018 OPPS/ASC final rule with comment period is whether drugs that do not have ASP pricing but instead receive WAC or AWP pricing are subject to the 340B payment adjustment. We did not receive public comments on this topic in response to the CY 2018 OPPS/ASC proposed rule. However, we have since heard from stakeholders that there has been some confusion about this issue. We clarified in the CY 2019 proposed rule that the 340B payment adjustment applies to drugs that are priced using either WAC or AWP, and has been our policy to subject 340B-acquired drugs that use these pricing methodologies to the 340B payment adjustment since the policy was first adopted. The 340B payment adjustment for WAC-priced drugs is WAC minus 22.5 percent and AWP-priced drugs have a payment rate of 69.46 percent of AWP when the 340B payment adjustment is applied. The 69.46 percent of AWP is calculated by first reducing the original 95 percent of AWP price by 6 percent to generate a value that is similar to ASP or WAC with no percentage markup. Then we apply the 22.5 percent reduction to ASP/WAC-similar AWP value to obtain the 69.46 percent of AWP, which is similar to either ASP minus 22.5 percent or WAC minus 22.5 percent. The number of separately payable drugs receiving WAC or AWP pricing that are affected by the 340B payment adjustment is small—consisting of less than 10 percent of all separately payable Medicare Part B drugs in April 2018.

Furthermore, data limitations previously inhibited our ability to identify which drugs were acquired under the 340B Program in the Medicare OPPS claims data. This lack of information within the claims data has limited researchers’ and our ability to precisely analyze differences in acquisition cost of 340B and non-340B acquired drugs with Medicare claims data. Accordingly, in the CY 2018 OPPS/ASC proposed rule (82 FR 33633), we stated our intent to establish a modifier, to be effective January 1, 2018, for hospitals to report with separately payable drugs that were not acquired under the 340B Program. Because a significant portion of hospitals paid under the OPPS participate in the 340B Program, we stated our belief that it is appropriate to presume that a separately payable drug reported on an OPPS claim was purchased under the 340B Program, unless the hospital identifies that the drug was not purchased under the 340B Program. We stated in the CY 2018 proposed rule that we intended to provide further details about this modifier in the CY 2018 OPPS/ASC final rule with comment period and/or through subregulatory guidance, including guidance related to billing for dual eligible beneficiaries (that is, beneficiaries covered under Medicare and Medicaid) for whom covered entities do not receive a discount under the 340B Program. As discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59369 through 59370), to effectuate the payment adjustment for 340B-acquired drugs, CMS implemented modifier “JG”, effective January 1, 2018. Hospitals paid under the OPPS, other than a type of hospital excluded from the OPPS (such as critical access hospitals or those hospitals paid under the Maryland waiver), or excepted from the 340B drug payment policy for CY 2018, are required to report modifier “JG” on the same claim line as the drug HCPCS code to identify a 340B-acquired drug. For CY 2018, rural sole community hospitals, children’s hospitals and PPS-exempt cancer hospitals are excepted from the 340B payment adjustment. These hospitals are required to report informational modifier “TB” for 340B-acquired drugs, and continue to be paid ASP+6 percent.

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59369 through 59370) for a full discussion and rationale for the CY 2018 policies and use of modifier “JG”. In the CY 2019 OPPS/ASC proposed rule (83 FR 37125), for CY 2019, we proposed to continue the 340B Program policies that were implemented in CY 2018 with the exception of the way we calculate payment for 340B-acquired biosimilars (that is, we proposed to pay for non-pass-through 340B-acquired biosimilars at ASP minus 22.5 percent of the biosimilar’s ASP, rather than of the reference product’s ASP). More information on our revised policy for the payment of biosimilars acquired through the 340B Program is available in section V.B.2.c. of this final rule. We proposed, in accordance with section 1833(t)(14)(A)(iii)(II) of the Act, to pay for separately payable Medicare Part B drugs (assigned status indicator “K”), other than vaccines and drugs on pass-through payment status, that meet the definition of “covered outpatient drug” as defined in section 1927(k) of the Act, that are acquired through the 340B Program at ASP minus 22.5 percent when billed by a hospital paid under the OPPS that is not excepted from the payment adjustment. Medicare Part B drugs or biologicals excluded from the 340B payment adjustment include vaccines (assigned status indicator “L” or “M”) and drugs with OPPS transitional pass-through payment status (assigned status indicator “G”). As discussed in section V.B.2.c. of the proposed rule, we proposed to pay non-pass-through biosimilars acquired under the 340B Program at the biosimilar’s ASP minus 22.5 percent of the biosimilar’s ASP. We also proposed that Medicare would continue to pay for drugs or biologicals that were not purchased with a 340B discount at ASP+6 percent.

As stated earlier, to effectuate the payment adjustment for 340B-acquired drugs, CMS implemented modifier “JG”, effective January 1, 2018. For CY 2019, we proposed that hospitals paid under the OPPS, other than a type of hospital excluded from the OPPS, or excepted from the 340B drug payment policy for CY 2018, continue to be required to report modifier “JG” on the same claim line as the drug HCPCS code to identify a 340B-acquired drug. We also proposed for CY 2019 that rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals continue to be excepted from the 340B payment adjustment. We proposed that these hospitals be required to report informational modifier “TB” for 340B-acquired drugs, and continue to be paid ASP+6 percent.

Comment: One commenter supported the proposal to continue to pay for separately payable drugs and biologicals obtained through the 340B program at ASP minus 22.5 percent. The commenter believed the payment rate of ASP minus 22.5 percent will help CMS address the large amount of growth in the 340B Program by increasing oversight and promoting the integrity of the program.

Another commenter, MedPAC, also supported the proposal. MedPAC believed a lower payment rate allows beneficiaries to share in the savings from the 340B Program, better targets resources to hospitals providing the most uncompensated care, and still allows 340B hospitals to make a profit off the drugs obtained through the program. MedPAC preferred that the payment rate be ASP+6 percent minus a 10 percent discount with the savings assigned to a Medicare-funded uncompensated care pool, but noted that this policy requires Congressional action.

Response: We appreciate the commenters’ support.
Comment: Several commenters opposed the CY 2019 proposal to continue to pay for separately payable drugs and biologicals obtained through the 340B Program at ASP minus 22.5 percent. Many commenters stated that the new payment rate has hurt hospitals financially and has hurt efforts by hospitals to provide safety-net care to their patients. The commenters were also concerned about the same service costing more at non-340B hospitals than at hospitals enrolled in the 340B Program because drugs furnished at a non-340B hospital would be paid at ASP+6 percent while drugs furnished at a 340B hospital would be paid at ASP minus 22.5 percent. One commenter whose hospital provides cancer treatment stated the reductions in 340B payment mean the hospital cannot provide the broader cancer care options available at non-340B hospitals. Commenters also stated that reducing payment for drugs acquired through the 340B Program does not help reduce high drug costs. Many commenters asserted, as they have previously done, that CMS does not have the legal authority to implement payment reductions for drugs and biologicals obtained through the 340B Program. The commenters requested that CMS end its policy of paying for drugs obtained through the 340B program at ASP minus 22.5 percent. Instead, the commenters suggested that CMS go back to the payment policy that was in place before CY 2018 where drugs acquired through the 340B Program were paid at ASP+6 percent.

Response: The commenters stated that the payment rate of ASP minus 22.5 percent for drugs and biologicals has caused financial harm to hospitals and has caused problems for hospitals to provide safety-net care to their patients. We noted in the CY 2018 final rule with comment period (82 FR 59358 through 59359) that the OPPS payment rate of ASP+6 percent at that time significantly exceeded the discounts received for covered outpatient drugs by hospitals enrolled in the 340B Program, which can be as high as 50 percent below ASP (or higher through the PVP). As stated throughout that section, ASP minus 22.5 percent represents the average minimum discount that 340B enrolled hospitals paid under the OPPS receive.

Regarding the concerns of the commenters that drugs and biologicals and services where drugs and biologicals are packaged into the cost of the service would cost more at hospitals that do not participate in the 340B Program as compared to hospitals participating in the 340B Program, any differential in these costs is a feature of the 340B Program rather than Medicare payment policy. In fact, one of the objectives of our payment policy for drugs and biologicals acquired through the 340B Program is to lower costs for Medicare beneficiaries, and we believe it is appropriate that hospitals participating in the 340B Program pass the cost savings they receive to their beneficiaries.

Finally, regarding the commenters’ assertion that CMS lacks the legal authority to continue requiring payment reductions for drugs and biologicals obtained through the 340B Program, we refer these commenters to our detailed response regarding our statutory authority to require payment reductions for drugs and biologicals obtained through the 340B Program in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59359 through 59364).

After consideration of the public comments we received, we are finalizing our proposals without modification. For CY 2019, we are continuing the 340B Program policies that were implemented in CY 2018 with the exception of the way we are calculating payment for 340B-acquired biosimilars, which is discussed in section V.B.2.c. of this final rule with comment period. We refer readers to the CY 2018 final rule with comment period (82 FR 59369 through 59370) for more detail on the policies implemented in CY 2018 for drugs acquired through the 340B Program.

VI. Estimate of OPPS Transitional Pass-Through Spending for Drugs, Biologicals, Radiopharmaceuticals, and Devices

A. Background

Section 1833(t)(6)(E) of the Act limits the total projected amount of transitional pass-through payments for drugs, biologicals, radiopharmaceuticals, and categories of devices for a given year to an “applicable percentage,” currently not to exceed 2.0 percent of total program payments estimated to be made for all covered services under the OPPS furnished for that year. If we estimate before the beginning of the calendar year that the total amount of pass-through payments in that year would exceed the applicable percentage, section 1833(t)(6)(E)(iii) of the Act requires a uniform prospective reduction in the amount of each of the transitional pass-through payments made in that year to ensure that the limit is not exceeded. We estimate the pass-through spending to determine whether payments exceed the applicable percentage and the appropriate pro-rata reduction to the conversion factor for the projected level of pass-through spending in the following year to ensure that total estimated pass-through spending for the prospective payment year is budget neutral, as required by section 1833(t)(6)(E) of the Act.

For devices, developing an estimate of pass-through spending in CY 2019 entails estimating spending for two groups of items. The first group of items consists of device categories that are currently eligible for pass-through payment and that will continue to be eligible for pass-through payment in CY 2019. The CY 2008 OPPS/ASC final rule with comment period (72 FR 66778) describes the methodology we have used in previous years to develop the pass-through spending estimates for known device categories continuing into the applicable update year. The second group of items consists of items that we know are newly eligible, or project may be newly eligible, for device pass-through payment in the remaining quarters of CY 2018 or beginning in CY 2019. The sum of the CY 2019 pass-through spending estimates for these two groups of device categories equals the total CY 2019 pass-through spending estimate for device categories with pass-through payment status. We base the device pass-through estimated payments for each device category on the amount of payment as established in section 1833(t)(6)(D)(ii) of the Act, and as outlined in previous rules, including the CY 2014 OPPS/ASC final rule with comment period (78 FR 75034 through 75036). We note that, beginning in CY 2010, the pass-through evaluation process and pass-through payment for implantable biologicals newly approved for pass-through payment beginning on or after January 1, 2010, that are surgically inserted or implanted (through a surgical incision or a natural orifice) use the device pass-through process and payment methodology (74 FR 60476). As has been our past practice (76 FR 74335), in the CY 2019 OPPS/ASC proposed rule (83 FR 37126), we proposed to include an estimate of any implantable biologicals eligible for pass-through payment in our estimate of pass-through spending for devices. Similarly, we finalized a policy in CY 2015 that applications for pass-through payment for skin substitutes and similar products be evaluated using the medical device pass-through process and payment methodology (79 FR 66888). Therefore, as we did beginning in CY 2015, for CY 2019, we...
also proposed to include an estimate of any skin substitutes and similar products in our estimate of pass-through spending for devices.

For drugs and biologicals eligible for pass-through payment, section 1833(t)(6)(D)(i) of the Act establishes the pass-through payment amount as the amount by which the amount authorized under section 1842(o) of the Act (or, if the drug or biological is covered under a competitive acquisition contract under section 1847B of the Act, an amount determined by the Secretary equal to the average price for the drug or biological for all competitive acquisition areas and year established under such section as calculated and adjusted by the Secretary) exceeds the portion of the otherwise applicable fee schedule amount that the Secretary determines is associated with the drug or biological. Our estimate of drug and biological pass-through payment for CY 2019 for this group of items is $0, as discussed below, because we proposed to pay for most nonpass-through separately payable drugs and biologicals under the CY 2019 OPPS at ASP+6 percent (with the exception of 340B-acquired separately payable drugs, for which we do not yet have sufficient data to estimate a share of total drug payments), and because we proposed to pay for CY 2019 pass-through payment drugs and biologicals at ASP+6 percent, as we discuss in section V.A. of the proposed rule and this final rule with comment period.

Furthermore, payment for certain drugs, specifically diagnostic radiopharmaceuticals and contrast agents without pass-through payment status is packaged into payment for the associated procedures, and these products will not be separately paid. In addition, we policy-package all nonpass-through drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test or procedure and drugs and biologicals that function as supplies when used in a surgical procedure, as discussed in section III.A.3. of the proposed rule and this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37126), we proposed that all of these policy-packaged drugs and biologicals with pass-through payment status would be paid at ASP+6 percent, like other pass-through drugs and biologicals, for CY 2019. Therefore, our estimate of pass-through payment for policy-packaged drugs and biologicals with pass-through payment status approved prior to CY 2019 was not $0, as discussed below. In section V.A.5. of the proposed rule, we discussed our policy to determine if the costs of certain policy-packaged drugs or biologicals are already packaged into the existing APC structure. If we determine that a policy-packaged drug or biological approved for pass-through payment resembles predecessor drugs or biologicals already included in the costs of the APCs that are associated with the drug receiving pass-through payment, we proposed to offset the amount of pass-through payment for the policy-packaged drug or biological. For these drugs or biologicals, the APC offset amount is the portion of the APC payment for the specific procedure performed with the pass-through drug or biological, which we refer to as the policy-packaged drug APC offset amount. If we determine that an offset is appropriate for a specific policy-packaged drug or biological receiving pass-through payment, we proposed to reduce our estimate of pass-through payments for these drugs or biologicals by this amount.

Similar to pass-through spending estimates for devices, the first group of drugs and biologicals requiring a pass-through payment estimate consists of those products that were recently made eligible for pass-through payment and that will continue to be eligible for pass-through payment in CY 2019. The second group contains drugs and biologicals that we know are newly eligible, or project will be newly eligible in the remaining quarters of CY 2018 or beginning in CY 2019. The sum of the CY 2019 pass-through spending estimates for these two groups of drugs and biologicals constitutes our CY 2019 pass-through spending estimate for drugs and biologicals with pass-through payment status.

**B. Estimate of Pass-Through Spending**

In the CY 2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to set the applicable pass-through payment percentage limit at 2.0 percent of the total projected OPPS payments for CY 2019, consistent with section 1833(t)(6)(E)(i)(II) of the Act and our OPPS policy from CY 2004 through CY 2018 (82 FR 59371 through 59373).

For the first group, consisting of device categories that are currently eligible for pass-through payment and will continue to be eligible for pass-through payment in CY 2019, there are no active categories for CY 2019. Because there are no active device categories for CY 2019, we proposed an estimate for the first group of devices of $0. We did not receive any public comments on the proposal. Therefore, we are finalizing the proposed estimate for the first group of devices of $0 for CY 2019.

In estimating our proposed CY 2019 pass-through spending for device categories in the second group, we included: Device categories that we knew at the time of the development of the proposed rule will be newly eligible for pass-through payment in CY 2019; additional device categories that we estimated could be approved for pass-through status subsequent to the development of the proposed rule and before January 1, 2019; and contingent projections for new device categories established in the second through fourth quarters of CY 2019. In the CY 2019 OPPS/ASC proposed rule (83 FR 37127), we proposed to use the general methodology described in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66778), while also taking into account recent OPPS experience in approving new pass-through device categories. For the proposed rule, the estimate of CY 2019 pass-through spending for this second group of device categories was $10 million.

We did not receive any public comments on this pass-through spending estimate. As stated earlier in this final rule with comment period, we have decided to approve one device to receive pass-through status, the remede® System Transvenous Neurostimulator. The manufacturer of the remede® System provided utilization data that indicate the spending for the device would be approximately $2.5 million. However, it is possible that additional new devices may receive pass-through payment status during CY 2019, which would lead to the higher pass-through spending for new devices closer to our proposed estimate of $10 million. Therefore, we are finalizing the proposed estimate for this second group of devices of $10 million for CY 2019.

To estimate proposed CY 2019 pass-through spending for drugs and biologicals in the first group, specifically those drugs and biologicals recently made eligible for pass-through payment and continuing on pass-through payment status for CY 2019, we proposed to use the most recent Medicare hospital outpatient claims data regarding their utilization, information provided in the respective pass-through applications, historical hospital claims data, pharmaceutical industry information, and clinical information regarding those drugs or biologicals to project the CY 2019 OPPS utilization of the products.

For the known drugs and biologicals (excluding policy-packaged diagnostic radiopharmaceuticals, contrast agents, drugs, biologicals, and radiopharmaceuticals that function as supplies when used in a diagnostic test
or procedure, and drugs and biologicals that function as supplies when used in a surgical procedure) that will be continuing on pass-through payment status in CY 2019, we estimated the pass-through payment amount as the difference between ASP+6 percent and the payment rate for nonpass-through drugs and biologicals that will be separately paid at ASP+6 percent, which is zero for this group of drugs. Because payment for policy-packaged drugs and biologicals is packaged if the product was not paid separately due to its pass-through payment status, we proposed to include in the CY 2019 pass-through estimate the difference between payment for the policy-packaged drug or biological at ASP+6 percent (or WAC+6 percent, or 95 percent of AWP, if ASP or WAC information is not available) and the policy-packaged drug APC offset amount, if we determine that the policy-packaged drug or biological approved for pass-through payment resembles a predecessor drug or biological already included in the costs of the APCs that are associated with the drug receiving pass-through payment. For the proposed rule, using the proposed methodology described above, we calculated a CY 2019 proposed spending estimate for this first group of drugs and biologicals of approximately $61.5 million.

We did not receive any public comments on our proposal. Using our methodology for this final rule with comment period, we calculated a CY 2019 spending estimate for this first group of drugs and biologicals of approximately $50.9 million.

To estimate proposed CY 2019 pass-through spending for drugs and biologicals in the second group (that is, drugs and biologicals that we knew at the time of development of the proposed rule were newly eligible for pass-through payment in CY 2019, additional drugs and biologicals that we estimated could be approved for pass-through status subsequent to the development of the proposed rule and before January 1, 2019, and projections for new drugs and biologicals that could be initially eligible for pass-through payment in the second through fourth quarters of CY 2019), we proposed to use utilization estimates from pass-through applicants, pharmaceutical industry data, clinical information, recent trends in the per unit ASPs of hospital outpatient drugs, and projected annual changes in service volume and intensity as our basis for making the CY 2019 pass-through payment estimate. We also proposed to consider the most recent OPPS experience in approving new pass-through drugs and biologicals. Using our proposed methodology for estimating CY 2019 pass-through payments for this second group of drugs, we calculated a proposed spending estimate for this second group of drugs and biologicals of approximately $55.2 million.

We did not receive any public comments on our proposal. Therefore, for CY 2019, we are continuing to use the general methodology described above. For this final rule with comment period, we calculated a CY 2019 spending estimate for this second group of drugs and biologicals of approximately $39.9 million.

In summary, in accordance with the methodology described earlier in this section, for this final rule with comment period, we estimate that total pass-through spending for the device categories and the drugs and biologicals that are continuing to receive pass-through payment in CY 2019 and those device categories, drugs, and biologicals that first became eligible for pass-through payment during CY 2019 is approximately $100.8 million (approximately $10 million for device categories and approximately $90.8 million for drugs and biologicals) which represents 0.14 percent of total projected OPPS payments for CY 2019 (approximately $74 billion). Therefore, we estimate that pass-through spending in CY 2019 will not amount to 2.0 percent of total projected OPPS CY 2019 program spending.

VII. OPPS Payment for Hospital Outpatient Visits and Critical Care Services

In the CY 2019 OPPS/ASC proposed rule (83 FR 37138), for CY 2019, we proposed to continue with our current clinic and emergency department (ED) hospital outpatient visits payment policies. For a description of the current clinic and ED hospital outpatient visits policies, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70449). We also proposed to continue and did not propose any change to our payment policy for critical care services for CY 2019. For a description of the current payment policy for critical care services, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70449), and for the history of the payment policy for critical care services, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75043). In the CY 2019 OPPS/ASC proposed rule, we sought public comments on any changes to these codes that we should consider for future rulemaking cycles. We continue to encourage commenters to provide the data and analysis necessary to justify any suggested changes.

We did not receive any public comments on our proposals to continue our current clinic and ED hospital outpatient visits payment policies and our current critical care services payment policies. Therefore, we are adopting these proposals as final without modification.

In section X.V. of the CY 2019 OPPS/ASC proposed rule (83 FR 37138 through 37143), for CY 2019, we proposed a method to control unnecessary increases in the volume of covered outpatient department services under section 1833(l)(2)(F) of the Act by utilizing a Medicare Physician Fee Schedule (PFS)-equivalent payment rate for the hospital outpatient clinic visit (HCPCS code G0463) when it is furnished by excepted off-campus provider-based departments (PBDs). For a full discussion of the proposal as well as the comment solicitation on potential methods to control for unnecessary increases in the volume of covered outpatient department services, we refer readers to section X.B. of this final rule with comment period.

VIII. Payment for Partial Hospitalization Services

A. Background

A partial hospitalization program (PHP) is an intensive outpatient program of psychiatric services provided as an alternative to inpatient psychiatric care for individuals who have an acute mental illness, which includes, but is not limited to, conditions such as depression, schizophrenia, and substance use disorders. Section 1861(f)(1) of the Act defines partial hospitalization services as the items and services described in paragraph (2) prescribed by a physician and provided under a program described in paragraph (3) under the supervision of a physician pursuant to an individualized, written plan of treatment established and periodically reviewed by a physician (in consultation with appropriate staff participating in such program), which sets forth the physician’s diagnosis, the type, amount, frequency, and duration of the items and services provided under the plan, and the goals for treatment under the plan. Section 1861(f)(2) of the Act describes the items and services included in partial hospitalization services. Section 1861(f)(3)(A) of the Act specifies that a PHP is a program furnished by a hospital to its outpatients or by a community mental health center (CMHC), as a distinct and organized
intensive ambulatory treatment service, offering less than 24-hour-daily care, in a location other than an individual’s home or inpatient or residential setting. Section 1861(ff)(3)(B) of the Act defines a CMHC for purposes of this benefit.

Section 1833(l)(1)(B)(i) of the Act provides the Secretary with the authority to designate the outpatient department (OPD) services to be covered under the OPPS. The Medicare regulations that implement this provision specify, at 42 CFR 419.21, that payments under the OPPS will be made for partial hospitalization services furnished by CMHCs as well as Medicare Part B services furnished to hospital outpatients designated by the Secretary, which include partial hospitalization services (65 FR 18444 through 18445).

Section 1833(l)(2)(C) of the Act requires the Secretary, in part, to establish relative payment weights for covered OPD services (and any groups of such services described in section 1833(l)(2)(A)(i) of the Act) based on median (or, at the election of the Secretary, mean) hospital costs using data on claims from 1996 and data from the most recent available cost reports. In pertinent part, section 1833(l)(2)(B) of the Act provides that the Secretary may establish groups of covered OPD services, within a classification system developed by the Secretary for covered OPD services, so that services classified within each group are comparable clinically and with respect to the use of resources. In accordance with these provisions, we have developed the PHP APCs. Because a day of care is the unit that defines the structure and scheduling of partial hospitalization services, we established a per diem payment methodology for the PHP APCs, effective for services furnished on or after July 1, 2000 (65 FR 18452 through 18455). Under this methodology, the median per diem costs were used to calculate the relative payment weights for the PHP APCs. Section 1833(l)(3)(A) of the Act requires the Secretary to review, not less often than annually, and revise the groups, the relative payment weights, and the wage and other adjustments described in section 1833(l)(2) of the Act to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors.

We began efforts to strengthen the PHP benefit through extensive data analysis, along with policy and payment changes finalized in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66670 through 66676). In that final rule with comment period, we made two refinements to the methodology for computing the PHP median: The first remapped 10 revenue codes that are common among hospital-based PHP claims to the most appropriate cost centers; and the second refined our methodology for computing the PHP median per diem cost by computing a separate per diem cost for each day rather than for each bill.

In CY 2009, we implemented several regulatory, policy, and payment changes, including a two-tier payment approach for partial hospitalization services under which we paid one amount for days with 3 services under PHP APC 0172 (Level 1 Partial Hospitalization) and a higher amount for days with 4 or more services under PHP APC 0173 (Level 2 Partial Hospitalization) (73 FR 68688 through 68693). We also finalized our policy to deny payment for any PHP claims submitted for days when fewer than 3 units of therapeutic services are provided (73 FR 68694). Furthermore, for CY 2009, we revised the regulations at 42 CFR 410.43 to codify existing basic PHP patient eligibility criteria and to add a reference to current physician certification requirements under 42 CFR 424.24 to conform our regulations to our longstanding policy (73 FR 68694 through 68695). We also revised the partial hospitalization benefit to include several coding updates (73 FR 68695 through 68697).

For CY 2010, we retained the two-tier payment approach for partial hospitalization services and used only hospital-based PHP data in computing the PHP APC per diem costs, upon which PHP APC per diem payment rates are based. We used only hospital-based PHP data because we were concerned about further reducing both PHP APC per diem payment rates without knowing the impact of the policy and payment changes we made in CY 2009. Because of the 2-year lag between data collection and rulemaking, the changes we made in CY 2009 were reflected for the first time in the claims data that we used to determine payment rates for the CY 2011 rulemaking (74 FR 60556 through 60559).

In the CY 2011 OPPS/ASC final rule with comment period (75 FR 71994), we established four separate PHP APC per diem payment rates: Two for CMHCs (APC 0172 (for Level 1 services) and APC 0173 (for Level 2 services)) and two for hospital-based PHPs (APC 0175 (for Level 1 services) and 0176 (for Level 2 services)), based on each provider type’s PHP data. For CY 2011, we also instituted a 2-year transition period for CMHCs to the CMHC APC per diem payment rates based solely on CMHC data. Under the transition methodology, CMHC APCs Level 1 and Level 2 per diem costs were calculated by taking 50 percent of the difference between the CY 2010 final hospital-based PHP median costs and the CY 2011 final CMHC median costs and then adding that number to the CY 2011 final CMHC median costs. A 2-year transition under this methodology moved us in the direction of our goal, which is to pay appropriately for partial hospitalization services based on each provider type’s data, while at the same time allowing providers time to adjust their business operations and protect access to care for Medicare beneficiaries. We also stated that we would review and analyze the data during the CY 2012 rulemaking cycle and, based on these analyses, we might further refine the payment mechanism. We refer readers to section X.B. of the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991 through 71994) for a full discussion.

In addition, in accordance with section 1301(b) of the Health Care and Education Reconciliation Act of 2010 (HCERA 2010), we amended the definition of a PHP in our regulations to specify that a PHP must be a distinct and organized intensive ambulatory treatment program offering less than 24-hour daily care other than in an individual’s home or in an inpatient or residential setting. In accordance with section 1301(a) of HCERA 2010, we revised the definition of a CMHC in the regulations to conform to the revised definition now set forth under section 1861(ff)(3)(B) of the Act (75 FR 71990). For CY 2012, as discussed in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74348 through 74352), we determined the relative payment weights for partial hospitalization services based on CMHCs and the relative payment weights for partial hospitalization services provided by hospital-based PHPs based exclusively on hospital data.

In the CY 2013 OPPS/ASC final rule with comment period, we finalized our proposal to base the relative payment weights that underpin the OPPS APCs, including the four PHP APCs (APCs 0172, 0173, 0175, and 0176), on the CMS APCs Level 1 and Level 2 per diem costs were calculated using the most recent claims and cost data for each provider type. For a detailed discussion on this policy, we refer readers to the CY 2013 OPPS/ASC
In the CY 2014 OPPS/ASC proposed rule (78 FR 43621 through 43622), we solicited comments on possible future initiatives that may help to ensure the long-term stability of PHPs and further improve the accuracy of payment for PHP services, but proposed no changes.

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75050 through 75053), we summarized the comments received on those possible future initiatives. We also continued to apply our established policies to calculate the four PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims data for each provider type. For a detailed discussion on this policy, we refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75047 through 75050).

In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66902 through 66908), we continued to apply our established policies to calculate the four PHP APC per diem payment rates based on PHP APC geometric mean per diem costs, using the most recent claims and cost data for each provider type.

In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70455 through 70465), we described our extensive analysis of the claims and cost data and rate-setting methodology. We found aberrant data from some hospital-based PHP providers that were not captured using the existing OPPS ±2 standard deviation trims for extreme cost-to-charge ratios (CCRs) and excessive CMHC charges resulting in CMHC geometric mean costs per day that were approximately the same as or more than the daily payment for inpatient psychiatric facility services. Consequently, we implemented a trim to remove hospital-based PHP service days that use a CCR that was greater than 5 to calculate costs for at least one of their component services, and a trim on CMHCs with a geometric mean cost per day that is above or below 2 (±2) standard deviations from the mean. We stated in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70456) that, without using a trimming process, the data from these providers would inappropriately skew the geometric mean per diem cost for Level 2 CMHC services.

In addition, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70459 through 70460), we corrected the cost inversion with an equitable adjustment to the actual geometric mean per diem costs by increasing the Level 2 hospital-based PHP APC geometric mean per diem costs and decreasing the Level 1 hospital-based PHP APC geometric mean per diem costs by the same factor, to result in a percentage difference equal to the average percent difference between the hospital-based Level 1 PHP APC and the Level 2 PHP APC for partial hospitalization services from CY 2013 through CY 2015.

Finally, we renumbered the PHP APCs, which were previously 0172, 0173, 0175, and 0176, to 5851, 5852, 5861, and 5862, respectively. For a detailed discussion of the PHP ratesetting process, we refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70467).

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 through 79691), we continued to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. However, we finalized a policy to combine the Level 1 and Level 2 PHP APCs for CMHCs and to combine the Level 1 and Level 2 APCs for hospital-based PHPs because we believed this would best reflect actual geometric mean per diem costs going forward, provide more predictable per diem costs, particularly given the small number of CMHCs, and generate more appropriate payments for these services, for example by avoiding the cost inversions for hospital-based PHPs addressed in the CY 2016 and CY 2017 OPPS/ASC final rules with comment period (80 FR 70459 and 81 FR 79682). We implemented an 8-percent outlier cap for CMHCs to mitigate potential outlier billing vulnerabilities by limiting the impact of inflated CMHC charges on outlier payments. We will continue to monitor the trends in outlier payments and consider policy adjustments as necessary.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59373 through 59381), we continued to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. We continued to designate a portion of the estimated 1.0 percent hospital outpatient outlier threshold specifically for CMHCs, consistent with the percentage of projected payments to CMHCs under the OPPS, excluding outlier payments.

For a comprehensive description of PHP payment policies and a detailed methodology for determining PHP per diem amounts, we refer readers to the CY 2016 and CY 2017 OPPS/ASC final rules with comment period (80 FR 70453 through 70455 and 81 FR 79678 through 79680).

B. PHP APC Update for CY 2019

1. PHP APC Geometric Mean per Diem Costs

For CY 2019, in the CY 2019 OPPS/ASC proposed rule (83 FR 37130), we proposed to continue to apply our established policies to calculate the PHP APC per diem payment rates based on geometric mean per diem costs using the most recent claims and cost data for each provider type. Specifically, we proposed to continue to use CMHC APC 5853 (Partial Hospitalization (3 or More Services Per Day)) and hospital-based PHP APC 5863 (Partial Hospitalization (3 or More Services Per Day)). We proposed to continue to calculate the geometric mean per diem costs for CY 2019 for APC 5853 for CMHCs using only CY 2017 CMHC claims data and the most recent CMHC cost data, and the CY 2019 geometric mean per diem costs for APC 5863 for hospital-based PHPs using only CY 2017 hospital-based PHP claims data and the most recent hospital cost data.

We summarize the public comments we received related to these PHP proposals and methodology and include our responses in the sections below focused on CMHC ratesetting and on hospital-based PHP ratesetting in this CY 2019 OPPS/ASC final rule with comment period.

2. Development of the PHP APC Geometric Mean per Diem Costs

In the CY 2019 OPPS/ASC proposed rule (83 FR 37130), for CY 2019 and subsequent years, we proposed to follow the PHP ratesetting methodology described in section VIII.B.2. of the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70466) to determine the PHP APCs’ geometric mean per diem costs and to calculate the payment rates for APCs 5853 and 5863, incorporating the modifications made in the CY 2017 OPPS/ASC final rule with comment period. As discussed in section VIII.B.1. of the CY 2017 OPPS/ASC final rule with comment period (81 FR 79680 through 79687), the geometric mean per diem cost for hospital-based PHP APC 5863 is based upon actual hospital-based PHP claims and costs for PHP service days providing 3 or more services. Similarly, the geometric mean per diem cost for CMHC APC 5853 is based upon actual CMHC claims and costs for CMHC service days providing 3 or more services.
The CMHC or hospital-based PHP APC per diem costs are the provider-type specific costs derived from the most recent claims and cost data. The CMHC or hospital-based PHP APC per diem payment rates are the national unadjusted payment rates calculated from the CMHC or hospital-based PHP APC per diem costs, after applying the OPPS budget neutrality adjustments described in section II.A.4. of this final rule with comment period.

As previously stated, in the CY 2019 OPPS/ASC proposed rule, we proposed to apply our established methodologies in developing the CY 2019 geometric mean per diem costs and payment rates, including the application of a ±2 standard deviation trim on costs per day for CMHCs and a CCR greater than 5 hospital service day trim for hospital-based PHP providers. These two trims were finalized in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70455 through 70462) for CY 2016 and subsequent years.

a. CMHC Data Preparation: Data Trims, Exclusions, and CCR Adjustments

For this CY 2019 final rule with comment period, prior to calculating the final geometric mean per diem cost for CMHC APC 5853, we prepared the data by first applying trims and data exclusions, and assessing CCRs as described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70463 through 70465), so that ratesetting is not skewed by providers with extreme data. For this CY 2019 OPPS/ASC final rule with comment period, we used the same data preparation steps. Before any trims or exclusions were applied, there were 45 CMHCs in the final PHP claims data file (compared to 44 in the CY 2019 OPPS/ASC proposed rule). Under the ±2 standard deviation trim policy, we excluded any data from a CMHC for ratesetting purposes when the CMHC’s geometric mean cost per day was more than ±2 standard deviations from the geometric mean cost per day for all CMHCs. By applying this trim for CY 2019 ratesetting, in this final rule with comment period, we excluded 4 CMHCs with geometric mean costs per day below the trim’s lower limit of $49.86 and 2 CMHCs with geometric mean costs per day above the trim’s upper limit of $293.60. This standard deviation trim removed 6 providers from the ratesetting whose overall effect on the data would have skewed downward the calculation of the final geometric mean per diem costs for CMHCs.

In accordance with our PHP ratesetting methodology, as stated in the proposed rule, we also remove service days with no wage index values, because we use the wage index data to remove the effects of geographic variation in costs prior to APC geometric mean per diem cost calculation (80 FR 70465). For this CY 2019 final rule with comment period ratesetting, 1 CMHC was missing wage index data for all of its service days and was excluded.

In addition to our trims and data exclusions, before determining the PHP APC geometric mean per diem costs, we also assess CCRs (80 FR 70463). Our longstanding PHP OPPS ratesetting methodology defaults any CMHC CCR greater than 1 to the statewide hospital CCR (80 FR 70457). For this CY 2019 final rule with comment period ratesetting, we identified 3 CMHCs that had CCRs greater than 1. These CMHCs’ CCRs were 1.053, 1.009, and 1.025, and each was defaulted to its appropriate statewide hospital CCR for CY 2019 ratesetting purposes.

In subsequent data preparation steps adjusted the CCR for 3 CMHCs by defaulting to the appropriate statewide hospital CCR and excluded 7 CMHCs, resulting in the inclusion of a total of 38 CMHCs (45 total—7 excluded) in our CY 2019 final rule with comment period ratesetting modeling (compared to a total of 36 CMHCs in our modeling in the CY 2019 OPPS/ASC proposed rule). The ±2 standard deviation trim and the exclusion for missing wage index data removed 425 CMHC claims out of a total of 14,431 CMHC claims, resulting in 14,006 CMHC claims used for ratesetting purposes. We believe that excluding providers with extremely low or high geometric mean costs per day or extremely low or high CCRs protects CMHCs from having that data inappropriately skew the calculation of the CMHC APC geometric mean per diem cost.

After applying all of the above trims, exclusions, and adjustments, we followed the methodology described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464 through 70465) and modified in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79687 through 79688, and 79691) to calculate the final PHP APC geometric mean per diem cost. The final CY 2019 geometric mean per diem cost for all CMHCs for providing 3 or more services per day (CMHC PHP APC 5853) is $121.62 (compared to the proposed geometric mean per diem cost of $119.51).

Below we summarize the public comments we received on our proposals related to continued to follow our existing CMHC ratesetting methodology and the calculation of the CMHC geometric mean per diem costs.

Comment: Two commenters objected to the continuation of separate APGs by provider type for CY 2019, stating that CMHCs and hospital-based PHPs provide the same services and follow the same regulations, but CMHCs provide them for less costs. One commenter acknowledged that hospitals have higher cost structures, which the commenter asserted was due to hospitals’ higher overhead allocation, but believed that CMHCs are being punished for providing more cost-effective and more intensive services.

Response: We disagree that CMHCs are being punished for providing more cost-effective and more intensive services. The difference in payment between CMHCs and hospital-based PHPs reflects differences in resource use. When Congress required the Secretary to implement a hospital outpatient prospective payment system, it required the payment system to group covered services with respect to clinical similarity and resource use (section 1833(f)(2) of the Act). Because CMHCs’ and hospital-based PHPs’ resource uses are different, these two provider types are paid under different APGs, based on their actual resource use.

Because the cost of providing partial hospitalization services differs significantly by site of service, we established different PHP payment rates for hospital-based PHPs and CMHCs in the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991 through 71994). With respect to the continued use of separate APGs, the commenter asserted that CMHCs and hospital-based PHPs should be punished for providing more cost-effective and more intensive services. The remaining PHP service days are used to calculate the geometric mean per diem cost for each PHP APC by taking the nth root of the product of n numbers for days where 3 or more services were provided.

59 Each revenue code on the CMHC claim must have a HCPCS code and charge associated with it. We're multiply each claim service line’s charges by the CMHC’s overall CCR (or statewide CCR, where the overall CCR was greater than 1) to estimate CMHC costs. Only the claims service lines containing PHP allowable HCPCS codes and PHP allowable revenue codes from the CMHC claims remaining after trimming are retained for CMHC cost determination. The costs, payments, and service units for all service lines occurring on the same service date, by the same provider, and for the same beneficiary are summed. CMHC service days must have 3 or more services provided to be assigned to CMHC APC 5853. The geometric mean per diem cost for CMHC APC 5853 is calculated by taking the nth root of the product of n numbers, for days where 3 or more services were provided. CMHC service days with costs ±3 standard deviations from the geometric mean costs within APC 5853 are deleted and removed from modeling. The remaining PHP service days are used to calculate the geometric mean per diem cost for each PHP APC by taking the nth root of the product of n numbers for days where 3 or more services were provided.
Comment: Two commenters opposed the continued use of the single-tiered payment system implemented in CY 2017 OPPS/ASC rulemaking. One of these commenters asserted that the single-tiered system was implemented due to the cost inversion in hospital-based PHP data and, therefore, was unfairly applied to CMHCs. Another commenter did not object to the single payment tier, but suggested that CMS monitor the data to ensure that the single-tiered APCs do not result in a decrease in the number of operational PHPs.

Response: We thank the commenters for their input. In the CY 2017 OPPS/ASC final rule with comment period, we cited several reasons for implementing the single-tiered payment system (81 FR 79682 through 79686), including the cost inversion in the hospital-based PHP data which the commenter cited. A cost inversion exists when, under a 2-tiered payment system, the Level 1 geometric mean per diem cost for providing exactly 3 services per day exceeds the Level 2 PHP APC geometric mean per diem cost for providing 4 or more services per day. The commenter is correct that CMHCs were not affected by a cost inversion as hospital-based PHPs were. However, in that same CY 2017 OPPS/ASC final rule with comment period, we noted that another primary reason for combining the 2-tiered system into a single tier, by provider type, was the decrease in the number of CMHCs (81 FR 79683). With a small number of providers, data from large providers with a high percentage of all PHP service days and unusually high or low geometric mean costs per day would have a more pronounced effect on the PHP APCs geometric mean per diem costs, skewing costs up or down. The effect would be magnified by continuing to split the geometric mean per diem costs further by distinguishing between Level 1 and Level 2 PHP services. A single PHP APC for each provider type for providing 3 or more PHP services per day reduces these cost fluctuations and provides more stability in the PHP APC geometric mean per diem costs.

We do not believe that the single-tier payment system will lead to a reduction in the number of PHPs because total payments to an individual CMHC using the single-tier payment system are approximately equal to total payments to that same CMHC if the previous 2-tiered payment system were used instead. The calculated rates for APCs 5853 and 5863 continue to be based upon the actual costs for CMHCs and hospital-based PHPs, respectively. Therefore, the payment rates for the single-tier PHP APCs are an appropriate approximation of provider costs, and should not result in reduced access. As we noted in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79685), the single-tier PHP APCs are calculated by following the existing methodology for ratesetting, except that the geometric mean per diem costs for each provider type were calculated for days providing 3 or more partial hospitalization services, as opposed to being calculated separately for days with exactly 3 services and for days with 4 or more services, as was previously done. The combined PHP APCs’ geometric mean costs are similar to a weighted average of actual provider costs. As such, combining the PHP APCs geometric mean per diem costs does not reduce total costs or total payments by provider type. We refer readers to the CY 2017 OPPS/ASC final rule with comment period for a detailed review of the methodology used in determining per diem costs using the single-tier PHP APCs (81 FR 79686 through 79688).

The 2017 claims data used for this CY 2019 ratesetting are the first year of data using the single-tier payment system. We will monitor the data for any unintended consequences on the number of operational PHPs associated with using the single-tier payment system. We note that the number of PHP providers is generally affected by multiple factors, such as business and market conditions, competition, estimated profit margins, private insurance coverage changes, Federal and State fraud and abuse efforts, and community support for mental health treatment.

Comment: Several commenters questioned CMS’ use of the ±2 standard deviation trim on CMHC costs per day, and asked why it was different from the OPPS ±3 standard deviation trim which is applied to hospital-based PHPs. The commenters noted that the trims were implemented to help prevent inappropriate fluctuations in the data, but were concerned that this trim removed costs from the data, and that this trim resulted in the decline in the costs per day.

Response: The ±2 standard deviation trim on CMHC costs per day was implemented in the CY 2016 OPPS final rule with comment period (80 FR 70455 through 70462) in order to protect CMHCs from having extreme costs per day inappropriately skew the CMHC PHP APC geometric mean per diem costs.

As part of the effort to increase the accuracy of the PHP per diem costs, for the CY 2016 ratesetting, we completed an extensive analysis of the claims and cost data. That analysis identified aberrant data from several providers that impacted the calculation of the proposed PHP geometric mean per diem costs. For example, we found claims with excessive CMHC charges resulting in CMHC geometric mean costs per day that were approximately the same as or more than the daily payment for inpatient psychiatric facility services. For an outpatient program like PHP, because it does not incur room and board costs such as an inpatient stay would, these costs per day were excessive. In addition, we found some CMHCs had very low costs per day (less than $25 per day) (80 FR 70456). The ±2 standard deviation trim on CMHC costs per day excludes providers with extremely low or extremely high costs per day, and protects CMHCs from having those extreme costs inappropriately skew the CMHC PHP APC geometric mean per diem costs.

In addition, in that CY 2016 OPPS final rule with comment, we noted that the ±2 standard deviation trim excludes CMHCs with aberrant data from the ratesetting process while allowing for the use of as much data as possible. In addition, we stated that implementing a ±2 standard deviation trim on CMHCs would target these aberrancies without limiting overall per diem cost increases. For normally distributed data, ±2 standard deviations from the mean capture approximately 95 percent of the data. Our analyses for the CY 2016 ratesetting also showed that a higher trim level, such as a ±2.5 standard deviation trim or the ±3 standard deviation trim used by the rest of OPPS, did not remove the CMHCs with aberrant data from the ratesetting process (80 FR 70456 and 70457).

In this CY 2019 OPPS/ASC final rule, the ±2 standard deviation trim for CMHC costs per day removed 6 CMHCs from ratesetting, which affected the final...
per diem costs. It removed both low-cost and high-cost providers that fail the trim; its net effect on the CY 2019 ratesetting data was to increase CMHC geometric mean per diem costs. For CY 2019, if we did not apply the ±2 standard deviation trim on CMHC costs/day, the final CMHC geometric mean per diem cost would have been $120.77. This is less than the geometric mean per diem cost of $121.62 which we are finalizing, and which is after applying the ±2 standard deviation trim.

With regard to the questions about why the same trims are not used for both CMHCs and hospital-based PHPs, we refer readers to the discussion in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70458). As we noted in that CY 2016 OPPS/ASC final rule with comment period, there are differences in the ratesetting process between hospital-based PHPs and CMHCs, which are largely due to differences between the hospital cost reports and the CMHC cost reports, and we believe that having different trims more appropriately targets aberrant data for each provider type. As noted previously, the OPPS ±3 standard deviation trim on per diem costs did not remove the aberrant CMHC data. We considered applying the ±2 standard deviation trim on per diem costs to hospital-based PHP providers, but an alternative trim on hospital-based CCRs greater than 5 allowed for use of more data from hospital-based providers and still removed aberrant data. We continue to believe this trim based on hospital-based CCRs is more effective in removing aberrant hospital-based PHP data and allows for the use and retention of more data than a ±2 standard deviation trim on hospital-based PHP costs per day.

**Comment:** Several commenters objected to the decline in the CMHC per diem costs that were proposed, and were concerned about the ability to maintain access to services. One commenter noted that CMHCs cannot provide all of the services they provide on a daily basis at the proposed payment rate. Some commenters also stated that CMHCs incur extra costs to meet the CMHC conditions of participation (CoPs), have more costly staff, or have experienced an increase in bad debt expense. A few commenters noted that the number of CMHCs nationally had declined greatly as a result of declines in payment and payment fluctuations. One commenter stated that setting CMHCs’ payment rates based on a small number of CMHCs does not reflect the actual cost of providing these services and expressed concern that basing payments at the mean or median level would result in half of CMHCs receiving payments less than their cost, which would warrant that more CMHCs would close, further limiting access. Commenters requested that CMS reconsider the payment rate reduction, which one commenter believed resulted in PHP services moving toward extinction in the current mode. Another commenter questioned if CMS had a veiled motivation to eliminate CMHCs altogether, and wondered if CMHCs were still considered the “fraud benefit.” Commenters also were concerned that if CMHC access declined, beneficiaries would be pushed toward higher-cost outpatient departments, resulting in higher out-of-pocket costs for beneficiaries. One commenter noted that CMHCs are in keeping with the health care trend to service patients in their communities, rather than forcing patients to travel to a medical center.

**Response:** The OPPS pays for outpatient services, including partial hospitalization services based on the geometric mean per diem costs of providing services using provider data from claims and cost reports, in accordance with statute. For this CY 2019 OPPS/ASC final rule with comment period, the final geometric mean per diem cost for CMHC APC 5853 is $121.62, which is a slight increase from the proposed geometric mean per diem cost, but a 15-percent reduction from the CY 2018 final geometric mean per diem cost. In response to commenters concerned that CMHCs cannot provide all of the services offered on a daily basis at the proposed payment rate, we remind commenters that we calculate the PHP APC geometric mean per diem costs based on the data provided for each type of provider to determine payment for these services. The final PHP APC geometric mean per diem costs for CY 2019 reflect actual provider costs of covered services. We believe that this system provides appropriate payment for covered partial hospitalization services based on actual provider costs. We further note that section 1861(ff)(2)(l) of the Act explicitly prohibits Medicare from paying for the costs of meals or transportation, which some CMHCs incur. Therefore, these costs, although incurred by CMHCs, are not covered under the OPPS.

In response to the commenters who stated that CMHCs incur extra costs to meet the CMHC CoPs, most (if not all) of the costs associated with adhering to CoPs should be captured in the data used in ratesetting and, therefore, are accounted for when computing the geometric mean per diem costs. Similar to the requirement for CMHCs to comply with CMHC CoPs, hospital-based PHPs must also comply with hospital CoPs. All Medicare-participating facilities have CoPs or other requirements that must be met, and CMHCs are specifically being singled out for compliance, nor are there “extra” costs associated with the CMHC CoPs.

Allowable labor costs for providing direct patient care would also be captured in the cost report data used for ratesetting. We refer the commenters to the instructions for the CMHC cost reports for more information on capturing the costs associated with meeting CoPs and with labor costs for direct patient care, which are available online in links to Chapters 18 and 45 found at: https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Paper-Based-Manuals-Items/CM5021935.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=descending. The covered costs of providing PHP care to beneficiaries at CMHCs are captured as part of CMHC ratesetting, and include allowable labor costs and the costs of complying with CoPs.

The reduction to bad debt reimbursement was a result of provisions of section 3201 of the Middle Class Tax Extension and Job Creation Act of 2012 (Pub. L. 112–96). The reduction to bad debt reimbursement impacted all providers eligible to receive bad debt reimbursement, as discussed in the CY 2013 End-Stage Renal Disease final rule (77 FR 67518). Medicare currently reimburses bad debt for eligible providers at 65 percent. Therefore, CMHCs are not specifically being singled out for a payment reduction as a result of bad debt expenses. Because this percentage was enacted by Congress, CMS does not have the authority to change the percentage.

We appreciate the commenter’s input regarding the effect any reduction in PHP payment rates would have on access to care, but we disagree with the commenter’s assertion that CMS considers CMHCs to be a “fraud benefit” or that CMS has any motivation (veiled or otherwise) to eliminate CMHCs. Both are simply not true; we appreciate the work CMHCs do to care for a particularly vulnerable population with serious mental illnesses. We are very concerned about the decline in the number of CMHCs, but, as noted in a previous comment response in this section, we believe that a number of factors affect PHP provider closures. We will continue working to strengthen...
access to both CMHCs and hospital-based PHPs for eligible Medicare beneficiaries. As part of that process, we regularly review our methodology to ensure that it is appropriately capturing the cost of care reported by providers. For example, for the CY 2016 ratesetting, we extensively reviewed the methodology used for PHP ratesetting. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462 through 70466), we also included a detailed description of the ratesetting process to help all PHP providers record costs correctly so that we can more fully capture PHP costs in ratesetting.

We want to ensure that CMHCs remain a viable option as providers of mental health care in the beneficiary’s own community. We agree that beneficiaries receiving care at a CMHC instead of a hospital-based PHP would have a lower out-of-pocket cost, which increases the attractiveness of CMHCs to those needing their services. We will continue to explore policy options for strengthening the PHP benefit and increasing access to the valuable services provided by CMHCs as well as by hospital-based PHPs.

Comment: One commenter suggested that CMS consider paying CMHCs using a quality-based payment system, and that CMS use value-based purchasing. The commenter recommended that, instead of basing payment rates on estimated actual median costs of claims, CMS look at the value provided by the quality of provided services using different methods such as records reviews, due to lack of medical necessity or inadequate documentation, site visits, interviews with patients, and, most importantly, patient outcomes. The commenter believed that rewarding providers for higher-quality care, as measured by selected standards instead of rewarding providers by increasing costs, is a better way to improve the quality of any service.

Response: Currently, there is no statutory language explicitly authorizing a value-based purchasing program for PHPs. We responded to a similar public comment in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70462) and refer readers to a summary of that comment and our response. To reiterate, sections 1833(t)(2) and 1833(t)(9) of the Act set forth the requirements for establishing and adjusting OPPS payment rates, which include PHP payment rates. Section 1833(t)(17) of the Act authorizes the Hospital OQR Program, which applies a payment reduction to subsection (d) hospital outpatient program requirements. In the CY 2015 OPPS/ASC proposed rule (79 FR 41040), we considered future inclusion of, and requested comments on, the following quality measures addressing PHP issues that would apply in the hospital outpatient setting: (1) 30-day Readmission; (2) Group Therapy; and (3) No Individual Therapy. We also refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66957 through 66958) for a more detailed discussion of PHP measures considered for inclusion in the Hospital OQR Program in future years. The Hospital OQR Program does not apply to CMHCs, and there are no quality measures applied to CMHCs.

Comment: One commenter noted that, in the past, CMS stated that CMHCs provide fewer services and have less costly staff than hospitals.

Response: We believe that the commenter may be referring to the CY 2011 OPPS/ASC final rule with comment period (75 FR 71991), wherein CMS stated we believe that CMHCs have a lower cost structure than their hospital-based counterparts, because the data showed that CMHCs provide fewer PHP services in a day and use less costly staff than hospital-based PHPs. Those statements were based on CY 2009 claims and cost data, which differ from more recent claims and cost data. Each year, we calculate geometric mean per diem costs based on updated claims and cost reports. For example, our CY 2019 geometric mean per diem costs and the APC payment rates are based upon CY 2017 claims and cost data. We refer the commenter to the utilization data in section VIII.B.4. of this CY 2019 final rule with comment period for details on current CMHC utilization. In addition, we continually seek to increase the accuracy of our payment rates. As noted previously, as part of the effort to increase the accuracy of the PHP APCs’ per diem costs, for the CY 2016 ratesetting, we completed an extensive analysis of the claims and cost data. That analysis identified aberrant data from several providers that impacted the calculation of the proposed PHP APCs’ geometric mean per diem costs.

For the CY 2019 proposed rule and for this CY 2019 final rule with comment period, we followed a data preparation process for hospital-based PHP providers that is similar to that used for CMHCs by applying trims and data exclusions as described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70465) so that our ratesetting is not skewed by providers with extreme data. Before any trimming or exclusions were applied, there were 426 hospital-based PHP providers in the final CY 2017 PHP claims data used in this CY 2019 OPPS/ASC final rule with comment period (compared to 394 hospital-based PHPs in the CY 2019 OPPS/ASC proposed rule).

For hospital-based PHP providers, we applied a trim on hospital service days when the CCR was greater than 5 at the cost center level. This trim removed hospital-based PHP service days that use a CCR greater than 5 to calculate costs for at least one of their component services. Unlike the ±2 standard deviation trim, which excluded CMHC providers that failed the trim, the CCR greater than 5 trim excluded any hospital-based PHP service day where any of the services provided on that day were associated with a CCR greater than 5 (in other words, the CCR greater than 5 trim is a (service) day-level trim in contrast to the CMHC ±2 standard deviation trim, which is a provider-level trim). Applying this CCR greater than 5 trim removed from our final rule ratesetting affected service days from 3 hospital-based PHP providers with CCRs greater than 5. However, 100 percent of the service days for 1 of these affected hospital-based PHP providers had at least 1 service associated with a CCR of 9.5744, so the trim removed that 1 provider entirely from our final rule ratesetting. The two other providers remained in the ratesetting data, but with affected service days trimmed out. In addition, 49 hospital-based PHPs were removed from our final rule ratesetting due to high hospital service day costs and, therefore, no days with PHP payment. No hospital-based PHPs were removed for missing wage index data or by the OPPS ±3 standard deviation trim on costs per day.

Therefore, we trimmed out 49 hospital-based PHP providers [1 with all service days having a CCR greater than 5] + (48 with zero daily costs and no PHP payment), resulting in 377 (426 total – 49 excluded) hospital-based PHP providers in the data used for final rule with comment period ratesetting (compared to 374 hospital-based PHPs in the CY 2019 OPPS/ASC proposed rule). No hospital-based PHP providers were defaulted to using their overall hospital ancillary CCRs due to outlier cost center CCR values. After completing these data preparation steps, we calculated the final CY 2019 geometric mean per diem cost for hospital-based PHP APC S663 for hospital-based PHP services by following the methodology described in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70464 through 70465) and modified in the CY 2017...
OPPS/ASC final rule with comment period (81 FR 79687 and 79691) to calculate the geometric mean per diem cost. The final CY 2019 geometric mean per diem cost for hospital-based PHP providers that provide 3 or more services per service day (hospital-based PHP APC 5863) is $222.76 (compared to $220.52 in the CY 2019 OPPS/ASC proposed rule).

Comment: One commenter appreciated the CY 2019 per diem increase for hospital-based PHPs. The commenter stated that the minimum rate should be set at the geometric mean rate, rather than at the 2-percent reduction rate of $216.55, as providers are hit with a second 2-percent reduction again at actual claim payout. The commenter stated this reduced the hospital-based PHP rate by 4 percent total, and places more than half of the providers in a payment setting below their daily costs of providing the services.

Response: The final hospital-based PHP APC geometric mean per diem cost is $222.76, which is a slight increase from the proposed $220.52 geometric mean per diem cost in the CY 2019 OPPS/ASC proposed rule (83 FR 37131), and a 7-percent increase from the $208.09 CY 2018 final geometric mean per diem cost (82 FR 59378). In the OPPS ratessetting, the geometric mean per diem costs are the basis for the final per diem rates. However, those costs undergo additional ratessetting steps before they are developed into payment rates, a process which is described in Part 2 of the Claims Accounting narrative under supporting documentation for this CY 2019 OPPS/ASC final rule with comment period available on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

The final CY 2019 PHP APC geometric mean per diem cost for CMHC APC 5853 is $212.62, and for hospital-based PHP APC 5863 are $222.76, as stated above and shown in Table 43. The final PHP APCs payment rates, which are derived from these PHP APCs geometric mean per diem costs, are included in Addendum A to this final rule with comment period (which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html).

61 As discussed in section II.A. of this CY 2019 OPPS/ASC final rule with comment period, OPPS APC geometric mean per diem costs (including PHP APC geometric mean per diem costs) are divided by the geometric mean per diem cost for APC 5812 (Clinic Visits and Related Services) to calculate each PHP APC’s unscaled relative payment weight. An unscaled relative payment weight is one that is not yet adjusted for budget neutrality. Budget neutrality is required under section 1833(t)(9)(B) of the Act, and ensures that the estimated aggregate weight under the OPPS for a calendar year is neither greater than nor less than the estimated aggregate weight that would have been made without the changes. To adjust for budget neutrality (that is, to scale the weights), we compare the estimated aggregated weight using the scaled relative payment weights from the previous calendar year at issue. We refer readers to the ratessetting procedures described in Part 2 of the OPPS Claims Accounting narrative and in section II. of this final rule with comment period for more information on scaling the weights, and for details on the final steps of the process that lead to PHP APC per diem payment rates. The OPPS Claims Accounting narrative is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html.
3. Changes to the Revenue-Code-to-Cost Center Crosswalk

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79691), we received public comments identifying an issue that may have contributed to a decreased PHP median cost for hospital-based PHPs. The commenters stated that the lack of a required standardized PHP cost center on the Medicare cost report may be creating some cost-finding nuances in the cost report itself—for example, inaccurate step-down of overhead cost allocations to the PHP program, diluted CCRs by the comingling of PHP and “Intensive Outpatient Program (IOP)” on the cost report, among others. We agreed with the commenters that, if PHP costs are combined with other less intensive outpatient mental health treatment costs in the same cost center, the CCR values could be diluted, leading to lower geometric mean per diem costs being calculated. We stated in response that we would consider adding a cost center to the hospital cost report for PHP costs only.

On November 17, 2017, in Transmittal No. 12, we added a new cost center, “Partial Hospitalization Program,” on Line 93.99 of Worksheet A (Line 93.99 is also displayed on Worksheets B, Parts I and II, B–1; and C, Parts I and II) for hospital-based PHPs, for cost reporting periods ending on or after August 31, 2017 (https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2017Downloads/R12P240.pdf). On January 30, 2018, in Transmittal No. 13, we changed the implementation date from cost reporting periods ending on or after August 31, 2017, to cost reporting periods ending on or after September 30, 2017 (https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2017Downloads/R12P240.pdf). The instructions for this new PHP cost center (Line 93.99) indicate that effective for cost reporting periods ending on or after September 30, 2017, the provider is to enter the costs of providing hospital-based partial hospitalization program (PHP) services as defined in section 1861(ff) of the Act. Therefore, this cost center is to include all costs associated with providing PHP services, as defined in the statute (for example, occupational therapy, individual and group therapy, among others). It should not include costs for non-PHP outpatient mental health services, such as costs from what providers refer to as “Intensive Outpatient Programs.”

During current hospital-based PHP ratesetting, costs are estimated by multiplying revenue code charges on the claim by the appropriate cost center-level CCR from the hospital cost report (80 FR 70465). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464). Each PHP revenue code is associated with particular cost centers on the cost report (80 FR 70464). The appropriate cost center-level CCR is identified by using the OPPS Revenue-Code-to-Cost-Center crosswalk; the current crosswalk must be updated for hospital-based PHP ratesetting (80 FR 70463 through 70464).

As such, CMHCs do not have a crosswalk for use in CY 2019 and subsequent years, which would provide a more accurate and operationally simpler method of matching hospital-based PHP charges to the correct hospital-based PHP cost center CCR without affecting non-PHP ratesetting. We note that, because CMHCs have their own cost reports, we use each CMHC’s overall CCR in estimating costs for PHP ratesetting (80 FR 70463 through 70464). As such, CMHCs do not have a crosswalk and, therefore, the proposal to create a PHP-only crosswalk does not apply to CMHCs. Therefore, we proposed that, for CY 2019 and subsequent years, hospital-

---

TABLE 43.—CY 2019 FINAL PHP APC GEOMETRIC MEAN PER DIEM COSTS

<table>
<thead>
<tr>
<th>CY 2019 APC</th>
<th>Group Title</th>
<th>Final PHP APC Geometric Mean Per Diem Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>5853</td>
<td>Partial Hospitalization (3 or more services per day) for CMHCs</td>
<td>$121.62</td>
</tr>
<tr>
<td>5863</td>
<td>Partial Hospitalization (3 or more services per day) for hospital-based PHPs</td>
<td>$222.76</td>
</tr>
</tbody>
</table>
based PHPs would follow a new Revenue-Code-to-Cost-Center crosswalk that only applies to hospital-based PHPs. We proposed that this new PHP-only Revenue-Code-to-Cost-Center crosswalk would be comprised of the existing PHP-allowable revenue codes and would map each of those PHP-allowable revenue codes to the new PHP cost center Line 93.99 as the primary cost center source for the CCR. We proposed that for revenue code 0904, the secondary cost center for CY 2019 and subsequent years would be the existing secondary cost center 3550 (“Psychiatric/Psychological Services”). Similarly, we proposed that for revenue code 0904, the tertiary cost center for CY 2019 and subsequent years would be existing tertiary cost center 9000 (“Clinic”). We considered expanding the Revenue-Code-to-Cost-Center crosswalk hierarchy to add a 4th or quaternary level to the hierarchy, before the system would default to the overall hospital ancillary CCR. However, we evaluated the usage of the current hierarchy for revenue code 0904 for the CY 2017, CY 2018, and CY 2019 PHP ratesetting modelling, and found that expanding the hierarchy would not be necessary. Our analysis showed that the existing primary cost center 3580 (“Recreational Therapy”) for revenue code 0904 had not been used during any of the past 3 years.

We did not receive any public comments on our proposals related to the PHP-only Revenue-Code-to-Cost-Center crosswalk and, therefore, are finalizing our proposals, as proposed, for CY 2019 and subsequent years.

Our previous and newly finalized PHP-only Revenue-Code-to-Cost-Center Crosswalks are shown in Table 44 below.

BILLING CODE 4120–01–P
<table>
<thead>
<tr>
<th>PHP Allowable Revenue Code</th>
<th>Previous Hierarchy (applicable in CY 2018)</th>
<th>Finalized New PHP-only Hierarchy (applicable in CY 2019 and beyond)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Primary Cost Center Source for CCR</td>
<td>Secondary Cost Center Source for CCR</td>
</tr>
<tr>
<td>0430</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0431</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0432</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0433</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0434</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0435</td>
<td>RESERVERED</td>
<td></td>
</tr>
<tr>
<td>0436</td>
<td>RESERVERED</td>
<td></td>
</tr>
<tr>
<td>0437</td>
<td>RESERVERED</td>
<td></td>
</tr>
<tr>
<td>0438</td>
<td>RESERVERED</td>
<td></td>
</tr>
<tr>
<td>0439</td>
<td>6700 Occupational Therapy</td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>3550 (Psychiatric/Psychological Services)</td>
<td>9000 (Clinic)</td>
</tr>
<tr>
<td>0904</td>
<td>3580 (Recreational Therapy)</td>
<td>3550 (Psychiatric/Psychological Services)</td>
</tr>
</tbody>
</table>
4. PHP Service Utilization Updates

We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37133 through 37134) that, while we were not proposing any changes to the policy on PHP service utilization, we would continue to monitor the provision of days with only 3 services. In the CY 2016 OPPS/ASC final rule with comment period (81 FR 79684 through 79685), we expressed concern over the low frequency of individual therapy provided to beneficiaries. The CY 2017 claims data used for this CY 2019 final rule with comment period revealed some changes in the provision of individual therapy compared to CY 2016 and CY 2015 claims data as shown in the Table 45 below.

<table>
<thead>
<tr>
<th>PHP Allowable Revenue Code</th>
<th>Previous Hierarchy (applicable in CY 2018)</th>
<th>Finalized New PHP-only Hierarchy (applicable in CY 2019 and beyond)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0914 PHP</td>
<td>3550 (Psychiatric/ Psychological Services)</td>
<td>9000 (Clinic)</td>
</tr>
<tr>
<td>0915 PHP</td>
<td>3550 (Psychiatric/ Psychological Services)</td>
<td>9000 (Clinic)</td>
</tr>
<tr>
<td>0916 PHP</td>
<td>3550 (Psychiatric/ Psychological Services)</td>
<td>9000 (Clinic)</td>
</tr>
<tr>
<td>0918 PHP</td>
<td>3550 (Psychiatric/ Psychological Services)</td>
<td>9000 (Clinic)</td>
</tr>
<tr>
<td>0942 PHP</td>
<td>9000 (Clinic)</td>
<td>9399 (PHP)</td>
</tr>
</tbody>
</table>

### TABLE 45.—PROVISION OF INDIVIDUAL THERAPY, BY PROVIDER TYPE AND CLAIMS YEAR

<table>
<thead>
<tr>
<th>Provider Type</th>
<th>Percent of Days with 3 Services Only</th>
<th>Percent of Days with 4 or More Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMHCs</td>
<td>CY 2015 Claims 7.9%</td>
<td>CY 2015 Claims 4.4%</td>
</tr>
<tr>
<td></td>
<td>CY 2016 Claims 8.5%</td>
<td>CY 2016 Claims 5.0%</td>
</tr>
<tr>
<td></td>
<td>CY 2017 Claims 4.0%</td>
<td>CY 2017 Claims 4.3%</td>
</tr>
<tr>
<td>Hospital-based PHPs</td>
<td>CY 2015 Claims 4.0%</td>
<td>Hospital-based PHPs CY 2015 Claims 4.0%</td>
</tr>
<tr>
<td></td>
<td>CY 2016 Claims 4.7%</td>
<td>CY 2016 Claims 5.8%</td>
</tr>
<tr>
<td></td>
<td>CY 2017 Claims 3.9%</td>
<td>CY 2017 Claims 5.1%</td>
</tr>
</tbody>
</table>
As shown in Table 45, both CMHCs and hospital-based PHPs have decreased the provision of individual therapy, based on the CY 2017 claims used for this final rule with comment period. In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33640 and 82 FR 59378), we stated that we are aware that our single-tier payment policy may influence a change in service provision because providers are able to obtain payment that is heavily weighted to the cost of providing 4 or more services when they provide only 3 services. We indicated that we are interested in ensuring that providers furnish an appropriate number of services to beneficiaries enrolled in PHPs. Therefore, with the CY 2017 implementation of APC 5853 and APC 5863 for providing 3 or more PHP services per day, we are continuing to monitor utilization of days with only 3 PHP services.

For this CY 2019 OPPS/ASC final rule with comment period, we used the final update of the CY 2017 claims data. Table 46 below shows the utilization findings based on the most recent claims data.

As shown in Table 46, both CMHCs and hospital-based PHPs have decreased the provision of individual therapy, based on the CY 2017 claims used for this final rule with comment period. In the CY 2018 OPPS/ASC proposed rule and final rule with comment period (82 FR 33640 and 82 FR 59378), we stated that we are aware that our single-tier payment policy may influence a change in service provision because providers are able to obtain payment that is heavily weighted to the cost of providing 4 or more services when they provide only 3 services. We indicated that we are interested in ensuring that providers furnish an appropriate number of services to beneficiaries enrolled in PHPs. Therefore, with the CY 2017 implementation of APC 5853 and APC 5863 for providing 3 or more PHP services per day, we are continuing to monitor utilization of days with only 3 PHP services.

For this CY 2019 OPPS/ASC final rule with comment period, we used the final update of the CY 2017 claims data. Table 46 below shows the utilization findings based on the most recent claims data.

### Table 46—Percentage of PHP Days by Service Unit Frequency

<table>
<thead>
<tr>
<th></th>
<th>CY 2015</th>
<th>CY 2016*</th>
<th>CY 2017*</th>
<th>% Change**</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMHCs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent of Days with 3 services</td>
<td>4.7%</td>
<td>4.8%</td>
<td>5.6%</td>
<td>16.7%</td>
</tr>
<tr>
<td>Percent of Days with 4 services</td>
<td>62.9%</td>
<td>70.3%</td>
<td>74.0%</td>
<td>5.3%</td>
</tr>
<tr>
<td>Percent of Days with 5 or more services</td>
<td>32.4%</td>
<td>24.9%</td>
<td>20.5%</td>
<td>-17.7%</td>
</tr>
<tr>
<td>Hospital-based PHPs:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent of Days with 3 services</td>
<td></td>
<td></td>
<td>12.4%</td>
<td>10.9%</td>
</tr>
<tr>
<td>Percent of Days with 4 services</td>
<td></td>
<td></td>
<td>69.8%</td>
<td>64.9%</td>
</tr>
<tr>
<td>Percent of Days with 5 or more services</td>
<td></td>
<td></td>
<td>17.8%</td>
<td>24.1%</td>
</tr>
</tbody>
</table>

*May not sum to 100 percent by provider type due to rounding.

As shown in Table 46, the CY 2017 claims data used for this final rule with comment period showed that PHPs maintained an appropriately low utilization of 3 service days compared to CY 2016 and CY 2015. Compared to CY 2016, hospital-based PHPs have provided fewer days with 3 services only, fewer days with 4 services only, and more days with 5 or more services. Compared to CY 2016, CMHCs have slightly increased their provision of 3 service days, increased their provision of days with 4 services, but have decreased their provision of days with 5 or more services.

As we noted in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79685), we will continue to monitor the utilization of 3 service days, particularly now that the single-tier PHP APCs are in place for providing 3 or more services per day to CMHCs and hospital-based PHPs, respectively. The CY 2017 data are the first year of claims data to reflect the change to the single-tier PHP APCs, and the declining level of utilization of days with 3 services only by hospital-based PHPs indicates that these providers did not reduce care for this patient population. It is too early to determine if the increase in days providing 3 services only by CMHCs is a trend. We will continue to monitor the data for both hospital-based PHPs and CMHCs.

It is important to reiterate our expectation that days with only 3 services are meant to be an exception and not the typical PHP day. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68694), we clearly stated that we consider the acceptable minimum units of PHP services required in a PHP day to be 3 and explained that it was never our intention that 3 units of service represent the number of services to be provided in a typical PHP day. PHP is furnished in lieu of inpatient psychiatric hospitalization and is intended to be more intensive than a half-day program. We further indicated that a typical PHP day should generally consist of 5 to 6 units of service (73 FR 68689). We explained that days with only 3 units of services may be appropriate to bill in certain limited circumstances, such as when a patient might need to leave early for a medical appointment and, therefore, would be unable to complete a full day of PHP treatment. At that time, we noted that if a PHP were to only provide days with 3 services, it would be difficult for patients to meet the eligibility requirement in 42 CFR 410.43(c)(1), that patients must require a minimum of 20 hours per week of therapeutic services as evidenced in their plan of care (73 FR 68689).

We made no proposals in this section of the CY 2019 OPPS/ASC proposed rule, but received several public comments related to utilization.

**Comment:** Some commenters were concerned that the single-tiered payment system implemented in CY 2017 could have unintended consequences, including reducing the number of services provided per day, and urged CMS to monitor the data.
Another commenter thanked CMS for not instituting a code edit for 20 hours per week, and welcomed a further discussion of clinical intensity and situations affecting weekly attendance. This commenter offered to convene a meeting of experts from the field to discuss, develop, and recommend ideas on how best to ensure the appropriate clinical intensity in PHPs. Another commenter wrote that the utilization data in Table 28 of the CY 2019 OPPS/ASC proposed rule demonstrated the commitment of both CMHCs and hospital-based PHPs to fully comply with and exceed the expectations of the 20-hour rule.

Response: We appreciate these comments and will take them into consideration.

C. Outlier Policy for CMHCs

In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), for CY 2019, we proposed to continue to calculate the CMHC outlier percentage, cutoff point and percentage payment amount, outlier reconciliation, outlier payment cap, and fixed-dollar threshold according to previously established policies. These topics are discussed in more detail below. We refer readers to section II.G. of this final rule with comment period for our general policies for hospital outpatient outlier payments.

1. Background

As discussed in the CY 2004 OPPS final rule with comment period (68 FR 63469 through 63470), we noted a significant difference in the amount of outlier payments made to hospitals and CMHCs for PHP services. Given the difference in PHP charges between hospitals and CMHCs, we did not believe it was appropriate to make outlier payments to CMHCs using the outlier percentage target amount and threshold established for hospitals. Therefore, beginning in CY 2004, we created a separate outlier policy specific to the estimated costs and OPPS payments provided to CMHCs. We designated a portion of the estimated OPPS outlier threshold specifically for CMHCs, consistent with the percentage of projected payments to CMHCs under the OPPS each year, excluding outlier payments, and established a separate outlier threshold for CMHCs. This separate outlier threshold for CMHCs resulted in $1.8 million in outlier payments to CMHCs in CY 2004 and $0.5 million in outlier payments to CMHCs in CY 2005 (82 FR 59381). In contrast, in CY 2003, more than $30 million was paid to CMHCs in outlier payments (82 FR 59381).

2. CMHC Outlier Percentage

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 through 59268), we described the current outlier policy for hospital outpatient payments and CMHCs. We note that we also discussed our outlier policy for CMHCs in more detail in section VIII. C. of that same final rule (82 FR 59381). We set our projected target for all OPPS aggregate outlier payments at 1.0 percent of the estimated aggregate total payments under the OPPS (82 FR 59267). We estimate CMHC per diem payments and outlier payments by using the most recent available utilization and charges from CMHC claims, updated CCRs, and the updated payment rate for APC 5853. For increased transparency, we are providing a more detailed explanation of the existing calculation process for determining the CMHC outlier percentages below. As previously stated, we proposed to continue to calculate the CMHC outlier percentage according to previously established policies, and we did not propose any changes to our current methodology for calculating the CMHC outlier percentage for CY 2019.

To calculate the CMHC outlier percentage, we followed three steps:

• Step 1: We multiplied the OPPS outlier threshold, which is 1.0 percent, by the total estimated OPPS Medicare payments (before outliers) for the prospective year to calculate the estimated total OPPS outlier payments: (0.01 × Estimated Total OPPS Payments) = Estimated Total OPPS Outlier Payments.

• Step 2: We estimated CMHC outlier payments by taking each provider’s estimated costs (based on their allowable charges multiplied by the provider’s CCR) minus each provider’s estimated CMHC outlier multiplier threshold (we refer readers to section VIII.C.3. of this final rule with comment period). That threshold was determined by multiplying the provider’s estimated paid days by 3.4 times the CMHC PHP APC payment rate. If the provider’s costs exceeded the threshold, we multiplied that excess by 50 percent, as described in section VIII.C.3. of this final rule with comment period, to determine the estimated outlier payments for that provider. CMHC outlier payments are capped at 8 percent of the provider’s estimated total per diem payments (including the beneficiary’s copayment), as described in section VIII.C.5. of this final rule with comment period, so any provider’s costs that exceed the CMHC outlier cap will have its payments adjusted downward. After accounting for the CMHC outlier cap, we summed all of the estimated outlier payments to determine the estimated total CMHC outlier payments. (Each Provider’s Estimated Costs— Each Provider’s Estimated Multiplier Threshold) = A. If A is greater than 0, then (A × 0.50) = Estimated CMHC Outlier Payment (before cap) = B. If B is greater than (0.08 × Provider’s Total Estimated Per Diem Payments), then cap-adjusted B = (0.08 × Provider’s Total Estimated Per Diem Payments); otherwise, B = B. Sum (B or cap-adjusted B) for Each Provider = Total CMHC Outlier Payments.

• Step 3: We determined the percentage of all OPPS outlier payments that CMHCs represent by dividing the estimated CMHC outlier payments from Step 2 by the total OPPS outlier payments from Step 1: (Estimated CMHC Outlier Payments/ Total OPPS Outlier Payments).

In CY 2018, we designated approximately 0.03 percent of that estimated 1.0 percent hospital outpatient outlier threshold for CMHCs (82 FR 59381), based on this methodology. In the proposed rule, we proposed to continue to use the same methodology for CY 2019. Therefore, based on our CY 2019 payment estimates, CMHCs are projected to receive 0.02 percent of total hospital outpatient payments in CY 2019, excluding outlier payments. We proposed to designate approximately less than 0.01 percent of the estimated 1.0 percent hospital outpatient outlier threshold for CMHCs. This percentage is based upon the formula given in Step 3 above.

We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue with this existing policy on outliers, and are implementing this policy as proposed for CY 2019.

3. Cutoff Point and Percentage Payment Amount

As described in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59381), our policy has been to pay CMHCs for outliers if the estimated cost of the day exceeds a cutoff point. In CY 2006, we set the cutoff point for outlier payments at 3.4 times the highest CMHC PHP APC payment rate implemented for that calendar year (70 FR 68551). This cutoff point is sometimes called a multiplier threshold (70 FR 68550). For CY 2018, the highest CMHC PHP APC payment rate is the payment rate for CMHC PHP APC 5853. In addition, in 2002, the final OPPS outlier payment percentage for costs above the multiplier threshold was set at 50 percent (66 FR
59889). In CY 2018, we continued to apply the same 50 percent outlier payment percentage that applies to hospitals to CMHCs and continued to use the existing cutoff point (82 FR 59381). Therefore, for CY 2018, we continued to pay for partial hospitalization services that exceeded 3.4 times the CMHC PHP APC payment rate at 50 percent of the amount of CMHC PHP APC geometric mean per diem costs over the cutoff point. For example, for CY 2018, if a CMHC’s cost for partial hospitalization services paid under CMHC PHP APC 5853 exceeds 3.4 times the CY 2018 payment rate for CMHC PHP APC 5853, the outlier payment would be calculated as 50 percent of the amount by which the cost exceeds 3.4 times the CY 2018 payment rate for CMHC PHP APC 5853 (0.50 \times (\text{CMHC Cost} - (3.4 \times \text{APC 5853 rate}))).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), for CY 2019, in accordance with our existing policy, we proposed to continue to pay for partial hospitalization services that exceed 3.4 times the CMHC PHP APC payment rate at 50 percent of the CMHC PHP APC geometric mean per diem costs over the cutoff point. That is, for CY 2019, if a CMHC’s cost for partial hospitalization services paid under CMHC PHP APC 5853 exceeds 3.4 times the payment rate for CMHC PHP APC 5853, the outlier payment will be calculated as [0.50 \times (\text{CMHC Cost} - (3.4 \times \text{APC 5853 rate}))).

We did not receive any public comments on our proposals. We are finalizing our proposals, without modification, to continue to calculate the CMHC outlier percentage according to previously established policies, and are implementing this policy as proposed for CY 2019.

4. Outlier Reconciliation

In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68594 through 68599), we established an outlier reconciliation policy to address charging aberrations related to OPPS outlier payments. We addressed vulnerabilities in the OPPS outlier payment system that lead to differences between billed charges and charges included in the overall CCR, which are used to estimate cost and would apply to all hospitals and CMHCs paid under the OPPS. The main vulnerability in the OPPS outlier payment system is the time lag between the update of the CCRs that are based on the latest settled cost report and the current charges that creates the potential for hospitals and CMHCs to set their own charges to exploit the delay in calculating new CCRs. CMS initiated steps to ensure that outlier payments appropriately account for the financial risk when providing an extraordinarily costly and complex service, but are only being made for services that legitimately qualify for the additional payment.

The current outlier reconciliation policy requires that providers whose outlier payments meet a specified threshold (currently $500,000 for hospitals and any outlier payments for CMHCs) and whose overall ancillary CCRs change by plus or minus 10 percentage points or more, are subject to outlier reconciliation. Pending approval of the CMS Central Office and Regional Office (73 FR 68596 through 68599), the policy also includes provisions related to CCRs and to calculating the time value of money for reconciled outlier payments due to or due from Medicare, as detailed in the CY 2009 OPPS/ASC final rule with comment period and in the Medicare Claims Processing Manual (73 FR 68595 through 68599 and Medicare Claims Processing Internet Only Manual, CHI Parts 4, Section 10.7.2 and its subsections, available online at: [https://www.cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c04.pdf]).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37135), we proposed to continue these policies for CY 2019. We did not receive any public comments on our proposals and, therefore, are finalizing our proposals, without modification, to continue our existing policy for CY 2019.

5. Outlier Payment Cap

In the CY 2017 OPPS/ASC final rule with comment period, we implemented a CMHC outlier payment cap to be applied at the provider level, such that in any given year, an individual CMHC will receive no more than a set percentage of its CMHC total per diem payments in outlier payments (81 FR 79692 through 79695). We finalized the CMHC outlier payment cap to be set at 8 percent of the CMHC’s total per diem payments (81 FR 79694 through 79695). This outlier payment cap only affects CMHCs, does not affect other provider types (that is, hospital-based PHPs), and is in addition to and separate from the current outlier policy and reconciliation policy in effect. For CY 2018, we continued this policy in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59381).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37135 through 37136), we proposed to continue this policy for CY 2019, such that the CMHC outlier payment cap will be 8 percent of the CMHC’s total per diem payments.

We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue our existing policy for CY 2019, such that the CMHC outlier payment cap will be 8 percent of the CMHC’s total per diem payments.

6. Fixed-Dollar Threshold

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59267 through 59268), for the hospital outpatient outlier payment policy, we set a fixed-dollar threshold in addition to an APC multiplier threshold. Fixed-dollar thresholds are typically used to drive outlier payments for very costly items or services, such as cardiac pacemaker insertions. CMHC PHP APC 5853 is the only APC for which CMHCs may receive payment under the OPPS, and is for providing a defined set of services that are relatively low cost when compared to other OPPS services. Because of the relatively low cost of CMHC services that are used to comprise the structure of CMHC PHP APC 5853, it is not necessary to also impose a fixed-dollar threshold on CMHCs. Therefore, in the CY 2018 OPPS/ASC final rule with comment period, we did not set a fixed-dollar threshold for CMHC outlier payments (82 FR 59381).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37134 through 37136), we proposed to continue this policy for CY 2019.

We did not receive any public comments on our proposal and, therefore, are finalizing our proposal, without modification, to continue with this existing policy, and are implementing this policy as proposed for CY 2019.

D. Proposed Update to PHP Allowable HCPCS Codes

CMS received the CY 2019 CPT codes from the AMA in time for inclusion in the CY 2019 OPPS/ASC proposed rule (83 FR 37088). The new, revised, and deleted CY 2019 Category I and III CPT codes were included in Addendum B to the proposed rule (which is available via the internet on the CMS website). We are aware that the AMA will be deleting the following psychological and neuropsychological testing CPT codes, which affect PHPs, as of January 1, 2019:

- CPT code 96101 (Psychological testing by psychologist/physician);
- CPT code 96102 (Psychological testing by technician);
- CPT code 96103 (Psychological testing administered by computer);
In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we proposed to delete these 6 CPT codes for the 2019 OPPS update under section III.A.4. ("Proposed Treatment of New and Revised CY 2019 Category I and III CPT Codes That Will Be Effective January 1, 2019 For Which We Are Soliciting Public Comments In This CY 2019 OPPS/ASC Proposed Rule").

In addition, the AMA will be adding the following psychological and neuropsychological testing CPT codes to replace the deleted codes, as of January 1, 2019:

- CPT code 96130 (Psychological testing evaluation by physician/qualified health care professional; first hour);
- CPT code 93131 (Psychological testing evaluation by physician/qualified health care professional; each additional hour);
- CPT code 96132 (Neuropsychological testing evaluation by physician/qualified health care professional; first hour);
- CPT code 96133 (Neuropsychological testing evaluation by physician/qualified health care professional; each additional hour);
- CPT code 96136 (Psychological/neuropsychological testing by physician/qualified health care professional; first 30 minutes);
- CPT code 96137 (Psychological/neuropsychological testing by physician/qualified health care professional; each additional 30 minutes);
- CPT code 96138 (Psychological/neuropsychological testing by technician; first 30 minutes);
- CPT code 96139 (Psychological/neuropsychological testing by technician; each additional 30 minutes);
- CPT code 96146 (Psychological/neuropsychological testing; automated result only).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37088), we also proposed to recognize and assign these 9 CPT codes under the CY 2019 OPPS in section III.A.4. ("Proposed Treatment of New and Revised CY 2019 Category I and III CPT Codes That Will Be Effective January 1, 2019 For Which We Are Soliciting Public Comments In This CY 2019 OPPS/ASC Proposed Rule").

While these proposed changes to the above-referenced codes were included in the CY 2019 OPPS/ASC proposed rule (and are being finalized in section III.A.3. in this final rule with comment period for the CY 2019 OPPS), PHP is a part of the OPPS and PHP providers may not have been aware of those proposed changes because we did not also include the proposals in the PHP discussion presented in the proposed rule. To ensure that PHP providers are aware of the codes and have the opportunity to comment on the proposed changes, we are utilizing a practice similar to the one we use under the OPPS for new Level II HCPCS codes that become effective after the proposed rule is published. Therefore, in this final rule with comment period, we are proposing to delete the same 6 CPT codes listed above from the PHP-allowable code set for CMHC APC 5853 and hospital-based PHP APC 5863, and replace them with 9 new CPT codes as shown in Table 47 below, effective January 1, 2019. We are soliciting public comments on these proposals. We will consider the public comments we receive and seek to finalize our proposed actions in the CY 2020 OPPS/ASC final rule with comment period.

<table>
<thead>
<tr>
<th>Existing Code</th>
<th>Proposed Action</th>
<th>Proposed Replacement(s)</th>
<th>Proposed APC Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>96101</td>
<td>Delete</td>
<td>96130, 96131, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
<tr>
<td>96102</td>
<td>Delete</td>
<td>96130, 96131, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
<tr>
<td>96103</td>
<td>Delete</td>
<td>96130, 96131, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
<tr>
<td>96118</td>
<td>Delete</td>
<td>96132, 96133, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
<tr>
<td>96119</td>
<td>Delete</td>
<td>96132, 96133, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
<tr>
<td>96120</td>
<td>Delete</td>
<td>96132, 96133, and may also include 96136, 96137, 96138, 96139, 96146</td>
<td>Add</td>
</tr>
</tbody>
</table>

**TABLE 47.—PROPOSED CHANGES TO THE ALLOWABLE CPT CODES FOR CMHC PHP APC 5853 and HOSPITAL-BASED PHP APC 5863**
IX. Procedures That Will Be Paid Only as Inpatient Procedures

A. Background

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74352 through 74353) for a full historical discussion of our longstanding policies on how we identify procedures that are typically provided only in an inpatient setting (referred to as the inpatient only (IPO) list) and, therefore, will not be paid by Medicare under the OPPS, and on the criteria that we use to review the IPO list each year to determine whether or not any procedures should be removed from the list. The complete list of codes that describe procedures that will be paid by Medicare in CY 2019 as inpatient only procedures is included as Addendum E to this CY 2019 OPPS/ASC final rule with comment period, which is available via the internet on the CMS website.

B. Changes to the Inpatient Only (IPO) List

1. Methodology for Identifying Appropriate Changes to IPO List

In the CY 2019 OPPS/ASC proposed rule (83 FR 37136 through 37143), for CY 2019, we proposed to use the same methodology (described in the November 15, 2004 final rule with comment period (69 FR 65834)) of reviewing the current list of procedures on the IPO list to identify any procedures that may be removed from the list. We have established five criteria that are part of this methodology. As noted in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74353), we utilize these criteria when reviewing procedures to determine whether or not they should be removed from the IPO list and assigned to an APC group for payment under the OPPS when provided in the hospital outpatient setting. We note that a procedure is not required to meet all of the established criteria to be removed from the IPO list. The criteria include the following:

1. Most outpatient departments are equipped to provide the services to the Medicare population.
2. The simplest procedure described by the code may be performed in most outpatient departments.
3. The procedure is related to codes that we have already removed from the IPO list.
4. A determination is made that the procedure is being performed in numerous hospitals on an outpatient basis.
5. A determination is made that the procedure can be appropriately and safely performed in an ASC and is on the list of approved ASC procedures or has been proposed by us for addition to the ASC list.

Using the above-listed criteria, for the CY 2019 OPPS, we identified two procedures described by the following codes that we proposed to remove from the IPO list for CY 2019: CPT code 31241 (Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery) and CPT code 01402 (Anesthesia for open or surgical arthroscopic procedures on knee joint; total knee arthroplasty). We also proposed to add to the IPO list for CY 2019 the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, arterectomy and angioplasty, including aspiration thrombectomy when performed, single vessel). Table 29 of the proposed rule (83 FR 37137) displayed the proposed changes to the IPO list for CY 2019 and subsequent years, including the HCPCS codes, long descriptors, and the proposed CY 2019 payment indicators.

As noted earlier, we proposed to remove the procedure described by CPT code 31241 from the IPO list and to assign the procedure to C–APC 5153 (Level 3 Airway Endoscopy) with a status indicator of “J1”. We sought public comments on whether the procedure described by CPT code 31241 from the IPO list is appropriate. In addition, we received support for the removal of CPT code 31241 from the IPO list from many other stakeholders.

After consideration of the public comments we received, we are finalizing our proposal, without modification, to remove CPT code 31241 from the IPO list and to assign the procedure to C–APC 5153 (Level 3 Airway Endoscopy) with a status indicator of “J1”. In the CY 2019 OPPS/ASC proposed rule (83 FR 37136), we also proposed to remove the procedure described by CPT code 01402 from the IPO list. We reviewed the clinical characteristics of the procedure described by CPT code 01402, and proposed that this procedure be removed from the IPO list because it meets above-listed criteria 3 and 4. This procedure is typically billed with the procedure described by CPT code 27447 (Arthroplasty, knee, condyle and plateau; medial and lateral compartments with or without patella resurfacing (total knee arthroplasty)), which was removed from the IPO list for CY 2018 (82 FR 52526). This procedure is also often performed safely in the outpatient department setting. We sought public comments on whether the procedure described by CPT code 01402 meets criteria 3 and 4 and whether the procedure meets any of the other five criteria for removal from the IPO list.

Comment: Commenters supported the removal of the procedure described by CPT code 01402 from the IPO list and agreed that the procedure described by CPT code 01402 was both related to codes that were previously removed from the IPO list and is performed safely in numerous hospitals on an outpatient basis. Response: We thank the commenters for their support.

Comment: Commenters opposed the removal of the procedure described by CPT code 01402 from the IPO list because the commenter believed that there would be potential detrimental lateral impacts on hospitals participating in the Comprehensive Care for Joint Replacement (CJR) Model, the Bundled Payments for Care Improvement (BPCI) Initiative, the Hospital Value-Based Purchasing (VBP)
Reduction Program (HRRP).

**Response:** Removal of the procedure described by CPT code 01402 does not in any way affect a provider's ability to participate in any of the initiatives the commenter mentioned. We remind readers that the removal of any procedure from the IPO list does not mandate that all cases be performed on an outpatient basis. Rather, such removal allows for Medicare payment to be made to the hospital when the procedure is performed in the hospital outpatient department setting. The decision to admit a patient is a complex medical judgment that is made by the treating physician. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79698 through 79699) in which we originally proposed to remove total knee arthroplasty (TKA) procedure codes from the IPO list and sought comments on how to modify the CJR Model and the BPCI Initiative to reflect the shift of some Medicare beneficiaries from an inpatient TKA procedure to an outpatient TKA procedure in the BPCI Initiative and the CJR Model pricing methodologies, including target price calculations and reconciliation processes. However, we invite interested parties to direct any questions about these initiatives to the CMS Center for Medicare and Medicaid Innovation.

**Comment:** One commenter representing a coalition of industry stakeholders recommended that CMS collect and publish data on morbidity and mortality rates for TKA performed in the outpatient setting versus in the inpatient setting. The commenter believed that collecting these data would allow CMS to evaluate the quality of services in both settings since the removal of TKA procedures from the IPO list.

**Response:** We note that since we removed the CPT codes related to TKA from the IPO list, TKA procedures have only been payable under the OPPS for less than one year. According to the commenter, we do not believe that we have sufficient data at this time for a meaningful comparison of quality outcomes associated with TKA procedures performed in the hospital outpatient setting versus the hospital inpatient setting. However, we will consider reviewing mortality rates in the future when appropriate data are available. We would not expect there to be statistically significant differences in morbidity and mortality among Medicare beneficiaries based solely on whether the patient was admitted to the hospital as a hospital outpatient (especially because it is likely the same surgeon, the same clinical protocol, and the same staff at a given hospital for both inpatient and outpatient orthopaedic procedures) and would expect that other factors, such as underlying disease-state and condition of the patient, surgical complications, and ability to avoid blood clots and other potential adverse event within 90 days postsurgery. We remind readers that there are several short stay inpatient cases with a length of stay of 1 or 2 days, which is generally similar to the length of stay for outpatient cases. To be clear, there is a plethora of surgical procedures that may be performed on either an inpatient basis or an outpatient basis. However, we are not aware of differences in clinical outcomes for patients based solely on this factor. While there are some studies relating to the non-Medicare population regarding differences in outcomes, depending on whether the care setting is inpatient versus outpatient (which could include ASCs), we are not aware of any such studies since the TKA has become a payable procedure under the OPPS in 2018. In addition, we note that interested stakeholders are welcome to research these or other statistics by analyzing data that Medicare makes available. The Hospital Inpatient Quality Reporting (IQR) Program and the Hospital Outpatient Quality Reporting (OQR) Program collect and share information regarding the quality of care in both the hospital inpatient setting and the hospital outpatient setting. Specifically, the Hospital IQR Program maintains measures that include complications and deaths during inpatient hip/knee replacement procedures. However, an analogous measure for outpatient procedures does not currently exist.

**Comment:** One commenter requested that CMS provide guidance and education regarding the removal of TKA procedures from the IPO list.

**Response:** As previously stated in the discussion of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59383), we continue to believe that the decision regarding the most appropriate care setting for a given surgical procedure is a complex medical judgment made by the physician based on the beneficiary’s individual clinical needs and preferences and on the general requirement that any procedure be reasonable and necessary. We also reiterate our previous statement that the removal of any procedure from the IPO list does not require the procedure to be performed only on an outpatient basis. Rather, we believe that as technology and clinical practice continue to evolve, beneficiaries should continue to receive care in the most appropriate setting.

While we continue to expect providers who perform an outpatient TKA procedure on Medicare beneficiaries to use comprehensive patient selection criteria to identify appropriate candidates for the procedure, we believe that the surgeons, clinical staff, and medical specialty societies representing physicians who perform outpatient TKA procedures and possess specialized clinical knowledge and experience are most suited to create such guidelines.

After consideration of the public comments we received, we are adopting, as final without modification, our proposal to remove the procedure described by CPT code 01402 from the IPO list. In accordance with the regulations at 42 CFR 419.2(b)(4), under the OPPS, this anesthesia service is packaged with the associated procedure and assigned status indicator “N” (Items and Services Packaged into APC Rates) for CY 2019.

In addition, in the CY 2019 OPPS/ASC proposed rule (83 FR 37136 through 37137), we proposed to add the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel) to the IPO list for CY 2019. The IPO list specifies those procedures and services for which the hospital will be paid only when the procedures are provided in the inpatient setting because of the nature of the procedure, the underlying physical condition of the patient, or the need for at least 24 hours of postoperative recovery time or monitoring before the patient can be safely discharged (76 FR 74353). After evaluating the procedure described by HCPCS code C9606 using the criteria described above, we believe that the procedure should be added to the IPO list because this procedure is performed during acute myocardial infarction and it is similar to a procedure already on the IPO list (that is, the procedure described by CPT code 92941 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial...
infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel), which was added to the IPO list for CY 2018 (82 FR 52526). We sought public comments on whether the procedure described by HCPCS code C9606 should be added to the IPO list for CY 2019 and subsequent years.

Comment: Several commenters, largely from specialty medical societies, supported adding the procedure described by HCPCS code C9606 to the IPO list for CY 2019.

Response: We appreciate the commenters’ support.

After consideration of the public comments we received, we are adopting as final without modification, our proposal to add the procedure described by HCPCS code C9606 (Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel) to the IPO list for CY 2019.

2. Summary of Public Comments Received in Response to CMS’ Solicitation on the Potential Removal of Procedure Described by CPT Code 0266T From the IPO List and Our Responses

CPT code 0266T describes the implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed). The procedure described by CPT code 0266T has been included on the IPO list since the procedure code became effective in CY 2011.

There are several codes that describe procedures that are similar to the procedure described by CPT code 0266T that are not on the IPO list, including: CPT code 0267T (Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)) and CPT code 0268T (Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)). The device that is billed with these two procedures has been granted a Category B Investigational Device Exemption (IDE) from FDA.

Currently, there is limited information available to determine the typical site of service and the ability for the procedure to be safely performed in the outpatient setting. At the time of development of the CY 2019 OPPS/ASC proposed rule, we did not believe that we had adequate information to determine whether the procedure described by CPT code 0266T should be removed from the IPO list. Therefore, we sought public comments on the removal of the procedure described by CPT code 0266T from the IPO list. Specifically, we sought public comments on whether the procedure described by CPT code 0266T meets any of the criteria to be removed from the IPO list as well as the appropriate APC assignment and status indicator for this code.

Comment: Numerous commenters responded to CMS’ solicitation for discussion of the removal of the Barostim procedure from the IPO list. Commenters included the manufacturer and practitioners, specifically cardiologists and cardiovascular surgeons, who have performed the Barostim procedure multiple times. Commenters referenced their personal experience with the procedure described by CPT code 0266T, the advancements and safety of the procedure, and patients’ experience after undergoing the procedure. These commenters argued that procedures related to CPT code 0266T are commonly being performed safely in the hospital outpatient department. The manufacturer specifically cited the CY 2019 NPRM CPT Cost Statistics Files associated with the proposed rule to show the number of related procedures that have been performed in the hospital outpatient department this year. Further, another commenter supported the assertion provided in the proposed rule that the simplest procedures described by CPT code 0266T, the procedure to implant or replace the lead or IPG, currently have separate and distinct CPT codes (0267T and 0268T) that are not included on the IPO list.

Response: We reviewed clinical characteristics of the Barostim procedure and related evidence, including input from multiple physician and cardiology specialty societies, and determined that the procedure described by CPT code 0266T is an appropriate candidate for removal from the IPO list. CPT code 0266T is similar to CPT code 0268T, which is performed in numerous hospitals on an outpatient basis (criterion 3). Furthermore, we believe that most outpatient departments are equipped to provide the described services to the Medicare population (criterion 1). Therefore, we are removing the procedure described by CPT code 0266T from the IPO list for CY 2019.

Comment: Several commenters recommended the removal of several procedures not originally proposed by CMS for removal from the IPO list for CY 2019. These recommended procedures related to other procedures that were recently removed from the IPO. In addition, several commenters recommended the removal of all orthopaedic, arthroplasty, and joint replacement procedures from the IPO list. Table 48 below contains the procedures that were explicitly requested by the commenters to be removed from the IPO list for CY 2019.
Response: We appreciate the diligence that commenters continue to show in proposing changes to the IPO list. For the CY 2019 OPPS, we believe that it is appropriate to remove the procedure described by CPT code 00670 from the IPO list, as recommended by the commenters. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79695 through 79696) in which CMS removed six related codes (four spine procedure codes and two laryngoplasty codes) from the IPO list for CY 2017. We believe that the procedure described by CPT code 00670 is appropriate for removal from the IPO list because it relates to the following codes that CMS removed from the IPO list in CY 2017: CPT code 22840 (Posterior non-segmental instrumentation (e.g., Harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at C1; facet screw fixation) (List separately in addition to code for primary procedure)); CPT code 22842 (Posterior segmental instrumentation (e.g., pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (List separately in addition to code for primary procedure)); CPT code 22845 (Anterior instrumentation; 2 to 3 vertebral segments (List separately in addition to code for primary procedure)); and CPT code 22858 (Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophytectomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)). We also believe that this procedure is being performed in numerous hospitals on an outpatient basis. Accordingly, we are removing the procedure described by CPT code 00670 from the IPO list for CY 2019. Because this spine procedure code is an add-on code, in accordance with the regulations at 42 CFR 419.2(b)(18), under the OPPS, this procedure is packaged with the associated procedure and assigned status indicator “N” (Items and Services Packaged into APC Rates) for CY 2019.

In regard to the commenters’ recommendation to remove all orthopaedic, arthroplasty, and joint replacement procedures from the IPO list, we do not believe that we have sufficient data to support removal of all orthopaedic, arthroplasty, and joint replacement procedures from the IPO list. However, we encourage stakeholders to submit specific procedures, along with evidence, to support their requests for removal from the IPO list.

In conclusion, the complete list of procedure codes that are placed on the IPO list for CY 2019 is included as Addendum E to this CY 2019 OPPS/ASC final rule with comment period (which is available via the internet on the CMS website).

Table 49 below contains the final changes that we are making to the IPO list for CY 2019.
### TABLE 49.—CHANGES TO THE INPATIENT ONLY LIST FOR CY 2019

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>31241</td>
<td>Nasal/sinus endoscopy, surgical; with ligation of sphenopalatine artery</td>
<td>Removed from IPO list</td>
<td>5153</td>
<td>J1</td>
</tr>
<tr>
<td>01402</td>
<td>Anesthesia for open or surgical arthroscopic procedures on knee joint; total knee arthroplasty</td>
<td>Removed from IPO list</td>
<td>N/A</td>
<td>N</td>
</tr>
<tr>
<td>0266T</td>
<td>Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed).</td>
<td>Removed from IPO list</td>
<td>5463</td>
<td>J1</td>
</tr>
<tr>
<td>00670</td>
<td>Anesthesia for extensive spine and spinal cord procedures (e.g., spinal instrumentation or vascular procedures)</td>
<td>Removed from the IPO</td>
<td>N/A</td>
<td>N</td>
</tr>
<tr>
<td>C9606</td>
<td>Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel</td>
<td>Added to IPO list</td>
<td>N/A</td>
<td>C</td>
</tr>
</tbody>
</table>

---

**X. Nonrecurring Policy Changes**

**A. Collecting Data on Services Furnished in Off-Campus Provider-Based Emergency Departments**

The June 2017 Report to Congress by the Medicare Payment Advisory Commission (MedPAC) states that, in recent years, there has been significant growth in the number of health care facilities located apart from hospitals that are devoted primarily to emergency department services. This includes both off-campus provider-based emergency departments that are eligible for payment under the OPPS and independent freestanding emergency departments not affiliated with a hospital that are not eligible for payment under the OPPS. Since 2010, we have observed a noticeable increase in the number of hospital outpatient emergency department visits furnished under the OPPS. MedPAC and other entities have expressed concern that services may be shifting to the higher acuity and higher cost emergency department setting due to: (1) Higher payment rates for services performed in off-campus provider-based emergency departments compared to similar services provided in other settings (that is, physician offices or urgent care clinics); and (2) the exemption for services provided in an emergency department included under section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–25), whereby all items and services (emergency and nonemergency) furnished in an emergency department are excepted from the payment implications of section 603, as long as the department maintains its status as an emergency department under the regulation at 42 CFR 489.24(b).

MedPAC and other entities are concerned that these payment incentives may be a key factor contributing to the growth in the number of emergency departments located off-campus from a hospital. MedPAC recommended in its March 2017 and June 2017 Reports to Congress that CMS require hospitals to append a modifier to claims for all services furnished in off-campus emergency departments.

---


64 Available at: [http://medpac.gov/docs/default-source/reports/mar17_entirereport.pdf](http://medpac.gov/docs/default-source/reports/mar17_entirereport.pdf).
provider-based emergency departments, so that CMS can track the growth of OPPS services provided in this setting.

In order to participate in Medicare as a hospital, the facility must meet the statutory definition of a hospital at section 1861(e) of the Act, which requires a facility to be primarily engaged in providing care and services to inpatients. In addition, 42 CFR 482.55 requires hospital emergency department services (to include off-campus provider-based emergency departments) to be fully integrated with departments and services of the hospital. The integration must be such that the hospital can immediately make available the full extent of its patient care resources to assess and furnish appropriate care for an emergency patient. Such services would include, but are not limited to, surgical services, laboratory services, and radiology services, among others. The emergency department must also be integrated with inpatient services, which means the hospital must have a sufficient number of inpatient beds and nursing units to support the volume of emergency department patients that could require inpatient services. The provision of services, equipment, personnel and resources of other hospital departments and services to emergency department patients must be within timeframes that protect the health and safety of patients and is within acceptable standards of practice.

We agree with MedPAC’s recommendation and believe we need to develop data to assess the extent to which OPPS services are shifting to off-campus provider-based emergency departments. Therefore, we announced in the CY 2019 OPPS/ASC proposed rule (83 FR 37138 through 37143) that we are implementing through the subregulatory HCPCS modifier process a new modifier for this purpose, effective beginning January 1, 2019.

We stated in the proposed rule that we will create a HCPCS modifier (“ER”—Items and services furnished by a provider-based off-campus emergency department) that is to be reported with every claim line for outpatient hospital services furnished in an off-campus provider-based emergency department. We specified in the proposed rule that the modifier would be reported on the UB–04 form (CMS Form 1450) for hospital outpatient services. We stated that critical access hospitals (CAHs) would not be required to report this modifier.

In response to our announcement of the creation of HCPCS modifier “ER” (Items and services furnished by a provider-based off-campus emergency department), we received the following feedback from commenters in response to the CY 2019 OPPS/ASC proposed rule: Some commenters, including MedPAC, supported the creation of HCPCS modifier “ER”, citing the opportunity to facilitate the collection of data on services furnished in off-campus emergency departments. Other commenters were opposed to the creation of the HCPCS modifier “ER” because they believed it would be an undue and unnecessary administrative burden on hospitals.

While we note that the creation of the HCPCS modifier “ER” was included in the CY 2019 OPPS/ASC proposed rule as an announcement, as opposed to a proposal, and therefore was not subject to public comment, we nonetheless appreciate the feedback provided by interested stakeholders, and will consider such feedback in potential future policy development.

B. Method To Control for Unnecessary Increases in the Volume of Outpatient Services

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37138 through 37143), when the Medicare program was first implemented, payment for hospital services (inpatient and outpatient) was based on hospital-specific reasonable costs attributable to furnishing services to Medicare beneficiaries. Although payment for most Medicare hospital inpatient services became subject to a prospective payment system (PPS) under section 1886(d) of the Act in 1983, Medicare hospital outpatient services continued to be paid based on hospital-specific costs. This methodology for payment provided little incentive for hospitals to furnish such outpatient services efficiently and in a cost effective manner. At the same time, advances in medical technology and changes in practice patterns were bringing about a shift in the site of medical care from the hospital inpatient setting to the hospital outpatient setting.

In the Omnibus Budget Reconciliation Act of 1986 (OBRA 1986) (Pub. L. 99–514), the Congress paved the way for development of a PPS for hospital outpatient services. Section 3943(g) of OBRA 1986 mandated that fiscal intermediaries to report claims for services under the Healthcare Common Procedure Coding System (HCPCS). Section 3943(c) of OBRA 1986 extended the prohibition against unbundling of hospital services under section 1862(a)(14) of the Act to include outpatient services as well as inpatient services. The codes under the HCPCS enabled us to determine which specific procedures and services were billed, while the extension of the prohibition against unbundling ensured that all nonphysician services provided to hospital outpatients were reported on hospital bills and captured in the hospital outpatient data that were used to develop an outpatient PPS.

The brisk increase in hospital outpatient services further led to an interest in creating payment incentives to promote more efficient delivery of hospital outpatient services through a Medicare outpatient PPS. Section 9343(f) of OBRA 1986 and section 4151(b)(2) of the Omnibus Budget Reconciliation Act of 1990 (OBRA 1990) (Pub. L. 101–508) required that we develop a proposal to replace the existing hospital outpatient payment system with a PPS and submit a report to the Congress on a new proposed system. The statutory framework for the Outpatient Prospective Payment System (OPPS) was established by section 4523 of the Balanced Budget Act of 1997 (Pub. L. 105–33), which amended section 1833 of the Act by adding subsection (l), which establishes a PPS for hospital outpatient department services, and by section 201 of the Balanced Budget Reconciliation Act (BBRA) of 1999 (Pub. L. 106–113), which amended section 1833(t) of the Act to require outlier and transitional pass-through payments. At the outset of the OPPS, there was significant concern over observed increases in the volume of outpatient services and corresponding rapidly growing beneficiary coinsurance. Accordingly, most of the focus was on finding ways to address those issues.

When section 4523 of the BBA of 1997 established the OPPS, it included specific authority under section 1833(t)(2)(F) of the Act that requires the Secretary to develop a method for controlling unnecessary increases in the volume of covered outpatient department (OPD) services.65 In the initial rule that proposed to implement the OPPS (63 FR 47585 through 47587), we discussed several possible approaches for controlling the volume of covered outpatient department services furnished in subsequent years, solicited comments on those options, and stated that the agency would propose an appropriate “volume control” mechanism for services furnished in CY 2001 and beyond after completing further analysis. For the CY

65 Available at: https://www.ssa.gov/OP_Home/ssact/title18/1833.htm.
2000 OPPS, we proposed to implement a method that was similar to the one used under the Medicare Physician Fee Schedule (PFS) (known as the sustainable growth rate or “SGR”), which would be triggered when expenditure targets, based on such factors as volume, intensity, and beneficiary enrollment, were exceeded (63 FR 47586 through 47587). However, as we discussed in the CY 2001 OPPS final rule (65 FR 18503) and the CY 2002 OPPS final rule (66 FR 59908), we delayed the implementation of the proposed volume control method as suggested by the “President’s Plan to Modernize and Strengthen Medicare for the 21st Century” to give hospitals time to adjust to the OPPS and CMS time to continue to examine methods to control unnecessarily increases in the volume of covered OPD services.

In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66611 through 66612), we noted that we had significant concerns about the growth in program expenditures for hospital outpatient services, and that while the OPPS was developed in order to address some of those concerns, its implementation had not generally slowed that growth in expenditures. To address some of those concerns, we established a set of packaging policies beginning in CY 2008 that would explicitly encourage efficiency in the provision of services in the hospital outpatient setting and potentially control future growth in the volume of OPPS services (72 FR 66612).

Specifically, in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66580), we adopted a policy to package seven categories of items and services into the payment for the primary diagnostic or therapeutic modality to which we believe these items are typically ancillary or supportive.

Similarly, in the CY 2014 OPPS/ASC final rule with comment period (78 FR 74925 through 74948), we expanded our packaging policies to include more categories of packaged items and services as part of a broader initiative to make the OPPS more like a prospective payment system and less like a per service fee schedule. Packaging can encourage hospitals to furnish services efficiently while also enabling hospitals to manage their resources with the maximum flexibility, thereby encouraging long-term cost containment, which is an essential component of a prospective payment system. While most of the packaging policies established in the CY 2014 OPPS focused on ancillary services that were part of a primary procedure, we also introduced the concept of comprehensive APCs (C–APCs) (78 FR 74861 through 74910), which were implemented beginning in the CY 2015 OPPS (79 FR 66798 through 66810). Comprehensive APCs package payment for adjunctive and secondary items, services, and procedures into the most costly primary procedure under the OPPS at the claim level.

While we have developed many payment policies with these goals in mind, growth in program expenditures for hospital outpatient services paid under the OPPS continues. As illustrated in Table 30 in the CY 2019 OPPS/ASC proposed rule (83 FR 37139), total spending has been growing at a rate of roughly 8 percent per year under the OPPS, and total spending under the OPPS is projected to further increase by more than $5 billion from approximately $70 billion in CY 2018 through CY 2019 to nearly $75 billion. This is approximately twice the total estimated spending in CY 2008, a decade ago. We continue to be concerned with this rate of increase in program expenditures under the OPPS for several reasons. The OPPS was originally designed to manage Medicare spending growth. What was once a cost-based system was mandated by law to become a prospective payment system, which arguably should have slowed the increases in program spending. To the contrary, the OPPS has been the fastest growing sector of Medicare payments out of all payment systems under Medicare Parts A and B. Furthermore, we are concerned that the rate of growth suggests that payment incentives, rather than patient acuity or medical necessity, are affecting site-of-service decision-making. This site-of-service selection has an impact on not only the Medicare program, but also on Medicare beneficiary out-of-pocket spending. Therefore, to the extent that there are lower-cost sites-of-service available, we believe that beneficiaries and the physicians treating them should have that choice and not be encouraged to receive or provide care in higher paid settings solely for financial reasons. For example, to provide for easier comparisons between hospital outpatient departments and ASCs, as previously discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59389), we stated in the CY 2019 OPPS/ASC proposed rule that we also will make available a website that provides comparison information between the OPPS and ASC payment and copayment rates, as required under section 4011 of the 21st Century Cures Act (Pub. L. 114–255). Making this information available can help beneficiaries and their physicians determine the cost and appropriateness of receiving care at different sites-of-service. Although resources such as this website will help beneficiaries and physicians select a site-of-service, we do not believe this information alone is enough to control unnecessary volume increases. The growth in OPPS expenditures and the increase in the volume and intensity of hospital outpatient services were illustrated in Tables 30 and 31, respectively, of the CY 2019 OPPS/ASC proposed rule (83 FR 37139 through 37140). These tables, which include updated information, are presented below.
As noted in its March 2018 Report to Congress, the Medicare Payment Advisory Commission (MedPAC) found that, from 2011 through 2016, combined program spending and beneficiary cost-sharing on services covered under the OPPS increased by 51 percent, from $39.8 billion to $60.0 billion, an average of 8.6 percent per year.\textsuperscript{66} In its 2018 report, MedPAC also noted that “A large source of growth in spending on services furnished in hospital outpatient departments (HOPDs) appears to be the result of the shift of services from (lower cost) physician offices to (higher cost) HOPDs”.\textsuperscript{67} We consider these shifts in the sites of service unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting.

As noted in MedPAC’s March 2017 Report to Congress, “from 2014 to 2015, the use of outpatient services increased by 2.2 percent per Medicare FFS beneficiary. Over the decade ending in 2015, volume per beneficiary grew by 47 percent. One-third of the growth in outpatient volume from 2014 to 2015 was due to an increase in the number of evaluation and management (E&M) visits billed as outpatient services. This growth in part reflects hospitals purchasing freestanding physician practices and converting the billing from the Physician Fee Schedule to higher paying hospital outpatient department (HOPD) visits. These conversions shift market share from freestanding physician offices to HOPDs. From 2012 to 2015, hospital-based E&M visits per beneficiary grew by 22 percent, compared with a 1-percent decline in physician office-based visits.”\textsuperscript{68}

MedPAC has documented how the billing for these services has shifted from physician offices to higher-cost outpatient sites of care for several years. At the same time, MedPAC has repeated its recommendation that the difference in payment rates between hospital outpatient departments and physician offices should be reduced or eliminated. It specifically recommended in its 2012

\textsuperscript{66} Available at: http://www.medpac.gov/docs/default-source/reports/mar18_medpac_entirereport_sec.pdf?sfvrsn=0.

\textsuperscript{67} Ibid.

\textsuperscript{68} Available at: http://www.medpac.gov/docs/default-source/reports/mar17_medpac_ch3.pdf?sfvrsn=0.

---

**TABLE 50.**—**GROWTH IN EXPENDITURES UNDER OPPS FROM CY 2010 THROUGH CY 2019**

* (in millions)

<table>
<thead>
<tr>
<th>Calendar Year (CY)</th>
<th>Incurred Cost</th>
<th>Percent Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2010</td>
<td>$36,774</td>
<td>-</td>
</tr>
<tr>
<td>CY 2011</td>
<td>$39,781</td>
<td>8.2%</td>
</tr>
<tr>
<td>CY 2012</td>
<td>$43,154</td>
<td>8.5%</td>
</tr>
<tr>
<td>CY 2013</td>
<td>$46,462</td>
<td>7.7%</td>
</tr>
<tr>
<td>CY 2014</td>
<td>$52,429</td>
<td>12.8%</td>
</tr>
<tr>
<td>CY 2015</td>
<td>$56,275</td>
<td>7.3%</td>
</tr>
<tr>
<td>CY 2016</td>
<td>$59,869</td>
<td>6.4%</td>
</tr>
<tr>
<td>CY 2017</td>
<td>$64,050</td>
<td>7.0%</td>
</tr>
<tr>
<td>CY 2018</td>
<td>$68,264</td>
<td>6.6%</td>
</tr>
<tr>
<td>CY 2019 (Estimated)</td>
<td>$74,468</td>
<td>9.1%</td>
</tr>
</tbody>
</table>

*Includes Medicare Part B Drug Expenditures.

**TABLE 51.**—**PERCENTAGE INCREASE IN VOLUME AND INTENSITY OF HOSPITAL OUTPATIENT SERVICES**

<table>
<thead>
<tr>
<th>Calendar Year (CY)</th>
<th>Percentage Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2011</td>
<td>3.7%</td>
</tr>
<tr>
<td>CY 2012</td>
<td>5.1%</td>
</tr>
<tr>
<td>CY 2013</td>
<td>5.5%</td>
</tr>
<tr>
<td>CY 2014</td>
<td>8.1%</td>
</tr>
<tr>
<td>CY 2015</td>
<td>3.4%</td>
</tr>
<tr>
<td>CY 2016</td>
<td>6.4%</td>
</tr>
<tr>
<td>CY 2017</td>
<td>5.4%</td>
</tr>
<tr>
<td>CY 2018</td>
<td>6.4%</td>
</tr>
<tr>
<td>CY 2019 (Estimated)</td>
<td>5.4%</td>
</tr>
</tbody>
</table>

*Includes Medicare Part B Drug Expenditures.
Report to Congress that the payment rates for E&M visits provided in hospital outpatient departments be reduced so that total payment rates for these visits are the same, whether the service is provided in a hospital outpatient department or a physician office. In its 2014 Report to Congress, MedPAC recommended that Congress direct the Secretary to reduce or eliminate differences in payment rates between hospital outpatient departments and physician offices for selected APCs.

Both of these recommendations were reiterated in MedPAC’s March 2017 Report to Congress. As previously noted, in addition to the concern that the difference in payment is leading to unnecessary increases in the volume of covered outpatient department services, we also are concerned that this shift in care setting increases beneficiary cost-sharing liability because Medicare payment rates for the same or similar services are generally higher in hospital outpatient departments than in freestanding physician offices. For example, MedPAC estimates that “the Medicare program spent $1.0 billion more in 2009, $1.3 billion more in 2014, and $1.6 billion more in 2015 than it would have if payment rates for E&M office visits in HOPDs were the same as freestanding office rates. Relatedly, beneficiaries’ cost-sharing was $260 million higher in 2009, $325 million higher in 2014, and $400 million higher in 2015 than it would have been because of the higher rates paid in HOPDs, respectively. We believe that this volume growth and the resulting increase in beneficiary cost-sharing is unnecessary because it appears to have been incentivized by the difference in payment for each setting rather than patient acuity. If there was not a difference in payment rates, we believe that we would not have seen the increase in beneficiaries’ cost-sharing and the shift in site-of-service.

In the CY 2015 OPPS/ASC proposed rule (79 FR 41013), we stated that we continued to seek a better rule (79 FR 41013), we stated that we needed information on the extent to which this shift was occurring. To that end, during the CY 2014 OPPS/ASC rulemaking cycle, we sought public comment regarding the best method for collecting information and data that would allow us to analyze the frequency, type, and payment for physicians’ services and hospital outpatient services furnished in off-campus PBDS of hospitals (78 FR 75061 through 75062 and 78 FR 74427 through 74428). Based on our analysis of the public comments we received, we believed that the most efficient and equitable means of gathering this important information across two different payment systems would be to create a HCPCS modifier to be reported with every code for physicians’ services and hospital outpatient services furnished in an off-campus PBD of a hospital on both the CMS–1500 claim form for physicians’ services and the UB–04 form (CMS Form 1450 and OMB Control Number 0938–0997) for hospital outpatient services. We noted that a main provider may treat an off-campus facility as provider-based if certain requirements at 42 CFR 413.65 are satisfied, and we define a “campus” at 42 CFR 413.65(a)(2) to be the physical area immediately adjacent to the provider’s main buildings, other areas and structures that are not strictly contiguous to the main buildings but are located within 250 yards of the main buildings, and any other areas determined on an individual case basis, by the CMS regional office, to be part of the provider’s campus.

In 2015, the Congress took steps to address the higher Medicare payments for services furnished by certain off-campus PBDS that may be associated with hospital acquisition of physicians’ offices through section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), enacted on November 2, 2015. In the CY 2017 OPPS/ASC proposed rule, we discussed section 603 of the Bipartisan Budget Act of 2015, which amended section 1833(t) of the Act. For the full discussion of our initial implementation of this provision, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and the interim final rule with comment period (79720 through 79731).

Section 603 of the Bipartisan Budget Act of 2015 (Section 603) amended section 1833(t) of the Act by adding a new paragraph (2)B and adding a new (21). As a general matter, under sections 1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services furnished by certain off-campus outpatient departments of a provider or after January 1, 2017 are not considered covered OPD services as defined under section 1833(t)(1)(B) of the Act for purposes of payment under the OPPS and are instead paid “under the applicable payment system” under Medicare Part B if the requirements for such payment are otherwise met. We note that, in order to be considered part of a hospital, an off-campus department of a hospital must meet the provider-based criteria established under 42 CFR 413.65.

Section 603 amended section 1833(t)(1)(B) of the Act by adding a new clause (v), which excludes from the definition of “covered OPD services” applicable items and services (defined in paragraph (21)A of the section) that are furnished on or after January 1, 2017, by an off-campus PBD, as defined in paragraph (21)B of the section. Section 603 also added a new paragraph (21) to section 1833(t) of the Act, which defines the terms “applicable items and services” and “off-campus outpatient department of a provider,” requires the Secretary to make payments for such applicable items and services furnished by an off-campus PBD under an applicable payment system (other than the OPPS), provides that hospitals shall report on information as needed for implementation of the provision, and establishes a limitation on administrative and judicial review of the Secretary’s determinations of applicable items and services, applicable payment system, whether a department meets the definition of an off-campus outpatient department of a provider, and information hospitals are required to report. In defining the term “off-campus outpatient department of a provider,” section 1833(t)(21)(B)(i) of the Act specifies that the term means a department of a provider (as defined at 42 CFR 413.65(a)(2) as that regulation was in effect on November 2, 2015, the date of enactment of Pub. L. 114–74) that is not located on the campus of such provider, or within the distance from a remote location of a hospital facility. Section 1833(t)(21)(B)(ii) of the Act excepts from the definition of “off-campus outpatient department of a provider,” for purposes of paragraphs (1)(B)(v) and (21)B of the section, an off-campus PBD that was billing under section 1833(t) of the Act with respect to covered OPD services furnished prior

69Ibid
to the date of enactment of the Bipartisan Budget Act of 2015, that is, November 2, 2015. We note that the definition of “applicable items and services” specifically excludes items and services furnished by a dedicated emergency department as defined at 42 CFR 489.24(b) and the definition of “off-campus outpatient department of a provider” does not include PBDs located on the campus of a hospital or within the distance (described in the definition of campus at §413.65(a)(2)) from a remote location of a hospital facility; the items and services furnished by these excepted off-campus PBDs on or after January 1, 2017 continued to be paid under the OPPS.

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79720), we established a number of policies to implement section 603 of the Bipartisan Budget Act of 2015. Broadly, we: (1) Defined applicable items and services in accordance with section 1833(t)(21)(A) of the Act for purposes of determining whether such items and services are covered OPD services under section 1833(t)(1)(B)(v) of the Act or whether payment for such items and services will instead be made under the applicable payment system designated under section 1833(t)(21)(C) of the Act; (2) defined off-campus PBD for purposes of sections 1833(t)(1)(B)(v) and (t)(21) of the Act; and (3) established policies for payment for applicable items and services furnished by an off-campus PBD (nonexcepted items and services) under section 1833(t)(21)(C) of the Act.

To do so, we finalized policies that define whether certain items and services furnished by a given off-campus PBD may be considered excepted and, thus, continue to be paid under the OPPS; established the requirements for the off-campus PBDs to maintain excepted status (both for the excepted off-campus PBDs and for the items and services furnished by such excepted off-campus PBDs); and described the applicable payment system for nonexcepted items and services (generally, the PFS).

As part of developing policies to implement the section 603 amendments to section 1833(t) of the Act, we solicited public comments on information collection requirements for implementing this provision in accordance with section 1833(t)(21)(D) of the Act (81 FR 45686; 81 FR 79709 through 79710). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79719 and 79725), we created modifier “PN” to collect data for purposes of implementing section 603 but also to trigger payment under the newly adopted PFS rates for nonexcepted items and services.

While the changes required by the section 603 amendments to section 1833(t) of the Act address some of the concerns related to shifts in settings of care and overutilization in the hospital outpatient setting, the majority of hospital off-campus departments continue to receive full OPPS payment (including off-campus emergency departments and excepted off-campus departments of a hospital), which is often higher than the payment that would have been made if a similar service had been furnished in the physician office setting. Therefore, the current site-based payment creates an incentive for an unnecessary increase in the volume of this type of OPD service, which results in higher costs for the Medicare program, its beneficiaries, and taxpayers more generally. These differences in payment rates have unnecessarily shifted services away from the lower paying physician’s office to the higher paying hospital outpatient department. We believe that the higher payment that is made under the OPPS, as compared to payment under the PFS, contributes to incentivizing providers to furnish care in the hospital outpatient setting rather than the physician office setting.

In 2012, Medicare was paying approximately 80 percent more for a 15-minute office visit in a hospital outpatient department than in a freestanding physician office.70

For example, under Medicare payment policy in effect for CY 2018, the Medicare program would pay more for a clinic visit (HCPCS code G0463) furnished under the OPPS than it would for the visit codes under the PFS. In the CY 2017 OPPS/ASC interim final rule, we noted that the most frequently billed service with the “PO” modifier was described by HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient), which is paid under APC 5012 (Clinic Visits and Related Services); the total number of CY 2017 claim lines for this service was approximately 10.8 million lines with the “PO” modifier as of October 2018, out of a total 30.5 million lines in CY 2017. When services are furnished in the hospital outpatient setting, an additional payment for the professional services is generally made under the PFS using the “facility” rate. For example, in CY 2017, the OPPS payment rate for APC 5012, which is the APC to which the outpatient clinic visit code was assigned, was $106.56. The CY 2017 PFS “facility” payment rate for a Level 3 visit, a service that commonly corresponds to the OPPS clinic visit, was $77.88 for a new patient and $51.68 for an established patient.

However, when services are furnished in the physician office setting, only one payment is made—typically, the “nonfacility” rate under the PFS. The CY 2017 PFS nonfacility payment rates for a Level 3 visit, a commonly billed service under the PFS, was $109.46 for a new patient and $73.93 for an established patient. Therefore, the total Medicare Part B payment rate (for the hospital and professional service) for a new patient when the service was furnished in the hospital outpatient setting was $184.44 ($106.56 + $77.88) compared to $109.46 in the physician office setting (approximately $75 or 68 percent more per visit), or for an established patient, $158.24 ($106.56 + $51.68) in the hospital outpatient setting compared to $73.93 in the physician office setting (approximately $84 or 114 percent more per visit). Under these examples, the payment rate was approximately $75 to $84 more for the same service when furnished in the hospital outpatient setting instead of the physician office setting, 20 percent of which was the responsibility of the beneficiary. Taking into account that this payment discrepancy occurs across tens of millions of claims each year, this is a significant source of unnecessary spending by Medicare beneficiaries directly (in the form of unnecessarily high copayments) and on behalf of Medicare beneficiaries (in the form of unnecessarily high Medicare payments for services that could be performed in a different setting).

We understand that many off-campus departments converted from physicians’ offices to hospital outpatient departments without a change in either the physical location or a change in the acuity of the patients seen. To the extent that similar services can be safely provided in more than one setting, we do not believe it is prudent for the Medicare program to pay more for these services in one setting than another. We believe the difference in payment for these services is a significant factor in the shift in services from the physician’s office to the hospital outpatient department, thus unnecessarily increasing hospital outpatient department volume and Medicare program and beneficiary expenditures.

We consider the shift of services from the physician office to the hospital outpatient department unnecessary if the beneficiary can safely receive the same services in a lower cost setting but is instead receiving services in the
higher paid setting due to payment incentives. We believe the increase in the volume of clinic visits is due to the payment incentive that exists to provide this service in the higher cost setting. Because these services could likely be safely provided in a lower cost setting, we believe that the growth in clinic visits paid under the OPPS is unnecessary. Further, we believe that capping the OPPS payment at the PFS-equivalent rate would be an effective method to control the volume of these unnecessary services because the payment differential that is driving the site-of-service decision will be removed.

In particular, we believe this method of capping payment will control unnecessary volume increases both in terms of numbers of covered outpatient department services furnished and costs of those services.

Therefore, given the unnecessary increases in the volume of clinic visits in hospital outpatient departments, in the CY 2019 OPPS/ASC proposed rule (83 FR 37142), for the CY 2019 OPPS, we proposed to use our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act (departments that bill the modifier “PO” on claim lines). Off-campus PBDs that are not excepted from section 603 (departments that bill the modifier “PN”) already receive a PFS-equivalent payment rate for the clinic visit.

In CY 2019, for an individual Medicare beneficiary, the standard unadjusted Medicare OPPS proposed payment for the clinic visit was approximately $116, with approximately $23 being the average copayment. The proposed PFS equivalent rate for Medicare payment for a clinic visit was approximately $46, and the copayment would be approximately $9. Under this proposal, an excepted off-campus PBD would continue to bill HCPCS code G0463 with the “PO” modifier in CY 2019, but the payment rate for services described by HCPCS code G0463 when billed with modifier “PO” would now be equivalent to the payment rate for services described by HCPCS code G0463 when billed with modifier “PN.” This would save beneficiaries an average of $14 per visit. For a discussion of the amount paid under the PFS for clinic visits furnished by excepted off-campus PBDs, we referred readers to the CY 2018 PFS final rule (82 FR 53023 through 53024), as well as the CY 2019 PFS proposed rule and final rule.

In addition, in the CY 2019 OPPS/ASC proposed rule (83 FR 37142), we proposed to implement this proposed method in a nonbudget neutral manner. Specifically, while section 1833(t)(9)(B) of the Act requires that certain changes made under the OPPS be made in a budget neutral manner, we note that this section does not apply to the volume control method under section 1833(t)(2)(F) of the Act. In particular, section 1833(t)(9)(A) of the Act, titled “Periodic review,” provides, in part, that the Secretary must annually review and revise the groups, the relative payment weights, and the wage and other adjustments described in paragraph (2) to take into account changes in medical practice, changes in technology, the addition of new services, new cost data, and other relevant information and factors” (emphasis added). Section 1833(t)(9)(B) of the Act, titled “Budget neutrality adjustment” provides that if “the Secretary makes adjustments under subparagraph (A), then the adjustments for a year may not cause the estimated amount of expenditures under this part for the year to increase or decrease from the estimated amount of expenditures under this part that would have been made if the adjustments had not been made” (emphasis added). However, section 1833(t)(2)(F) of the Act is not an “adjustment” under paragraph (2). Unlike the wage adjustment under section 1833(t)(2)(D) of the Act and the outlier, transitional pass-through, and equitable adjustments under section 1833(t)(2)(E) of the Act, section 1833(t)(2)(F) of the Act refers to a “method” for controlling unnecessary increases in the volume of covered OPD services, not an adjustment. Likewise, sections 1833(t)(2)(D) and (E) of the Act also explicitly require the adjustments authorized by those paragraphs to be budget neutral, while the volume control method authority at section 1833(t)(2)(F) of the Act does not.

Therefore, the volume control method proposed under section 1833(t)(2)(F) of the Act is not one of the adjustments under section 1833(t)(2) of the Act that is referenced under section 1833(t)(9)(A) of the Act that must be included in the budget neutrality adjustment under section 1833(t)(9)(B) of the Act. Moreover, section 1833(t)(9)(C) of the Act specifies that if the Secretary determines under methodologies described in paragraph (2)(F) that the volume control method under this subsection increased beyond amounts established through those methodologies, the Secretary may appropriately adjust the update to the conversion factor otherwise applicable in a subsequent year. We interpret this provision to mean that the Secretary will have implemented a volume control method under section 1833(t)(2)(F) of the Act in a nonbudget neutral manner in the year in which the method is implemented, and that the Secretary may then make further adjustments to the conversion factor in a subsequent year to account for volume increases that are beyond the amounts estimated by the Secretary under the volume control method.

We stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37143) that we believe implementing a volume control method in a budget neutral manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the movement of the volume within the OPPS system in the aggregate, a concern similar to the one we discussed in the CY 2008 OPPS final rule with comment period (72 FR 66613). This estimated payment impact was displayed in Column 5 of Table 42.—Estimated Impact of the Proposed Changes for the Hospital Outpatient Prospective Payment System in the CY 2010 OPPS/ASC proposed rule (83 FR 37228 through 37229). An estimate that includes the effects of estimated changes in enrollment, utilization, and case-mix based on the FY 2019 President’s Budget approximates the estimated savings at $760 million, with $630 million of the savings accruing to Medicare, and $150 million saved by Medicare beneficiaries in the form of reduced copayments. In order to effectively establish a method for controlling the unnecessary growth in the volume of clinic visits furnished by excepted off-campus PBDs that does not simply reallocate expenditures that are unnecessary within the OPPS, we believe that this method must be adopted in a nonbudget neutral manner. The impact associated with this proposal is further described in section XXI. of the CY 2019 OPPS/ASC proposed rule.

Comment: Numerous commenters, including organizations representing private health insurance plans, physician associations, specialty medical associations, and individual Medicare beneficiaries, supported the proposal. Some of these commenters commended CMS for its proposal, which they believed will help to control costs for both beneficiaries and the Medicare program, as well as foster greater competition in the physician services market. Commenters were
supportive of the immediate impact this policy would have in lowering Medicare beneficiaries’ out-of-pocket costs. One commenter noted that there “is no principled basis for treating excepted and nonexcepted PBPs differently with respect to payment for E&M services or for perpetuating the payment differential between off-campus PBPs and physician offices.” Several commenters supported implementing this policy in a nonbudget neutral manner because they believed to do otherwise would be simply to redistribute expenditures for unnecessary services within the OPPS rather than eliminating those expenditures from the OPPS altogether. A number of commenters urged CMS to continue on a path to bring full parity in payment for outpatient services, regardless of the site-of-service, to lower beneficiary cost-sharing, reduce Medicare expenditures, and stem the tide of provider consolidation. Two commenters believed that several factors demonstrate to them that HOPDs drive up volume for several other common outpatient services, including:

- Patients receive more chemotherapy administration sessions, on average, when treated in the HOPD. Chemotherapy days per beneficiary were estimated 9 to 12 percent higher in the hospital outpatient department than the physician office setting.71
- Differences in utilization of chemotherapy drugs and services between hospital outpatient departments and physicians’ offices resulted in an estimated increase in Medicare payments and Medicare beneficiary copayments of $167 million. Over 93 percent of the additional payments were related to chemotherapy and other chemotherapy-related drugs.72
- Cardiac imaging procedures resulted in higher payments for a 3-day episode (217 percent) and 22-day episodes (80 percent) when performed in a HOPD compared to a physician’s office.73
- For certain cardiology, orthopedic, and gastroenterology services, employed physicians were seven times more likely to perform services in a HOPD setting than independent physicians, resulting in additional costs of $2.7 billion to Medicare and $411 million in patient copayments over a 3-year period.74

One commenter believed that payment differentials between independent physician practices and hospital outpatient departments stem in part from inadequate Medicare physician payment rates and that any savings from site neutrality proposals derived from OPPS should be reinvested in increasing payment rates elsewhere in Part B, including payments to physicians. Some commenters urged HHS to work with Congress to expand site-neutral policies in the OPPS.

Response: We appreciate the commenters’ support. As mentioned in the proposed rule (83 FR 37138 through 37143), we share the commenters’ concern that the current payment incentives, rather than patient acuity or medical necessity, are affecting site-of-service decision-making. As we noted in the proposed rule (83 FR 37138 through 37143), “[a] large source of growth in spending on services furnished in hospital outpatient departments (HOPDs) appears to be the result of the shift of services from (lower cost) physician offices to (higher cost) HOPDs.”75 We continue to believe that these shifts in the sites of service are unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting due to payment incentives. In addition to the concern that the difference in payment is leading to unnecessary increases in the volume of covered outpatient department services, we continue to be concerned that this shift in care setting increases beneficiary cost-sharing liability because Medicare payment rates for the same or similar services are generally higher in hospital outpatient departments than in physician offices.

We appreciate the comments supporting the implementation of this policy in a nonbudget neutral manner. As we stated in the proposed rule (83 FR 37138 through 37143), we believe implementing a volume control method in a budget neutral manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the volume of services within the OPPS system in the aggregate. As detailed later in this section, we are finalizing our proposal, with modifications, in response to public comments. We will continue to take information submitted by the commenters into consideration for future study.

With respect to the comment that it is inappropriate to establish a PFS-equivalent rate because PFS rates are inadequate and that any savings should be redistributed across Medicare Part B, we disagree that PFS rates as a whole are inadequate and note that the methodology to develop such rates was established by law and regulations and is updated each year through notice-and-comment rulemaking. We note that the overall amount of Medicare payments to physicians and other entities made under the PFS is determined by the PFS statute, and the rates for individual services are determined based on the resources involved in furnishing these services relative to other services paid under the PFS. To the extent the commenter believes that the PFS rate for a particular service is misvalued relative to other PFS services, we encourage the commenter to nominate the service for review as a potentially misvalued service under the PFS.

Comment: MedPAC supported the proposal to reduce the OPPS payment rate for clinic visits provided in an excepted off-campus PBP to a PFS-equivalent payment rate. MedPAC noted that the policy would be consistent with its past recommendations for site-neutral payments between HOPDs and freestanding physician offices. In its comments, MedPAC highlighted two key points from its March 2012 recommendation on site-neutral payments. While MedPAC recommended that OPPS payment rates for clinic visits be reduced so that Medicare payments for these services are the same whether they are provided in HOPDs or physician offices, it also recommended that this policy be phased in over 3 years to allow providers time to adjust to lower payment rates. During the phase-in, MedPAC recommended that payment reductions to hospitals with a disproportionate share (DSH) patient percentage at or above the median be limited to 2 percent of overall Medicare payments because these hospitals are often the primary source of care for low-income beneficiaries and limiting the reduction in revenue would help maintain access to care for these beneficiaries.

Response: We thank MedPAC for its comments and support of this policy. In its comments, MedPAC recommended this policy be phased in over 3 years to allow providers time to adjust to lower payment rates. As detailed later in this section, we will be implementing this policy with a 2-year phase-in. We believe that a 2-year phase-in allows us...
to balance the immediate need to address the unnecessary increases in the volume of clinic visits with concerns like those articulated by MedPAC regarding providers’ need for time to adjust to these payment changes. While we acknowledge and share MedPAC’s concern about beneficiary access to care, we do not believe that a limit on the payment reduction to hospitals with a DSH patient percentage at or above the median is necessary because we believe the increase in the volume of clinic visits in exempted off-campus provider-based departments of hospitals with high DSH percentages is equally unnecessary as it is at other hospitals.

Many commenters challenged the statutory authority for various aspects of the proposal. These comments are summarized below.

Comment: Several commenters disagreed with CMS’ interpretation of section 1833(t)(2)(F) of the Act. The commenters contended that section 1833(t)(2)(F) of the Act does not confer direct authority on CMS to modify OPPS payment rates for specific services. Rather, the commenters asserted that section 1833(t)(2)(F) of the Act only permits the agency to develop a “method,” which the commenters interpreted to mean a “way of doing things” or a “plan.” The commenters stated that utilizing the authority at section 1833(t)(2)(F) of the Act to reduce payments to excepted off-campus PBDs to rates that equal the lower payment amounts received by nonexcepted off-campus PBDs was improper. The commenters contended that the Secretary can only control unnecessary increases in volume using authority conferred by other provisions of section 1833(t) of the Act, such as through the equitable adjustment authority at section 1833(t)(2)(E) of the Act. The commenters believed that the clinic visit proposal was arbitrary and capricious for this and other reasons. In particular, the commenters expressed concern that there was no data-driven basis to conclude that OPD services have increased unnecessarily. The commenters also claimed that the proposal is based on unsupported assertions and assumptions regarding increases in volume. The commenters were concerned that other factors, such as the shift from inpatient services to outpatient services or the 2-midnight policy, might be driving the increases in the volume of outpatient services. Other commenters asserted that CMS should consider the impact of severity of illness and patient demographics on outpatient volume prior to moving forward with any payment changes. One commenter stated that, relative to patients seen in

physician offices, patients seen in HOPDs:
- Have more severe chronic conditions;
- Have higher prior utilization of hospitals and EDs;
- Are more likely to live in low-income areas;
- Are 1.8 times more likely to be dually eligible for Medicare and Medicaid;
- Are 1.4 times more likely to be nonwhite;
- Are 1.6 times more likely to be under age 65 and disabled; and
- Are 1.1 times more likely to be over 85 years old.

The commenters also noted that Medicare beneficiaries with cancer seen in HOPDs relative to those beneficiaries seen in physician offices have more severe chronic conditions, higher prior utilization of services in hospitals and emergency departments, and higher likelihood of residing in low-income areas. In addition, the commenters noted that these cancer patients were more likely to be dually eligible for Medicare and Medicaid and be nonwhite, under age 65, and disabled.

Response: After consideration of these comments, we continue to believe that section 1833(t)(2)(F) of the Act gives the Secretary broad authority to develop a method for controlling unnecessary increases in the volume of covered outpatient department (OPD) services, including a method that controls unnecessary volume increases by removing a payment differential that is driving a site-of-service decision, and as a result, is unnecessarily increasing service volume. We continue to believe shifts in the sites of service described in the preceding paragraphs are inherently unnecessary if the beneficiary can safely receive the same services in a lower cost setting but instead receives care in a higher cost setting due to the payment incentives created by the difference in payment amounts. While we did receive some data illustrating that HOPDs serve unique patient populations and provide services to medically complex beneficiaries, these data did not demonstrate the need for higher payment for all clinic visits provided in HOPDs. The fact that the commenters did not supply data supporting these assertions is suggestive that the payment differential may be the main driver for unnecessary volume increases in outpatient department services, particularly clinic visits.

In fact, the Government Accountability Office (GAO) found that “the percentage of E/M visits—as well as the number of E/M office visits per beneficiary—performed in HOPDs, rather than physician offices, was generally higher in counties with higher levels of vertical consolidation in 2007–2013.” Vertical consolidation is the practice of hospitals acquiring physician practices. We believe that higher payment rates for services furnished in HOPDs, which include clinic visits, have led hospitals to increasingly purchase physician practices. We believe there is a correlation among the increasing volume of HOPD clinic visits, vertical integration, and the higher OPPS payment rates for clinic visits. The GAO discovered that “the median percentage of E/M office visits performed in HOPDs in counties with the lowest levels of vertical consolidation was 4.1 percent in 2013. In contrast, this rate was 14.1 percent for counties with the highest levels of consolidation.” The GAO also found that, in 2013, the number of E/M office visits performed in HOPDs per 100 beneficiaries was 26 for the counties with low levels of vertical consolidation, whereas the number was substantially higher—82 services per 100 beneficiaries—in counties with the highest levels of vertical consolidation. The GAO determined that the association between higher levels of vertical consolidation and high utilization of E/M office visits in HOPDs remained even after controlling for differences in county-level characteristics and other market factors that could affect the setting in which E/M office visits are performed. The GAO describes the model it ran as a “regression model that controlled for county characteristics that do not change over relatively short periods of time, such as whether a county is urban or rural, and county characteristics that could change over time, such as the level of competition among hospitals and physicians within counties.” The GAO explained that its “regression model’s results were similar to [its] initial results: the level of vertical consolidation in a county was significantly and positively associated with a higher number and percentage of E/M office visits performed in HOPDs—that is, as vertical consolidation increased in a given county, the number and percentage of E/M office visits

[78] Ibid.
performed in HOPDs in that county also tended to be higher.”

The GAO findings align with our assertions in the proposed rule (83 FR 37138 through 37143). Paying substantially more for the same service when performed in an HOPD rather than a physician office provides an incentive to shift services that were once performed in physician offices to HOPDs after consolidation has occurred. The GAO findings suggest that providers responded to this financial incentive: E/M office visits were more frequently performed in HOPDs in counties with higher levels of vertical consolidation. The GAO found this association in both of its analyses of E/M office visit utilization in counties with varying levels of vertical consolidation and in its regression analyses.

We heard from many commenters that the higher payment rate was justified by the fact that HOPDs were treating sicker patient populations. The GAO’s study did not support this conclusion. It examined counties that experienced large growth in the billing of clinic visits in HOPDs and was able to determine that: “Beneficiaries from counties with higher levels of vertical consolidation were not sicker, on average, than beneficiaries from counties with lower levels of consolidation. Specifically, beneficiaries from counties with higher levels of vertical consolidation tended to have either similar or slightly lower median risk scores, death rates, rates of end-stage renal disease, and rates of disability compared to those from counties with lower levels of consolidation. Further, counties with higher levels of consolidation had a lower percentage of beneficiaries dually eligible for Medicaid, who tend to be sicker and have higher Medicare spending than Medicare beneficiaries who are not dually eligible for Medicaid.”

This suggests that areas with higher E/M office visit utilization in HOPDs are not composed of sicker-than-average beneficiaries. As we stated in the proposed rule (83 FR 37138 through 37143), paying more for the same service when performed in an HOPD rather than a physician’s office provides an incentive to shift services that were once performed in physician offices to HOPDs. The GAO’s findings suggest that providers responded to this financial incentive. As we noted in the proposed rule (83 FR 37138 through 37143), we have developed many payment policies, such as packaging policies and comprehensive APCs, to address the rapid growth of services in the OPPS. However, these policies have not been able to control for unnecessary increases in volume that are due to site-of-service payment differentials, which create an incentive to furnish a service in the OPD that could be furnished in a lower cost setting based solely on the higher payment amount available under the OPPS. Here, the clinic visit service furnished in excepted off-campus PBDS is the same as the clinic visit service furnished in nonexcepted off-campus PBDS. We believe that applying an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD excepted from section 1833(t)(21) of the Act is an appropriate method to control the unnecessary increase in the volume of outpatient services.

Several commenters expressed concern that CMS lacks the statutory authority to reduce OPPS payments for certain clinic visit services furnished at off-campus PBDS that are excepted from payment “under the applicable payment system” under section 1833(t)(21) of the Act. The commenters stated that Congress expressly chose in section 603 of the Bipartisan Budget Act of 2015 not to confer on CMS authority to pay excepted off-campus PBDS at the reduced rates paid to nonexcepted off-campus PBDS. The commenters asserted that CMS is ignoring the express and statutorily mandated grandfathering exception created by section 603.

Response: We believe the changes required by section 603 of the Bipartisan Budget Act of 2015 made in section 1833(t) of the Act address some of the concerns related to shifts in settings of care and overutilization of services in the hospital outpatient setting for new off-campus PBDS after November 1, 2015. However, the majority of hospital off-campus departments continue to receive full OPPS payment (including off-campus emergency departments and excepted off-campus departments of a hospital), which is often higher than the payment that would have been made if a similar service had been furnished in the physician office setting. Therefore, the current site-based payment creates an incentive for an unnecessary increase in the volume of this type of OPD service, which results in higher costs for the Medicare program, beneficiaries, and taxpayers more generally. We interpret our authority under section 1833(t)(2)(F) of the Act to allow us to implement our proposed method of applying an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at off-campus PBDS, even those that are excepted from section 1833(t)(21) of the Act. We believe that this is an appropriate method because the clinic visit service is the same service furnished in excepted and nonexcepted off-campus PBDS.

When Congress passed the Bipartisan Budget Act of 2015, Medicare OPPS expenditures were $56 billion and growing at an annual rate of about 7.3 percent. In addition, the percentage increase in volume and intensity of outpatient services was increasing at 3.4 percent. For the upcoming 2019 calendar year, we estimate that, without this policy, OPPS expenditures would be $74.5 billion, growing at a rate of 9.1 percent, with the volume and intensity of outpatient services increasing at 5.4 percent, based on the Midsession Review for 2019. While it is clear that the action Congress took in 2015 to address certain off-campus PBDS helped stem the tide of these increases in the volume of OPD services, it is likewise clear that the more specific payment adjustment has not adequately addressed the overall increase in the volume of these types of OPD services because most off-campus PBDS continue to be paid the higher OPPS amount for these services. We would not be able to adequately address the unnecessary increases in the volume of clinic visits in HOPDs if we did not apply this policy to all off-campus HOPDs. We do not believe that the section 603 amendments to section 1833(t) of the Act, which exclude applicable items and services furnished by nonexcepted off-campus PBDS from payments under the OPPS, preclude us from exercising our authority in section 1833(t)(2)(F) of the Act to develop a method for controlling unnecessary increases in the volume of covered outpatient department services under the OPPS.

Comment: Several commenters believed that CMS does not have statutory authority to implement this policy in a nonbudget neutral manner. The commenters explained that, because CMS lacks the authority to reduce clinic visit payment rates as a method to control unnecessary increases in the volume of covered outpatient department services under section 1833(t)(2)(F) of the Act, that provision cannot provide authority for the
other commenters stated that if this policy is finalized, it should be done so in a "neutral" manner. The response: We maintain that while section 1833(t)(9)(B) of the Act does require that certain changes made under the OPPS be made in a neutral manner, this provision does not apply to the volume control method under section 1833(t)(2)(F) of the Act as outlined through our proposal. As we noted in the proposed rule (83 FR 37138 through 37143), unlike the wage adjustment under section 1833(t)(2)(D) of the Act and the outlier, transitional pass-through, and equitable adjustments under section 1833(t)(2)(E) of the Act, section 1833(t)(2)(F) of the Act refers to a "method" for controlling unnecessary increases in the volume of covered OPD services, not an adjustment. Likewise, sections 1833(t)(2)(D) and (E) of the Act also explicitly require the adjustments authorized by those paragraphs to be budget neutral, while the volume control method authority at section 1833(t)(2)(F) of the Act does not include such a requirement. Therefore, we maintain that the volume control method proposed under section 1833(t)(2)(F) of the Act is not one of the adjustments under section 1833(t)(2) of the Act that is referenced under section 1833(t)(9)(A) of the Act that must be included in the budget neutrality adjustment under section 1833(t)(9)(B) of the Act. Moreover, section 1833(t)(9)(C) of the Act specifies that if the Secretary determines under methodologies described in paragraph (2)(F) of section 1833(t) of the Act that the volume of services paid for under this subsection increased beyond amounts established through those methodologies, the Secretary may appropriately adjust the update to the conversion factor otherwise applicable in a subsequent year. We continue to interpret this provision to mean that the Secretary will have implemented a volume control method under section 1833(t)(2)(F) of the Act in a "neutral" manner in the year in which the method was adopted. Further, as we stated in the proposed rule (83 FR 37138 through 37143), we believe that implementing a volume control method in a "neutral" manner would not appropriately reduce the overall unnecessary volume of covered OPD services, and instead would simply shift the volume within the OPPS system in the aggregate.

Comment: Several commenters supported the recommendation from the HOP Panel not to implement this proposal and to instead study the matter to better understand the reasons for increased utilization.

Response: Section 1833(t)(9)(A) of the Act provides that the Secretary shall consult with the Panel on policies affecting the clinical integrity of the ambulatory payment classifications and their associated weights under the OPPS. The Panel met on August 20, 2018 and made recommendations on this proposed policy, and we consulted with the Panel on those recommendations. The HOP Panel’s recommendations, along with public comments on provisions of the proposed rule, have been taken into consideration in the development of this final rule with comment period. While we are not accepting the HOP Panel’s recommendation to not implement this proposal, we will continue to monitor and study the utilization of outpatient services as recommended by the Panel.

Comment: Several commenters expressed concern that this policy proposal would disproportionately affect safety net hospitals and rural providers. Numerous commenters representing providers and beneficiaries in the State of Washington expressed concern about the impact this proposal would have on their area. Several commenters also requested that sole community hospitals (urban and rural), rural referral centers, and Medicare-dependent hospitals be exempted from this policy. A number of commenters, including many State hospital associations, expressed concern that the magnitude of the proposed payment reduction would have a drastic effect on their margins and endanger the investments many hospitals have made in their provider-based facilities. In addition, commenters suggested that the reduction in payment would ultimately lead to a reduction of services that would adversely affect vulnerable patient populations. One commenter conducted a trend analysis and found that 200 hospitals would shoulder 73 percent of the proposed payment reduction. According to this commenter’s analysis, for the 200 hospitals most affected by this proposal, the average reduction would be 5.5 percent. For the remaining hospitals, the average reduction would be 0.5 percent. Response: We share the commenters’ concerns about access to care, especially in rural areas where access issues may be more pronounced than in other areas of the country. Medicare has long recognized the unique needs of rural communities and the financial challenges for rural providers. Across the various Medicare payment systems, CMS has implemented a number of special payment provisions for rural providers to maintain access and deliver high quality care to beneficiaries in rural areas. With respect to the OPPS, section 1833(t)(13) of the Act provided the Secretary the authority to make an adjustment to OPPS payments for rural hospitals effective January 1, 2006, if justified by a study of the difference in costs by APC between hospitals in rural areas and hospitals in urban areas. Our analysis showed a difference in costs for rural sole community hospitals. Therefore, for the CY 2006 OPPS, we finalized a payment adjustment for rural sole community hospitals of 7.1 percent for all services and procedures paid under the OPPS, excluding separately payable drugs and biologicals, brachytherapy sources, and devices paid under the pass-through payment policy, in accordance with section 1833(t)(13)(B) of the Act. We have continued this 7.1 percent payment adjustment since 2006. In the CY 2019 OPPS/ASC proposed rule (83 FR 37143), we sought public comment on how we might account in the future for providers that serve Medicare beneficiaries in provider shortage areas, which may include certain rural areas. In addition, we sought public comment on whether there should be exceptions from this policy for rural providers, such as those providers that are at risk of hospital closure or those providers that are sole community hospitals. Taking into consideration the comments regarding rural hospitals, we believe that implementing this policy with a 2-year phase-in will help to mitigate the immediate impact on rural hospitals. We may revisit this policy to consider potential exemptions in the CY 2020 OPPS rulemaking.

After consideration of the public comments we received, we are finalizing our proposal to use our authority under section 1833(t)(2)(F) of the Act to apply an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate) for the clinic visit service, as described by HCPCS code G0463, when provided at an off-campus PBD exempted from section 1833(t)(21) of the Act...
In addition, we solicited public comments on how to expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in the utilization of OPD services. Therefore, we sought public comment on the following:

- How might Medicare define the terms “unnecessary” and “increase” for services (other than the clinic visit) that can be performed in multiple settings of care? Should the method to control for unnecessary increases in the volume of covered OPD services include consideration of factors such as enrollment, severity of illness, and patient demographics?
- While we proposed to pay the site-specific PFS payment rate for clinic visits beginning in CY 2019, we also were interested in other methods to control for unnecessary increases in the volume of outpatient services. Prior authorization is a requirement that a health care provider obtain approval from the insurer prior to providing a given service in order for the insurer to cover the service. Private health insurance plans often require prior authorization for certain services. Should prior authorization be considered as a method for controlling overutilization of services?
- For what reasons might it ever be appropriate to pay a higher OPPS rate for services that can be performed in lower cost settings?
- Several private health plans use utilization management as a cost-containment strategy. How might Medicare use the authority at section 1833(t)(2)(F) of the Act to implement an evidence-based, clinical support process to assist physicians in evaluating the use of medical services based on medical necessity, appropriateness, and efficiency? Could utilization management help reduce the overuse of inappropriate or unnecessary services?
- How should we account for providers that serve Medicare beneficiaries in provider shortage areas, which may include certain rural areas? With respect to rural providers, should there be exceptions from this policy, such as for providers who are at risk of hospital closure or that are sole community hospitals?
- What impact on beneficiaries and the health care market would such a method for control for unnecessary increases in the volume of covered OPD services have?
- What exceptions, if any, should be made in additional proposals to control for unnecessary increases in the volume of outpatient services are made?

We received feedback on a variety of issues in response to the comment solicitation on additional future considerations. These comments are summarized below.

Comment: In response to the solicitation on how CMS might expand the application of the Secretary’s statutory authority under section 1833(t)(2)(F) of the Act to additional items and services paid under the OPPS that may represent unnecessary increases in OPD volume, MedPAC suggested that CMS consider using the five criteria that MedPAC has developed for identifying services for which it is reasonable to have site-neutral payments between freestanding physician offices and HOPDs.

In response to the solicitation on whether prior authorization should be considered as a method for controlling overutilization of services, most commenters believed that, while prior authorization may be a good method for controlling overutilization of services, it can also lead to increased administrative burden and inhibit patient access. One commenter suggested that CMS consider applying prior authorization for providers with service volumes that are statistical outliers or for those whose ordering rates are not in compliance with clinical guidelines.

In response to the comment solicitation on when it might be appropriate to pay a higher OPPS payment rate for a service that can be performed safely in a lower cost setting, several commenters believed that it would be appropriate to pay a higher OPPS rate for services that can be performed in a lower cost setting if providing this higher payment can improve patient experience, efficiency, and quality of care. Several commenters also mentioned that the comprehensive care management and coordination that accompanies receiving services at an off-campus PBD of a hospital might justify the higher OPPS payment rate.

Commenters also asserted that the comprehensive care management and coordination that accompanies receiving services at an off-campus PBD of a hospital might justify the higher OPPS payment rate.

Commenters also asserted that the comprehensive care management and coordination that accompanies receiving services at an off-campus PBD of a hospital might justify the higher OPPS payment rate.

Commenters also asserted that the comprehensive care management and coordination that accompanies receiving services at an off-campus PBD of a hospital might justify the higher OPPS payment rate.

In response to the comment solicitation on utilization management, several commenters were opposed to this concept and stated that utilization management would increase provider burden and delay patient access to care. One commenter supported the concept.

of utilization management, but believed that it must be based on clinical validity, support the continuity of patient care, be transparent and fair, provide timely access to care and administrative efficiency, and provide alternatives and exemptions to those clinicians with appropriate utilization rates. Other commenters supported appropriate use criteria and evidence-based clinical guidelines and pathways as effective clinical-decision support tools to assist clinicians and hospitals in the reduction of potentially harmful or rarely appropriate services.

Response: We thank commenters for their responses to our comment solicitation. We will consider these comments for future rulemaking.

C. Application of the 340B Drug Payment Policy to Nonexcepted Off-Campus Departments of a Hospital

1. Historical Perspective
a. Section 603 of the Bipartisan Budget Act of 2015

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699), we discussed implementation of section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), enacted on November 2, 2015, which amended section 1833(t) of the Act. Specifically, this provision amended section 1833(t) of the Act by adding paragraph (1)(B) and adding a new paragraph (21). As a general matter, under sections 1833(t)(1)(B)(v) and (t)(21) of the Act, applicable items and services furnished by certain off-campus outpatient departments of a provider or after January 1, 2017 are not considered covered OPD services as defined under section 1833(t)(1)(B) of the Act for purposes of payment under the OPPS and are instead paid “under the applicable payment system” under Medicare Part B if the requirements for such payment are otherwise met. We indicated that, in order to be considered part of a hospital, an off-campus department of a hospital must meet the provider-based criteria established under 42 CFR 413.65. Accordingly, we refer to an “off-campus outpatient department of a provider,” which is the term used in section 603 of the Bipartisan Budget Act of 2015, as an “off-campus outpatient provider-based department” or an “off-campus PBD.”

For a detailed discussion of the legislative history and statutory authority related to payments under section 603 of the Bipartisan Budget Act of 2015, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719) and interim final rule with comment period (81 FR 79720 through 79729).

b. Applicable Payment System

As we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37143 through 37144), to implement the amendments made by section 603 of Public Law 114–74, we issued an interim final rule with comment period (81 FR 79720) which accompanied the CY 2017 OPPS/ASC final rule with comment period to establish the Medicare PFS as the “applicable payment system” that applies in most cases, and we established payment rates under the PFS for those nonexcepted items and services furnished by nonexcepted off-campus PBDS. As we discussed in the CY 2017 OPPS/ASC interim final rule with comment period (81 FR 79718) and reiterated in the CY 2018 PFS final rule with comment period (82 FR 52981), payment for Medicare Part B drugs that would be separately payable under the OPPS (assigned a status indicator of “K”), but are not payable under the OPPS because they are furnished by nonexcepted off-campus PBDS, is made in accordance with section 1847A of the Act (generally, at a rate of ASP+6 percent), consistent with Part B drug payment policy for items or services furnished in the physician office (nonfacility) setting. We did not propose or make an adjustment to payment for 340B-acquired drugs in nonexcepted off-campus PBDS in CY 2018, but indicated we may consider doing so through future notice-and-comment rulemaking.

In the interim final rule with comment period that accompanied the CY 2017 OPPS/ASC final rule with comment period, we established payment policies under the Medicare PFS for nonexcepted items and services furnished by a nonexcepted off-campus PBD on or after January 1, 2017. In accordance with sections 1848(b) and (c) of the Act, Medicare PFS payment is based on the relative value of the resources involved in furnishing particular services (81 FR 79790). Resource-based relative values are established for each item and service (described by a HCPCS code(s)] based on the work (time and intensity), practice expense (such as clinical staff, supplies and equipment, office rent, and overhead), and malpractice expense required to furnish the typical case of the service. Because Medicare makes separate payment under institutional payment systems (such as the OPPS) for the facility costs associated with many of the same services that are valued under the PFS, we establish two different payment rates for many of these services—one that applies when the service is furnished in a location where a facility bills and is paid for the service under a Medicare payment system other than the PFS (the facility rate), and another that applies when the billing practitioner or supplier furnishes and bills for the entire service (the nonfacility rate). Consistent with the long-established policy under the PFS to make payment to the billing practitioner at the facility rate when Medicare makes a corresponding payment to the facility (under the OPPS, for instance) for the same service, physicians and nonphysician practitioners furnishing services in nonexcepted PBDS continue to report their services on a professional claim form and are paid for their services at the PFS facility rate.

Similarly, there are many (mostly diagnostic) services paid under the PFS that have two distinct portions of the service: A technical component (TC) and a professional component (PC). These components can be furnished independently in time or by different suppliers, or they may be furnished and billed together as a “global” service (82 FR 52981). Payment for these services can also be made under a combination of payment systems; for example, under the PFS for the professional component and the OPPS for the facility portion. For instance, for a diagnostic CT scan, the technical component relates to the portion of the service during which the image is captured and might be furnished in an office or HOPD setting, and the professional component relates to the interpretation and report by a radiologist.

In the CY 2017 interim final rule with comment period, we stated that we continue to believe that it is operationally infeasible for nonexcepted off-campus PBDS to bill directly under the PFS for the subset of PFS services for which there is a separately valued technical component (81 FR 79721). In addition, we explained that we believe hospitals that furnish nonexcepted items and services are likely to furnish a broader range of services than other provider or supplier types for which there is a separately valued technical component under the PFS. We stated that we therefore believe it is necessary to establish a new set of payment rates under the PFS that reflect the relative resource costs of furnishing the technical component of a broad range of services to be paid under the PFS that is specific to one site of service (the off-campus PBD of a hospital) with the packaging (bundling) rules that are significantly different from current PFS rules (81 FR 79721).
there is no established mechanism for allowing hospitals to report and bill under the PFS for the portion of resources incurred in furnishing the full range of nonexcepted items and services. This is because hospitals with nonexcepted off-campus PBDs that furnish nonexcepted items and services generally furnish a broader range of services than other provider or supplier types for which there is a separately valued technical component under the PFS. As such, we established a new set of payment rates under the PFS that reflected the relative resource costs of furnishing the technical component of a broad range of services to be paid under the PFS specific to the nonexcepted off-campus PBDs of a hospital. Specifically, we established a PFS relativity adjuster that is applied to the OPPS rate for the billed nonexcepted items and services furnished in a nonexcepted off-campus PBD in order to calculate payment rates under the PFS. The PFS relativity adjuster reflects the estimated overall difference between the payment that would otherwise be made to a hospital under the OPPS for the nonexcepted items and services furnished in nonexcepted off-campus PBDs and the resource-based payment under the PFS for the technical aspect of those services with reference to the difference between the facility and nonfacility (office) rates and policies under the PFS. The current PFS relativity adjuster is set at 40 percent of the amount that would have been paid under the OPPS (82 FR 53028). These PFS rates incorporate the same packaging rules that are unique to the hospital outpatient setting under the OPPS, including the packaging of drugs that are unconditionally packaged under the OPPS. This includes packaging certain drugs and biologicals that would ordinarily be separately payable under the PFS when furnished in the physician office setting.

Nonexcepted off-campus PBDs continue to bill for nonexcepted items and services on the institutional claim utilizing a new claim line (modifier “PN”) to indicate that an item or service is a nonexcepted item or service. For a detailed discussion of the current PFS relativity adjuster related to payments under section 603 of Public Law 114–74, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 52356 through 52637), the CY 2018 PFS final rule with comment period (82 FR 53019 through 53025), and the CY 2019 PFS proposed rule.

c. Section 340B of the Public Health Service Act

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37144 through 37145), the 340B Program, which was established by section 340B of the Public Health Service Act by the Veterans Health Care Act of 1992, is administered by the Health Resources and Services Administration (HRSA) within HHS. The 340B Program allows participating hospitals and other health care providers to purchase certain “covered outpatient drugs” (as defined under section 1927(k) of the Act and interpreted by HRSA through various guidance documents) at discounted prices from drug manufacturers.

In the CY 2018 OPPS/ASC proposed rule (82 FR 33632 through 33635), we proposed changes to the payment methodology under the OPPS for separately payable drugs and biologicals acquired under the 340B Program. We stated that these changes would better, and more appropriately, reflect the resources and acquisition costs that these hospitals incur. Such changes would allow Medicare beneficiaries (and the Medicare program) to pay less when hospitals participating in the 340B Program furnish drugs that are purchased under the 340B Program to Medicare beneficiaries. Subsequently, in the CY 2018 OPPS/ASC final rule with comment period, we finalized our proposal that separately payable, covered outpatient drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program will be paid ASP minus 22.5 percent, rather than ASP+6 percent, when billed by a hospital paid under the OPPS that is not excepted from the payment adjustment. CAHs are not subject to this 340B policy change because they are paid under section 1834(g) of the Act. Rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals are excepted from the alternative payment methodology for 340B-acquired drugs and biologicals. In addition, as stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs with pass-through payment status, which are required to be paid based on ASP methodology, or to vaccines, which are excluded from the 340B Program.

2. Proposal and Final Policy To Pay an Adjusted Amount for 340B-Acquired Drugs and Biologicals Furnished In Nonexcepted Off-Campus PBDs In CY 2019 and Subsequent Years

As noted in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79726; 82 FR 53024 through 53025), the CY 2018 OPPS/ASC proposed rule (82 FR 33632 through 33635), we proposed changes to the payment methodology under the OPPS for separately payable drugs and biologicals acquired under the 340B program, separately payable drugs and biologicals were paid the same rate at both excepted and nonexcepted off-campus departments of a hospital. The policy we finalized in the CY 2018 OPPS/ASC final rule with comment period, in which we adjusted the payment rate for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program from ASP+6 percent to ASP minus 22.5 percent, applies to separately payable drugs and biologicals paid under the OPPS (81 FR 59353 through 59369). Under sections 1833(i)(1)(B)(v) and (t)(21) of the Act, however, in accordance with our policy in effect as of CY 2018, nonexcepted items and services furnished by nonexcepted off-campus PBDs are no longer covered outpatient department services and, therefore, are not payable under the OPPS. This means that nonexcepted off-campus PBDs are not subject to the payment changes finalized in the CY 2018 OPPS/ASC final rule with comment period that apply to hospitals and PBDs paid under the OPPS. Because the separately payable drugs and biologicals acquired under the 340B Program and furnished in nonexcepted off-campus PBDs are no longer covered outpatient department services, as of CY 2018, these drugs and biologicals are currently paid in the same way Medicare Part B drugs are paid in the physician office and other nonhospital settings—typically at ASP+6 percent—regardless of whether they are acquired under the 340B Program.

The current PFS payment policies for nonexcepted items and services incorporate a significant number of payment policies and adjustments made under the OPPS (81 FR 79726; 82 FR 53024 through 53025). In establishing these policies in prior rulemaking, we pointed out that the adoption of these policies was necessary in order to maintain the integrity of the PFS relativity adjuster because it adjusts payment rates developed under the OPPS (81 FR 79726). For example, it is necessary to incorporate OPPS packaging rules into the site-specific PFS rate because the PFS relativity adjuster is applied to OPPS rates that were developed based on those packaging rules. In addition, many of the OPPS policies and adjustments are replicated under the nonexcepted off-campus PBD site-specific PFS rates because they are specifically applicable to hospitals as a setting of care. For these reasons, we adopted the geographic adjustments used for hospitals instead of the adjustments developed for the
PFS localities, which reflect cost differences calculated for professionals and suppliers rather than hospitals (81 FR 79726).

We note that, ordinarily, Medicare pays for drugs and biologicals furnished in the physician’s office setting at ASP+6 percent. This is because section 1842(o)(1)(A) of the Act provides that if a physician’s, supplier’s, or any other person’s bill or request for payment for services includes a charge for a drug or biological for which payment may be made under Medicare Part B and the drug or biological is not paid on a cost or prospective payment basis as otherwise provided in this part, the amount for the drug or biological is equal to the following: The amount provided under section 1847, section 1847A, section 1847B, or section 1881(b)(13) of the Act, as the case may be for the drug or biological.

Generally, in the hospital outpatient department setting, low-cost drugs and biologicals are packaged into the payment for services billed under the OPPS. Separately payable drugs (1) have pass-through payment status, (2) have a per-day cost exceeding a threshold, or (3) are not policy-packaged or packaged in a C–APC. As described in section V.A.1. of the CY 2019 OPPS/ASC proposed rule, section 1847A of the Act establishes the ASP methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the WAC, and the AWP (82 FR 59337). As noted in section V.B.2.b. of the CY 2019 OPPS/ASC proposed rule, since CY 2013, our policy has been to pay for separately payable drugs and biologicals at ASP plus 6 percent in accordance with section 1833(t)(14)(A)[iii][ii] of the Act (the statutory default) (82 FR 59350).

Consequently, in the case of services furnished in a hospital outpatient department, Medicare pays ASP+6 percent for separately payable Part B drugs and biologicals unless those drugs or biologicals are acquired under the 340B Program, in which case they are paid at ASP minus 22.5 percent. For a detailed discussion of our current OPPS drug payment policies, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59343 through 59371).

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37146), as a general matter, in the nonexcepted off-campus PBD setting, we pay hospitals under the PFS for all drugs and biologicals that are packaged under the OPPS based on a percentage of the OPPS payment rate, which is determined using the PFS relativity adjuster. Because OPPS packaging rules apply to the PFS payments to nonexcepted off-campus PBDs, the PFS payment for some nonexcepted items and services that are packaged includes payment for some drugs and biologicals that would be separately payable under the PFS if a similar service had been furnished in the office-based setting. As we noted in the CY 2017 final rule with comment period, in analyzing the term “applicable payment system,” we considered whether and how the requirements for payment could be met under alternative payment systems in order to pay for nonexcepted items and services, and considered several payment systems under which payment is made for similar items and services (81 FR 79712). Because the PFS relativity adjuster that is applied to calculate payment to hospitals for nonexcepted items and services furnished in nonexcepted off-campus PBDs is based on a percentage (40 percent) of the amount determined under the OPPS for a particular item or service, and the OPPS is a prospective payment system, we believe that items and services furnished by nonexcepted off-campus PBDs paid under the PFS are payable on a prospective payment basis.

Therefore, we believe we have flexibility to pay for separately payable drugs and biologicals furnished in nonexcepted off-campus PBDs at an amount other than the amount dictated by sections 1842(o)(1)(C) and 1847A of the Act. As we discussed in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59354), several recent studies and reports on Medicare Part B payments for 340B-acquired drugs highlight a difference in Medicare Part B drug spending between 340B hospitals and non-340B hospitals as well as varying differences in the amount by which the Part B payment exceeds the drug acquisition cost. When we initially developed the policy for nonexcepted off-campus PBDs, most separately payable drugs and biologicals were paid, both in the OPPS and in other Part B settings, such as physician offices, through similar methodologies under section 1847A/1842(o) of the Act. For drugs and biologicals that are packaged in the OPPS, we adopted similar packaging payment policies for purposes of making the site-specific payment systems more consistent for nonexcepted off-campus PBDs. Because hospitals can, in some cases, acquire drugs and biologicals under the 340B Program for use in nonexcepted off-campus PBDs, we believe that adjusting payment exclusively for these departments would present a significant incongruity between the payment amounts for these drugs depending upon where (for example, excepted PBD or nonexcepted PBD) they are furnished. This incongruity would distort the relative accuracy of the resource-based payment amounts under the site-specific PFS rates and could result in significant perverse incentives for hospitals to acquire drugs and biologicals under the 340B Program and avoid Medicare payment adjustments that account for the discount by providing these drugs to patients predominantly in nonexcepted off-campus PBDs. In light of the significant drug payment differences between excepted and nonexcepted off-campus PBDs, in combination with the potential eligibility for discounts, which result in reduced costs under the 340B Program for both kinds of departments, our current payment policy could undermine the validity of the use of the OPPS payment structure in nonexcepted off-campus PBDs. In order to avoid such perverse incentives and the potential resulting distortions in drug payment, in the CY 2019 OPPS/ASC proposed rule (83 FR 37146), we proposed, pursuant to our authority at section 1833(t)(21)(C) of the Act, to identify the PFS as the “applicable payment system” for 340B-acquired drugs and biologicals and, accordingly, to pay under the PFS instead of under section 1847A/1842(o) of the Act an amount equal to ASP minus 22.5 percent for drugs and biologicals acquired under the 340B Program that are furnished by nonexcepted off-campus PBDs. We stated in the proposed rule that we believe this proposed change in policy would eliminate the significant incongruity between the payment amounts for these drugs, depending upon whether they are furnished by excepted off-campus PBDs or nonexcepted off-campus PBDs, which we believe is an unnecessary difference in payment where the 340B Program does not differentiate between PBDs paid under the OPPS and PBDs paid under the PFS using the PFS relativity adjuster.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59367 through 59368), we discussed public comments that we received that noted that the alternative payment methodology for 340B-acquired drugs and biologicals did not apply to nonexcepted off-campus PBDs of a hospital and could result in behavioral
changes that may undermine CMS’ policy goals of reducing beneficiary cost-sharing liability and undercut the goals of section 603 of Public Law 114–74. Commenters recommended that, if CMS adopted a final policy to establish an alternative payment methodology for 340B drugs in CY 2018, CMS also apply the same adjustment to payment rates for drugs furnished in nonexcepted off-campus PBDs of a hospital if such drugs were acquired under the 340B Program (82 FR 59367). While we did not propose to adjust payment for 340B-acquired drugs in nonexcepted off-campus PBDs in CY 2018, we indicated that we would consider adopting such a policy in future rulemaking.

We agree with commenters that the difference in the payment amounts for 340B-acquired drugs furnished by hospital outpatient departments, excepted off-campus PBDs versus nonexcepted off-campus PBDs, creates an incentive for hospitals to move drug administration services for 340B-acquired drugs to nonexcepted off-campus PBDs to receive a higher payment amount for these drugs, thereby undermining our goals of reducing beneficiary cost-sharing for these drugs and biologicals and moving towards site neutrality through the section 603 amendments to section 1833(t) of the Act. Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37145), we proposed changes to the Medicare Part B drug payment methodology for drugs and biologicals furnished and billed by nonexcepted off-campus PBDs of a hospital that were acquired under the 340B Program. Specifically, for CY 2019 and subsequent years, we proposed to pay under the PFS the adjusted payment amount of ASP minus 22.5 percent for separately payable drugs and biologicals (other than drugs on pass-through payment status and vaccines) acquired under the 340B Program when they are furnished by nonexcepted off-campus PBDs of a hospital. Furthermore, we proposed to except rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals from this payment adjustment (83 FR 37145). We stated that we believe that our proposed payment policy would better reflect the resources and acquisition costs that nonexcepted off-campus PBDs incur for these drugs and biologicals.

Comment: Some commenters, including organizations representing physician oncology practices, orthopaedic surgeons, pharmaceutical research and manufacturing companies, a large network of community-based oncology practices, physician organizations, and health insurers, supported the proposal. Some of these commenters commended CMS for its proposal, which they believed would help address the growth of the 340B Program, stem physician practice consolidation with hospitals, preserve patient access to community-based care, and address the significant incongruity between the payment amounts for 340B-acquired drugs, depending upon the setting in which they are furnished. One of these commenters, a pharmaceutical company, stated that the 340B Program has grown beyond its original intent and needs to be re-focused to better meet the needs of vulnerable patients. The commenter noted that there is an incentive to inappropriately shift administration of drugs from excepted to nonexcepted off-campus PBDs for the purpose of securing higher payment. In addition, the commenter urged HHS to adopt policies “that prevent the unjustified expansion of the 340B program to unintended populations through contract pharmacies, child sites, and individuals who Congress did not intend to be considered 340B patients.”

A few commenters, including organizations representing community oncology practices, stated that the opportunity for 340B-participating hospitals to get substantial revenue from cancer drugs has created financial incentives for hospitals to expand oncology services, notably through the acquisition of independent community oncology practices. Furthermore, one of these commenters asserted that, when these facilities purchased by 340B-participating entities become off-campus PBDs, they also become eligible for 340B Program discounts, thus “further fueling the program’s staggering growth.” These commenters cited a report that states that, over the last decade, 650 community oncology practices have been acquired by hospitals, and 3 out of 4 of these acquisitions were by hospitals already eligible for the 340B Program. Accordingly, these commenters believe that the growth of Part B drug spending in recent years has been disproportionately driven by higher payments in the hospital outpatient setting. Another commenter asserted that the current situation creates two undesirable incentives. First, it creates an incentive for physicians to join a hospital to furnish the same types of services that have been furnished in the physician office setting, thereby increasing costs to the Medicare program, Medicare beneficiaries, and taxpayers without any associated increase in access to care for Medicare beneficiaries, particularly low-income beneficiaries. Second, it encourages hospitals to move services off the hospital campus for financial incentives.

Some commenters urged CMS and HRSA to work with Congress to reform the 340B Program. One commenter recommended that CMS gather additional data to better understand 340B Program acquisition costs and the impact of payment reductions on 340B Program providers. In addition, a few commenters recommended that CMS revise the definition of “patient” to reflect the program’s original intent.

Response: We thank commenters for their support and recommendations. We agree with the commenters that the difference in the payment amounts for 340B-acquired drugs furnished by different types of hospital outpatient departments, excepted off-campus PBDs versus nonexcepted off-campus PBDs, creates an incentive for hospitals to move drug administration services for 340B-acquired drugs to nonexcepted off-campus PBDs to receive a higher payment amount for these drugs, thereby undermining our goals of reducing beneficiary cost-sharing for these drugs and biologicals and moving towards site neutrality through the section 603 amendments to section 1833(t) of the Act. Therefore, we continue to believe that our proposed policy will better align Medicare payment for separately payable drugs acquired under the 340B Program with the actual resources expended to acquire such drugs in nonexcepted off-campus PBDs of a hospital.

As we previously stated, CMS does not administer the 340B Program. Accordingly, comments related to eligibility for the 340B Program as well as 340B Program policies are outside the scope of the proposed rule and are not addressed in this final rule with comment period.

Comment: One commenter, who cited studies conducted by the GAO, OIG, and MedPAC, suggested that CMS make additional downward adjustments to drug payments under the 340B Program in future years because the 22.5 percent payment reduction “was conservative” and the actual average discount experienced by 340B hospitals is likely much higher than 22.5 percent. The commenter asserted that 22.5 percent reflects the average minimum discount that 340B hospitals receive for drugs acquired under the program, and that discounts across all 340B providers average 33.6 percent of ASP.

Response: We thank the commenter for this feedback. We will continue to
analyze the data on these drugs for future rulemaking. As we mentioned in the CY 2019 OPPS/ASC proposed rule, we share the commenter’s concern that current Medicare payments for drugs acquired by nonexcepted off-campus PBDs are well in excess of the overhead and acquisition costs for drugs purchased under the 340B Program. We also continue to believe that Medicare beneficiaries should be able to benefit from the significant discounts hospitals receive on 340B-acquired drugs through reduced copayments.

Comment: One commenter, an organization representing children’s hospitals, supported the proposal to except children’s hospitals from the proposed payment policy for drugs purchased under the 340B Program. However, the commenter asserted that children’s hospitals are undercompensated by government programs, and that a recent report found that the overall Medicare margin for all hospitals is negative. Furthermore, the commenter stated that, while self-governing children’s hospitals are excepted from the payment policy, children’s hospitals within academic medical centers or health care systems remain subject to this policy, which will curtail the ability of such children’s hospitals to care for needy children. The commenter urged CMS not to apply this policy to children’s hospitals within academic medical centers or health care systems.

Response: We thank the commenter for its support and feedback. As we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59366), because of how children’s hospitals are paid under the OPPS, we acknowledged that the 340B drug payment policy may not result in reduced payments for these hospitals in the aggregate. While the payment policy we are establishing in this final rule with comment period applies to nonexcepted departments of a hospital that are paid under the OPPS rather than the OPPS, we believe that adopting an analogous policy, regardless of status, is prudent so that a generally excepted hospital receives payment for drugs in the same manner, regardless of the status (excepted or nonexcepted) of each PBD of the hospital.

In addition, it is unclear from the comment whether the referenced children’s hospitals “within academic medical centers or health care systems” are enrolled in the Medicare program as children’s hospitals or whether they are simply a department of an enrolled hospital provider. However, any separately enrolled children’s hospital that is paid as such is exempt from the 340B-acquired drug payment reduction, while children’s units that are not separately enrolled would not be exempt from the 340B-acquired drug payment policy.

Comment: A few commenters, including organizations representing sole community hospitals, supported the proposal to extend the exception for rural sole community hospitals from the proposed 340B Program payment adjustment. However, these commenters remained concerned that other vulnerable hospitals continue to be subject to the 340B Program payment reduction. Accordingly, these commenters recommended that CMS exempt urban sole community hospitals, Medicare-dependent hospitals, and hospitals with rural referral center status from the payment adjustment. In addition, rural hospitals recommended that rural providers be permanently excepted from this policy.

Response: We share commenters’ concerns about access to care, especially in rural areas, as issues may be more pronounced than in other areas of the country. Medicare has long recognized the unique needs of rural communities and the financial challenges rural hospital providers face. Across the various Medicare payment systems, CMS has established a number of special payment provisions for rural providers to maintain access to care and to deliver high quality care to beneficiaries in rural areas. Consequently, for CY 2019, we are excluding rural sole community hospitals (as described under the regulations at 42 CFR 412.92 and designated as rural for Medicare purposes) from this policy. However, we do not believe that a payment exemption for nonexcepted off-campus departments of urban SCHs is necessary because these hospitals are not exempted from the 340B payment policy for hospital departments paid under the OPPS. Nonetheless, we will continue to analyze the data for these hospitals to determine whether urban SCHs should be exempt from this payment policy, as well as whether permanent exemption for rural SCHs is warranted in future rulemaking.

With respect to rural referral centers, in the CY 2018 OPPS/ASC final rule with comment period, we noted that there is no special payment designation for rural referral centers under the OPPS. By definition, rural referral centers must have at least 275 beds and therefore are larger relative to rural sole community hospitals. In addition, rural referral centers are exempt from a distance requirement from other hospitals. Accordingly, rural referral centers are neither as small (in terms of bed size) or as isolated (in terms of proximity to other hospitals) as rural SCHs, nor are they generally eligible for special payment status under the OPPS, and we do not believe that a payment exemption from this policy for these centers is warranted.

Furthermore, as stated earlier in this section, we believe that we should adopt an analogous payment policy across hospital settings, regardless of the status of each PBD. Because we did not exempt grandfathered off-campus PBDs with MDH classification from the 340B payment adjustment in CY 2018, we do not believe that nonexcepted off-campus PBDs with Medicare-dependent hospital status should be exempted at this time. Therefore, for CY 2019, Medicare-dependent hospitals will not be exempt from this payment policy.

For CY 2019, rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals will be excepted from the alternative payment methodology for 340B-acquired drugs and biologicals furnished in nonexcepted off-campus PBDs, and therefore will be required to bill under the PFS using the institutional claim form and report the informational modifier “TB” for 340B-acquired drugs and biologicals. These providers will continue to be paid ASP+6 percent for 340B-acquired drugs and biologicals under the PFS. In addition, as we stated in the CY 2018 OPPS/ASC final rule with comment period, this policy change does not apply to drugs with pass-through payment status, which are required to be paid based on the ASP methodology, or to vaccines, which are excluded from the 340B Program.

We note that this policy does not alter covered entities’ access to the 340B Program. The expansion of the alternative 340B drug payment methodology solely changes Medicare payment for drugs furnished in nonexcepted off-campus PBDs of a hospital if such drugs were acquired under the 340B Program. We may revisit our policy regarding exceptions to the 340B drug payment reduction in the CY 2020 OPPS/ASC rulemaking.

Comment: In its comment, MedPAC reiterated recommendations included in its March 2016 Report to Congress. In this report, MedPAC recommended that payment rates for all separately payable drugs provided in a 340B hospital be reduced by 10 percent of the current payment rate of ASP+6 percent (resulting in ASP minus 3.3 percent after taking application of the sequester into account). We note that its March 2016 report also included a recommendation to Congress that
savings from the reduced payment rates be directed to the Medicare-funded uncompensated care pool, which would target hospitals providing the most care to the uninsured and in that way benefit indigent patients, and that payments be distributed in proportion to the amount of uncompensated care that hospitals provide. MedPAC believed that legislation would be needed to direct drug payment savings to the uncompensated care pool and noted that current law requires the savings to be retained with the OPPS to make the payment system budget neutral. MedPAC encouraged the Secretary to work with Congress to enact legislation necessary to allow MedPAC’s recommendation to be implemented, if such a recommendation could not be implemented administratively. MedPAC further noted that legislation would also allow Medicare to apply the policy to all OPPS separately payable drugs, including those on pass-through payment status. Accordingly, MedPAC recognized that CMS does not have the legal authority to implement its March 2016 recommendation and shares CMS’ concern that the lack of site-neutral payments may cause a shift in administration of nonpass-through separately payable drugs to nonexcepted off-campus PBDs. Additionally, MedPAC stated that CMS should ensure that payment for 340B-acquired drugs is equal across settings.

Response: We thank MedPAC for its support and feedback. As we stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59364 through 59365), we do not believe that reducing the Medicare payment rate by only 10 percentage points below the current payment rate of ASP+6 percent (that is, ASP minus 4 percent) would better reflect the acquisition costs incurred by 340B-participating hospitals.

We note that we responded to a similar public comment in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59364 through 59365) and refer readers to a summary of that comment and our response.

Comment: Many commenters stated that the Secretary lacks statutory authority to impose such a large reduction in the payment rate for 340B drugs acquired in off-campus PBDs, and contended that the expansion of the 340B payment policy at nonexcepted off-campus PBDs would “effectively eviscerate” the 340B Program. These commenters further noted that extending the Medicare payment cuts to nonexcepted off-campus PBDs would greatly undermine 340B hospitals’ ability to continue programs designed to improve access to services.

One commenter, an organization representing over 1,300 public and nonprofit providers enrolled in the 340B Program, argued that since the 340B payment policy took effect in January 2018, many hospitals have experienced financial and operational challenges, including staff reductions, fewer free or discounted drugs for patients, clinic and pharmacy closures, and reductions in services provided. The commenter opposed the 340B payment proposal for a number of reasons, primarily because the commenter believed that the current OPPS 340B payment rate harms hospitals’ ability to treat low-income patients and the proposals to continue and expand the cuts would worsen the impact. Furthermore, the commenter argued that CMS’ proposed payment reduction does not reduce patient costs or Medicare spending or address “skyrocketing drug prices”; CMS’ payment reduction violates the 340B statute; and CMS’ payment reduction violates the Medicare statute; and CMS’ payment reduction relies on a “faulty premise that fails to recognize that 340B hospitals serve patients with more expensive medical needs.” The commenter further asserted that Congress, as well as “one-hundred percent of hospitals,” have expressed concern about the payment reduction’s impact on 340B providers’ ability to serve their patients.

Many additional commenters, including some hospital associations, contended that CMS does not have the legal authority to apply the OPPS Medicare payment rate to nonexcepted off-campus PBDs in 340B-participating hospitals because section 1833(t)(21)(C) of the Act does not authorize CMS to pay at a rate that is less than the rate paid under the selected “applicable payment system.” Specifically, a few commenters asserted that payment for these drugs and biologicals is determined pursuant to the rules of section 1847A(1) of the Act, which mandates that payment is to be made for these drugs and biologicals when furnished by nonexcepted off-campus PBDs pursuant to the rules of section 1847A of the Act.

Response: We do not believe that the proposed payment policy violates section 340B of the Public Health Service Act or the Social Security Act. There is no requirement in the Public Health Service Act that drugs or biologicals acquired under the 340B Program generate a profit margin for hospitals through Medicare payments, and there is no requirement in any part of section 1833(t) of the Social Security Act to pay a particular minimum rate for a hospital enrolled in the 340B Program. Further, we disagree with the commenter’s assertion that CMS’ payment reduction does not reduce patient costs or Medicare spending. Based on our proposed adjustment for CY 2019, we estimated that the Medicare Program and beneficiaries would save approximately $49 million under the PFS.

We also disagree with commenters who believe that the OPPS payment rate for 340B-acquired drugs will “effectively eviscerate” the 340B Program as well as the implication that extending the same rate that applies to 340B-acquired drugs and biologicals furnished by hospital departments under the OPPS to nonexcepted off-campus PBDs will perpetuate that concern. The findings from several 340B studies conducted by the GAO, OIG, and MedPAC show a wide range of discounts that are afforded to 340B hospitals, with some reports finding discounts of up to 50 percent. Indeed, in some cases, beneficiary coinsurance alone exceeds the amount the hospital would have to acquire the drug under the 340B Program (OIG November 2015, Report OEI–12–14–00030, page 9). As stated in the CY 2018 final rule with comment period, we believe that ASP minus 22.5 percent is a conservative estimate of the discount for 340B-acquired drugs, and that even with the reduced payments, hospitals will continue to receive savings that can be directed at programs and services to carry out the intent of the 340B Program. We also have noted that 340B Program participation does not have to be well aligned with the provision of uncompensated care, as some commenters suggested (82 FR 59359).

Payment under the “applicable payment system” pursuant to section 1833(t)(21)(C) of the Act is made under the PFS for most services, including for the many drugs that are packaged under the OPPS, using a PFS relativity adjuster that is applied to the OPPS payment rate. As such, the PFS payment for nonexcepted items and services in nonexcepted off-campus PBDs is made on a prospective payment basis, and we are therefore not required to make payment under section 1847A(1) of the Act for those packaged drugs, many of which would be separately payable under the PFS. Further, as we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37145), the current PFS payment policies for nonexcepted items and services incorporate a significant number of payment policies and adjustments made under the OPPS (81 FR 79726; 82 FR 53024 through 53025). In establishing these policies in prior rulemaking, we pointed out that
the adoption of these policies was necessary in order to maintain the integrity of the PFS relativity adjuster because it adjusts payment rates developed under the OPPS (81 FR 79726). For example, it is necessary to incorporate OPPS packaging rules into the site-specific PFS rate because the PFS relativity adjuster is applied to OPPS rates that were developed based on those packaging rules. In addition, many of the OPPS policies and adjustments are replicated under the nonexcepted off-campus PBD site-specific PFS rates because they are specifically applicable to hospitals as a setting of care. For example, we adopted the geographic adjustments used for hospitals instead of the adjustments developed for the PFS localities, which reflect cost differences calculated for professionals and suppliers rather than hospitals (81 FR 79726).

Since we have adopted the payment adjustment under the OPPS for 340B-acquired separately payable drugs, we have become concerned that there would be a perverse incentive for hospitals to circumvent the OPPS payment adjustment by furnishing 340B-acquired drugs in nonexcepted off-campus PBDs where Medicare currently makes payment for those drugs at ASP+6 percent. To avoid this payment inconstancy and perverse incentive, we proposed to designate the PFS as the “applicable payment system” for 340B-acquired separately payable drugs furnished in nonexcepted off-campus PBDs, and to make payment at the OPPS-comparable rate.

Comment: A few commenters asserted that, while CMS estimated that the payment change would result in a payment cut of $48.5 million in CY 2019, CMS provided no data to support this estimate and failed to provide sufficient access to data, its methodology, or its analysis to allow the public to understand and replicate the proposed CY 2019 340B payment policy. One commenter recommended that CMS delay extension of the 340B payment policy until more information is available related to the impact on Medicare beneficiaries.

Many commenters opposed reducing payments to hospitals for 340B drugs in a nonbudget-neutral manner and instead suggested that such policy be implemented in a budget neutral manner as was implemented in the CY 2018 OPPS/ASC final rule with comment period. In addition, some commenters recommended that CMS annually calculate a budget neutral adjustment for the 340B policy, as the approach is consistent with other budget neutral policies included in the OPPS.

Response: We thank the commenters for their input. We disagree that this policy should be implemented in a budget neutral manner because the payments made to nonexcepted off-campus departments of a hospital are not paid under the OPPS. As we stated in the CY 2019 OPPS/ASC proposed rule, to develop an estimated impact of this proposal, we analyzed the CY 2017 outpatient claims data used in ratesetting for the CY 2019 proposed rule. Based on the most recent claims data from CY 2017 reporting, we found 117 unique nonexcepted off-campus PBDs associated with 340B hospitals that billed for status indicator “K” drugs. Their “K” billing represents approximately $182.5 million in Medicare payments based on a payment rate of ASP+6 percent. Based on our proposed adjustment, for CY 2019, we estimated that the Medicare Program and beneficiaries would save approximately $49 million under the PFS. Regarding budget neutrality requirements, we note that when we initially developed the payment policy for nonexcepted items and services furnished by nonexcepted off-campus PBDs, most separately payable drugs and biologicals were paid at the same rates specified under section 1847A/1842(o) of the Act as the “applicable payment system” for separately payable drugs under section 1833(t)(21)(C) of the Act, there was no applicable budget neutrality requirement. For the proposed change in CY 2019 to establish the PFS as the applicable payment system for separately payable 340-B-acquired drugs furnished by nonexcepted off-campus PBDs, we believe the site-specific PFS payment for these drugs and biologicals represents new utilization under the PFS and would, consequently, be subject to the PFS budget neutrality requirements under 1848(c) of the Act for CY 2019. We will consider any applicable budget neutrality requirements regarding the site-specific payment under the PFS for future rulemaking.

Comment: Numerous commenters argued that reducing payments for 340B-acquired drugs could encourage hospitals to selectively purchase certain drugs at higher prices outside of the 340B Program to maximize revenue. One of these commenters recommended the implementation of alternate reimbursement methodologies for 340B-purchased drugs, such as a 6 percent add-on payment to the product-specific estimated 340B cost, in order to discourage hospitals from selectively purchasing some drugs outside of the 340B Program (resulting in ASP minus 16.5 percent after taking application of the add-on payment into account).

Response: While participation in the 340B Program has always been voluntary and hospitals have always had the ability to choose to purchase drugs outside the 340B Program, we do not see the relevance of these points to our proposed policy. That is, the policy we proposed with respect to payment for 340B-acquired drugs in nonexcepted departments for CY 2019 simply aligns with the policy already established for 340B-acquired drugs under the OPPS for CY 2018. In addition, as we explained in CY 2018 OPPS rulemaking, the payment rate of ASP minus 22.5 percent is better aligned with the average resources to acquire a 340B drug, and therefore, we do not believe that a higher payment rate for 340B-acquired drugs in nonexcepted departments is warranted.

We thank the commenters for their feedback. After consideration of the public comments we received, we are finalizing our proposal, without modification, to make payment for separately payable 340B-acquired drugs furnished by nonexcepted off-campus departments of a hospital under the PFS, and to establish the payment rate for those drugs at ASP minus 22.5 percent. This policy is expected to lower the cost of drugs and biologicals for Medicare beneficiaries and ensure that they benefit from the discounts provided through the program, and to do so more equitably across HOPD settings.

In summary, for CY 2019, in accordance with section 1833(t)(21)(C) of the Act and our established 340B payment methodology as described in the CY 2018 OPPS/ASC final rule with comment period, separately payable Part B drugs and biologicals (assigned status indicator “K”), other than vaccines and drugs with pass-through payment status, that are acquired through the 340B Program or through the 340B PVP at or below the 340B ceiling price will be paid at a rate of ASP minus 22.5 percent when billed by a hospital that is not excepted from the payment adjustment. Part B drugs or biologicals excluded from the 340B payment adjustment include vaccines (assigned status indicator “L” or “M”) and drugs and biologicals with transitional pass-through payment status (assigned status indicator “G”).
Medicare will continue to pay for drugs and biologicals that are not purchased with a 340B Program discount at ASP+6 percent.

To effectuate the payment adjustment for 340B-acquired drugs and biologicals, CMS implemented modifier “JG”, effective January 1, 2018. Hospitals paid under the OPPS (other than a type of hospital excluded from the OPPS or excepted from the 340B drug payment policy for CY 2019) and, beginning January 1, 2019, nonexcepted off-campus PBDs of a hospital paid under the PFS, are required to report modifier “JG” on the same claim line as the drug or biological HCPCS code to identify a 340B-acquired drug or biological. For CY 2019, rural sole community hospitals, children’s hospitals, and PPS-exempt cancer hospitals are excepted from the 340B payment adjustment. These hospitals will be required to report informational modifier “TB” for 340B-acquired drugs and biologicals, and will continue to be paid ASP+6 percent.

D. Expansion of Clinical Families of Services at Exempted Off-Campus Departments of a Provider

1. Background

a. Section 603 of the Bipartisan Budget Act of 2015

We refer readers to section X.C.1.a. of the CY 2019 OPPS/ASC proposed rule (83 FR 37143) for a discussion of the provisions of section 603 of the Bipartisan Budget Act of 2015 (Pub. L. 114–74), as implemented in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79699 through 79719). As discussed in the CY 2017 OPPS/ASC final rule with comment period, we adopted the PFS as the applicable payment system for nonexcepted items and services furnished and billed by nonexcepted off-campus PBDs. In addition, we indicated that, in order to be considered part of a hospital, an off-campus department of a hospital must meet the provider-based criteria established under 42 CFR 413.65. For a detailed discussion of the history and statutory authority related to payments under section 603 of Public Law 114–74, we refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79720 through 79729).

b. Expansion of Services at an Off-Campus PBD Exempted Under Section 1833(t)(21)(B)(iii) of the Act

In the CY 2017 OPPS/ASC proposed rule (81 FR 45685), we noted that we had received questions from some hospitals regarding whether an excepted off-campus PBD could expand the number or type of services the department furnishes and maintain excepted status for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act. We indicated that we were concerned that if excepted off-campus PBDs could expand the types of services provided at the excepted off-campus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and expand services furnished by existing excepted off-campus PBDs as a result (81 FR 45685). This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believed these amendments to section 1833(t) of the Act were intended to address (81 FR 45685). We believed section 1833(t)(21)(B)(iii) of the Act excepted off-campus PBDs and the items and services that are furnished by such excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act as they were being furnished on the date of enactment of section 603 of the Bipartisan Budget Act of 2015, as guided by our regulatory definition at §413.65(a)(2) of a department of a provider (81 FR 45685). Thus, in the CY 2017 OPPS/ASC proposed rule, we proposed that if an excepted off-campus PBD furnished items and services from a clinical family of services (clinical families of services were identified in Table 21 of the CY 2017 proposed rule) that did not furnish prior to November 2, 2015, and thus did not also bill for services from these new expanded clinical families of services would not be covered OPD services, and instead would be subject to paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act, as described in section X.A.1.c. of the CY 2017 proposed rule. In addition, in that rule, we proposed not to limit the volume of excepted items and services within a clinical family of services that an excepted off-campus PBD could furnish (81 FR 45685).

The majority of commenters, including several hospital associations, regional health systems, and medical equipment manufacturers opposed the proposal primarily because they believed: (1) CMS exceeded its statutory authority, as the statutory language included in section 603 does not address changes in service mix by excepted off-campus PBDs; (2) CMS’ proposal did not account for evolving technologies and would hinder beneficiary access to those innovative technologies; (3) the term “clinical families of service” appeared to be a new term created by CMS for the purpose of implementing section 603 and it would be difficult for CMS and hospitals to manage changes in the composition of APCs and HCPCS code changes contained in those APCs; and (4) the proposal created significant operational challenges and administrative burden for both CMS and hospitals because commenters believed it was unnecessarily complex (81 FR 79706 through 79707).

In addition, MedPAC explained in its comment letter that the proposal was unnecessarily complex and instead suggested that CMS adopt a different approach by determining how much the Medicare program had paid an excepted off-campus PBD for services billed under the OPPS during a 12-month baseline period that preceded November 2, 2015 and to cap the OPPS payment made to the off-campus PBD at the amount paid during the baseline period. Some commenters, including physician group stakeholders, supported CMS’ intent to monitor service line expansion and changes in billing patterns by excepted off-campus PBDs. These commenters urged CMS to work to operationalize a method that would preclude an excepted off-campus PBD from expanding the excepted services for which it is paid under the OPPS into wholly new clinical areas, as they believed an excepted, off-campus PBD should only be able to bill under the OPPS for those items and services for which it submitted claims prior to November 2, 2015 (82 FR 33647). In response to public comments, we did not finalize our proposal to limit the expansion of excepted services at excepted off-campus PBDs. However, we stated our intent to monitor this issue and expressed interest in additional feedback to help us consider whether excepted off-campus PBDs that expand the types of services offered after November 2, 2015 should be paid for furnishing those items and services under the applicable payment system (that is, the PFS) instead of the OPPS. Specifically, we requested comments on how either a limitation on volume or a limitation on lines of service would work in practice (81 FR 79707).

In addition, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79707), we sought public comments on how either a limitation on volume of services, or a limitation on lines of services...
service, as we laid out in the CY 2017 OPPS/ASC proposed rule, could be implemented. Specifically, we stated that we were interested in what data were available or could be collected that would have allowed us to implement a limitation on the expansion of excepted services. We provided a summary of and responses to comments received in response to the CY 2017 OPPS/ASC final rule with comment period in the CY 2018 OPPS/ASC proposed rule. As stated in that rule, several of the public comments received in response to the comment solicitation included in the CY 2017 OPPS/ASC final rule with comment period were repeated from the same stakeholders in response to the CY 2017 OPPS/ASC proposed rule. These commenters again expressed concern regarding CMS’ authority to address changes in service mix; that a limitation on service expansion or volume would stifle innovative care delivery and use of new technologies; and that limiting service line expansion using clinical families of hospitals, resulted in the same situation as if service was not workable. Because these commenters did not provide new information, we referred readers to the CY 2017 OPPS/ASC final rule with comment period for our responses to comments on statutory authority and concerns about hindering access to innovative technologies (81 FR 79707 and 82 FR 59388). A summary of and our responses to the other comments received in response to the comment solicitation included in the CY 2017 OPPS/ASC final rule with comment period were included in the CY 2018 OPPS/ASC proposed rule (82 FR 33645 through 33648).

In the CY 2018 OPPS/ASC proposed rule, we did not propose any policies related to clinical service line expansion or volume increases at excepted off-campus PBDS. However, we stated that we would continue to monitor claims data for changes in billing patterns and utilization, and we again invited public comments on the issue of service line expansion. In response to the CY 2018 comment period, MedPAC largely reiterated the comments it submitted in response to the CY 2017 OPPS/ASC rulemaking and acknowledged the challenges of implementing its recommended approach as such approach would necessitate CMS requiring hospitals to report the amount of OPPS payments received by each excepted off-campus PBD during the baseline period (such as November 2014 through November 2015) because CMS was not collecting data on payments made to each individual PBD during that period. In its comments, MedPAC recommended that, to help ensure the accuracy of these data, CMS could selectively audit hospitals. Another commenter expressed support for CMS’ efforts to continue to implement and expand site-neutral payment policies for services where payment differentials are not warranted, such as between HOPDs and ASCs or physician offices.

2. CY 2019 Proposal and Final Policy As we previously expressed in CYs 2017 and 2018 OPPS/ASC rulemaking, we continue to be concerned that if excepted off-campus PBDS may furnish new types of services that were not provided at the excepted off-campus PBDS prior to the date of enactment of the Bipartisan Budget Act of 2015 and can be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted off-campus PBDS. This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believe the section 603 amendments to section 1833(t) of the Act are intended to prevent. Of note, these statutory amendments “came after years of nonpartisan economists, health policy experts, and providers expressing concern over the Medicare program’s [OPPS] paying more for the same services provided at HOPDs than in other settings—such as an ambulatory surgery center, physician office, or community outpatient facility.” Experts raised concerns that this payment inequity drove the acquisition of “standalone or independent practices and facilities, resulting in higher costs for the Medicare system and taxpayers, and also resulted in beneficiaries needlessly facing higher cost-sharing in some settings than in others.” In addition, some experts argued that, “to the extent this payment differential accelerated consolidation of providers, this would result in reduced competition among both hospitals and nonaffiliated outpatient service providers. This, in turn, could reduce large hospital systems’ incentives to reduce costs, increase efficiency, or focus on patient outcomes.”

The Government Accountability Office (GAO) stated in its December 2015 Report to the Congress that “from 2007 through 2013, the number of vertically consolidated physicians nearly doubled, with faster growth in more recent years.” GAO concluded that, “regardless of what has driven hospitals and physicians to vertically consolidate, paying substantially more for the same service when performed in an HOPD rather than a physician office provides an incentive to shift services that were once performed in physician offices to HOPDs after consolidations have occurred.”

While there is no Congressional Record available for section 603 of the Bipartisan Budget Act of 2015, we do not believe that Congress intended to allow for new service lines to be paid OPPS rates because providing for such payment would allow for excepted off-campus PBDS to be paid higher rates for types of services they were not furnishing prior to the date of enactment of the Bipartisan Budget Act of 2015 and that would be paid at lower rates if performed in a nonexcepted off-campus PBD. Similarly, we are concerned that a potential shift of services from nonexcepted off-campus PBDS to excepted off-campus PBDS may be occurring, given the higher payment rate in this setting. We believe that the growth of service lines in currently excepted off-campus PBDS may be an unintended consequence of our current policy, which allows continued full OPPS payment for any services furnished by excepted off-campus PBDS, including services in new service lines.

In prior rulemaking, and as discussed in section X.A. of the CY 2019 OPPS/ASC proposed rule, we noted our concerns and discussed our efforts to begin collecting data and monitoring billing patterns for off-campus PBDS. Specifically, as described in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66910 through 66914), we created HCPCS modifier “PO” (Services, procedures, and/or surgeries furnished at off-campus provider-based outpatient departments) for hospital claims to be reported with every code for outpatient hospital items and services furnished in an off-campus PBD of a hospital. Reporting of this new modifier was voluntary for CY 2015, with reporting required beginning on January 1, 2016. In addition, we established modifier “PN” (Nonexcepted service provided at an off-campus, outpatient, provider-based department of a hospital) to identify and pay nonexcepted items and services billed on an institutional claim.

82 Available at: http://medpac.gov/docs/default-source/comment-letters/09082017_opps_asc_2018_medpac_comment_sec_pdf/fsvrm=0.
83 Available at: https://archives.energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/114/Letters/20160202SiteNeutralLetter%5b1%5d.pdf.
84 Ibid.
85 Ibid.
Effective January 1, 2017, nonexcepted off-campus PBDs of a hospital were required to report this modifier on each claim line for nonexcepted items and services to trigger payment under the PFS instead of the OPPS. As a conforming revision, effective January 1, 2017, the modifier “PO” descriptor was revised to “excepted service provided at an off-campus, outpatient, provider-based department of a hospital” and this modifier continued to be used to identify items and services furnished by an excepted off-campus PBD of a hospital.

As discussed in the CY 2018 OPPS/ASC proposed rule (82 FR 33647), a few commenters supported CMS’ intent to monitor service line expansion and changes in billing patterns by excepted off-campus PBDs. These commenters urged CMS to operationalize a method that would preclude an excepted off-campus PBD from increasing its payment advantage under the OPPS by expanding into wholly new clinical areas (82 FR 33647). Moreover, a few commenters urged CMS to pursue a limitation on service line expansion to ensure designation as an excepted off-campus PBD is not “abused” (82 FR 33647). One commenter suggested that CMS evaluate outpatient claims with the “PO” modifier to develop a list of “grandfathered” items and services for which the excepted off-campus PBD may continue to be paid under the OPPS (82 FR 33647). In response to these comments, we stated that we were concerned with the practicality of developing a list of excepted items and services for each excepted off-campus PBD, given the magnitude of such a list (82 FR 33647). We noted in the CY 2018 OPPS/ASC final rule with comment period, however, that we continued to monitor claims data for changes in billing patterns and utilization, and invited comments on this issue (82 FR 59388).

In light of our prior stated concerns about the expansion of services in excepted off-campus PBDs, in the CY 2019 OPPS/ASC proposed rule (83 FR 37148 through 37149), for CY 2019 and subsequent years, we proposed that if an excepted off-campus PBD furnishes services from any clinical family of services (as clinical families of services are defined in Table 32 of that proposed rule) from which it did not furnish an item or service during a baseline period from November 1, 2014 through November 1, 2015 (and subsequently bill under the OPPS for that item or service), items and services from these new clinical families of services would not be excepted items and services and, thus, would not be covered OPD services. Instead, they would be subject to paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act and paid under the PFS. Furthermore, in the CY 2019 OPPS/ASC proposed rule, we proposed to revise 42 CFR 419.48 to limit the definition of “excepted items and services” in accordance with this proposal. Generally, excepted items and services are items or services that are furnished on or after January 1, 2017 by an excepted off-campus PBD (as defined in §419.48) that has not impermissibly relocated or changed ownership. Under this proposal, beginning on January 1, 2019, excepted items and services would be items or services that are furnished and billed by an excepted off-campus PBD (defined in §419.48) only from the clinical families of services (described later in this section) for which the excepted off-campus PBD furnished (and subsequently billed under the OPPS) for at least one item or service from November 1, 2014 through November 1, 2015. Further, for purposes of this section, “new clinical families of services” would be items or services: (1) That are furnished and billed by an excepted off-campus PBD; (2) that are otherwise paid under the OPPS through one of the APCs included in Table 32 of the CY 2019 OPPS/ASC proposed rule; and (3) that belong to a clinical family listed in Table 32 of the proposed rule from which the excepted off-campus PBD did not furnish an item or service during the baseline period from November 1, 2014 through November 1, 2015 (and subsequently bill for that service under the OPPS). In addition, for CY 2019, we proposed that if an excepted off-campus PBD furnishes a new item or service from a clinical family of services listed in Table 32 of the proposed rule from which the off-campus PBD furnished a service from November 1, 2014 through November 1, 2015, such service would continue to be paid under the OPPS because items and services from within a clinical family of services for which the excepted off-campus PBD furnished an item or service during the baseline period would not be considered a “service expansion.”

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37149), in order to determine the types of services provided at an excepted off-campus PBD, for purposes of OPPS payment eligibility, excepted off-campus PBDs would be required to ascertain the clinical families from which they furnished services from November 1, 2014 through November 1, 2015 (that were subsequently billed under the OPPS). In addition, items and services furnished by an excepted off-campus PBD that were not identified in Table 32 of the proposed rule would be reported with modifier “PN”. We selected the year prior to the date of enactment of the Bipartisan Budget Act of 2015 as the baseline period because it is the most recent year preceding the date of enactment of section 603 and we believed that a full year of claims data would adequately reflect the types of service lines furnished and billed by an excepted off-campus PBD. We considered expanding the baseline period to include a timeframe prior to November 2014, but did not propose this alternative due to the possibility that hospital claims data for an earlier time period might not be readily available and reviewing claims from a longer timeframe may impose undue burden. If an excepted off-campus PBD did not furnish services under the OPPS until after November 1, 2014, we proposed that the 1-year baseline period begins on the first date the off-campus PBD furnished covered OPD services prior to November 2, 2015. For providers that met the mid-build requirement (as defined at section 1833(t)(21)(B)(v) of the Act), we proposed to establish a 1-year baseline period that begins on the first date the off-campus PBDs furnished a service billed under the OPPS. We proposed changes to our regulation at 42 CFR 419.48 to include these alternative baseline periods. For guidance on the implementation of sections 16001 and 16002 of the 21st Century Cures Act, we refer readers to the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Downloads/Sections-16001-16002.pdf. We stated in the proposed rule that we were concerned that a 1-year baseline may be unnecessarily long to the extent that such baseline would be, at least in part, a prospective period during which such departments would have time and an incentive to bill services from as many service lines as possible, thereby limiting the effect of this policy. We welcomed public comment on whether a different baseline period, such as 3 or 6 months, should be used for off-campus PBDs that began furnishing services and billing after November 1, 2014, or that met the mid-build requirement.

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37149), we were aware of past stakeholder concern regarding limiting service line expansion for excepted off-campus PBDs using the 19 clinical families identified in Table 32 of the proposed
rule. However, we believed that the proposed clinical families recognized all clinically distinct service lines for which a PBD might bill under the OPPS, while at the same time allowing for new services within a clinical family of services to be considered for designation as “excepted items and services”, as defined in the regulations at 42 CFR 419.48 where the types of services within a clinical family expand due to new technology or innovation. We stated in the proposed rule that we believed that requiring excepted off-campus PBDs to limit their services to the exact same services they furnished during the proposed baseline period would be too restrictive and administratively burdensome. We requested public comments on the proposed clinical families. We also solicited public comments on whether any specific groups of hospitals should be excluded from our proposal to limit the expansion of excepted services, such as specific rural hospitals (for example, rural sole community hospitals), in light of recent reports of hospital closures in rural areas.

In addition, we solicited public comments on alternate methodologies to limit the expansion of excepted services in excepted off-campus PBDs for CY 2019. Specifically, we invited public comments on the adoption and implementation of other methodologies, such as the approach recommended by MedPAC (discussed earlier in this section) in response to the CY 2017 and CY 2018 proposals whereby CMS would establish a baseline service volume for each applicable off-campus PBD, cap excepted services (regardless of clinical family) at that limit, and when the hospital reaches the annual cap for that location, additional services furnished by that off-campus PBD would no longer be considered covered OPD services and would instead be paid under the PFS (the annual cap could be updated based on the annual updates to the OPPS payment rates). Under such alternate approach, hospitals would need to report service volume for each off-campus PBD for the applicable period (such as November 1, 2014–November 1, 2015) and such applicable periods would be subject to audit.

Comment: Some commenters, including an organization representing orthopaedic surgeons, commended CMS for its efforts to expand the application of site neutral payments to additional items and services in excepted off-campus PBDs. These commenters asserted that the expansion of services in excepted off-campus PBDs has an adverse effect on the control of unnecessary utilization of services in PBDs. One commenter who supported the proposal stated that “all sites of service should provide the same service at the same cost” and that Medicare “should not be in the business of supporting or favoring more expensive sites of service, when the service can be furnished safely at a less expensive” and more efficient setting. Another commenter argued that the consolidation of these facilities effectively inhibits a physician’s ability to refer freely to the best specialists or most affordable health centers, and obstructs patients’ access to potentially better, more affordable care without their knowledge.

One commenter, a pharmaceutical research and manufacturing organization, stated that this proposal “strikes a reasonable balance” in that the proposal would not limit PBDs to exactly the same services that they provided in the past, but would allow them to adjust their service-mix within relevant clinical families that reflect their specialties. The commenter contended that this provision would allow appropriate changes to the services excepted off-campus PBDs offer as clinical practices evolve. Additionally, the commenter stated that this policy proposal would prevent attempts to circumvent “the obvious intent of the law to reign in conversion of non-hospital entities into PBDs primarily in order to secure better payment, but without commensurate clinical benefit.”

A few commenters stated that most off-campus PBDs are able to take advantage of higher payment rates for a wide variety of services. Specifically, the commenters asserted that given the significant payment disparities for certain services (for example, based on OPPS rates versus PFS rates—chemotherapy: $281 versus $136; cardiac imaging: $2,078 versus $655; and colonoscopy: $1,383 versus $625), hospital systems have been purchasing physician practices and, by integrating them with excepted off-campus PBDs, secured higher payment rates for these services.

Another commenter asserted that CMS is taking important steps to close loopholes that have enabled hospitals to continue driving volume of services through excepted off-campus PBDs. Moreover, the commenter noted that the current policy has caused “hundreds” of hospitals that have already absorbed physician practices and converted them into PBDs . . . to enjoy an unfair reimbursement advantage” over other providers. The commenter further asserted that the proposal does not sufficiently limit the items and services for which an excepted off-campus PBD can seek payment under the OPPS, and that the proposal would still allow a PBD to expand its services “no matter how limited the PBD’s range or volume of services were within that clinical family” during the baseline period. The commenter also expressed concern that CMS did not propose to limit the volume of excepted items and services within a clinical family of services that an excepted off-campus PBD can furnish, and indicated that, without such limitation, an excepted off-campus PBD has every incentive to grow the scope of its practice in order to maximize its ability to seek payment under the OPPS. Moreover, this commenter contended that CMS could require that “excepted” status be tied to those physicians and particular services that were in place at the off-campus PBD prior to November 2, 2015. In other words, an excepted off-campus PBD would not be able to seek payment under the OPPS with respect to: (1) Items or services furnished by a physician (as identified by National Provider Identifier) who did not furnish items or services at the off-campus PBD prior to November 2, 2015; or (2) any items or services that were not among the items or services for which the off-campus PBD billed Medicare at any point in the 12 months preceding November 2, 2015.

Accordingly, the commenter urged CMS to modify the portion of the proposed rule that would enable excepted PBDs to bill under the OPPS for any and all items and services within the clinical families through which the excepted PBDs had furnished care during the 12 months prior to November 2, 2015, and to adopt, instead, a policy that would limit excepted off-campus PBDs to billing under the OPPS for those items and services furnished in a hospital’s outpatient department in the year prior to November 2, 2015, and within the specific, excepted PBD in 2016.

Response: We thank the commenters for their support and for the many detailed comments on this topic. As mentioned in the proposed rule, we are concerned that if excepted off-campus PBDs can expand the types of services provided at the excepted off-campus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted off-campus PBDs. This could result in newly purchased physician practices furnishing services that are paid at OPPS rates, which we believe the
amendments to section 1833(t) of the Act are intended to prevent.

However, while we continue to believe that section 1833(t)(21)(B)(ii) of the Act excepted off-campus PBDs as they existed at the time that Pub. L. 114–74 was enacted, and provides the authority to define excepted off-campus PBDs, including those items and services furnished and billed by such a PBD that may be paid under the OPPS, we are concerned that the implementation of this payment policy may pose operational challenges and administrative burden for both CMS and hospitals. After consideration of the public comments we received, we are not finalizing this policy as detailed below.

**Comment:** A few commenters suggested that CMS revise the proposed clinical families to modify the proposed 19 clinical APC groups and services. We will continue to study issues related to the expansion of services at excepted off-campus PBDs and take these comments into consideration for future rulemaking.

**Response:** We appreciate the feedback we received from the commenters.

**Comment:** One commenter asserted that the proposed 12-month baseline period was not “necessary,” and suggested that a 6-month baseline period would adequately capture any service line initially intended for provision at a PBD. However, another commenter suggested that CMS extend the baseline period to 3 years prior to the enactment of the BBA of 2015, to ensure that all items and services provided by an excepted off-campus PBD prior to November 2, 2015 would be excepted from the proposed payment policy.

**Response:** We thank the commenters for their feedback. We are not finalizing our proposed policy at this time. We intend to monitor the expansion of services in excepted off-campus PBDs. We may propose to adopt a limitation on the expansion of services in future rulemaking and will take this comment into consideration.

**Comment:** The majority of commenters, including individual stakeholders and hospital systems and associations, opposed the proposal to limit the expansion of services in excepted off-campus PBDs. The commonly cited concerns among the commenters who opposed the proposed policy were as follows:

- Many commenters stated that the proposal is arbitrary and capricious, that CMS lacks statutory authority to pay new clinical families of service in excepted off-campus PBDs at the rate paid to nonexcepted PBDs, and that the proposal would pose operational challenges and create administrative burden on hospitals. In addition, some commenters asserted that the requirements for provider-based status are designed to “ensure integration with the main hospital” and, accordingly, these facilities should be able to “furnish health care services of the same type as the main provider.”
- MedPAC expressed concern that CMS’ proposed approach to address the issue of undesirable incentives for excepted PBDs was unnecessarily complex. MedPAC believed that a better approach would be for CMS to determine how much the Medicare program had paid an off-campus PBD for items and services billed under the OPPS during a 12-month baseline period, specifically, CY 2017. Then, beginning January 1, 2019, annual program spending for items and services billed by the PBD under the OPPS would be capped at the amount paid to the PBD during the baseline period. However, MedPAC acknowledged that, for hospitals that have more than one excepted off-campus PBD, CMS would have to determine which claims to attribute to each excepted off-campus PBD. MedPAC believed that this approach would be easier to administer and would curb the ability of hospitals to benefit financially from purchasing freestanding physician practices and converting them to off-campus PBDs.
- Several commenters argued that off-campus PBDs must be able to expand the items and services that they offer in order to meet changes in clinical practice and the changing needs of their communities without losing their ability to be paid under the OPPS. Generally, these commenters asserted that finalizing this proposal would significantly discourage hospitals from offering new and enhanced outpatient services and, as a result, the payment policy would hinder beneficiary access to innovative technologies.
- Many commenters asserted that it is unclear how CMS or hospitals will determine what service families were being provided during the baseline period, given the lack of department-specific data and that provider-based attestations are voluntary. In addition, these commenters contended that, even if CMS and the providers could identify the clinical families of services furnished during the baseline period, it would be exceedingly complicated and burdensome to providers and CMS to ensure services belonging to a new clinical family for the PBD are accurately reported.

**Response:** We appreciate the detailed comments that were submitted, and we recognize that services provided in off-campus PBDs may evolve to reflect changes in clinical practice and community health care needs. As discussed in the CY 2017 OPPS/ASC proposed rule and final rule with comment period (81 FR 45685 through 45686 and 81 FR 79706 through 79707), we believe section 1833(t)(21)(B)(ii) of the Act, as added by section 603 of Public Law 114–74, excepts off-campus provider-based departments and the items and services that are furnished by such excepted off-campus PBDs for purposes of paragraphs (1)(B)(v) and (21) of section 1833(t) of the Act as they were being furnished on the date of enactment of section 603 of Public Law 114–74, as guided by our regulatory definition of a department of a provider at § 413.65(a)(2). We also believe that we have the authority to define excepted items and services furnished and billed by excepted off-campus PBDs that may be paid under the OPPS. While we disagree with the commenters’ assertion that section 603 does not provide us the authority to adopt a policy that would limit OPPS payment to the type of services that had been furnished and billed at an off-campus PBD prior to enactment of Public Law 114–74, we are concerned that the implementation of this payment policy may be operationally complex and could create an administrative burden for hospitals.

We believe the statute gives us the authority to limit the volume of services furnished to the level that was furnished prior to the date of enactment; however, we did not propose to do so. As we mentioned in the proposed rule and reiterated earlier in this section, we are concerned that if excepted off-campus PBDs could expand the types of services provided at the excepted off-campus PBDs and also be paid OPPS rates for these new types of services, hospitals may be able to purchase additional physician practices and add those physicians to existing excepted off-campus PBDs.

- Several commenters, including MedPAC, asserted that our proposed policy could be operationally complex and could create an administrative burden for hospitals, CMS, and CMS contractors to identify, track, and monitor billing for clinical services. We agree with these commenters regarding these concerns. Therefore, we are not finalizing our proposed policy.

**Comment:** Some commenters, specifically hospital associations that opposed the proposal, asserted that CMS did not provide any claims-based or other supporting evidence that demonstrates that excepted off-campus PBDs are taking advantage of the current
policy. Further, these commenters noted that many of the services listed in the detailed families of services are not payable in a physician office setting and can only be provided in a hospital setting. In addition, some of these commenters urged CMS to exempt rural sole community hospitals and other vulnerable facilities from the policy proposal.

Response: We appreciate the commenters’ detailed responses to our proposal. We are collecting data on the claims billed by off-campus PBDs with modifier “PO” (for excepted services) and modifier “PN” (for nonexcepted services). We believe that data collected using these modifiers will be a useful tool in furthering our efforts to monitor the expansion of services at excepted off-campus PBDs and to address any issues as they may arise. We will continue to monitor claims data for changes in billing patterns and utilization and investigate methods to ensure all hospitals are treated as fairly as possible within the program.

After consideration of the public comments we received, we are not finalizing this proposal at this time. However, we intend to monitor expansion of services in off-campus PBDs and, if appropriate, may propose to adopt a limitation on the expansion of excepted services in future rulemaking. In that event, we will consider the concerns expressed by commenters on the proposed policy in development of any future rulemaking on service line expansion. Therefore, an excepted off-campus PBD will continue to receive payments under the OPPS in CY 2019 for all billed items and services that are paid under the OPPS, regardless of whether it furnished such items and services prior to the date of enactment of Public Law 114–74, as long as the excepted off-campus PBD remains excepted, including meeting the relocation and change of ownership requirements adopted in the CY 2017 OPPS/ASC final rule with comment period if applicable (81 FR 79075 through 79706 and 79708 through 79709). As mentioned earlier in this section, we intend to monitor this issue and continue to consider how potential policies could address this issue.

XI. CY 2019 OPPS Payment Status and Comment Indicators

A. CY 2019 OPPS Payment Status Indicator Definitions

Payment status indicators (SIs) that we assign to HCPCS codes and APCs serve an important role in determining payment for services under the OPPS. They indicate whether a service represented by a HCPCS code is payable under the OPPS or another payment system, and also, whether particular OPPS policies apply to the code.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), for CY 2019, we did not propose to make any changes to the definitions of status indicators that were listed in Addendum D1 to the CY 2018 OPPS/ASC final rule with comment period available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices-Items/CMS-1656-FC.html?DLPage=1&DLEntries=10&DLSort=2&DLSortDir=descending.

Comment: One commenter recommended that CMS split status indicator “C” into “C1” and “C2” in the interest of improved clarity and transparency. The commenter noted this methodology is very similar to the way Medicare split status indicator “E” into indicators “E1” and “E2.” The commenter noted that CMS identify inpatient only (IPO) procedures that are on the separate procedure list (as determined by the American Medical Association) with a unique status indicator such as “C1” and others as “C2.” The commenter believed that the presence of a unique status indicator would ultimately assist providers in ensuring that their claims processing system edits are set up to bill these scenarios on an OPPS claim to CMS, and that CMS would benefit by having more accurate claims data submitted. The commenter believed that this will also increase the number of claims available for capturing cost data and utilizing for future rate setting.

The commenter also requested that CMS reiterate that the I/OCE logic regarding IPO procedures that are classified as a separate procedure (for example, status indicator of “C1”) is a line item rejection and does not cause the entire claim to be rejected.

Response: We appreciate the commenter’s concerns. However, at this time, we do not believe it is necessary to establish a unique status indicator to identify IPO procedures that are on the separate procedures list. As stated in the latest October 2018 Integrated (I/OCE) CMS Specifications V19.3 document, these procedures are bypassed when performed incidental to a surgical procedure with status indicator “T,” or effective January 1, 2015, if reported on a claim with a comprehensive APC procedure (status indicator = “F1”). The line(s) with the inpatient-separate procedures is/are rejected by the I/OCE with Edit 45 “Inpatient separate procedures not paid” and the claim is processed per usual OPPS rules. Therefore, there is no need to split the definition of status indicator “C” and to establish a new status indicator “C1” as suggested by the commenter. As discussed previously, our status indicators exist for purposes of assisting in determining payment, and a single status indicator “C” is sufficient for services that CMS designates to be “inpatient only” services, regardless of whether or not they are on the separate procedure list.

There are currently 26 different status indicators in Addendum D1 that are used to indicate whether a service described by a HCPCS code is payable under the OPPS or another payment system and whether particular OPPS payment policies apply to the code. We believe that it is important to maintain only status indicators in the OPPS that convey the necessary payment-related information, and that additional indicators should only be created when necessary for payment policy purposes.

In regard to the comment related to the I/OCE, the latest October 2018 I/OCE CMS Specifications V19.3 document on the CMS website located at: https://www.cms.gov/Medicare/Coding/OutpatientCodeEdit/OCEQtrReleaseSpecs.html already contains the correct logic regarding IPO procedures that are classified as a separate procedures.

After considering the comments received, we continue to believe that the existing definitions of the OPPS status indicators will be appropriate for CY 2019. Therefore, we are finalizing our proposed policy without modifications.

The complete list of the payment status indicators and their definitions that will apply for CY 2019 is displayed in Addendum D1 to this final rule with comment period, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

The CY 2019 payment status indicator assignments for APCs and HCPCS codes are shown in Addendum A and Addendum B, respectively, to this final rule with comment period, which are available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

B. CY 2019 Comment Indicator Definitions

In the CY 2019 OPPS/ASC proposed rule (83 FR 37150), we proposed to use four comment indicators for the CY 2019 OPPS. These comment indicators, “CH”, “PC”, “NT”, and “NP”, are in effect for CY 2018 and we proposed to continue their use in CY 2019. The
proposed CY 2019 OPPS comment indicators are as follows:

- “CH”—Active HCPCS code in current and next calendar year, status indicator and/or APC assignment has changed; or active HCPCS code that will be discontinued at the end of the current calendar year.
- “NC”—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year, and final APC assignment; comments will not be accepted on the final APC assignment for the new code.
- “NI”—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year, and interim APC assignment; comments will be accepted on the interim APC assignment for the new code.
- “NP”—New code for the next calendar year or existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year, proposed APC assignment; comments will be accepted on the proposed APC assignment for the new code.

We did not receive any public comments regarding the proposed CY 2019 OPPS comment indicators. Therefore, we are adopting, as final, our proposal to continue to use for CY 2019 comment indicators “CH”, “NI”, “NP”, and “NC”. The definitions of the final OPPS comment indicators for CY 2019 are listed in Addendum D2 to this final rule with comment period, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html.

XII. Updates to the Ambulatory Surgical Center (ASC) Payment System

A. Background

1. Legislative History, Statutory Authority, and Prior Rulemaking for the ASC Payment System

For a detailed discussion of the legislative history and statutory authority related to payments to ASCs under Medicare, we refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74377 through 74378) and the June 12, 1998 proposed rule (63 FR 32291 through 32292). For a discussion of prior rulemaking on the ASC payment system, we refer readers to the CYs 2012, 2013, 2014, 2015, 2016, and 2017 OPPS/ASC final rules with comment period (76 FR 74378 through 74379; 77 FR 68434 through 68467; 78 FR 75064 through 75090; 79 FR 66915 through 66940; 80 FR 70474 through 70502; 81 FR 79732 through 79753; and 82 FR 59401 through 59424, respectively).

2. Policies Governing Changes to the Lists of Codes and Payment Rates for ASC Covered Surgical Procedures and Covered Ancillary Services

Under 42 CFR 416.2 and 416.166 of the Medicare regulations, subject to certain exclusions, surgical procedures in an ASC are surgical procedures that are separately paid under the OPPS, that would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, and for which standard medical practice dictates that the beneficiary would not typically be expected to require active medical monitoring and care at midnight following the procedure (“overnight stay”).

The CY 2012 OPPS/ASC final rule with comment period, which we requested comments in the proposed rule, final APC assignment; comments will not be accepted on the final APC assignment for the new code.

We adopt this standard for defining which surgical procedures are covered under the ASC payment system as an indicator of the complexity of the procedure and its appropriateness for Medicare payment in ASCs. We use this standard only for purposes of evaluating procedures to determine whether or not they are appropriate to be furnished to Medicare beneficiaries in ASCs. We define surgical procedures as those described by Category I CPT codes in the surgical range from 00000 through 69999 as well as those Category III CPT codes and Level II HCPCS codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, that we would not expect to require an overnight stay when performed in ASCs, and that are separately paid under the OPPS (72 FR 42478).

In the August 2, 2007 final rule (72 FR 42495), we also established our policy to make separate ASC payments for the following ancillary items and services when they are provided integral to ASC covered surgical procedures: (1) Brachytherapy sources; (2) certain implantable items that have pass-through payment status under the OPPS; (3) certain items and services that we designate as contractor-priced, including, but not limited to, procurement of corneal tissue; (4) certain drugs and biologicals for which separate payment is allowed under the OPPS; and (5) certain radiology services for which separate payment is allowed under the OPPS. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66915 through 66940), we removed the scope of ASC covered ancillary services to include certain diagnostic tests within the medicine range of CPT codes for which separate payment is allowed under the OPPS when they are provided integral to an ASC covered surgical procedure. Covered ancillary services are specified in § 416.164(b) and, as stated previously, are eligible for separate ASC payment. Payment for ancillary items and services that are not paid separately under the ASC payment system is packaged into the ASC payment for the covered surgical procedure.

We update the lists of, and payment rates for, covered surgical procedures and covered ancillary services in ASCs in conjunction with the annual proposed and final rulemaking process to update the OPPS and the ASC payment system (§ 416.173; 72 FR 42535). We base ASC payment and policies for most covered surgical procedures, drugs, biologicals, and certain other covered ancillary services on the OPPS payment policies, and we use quarterly change requests (CRs) to update services covered under the OPPS. We also provide quarterly update CRs for ASC covered surgical procedures and covered ancillary services throughout the year (January, April, July, and October). We release new and revised Level II HCPCS codes and recognize the release of new and revised CPT codes by the AMA and make these codes effective (that is, the codes are recognized on Medicare claims) via these ASC quarterly update CRs. We recognize the release of new and revised Category III CPT codes in the July and January CR updates. These updates implement newly created and revised Level II HCPCS and Category III CPT codes for ASC payments and update the payment rates for separately paid drugs and biologicals based on the most recently submitted ASP data. New and revised Category I CPT codes, except vaccine codes, are released only once a year, and are implemented only through the January quarterly CR update. New and revised Category I CPT vaccine codes are released twice a year and are implemented through the January and July quarterly CR updates. We refer readers to Table 41 in the CY 2012 OPPS/ASC proposed rule for an example of how this process, which we finalized in the CY 2012 OPPS/ASC final rule with comment period, is used to update HCPCS and CPT codes (76 FR 42291; 76 FR 74380 through 74381).

In our annual updates to the ASC list of, and payment rates for, covered surgical procedures and covered ancillary services, we undertake a review of excluded surgical procedures (including all procedures newly proposed for removal from the OPPS
inpatient list), new codes, and codes with revised descriptors, to identify any that we believe meet the criteria for designation as ASC covered surgical procedures or covered ancillary services. Updating the lists of ASC covered surgical procedures and covered ancillary services, as well as their payment rates, in association with the annual OPPS rulemaking cycle is particularly important because the OPPS relative payment weights and, in some cases, payment rates, are used as the basis for the payment of many covered surgical procedures and covered ancillary services under the revised ASC payment system. This joint update process ensures that the ASC updates occur in a regular, predictable, and timely manner.

3. Definition of ASC Covered Surgical Procedures

Since the implementation of the ASC prospective payment system, we have defined a “surgical” procedure under the payment system as any procedure described within the range of Category I CPT codes that the CPT Editorial Panel of the American Medical Association (AMA) defines as “surgery” (CPT codes 10000 through 69999) (72 FR 42478). We also have included as “surgical,” procedures that are described by Level II HCPCS codes or by Category III CPT codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, would not expect to require an overnight stay when performed in an ASC, and are separately paid under the OPPS (72 FR 42478).

As we noted in the CY 2008 final rule that implemented the revised ASC payment system, using this definition of surgery would exclude from ASC payment certain invasive, “surgery-like” procedures, such as cardiac catheterization or certain radiation treatment services that are assigned codes outside the CPT surgical range (72 FR 42477). We stated in that final rule that we believed continuing to rely on the CPT definition of surgery is administratively straightforward, is logically related to the categorization of services by physician experts who both establish the codes and perform the procedures, and is consistent with a policy to allow ASC payment for all outpatient surgical procedures (72 FR 42477).

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59402 through 59403), we noted that some stakeholders suggested that certain procedures that are outside the CPT surgical range but that are similar to surgical procedures currently covered in an ASC setting should be ASC covered surgical procedures. For example, some stakeholders have recommended adding certain cardiovascular procedures to the ASC Covered Procedures List (CPL) due to their similarity to currently covered peripheral endovascular procedures in the surgical code range for surgery and the cardiovascular system. Further, stakeholders also noted that the AMA’s CPT code manual states that the listing of a procedure in a specific section of the book may reflect historical or other considerations and should not be interpreted as strictly classifying the procedure as “surgery” or “not surgery” for insurance purposes. As the CPT codebook states: “It is equally important to recognize that as techniques in medicine and surgery have evolved, new types of services, including minimally invasive surgery, as well as endovascular, percutaneous, and endoscopic interventions have challenged the traditional distinction of Surgery vs Medicine. Thus, the listing of a service or procedure in a specific section of this book should not be interpreted as strictly classifying the service or procedure as ‘surgery’ or ‘not surgery’ for insurance or other purposes.” The placement of a given service in a specific section of the book may reflect historical or other considerations (e.g., placement of the percutaneous peripheral vascular endovascular interventions in the Surgery/Cardiovascular System section, while the percutaneous coronary interventions appear in the Medicine/Cardiovascular section”) (emphasis added) (CPT® Professional Edition, “Instructions for Use of the CPT Code Book,” page xii.). While we continue to believe that using the CPT code range to define surgery represents a logical, appropriate, and straightforward approach to defining a surgical procedure, we also believe it may be appropriate for us to use the CPT surgical range as a guide rather than a strict determinant as to whether a procedure is surgical, which would give us more flexibility to include “surgery-like” procedures on the ASC CPL.

We also are cognizant of the dynamic nature of ambulatory surgery and the continued shift of services from the inpatient setting to the outpatient setting over the past decade. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59402 through 59403), we responded to public comments that we had solicited regarding services that are described by Category I CPT codes outside of the surgical range, or Level II HCPCS codes or Category III CPT codes that do not directly crosswalk and are not clinically similar to procedures in the CPT surgical range, but that nonetheless may be appropriate to include as covered surgical procedures that are payable when furnished in the ASC setting. Commenters offered mixed views of changing the current definition of surgery; however, most commenters were supportive of changing the definition. Some commenters recommended broadening the definition of surgery to include procedures not described by the CPT surgical range. Another commenter recommended making all surgical codes payable in a hospital outpatient department payable in an ASC and further suggested that CMS at least redefine surgical procedures to include invasive procedures such as percutaneous transluminal angioplasty and cardiac catheterization.

One commenter recommended using a definition of surgery developed by the AMA Specialty Society Relative Value Scale Update Society, for use in the agency’s Physician Fee Schedule (PFS) professional liability insurance relative values. In calculating the professional liability insurance relative values, certain cardiology codes outside the CPT surgical range are considered surgical codes for both the calculation and assignment of the surgery-specific malpractice risk factors. However, we note that the distinction between “surgical” and “nonsurgical” codes developed by the AMA Specialty Society Relative Value Scale Update Society is used by CMS to calculate professional liability risk factors and not necessarily to define surgery. The codes considered surgeries by the AMA Specialty Society Relative Value Scale Update Society were most recently displayed on the CMS website for the CY 2018 Medicare Physician Fee Schedule final rule under the file “Invasive Cardiology Services Outside of Surgical HCPCS Code Range Considered Surgery.” We refer readers to that file, which is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Downloads/CY2018-PFS-FR-Invasive-Cardiology.zip.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37152), after further consideration of comments we received in response to the CY 2018 OPPS/ASC final rule with comment period, we proposed to revise our definition of surgery for CY 2019 to account for “surgery-like” procedures that are assigned codes outside the CPT surgical range (10000 through 69999). We...
believe it is appropriate to expand our definition of covered surgical procedures to include Category I CPT codes that are not in the Category I CPT surgical range but that directly crosswalk or are clinically similar to procedures in the Category I CPT code surgical range because, as commenters have noted, the CPT Codebook’s classification of certain procedures as “surgical” should not be considered dispositive of whether a procedure is or is not surgery. We also believe that considering these codes for potential inclusion on the covered surgical procedures list is consistent with our policy for Level II HCPCS codes and Category III CPT codes.

For CY 2019, we proposed that these newly eligible “surgery-like” procedures are procedures that are described by Category I CPT codes that are not in the surgical range but, like procedures described by Level II HCPCS codes or by Category III CPT codes under our current policy, directly crosswalk or are clinically similar to procedures in the Category I CPT surgical range. These Category I CPT codes would be limited to those that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS.

We invited comments on our proposal to revise the definition of surgery for the ASC prospective payment system. We also solicited comments on whether we should expand our definition of “surgery-like” procedures that fall outside the CPT surgical range, but fall within the definition of “surgery” developed by the AMA Specialty Society Relative Value Scale Update Society for use in the agency’s Physician Fee Schedule (PFS) professional liability insurance relative values, that we determine do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS.

Comment: A majority of commenters supported the proposal, stating that the expansion of the definition of surgery would allow Medicare beneficiaries access to these procedures at a safe, lower-priced and more convenient site of service. One commenter expressed general concern about the proposal to revise the definition of surgery, citing “surgery-like” procedures that might expose Medicare beneficiaries to a significant safety risk when performed in an ASC.

Response: We appreciate commenters’ support. As we stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37152), we are cognizant of the dynamic nature of ambulatory surgery and the continued shift of services from the inpatient setting to the outpatient setting over the past decade. We also noted that the AMA’s CPT code manual states that the listing of a procedure in a specific section of the book may reflect historical or other considerations and should not be interpreted as strictly classifying the procedure as “surgery” or “not surgery” for insurance or other purposes.

With respect to the commenter’s concern that this proposal may expose beneficiaries to significant safety risk, we note that any procedure added to the ASC CPL is evaluated against the existing regulatory criteria and would not be expected pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and is separately paid under the OPPS. In addition, we expect that physicians treating beneficiaries are well-equipped to decide whether the ASC setting would be appropriate based on the clinical needs of the patient, among other factors. Therefore, we do not share the commenter’s concern.

Response: One commenter asked CMS to clarify if it bases its determination of whether a procedure is an ASC covered surgical procedure on the fact that the procedure does not require an “overnight” stay or the fact that the procedure requires less than 24 hours of active medical care following the procedure.

Response: As codified in our regulations at 42 CFR 416.166(b), covered surgical procedures are surgical procedures for which, among other things, standard medical practice dictates that the beneficiary would not typically be expected to require active medical monitoring and care at midnight following the procedure. In the CY 2019 OPPS/ASC proposed rule (83 FR 37151), we explained this requirement by stating that we would not expect a covered surgical procedure to require an overnight stay when performed in the ASC. Also in the CY 2019 OPPS/ASC proposed rule, we explained that we adopted this standard for defining which surgical procedures are covered surgical procedures under the ASC payment system as an indicator of the complexity of the procedure and its appropriateness for Medicare payment in ASCs (83 FR 37151). We use this standard only for purposes of evaluating procedures to determine whether or not they are appropriate for Medicare beneficiaries in ASCs. After consideration of the public comments we received, we are finalizing our proposal to define a surgical procedure under the ASC payment system as any procedure described within the range of Category I CPT codes that the CPT Editorial Panel of the American Medical Association (AMA) defines as “surgery” (CPT codes 10000 through 69999) (72 FR 42478), as well as procedures that are described by Level II HCPCS codes or by Category I CPT codes or by Category III CPT codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined are not expected to pose a significant risk to beneficiary safety when performed in an ASC, for which standard medical practice dictates that the beneficiary would not typically be expected to require an overnight stay following the procedure, and are separately paid under the OPPS.

B. Treatment of New and Revised Codes

1. Background on Current Process for Recognizing New and Revised Category I and Category III CPT Codes and Level II HCPCS Codes

Category I CPT, Category III CPT, and Level II HCPCS codes are used to report procedures, services, items, and supplies under the ASC payment system. Specifically, we recognize the following codes on ASC claims:

• Category I CPT codes, which describe surgical procedures and vaccine codes;

• Category II CPT codes, which describe new and emerging technologies, services, and procedures; and

• Level II HCPCS codes, which are used primarily to identify items, supplies, temporary procedures, and services not described by CPT codes.

We finalized a policy in the August 2, 2007 final rule (72 FR 42533 through 42535) to evaluate each year all new and revised Category I and Category III CPT codes and Level II HCPCS codes that describe surgical procedures, and to make preliminary determinations during the annual OPPS/ASC rulemaking process regarding whether or not they meet the criteria for payment in the ASC setting as covered surgical procedures and, if so, whether or not they are office-based procedures. In addition, we identify new and revised codes as ASC covered ancillary services based upon the final payment policies of the revised ASC payment system. In prior rulemakings, we refer to this process as recognizing new codes. However, this process has always involved the recognition of new and revised codes. We consider revised codes to be new when they have substantial revision to their code...
descriptors that necessitate a change in the current ASC payment indicator. To clarify, we referred to these codes as new and revised in the CY 2018 OPPS/ASC proposed rule.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37152 through 37155), we separated our discussion based on when the codes were released and whether we were soliciting public comments in the proposed rule (and responding to those comments in this CY 2019 OPPS/ASC final rule with comment period) or whether we would be soliciting public comments in this CY 2019 OPPS/ASC final rule with comment period (and responding to those comments in the CY 2020 OPPS/ASC final rule with comment period).

We note that we sought public comments in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59405 through 59406) on the new and revised Level II HCPCS codes effective October 1, 2017 or January 1, 2018. These new and revised codes, with an effective date of October 1, 2017 or January 1, 2018, were flagged with comment indicator “NI” in Addenda AA and BB to the CY 2018 OPPS/ASC final rule with comment period to indicate that we were assigning them an interim payment status and payment rate, if applicable, which were subject to public comment following publication of the CY 2018 OPPS/ASC final rule with comment period. In the CY 2019 OPPS/ASC proposed rule, we stated that we will respond to public comments and finalize the treatment of these codes under the ASC payment system in this CY 2019 OPPS/ASC final rule with comment period.

As we did in Table 33 of the CY 2019 OPPS/ASC proposed rule (83 FR 37153), in Table 52 below, we summarize our process for updating codes through our ASC quarterly update CRs, seeking public comments, and finalizing the treatment of these new codes under the OPPS.

**TABLE 52.—COMMENT AND FINALIZATION TIMEFRAMES FOR NEW OR REVISED HCPCS CODES**

<table>
<thead>
<tr>
<th>ASC Quarterly Update CR</th>
<th>Type of Code</th>
<th>Effective Date</th>
<th>Comments Sought</th>
<th>When Finalized</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>April 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td>July 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>July 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td></td>
<td>Category I (certain vaccine codes) and III CPT codes</td>
<td>July 1, 2018</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td>October 1, 2018</td>
<td>Level II HCPCS Codes</td>
<td>October 1, 2018</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
<td>CY 2020 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td>January 1, 2019</td>
<td>Category I and III CPT Codes</td>
<td>January 1, 2019</td>
<td>CY 2019 OPPS/ASC proposed rule</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
</tr>
<tr>
<td></td>
<td>Level II HCPCS Codes</td>
<td>January 1, 2019</td>
<td>CY 2019 OPPS/ASC final rule with comment period</td>
<td>CY 2020 OPPS/ASC final rule with comment period</td>
</tr>
</tbody>
</table>
2. Treatment of New and Revised Level II HCPCS Codes Implemented in April 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37153), in the April 2018 ASC quarterly update (Transmittal 3996, Change Request 10530, dated March 09, 2018), we added nine new Level II HCPCS codes to the ASC CPL and list of covered ancillary services. Table 34 of the proposed rule (83 FR 37153) listed the new Level II HCPCS codes that were implemented April 1, 2018, along with their proposed payment indicators for CY 2019. We invited public comments on these proposed payment indicators and the proposed payment rates for the new Level II HCPCS codes that were recognized as ASC covered surgical procedures or ancillary services in April 2018 through the quarterly update CRs, as listed in Table 34 of the proposed rule. We proposed to finalize their payment indicators and their payment rates in this CY 2019 OPPS/ASC final rule with comment period.

Comment: Several commenters supported the addition of HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)), which describes the Latera implant surgical procedure, to the ASC covered surgical procedures list and its designation as a device-intensive procedure. However, they expressed concern that the proposed ASC payment rate for the procedure does not sufficiently cover the full cost of providing the surgery. One commenter stated that the proposed ASC payment rate of approximately $1,271 does not cover the cost of the device implant, let alone the full cost of the procedure including the device. These commenters believed that the low payment rate would hinder physicians from offering the procedure in ASCs. The commenters requested that CMS review the payment rate and adjust it appropriately so that physicians can continue to perform this procedure safely and effectively in the ASC setting.

Response: The OPPS and the ASC payment system utilize different conversion factors to establish payment rates for covered services to account for changes in expenditures. In the CY 2019 OPPS/ASC proposed rule, we stated that the proposed OPPS conversion factor was $79.546, while the proposed ASC conversion factor was $46.500. Consequently, the proposed ASC payment rate of approximately $1,271 for HCPCS code C9749 would be less than the proposed OPPS payment rate of approximately $2,241. We have used different conversion factor updates for the OPPS and the ASC payment system since the revised ASC payment system was implemented on January 1, 2008. For more information regarding the payment methodology for ASC services, we refer readers to section XII.G. (Calculation of the ASC Payment Rates and the ASC Conversion Factor) of this CY 2019 OPPS/ASC final rule with comment period.

Further, we also note that HCPCS code C9749 has been assigned a payment indicator of “J8” and is therefore designated as a device-intensive procedure. As discussed in section XII.C.1.b. of this final rule with comment period, under the ASC payment system, device-intensive procedures are paid a higher payment than if the procedure was not designated as device-intensive.

After consideration of the public comments we received, we are adopting as final the CY 2019 proposed payment indicators for new level II HCPCS codes for covered surgical procedures and ancillary services effective on April 1, 2018, as indicated in Table 53. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. The replacement codes are listed in Table 53. The final payment rates for these codes can be found in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website). In addition, the payment indicator definitions can be found in Addendum DD1 to this final rule with comment period (which is available via the internet on the CMS website).
3. Treatment of New and Revised Category III CPT and Level II HCPCS Codes Implemented in July 2018 for Which We Solicited Public Comments in the CY 2019 OPPS/ASC Proposed Rule

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37154), in the July 2018 ASC quarterly update (Transmittal 4076, Change Request 10788, dated June 26, 2018), we added eight new Level II HCPCS codes to the list of covered ancillary services. In Table 35 of the proposed rule (83 FR 37154), we listed the new HCPCS codes that are effective July 1, 2018.

In addition, through the July 2018 quarterly update CR, we also implemented one new Category III CPT code as an ASC covered ancillary service effective July 1, 2018. This code was listed in Table 36 of the proposed rule, along with its proposed payment indicator. The proposed payment rate for this new Category III CPT code was included in Addendum AA to the proposed rule (which is available via the internet on the CMS website).

We invited public comments on these proposed payment indicators and the proposed payment rates for the new Category III CPT code and Level II HCPCS codes that were expected to be newly recognized as ASC covered surgical procedures or covered ancillary services in July 2018 through the quarterly update CRs, as listed in Tables 35 and 36 of the proposed rule. We proposed to finalize their payment indicators and their payment rates in the CY 2019 OPPS/ASC final rule with comment period.

We did not receive any public comments regarding these proposed ASC payment indicators and payment rates. Therefore, we are adopting as final the CY 2019 proposed payment indicators for these codes, as indicated in Tables 54 and 55. We note that several of the HCPCS C-codes have been replaced with HCPCS J-codes, effective January 1, 2019. Their replacement codes are listed in Table 55. The final payment rates for these codes for CY 2019 can be found in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website). In addition, the payment indicator definitions can be found in Addendum DD1 to this final rule with comment period (which is available via the internet on the CMS website).

### Table 35—New Level II HCPCS Codes for Covered Surgical Procedures and Ancillary Services Effective on April 1, 2018

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>C9462</td>
<td>C9462</td>
<td>Injection, delafloxacin, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9463</td>
<td>J0185</td>
<td>Injection, aprepitant, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9464</td>
<td>J2797</td>
<td>Injection, rolapitant, 0.5 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9465</td>
<td>J7318</td>
<td>Hyaluronan or derivative, Duolane, for intra-articular injection, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9466</td>
<td>J0517</td>
<td>Injection, benralizumab, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9467</td>
<td>J9311</td>
<td>Injection, rituximab 10 mg and hyaluronidase</td>
<td>K2</td>
</tr>
<tr>
<td>C9468</td>
<td>J7203</td>
<td>Injection factor ix, (anthemophilic factor, recombinant), glycopegylated, (rebinyn), 1iu</td>
<td>K2</td>
</tr>
<tr>
<td>C9469*</td>
<td>J3304*</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9749</td>
<td>C9749</td>
<td>Repair of nasal vestibular lateral wall stenosis with implant(s)</td>
<td>J8</td>
</tr>
</tbody>
</table>

*HCPCS code C9469 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), which was effective April 1, 2018, was deleted June 30, 2018 and replaced with HCPCS code Q9993 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg) effective July 1, 2018. HCPCS code Q9993 was deleted December 31, 2018, and replaced with HCPCS code J3304 effective January 1, 2019.
4. Process for New and Revised Level II HCPCS Codes That Will Be Effective October 1, 2018 and January 1, 2019 for Which We Are Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With Comment Period

As has been our practice in the past, we incorporate those new and revised Level II HCPCS codes that are effective January 1 in the final rule with comment period, thereby updating the OPPS and the ASC payment system for the following calendar year. These codes are released to the public via the CMS HCPCS website, and also through the January OPPS quarterly update CRs. In the past, we also released new and revised Level II HCPCS codes that are effective October 1 through the October OPPS quarterly update CRs and incorporated these new codes in the final rule with comment period.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37154), for CY 2019, consistent with our established policy, we proposed that the Level II HCPCS codes that will be effective October 1, 2018 and January 1, 2019 would be flagged with comment indicator “NI” in Addendum B to the CY 2019 OPPS/ASC final rule with comment period to indicate that we have assigned the codes an interim OPPS payment status for CY 2019. We did not receive any public comments on our proposal. As we stated that we would do in the proposed rule, we are inviting public comments in this CY 2019 OPPS/ASC final rule with comment period on the interim status indicator and APC assignments, and

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>C9030</td>
<td>J9057</td>
<td>Injection, copanlisib, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>C9032</td>
<td>J3398</td>
<td>Injection, voretigene neparvovec-rzyl, 1 billion vector genomes</td>
<td>K2</td>
</tr>
<tr>
<td>Q5105</td>
<td>Q5105</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units</td>
<td>K2</td>
</tr>
<tr>
<td>Q5106</td>
<td>Q5106</td>
<td>Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units</td>
<td>K2</td>
</tr>
<tr>
<td>Q9991</td>
<td>Q9991</td>
<td>Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg</td>
<td>K2</td>
</tr>
<tr>
<td>Q9992</td>
<td>Q9992</td>
<td>Injection, buprenorphine extended-release (Sublocade), greater than 100 mg</td>
<td>K2</td>
</tr>
<tr>
<td>Q9993*</td>
<td>J3304*</td>
<td>Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg</td>
<td>K2</td>
</tr>
<tr>
<td>Q9995</td>
<td>J7170</td>
<td>Injection, emicizumab-kxwh, 0.5 mg</td>
<td>K2</td>
</tr>
</tbody>
</table>

*HCPCS code C9469 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg), which was effective April 1, 2018, was deleted June 30, 2018 and replaced with HCPCS code Q9993 (Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg) effective July 1, 2018. HCPCS code Q9993 was deleted December 31, 2018, and replaced with HCPCS code J3304 effective January 1, 2019.
payment rates for these codes that will be finalized in the CY 2020 OPPS/ASC final rule with comment period.

5. Process for Recognizing New and Revised Category I and Category III CPT Codes That Will Be Effective January 1, 2019 for Which We Are Soliciting Public Comments in This CY 2019 OPPS/ASC Final Rule With Comment Period

We generally include the new and revised CPT codes that are effective January 1 of a calendar year in the proposed rule to request public comments on the ASC payment indicator assignments. In addition, these codes are assigned to comment indicator “NP” to indicate that the code is new for the next calendar year or the code is an existing code with substantial revision to its code descriptor in the next calendar year as compared to current calendar year and that comments will be accepted on the proposed payment indicator. There are no existing codes with substantial revision to the code descriptor effective January 1, 2019. However, we inadvertently omitted most of the new Category I and III CPT codes effective January 1, 2019 from ASC Addendum AA, BB, and EE to the CY 2019 OPPS/ASC proposed rule. We did not omit eight new CPT codes that we proposed to designate as temporarily office based effective January 1, 2019. We refer readers to Table 39 of the proposed rule.

Therefore, in addition to the Level II HCPCS codes that will be effective October 1, 2018, and January 1, 2019, we are flagging the new Category I and III CPT codes that will be effective January 1, 2019, that were omitted from the CY 2019 OPPS/ASC proposed rule, with comment indicator “NI” in ASC Addendum AA, BB, and EE to this CY 2019 OPPS/ASC final rule with comment period to indicate that we have assigned the codes an interim ASC payment indicator for CY 2019. We are inviting public comments on the interim ASC payment indicator assignments and payment rates for these codes that we intend to finalize in the CY 2020 OPPS/ASC final rule with comment period. We note that we are finalizing the ASC payment indicators for the eight codes that were proposed to designate as temporarily office based effective January 1, 2019 because we previously sought comments on their ASC payment indicator assignment. Table 38 of this final rule with comment period contains the list of these eight codes and their final ASC payment indicators.

Further, readers that the CPT code descriptors that appear in ASC Addendum AA, BB, and EE are short descriptors and do not fully describe the complete procedure, service, or item described by the CPT code. Therefore, we have included the 5-digit CPT codes and their long descriptors for the new CPT codes in Addendum O (which is available via the internet on the CMS website) so that the public can adequately comment on our interim ASC payment indicator assignments.

In summary, we are soliciting public comments on the interim ASC payment indicators for the new Category I and III CPT codes that will be effective January 1, 2019, which we have assigned to ASC comment indicator “NI” in this CY 2019 OPPS/ASC final rule with comment period. We intend to finalize the interim ASC payment indicators in the CY 2020 OPPS/ASC final rule with comment period. The CPT codes are listed in ASC Addendum AA, BB, and EE with short descriptors only but we list them again in Addendum O with long descriptors.

C. Update to the List of ASC Covered Surgical Procedures and Covered Ancillary Services

1. Covered Surgical Procedures
a. Covered Surgical Procedures Designated as Office-Based
(1) Background

In the August 2, 2007 ASC final rule, we finalized our policy to designate as “office-based” those procedures that are added to the ASC CPL in CY 2008 or later years that we determine are performed predominantly (more than 50 percent of the time) in physicians’ offices based on consideration of the most recent available volume and utilization data for each individual procedure code and/or, if appropriate, the clinical characteristics, utilization, and volume of related codes. In that rule, we also finalized our policy to exempt all procedures on the CY 2007 ASC list from application of the office-based classification (72 FR 42512). The procedures that were added to the ASC CPL beginning in CY 2008 that we determined were office-based were identified in Addendum AA to that rule by payment indicator “P2” (Office-based surgical procedure added to ASC list in CY 2008 or later with MPFS nonfacility PE RVUs; payment based on OPPS relative payment weight), depending on whether we estimated the procedure would be paid according to the standard ASC payment methodology based on its OPPS relative payment weight or at the MPFS nonfacility PE RVU-based amount.

Consistent with our final policy to annually review and update the ASC CPL eligible for payment in ASCs, each year we identify covered surgical procedures as either temporarily office-based (these are new procedure codes with little or no utilization data that we have determined are clinically similar to other procedures that are permanently office-based), permanently office-based, or nonoffice-based, after taking into account updated volume and utilization data.

(2) Changes for CY 2019 to Covered Surgical Procedures Designated as Office-Based

In developing the CY 2019 OPPS/ASC proposed rule and this final rule with comment period, we followed our policy to annually review and update the covered surgical procedures for which ASC payment is made and to identify new procedures that may be appropriate for ASC payment, including their potential designation as office-based. We reviewed CY 2017 volume and utilization data and the clinical characteristics for all covered surgical procedures that are assigned payment indicator “G2” (Nonoffice-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight) in CY 2017, as well as for those procedures assigned one of the temporary office-based payment indicators, specifically “P2”, “P3”, or “R2” in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59406 through 59408).

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37155 through 37157), our review of the CY 2017 volume and utilization data resulted in our identification of 4 covered surgical procedures that we believe meet the criteria for designation as office-based. The data indicate that these procedures are performed more than 50 percent of the time in physicians’ offices, and we believe that the services are of a level of complexity consistent with other procedures performed routinely in physicians’ offices. The CPT codes that we proposed to permanently designate as office-based for CY 2019 were listed in Table 37 of the proposed rule (83 FR 37156).

Comment: Several commenters disagreed with the proposal to designate CPT codes 36902 (Intro cath dialysis circuit) and 36905 (Thrbc/nfs dialysis
circuit) as permanently office-based. Commenters suggested that a permanent office-based designation, and therefore a permanent payment rate of the lesser of the PFS nonfacility PE RVU-based or the OPPS relative weight amount, would pay too little to make it a viable option for ASCs to perform these vascular access services, which the commenters suggested is the optimal setting for receiving vascular access services. Commenters also suggested that a permanent office-based designation may inadvertently incentivize the migration of vascular access procedures to the more costly hospital setting. Further, commenters noted that vascular access procedure codes (CPT codes 36901 through 36909) became effective January 1, 2017, and were added to the ASC CPL for CY 2017. Because several of these procedures were not included on the ASC CPL prior to that time, commenters expressed concern that CMS is not likely to have data that accurately reflect the ASC utilization of the full suite of vascular access procedures until CY 2020 or later.

Some commenters recommended that CMS delay the proposal to designate CPT codes 36902 and 36905 as office-based procedures. Other commenters recommended that CMS permanently exempt such CPT codes from office-based designations, similar to the existing exemptions from the policy governing payment for covered ancillary radiology services for certain nuclear medicine procedures (CPT codes 78000 through 78999) and those covered ancillary radiology services that use a contrast agent as codified under 42 CFR 416.171(d). Commenters believed that such an exemption is warranted because certain vascular access add-on procedures (that is, CPT codes 36907, 36908, and 36909) are often billed with CPT codes 36902 and 36905, which are separately payable under the PFS but are packaged under the OPPS and the ASC payment system. Therefore, the commenters stated, the ASC payment rate for an office-based vascular access procedure with a vascular access add-on procedure may be lower than would otherwise be paid under the PFS.

**Response:** We appreciate the commenters’ feedback on our proposal. As noted in the proposed rule, we assign office-based designations when our data indicate that these procedures are performed more than 50 percent of the time in physicians’ offices, and we believe that the services are of a level of complexity consistent with other procedures performed routinely in physicians’ offices. We believe this is the most appropriate approach to prevent creating a payment incentive to migrate lower complexity services on the ASC CPL from physicians’ offices to ASCs.

In response to the comment recommending that we establish a permanent office-based designation exemption for vascular access procedures, we do not believe such an exemption is necessary at this time. However, we would like to study this issue further in future policy development. As stated in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), we established an exemption to the policy governing payment for covered ancillary radiology services for certain nuclear medicine procedures (CPT codes 78000 through 78999) because the PFS nonfacility PE RVU amounts did not reflect the diagnostic radiopharmaceutical costs, which are paid separately under the MPFS. In addition, as stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74429 through 74430), because the same issue exists for radiology procedures that use contrast agents (the contrast agent is packaged under the ASC payment system but is separately paid under the PFS), we exempted radiology services that use contrast agents from our policy governing payment for covered ancillary radiology services so that payment for these procedures will be based on the OPPS relative payment weight and will, therefore, include the cost for the contrast agent. We did not propose an equivalent exemption for vascular access procedures for CY 2015, and do not believe a permanent exemption would be appropriate at this time. However, we intend to examine whether CPT codes 36902 and 36905 may be subject to circumstances similar to those that led to the exemptions for certain nuclear medicine procedures and radiology procedures that use contrast agents in future rulemaking.

The most recent full year for which we have claims, volume, and utilization data is CY 2017. We believe these data are generally an appropriate source to inform our decisions regarding the predominant site of service for procedures. As stated in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60605 through 60606), when we believe that the available data in our review process are inadequate to make a determination that a procedure should be office-based, we either make no change to the procedure’s payment status or make the change temporary and reevaluate our decision using data that become available for our next evaluation. We believe that it is appropriate to continue using our judgment regarding whether the volume of cases and the proportion of cases that are provided in the physicians’ office setting indicate that the procedures is an office-based procedure in addition to our medical advisors’ clinical judgments, utilization data for procedures that are closely related to the procedures being evaluated, and any other information that is available to us.

While the currently available data for CPT codes 36902 and 36905 support our office-based designation proposal, we agree with the commenters that CY 2017 claims data may not be sufficiently adequate to capture the current volume and utilization for the ASC and physician office sites of service for CPT codes 36902 and 36905. Because we share commenters’ concerns that the available data may not be adequate to make a determination that these procedures should be office-based, we believe it is premature to assign office-based payment for these procedures at this time. Therefore, we are not designating CPT codes 36902 and 36905 as office-based procedures for CY 2019. We will reevaluate these procedures in our CY 2020 rulemaking period. For CY 2019, these procedures will retain their current payment indicator, “G2.”

We did not receive any public comments related to our proposal to designate CPT codes 31573 (Laryngoscopy, flexible; with therapeutic injection(s) (e.g., chemodenervation agent or corticosteroid, injected percutaneous, transoral, or via endoscope channel), unilateral) and 36513 (Therapeutic apheresis; for platelets) as office-based procedures. Therefore, we are finalizing our proposal, without modification, to designate CPT codes 31573 and 36513 as permanently office-based procedures. However, in response to public comments we received, we are not finalizing our proposal to designate CPT codes 36902 and 36905 as office-based. CPT codes 36902 and 36905 will retain the same payment indicator, “G2”, that the procedures were assigned in CY 2018. We intend to reevaluate these using the most recent available volume and utilization data procedures in our CY 2020 rulemaking period. The procedures we are designating as permanently office-based beginning in CY 2019 are listed in Table 56 below.
We also reviewed CY 2017 volume and utilization data and other information for 10 procedures designated as temporarily office-based in Tables 84 and 85 in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59408). Of these 10 procedures, there were very few claims in our data and no claims data for 4 procedures described by CPT codes 38222, 65785, 67229, and 0402T. Consequently, we proposed to maintain the temporary office-based designations for these 4 CPT codes for CY 2019. We included codes for which we proposed to maintain the temporary office-based designations for CY 2019 in Table 38 of the proposed rule which listed the covered surgical procedures we designated as temporary office-based in the CY 2018 OPPS/ASC final rule with comment period. The procedures for which the proposed office-based designations for CY 2019 are temporary also were indicated by asterisks in Addendum AA to the proposed rule (which is available via the internet on the CMS website).

The volume and utilization data for 3 procedures that have a temporary office-based designation for CY 2018, described by CPT codes 36473 and 36901 and HCPCS code G0429, are sufficient to indicate that these procedures are performed predominantly in physicians’ offices and, therefore, should be assigned an office-based payment indicator in CY 2019. Consequently, we proposed to designate these procedures as permanently office based and assign payment indicators “P2”, “P3”, “R2” to these covered surgical procedure codes in CY 2019. These procedures are displayed above in Table 56. The volume and utilization data for the remaining three procedures that have a temporary office-based designation for CY 2018, described by CPT codes 10030, 64461, and 64463, are sufficient

**TABLE 56.—ASC COVERED SURGICAL PROCEDURES NEWLY DESIGNATED AS PERMANENTLY OFFICE-BASED FOR CY 2019**

<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2018 ASC Payment Indicator</th>
<th>CY 2019 ASC Payment Indicator*</th>
</tr>
</thead>
<tbody>
<tr>
<td>31573</td>
<td>Laryngoscopy, flexible; with therapeutic injection(s) (e.g., chemodenervation agent or corticosteroid, injected percutaneous, transoral, or via endoscope channel), unilateral</td>
<td>G2</td>
<td>P3</td>
</tr>
<tr>
<td>36473</td>
<td>Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechnochemical; first vein treated.</td>
<td>P2</td>
<td>P2</td>
</tr>
<tr>
<td>36513</td>
<td>Therapeutic apheresis; for platelets</td>
<td>G2</td>
<td>R2</td>
</tr>
<tr>
<td>36901</td>
<td>Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report.</td>
<td>P2</td>
<td>P3</td>
</tr>
<tr>
<td>G0429</td>
<td>Dermal injection procedure(s) for facial lipodystrophy syndrome (LDS) and provision of Radiesse or Sculptra dermal filler, including all items and supplies</td>
<td>P3</td>
<td>P3</td>
</tr>
</tbody>
</table>

* Payment indicators are based on a comparison of the proposed rates according to the ASC standard ratesetting methodology and the PFS final rates. Current law specifies a 0.25 percent update to the PFS payment rates for CY 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period.
to indicate that these covered surgical procedures were not performed predominantly in physicians’ offices and, therefore, should be assigned non-office-based payment indicator “G2” in CY 2019.

Comment: One commenter requested that CMS exempt CPT code 36901 from the office-based designation, similar to the existing office-based exemptions for certain nuclear medicine procedures (CPT codes 78000 through 78999) as well as ancillary radiology services that use a contrast agent as codified under 42 CFR 416.171(d). The commenter suggested that the payment volatility over the past several years would limit patient access to vascular access services in the ASC setting and encourage the migration of these services to the more expensive hospital setting.

Response: We do not believe establishing an office-based exemption for CPT code 36901 is warranted. We note that the exceptions for certain nuclear medicine procedures and for ancillary radiology services that use a contrast agent are exceptions to our policy governing payment for covered ancillary radiology services, not exceptions to our office-based policy. In addition, as stated in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), we established the exemption to our policy governing payment for covered ancillary radiology services for certain nuclear medicine procedures (CPT codes 78000 through 78999) because the PFS nonfacility PE RVU amounts did not reflect the diagnostic radiopharmaceutical costs which are paid separately under the MPFS. In addition, as stated in the CY 2012 OPPS/ASC final rule with comment period (76 FR 74429 through 74430), because the same issue exists for radiology procedures that use contrast agents (the contrast agent is packaged under the ASC payment system but is separately paid under the MPFS), we also exempted radiology services that use contrast agents from this policy, so that payment for these procedures will be based on the OPPS relative payment weight which includes the cost for the contrast agent.

Because its predecessor code was office-based, we have designated CPT code 36901 as office-based since it was established in CY 2017. As stated in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59407), we reviewed the clinical characteristics, utilization, and volume of related codes and determined that the procedure described by CPT code 36901 would be predominantly performed in physician offices. However, because we did not have utilization data for this procedure, we made the office-based designation temporary rather than permanent for CY 2018. Our review of the CY 2017 volume and utilization data indicates that CPT code 36901 is performed 54 percent of the time in physicians’ offices. Our policy is to designate as office-based those procedures that are performed more than 50 percent of the time in physicians’ offices. We do not believe that there is a justification for exempting this procedure from office-based status for CY 2019. Therefore, we are designating CPT code 36901 as permanently office-based for CY 2019 as proposed.

While we assigned CPT codes 10030, 64461, and 64463 payment indicators of “G2” (Non-office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight) in Table 38 of the CY 2019 OPPS/ASC proposed rule, we inadvertently indicated in the preamble of the proposed rule that those were office-based procedures (83 FR 37156). We are not designating CPT codes 10030, 64461, and 64463 as office-based procedures for CY 2019 and are finalizing our payment indicator of “G2” for such procedures. We note that we did not receive any public comments on these codes.

After consideration of the public comments received, we are finalizing our proposal, with modification, to designate the procedures shown in Table 57 below as temporarily office-based for CY 2019.
For CY 2019, we proposed to designate 8 new CY 2019 CPT codes for ASC covered surgical procedures as temporarily office-based, as displayed in Table 39 of the proposed rule. After reviewing the clinical characteristics, utilization, and volume of related procedure codes, we determined that the procedures described by the new CPT codes would be predominantly performed in physicians’ offices. However, because we had no utilization data for the procedures specifically described by these new CPT codes, we proposed to make the office-based designation temporary rather than permanent, and stated that we will reevaluate the procedures when data become available. The procedures for which the proposed office-based designation for CY 2019 is temporary were indicated by asterisks in Addendum AA to the proposed rule (which is available via the internet on the CMS website).

We did not receive any public comments on our proposal. Therefore, we are finalizing our proposal, without modification, to designate the procedures shown in Table 58 below as temporarily office-based. The procedures for which the office-based designation for CY 2019 is temporary are indicated by an asterisk in Addendum AA to this final rule with comment period (which is available via the internet on the CMS website).

<table>
<thead>
<tr>
<th>CY 2019 CPT/HCPCS Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2018 ASC Payment Indicator</th>
<th>CY 2019 ASC Payment Indicator*</th>
</tr>
</thead>
<tbody>
<tr>
<td>38222</td>
<td>Diagnostic bone marrow; biopsy(ies) and aspiration(s)</td>
<td>P3</td>
<td>P3*</td>
</tr>
<tr>
<td>65785</td>
<td>Implantation of intrastral corneal ring segments</td>
<td>P2</td>
<td>P2*</td>
</tr>
<tr>
<td>67229</td>
<td>Treatment of extensive or progressive retinopathy, 1 or more sessions, preterm infant (less than 37 weeks gestation at birth), performed from birth up to 1 year of age (eg, retinopathy of prematurity), photocoagulation or cryotherapy</td>
<td>R2</td>
<td>R2*</td>
</tr>
<tr>
<td>0402T</td>
<td>Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)</td>
<td>R2</td>
<td>R2*</td>
</tr>
</tbody>
</table>

* Payment indicators are based on a comparison of the final rates according to the ASC standard ratesetting methodology and the PFS final rates. Current law specifies a 0.25 percent update to the PFS payment rates for CY 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period.
b. ASC Covered Surgical Procedures To Be Designated as Device-Intensive

(1) Background

As discussed in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79739 through 79740), we implemented a payment methodology for calculating the ASC payment rates for covered surgical procedures that are designated as device-intensive.

According to this ASC payment methodology, we apply the device offset percentage based on the standard OPPS APC ratesetting methodology (which does not include the C–APC methodology) to the OPPS national unadjusted payment to determine the device cost included in the OPPS payment rate for a device-intensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We calculate the service portion of the ASC payment for device-intensive procedures by applying the uniform ASC conversion factor to the service (non-device) portion of the OPPS relative payment weight for the device-intensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device-intensive procedure under the ASC payment system.

We also finalized in the CY 2017 OPPS/ASC final rule that device-intensive procedures will be subject to all of the payment policies applicable to procedures designated as an ASC device-intensive procedure under our established methodology, including our policies on no cost/full credit and partial credit devices and discontinued procedures.

In addition, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79739 through 79740), we adopted a policy for new HCPCS codes describing procedures involving the implantation of medical devices that do not yet have associated claims data, to designate these procedures as device-intensive with a default device offset set at 41 percent until claims data are available to establish the HCPCS code-level device offset for the procedures. This default device offset amount of 41 percent is not calculated from claims data; instead, it is based on a percentage calculated by taking the ratio of the device portion of the OPPS payment rate for the procedure to the total OPPS payment rate for the procedure and rounding to the nearest integer.

**Payment indicators are based on a comparison of the proposed rates according to the ASC standard ratesetting methodology and the PFS final rates. Current law specifies a 0.25 percent update to the PFS payment rates for CY 2019. For a discussion of the MPFS rates, we refer readers to the CY 2019 PFS final rule with comment period.**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>06X1T</td>
<td>0512T</td>
<td>Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound</td>
<td>R2</td>
</tr>
<tr>
<td>10X12</td>
<td>10005</td>
<td>Fine needle aspiration biopsy, including ultrasound guidance; first lesion</td>
<td>P3</td>
</tr>
<tr>
<td>10X14</td>
<td>10007</td>
<td>Fine needle aspiration biopsy, including fluoroscopic guidance; first lesion</td>
<td>P3</td>
</tr>
<tr>
<td>10X16</td>
<td>10009</td>
<td>Fine needle aspiration biopsy, including CT guidance; first lesion</td>
<td>P2</td>
</tr>
<tr>
<td>10X18</td>
<td>10011</td>
<td>Fine needle aspiration biopsy, including MR guidance; first lesion</td>
<td>R2</td>
</tr>
<tr>
<td>11X02</td>
<td>11102</td>
<td>Tangential biopsy of skin (eg, shave, scoop, saucerize, curette); single lesion</td>
<td>P3</td>
</tr>
<tr>
<td>11X04</td>
<td>11104</td>
<td>Punch biopsy of skin (including simple closure, when performed); single lesion</td>
<td>P2</td>
</tr>
<tr>
<td>11X06</td>
<td>11106</td>
<td>Incisional biopsy of skin (eg, wedge) (including simple closure, when performed); single lesion</td>
<td>P3</td>
</tr>
</tbody>
</table>
is applied as a default until claims data are available upon which to calculate an actual device offset for the new code. The purpose of applying the 41-percent default device offset to new codes that describe procedures that involve the implantation of medical devices would be to ensure ASC access for new procedures until claims data become available. However, in certain rare instances, for example, in the case of a very expensive implantable device, we indicated we might temporarily assign a higher offset percentage if warranted by additional information, such as pricing data from a device manufacturer. Once claims data are available for a new procedure involving the implantation of a medical device, the device-intensive designation is applied to the code if the HCPCS code device offset is greater than 40 percent, according to our policy of determining device-intensive status, by calculating the HCPCS code-level device offset.

(2) Changes to List of ASC Covered Surgical Procedures Designated as Device-Intensive for CY 2019

In the CY 2019 OPPS/ASC proposed rule (83 FR 37158), we noted that, as discussed in section IV.B.2. of the proposed rule, for CY 2019 we proposed to modify our criteria for device-intensive procedures to better capture costs for procedures with significant device costs. We proposed to allow procedures that involve surgically inserted or implanted, high-cost, single-use devices to qualify as device-intensive procedures. In addition, we proposed to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. Specifically, for CY 2019 and subsequent years, we proposed that device-intensive procedures would be subject to the following criteria:

- All procedures must involve implantable devices assigned a CPT or HCPCS code.
- The required devices (including single-use devices) must be surgically inserted or implanted; and
- The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost. Corresponding to this change in the cost criterion we proposed that the default device offset for new codes that describe procedures that involve the implantation of medical devices would be 31 percent beginning in CY 2019. For new codes describing procedures that are payable when furnished in an ASC involving the implantation of a medical device, we proposed that the default device offset would be applied in the same manner as proposed in section IV.B.2. of the proposed rule. We proposed to amend §416.171(b)(2) of the regulations to reflect these new device criteria.

In addition, as also proposed in section IV.B.2. of the proposed rule, to further align the device-intensive policy with the criteria used for device pass-through status, we proposed to specify, for CY 2019 and subsequent years, that for purposes of satisfying the device-intensive criteria, a device-intensive procedure must involve a device that:

- Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review;
- Is an integral part of the service furnished;
- Is used for one patient only;
- Comes in contact with human tissue;
- Is surgically implanted or inserted (either permanently or temporarily); and
- Is not any of the following:
  (a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15–1); or
  (b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker).

Based on our proposed modifications to our device-intensive criteria, for CY 2019, we proposed to update the ASC CPL that are eligible for payment according to our proposed device-intensive procedure payment methodology, reflecting the proposed individual HCPCS code device-offset percentages based on CY 2017 OPPS claims and cost report data available for the proposed rule.

The ASC covered surgical procedures that we proposed to designate as device-intensive, and therefore subject to the device-intensive procedure payment methodology for CY 2019, were assigned payment indicator “J8” and were included in ASC Addendum AA to the proposed rule (which is available on the CMS website). The CPT code, the CPT code short descriptor, and the proposed CY 2019 ASC payment indicator, and an indication of whether the full credit/partial credit (FC/PC) device adjustment policy would apply because the procedure is designated as device intensive also are included in Addendum AA to the proposed rule. In addition, for CY 2019, we proposed to only apply our proposed device-intensive procedure payment methodology to device-intensive procedures under the ASC payment system when the device-intensive procedure is furnished with a surgically inserted or implanted device (including single use medical devices). Under this proposal, the payment rate under the ASC payment system for device-intensive procedures furnished without an implantable or inserted medical device would be calculated by applying the uniform ASC conversion factor to both the device portion and service (nondevice) portion of the OPPS relative payment weight for the device-intensive procedure and summing both portions (device and service) to establish the ASC payment rate.

Comment: The majority of commenters supported CMS proposal to lower the device offset percentage threshold for procedures to qualify as device-intensive from greater than 40 percent to greater than 30 percent. The commenters believed that the proposed policy change will encourage migration of services into the high-quality, less-expensive ASC setting, resulting in cost savings to the Medicare program and Medicare beneficiaries. Some of these commenters encouraged CMS to further modify its proposal and instead lower the device offset percentage threshold for procedures to qualify as device-intensive to 25 percent instead of 30 percent.

Response: We appreciate commenters’ support. At this time, we continue to believe that applying a device offset percentage threshold of greater than 30 percent for procedures to qualify as device-intensive is most appropriate for the reasons described in our original proposal. We will take commenters’ suggestion of applying a device offset percentage threshold of greater than 25 percent for procedures to qualify as device-intensive into consideration for future rulemaking.

Comment: The majority of commenters supported CMS proposal to modify the device-intensive criteria to allow procedures that involve single-use devices, regardless of whether they remain in the body after the conclusion of the procedure, to qualify as device-intensive procedures. The commenters believed that this proposed policy change will better support accurate payment for procedures where an implantable device is a significant proportion of total costs and, ultimately, will spur innovation.
Response: We appreciate the commenters’ support.

Comment: One commenter requested that CMS assign device-intensive status, payment indicator “J8”, to CPT codes 0410T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only), 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only), and 0414T (Removal and replacement of permanent cardiac contractility modulation system pulse generator only).

Response: We agree with the commenter’s request and have assigned CPT codes 0410T, 0411T, and 0414T to payment indicator “J8” for CY 2019. These CPT codes represent procedures requiring the implantation of medical devices that do not yet have associated claims data and therefore have been granted device-intensive status with our current default device offset percentage of 31 percent, in accordance with our current policy outlined in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79658).

Comment: A few commenters suggested that CMS only adjust the non-device portion of the payment by the wage index, consistent with the Agency’s policy for separately payable drugs and biologicals.

Response: In response to the commenters’ suggestion that CMS only adjust the non-device portion of the payment by the wage index, we note that such a policy would increase payment for providers with a relatively low wage index (that is, a wage index value of less than 1) and decrease it for providers with a relatively high wage index (that is, a wage index value of greater than 1), and that we did not make such a proposal. However, we will take this comment into consideration for future rulemaking.

Comment: A few commenters urged CMS to calculate the device offset percentage for potential device-intensive procedures using the standard (non-comprehensive APC) ASC ratesetting methodology and to assign device-intensive status in the ASC system based on that device offset percentage because they believed it is more consistent with the overall ASC payment system. One commenter requested inclusion in the final rule with comment period about CMS’ current methodology for calculating the device offset percentage for device-intensive procedures and specifically asked that CMS:

- Confirm that the ASC device-intensive status as assigned by CMS is based on the offset calculated according to the ASC rate setting methodology;
- Disclose what offset data (meaning the calculation methodology used) appears in the second spreadsheet of Addendum P titled “2019 NPRM HCPCS Offsets”.

Response: As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37158), according to our established ASC payment methodology, we apply the device offset percentage based on the standard OPPS APC ratesetting methodology (which does not include the C–APC methodology) to the OPPS national unadjusted payment to determine the device cost included in the OPPS payment rate for a device-intensive ASC covered surgical procedure, which we then set as equal to the device portion of the national unadjusted ASC payment rate for the procedure. We calculate the service portion of the ASC payment for device-intensive procedures by applying the uniform ASC conversion factor to the service (nondevice) portion of the OPPS relative payment weight for the device-intensive procedure. Finally, we sum the ASC device portion and ASC service portion to establish the full payment for the device-intensive procedure under the ASC payment system.

In response to commenter’s questions and suggestions relating to Addendum P, we note that the device offset percentages reflected in both worksheets of Addendum P are based upon the OPPS C–APC methodology. We believe this is appropriate as Addendum P is created to display the device offsets, device offset percentages, and device-intensive codes under the OPPS. Specific to the commenter’s suggestion that we modify the second worksheet of Addendum P titled “2019 NPRM HCPCS Offsets” to only include the codes for procedures that employ implantable and insertable devices and exclude all of the codes that do not employ implantable or insertable devices, we note that the second worksheet of Addendum P is intended to display the device offsets and device offset percentages for all codes for which we have such data for under the OPPS. The applicable device offset percentages for the ASC payment system are included on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/ASC-Policy-Files.html under the revised title of “CY 2019 Final ASC Device Offset Percentages and Procedures to which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies.”

Comment: Commenters supported the existing policy of granting device-intensive status and applying a default device offset to procedures requiring devices that do not yet have claims data, as well as the proposal to use claims data from clinically similar and related codes to establish device offsets for procedures with new codes that do not have direct predecessor codes according to CPT.

Response: We appreciate the commenters’ support.

Comment: Commenters supported CMS’ proposed device-intensive status for CPT codes:

- 28297 (Correction, hallux valgus (bunionectomy), with sesamoidectomy, when performed; with first metatarsal and medial cuneiform joint arthrodesis, any method);
- 28730 (Arthrodesis, midtarsal or tarsometatarsal, multiple or transverse); 28740 (Arthrodesis, midtarsal or tarsometatarsal, single joint);
- 36903 (Introduction of needle(s) and/or catheter(s), dialysis circuit, with diagnostic angiography of the dialysis circuit, including all direct puncture(s) and catheter placement(s), injection(s) of contrast, all necessary imaging from the arterial anastomosis and adjacent artery through entire venous outflow including the inferior or superior vena cava, fluoroscopic guidance, radiological supervision and interpretation and image documentation and report; with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis segment); 36904 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic
angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s); and

• 36906 (Percutaneous transluminal mechanical thrombectomy and/or infusion for thrombolysis, dialysis circuit, any method, including all imaging and radiological supervision and interpretation, diagnostic angiography, fluoroscopic guidance, catheter placement(s), and intraprocedural pharmacological thrombolytic injection(s); with transcatheter placement of intravascular stent(s), peripheral dialysis segment, including all imaging and radiological supervision and interpretation necessary to perform the stenting, and all angioplasty within the peripheral dialysis circuit).

Other commenters requested that CMS assign device-intensive status to—

• HCPCS code C9747 (Ablation of prostate, transrectal, high intensity focused ultrasound (hifu), including imaging guidance);
• CPT code 43210 (Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed), 0275T (Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (e.g., fluoroscopic, ct), single or multiple levels, unilateral or bilateral; lumbar);
• CPT code 55874 (Transperineal placement of biodegradable material, peri-prostatic, single or multiple injection(s), including image guidance, when performed);
• CPT code 0409T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only);
• CPT code 0411T (Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only);
• CPT code 0414T (Removal and replacement of permanent cardiac contractility modulation system pulse generator only).

Response: We appreciate the commenters’ support. With respect to the commenters’ request that we assign the device-intensive designation to HCPCS code C9747 and CPT codes 43210, 0275T, and 55874, we note that the device offset percentage for all four of these procedures (as identified by the above mentioned HCPCS codes or predecessor codes) is not above the 30-percent threshold, and therefore these procedures are not eligible to be assigned device-intensive status.

CPT codes 0409T, 0410T, 0411T, and 0414T were inadvertently omitted from the listing of proposed device-intensive procedures in the CY 2019 OPPS/ASC proposed rule. We are including them as device-intensive procedures in this final rule with comment period. CPT code 36904 was proposed as a device-intensive procedure. However, using the most currently available data for this CY 2019 OPPS/ASC final rule with comment period, we determined that its device offset percentage is not above the 30-percent threshold, and therefore this procedure is not eligible to be assigned device-intensive status.

For new codes describing procedures that are payable when furnished in an ASC involving the implantation of a medical device, we proposed that the default device offset would be applied in the same manner as proposed in section IV.B.2. of the proposed rule.

In addition, as also discussed in section IV.B.2. of this final rule with comment period, to further align the device-intensive policy with the criteria used for device pass-through payment status, we are finalizing our proposal to specify, for CY 2019 and subsequent years, that for purposes of satisfying the device-intensive criteria, a device-intensive procedure must involve a device that:

• Has received FDA marketing authorization, has received an FDA investigational device exemption (IDE) and has been classified as a Category B device by the FDA in accordance with 42 CFR 405.203 through 405.207 and 405.211 through 405.215, or meets another appropriate FDA exemption from premarket review;

• Is an integral part of the service furnished:

  • Is used for one patient only;
  • Comes in contact with human tissue;
  • Is surgically implanted or inserted (either permanently or temporarily); and
  • Is not any of the following:

    (a) Equipment, an instrument, apparatus, implement, or item of this type for which depreciation and financing expenses are recovered as depreciable assets as defined in Chapter 1 of the Medicare Provider Reimbursement Manual (CMS Pub. 15–1); or

  (b) A material or supply furnished incident to a service (for example, a suture, customized surgical kit, scalpel, or clip, other than a radiological site marker).

In conjunction with our modifications to the device-intensive criteria, we are finalizing our proposal, without modification, to amend § 416.171(b)(2) of the regulations to reflect three new device criteria.

After consideration of the public comments we received, we are finalizing our proposal to modify our criteria for device-intensive procedures to better capture costs for procedures with significant device costs. We are finalizing our proposal to allow procedures that involve surgically inserted or implanted, high-cost, single-use devices to qualify as device-intensive procedures. In addition, we are finalizing our proposal to modify our criteria to lower the device offset percentage threshold from 40 percent to 30 percent. Specifically, for CY 2019 and subsequent years, we are finalizing our proposal that device-intensive procedures would be subject to the following criteria:

• All procedures must involve implantable devices assigned a CPT or HCPCS code;
• The required devices (including single-use devices) must be surgically inserted or implanted;
• The device offset amount must be significant, which is defined as exceeding 30 percent of the procedure’s mean cost. Corresponding to this change in the cost criterion we proposed that the default device offset for new codes that describe procedures that involve the implantation of medical devices would be 31 percent beginning in CY 2019.

Further, after consideration of the public comments we received, we are finalizing the ASC covered surgical procedures displayed in Addendum AA as device-intensive and subject to the device-intensive procedure payment methodology for CY 2019.

c. Adjustment to ASC Payments for No Cost/Full Credit and Partial Credit Devices

Our ASC payment policy for costly devices implanted in ASCs at no cost/ full credit or partial credit, as set forth in §416.179 of our regulations, is consistent with the OPPS policy that was in effect until CY 2014. Specifically, the OPPS policy that was
in effect through CY 2013 provided a reduction in OPPS payment by 100 percent of the device offset amount when a hospital furnishes a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital receives partial credit in the amount of 50 percent or more of the cost for the specified device (77 FR 68356 through 68358). The established ASC policy reduces payment to ASCs when a specified device is furnished without cost or with full credit or partial credit for the cost of the device for those ASC covered surgical procedures that are assigned to APCs under the OPPS to which this policy applies. We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68742 through 68744) for a full discussion of the ASC payment adjustment policy for no cost/full credit and partial credit devices.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37159), we noted that, as discussed in section IV.B. of the CY 2014 OPPS/ASC final rule with comment period (78 FR 75005 through 75006), we finalized our proposal to modify our former policy of reducing OPPS payment for specified APCs when a hospital furnishes a specified device without cost or with a full or partial credit. Formerly, under the OPPS, our policy was to reduce OPPS payment by 100 percent of the device offset amount when a hospital furnished a specified device without cost or with a full credit and by 50 percent of the device offset amount when the hospital received partial credit in the amount of 50 percent or more (but less than 100 percent) of the cost for the specified device. For CY 2014, we finalized our proposal to reduce OPPS payment for applicable APCs by the full or partial credit a provider receives for a replaced device, capped at the device offset amount.

Although we finalized our proposal to modify the policy of reducing payments when a hospital furnishes a specified device without cost or with full or partial credit under the OPPS, in that final rule with comment period (78 FR 75076 through 75080), we finalized our proposal to maintain our ASC policy for reducing payments to ASCs for specified device-intensive procedures when the ASC furnishes a device without cost or with full or partial credit. Unlike the OPPS, there is currently no mechanism within the ASC claims processing system for ASCs to submit to CMS the actual credit received when furnishing a specified device at full or partial credit. Therefore, under the ASC payment system, we finalized our proposal for CY 2014 to continue to reduce ASC payments by 100 percent or 50 percent of the device offset amount when an ASC furnishes a device without cost or with full or partial credit, respectively.

All ASC covered device-intensive procedures are subject to the no cost/full credit and partial credit device adjustment policy. Specifically, when a device-intensive procedure is performed to implant a device that is furnished at no cost or with full credit from the manufacturer, the ASC would append the HCPCS “FB” modifier on the line in the claim with the procedure to implant the device. The contractor would reduce payment to the ASC by the device offset amount that we estimate represents the cost of the device when the necessary device is furnished without cost or with full credit to the ASC. We continue to believe that the reduction of ASC payment in these circumstances is necessary to pay appropriately for the covered surgical procedure furnished by the ASC.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37159 through 37160), for partial credit, we proposed to reduce the payment for a device-intensive procedure for which the ASC receives partial credit by one-half of the device offset amount that would be applied if a device was provided at no cost or with full credit, if the credit to the ASC is 50 percent or more (but less than 100 percent) of the cost of the new device. The ASC would append the HCPCS “FC” modifier to the HCPCS code for the device-intensive surgical procedure when the device receives a partial credit of 50 percent or more (but less than 100 percent) of the cost of a device. To report that the ASC received a partial credit of 50 percent or more (but less than 100 percent) of the cost of a new device, ASCs would have the option of either: (1) Submitting the claim for the device replacement procedure to their Medicare contractor after the procedure’s performance, but prior to manufacturer acknowledgment of credit for the device, and subsequently contacting the contractor regarding a claim adjustment, once the credit determination is made; or (2) holding the claim for the device implantation procedure until a determination is made by the manufacturer on the partial credit and submitting the claim with the “FC” modifier appended to the implantation procedure HCPCS code if the partial credit is 50 percent or more (but less than 100 percent) of the cost of the replacement device. Beneficiary coinsurance would be based on the reduced payment amount. As finalized in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66926), to ensure our policy covers any situation involving a device-intensive procedure where an ASC may receive a device at no cost or receive full credit or partial credit for the device, we apply our “FB”/“FC” modifier policy to all device-intensive procedures.

We did not receive any public comment on these proposals. Therefore, we are finalizing these proposals without modification. Specifically, we will apply the HCPCS “FB”/“FC” modifier policy to all device-intensive procedures in CY 2019. For CY 2019, we will reduce the payment for the procedures in the ASC device adjustment file by the full device offset amount if a device is furnished without cost or with full credit. ASCs must append the HCPCS modifier “FB” to the HCPCS code for a surgical procedure listed in the ASC device adjustment file previously mentioned when the device is furnished without cost or with full credit. In addition, for CY 2019, we will reduce the payment for the procedures listed in the ASC device adjustment file by one-half of the device offset amount if a device is provided with partial credit, if the credit to the ASC is 50 percent or more (but less than 100 percent) of the device cost. The ASC must append the HCPCS “FC” modifier to the HCPCS code for a surgical procedure listed in the ASC device adjustment file when facility receives a partial credit of 50 percent or more (but less than 100 percent) of the cost of a device.

The CPT code, the CPT code short descriptor, the final CY 2019 ASC payment indicator, and an indication of whether the full credit/partial credit (FB/FC) device adjustment policy will apply are included in the ASC policy file labeled “CY 2019 Final ASC Device Offset Percentages and Procedures to which the No Cost/Full Credit and Partial Credit Device Adjustment Policy Applies”, which is available via the internet on the CMS website at: https://www.cms.gov/Medicare?medicare-Fee-for-Service-Payment/ASCPayment/ASC-Policy-Files.html.

d. Additions to the List of ASC Covered Surgical Procedures

As discussed in section XII.A.3. of the proposed rule (83 FR 37159), we proposed to revise our definition of surgery for CY 2019 to include certain “surgery-like” procedures that are assigned codes outside the CPT surgical range. For CY 2019, we proposed to include procedures that are described by Category I CPT codes that are not in the surgical range but directly crosswalk or are clinically similar to procedures in
the Category I CPT code surgical range that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS. We also are continuing to include in our definition of surgical procedures those procedures described by Category I CPT codes in the surgical range from 10000 through 69999 as well as those Category III CPT codes and Level II HCPCS codes that directly crosswalk or are clinically similar to procedures in the CPT surgical range that we have determined do not pose a significant safety risk, that we would not expect to require an overnight stay when performed in ASCs, and that are separately paid under the OPPS. As discussed in section X.I.A.3. of this final rule with comment period, we are finalizing our proposal to revise our definition of “surgery” for CY 2019 and subsequent years to include procedures that are described by Category I CPT codes that are not in the CPT surgical range but directly crosswalk or are clinically similar to procedures in the Category I CPT code surgical range that we have determined do not pose a significant safety risk, would not be expected to require an overnight stay when performed in an ASC, and are separately paid under the OPPS.

We conducted a review of HCPCS codes that currently are paid under the OPPS, but not included on the ASC CPL, and that meet our proposed definition of surgery to determine if changes in technology and/or medical practice affected the clinical appropriateness of these procedures for the ASC setting. Based on this review, we proposed to update the list of ASC covered surgical procedures by adding 12 cardiac catheterization procedures to the list for CY 2019, as shown in Table 40 of the proposed rule (83 FR 37160). After reviewing the clinical characteristics of these procedures and consulting with stakeholders and our clinical advisors, we determined that these 12 procedures are separately paid under the OPPS, would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, and would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure. Our regulation at 42 CFR 416.166(c) lists general exclusions from the list of ASC covered surgical procedures based primarily on factors relating to safety, including procedures that generally result in extensive blood loss, require major or prolonged invasion of body cavities, or directly involve major blood vessels. We have assessed each of the proposed added procedures against the regulatory safety criteria and believe that these procedures meet each of the criteria. Although the proposed cardiac catheterization procedures may involve blood vessels that could be considered major, based on our review of the clinical characteristics of the procedures and their similarity to other procedures that are currently included on the ASC CPL, we believe these procedures may be appropriately performed in an ASC. Therefore, we proposed to include these 12 procedures on the list of ASC covered surgical procedures for CY 2019.

As stated in the August 2, 2007 ASC final rule (72 FR 42481), we believe the involvement of major blood vessels is best considered in the context of the clinical characteristics of individual procedures, and we do not believe that it is logically or clinically consistent to exclude certain cardiac procedures from the list of ASC covered surgical procedures on the basis of the involvement of major blood vessels, yet continue to provide ASC payment for similar procedures involving major blood vessels that have a history of safe performance in ASCs, such as CPT code 36473 (Mechanicochemical destruction of insufficient vein of arm or leg, accessed through the skin using imaging guidance) and CPT code 37223 (Insertion of stents into groin artery, endovascular, accessed through the skin or open procedure). However, in the CY 2019 proposed rule, we stated that we were interested in hearing any specific safety concerns from stakeholders regarding these 12 cardiac catheterization procedures and requested comments on whether these procedures may be safely performed in an ASC in light of the regulatory criteria governing which procedures may be added to the ASC covered procedures list.

Comment: The majority of commenters supported the proposal to add 12 cardiac catheterization procedures to the list of ASC covered surgical procedures. Commenters noted that these procedures may be performed in a physician office setting, would not inherently pose a significant risk to beneficiary safety or require active medical monitoring at midnight following the procedure, and are regularly performed on commercial patients in the ASC setting. The commenters also noted that many of these services are currently provided in a hospital outpatient setting and, therefore, the Medicare program and beneficiaries would achieve savings to the extent such services migrate to the ASC setting.

Some commenters were concerned that the proposal would expose beneficiaries to significant risks. The commenters noted that certain cardiac catheterization procedures may reveal blockages in the coronary arteries that require an immediate intervention involving hospital-level care. One commenter requested that CMS ensure that the same facility standards that apply to hospital-based cardiac catheterization laboratories also apply to ASCs performing these services. The commenter further stated that CMS should not add any cardiac catheterization procedures to the list of ASC covered services until it has ensured that the conditions of coverage and accreditation requirements that would be applied to ASCs furnishing such services are at least as stringent as the standards applied to hospital cardiac catheterization labs, with additional attention to the issues created by engaging in procedures involving the major vessels and the heart without the immediate accessibility of the facilities of an acute care hospital. In addition, the commenters suggested that the proposal may lead to “cherry-picking” with a sicker, more complex, and higher cost patient population being treated in the hospital outpatient setting.

Response: We appreciate the commenters’ support. We disagree with the commenters that our proposal to add 12 cardiac catheterization procedures would expose beneficiaries to significant risks. As noted by many of the commenters, many of these procedures are already performed safely in the physician’s office setting. The procedures have been reviewed by CMS medical officers and we have assessed each against the regulatory safety criteria and believe that they meet all of those criteria. Further, we believe these procedures are clinically similar to peripheral endovascular procedures which are already currently included on the ASC CPL.

As stated in the proposed rule, although the proposed cardiac catheterization procedures may involve blood vessels that could be considered major, based on our review of the clinical characteristics of the procedures and their similarity to other procedures that are currently included on the ASC CPL, we believe these procedures may be appropriately performed in an ASC. While we acknowledge that it may be more appropriate for certain beneficiaries to receive these procedures in a hospital-level setting, which typically have a greater range of items and services available when compared...
to an ASC setting, including onsite cardiac surgery backup, we believe that many beneficiaries could be ideal candidates to receive these services in an ASC setting and that beneficiaries and their physicians should be able to choose an appropriate site of service for surgeries based on the clinical characteristics of the patient and other factors. We also note that our conditions of coverage for ASCs, including 42 CFR 416.42, require surgical procedures to be performed in a safe manner by qualified physicians who have been granted clinical privileges by the governing body of the ASC in accordance with approved policies and procedures of the ASC.

While we agree with commenters that a relatively healthier and less complex Medicare patient population would, in general, be a more ideal patient population to receive cardiac catheterization procedures in an ASC setting, we disagree that we should prohibit such procedures on that basis. We believe that relatively healthy and less complex patients would benefit from the shorter length of stay and reduced cost-sharing that would be expected in an ASC setting.

Comment: Commenters recommended that CMS add additional cardiovascular procedures that are related to the proposed additions to the ASC CPL. The commenters’ recommended codes are shown in Table 59 below.

BILLING CODE 4120–01–P
### TABLE 59.—CARDIOVASCULAR PROCEDURES REQUESTED BY COMMENTERS FOR ADDITION TO THE CY 2019 LIST OF ASC COVERED SURGICAL PROCEDURES

<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>92920</td>
<td>Percutaneous transluminal coronary angioplasty; single major coronary artery or branch</td>
</tr>
<tr>
<td>92921</td>
<td>Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>92924</td>
<td>Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch</td>
</tr>
<tr>
<td>92928</td>
<td>Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch</td>
</tr>
<tr>
<td>92929</td>
<td>Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>92937</td>
<td>Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel</td>
</tr>
<tr>
<td>92938</td>
<td>Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>92960</td>
<td>Cardioversion, elective, electrical conversion of arrhythmia; external</td>
</tr>
<tr>
<td>92973</td>
<td>Percutaneous transluminal coronary thrombectomy mechanical (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>92978</td>
<td>Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; initial vessel (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>92979</td>
<td>Endoluminal imaging of coronary vessel or graft using intravascular ultrasound (ivus) or optical coherence tomography (oct) during diagnostic evaluation and/or therapeutic intervention including imaging supervision, interpretation and report; each additional vessel (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>93282</td>
<td>Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; single lead transvenous implantable defibrillator system</td>
</tr>
<tr>
<td>93284</td>
<td>Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional; multiple lead transvenous implantable defibrillator system</td>
</tr>
<tr>
<td>93312</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report</td>
</tr>
<tr>
<td>93313</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); placement of transesophageal probe only</td>
</tr>
<tr>
<td>93315</td>
<td>Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
</tr>
<tr>
<td>93316</td>
<td>Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only</td>
</tr>
<tr>
<td>93463</td>
<td>Pharmacologic agent administration (eg, inhaled nitric oxide, intravenous infusion of nitroprusside, dobutamine, milrinone, or other agent) including assessing hemodynamic measurements before, during, after and repeat pharmacologic agent administration, when performed (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93464</td>
<td>Physiologic exercise study (eg, bicycle or arm ergometry) including assessing hemodynamic measurements before and after (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93505</td>
<td>Endomyocardial biopsy</td>
</tr>
<tr>
<td>93530</td>
<td>Right heart catheterization, for congenital cardiac anomalies</td>
</tr>
<tr>
<td>93531</td>
<td>Combined right heart catheterization and retrograde left heart catheterization, for congenital cardiac anomalies</td>
</tr>
<tr>
<td>93532</td>
<td>Combined right heart catheterization and transseptal left heart catheterization through intact septum with or without retrograde left heart catheterization, for congenital cardiac anomalies</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>93533</td>
<td>Combined right heart catheterization and transseptal left heart catheterization through existing septal opening, with or without retrograde left heart catheterization, for congenital cardiac anomalies</td>
</tr>
<tr>
<td>93561</td>
<td>Indicator dilution studies such as dye or thermodilution, including arterial and/or venous catheterization; with cardiac output measurement (separate procedure)</td>
</tr>
<tr>
<td>93562</td>
<td>Indicator dilution studies such as dye or thermodilution, including arterial and/or venous catheterization; subsequent measurement of cardiac output</td>
</tr>
<tr>
<td>93563</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective coronary angiography during congenital heart catheterization (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93564</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective opacification of aortocoronary venous or arterial bypass graft(s) (eg, aortocoronary saphenous vein, free radial artery, or free mammary artery graft) to one or more coronary arteries and in situ arterial conduits (eg, internal mammary), whether native or used for bypass to one or more coronary arteries during congenital heart catheterization, when performed (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93565</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective left ventricular or left atrial angiography (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93566</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93567</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93568</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>93571</td>
<td>Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>93572</td>
<td>Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>C9600</td>
<td>Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch</td>
</tr>
<tr>
<td>C9601</td>
<td>Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>C9602</td>
<td>Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch</td>
</tr>
<tr>
<td>C9603</td>
<td>Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>C9604</td>
<td>Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel</td>
</tr>
<tr>
<td>C9605</td>
<td>Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

Response: We appreciate the commenters’ recommendations for procedures that may be suitable candidates for addition to the list of ASC covered surgical procedures. We have reviewed the recommended procedures and believe some procedures would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure, and are separately paid under the OPPS. Therefore, we are accepting the commenters’ recommendation, in part, to include the following procedures to our list of ASC covered surgical procedures:

- CPT code 93566 (Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure));
- CPT code 93567 (Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure));
- CPT code 93568 (Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure));
- CPT code 93571 (Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (list separately in addition to code for primary procedure));
- CPT code 93572 (Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (list separately in addition to code for primary procedure)).

However, we do not believe that the remaining procedures displayed in Table 59 above meet the criteria to be added to the ASC CPL. If new evidence, clinical studies, or data become available that may support adding such procedures to the ASC CPL, we will
consider the commenters’ recommendations in future rulemaking.

Comment: Commenters recommended that CMS add several additional procedures to the covered surgical procedures list that were not proposed to be added to the ASC CPL. These included discography, wound therapy, joint replacement, urological, gastroenterological, and peripheral arterial disease diagnostic procedures. Some commenters suggested that any procedure that is payable under the OPPS should automatically be added to the ASC CPL.

Response: We appreciate the commenters’ recommendations. Based on our review, we did not determine that any of these procedures should be added to the ASC CPL for CY 2019, however, we recognize that ongoing review is necessary to determine if changes in technology and/or medical practice affect the clinical appropriateness of these procedures for the ASC setting. Accordingly, while we are not adding the recommended procedures to the ASC CPL for CY 2019, we will take these public comments into consideration in future rulemaking.

With respect to automatically adding procedures that are payable under the OPPS, we note that we must evaluate each procedure against the regulatory criteria for inclusion on the ASC CPL; therefore, we are not accepting this recommendation.

After consideration of the public comments we received, we are finalizing our proposal to add 12 cardiac catheterization procedures to the list of ASC covered surgical procedures. In addition, based on public comments, we are adding five procedures performed during cardiac catheterization procedures to the list of ASC covered surgical procedures (CPT codes 93566, 93567, 93568, 93571, and 93572). We believe these procedures would not be expected to pose a significant risk to beneficiary safety when performed in an ASC, would not be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure and are separately paid under the OPPS. The 17 procedures that we are adding to the ASC CPL, including the long code descriptors and the final CY 2019 payment indicators, are displayed in Table 60 below.
<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2019 ASC Payment Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>93451</td>
<td>Right heart catheterization including measurement(s) of oxygen saturation and cardiac output, when performed</td>
<td>G2</td>
</tr>
<tr>
<td>93452</td>
<td>Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed</td>
<td>G2</td>
</tr>
<tr>
<td>93453</td>
<td>Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging supervision and interpretation, when performed</td>
<td>G2</td>
</tr>
<tr>
<td>93454</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation;</td>
<td>G2</td>
</tr>
<tr>
<td>93455</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography</td>
<td>G2</td>
</tr>
<tr>
<td>93456</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right heart catheterization</td>
<td>G2</td>
</tr>
<tr>
<td>93457</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) including intraprocedural injection(s) for bypass graft angiography and right heart catheterization</td>
<td>G2</td>
</tr>
<tr>
<td>93458</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed</td>
<td>G2</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2019 ASC Payment Indicator</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>93459</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography</td>
<td>G2</td>
</tr>
<tr>
<td>93460</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed</td>
<td>G2</td>
</tr>
<tr>
<td>93461</td>
<td>Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed, catheter placement(s) in bypass graft(s) (internal mammary, free arterial, venous grafts) with bypass graft angiography</td>
<td>G2</td>
</tr>
<tr>
<td>93462</td>
<td>Left heart catheterization by transseptal puncture through intact septum or by transapical puncture (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
<tr>
<td>93566</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for selective right ventricular or right atrial angiography (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
<tr>
<td>93567</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for supravalvular aortography (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
<tr>
<td>93568</td>
<td>Injection procedure during cardiac catheterization including imaging supervision, interpretation, and report; for pulmonary angiography (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
</tbody>
</table>
Table 41: ASC Procedural Procedures

<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2019 ASC Payment Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>93571</td>
<td>Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; initial vessel (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
<tr>
<td>93572</td>
<td>Intravascular doppler velocity and/or pressure derived coronary flow reserve measurement (coronary vessel or graft) during coronary angiography including pharmacologically induced stress; each additional vessel (list separately in addition to code for primary procedure)</td>
<td>N1</td>
</tr>
</tbody>
</table>

Section 1833(i)(1) of the Act requires us to specify, in consultation with appropriate medical organizations, surgical procedures that are appropriately performed on an inpatient basis in a hospital but that can be safely performed in an ASC, a CAH, or a HOPD and to review and update the list of ASC procedures at least every 2 years. As noted in section XII.C.1. of the CY 2019 OPPS/ASC proposed rule, we evaluate the ASC covered procedures list (ASC CPL) each year to determine whether procedures should be added or removed from the list, and changes to the list are often made in response to specific concerns raised by stakeholders. Often, when a procedure is added to the ASC CPL, the provider community has limited experience in performing the procedure on the Medicare population, even if providers have greater experience with other patient populations. Because ASCs generally provide a subset of items and services that are offered by hospitals and because Medicare beneficiaries tend to be older and exhibit a higher number of comorbidities than other populations, we believe it may be appropriate to reevaluate recently added procedures.

Specifically, in the CY 2019 OPPS/ASC proposed rule (83 FR 37161 through 37162), we proposed to review all procedures that were added to the ASC CPL within the 3 calendar years prior to the year in which we are engaging in rulemaking to assess the safety, effectiveness, and beneficiary experience of these newly added procedures when performed in the ASC setting. Our review began with procedures added to the ASC CPL in CYs 2015, 2016, and 2017, to assess whether newly added procedures continue to meet our criteria, including whether they continue not to be expected to pose a significant safety risk to a Medicare beneficiary when performed in an ASC and continue not to be expected to require active medical monitoring and care of the beneficiary at midnight following the procedure. This review included taking into account recent clinical developments and available safety findings related to the recently added procedures.

We proposed to review all 38 procedures that were added to the ASC CPL for CYs 2015, 2016, and 2017. The 38 procedures that were added to the ASC CPL during this time were displayed in Table 41 of the proposed rule (82 FR 37161 through 37162), along with their HCPCS code long descriptors, the CY 2018 payment indicators, and the calendar year that each procedure was added to the ASC CPL. We also sought public comment about these recently added procedures from members of the public, including Medicare beneficiaries, ASCs, and physicians performing these procedures in the ASC setting. In addition, we sought public comment on whether these procedures continue to meet the criteria to remain on the ASC CPL. We stated our intent to evaluate each of these 38 procedures using all available data, including clinical characteristics, utilization reflected in ASC claims and pricing data, prevailing medical practice, and any public comments we received to determine whether they continue to meet the criteria to be a covered surgical procedure.

In addition, we solicited public comment regarding how our systematic review should be structured in the future, including the length of time procedures should be considered recently added, how frequently reviews should be performed in light of the time required to accumulate meaningful data and whether any future reviews should examine procedures added during a period of time greater or less than the previous 3 completed calendar years.

Comment: Many commenters supported the proposal to review procedures that were recently added to the ASC CPL. A number of commenters (patients and providers) noted that the procedures shown in Table 41 of the proposed rule can be safely and effectively performed in an ASC setting and recommended retaining the procedures on the ASC CPL. One commenter also noted that CPT codes 0171T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level) and 0172T (Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level) were deleted as of January 1, 2017.

A number of commenters believed there may not be enough data on the 38 procedures to adequately assess if the procedures continue to meet the criteria to remain on the ASC CPL. The commenters recommended reviewing procedures on the CPL after the procedure has been added to the CPL for a minimum of 3 to 5 years.

Further, commenters requested additional information regarding the methodology and supporting materials that CMS would use to determine that a procedure should no longer remain on the ASC CPL. The commenters requested that stakeholders receive appropriate notice that CMS is
proposing to remove a procedure so that stakeholders have an opportunity to comment.

Response: We appreciate the commenters’ feedback regarding the safety and efficacy of these procedures in the ASC setting. We note that we did not receive any public comments in support of removing these recently added procedures from the ASC CPL.

We note that CPT codes 0171T and 0172T were inadvertently included in Table 41 of the proposed rule. These codes were deleted effective January 1, 2017, and no longer remain on the ASC CPL. In our evaluation of the remaining 36 procedures, we did not find any clinical evidence, data, or other materials to justify removing these procedures from the ASC CPL. Therefore, for CY 2019, we are not removing any of the remaining 36 procedures displayed in Table 41 of the proposed rule from the ASC CPL.

In response to commenters’ recommendation to wait a minimum of 3 to 5 years to assess whether a procedure meets our criteria to remain on the ASC CPL, we agree that a longer timeframe may provide better data to adequately determine whether or not the procedure meets our criteria. We will consider the commenters’ recommendations in future rulemaking.

In response to the commenters’ request for additional information regarding the methodology and supporting materials that we would use to determine that a procedure no longer meets the criteria to remain on the ASC CPL, we note that in the CY 2019 OPPS/ASC proposed rule (83 FR 37161), we stated our intent to evaluate each of the procedures using all available data, including clinical characteristics, utilization reflected in ASC claims and pricing data, prevailing medical practice, and any public comments we receive.

After consideration of the public comments we received, we are retaining the procedures displayed in Table 61 on the ASC CPL for CY 2019, with the exception of CPT codes 0171T and 0172T, which were deleted from the ASC CPL effective January 1, 2017 and, therefore, will not be included on the ASC CPL for CY 2019. However, based on the public comments we received about the re-review process generally, we do not believe it is necessary to finalize any proposal regarding ongoing reviews of recently added procedures at this time. Rather, we will take all commenters’ suggestions into account as we consider future refinements to our review of the ASC CPL.

BILLING CODE 4120–01–P
### TABLE 61.—ADDITIONS TO THE LIST OF ASC COVERED SURGICAL PROCEDURES FOR CY 2015, 2016, AND 2017

<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2018 ASC Payment Indicator</th>
<th>Calendar Year Added to ASC CPL</th>
<th>ASC CPL Review Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>0171T</td>
<td>Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; single level</td>
<td>J8</td>
<td>2016</td>
<td>CPT code deleted</td>
</tr>
<tr>
<td>0172T</td>
<td>Insertion of posterior spinous process distraction device (including necessary removal of bone or ligament for insertion and imaging guidance), lumbar; each additional level</td>
<td>N1</td>
<td>2016</td>
<td>CPT code deleted</td>
</tr>
<tr>
<td>20936</td>
<td>Autograft for spine surgery only (includes harvesting the graft); local (eg, ribs, spinous process, or laminar fragments) obtained from same incision (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>20937</td>
<td>Autograft for spine surgery only (includes harvesting the graft); morselized (through separate skin or fascial incision) (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>20938</td>
<td>Autograft for spine surgery only (includes harvesting the graft); structural, bicortical or tricortical (through separate skin or fascial incision) (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2018 ASC Payment Indicator</td>
<td>Calendar Year Added to ASC CPL</td>
<td>ASC CPL Review Results</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>--------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>22551</td>
<td>Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2</td>
<td>J8</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22552</td>
<td>Arthrodesis, anterior interbody, including disc space preparation, discectomy, osteophytectomy and decompression of spinal cord and/or nerve roots; cervical below c2, each additional interspace (list separately in addition to code for separate procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22554</td>
<td>Arthrodesis, anterior interbody technique, including minimal discectomy to prepare interspace (other than for decompression); cervical below c2</td>
<td>J8</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22612</td>
<td>Arthrodesis, posterior or posterolateral technique, single level; lumbar (with lateral transverse technique, when performed)</td>
<td>J8</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22614</td>
<td>Arthrodesis, posterior or posterolateral technique, single level; each additional vertebral segment (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22840</td>
<td>Posterior non-segmental instrumentation (eg, harrington rod technique, pedicle fixation across 1 interspace, atlantoaxial transarticular screw fixation, sublaminar wiring at c1, facet screw fixation) (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2018 ASC Payment Indicator</td>
<td>Calendar Year Added to ASC CPL</td>
<td>ASC CPL Review Results</td>
</tr>
<tr>
<td>------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>22842</td>
<td>Posterior segmental instrumentation (eg, pedicle fixation, dual rods with multiple hooks and sublaminar wires); 3 to 6 vertebral segments (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22845</td>
<td>Anterior instrumentation; 2 to 3 vertebral segments (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22853</td>
<td>Insertion of interbody biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to intervertebral disc space in conjunction with interbody arthrodesis, each interspace (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>22854</td>
<td>Insertion of intervertebral biomechanical device(s) (eg, synthetic cage, mesh) with integral anterior instrumentation for device anchoring (eg, screws, flanges), when performed, to vertebral corpectomy(ies) (vertebral body resection, partial or complete) defect, in conjunction with interbody arthrodesis, each contiguous defect (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2018 ASC Payment Indicator</td>
<td>Calendar Year Added to ASC CPL</td>
<td>ASC CPL Review Results</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>22859</td>
<td>Insertion of intervertebral biomechanical device(s) (e.g., synthetic cage, mesh, methylmethacrylate) to intervertebral disc space or vertebral body defect without interbody arthrodesis, each contiguous defect (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2017</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>37241</td>
<td>Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (e.g., congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)</td>
<td>J8</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>37242</td>
<td>Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; arterial, other than hemorrhage or tumor (e.g., congenital or acquired arterial malformations, arteriovenous malformations, arteriovenous fistulas, aneurysms, pseudoaneurysms)</td>
<td>J8</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2018 ASC Payment Indicator</td>
<td>Calendar Year Added to ASC CPL</td>
<td>ASC CPL Review Results</td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------</td>
<td>------------------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>37243</td>
<td>Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction</td>
<td>J8</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>49406</td>
<td>Image-guided fluid collection drainage by catheter (eg, abscess, hematoma, seroma, lymphoceles, cyst); peritoneal or retroperitoneal, percutaneous</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>57120</td>
<td>Colpocleisis (le fort type)</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>57310</td>
<td>Closure of urethrovaginal fistula;</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58260</td>
<td>Vaginal hysterectomy, for uterus 250 g or less;</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58262</td>
<td>Vaginal hysterectomy, for uterus 250 g or less; with removal of tube(s), and/or ovary(s)</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58543</td>
<td>Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g;</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58544</td>
<td>Laparoscopy, surgical, supracervical hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58553</td>
<td>Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g;</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>58554</td>
<td>Laparoscopy, surgical, with vaginal hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>CY 2019 CPT Code</td>
<td>CY 2019 Long Descriptor</td>
<td>CY 2018 ASC Payment Indicator</td>
<td>Calendar Year Added to ASC CPL</td>
<td>ASC CPL Review Results</td>
</tr>
<tr>
<td>------------------</td>
<td>----------------------------------------------------------------------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>58573</td>
<td>Laparoscopy, surgical, with total hysterectomy, for uterus greater than 250 g; with removal of tube(s) and/or ovary(s)</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63020</td>
<td>Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, cervical</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63030</td>
<td>Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc; 1 interspace, lumbar</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63042</td>
<td>Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; lumbar</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63044</td>
<td>Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and/or excision of herniated intervertebral disc, reexploration, single interspace; each additional lumbar interspace (list separately in addition to code for primary procedure)</td>
<td>N1</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
</tbody>
</table>
## Covered Ancillary Services

In the CY 2019 OPPS/ASC proposed rule (83 FR 37163), consistent with the established ASC payment system policy (72 FR 42497), we proposed to update the ASC list of covered ancillary services to reflect the payment status for the services under the CY 2019 OPPS.

Maintaining consistency with the OPPS may result in proposed changes to ASC payment indicators for some covered ancillary services because of changes that we proposed under the OPPS for CY 2019. For example, if a covered ancillary service was separately paid under the ASC payment system in CY 2018, but is proposed for packaged status under the CY 2019 OPPS, to maintain consistency with the OPPS, we also proposed to package the ancillary service under the ASC payment system for CY 2019. We proposed to continue this reconciliation of packaged status for subsequent calendar years. Comment indicator “CH”, which is discussed in section XII.F. of the proposed rule, was used in Addendum BB to the proposed rule (which is available via the internet on the CMS website) to indicate covered ancillary services for which we proposed a change in the ASC payment indicator to reflect a proposed change in the OPPS treatment of the service for CY 2019.

<table>
<thead>
<tr>
<th>CY 2019 CPT Code</th>
<th>CY 2019 Long Descriptor</th>
<th>CY 2018 ASC Payment Indicator</th>
<th>Calendar Year Added to ASC CPL</th>
<th>ASC CPL Review Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>63045</td>
<td>Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; cervical</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63046</td>
<td>Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; thoracic</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63047</td>
<td>Laminectomy, facetectomy and foraminotomy (unilateral or bilateral with decompression of spinal cord, cauda equina and/or nerve root[s], [eg, spinal or lateral recess stenosis]), single vertebral segment; lumbar</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63055</td>
<td>Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; thoracic</td>
<td>G2</td>
<td>2016</td>
<td>Will remain on ASC CPL</td>
</tr>
<tr>
<td>63056</td>
<td>Transpedicular approach with decompression of spinal cord, equina and/or nerve root(s) (eg, herniated intervertebral disc), single segment; lumbar (including transfacet, or lateral extraforaminal approach) (eg, far lateral herniated intervertebral disc)</td>
<td>G2</td>
<td>2015</td>
<td>Will remain on ASC CPL</td>
</tr>
</tbody>
</table>
All ASC covered ancillary services and their proposed payment indicators for CY 2019 were included in Addendum BB to the proposed rule (which is available via the internet on the CMS website).

We did not receive any public comments on these proposals. Therefore, we are finalizing, without modification, our proposal to update the ASC list of covered ancillary services to reflect the payment status for the services under the OPPS. All CY 2019 ASC covered ancillary services and their final payment indicators are included in Addendum BB to this final rule with comment period (which is available via the internet on the CMS website).

D. ASC Payment for Covered Surgical Procedures and Covered Ancillary Services

1. ASC Payment for Covered Surgical Procedures
   a. Background
   
   Our ASC payment policies for covered surgical procedures under the revised ASC payment system are fully described in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66828 through 66831). Under our established policy, we use the ASC standard ratesetting methodology of multiplying the ASC relative payment weight for the procedure by the ASC conversion factor for that same year to calculate the national unadjusted payment rates for procedures with payment indicators “G2” and “A2.” Payment indicator “A2” was developed to identify procedures that were included on the list of ASC covered surgical procedures in CY 2007 and, therefore, were subject to transitional payment prior to CY 2011. Although the 4-year transitional period has ended and payment indicator “A2” is no longer required to identify surgical procedures subject to transitional payment, we retained payment indicator “A2” because it is used to identify procedures that are exempted from the application of the office-based designation.

   The rate calculation established for device-intensive procedures (payment indicator “J8”) is structured so that the packaged device payment amount is the same as under the OPPS, and only the service portion of the rate is subject to the ASC standard ratesetting methodology. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79732 through 79753), we updated the CY 2016 ASC payment rates for ASC covered surgical procedures with payment indicators of “A2,” “G2,” and “J8” using CY 2015 data, consistent with the CY 2017 OPPS update. We also updated payment rates for device-intensive procedures to incorporate the CY 2017 OPPS device offset percentages calculated under the standard APC ratesetting methodology, as discussed earlier in this section.

   Payment rates for office-based procedures (payment indicators “P2,” “P3,” and “R2”) are the lower of the PFS nonfacility PE RVU-based amount (we refer readers to the CY 2018 PFS proposed and final rules) or the amount calculated using the ASC standard rate setting methodology for the procedure. In the CY 2018 OPPS/ASC final rule with comment period, we updated the payment amounts for office-based procedures (payment indicators “P2,” “P3,” and “R2”) using the most recent available MPFS and OPPS data. We compared the estimated CY 2018 rate for each of the office-based procedures, calculated according to the ASC standard rate setting methodology, to the PFS nonfacility PE RVU-based amount to determine which was lower, and, therefore, would be the CY 2018 payment rate for the procedure under our final policy for the revised ASC payment system (§ 416.171(d)).

   In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75081), we finalized our proposal to calculate the CY 2014 payment rates for ASC covered surgical procedures according to our established methodologies, with the exception of device removal procedures. For CY 2014, we finalized a policy to conditionally package payment for device removal procedures under the OPPS. Under the OPPS, a conditionally packaged code (status indicators “Q1” and “Q2”) describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a covered surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are always packaged (payment indicator “N1”) under the ASC payment system. Unpackaged device removal procedures are conditionally packaged and, therefore, would be packaged under the ASC payment system. There would be no Medicare payment made when a device removal procedure is performed in an ASC without another surgical procedure included on the claim; therefore, no Medicare payment would be made if a device was removed but not replaced.

   To address this concern, for the device removal procedures that are conditionally packaged in the OPPS (status indicator “Q2”), we assigned the current ASC payment indicators associated with these procedures and continued to provide separate payment since CY 2014.

b. Update to ASC Covered Surgical Procedure Payment Rates for CY 2019

   In the CY 2019 OPPS/ASC proposed rule (83 FR 37163 through 37164), we proposed to update ASC payment rates for CY 2019 and subsequent years using the established rate calculation methodologies under § 416.171 and using our definition of device-intensive procedures, as discussed in section XII.C.1.b. of the proposed rule. Because the proposed OPPS relative payment weights are based on geometric mean costs, the ASC system would use geometric means to determine proposed relative payment weights under the ASC standard methodology. We proposed to continue to use the amount calculated under the ASC standard ratesetting methodology for procedures assigned payment indicators “A2” and “G2.”

   We proposed to calculate payment rates for office-based procedures (payment indicators “P2,” “P3,” and “R2”) and device-intensive procedures (payment indicator “J8”) according to our established policies and, for device-intensive procedures, using our modified definition of device-intensive procedures, as discussed in section XII.C.1.b. of the proposed rule. Therefore, we proposed to update the payment amount for the service portion of the device-intensive procedures using the ASC standard rate setting methodology and the payment amount for the device portion based on the proposed CY 2019 OPPS device offset percentages that have been calculated using the standard OPPS APC ratesetting methodology. Payment for office-based procedures would be at the lesser of the proposed CY 2019 MPFS nonfacility PE RVU-based amount or the proposed CY 2018 ASC payment amount calculated according to the ASC standard ratesetting methodology.

   As we did for CYs 2014 through 2018, for CY 2019, we proposed to continue our policy for device removal procedures, such that device removal procedures that are conditionally packaged in the OPPS (status indicators “Q1” and “Q2”) would be assigned the current ASC payment indicators associated with these procedures and would continue to be paid separately under the ASC payment system.

Comment: One commenter recommended that CMS change CPT code 0356T (Insertion of drug delivery implant into tear ducts) from payment indicator “D1” to “J1.”

Response: We note that, in the CY 2019 OPPS/ASC proposed rule, we
proposed to assign CPT code 0356T a status indicator of “Q1” under the OPPS. As stated in the CY 2019 OPPS/ASC proposed rule (83 FR 37163 through 37164), HCPCS codes that are conditionally packaged under the OPPS (status indicators “Q1” and “Q2”) and are not a device removal procedure are always packaged (payment indicator “N1”) under the ASC payment system. Therefore, we are finalizing our proposal to assign payment indicator “N1” to CPT code 0356T under the ASC payment system for CY 2019.

Comment: Several commenters disagreed with the proposed CY 2019 ASC payment rates for the surgical procedures described by the following CPT/HCPCS codes:

- CPT code 22513 (Injection of bone cement into body of middle spine bone accessed through the skin using imaging guidance);
- CPT code 22514 (Injection of bone cement into body of lower spine bone accessed through the skin using imaging guidance);
- CPT code 43210 (Diagnostic examination of esophagus, stomach, and/or upper small bowel with repair of muscle at esophagus and stomach using an endoscope);
- CPT code 62264 (Injection or mechanical removal of spinal canal scar tissue, percutaneous procedure, accessed through the skin, multiple sessions in 1 day);
- CPT code 62321 (Injection of substance into spinal canal of upper or middle back using imaging guidance);
- CPT code 62323 (Injection of substance into spinal canal of lower back or sacrum using imaging guidance);
- CPT code 62380 (Decompression of spinal cord and/or nerve root in lower back using endoscope);
- CPT code 63650 (Implantation of spinal neurostimulator electrodes, accessed through the skin);
- CPT code 63685 (Insertion of spinal neurostimulator pulse generator or receiver); and
- HCPCS code C9749 (Repair of nasal vestibular lateral wall stenosis with implant(s)).

Some commenters noted that payment rates for some of these procedures are lower than their payment levels from several years ago. Other commenters suggested that the cost of the procedure significantly exceeds Medicare’s payment and questioned the validity of some of the hospital cost data on which the ASC payment rates were based.

Response: We are required by law to review and update the data on which we establish payment rates on an annual basis. The ASC payment is dependent upon the APC assignment for the procedure. Based on our analysis of the latest hospital outpatient and ASC claims data used for this final rule with comment period, we are updating ASC payment rates for CY 2019 using the established rate calculation methodologies under §416.171 of the regulations and using our finalized modified definition of device-intensive procedures, as discussed in section XII.C.1.b. of this final rule with comment period. We do not generally make additional payment adjustments to specific procedures. As such, we are finalizing the APC assignment and payment indicators for CPT codes 22213, 22214, 43210, 62264, 63385, 63650, 63665, and C9749.

Comment: One commenter recommended that the ASC payment system allow procedures conditionally packaged under the OPPS (status indicator “Q1” and “Q2”) to be paid separately under the ASC payment system when they are performed with another procedure. The commenters also suggest that certain conditionally packaged codes are performed without another major procedure more than half of the time.

Response: Under the OPPS, a conditionally packaged code describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS, and which are not device removal procedures, are always packaged (payment indicator “N1”) under the ASC payment system, no matter how frequently they are billed without a significant procedure under the OPPS. Therefore, we are not accepting this recommendation.

Comment: One commenter recommended that CMS eliminate the prohibition against billing for services using an unlisted CPT surgical procedure code.

Response: Under 42 CFR 416.166(c)(7), covered surgical procedures do not include procedures that can only be reported using a CPT unlisted surgical procedure code. Therefore, such procedures are not payable under the ASC payment system. As discussed in the August 2, 2008 final rule (72 FR 42484 through 42486), it is not possible to know what specific procedure would be represented by an unlisted code. CMS is required to evaluate such procedure for potential safety risk and the expected need for oversight monitoring and to exclude such procedures from ASC payment. It is not possible to evaluate procedures that would be reported by unlisted CPT codes according to these criteria. Therefore, we are not accepting this recommendation.

After consideration of the public comments we received, we are finalizing our proposed policies, without modification, to calculate the CY 2019 payment rates for ASC covered surgical procedures according to our established methodologies using the modified definition of device-intensive procedures. For those covered office-based surgical procedures where the payment rate is the lower of the final rates under the ASC standard ratesetting methodology and the PFS nonfacility PE RVU-based amount, the final payment indicators and rates set forth in this final rule with comment period are based on a comparison using the PFS PE RVUs and the conversion factor effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period.

2. Payment for Covered Ancillary Services

a. Background

Our payment policies under the ASC payment system for covered ancillary services vary according to the particular type of service and its payment policy under the OPPS. Our overall policy provides separate ASC payment for certain ancillary items and services integrally related to the provision of ASC covered surgical procedures that are paid separately under the OPPS and provides packaged ASC payment for other ancillary items and services that are packaged or conditionally packaged (status indicators “N”, “Q1”, and “Q2”) under the OPPS. In the CY 2013 OPPS/ASC rulemaking (77 FR 45169 and 77 FR 68457 through 68458), we further clarified our policy regarding the assignment of payment indicator assignment of codes that are conditionally packaged in the OPPS (status indicators “Q1” and “Q2”). Under the OPPS, a conditionally packaged code describes a HCPCS code where the payment is packaged when it is provided with a significant procedure but is separately paid when the service appears on the claim without a significant procedure. Because ASC services always include a surgical procedure, HCPCS codes that are conditionally packaged under the OPPS are generally packaged (payment indicator “N1”) under the ASC payment system (except for device removal codes, as discussed in section IV, of the proposed rule). Thus, our policy
generally aligns ASC payment bundles with those under the OPPS (72 FR 42495). In all cases, in order for those ancillary services also to be paid, ancillary items and services must be provided integral to the performance of ASC covered surgical procedures for which the ASC bills Medicare.

Our ASC payment policies generally provide separate payment for drugs and biologicals that are separately paid under the OPPS at the OPPS rates. We generally pay for separately payable radiology services at the lower of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the ASC standard ratesetting methodology (72 FR 42497). However, as finalized in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72050), payment indicators for all nuclear medicine procedures (defined as CPT codes in the range of 78000 through 78999) that are designated as radiology services that are paid separately when provided integral to a surgical procedure are set to "Z2" so that payment is made based on the ASC standard ratesetting methodology rather than the MPFS nonfacility PE RVU amount ("Z3"), regardless of which is lower. 42 CFR 416.171(d)(1).

Similarly, we also finalized our policy to set the payment indicator to "Z2" for radiology services that use contrast agents so that payment for these procedures will be based on the OPPS relative payment weight using the ASC standard methodology and, therefore, will include the cost for the contrast agent. 42 CFR 416.171(d)(2).

ASC payment policy for brachytherapy sources mirrors the payment policy under the OPPS. ASCs are paid for brachytherapy sources provided integral to ASC covered surgical procedures at prospective rates adopted under the OPPS or, if OPPS rates are unavailable, at contractor-priced rates (72 FR 42499). Since December 31, 2009, ASCs have been paid for brachytherapy sources provided integral to ASC covered surgical procedures at prospective rates adopted under the OPPS.

Our ASC policies also provide separate payment for: (1) Certain items and services that CMS designates as contractor-priced, including, but not limited to, the procurement of corneal tissue; and (2) certain implantable items that have pass-through payment status under the OPPS. These categories do not have prospectively established ASC payment policy according to ASC payment system policies (72 FR 42502 and 42508 through 42509; 42 CFR 416.164(b)). Under the ASC payment system, we have designated corneal tissue acquisition and hepatitis B vaccines as contractor-priced. Corneal tissue acquisition is contractor-priced based on the invoiced costs for acquiring the corneal tissue for transplantation. Hepatitis B vaccines are contractor-priced based on invoiced costs for the vaccine.

Devices that are eligible for pass-through payment under the OPPS are separately paid under the ASC payment system and are contractor-priced. Under the revised ASC payment system (72 FR 42502), payment for the surgical procedure associated with the pass-through device is made according to our standard methodology for the ASC payment system, based on only the service (non-device) portion of the procedure’s OPPS relative payment weight if the APC weight for the procedure includes other packaged device costs. We also refer to this methodology as applying a “device offset” to the ASC payment for the associated surgical procedure. This ensures that duplicate payment is not provided for any portion of an implanted device with OPPS pass-through payment status.

In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66933 through 66934), we finalized that, beginning in CY 2015, certain diagnostic tests within the medicine range of CPT codes for which separate payment is allowed under the OPPS are covered ancillary services when they are integral to an ASC covered surgical procedure. We finalized that diagnostic tests within the medicine range of CPT codes include all Category I CPT codes in the medicine range established by CPT, from 90000 to 99999, and Category III CPT codes and Level II HCPCS codes that describe diagnostic tests that crosswalk or are clinically similar to procedures in the medicine range established by CPT. In the CY 2015 OPPS/ASC final rule with comment period, we also finalized our policy to pay for these tests at the lower of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the ASC standard ratesetting methodology (79 FR 66933 through 66934). We finalized that the diagnostic tests for which the payment is based on the ASC standard ratesetting methodology be assigned to payment indicator “Z2” and revised the definition of payment indicator “Z2” to include a reference to diagnostic services and those for which the payment is based on the nonfacility PE RVU-based amount be assigned payment indicator “Z3,” and revised the definition of payment indicator “Z3” to include a reference to diagnostic services.

b. Payment for Covered Ancillary Services for CY 2019

In the CY 2019 OPPS/ASC proposed rule (83 FR 37164 through 37165), for CY 2019 and subsequent years, we proposed to update the ASC payment rates and to make changes to ASC payment indicators, as necessary, to maintain consistency between the OPPS and ASC payment system regarding the packaged or separately payable status of services and the proposed CY 2019 OPPS and ASC payment rates and subsequent year payment rates. We also proposed to continue to set the CY 2019 ASC payment rates and subsequent year payment rates for brachytherapy sources and separately payable drugs and biologicals equal to the OPPS payment rates for CY 2019 and subsequent year payment rates.

Covered ancillary services and their proposed payment indicators for CY 2019 were listed in Addendum BB to the proposed rule (which is available via the internet on the CMS website). For those covered ancillary services where the payment rate is the lower of the proposed rates under the ASC standard rate setting methodology and the PFS proposed rates, the proposed payment indicators and rates set forth in the proposed rule are based on a comparison using the proposed PFS rates effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS proposed rule that is available on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Federal-Regulation- Notices.html.

Comment: Commenters recommended that CMS pay separately for Cysview®, HCPCS code C9275 (hexaminolevulinate HCl), similar to the proposal to pay separately for Exarel®. Commenters also recommended that CMS use its equitable payment adjustment authority under section 1833(t)(2)(E) of the Act to provide a drug “add-on” payment for certain procedures.

Response: As discussed in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79668), we continue to believe that Cysview® is a drug that functions as a supply in a diagnostic test or procedure and therefore is packaged with payment for the surgical procedure. In the CY 2019 OPPS/ASC proposed rule, we did not propose to make the "drugs that function as a supply in a diagnostic test or procedure", packaging
policy or propose any drug “add-on” policies. Therefore, we are not accepting the commenters’ recommendation.

Comment: One commenter recommended that CMS develop a policy that pays separately for drugs that are administered at the time of cataract surgery, but are not integral or necessary to the cataract procedure, and have an FDA-approved indication to treat/prevent postoperative issues.

Response: We appreciate the commenter’s recommendation. We refer readers to section II.A.3. of this final rule with comment period for details related to the packaging policy for drugs that function as a supply in a surgical procedure or diagnostic test. While we did not propose such a change in the CY 2019 OPPS/ASC proposed rule, we will consider this recommendation in future rulemaking.

3. CY 2019 OPPS/ASC Packaging Policy for Non-Opioid Pain Management Treatments

In the CY 2018 OPPS/ASC proposed rule (82 FR 33588), within the framework of existing packaging categories, such as drugs that function as supplies in a surgical procedure or diagnostic test or procedure, we requested stakeholder feedback on common clinical scenarios involving currently packaged items and services described by HCPCS codes that stakeholders believe should not be packaged under the OPPS. We also expressed interest in stakeholder feedback on common clinical scenarios involving separately payable HCPCS codes for which payment would be most appropriately packaged under the OPPS. Commenters expressed a variety of views on packaging under the OPPS. In the CY 2018 OPPS/ASC final rule with comment period, we summarized the comments received in response to our request (82 FR 59255). The comments ranged from requests to unpackage most items and services that are either conditionally or unconditionally packaged under the OPPS, including drugs and devices, to specific requests for separate payment for a specific drug or device. We stated in the CY 2018 OPPS/ASC final rule with comment period that CMS would continue to explore and evaluate packaging policies under the OPPS and consider these policies in future rulemaking.

In addition to stakeholder feedback regarding OPPS packaging policies, the President’s Commission on Combating Drug Addiction and the Opioid Crisis (the Commission) recently recommended that CMS examine payment policies for certain drugs that function as a supply, specifically non-opioid pain management treatments. The Commission was established in 2017 to study ways to combat and treat drug abuse, addiction, and the opioid crisis. The Commission’s report included a recommendation for CMS to “review and modify ratesetting policies that discourage the use of non-opioid treatments for pain, such as certain bundled payments that make alternative treatment options cost prohibitive for hospitals and doctors, particularly those options for treating immediate postsurgical pain. . . .” With respect to the packaging policy, the Commission’s report states that “the current CMS payment policy for 'supplies' related to surgical procedures creates unintended incentives to prescribe opioid medications to patients for postsurgical pain instead of administering non-opioid pain medications. Under current policies, CMS provides one all-inclusive bundled payment to hospitals for all 'surgical supplies,' which includes hospital-administered drug products intended to manage patients' postsurgical pain. This policy results in the hospitals receiving the same fixed fee from Medicare whether the surgeon administers a non-opioid medication or not.” HHS also presented an Opioid Strategy in April 2017 that aims in part to support cutting-edge research and advance the practice of pain management. On October 26, 2017, the opioid crisis was declared a national public health emergency under Federal law and this determination was renewed on April 20, 2018.

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37067 through 37071), in response to stakeholder comments on the CY 2018 OPPS/ASC proposed rule and in light of the recommendations regarding payment policies for certain drugs, we recently evaluated the impact of our packaging policy for drugs that function as a supply when used in a surgical procedure on the utilization of these drugs in both the hospital outpatient department and the ASC setting. Currently, as noted above, drugs that function as a supply are packaged under the OPPS and the ASC payment system, regardless of the costs of the drugs. The costs associated with packaged drugs that function as a supply are included in the ratesetting methodology for the surgical procedures with which they are billed and the payment rate for the associated procedure reflects the costs of the packaged drugs and other packaged items and services to the extent they are billed with the procedure. In our evaluation, we used currently available data to analyze the utilization patterns associated with specific drugs that function as a supply over a 5-year time period (CYs 2013 through 2017) to determine whether this packaging policy has reduced the use of these drugs. If the packaging policy discouraged the use of drugs that function as a supply or impeded access to these products, we would expect to see a significant decline in utilization of these drugs over time, although we note that a decline in utilization could also reflect other factors, such as the availability of alternative products. We did not observe significant declines in the total number of units used in the hospital outpatient department for a majority of the drugs included in our analysis.

In fact, under the OPPS, we observed the opposite effect for several drugs that function as a supply, including Exparel (HCPCS code C9290). Exparel is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In 2011, Exparel was approved by the FDA for administration into the postsurgical site to provide postsurgical analgesia. Exparel had pass-through payment status from CYs 2012 through 2014 and was separately paid under both the OPPS and the ASC payment system during this 3-year period. Beginning in CY 2015, Exparel was packaged as a surgical supply under both the OPPS and the ASC payment system. Exparel is currently the only non-opioid pain management drug that is packaged as a drug that functions as a supply when used in a surgical procedure under the OPPS and the ASC payment system. From CYs 2013 through 2017, there was an overall increase in the OPPS Medicare utilization of Exparel of approximately 229 percent (from 2.3 million units to 7.7 million units) during this 5-year time period. The total number of claims reporting Exparel utilization at the OPPS peaked in CY 2017 at 9,147,171 claims, representing 2.3 million units, representing a 229 percent increase from CY 2012 and a 31 percent increase from CY 2016.
increased by 222 percent (from 10,609 claims to 34,183 claims) over this time period. This increase in utilization continued, even after the 3-year drug pass-through payment period ended for this product in 2014, with 18 percent overall growth in the total number of units used from CYs 2015 through 2017 (from 6.5 million units to 7.7 million units). The number of claims reporting Exparel increased by 21 percent during this time period (from 28,166 claims to 34,183 claims).

Thus, we have not found evidence to support the notion that the OPPS packaging policy has had an unintended consequence of discouraging the use of non-opioid treatment for postsurgical pain management in the hospital outpatient department. Therefore, based on this data analysis, we stated in the CY 2019 OPPS/ASC proposed rule that we did not believe that changes were necessary under the OPPS for the packaged drug policy for drugs that function as a surgical supply when used in a surgical procedure in this setting at this time.

In terms of Exparel in particular, we have received several requests to pay separately for the drug rather than packaging payment for it as a surgical supply. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66874 and 66875), in response to comments from stakeholders requesting separate payment for Exparel, we stated that we considered Exparel to be a drug that functions as a surgical supply because it is indicated for the alleviation of postoperative pain. We also stated that we consider all items related to the surgical outcome and provided during the hospital stay in which the surgery is performed, including postsurgical pain management drugs, to be part of the surgery for purposes of our drug and biological surgical supply packaging policy. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59345), we reiterated our position that, although we found increases in utilization for Exparel when it is paid for as a surgical supply, we did not believe that changes were necessary under the OPPS for the packaging policy for drugs that function as a surgical supply when used in a surgical procedure in this setting at this time.

In light of the results of our evaluation of packaging policies under the OPPS and the ASC payment system, which showed decreased utilization for certain drugs that function as a supply in the ASC setting in comparison to the hospital outpatient department setting, as well as the Commission’s recommendation to examine payment

pharmaceutical ingredient in Exparel, is a local anesthetic that has been used for infiltration/field block and peripheral nerve block for decades” and that “since its approval, Exparel has been used extensively, with an estimated 3.5 million patient exposures in the US.” On April 6, 2018, the FDA approved Exparel’s new indication for use as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Therefore, we also stated in the CY 2019 OPPS/ASC proposed rule that, based on our review of currently available OPPS Medicare claims data and public information from the manufacturer of the drug, we did not believe that the OPPS packaging policy had discouraged the use of Exparel for either of the drug’s indications.

Accordingly, we continue to believe it is appropriate to package payment for Exparel as we do with other postsurgical pain management drugs when it is furnished in a hospital outpatient department. However, we invited public comments on whether separate payment would nonetheless further incentivize appropriate use of Exparel in the hospital outpatient setting and peer-reviewed evidence that such increased utilization would lead to a decrease in opioid use and addiction among Medicare beneficiaries.

**Comment:** Several commenters requested that CMS pay separately for Exparel in the hospital outpatient setting. Some of these commenters noted that Exparel is used more frequently in this setting and the use of non-opioid pain management treatments should also be encouraged in the hospital outpatient (HOPD) setting. One commenter stated that since drug became packaged in 2015, utilization of the drug in the HOPD has remained flat while the opioid crisis has continued to worsen. The commenter suggested that to address the opioid crisis among Medicare beneficiaries, CMS should promote “increased penetration of non-opioid therapies in the HOPD setting—or in other words, higher rates of usage of non-opioid treatments for the same number of surgical procedures.”

**Response:** This comment and other comments specific to packaging under the OPPS payment system are addressed in section II.A.3.b. of this final rule with comment period.

We also stated in the proposed rule that, although we found increases in utilization for Exparel when it is paid under the OPPS, we did notice different effects on Exparel utilization when


96 Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022496s001blidb.pdf.
policies for non-opioid pain management drugs that function as a supply, we stated in the proposed rule that we believe a change in how we pay for non-opioid pain management drugs that function as surgical supplies may be warranted. In particular, we believe it may be appropriate to pay separately for evidence-based non-opioid pain management drugs that function as a supply in a surgical procedure in the ASC setting to address the decreased utilization of these drugs and to encourage use of these types of drugs rather than prescription opioids. Therefore, we proposed in section XII.D.3. of the CY 2019 OPPS/ASC proposed rule (83 FR 37068 through 37071) to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019.

We have stated previously (82 FR 59250) that our packaging policies are designed to support our strategic goal of using larger payment bundles in the OPPS to maximize hospitals’ incentives to provide care in the most efficient manner. The packaging policies established under the OPPS also typically apply when services are provided in the ASC setting, and the policies have the same strategic goals in both settings. While the CY 2019 proposal is a departure from our current ASC packaging policy for drugs (specifically, non-opioid pain management drugs) that function as a supply when used in a surgical procedure, we stated in the proposed rule we believe that the proposed change will incentivize the use of non-opioid pain management drugs and is responsive to the Commission’s recommendation to examine payment policies for non-opioid pain management drugs that function as a supply, with the overall goal of combating the current opioid addiction crisis. As previously noted, a discussion of the CY 2019 proposal for payment of non-opioid pain management drugs in the ASC setting was presented in further detail in the proposed rule, and we include a further discussion of the final policy for CY 2019 below. However, we also stated in the CY 2019 OPPS/ASC proposed rule that we were interested in peer-reviewed evidence that demonstrates that non-opioid alternatives, such as Exparel, in the outpatient setting actually do lead to a decrease in prescription opioid use and addiction and invited public comments containing evidence that demonstrate whether and how such non-opioid alternatives affect prescription opioid use during or after an outpatient visit or procedure.

As noted above, for CY 2019, we proposed to pay separately at average sales price (ASP)+6 percent for non-opioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in the ASC setting. As described in section V.A.1. of the proposed rule, section 1847A of the Act establishes the ASP methodology, which is used for payment for drugs and biologicals described in section 1842(o)(1)(C) of the Act furnished on or after January 1, 2005. The ASP methodology, as applied under the OPPS, uses several sources of data as a basis for payment, including the ASP, the wholesale acquisition cost (WAC), and the average wholesale price (AWP) (82 FR 59337). As noted in section V.B.2.b. of the proposed rule, since CY 2013, our policy has been to pay for separately payable drugs and biologicals at ASP+6 percent in accordance with section 1833(t)(14)(A)(iii)(II) of the Act (the statutory default) (82 FR 59350).

In the proposed rule (83 FR 37167), we did not propose a change to the packaging policy under the OPPS for CY 2019. However, we proposed to pay separately at ASP+6 percent for non-opioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in the ASC setting for CY 2019. Because the ASC payment rate also includes packaged payment for non-opioid pain management drugs, we intend to remove the packaged costs attributable to non-opioid pain management drugs—at this time, only Exparel qualifies—from the applicable OPPS rates prior to establishing the ASC rates in order to prevent potential overpayment of these procedures when separate payment is provided in the ASC setting.

Of the drugs that are currently packaged in the ASC setting, this policy would apply to Exparel. Exparel is the only non-opioid pain management drug that functions as a supply when used in a surgical procedure that is covered under Medicare Part B. While there are other non-opioid pain management drugs available that are also administered post-surgically, such as non-steroidal anti-inflammatory drugs (“NSAIDs”), Exparel is the currently the only drug used in the ASC setting that is both covered under Medicare Part B and policy packaged as a drug that functions as a supply in a surgical procedure. However, other non-opioid drugs that function as surgical supplies come onto the U.S. market, we proposed that this policy would apply to them as well in CY 2019.

This proposal was also presented in section II.A.3.b. of the proposed rule for the OPPS. We proposed several conforming changes to the ASC regulation to implement this proposal. Specifically, at 42 CFR 416.164(a)(4), we proposed a change to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to package drugs and biologicals for which separate payment is not allowed under the OPPS into the ASC payment for a covered surgical procedure. Similarly, we proposed to add 42 CFR 416.164(b)(6) to include non-opioid pain management drugs that function as a supply when used in a surgical procedure as a covered ancillary service. Finally, we proposed a conforming change to 42 CFR 416.171(b)(1) to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to pay for ASC covered ancillary services at an amount derived from the payment rate for the equivalent item or service set under the OPPS.

Comment: Several commenters supported the proposal to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as a supply in the ASC setting, such as Exparel, for CY 2019. These commenters believed that packaged payment for non-opioid alternatives presents a barrier to care and that separate payment for non-opioid pain management drugs would be an appropriate response to the opioid drug abuse epidemic.

Other commenters, including MedPAC, did not support this proposal and stated that the policy was counter to the OPPS packaging policies created to encourage efficiencies and could set a precedent for unpackaging services. One commenter stated that Exparel is more costly, but not more effective than bupivacaine, a less costly non-opioid alternative. Other commenters expressed concerns that the proposal may have the unintended consequence of limiting access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. The commenters noted that some non-opioid pain management treatments may pose other risks for patients and patient safety.

Response: We appreciate the commenters’ input. We continue to believe that, under current circumstances, it is appropriate to pay separately for non-opioid pain management drugs that function as a supply in a surgical procedure in the
ASC setting where there is evidence that their use leads to decreased opioid use and/or addiction among Medicare beneficiaries following an outpatient visit or procedure. We believe this policy will encourage use of these types of drugs rather than prescription opioids. With regard to the comments that paying separately for these drugs could set a precedent for unpackaging other services, while we acknowledge that this policy is a departure from the current ASC packaging policy for drugs that function as a supply, we also believe that the limited scope of this policy, in terms of both the services included (evidence-based non-opioid pain management drugs) and the setting (ASCs) is sufficiently narrow and will not set an unwarranted precedent for the unpackaging of other OPPS or ASC services. We also do not believe that this policy will limit access to opioid prescriptions for beneficiaries for whom an opioid prescription would be appropriate. Exparel and other non-opioid pain management drugs packaged under the drugs that function as a supply policy are used to treat acute post-surgical pain and paying separately for these drugs under the ASC payment system will not prevent physicians from prescribing opioids for treating pain when appropriate. Also, we have a longstanding recognition that the decision on how to best treat a patient is a complex medical judgment made by the physician based on each individual beneficiary’s unique clinical circumstances. With regard to concerns that some non-opioid pain management treatments pose other risks for patients and patient safety, the commenter did not identify any specific non-opioid pain management treatments in its comment. Exparel, the only drug to which the proposed policy applies, is currently being safely used in both the OPPS and ASC settings. This comment is also presented in section II.A.3.b of this final rule with comment period.

In addition, as noted in section XI.D.3. of the proposed rule, we sought comments on whether the proposed policy would decrease the dose, duration, and/or number of opioid prescriptions beneficiaries receive during and following an outpatient visit or procedure (especially for beneficiaries at high-risk for opioid addiction) as well as whether there are other non-opioid pain management alternatives that would have similar effects and may warrant separate payment. For example, we stated we were interested in identifying whether single post-surgical analgesic injections, such as Exparel, or other non-opioid drugs or devices that are used during an outpatient visit or procedure are associated with decreased opioid prescriptions and/or reduced cases of associated opioid addiction following such an outpatient visit or procedure. We also requested comments that provide evidence (such as published peer-reviewed literature) we could use to determine whether these products help to deter or avoid prescription opioid use and addiction as well as evidence that the current packaged payment for such non-opioid alternatives presents barriers to access to care and, therefore, warrants separate payment under either or both the OPPS and the ASC payment system. We stated that any evidence demonstrating the reduction or avoidance of prescription opioids would be the criteria we use to determine whether separate payment is warranted for CY 2019. We also stated that, should evidence change over time, we would consider whether a reexamination of any policy adopted in the final rule would be necessary.

Comment: Other commenters representing hospitals, hospital associations, and clinical specialty organizations requested separate payment for IV acetaminophen, IV ibuprofen, and epidural steroid injections. In addition, one commenter, the manufacturers of a non-opioid analgesic containing bupivacaine hcl, but not currently approved by FDA, requested clarification regarding whether the proposal would also apply to this drug once it receives FDA approval. Several commenters requested separate payment for a drug which treats post-operative pain after cataract surgery, currently has drug pass-through status, and therefore is not packaged under the OPPS or ASC. The commenters requested that CMS explicitly state this drug will also be paid for separately in the ASC setting after pass-through status ends for the drug in 2020. Lastly, one commenter requested that a diagnostic drug that is not a non-opioid receive separate payment.

Response: We appreciate these comments. After reviewing the studies provided by the commenters, we continue to believe the separate payment is appropriate for Exparel in the ASC setting. At this time, we have not found compelling evidence for other non-opioid pain management drugs described above to warrant separate payment at this time. Also, with regard to the requests for CMS to confirm that the proposed policy would also apply in the future to certain non-opioid pain management drugs, we reiterate that the proposed policy is for CY 2019 and is applicable to non-opioid pain management drugs that are currently packaged under the OPPS and ASC. After pass-through status ends for the drug Exparel that might be affected by OPPS and ASC packaging policies, including alternative, non-opioid pain treatments, such as devices or therapy services that are not currently separable payable. We stated that we were specifically interested in comments regarding whether CMS should consider separate payment for items and services for which payment is currently packaged under the OPPS and the ASC payment system that are effective non-opioid alternatives as well as evidence that demonstrates such items and services lead to a decrease in prescription opioid use and/or

97 Michael A. Mont et al., Local Infiltration Analgesia With Liposomal Bupivacaine Improves Pain Scores and Reduces Opioid Use After Total Knee Arthroplasty: Results of a Randomized Controlled Trial. J. of Arthroplasty (2018).
addiction during or after an outpatient visit or procedure in order to determine whether separate payment may be warranted. As previously stated, we intended to examine the evidence submitted to determine whether to adopt a final policy in this final rule with comment period that incentives use of non-opioid alternative items and services that have evidence to demonstrate an associated decrease in prescription opioid use and/or addiction following an outpatient visit or procedure. Some examples of evidence that may be relevant could include an indication on the product’s FDA label or studies published in peer-reviewed literature that such product aids in the management of acute or chronic pain and is an evidence-based non-opioid alternative for acute and/or chronic pain management. We indicated in the proposed rule that we also were interested in evidence relating to products that have shown clinical improvement over other alternatives, such as a device that has been shown to provide a substantial clinical benefit over the standard of care for pain management. We stated this could include, for example, spinal cord stimulators used to treat chronic pain such as the devices described by HCPCS codes C1822 (Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system), C1820 (Generator, neurostimulator (implantable), with rechargeable battery and charging system), and C1767 (Generator, neurostimulator (implantable), nonrechargeable) which are primarily assigned to APCs 5463 and 5464 (Levels 3 and 4 Neurostimulator and Related Procedures) with proposed CY 2019 payment rates of $18,718 and $27,662, respectively, that have received pass-through payment status as well as other similar devices.

Currently, all devices are packaged under the OPPS and the ASC payment system unless they have pass-through payment status. However, we stated in the proposed rule that, in light of the Commission’s recommendation to review and modify rate-setting policies that discourage the use of non-opioid treatments for pain, we were interested in comments from stakeholders regarding whether, similar to the goals of the proposed payment policy for non-opioid pain management drugs that function as a supply when used in a surgical procedure, a policy of providing separate payment (rather than packaged payment) for these products, indefinitely or for a specified period of time, would also incentivize the use of alternative non-opioid pain management treatments and improve access to non-opioid alternatives, particularly for innovative and low-volume items and services. We also stated that we were interested in comments regarding whether we should provide separate payment for non-opioid pain management treatments or products using a mechanism such as an equitable payment adjustment under our authority at section 1833((i)(2)(E)) of the Act, which states that the Secretary shall establish, in a budget neutral manner, other adjustments as determined to be necessary to ensure equitable payments. For example, we stated in the proposed rule that we were considering whether an equitable payment adjustment in the form of an add-on payment for APCs that use a non-opioid pain management drug, device, or service would be appropriate. We indicated that, to the extent that commenters provided evidence to support this approach, we would consider adopting a final policy in this final rule with comment period, which could include regulatory changes that would allow for an exception to the packaging of certain nonpass-through devices that represent non-opioid alternatives for acute or chronic pain that have evidence to demonstrate that their use leads to a decrease in opioid prescriptions and/or addictions during or after an outpatient visit or procedure to effectuate such change.

Comment: Several commenters stated that separate payment for spinal cord stimulators (SCS) was also warranted because these devices provide an alternative treatment option to opioids for patients with chronic, leg or back pain. One commenter provided supporting studies which claimed that patients treated with their device reported a statistically significant average decrease in opioid use compared to the control group.98 This commenter also submitted data that showed a decline in the mean daily dosage of opioid medication taken and that fewer patients were relying on opioids at all to manage their pain when they used the manufacturer’s device.99 Another commenter stated that there were few peer-reviewed studies that evaluate opioid elimination and/or reduction following SCS and that there is a need for more population based research with opioid reduction or elimination as a study endpoint. However, this commenter believed that current studies suggest that opioid use may be reduced following SCS therapy.

Other commenters requested separate payments for various non-opioid pain management treatments such as: Continuous nerve blocks (including a disposable elastomeric pump that delivers non-opioid local anesthetic to a surgical site or nerve); cooled thermal radiofrequency ablation for non-surgical, chronic nerve pain; and physical therapy services. These commenters also stated that while “certainly not a solution to the opioid epidemic, unpackaging appropriate non-opioid therapies, like Exparel, is a low-cost tactic that could change long-standing practice patterns without major negative consequences.”

One commenter suggested that Medicare consider separate payment for Polar ice devices for post-operative pain relief after knee procedures. The commenter also noted that therapeutic massage, topically applied THC oil, acupuncture, and dry needling procedures are very effective therapies for relief of both postoperative pain and long-term and chronic pain.

Commenters suggested various mechanisms through which separate payment or a higher paying APC assignment for the primary service could be made. Commenters offered reports, studies and anecdotal evidence to support why the items or services about which the commenters believed offered alternatives to or reduction of the need for opioid prescriptions.

Response: We appreciate the thoughtful response to our solicitation for comments on this topic. We plan to take these suggestions into consideration for future rulemaking. We agree that providing incentives to avoid and/or reduce opioid prescriptions may be one of several strategies for addressing the opioid epidemic. To the extent that the items and services mentioned by the commenters are effective alternatives to opioid prescriptions, we encourage providers to use them when medically necessary. We note that some of the items and services mentioned by commentators are not covered by Medicare and we do not intend to establish payment for noncovered items and services. We look forward to working with stakeholders as we further consider suggested refinements to the OPPS and the ASC.

payment system that will encourage use of medically necessary items and services that have demonstrated efficacy in decreasing opioid prescriptions and/or addictions during or after an outpatient visit or procedure. Comment: One commenter suggested that CMS provide separate payment for HCPCS code A4306 (Disposable drug delivery system, flow rate of less than 50 ml per hour) in the hospital outpatient department and the ASC settings following a post-surgery procedure. This commenter explained that if a patient needs additional pain relief three to five days post-surgery, a facility cannot receive payment for providing a replacement disposable drug delivery system HCPCS code A4306 unless the entire continuous nerve block procedure is performed. This commenter believed that CMS should allow for HCPCS code A4306 to be dispensed to the patient as long as the patient is in pain, the pump is empty, and the delivery catheters are still in place. The commenter believed that the ASC payment system should incentivize the continued use of non-opioid alternatives when needed. Several commenters stated that CMS should use an equitable payment adjustment under its authority at section 1833(t)(2)(E) of the Act to establish add-on payments for packaged devices used as non-opioid alternatives. Response: We appreciate the comments’ suggestions. We acknowledge that use of these items may help in the reduction of opioid use post operatively. However, we noted that packaged payment of such item does not prevent the use of these items. We remind readers that payment for packaged items is included in the payment for the primary service. We share the commenter’s concern about the need to reduce opioid use and will take the commenter’s suggestion into consideration for future rulemaking. After reviewing the non-opioid pain management alternatives suggested by the commenters as well as the studies and other data provided to support the request for separate payment, we have not determined that separate payment is warranted at this time for any of the non-opioid pain management alternatives discussed above. We also invited comments on whether a reorganization of the APC structure for procedures involving non-opioid products or establishing more granular APC groupings for specific procedure and device combinations to ensure that the payment rate for such services is aligned with the resources associated with procedures involving specific devices would better achieve our goal of incentivizing increased use of non-opioid alternatives, with the aim of reducing opioid use and subsequent addiction. For example, we stated we would consider finalizing a policy to establish new APCs for procedures involving non-opioid pain management packaged items or services if such APCs would better recognize the resources involved in furnishing such items and services and decrease or eliminate the need for prescription opioids. In addition, given the general desire to encourage provider efficiency through creating larger bundles of care and packaging items and services that are integral, ancillary, supportive, dependent, or adjunctive to a primary service, we also invited comments on how such alternative payment structures would continue to balance the goals of incentivizing provider efficiencies with encouraging the use of non-opioid alternatives to pain management. Furthermore, because patients may receive opioid prescriptions following receipt of a non-opioid drug or implantation of a device, we stated that we were interested in identifying any cost implications for the patient and the Medicare program caused by this potential change in policy. We also stated that the implications of incentivizing use of non-opioid pain management drugs available for postsurgical acute pain relief during or after an outpatient visit or procedure are of interest. The goal is to encourage appropriate use of such non-opioid alternatives. As previously stated, this comment solicitation is also discussed in section XII.D.3. of this final rule with comment period. Comment: One commenter suggested that CMS restructure the two-level Nerve Procedure APCs (5431 and 5432) to provide more payment granularity for the procedures included in the APCs by creating a third level. Response: We refer readers to section III.D.6. of this final rule with comment period for a discussion of this comment. We believe that the current two-level APCs for the Nerve Procedures provide an appropriate distinction between the resource costs at each level and provide clinical homogeneity. We will continue to review this APC structure, to determine if additional granularity is necessary for this APC family in future rulemaking. In addition, we believe that more analysis of such groupings is necessary before adopting such change. In addition, we invited the public to submit ideas on regulatory, subregulatory policy practice, and procedural changes to help prevent opioid use disorders and improve access to treatment under the Medicare program. We stated that we were interested in identifying barriers that may inhibit access to non-opioid alternatives for pain treatment and management or access to opioid use disorder treatment, including those barriers related to payment methodologies or coverage. In addition, consistent with our “Patients Over Paperwork” Initiative, we stated that we were interested in suggestions to improve existing requirements in order to more effectively address the opioid epidemic. Comment: Several commenters offered views regarding payment barriers that may inhibit access to non-opioid pain management treatments which have been previously discussed throughout this section. With regard to barriers related to payment methodologies or coverage, some commenters suggested that CMS support multi-modal pain management and enhanced recovery after surgery (ERAS) and encourage patient access to certified registered nurse anesthetist (CRNA) pain management. One commenter also suggested that CMS reduce cost sharing and eliminate the need for prior authorization for non-opioid pain management strategies. Response: We appreciate the various, insightful comments received from stakeholders regarding barriers that may inhibit access to non-opioid alternatives for pain treatment and management in order to more effectively address the opioid epidemic. Many of these comments have been previously addressed throughout this section. After consideration of the public comments that we received, we are finalizing the policy to unpackage and pay separately at ASP+6 percent for the cost of non-opioid pain management drugs that function as surgical supplies when they are furnished in the ASC setting for CY 2019 as proposed. We also are finalizing our conforming changes to the ASC regulation as proposed. Specifically, we are finalizing our proposed conforming changes to 42 CFR 416.164(a)(4) to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to package payment for drugs and biologicals for which separate payment is not allowed under the OPPS into the ASC payment for the covered surgical procedure. We also are adding a new paragraph (6) to 42 CFR 416.164(b) to include non-opioid pain management drugs that function as a supply when used in a surgical procedure for ancillary services that are integral to a covered surgical procedure. Finally, we are...
finalizing our proposed change to 42 CFR 416.171(b)(1) to exclude non-opioid pain management drugs that function as a supply when used in a surgical procedure from our policy to pay for ASC covered ancillary services an amount derived from the payment rate for the equivalent item or service set under the OPPS.

We will continue to analyze this issue on access to non-opioid alternatives in the OPPS and ASC settings as we implement section 6082 of the Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (Pub. L. 115–271) enacted on October 24, 2018. This policy is also discussed in section II.A.3.b. of this final rule with comment period.

E. New Technology Intraocular Lenses (NTIOLs)

New Technology Intraocular Lenses (NTIOLs) are intraocular lenses that replace a patient’s natural lens that has been removed in cataract surgery and that also meet the requirements listed in 42 CFR 416.195.

1. NTIOL Application Cycle

Our process for reviewing applications to establish new classes of NTIOLs is as follows:

- Applicants submit their NTIOL requests for review to CMS by the annual deadline. For a request to be considered complete, we require submission of the information that is found in the guidance document entitled “Application Process and Information Requirements for Requests for a New Class of New Technology Intraocular Lenses (NTIOLs) or Inclusion of an IOL in an Existing NTIOL Class” posted on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/NTIOLs.html.
- We announce annually, in the proposed rule updating the ASC and OPPS payment rates for the following calendar year, a list of all requests to establish new NTIOL classes accepted for review during the calendar year in which the proposal is published. In accordance with section 141(b)(3) of Public Law 103–432 and our regulations at 42 CFR 416.185(b), the deadline for receipt of public comments is 30 days following publication of the list of requests in the proposed rule.
- In the final rule updating the ASC and OPPS payment rates for the following calendar year, we—
  ++ Provide a list of determinations made as a result of our review of all new NTIOL class requests and public comments;
++ When a new NTIOL class is created, identify the predominant characteristic of NTIOLs in that class that sets them apart from other IOLs (including those previously approved as members of other expired or active NTIOL classes) and that is associated with an improved clinical outcome.
++ Set the date of implementation of a payment adjustment in the case of approval of an IOL as a member of a new NTIOL class prospectively as of 30 days after publication of the ASC payment update final rule, consistent with the statutory requirement.
++ Announce the deadline for submitting requests for review of an application for a new NTIOL class for the following calendar year.

2. Requests To Establish New NTIOL Classes for CY 2019

We did not receive any requests for review to establish a new NTIOL classes for CY 2019 by March 1, 2018, the due date published in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59416).

3. Payment Adjustment

The current payment adjustment for a 5-year period from the implementation date of a new NTIOL class is $50 per lens. Since implementation of the process for adjustment of payment amounts for NTIOLs in 1999, we have not revised the payment adjustment amount, and we are not proposing to revise the payment adjustment amount for CY 2019.

4. Announcement of CY 2020 Deadline

For Submitting Requests for CMS Review of Applications for a New Class of NTIOLs

In accordance with § 416.185(a) of our regulations, CMS announces that in order to be considered for payment effective beginning in CY 2020, requests for review of applications for a new class of new technology IOLs must be received at CMS by 5:00 p.m. EST, on March 1, 2019. Send requests to ASC/NTIOL, Division of Outpatient Care, Mailstop C4–05–17, Centers for Medicare and Medicaid Services, 7500 Security Boulevard, Baltimore, MD 21244–1850. To be considered, requests for NTIOL reviews must include the information requested on the CMS website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ASCPayment/NTIOLs.html.

F. ASC Payment and Comment Indicators

1. Background

In addition to the payment indicators that we introduced in the August 2, 2007 final rule, we created final comment indicators for the ASC payment system in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66855). We created Addendum DD1 to define ASC payment indicators that we use in Addenda AA and BB to provide payment information regarding covered surgical procedures and covered ancillary services, respectively, under the revised ASC payment system. The ASC payment indicators in Addendum DD1 are intended to capture policy-relevant characteristics of HCPCS codes that may receive packaged or separate payment in ASCs, such as whether they were on the ASC CPL prior to CY 2008; payment designation, such as device-intensive or office-based, and the corresponding ASC payment methodology; and their classification as separately payable ancillary services, including radiology services, brachytherapy sources, OPPS pass-through devices, corneal tissue acquisition services, drugs or biologicals, or NTIOLs.

We also created Addendum DD2 that lists the ASC comment indicators. The ASC comment indicators used in Addenda AA and BB to the proposed rules and final rules with comment period serve to identify, for the revised ASC payment system, the status of a specific HCPCS code and its payment indicator with respect to the timeframe when comments will be accepted. The comment indicator “NP” is used in the OPPS/ASC proposed rule to indicate new codes for the next calendar year for which the interim payment indicator assigned is subject to comment. The comment indicator “NP” also is assigned to existing codes with substantial revisions to their descriptors, such that we consider them to be describing new services, as discussed in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60622). In the CY 2017 OPPS/ASC final rule with comment period, we responded to public comments and finalized the ASC treatment of all codes that were labeled with comment indicator “NP” in Addenda AA and BB to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70497).

The “CH” comment indicator is used in Addenda AA and BB to the proposed rule (which are available via the internet on the CMS website) to indicate that the payment indicator assignment has changed for an active HCPCS code in the current year and the next calendar year, for example if an active HCPCS code is newly recognized as payable in ASCs, or an active HCPCS code is discontinued at the end of the current calendar year. The “CH” comment
indicators that are published in the final rule with comment period are provided to alert readers that a change has been made from one calendar year to the next, but do not indicate that the change is subject to comment.

In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79748 through 79749), for CY 2017 and subsequent years, we finalized our policy to continue using the current comment indicators of “NP” and “CH”.

2. ASC Payment and Comment Indicators

In the CY 2019 OPPS/ASC proposed rule, for CY 2019, there were proposed new and revised Category I and III CPT codes as well as new and revised Level II HCPCS codes. Therefore, proposed Category I and III CPT codes that are new and revised for CY 2018 and any new and existing Level II HCPCS codes with substantial revisions to the code descriptors for CY 2019 compared to the CY 2018 descriptors that were included in ASC Addenda AA and BB to the proposed rule are labeled with proposed comment indicator “NP” to indicate that these CPT and Level II HCPCS codes are open for comment as part of the proposed rule. Proposed comment indicator “NP” means a new code for the next calendar year or an existing code with substantial revision to its code descriptor in the next calendar year, as compared to current calendar year; and denotes that comments will be accepted on the proposed ASC payment indicator for the new code.

In the proposed rule, we stated that we would respond to public comments on ASC payment and comment indicators and finalize their ASC assignment in this CY 2019 OPPS/ASC final rule with comment period. We refer readers to Addenda DD1 and DD2 to the proposed rule (which are available via the internet on the CMS website) for the complete list of ASC payment and comment indicators proposed for the CY 2019 update.

We did not receive any public comments on the ASC payment and comment indicators. Therefore, we are finalizing their use as proposed without modification. Addenda DD1 and DD2 to this final rule with comment period (which are available via the internet on the CMS website) contain the complete list of ASC payment and comment indicators for the CY 2019 update.

G. Calculation of the ASC Payment Rates and the ASC Conversion Factor

1. Background

In the August 2, 2007 final rule (72 FR 42493), we established our policy to base ASC relative payment weights and payment rates under the revised ASC payment system on APC groups and the OPPS relative payment weights. Consistent with that policy and the requirement at section 1833(i)(2)(D)(ii) of the Act that the revised payment system be implemented so that it would be budget neutral, the initial ASC conversion factor (CY 2008) was calculated so that estimated total Medicare payments under the revised ASC payment system in the first year would be budget neutral to estimated total Medicare payments under the prior CY 2007 ASC payment system (the ASC conversion factor is multiplied by the relative payment weights calculated for many ASC services in order to establish payment rates). That is, application of the ASC conversion factor was designed to result in aggregate Medicare expenditures under the revised ASC payment system in CY 2008 being equal to aggregate Medicare expenditures that would have occurred in CY 2008 in the absence of the revised system, taking into consideration the cap on ASC payments in CY 2007, as required under section 1833(i)(2)(E) of the Act (72 FR 42522). We adopted a policy to make the system budget neutral in subsequent calendar years (72 FR 42532 through 42533; 42 CFR 416.171(e)).

We note that we consider the term “expenditures” in the context of the budget neutrality requirement under section 1833(i)(2)(D)(ii) of the Act to mean expenditures from the Medicare Part B Trust Fund. We do not consider expenditures to include beneficiary coinsurance and copayments. This distinction was important for the CY 2008 ASC budget neutrality model that considered payments across the OPPS, ASC, and MPFS payment systems. However, because coinsurance is almost always 20 percent for ASC services, this interpretation of expenditures has minimal impact for subsequent budget neutrality adjustments calculated within the revised ASC payment system.

In the CY 2008 OPPS/ASC final rule with comment period (72 FR 66841 through 66843), we also adopted alternative ratessetting methodologies for specific types of services (for example, device-intensive procedures).

As discussed in the August 2, 2007 final rule (72 FR 42451 through 42518) and as codified at §416.172(c) of the regulations, the revised ASC payment system accounts for geographic wage variation when calculating individual ASC payments by applying the pre-floor and pre-reclassified OPPS hospital wage indexes to the labor-related share, which is 50 percent of the ASC payment amount based on a report of ASC costs using 2004 survey data. Beginning in CY 2008, CMS accounted for geographic wage variation in labor costs when calculating individual ASC payments by applying the pre-floor and pre-reclassified hospital wage index values that CMS calculates for payment under the IPPS, using updated Core Based Statistical Areas (CBSAs) issued by OMB in June 2003.

The reclassification provision in section 1886(d)(10) of the Act is specific to hospitals. We believe that using the most recently available pre-floor and pre-reclassified IPPS hospital wage indexes results in the most appropriate adjustment to the labor portion of ASC costs. We continue to believe that the unaadjusted hospital wage indexes, which are updated yearly and are used by many other Medicare payment systems, appropriately account for geographic variation in labor costs for ASCs. Therefore, the wage index for an ASC is the pre-floor and pre-reclassified hospital wage index under the IPPS of the CBBSA that maps to the CBSA where the ASC is located.

For CY 2008, we adopted the OPPS relative payment weights as the ASC relative payment weights for most services and, consistent with the final policy, we calculated the CY 2008 ASC payment rates by multiplying the ASC relative payment weights by the final CY 2008 ASC conversion factor of $41.401. For covered office-based surgical procedures, covered ancillary radiology services (excluding covered ancillary radiology services involving certain nuclear medicine procedures or involving the use of contrast agents, as discussed in section XII.D.2. of this final rule with comment period), and certain diagnostic tests within the medicine range that are covered ancillary services, the established policy is to set the payment rate at the lower of the MPFS unaadjusted nonfacility PE RVU-based amount or the amount calculated using the ASC standard ratesetting methodology. Further, as discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66841 through 66843), we also adopted alternative ratessetting methodologies for specific types of services (for example, device-intensive procedures).
On February 28, 2013, OMB issued OMB Bulletin No. 13–01, which provides the delineations of all Metropolitan Statistical Areas, Metropolitan Divisions, Micropolitan Statistical Areas, Combined Statistical Areas, and New England City and Town Areas in the United States and Puerto Rico based on the standards published on June 28, 2010 in the Federal Register (75 FR 37246 through 37252) and 2010 Census Bureau data. (A copy of this bulletin may be obtained at: https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2013/b13-01.pdf.) In the FY 2015 IPPS/LTCH PPS final rule (79 FR 49951 through 49963), we implemented the use of the CBSA delineations issued by OMB in OMB Bulletin 13–01 for the IPPS hospital wage index beginning in FY 2015. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66937), we finalized a 1-year transition policy that we applied in CY 2015 for all ASCs that experienced any decrease in their actual wage index exclusively due to the implementation of the new OMB delineations. This transition does not apply in CY 2019.

Generally, OMB issues major revisions to statistical areas every 10 years, based on the results of the decennial census. However, OMB occasionally issues minor updates and revisions to statistical areas in the years between the decennial censuses. On July 15, 2015, OMB issued OMB Bulletin No. 15–01, which provides updates to and supersedes OMB Bulletin No. 13–01 that was issued on February 28, 2013. The attachment to OMB Bulletin No. 15–01 provides detailed information on the update to statistical areas since February 28, 2013. The updates provided in OMB Bulletin No. 15–01 are based on the application of the 2010 Standards for Delineating Metropolitan and Micropolitan Statistical Areas to Census Bureau population estimates for July 1, 2012 and July 1, 2013. The complete list of statistical areas incorporating these changes is provided in the attachment to OMB Bulletin No. 15–01. According to OMB, “[t]his bulletin establishes revised delineations for the Nation’s Metropolitan Statistical Areas, Micropolitan Statistical Areas, and Combined Statistical Areas. The bulletin also provides delineations of Metropolitan Divisions as well as delineations of New England City and Town Areas.” (A copy of this bulletin may be obtained at: https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2015/15-01.pdf)

OMB Bulletin No. 15–01 made changes that are relevant to the IPPS and ASC wage index. We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79750) for a discussion of these changes and our implementation of these revisions.

In OMB Bulletin No. 17–01, OMB announced that one Micropolitan Statistical Area now qualifies as a Metropolitan Statistical Area. The new urban CBSA is as follows:

- Twin Falls, Idaho (CBSA 46300). This CBSA is comprised of the principal city of Twin Falls, Idaho in Jerome County, Idaho and Twin Falls County, Idaho.

The OMB bulletin is available at: https://www.whitehouse.gov/sites/whitehouse.gov/files/omb/bulletins/2017/b-17-01.pdf. We note that we did not have sufficient time to include this change in the computation of the proposed FY 2019 IPPS wage index. We stated that this new CBSA may affect the budget neutrality factors and wage indexes, depending on the impact of the overall payments of ASCs located in this new CBSA. In the CY 2019 OPPS/ASC proposed rule (83 FR 37075), we provided an estimate (shown below) of this new area’s wage index based on the average hourly wages for new CBSA 46300 and the national average hourly wages from the wage data for the proposed FY 2019 wage index (described in section III.B. of the preamble of the FY 2019 IPPS/LTCH PPS proposed rule). Currently, provider 130002 is the only hospital located in Twin Falls County, Idaho, and there are no hospitals located in Jerome County, Idaho. Thus, the proposed wage index for CBSA 46300 was calculated using the average hourly wage data for one provider (provider 130002).

<table>
<thead>
<tr>
<th>Proposed National Average Hourly Wage</th>
<th>Estimated Unadjusted Wage Index for New CBSA 46300</th>
<th>Estimated Occupational Mix Adjusted Wage Index for New CBSA 46300</th>
</tr>
</thead>
<tbody>
<tr>
<td>42.990625267</td>
<td>42.948428861</td>
<td></td>
</tr>
<tr>
<td>35.833564813</td>
<td>38.127590025</td>
<td></td>
</tr>
<tr>
<td>0.8335</td>
<td>0.8878</td>
<td></td>
</tr>
</tbody>
</table>

Other than the previously described wage index, for CY 2019, the final CY 2019 ASC wage indexes fully reflect the OMB labor market area delineations (including the revisions to the OMB labor market delineations discussed above, as set forth in OMB Bulletin Nos. 15–01 and 17–01).

We note that, in certain instances, there might be urban or rural areas for which there is no IPPS hospital that has wage index data that could be used to set the wage index for that area. For these areas, our policy has been to use the average of the wage indexes for CBSAs (or metropolitan divisions as applicable) that are contiguous to the area that has no wage index (where “contiguous” is defined as sharing a border). For example, for CY 2014, we applied a proxy wage index based on this methodology to ASCs located in CBSA 25980 (Hinesville-Fort Stewart, GA) and CBSA 08 (Rural Delaware).

When all of the areas contiguous to the urban CBSA of interest are rural and there is no IPPS hospital that has wage index data that could be used to set the wage index for that area, we determine the ASC wage index by calculating the average of all wage indexes for urban areas in the State (75 FR 72058 through 72059). (In other situations, where there are no IPPS hospitals located in a relevant labor market area, we continue our current policy of calculating an urban or rural area’s wage index by calculating the average of the wage indexes for CBSAs (or metropolitan
Calculate the ASC Payment Rates

We update the ASC relative payment weights each year using the national OPPS relative payment weights (and PFS nonfacility PE RVU-based amounts, as applicable) for that same calendar year and uniformly scale the ASC relative payment weights for each update year to make them budget neutral (72 FR 42533). In the CY 2019 OPPS/ASC proposed rule (83 FR 37171), consistent with our established policy, we proposed to scale the CY 2019 relative payment weights for ASCs according to the following method. Holding ASC utilization, the ASC conversion factor, and the mix of services constant from CY 2017, we proposed to compare the total payment using the CY 2018 ASC relative payment weights with the total payment using the CY 2019 ASC relative payment weights to take into account the changes in the OPPS relative payment weights between CY 2018 and CY 2019. We proposed to use the ratio of CY 2018 to CY 2019 total payments (the weight scalar) to scale the ASC relative payment weights for CY 2019. The proposed CY 2019 ASC weight scalar was 0.8854 and scaling would apply to the ASC relative payment weights of the covered surgical procedures, covered ancillary radiology services, and certain diagnostic tests within the medicine range of CPT codes, which are covered ancillary services for which the ASC payment rates are based on OPPS relative payment weights.

Scaling would not apply in the case of ASC payment for separately payable covered ancillary services that have a predetermined national payment amount (that is, their national ASC payment amounts are not based on OPPS relative payment weights), such as drugs and biologicals that are separately paid or services that are contractor-priced or paid at reasonable cost in ASCs. Any service with a predetermined national payment amount would be included in the ASC budget neutrality comparison, but scaling of the ASC relative payment weights would not apply to those services. The ASC payment weights for those services without predetermined national payment amounts (that is, those services with national payment amounts that would be based on OPPS relative payment weights) would be scaled to eliminate any difference in the total payment between the current year and the update year.

For any given year’s ratesetting, we typically use the most recent full calendar year of claims data to model budget neutrality adjustments. At the time of the proposed rule, we had available 98 percent of CY 2017 ASC claims data. To create an analytic file to support calculation of the weight scalar and budget neutrality adjustment for the wage index (discussed below), we summarized available CY 2017 ASC claims by ASC and by HCPCS code. We used the National Provider Identifier for the purpose of identifying unique ASCs within the CY 2017 claims data. We used the supplier zip code reported on the claim to associate State, county, and CBSA with each ASC. This file, available to the public as a supporting data file for the proposed rule, is posted on the CMS website at: [http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/ASCPaymentSystem.html](http://www.cms.gov/Research-Statistics-Data-and-Systems/Files-for-Order/LimitedDataSets/ASCPaymentSystem.html).

Update the ASC Conversion Factor

Under the OPPS, we typically apply a budget neutrality adjustment for provider level changes, most notably a change in the wage index values for the upcoming year, to the conversion factor. Consistent with our final ASC payment policy, for the CY 2017 ASC payment system and subsequent years, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79751 through 79753), we finalized our policy to calculate and apply a budget neutrality adjustment to the ASC conversion factor for supplier level changes in wage index values for the upcoming year, just as the OPPS wage index budget neutrality adjustment is calculated and applied to the OPPS conversion factor. For CY 2019, we calculated the proposed adjustment for the ASC payment system by using the most recent CY 2017 claims data available and estimating the difference in total payment that would be created by introducing the proposed CY 2019 ASC wage indexes. Specifically, holding CY 2017 ASC utilization, service-mix, and the proposed CY 2019 national payment rates after application of the weight scalar constant, we calculated the total adjusted payment using the CY 2018 ASC wage indexes (which would fully reflect the new OMB delineations) and the total adjusted payment using the proposed CY 2019 ASC wage indexes. We used the 50-percent labor-related share for both total adjusted payment calculations. We then compared the total adjusted payment calculated with the CY 2018 ASC wage indexes to the total adjusted payment calculated with the proposed CY 2019 ASC wage indexes and applied the resulting ratio of 1.0003 (the proposed CY 2019 ASC wage index budget neutrality adjustment) to the CY 2018 ASC conversion factor to calculate the proposed CY 2019 ASC conversion factor.

Section 1833(i)(2)(C)(i) of the Act requires that, if the Secretary has not updated amounts established under the revised ASC payment system in a calendar year, the payment amounts shall be increased by the percentage increase in the Consumer Price Index for all urban consumers (CPI–U), U.S. city average, as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved. The statute does not mandate the adoption of any particular update mechanism, but it requires the payment amounts to be increased by the CPI–U in the absence of any update. Because the Secretary updates the ASC payment amounts annually, we adopted a policy, which we codified at 42 CFR 416.171(a)(2)(iii), to update the ASC conversion factor using the CPI–U for CY 2010 and subsequent calendar years.

In the CY 2018 OPPS/ASC rulemaking (82 FR 33668 through 33670; 59422 through 59424), we solicited and discussed comments regarding our current policy, codified at 42 CFR 416.171(a)(2)(ii), to update the ASC conversion factor using the CPI–U for CY 2010 and subsequent calendar years. In the CY 2018 OPPS/ASC final rule with comment period, we noted that in 2008 facilities paid under the ASC payment system received approximately 65 percent of the payment that hospitals paid under the OPPS received for an average service. The differential between ASC facility payment and OPPS provider payment has continued to increase since 2008, and by 2017, facilities paid under the ASC payment system received approximately 56 percent of the payment that hospitals paid under the OPPS received for an average service. At the same time, indicators of ASC payment adequacy, such as capacity and supply of providers and providers’ access to capital, suggest that Medicare beneficiaries have adequate access to ASC services.100

The Administration recognizes the value that ASCs may bring to the Medicare Program that results in the delivery of efficient, high-quality care to beneficiaries at a lower cost. The Administration is promoting greater

100MedPAC. Report to the Congress: March 2018.
price transparency across all of Medicare’s payment systems. Both beneficiaries and the Medicare Program benefit from reduced expenditures when a beneficiary’s clinical needs allow for a procedure to be performed in lower cost settings, such as ASCs relative to hospital outpatient departments.

As articulated in the FY 2019 President’s Budget, the Administration supports payment reforms that base payment on patient characteristics rather than the site of care. To that end, we are exploring ways to align payments with the costs of care and to incentivize use of the most efficient and clinically appropriate sites of care including hospital outpatient departments, ASCs, and physician offices, to the extent feasible, in future rulemaking. In the near term, however, there is concern by some stakeholders that the differential between payment updates for HOPDs and ASCs is resulting in inefficient and unnecessary shifts of care to the hospital outpatient setting and away from ASCs. We are therefore their rates are not updated based on the most efficient and clinically appropriate sites of care including hospital outpatient departments, ASCs, and physician offices, to the extent feasible, in future rulemaking. In the near term, however, there is concern by some stakeholders that the differential between payment updates for HOPDs and ASCs is resulting in inefficient and unnecessary shifts of care to the hospital outpatient setting and away from ASCs. We are concerned about the potential unintended consequences of using the CPI–U to update payments for ASCs, such as consolidation of ASCs or fewer physician-owned ASCs, which may contribute to higher prices; stagnation in number of ASC facilities and number of multispecialty ASC facilities; and payments being misaligned with the cost of treatment for complex patients.

We recognize prior public commenters’ belief that ASCs may incur some of the same costs that hospitals incur, which may be better reflected in the hospital market basket update than the CPI–U. Nevertheless, we recognize also that ASCs are among the only health care facilities in Medicare that do not submit cost information and therefore their rates are not updated based on a related market basket. We do not believe that the ASC cost structure is identical to the hospital cost structure for a few reasons (these differences are illustrative and not exhaustive). First, the majority of ASCs are single specialty (61 percent based on 2016 data), whereas hospital ownership is varied and geographically diverse locations. Third, compliance with certain laws, such as the Emergency Medical Treatment and Labor Act (EMTALA), apply to hospitals and do not apply to ASCs. These differences illustrate why there is reason to believe there is a measure of misalignment between the HOPD and ASC cost structure, and should be considered when assessing the suitability of using the hospital market basket as a better proxy for ASC costs than the CPI–U.

According to commenters on the CY 2018 OPPS/ASC proposed rule, only 8.5 percent of the CPI–U inputs are related to health care, and even those inputs are based on a consumer’s experience purchasing health care items, rather than a provider’s experience purchasing the items necessary to furnish a health care service, and do not measure whether a facility’s costs increase, such as the cost of purchasing supplies and equipment or personnel labor costs. We also acknowledge prior public commenters’ concern that the disparity in payment between the OPPS and the ASC payment system may reduce the migration of services from the HOPD setting to the less costly ASC setting. For example, one study looked at the impact of the difference in facility fees paid to ASCs versus hospital outpatient departments on ASC growth using a fixed effects model.102 The study found results indicating that, as ASC payments increase, patients are more likely to undergo outpatient procedures in an ASC than they are in a hospital. Another study found that the opening of an ASC in a hospital service area resulted in a decline in hospital-based outpatient surgery without increasing mortality or admission.103 In markets where facilities opened, procedural growth at ASCs was greater than the decline in outpatient surgery use at their respective hospitals.

If a migration of services from the hospital setting to ASCs occurred, it may potentially yield savings to the Medicare program and beneficiaries if the savings from the migration of services net of any increases in total volume of services does not exceed the cost of a higher rate update factor. ASC payment rates would still generally be significantly less than under the OPPS.

To the extent that it is clinically appropriate for a beneficiary to receive services in a lower cost setting, we believe it would be appropriate to continue to develop payment incentives and remove payment disincentives to facilitate this choice. While there are several factors that contribute to the divergence in payment between the two systems (which were identified in the comment solicitation on ASC payment reform in the CY 2018 OPPS/ASC rulemaking), such as different distribution of costs between hospitals and ASCs and different ratesetting methodologies between the OPPS and the ASC payment system, we believe that an alternative update factor could stabilize the differential between the OPPS payment and the ASC payment, to the extent that the CPI–U has been lower than the hospital market basket, and encourage the migration of services to lower cost settings as clinically appropriate (82 FR 59422 through 59424). In addition, we note that there are many services that can safely be performed in either the hospital setting or the ASC setting and a common rate update factor recognizes that the two provider types often compete for the same patients though patient acuity is likely higher in hospitals.

Therefore, we believe providing ASCs with the same rate update mechanism as hospitals could encourage the migration of services from the hospital setting to the ASC setting and increase the presence of ASCs in health care markets or geographic areas where previously there were none or few, thus promoting better beneficiary access to care. However, because physicians have a financial interest in ASCs, higher payments could also lead to greater utilization of services. At the same time, we are cognizant of concerns that Medicare does not currently collect cost data from ASCs, which makes it difficult to assess payment adequacy in the same way that it is assessed for hospitals, to validate alignment between ASC and hospital cost structure, or to establish an ASC-specific market basket. Accordingly, until we have information on the ASC cost structure, we would like to balance our desire to promote migration of services away from the HOPD to ASCs where clinically appropriate with our desire to minimize increases in beneficiary out-of-pocket costs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37173 through 37175), therefore, as described in more specific detail below, we proposed to apply a hospital market basket update to

---


ASCs for an interim period of 5 years but sought comments on ASC costs to assess whether the hospital market basket is an appropriate proxy for ASC costs. We noted that the hospital market basket is collected under OMB Control No. 0938–0050 and the information collected through hospital cost reports is used, in part, to inform the calculation of the hospital market basket.

We proposed that the hospital market basket update applied to ASC payment rates would be derived using the same hospital inpatient market basket percentage increase that we proposed to use to derive the OPPD fee increase factor as described in section II.B. of the CY 2019 OPPS/ASC proposed rule and would be adjusted for multifactor productivity. We proposed this payment update methodology for a 5-year period, during which we proposed to assess whether there is a migration of procedures from the hospital setting to the ASC setting as a result of the use of a hospital market basket update, as well as whether there are any unintended consequences (for example, an unnecessary increase in the overall volume of services or beneficiaries’ out-of-pocket costs). We believed that 5 years would be an appropriate number of years to assess changes in the migration of services, as it should provide us enough time to confirm that trends in the data are consistent over time. In the proposed rule, we welcomed comment on whether implementing the hospital market basket update for a different number of years might be more appropriate.

In the proposed rule, we stated that we were interested in commenter feedback on additional ways we can evaluate the impacts of this payment change over the 5-year period. For example, we welcomed input on how we should delineate between changes in the volume of a particular service due to the higher update, versus changes in the volume of a service due to changes in enrollment, patient acuity, or utilization, and what would be an appropriate interval to measure such migration of services.

During this 5-year period, we intend to assess the feasibility of collaborating with stakeholders to collect ASC cost data in a minimally burdensome manner and could propose a plan to collect such information. As previously mentioned, in response to the comment solicitation in the CY 2018 OPPS/ASC proposed rule, stakeholders indicated a willingness to work with CMS to collect cost information in the least burdensome manner (82 FR 59422 through 59424).

Therefore, for CY 2019 through 2023, in response to stakeholder concerns described in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59420 through 59421) that ASCs may incur some of the same costs that hospitals incur and that are better reflected in the hospital market basket update than the CPI–U, and including the concern that the payment differentials between the different settings of care due to the use of the CPI–U may stagnate the migration of services from hospitals to the ASC setting, even though those services can be safely performed in ASCs, we proposed to update ASC payment rates using the hospital market basket and to revise our regulations under 42 CFR 416.171(a)[2], which address the annual update to the ASC conversion factor, to reflect this proposal. In addition, we requested comments and evidence to assess whether the hospital market basket is an appropriate proxy for ASC costs. Under this proposal, for CY 2019, we proposed to use the FY 2019 hospital market basket update as published in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20381). This proposed update to ASC payment rates was derived using the same hospital inpatient market basket percentage increase that we proposed to use to derive the OPPD fee increase factor as described in section II.B. of the CY 2019 OPPS/ASC proposed rule. We also sought comments on an alternative proposal to maintain using the CPI–U for the annual ASC payment update while collecting evidence to justify a different payment update, or adopting the new proposed payment update based on the hospital market basket permanently. We requested comments on what type of evidence should be used to justify a different payment update and how CMS should go about collecting that information in the least burdensome way possible.

Section 1833(f)(3)(G)(v) of the Act applies an additional adjustment of 0.75 for CY 2019 to hospitals. We noted that such adjustment was authorized by the Affordable Care Act and that, while the Affordable Care Act authorized a productivity adjustment for ASCs (as it did for hospitals), it expressly did not authorize the “additional adjustment” that was mandated for hospitals. The additional adjustment is separate and distinct from the productivity adjustment that already applies to both hospitals and ASCs and there does not appear to be a correlation between the productivity adjustment and the additional adjustment. Further, application of the additional adjustment may be contrary to the goals we have articulated that led us to propose to apply the hospital market basket to the ASC payment system in the first place; that is, we believe that proposing to apply the hospital market basket to ASC rates may encourage the migration of services from the hospital setting to the ASC setting. However, if we had proposed to apply the additional adjustment, the ASC rate update would have been 1.25 percent, instead of the proposed 2.0 percent. The 1.25 percent was lower than applying the CPI–U rate update factor, which at the time of the CY 2019 OPPS/ASC proposed rule would have been 1.3 percent for CY 2019. This lower update would appear contrary to the goals set forth earlier in this section. However, we sought comment on whether applying this additional adjustment may nonetheless be appropriate.

While we expect this policy will increase spending, by both the government and beneficiaries, relative to the current update factor over the 5-year period, as previously stated, we also believe that the proposal could encourage the migration of services that are currently performed in the hospital outpatient setting to the ASC setting, which could result in savings to beneficiaries and the Medicare program. We believe that it is important to maximize patient choice to obtain services at a lower cost to the extent feasible. We believe also that without cost data from ASCs to examine their cost structure and adequacy of payment, we lack key data that may inform the development of payment policies that are based on patients’ clinical needs rather than the site of care.

In the proposed rule, we stated that, if, after review of all comments and all available evidence, we chose to finalize this proposal, we would continue to monitor site-of-service shifts for the duration of this policy to determine if services move safely to lower cost settings and to explore collecting additional data that may help inform further development of the ASC payment system. We proposed to continue to use the adjusted hospital market basket update through CY 2023 (for 5 years total). We proposed that we intend to reassess whether application of the hospital market basket update to ASC rates has provided more patient choice to obtain services at a lower cost beginning with the CY 2024 rulemaking period, or sooner if appropriate.

Section 3401(k) of the Affordable Care Act amended section 1833(i)(2)(D) of the Act by adding a new clause (v) which requires that any annual update under the ASC payment system for the year,
after application of clause (iv), shall be reduced by the productivity adjustment described in section 1866(b)(3)(B)(xi)(II) of the Act, effective with the calendar year beginning January 1, 2011. The statute defines the productivity adjustment to be equal to the 10-year moving average of changes in annual economy-wide private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period ending with the applicable fiscal year, year, cost reporting period, or other annual period) (the “MFP adjustment”). Clause (iv) of section 1833(i)(2)(D) of the Act authorizes the Secretary to provide for a reduction in any annual update for failure to report on quality measures. Clause (v) of section 1833(i)(2)(D) of the Act states that application of the MFP adjustment to the ASC payment system may result in the update to the ASC payment system being less than zero for a year and may result in payment rates under the ASC payment system for a year being less than such payment rates for the preceding year.

In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74516), we finalized a policy that ASCs begin submitting data on quality measures for services beginning on October 1, 2012 for the CY 2014 payment determination under the ASC Quality Reporting (ASCQR) Program. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499 through 68500), we finalized a methodology to calculate reduced national unadjusted payment rates using the ASCQR Program reduced update conversion factor that would apply to ASCs that fail to meet their quality reporting requirements for the CY 2014 payment determination and subsequent years. The application of the 2.0 percentage point reduction to the annual update factor, which we proposed to be the hospital market basket update factor for a year is negative, we proposed to hold the hospital market basket update factor for the ASC payment system to zero. For the CY 2014 payment determination and subsequent years, under section 1833(i)(2)(D)(iv) of the Act, we would reduce the annual update by 2.0 percentage points for an ASC that fails to submit quality information under the policies established by the Secretary in accordance with section 1833(i)(7) of the Act. Section 1833(i)(2)(D)(v) of the Act, as added by section 3401(k) of the Affordable Care Act, requires that the Secretary reduce the annual update factor, after application of any quality reporting reduction, by the MFP adjustment, and states that application of the MFP adjustment to the annual update factor after application of any quality reporting reduction may result in the update being less than zero for a year. If the application of the MFP adjustment to the annual update factor after application of any quality reporting reduction would result in an MFP-adjusted update factor that is less than zero, the resulting update to the ASC payment rates would be negative and payments would decrease relative to the prior year. We refer readers to the CY 2011 OPPS/ASC final rule with comment period (75 FR 72062 through 72064) for examples of how the MFP adjustment is applied to the ASC payment system.

For the CY 2019 OPPS/ASC proposed rule, the hospital market basket update for CY 2019 was projected to be 2.8 percent discussed above, which resulted in a proposed CY 2019 ASC conversion factor of 0.8 percentage point minus the MFP adjustment of 0.8 percentage point, resulting in an MFP-adjusted hospital market basket update factor of 2.0 percent for ASCs meeting the quality reporting requirements. Therefore, we proposed to apply a 2.0 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs meeting the quality reporting requirements to determine the CY 2019 ASC payment amounts. The ASCQR Program affected payment rates beginning in CY 2014 and, under this program, there is a 2.0 percentage point reduction to the update factor for ASCs that fail to meet the ASCQR Program requirements. We proposed to utilize the hospital market basket update of 2.8 percent reduced by 2.0 percentage points for ASCs that do not meet the quality reporting requirements and then subtract the 0.8 percentage point MFP adjustment. Therefore, we proposed to apply a 0.0 percent MFP-adjusted hospital market basket update factor to the CY 2018 ASC conversion factor for ASCs not meeting the quality reporting requirements. We also proposed that if more recent data were subsequently available (for example, a more recent estimate of the hospital market basket update and MFP), we would use such data, if appropriate, to determine the CY 2019 ASC update for the final rule with comment period.

For CY 2019, we proposed to adjust the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0003 in addition to the MFP-adjusted hospital market basket update factor of 2.0 percent discussed above, which resulted in a proposed CY 2019 ASC conversion factor.
factor of $46,500 for ASCs meeting the quality reporting requirements. For
ASCs not meeting the quality reporting requirements, we proposed to adjust the
CY 2018 ASC conversion factor ($45.575) by the proposed wage index
budget neutrality factor of 1.0003 in addition to the quality reporting/MFP-
adjusted hospital market basket update factor of 0.0 percentage point discussed above,
which resulted in a proposed CY 2019 ASC conversion factor of $45.589.

Comment: The majority of
commenters supported the proposal to
update ASC payment rates using the
hospital market basket update. A
number of commenters suggested that
the CPI–U is not a suitable inflation
index to update ASC payments because
it does not accurately represent the costs
of ASCs or health care facilities,
broadly. One commenter noted that only
8 percent of the CPI–U index is
comprised of health care–related items and
no other Medicare payment system
utilizes the CPI–U as a provider
inflation-metric as many payment systems
for other providers utilize a
provider-specific market basket index.
The commenter also noted that, while
the hospital market basket update is the most appropriate update factor to apply
to ASC payment system rates, alternative update factors (for example, the Medicare Economic Index) would have been preferable to the CPI–U.

Other commenters in support of the proposal suggested that ASCs may incur
some of the same costs that hospitals incur. In addition, commenters
suggested that utilizing the hospital
market basket update as the update
mechanism would promote site
neutrality and help restore relativity of
average ASC payment rates to average
HOPD payment rates. Some commenters
recommended that CMS establish the hospital market basket update permanently as the ASC rate update mechanism rather than on an interim basis over 5 years.

Commenters also supported the
proposal to not apply the additional
adjustment of 0.75 percentage points that applies to hospitals under section 1833(l)(3)[G](v) of the Act.

However, some commenters,
including MedPAC, disagreed with the proposal and recommended collecting
cost data from ASCs to inform an ASC-
specific market basket index for
updating payment rates under the ASC payment system. MedPAC noted that
ASCs are fully capable of submitting
cost report data, similar to other
providers, such as ESRD facilities,
hospital and ESRD facilities, and
health agencies. In addition, MedPAC suggested that, to minimize burden on ASCs and CMS,
CMS could require all ASCs to submit streamlined cost reports or require a
random sample of ASCs to submit cost data.

Response: We appreciate the
commenters’ support. We recognize the
commenters’ belief that ASCs may incur
some of the same costs that hospitals incur, which may be better reflected in
the hospital market basket update than the
CPI–U. We also are aware that only
a relatively small percentage of the CPI–
U inputs are related to health care, and
even those inputs are based on a
consumer’s experience purchasing
health care items, rather than a
provider’s experience purchasing the
items necessary to furnish a health care
service, and do not directly relate to a
facility’s costs, such as the cost of
purchasing supplies and equipment or
labor costs. We also acknowledge
commenters’ concern that the disparity in payments between the OPPS and the ASC payment system may reduce the
migration of services from the HOPD
setting to the less costly ASC setting. We
believe providing ASCs with the same
rate update mechanism as hospitals
could encourage the migration of
services from the hospital setting to the
ASC setting and increase the presence of
ASCs in health care markets or
geographic areas where previously there
were none or few, thus promoting better
beneficiary access to care. We believe
that it is important to encourage such
migration of services and that this policy
would give physicians and
patients greater choice in selecting the
best care setting.

In addition, we acknowledge
commenters recommendations
regarding the collection of ASC cost data to inform an ASC-specific market
basket index for updating payment rates
under the ASC payment system. We
appreciate these comments and will
take these comments into consideration in future policy development.

Comment: Many commenters
recommended that CMS discontinue
“rescaling” the ASC relative weights and, instead, apply the OPPS relative
weights as developed under the
standard ratesetting methodology. The
commenters argued that the weight
scalar distorts ASC payments and
further increases the payment
differential between HOPDs and ASCs.

Response: We note that applying the
weight scalar in calculation of ASC
payment rates, which for this final rule
with comment period is 0.8792, ensures
that the ASC payment system remains
budget neutral. For a detailed
discussion of how to apply a budget
neutrality adjustment to the ASC
ratesetting methodology, we refer
readers to the August 2, 2008 final rule
(72 FR 42531 through 42533).

After consideration of the public
comments we received, we are
finalizing our proposal to apply the
hospital market basket update to ASC
payment system rates for an interim
period of 5 years (CY 2019 through CY
2023), during which we will assess
whether there is a migration of the
performance of procedures from the
hospital setting to the ASC setting as a
result of the use of a hospital market
basket update, as well as whether there
are any unintended consequences, such
as less than expected migration of the
performance of procedures from the
hospital setting to the ASC setting. In
addition, we are finalizing our proposal
to revise our regulations under 42 CFR
416.171(a)(2), which address the annual update to the ASC conversion factor.

Therefore, as proposed, to determine the CY 2019 ASC update for this final
rule with comment period, we are
incorporating a more recent estimate of the hospital market basket update and
the MFP adjustment. For this CY 2019
OPPS/ASC final rule with comment
period, as published in the FY 2019
IPPS/LTCH PPS final rule (83 FR
41395), based on IGI’s 2018 second
quarter forecast with historical data
through the first quarter of 2018, the
MFP-adjusted hospital market basket
update for CY 2019 is 2.1 percent (that is, the hospital market basket increase of
2.9 percent minus the MFP adjustment
of 0.8 percentage point). Therefore, we
are finalizing the application of a 2.1
percent MFP-adjusted hospital market
basket update factor to the CY 2018 ASC
conversion factor for ASCs meeting the
quality reporting requirements to
determine the CY 2019 ASC payment
amounts. The ASCQR Program affected
payment rates beginning in CY 2014
and, under this program, there is a 2.0
percentage point reduction to the
update factor for ASCs that fail to meet
the ASCQR Program requirements. We
are finalizing to utilize the hospital
market basket update of 2.9 percent
reduced by 2.0 percentage points for
ASCs that do not meet the quality
reporting requirements and then
subtract the 0.8 percentage point MFP
adjustment. Therefore, we are applying
a 0.1 percent MFP-adjusted hospital
market basket update factor to the CY
2018 ASC conversion factor for ASCs
not meeting the quality reporting
requirements.

For CY 2019, we are adjusting the CY
2018 ASC conversion factor ($45.575)
by the proposed wage index
budget neutrality factor of 1.0003 in addition to the MFP-adjusted hospital market
basket update factor of 2.1 percent

Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59079
discussed above, which results in a CY 2019 ASC conversion factor of $46.551 for ASCs meeting the quality reporting requirements. For ASCs not meeting the quality reporting requirements, we are adjusting the CY 2018 ASC conversion factor ($45.575) by the proposed wage index budget neutrality factor of 1.0004 in addition to the quality reporting/ MFP-adjusted hospital market basket update factor of 0.1 percent discussed above, which results in a CY 2019 ASC conversion factor of $45.639.

3. Display of CY 2019 ASC Payment Rates

Addenda AA and BB to this final rule with comment period (which are available on the CMS website) display the final updated ASC payment rates for CY 2019 for covered surgical procedures and covered ancillary services, respectively. For those covered surgical procedures and covered ancillary services where the payment rate is the lower of the final rates under the ASC standard ratesetting methodology and the MPFS final rates, the final payment indicators and rates set forth in this final rule with comment period are based on a comparison using the final PFS rates that will be effective January 1, 2019. For a discussion of the PFS rates, we refer readers to the CY 2019 PFS final rule with comment period.

The final payment rates included in these addenda reflect the full ASC payment update and not the reduced payment update used to calculate payment rates for ASCs not meeting the quality reporting requirements under the ASCQR Program. These addenda contain several types of information related to the final CY 2019 payment rates. Specifically, in Addendum AA, a “Y” in the column titled “To be Subject to Multiple Procedure Discounting” indicates that the surgical procedure would be subject to the multiple procedure payment reduction policy. As discussed in the CY 2008 OPPS/ASC final rule with comment period (72 FR 66829 through 66830), most covered surgical procedures are subject to a 50-percent reduction in the ASC payment for the lower-paying procedure when more than one procedure is performed in a single operative session.

Display of the comment indicator “CH” in the column titled “Comment Indicator” indicates a change in payment policy for the item or service, including identifying discontinued HCPCS codes, designating items or services newly payable under the ASC payment system, and identifying items or services in the ASC payment indicator for CY 2018. Display of the comment indicator “NT” in the column titled “Comment Indicator” indicates that the code is new (or substantially revised) and that comments will be accepted on the interim payment indicator for the new code. Display of the comment indicator “NP” in the column titled “Comment Indicator” indicates that the code is new (or substantially revised) and that comments will be accepted on the ASC payment indicator for the new code.

The values displayed in the column titled “Final CY 2019 Payment Weight” are the final relative payment weights for each of the listed services for CY 2019. The final relative payment weights for all covered surgical procedures and covered ancillary services where the ASC payment rates are based on OPPS relative payment weights were scaled for budget neutrality. Therefore, scaling was not applied to the device portion of the device-intensive procedures, services that are paid at the MPFS nonfacility PE RVU-based amount, separately payable covered ancillary services that have a predetermined national payment amount, such as drugs and biologicals and brachytherapy sources that are separately paid under the OPPS, or services that are contractor-priced or paid at reasonable cost in ASCs.

To derive the final CY 2019 payment rate displayed in the “Final CY 2019 Payment Rate” column, each ASC payment weight in the “Final CY 2019 Payment Weight” column was multiplied by the final CY 2019 conversion factor of $46.551. The final conversion factor includes a budget neutrality adjustment for changes in the wage index values and the annual update factor as reduced by the productivity adjustment (as discussed in section XII.G.2.b. of this final rule with comment period).

In Addendum BB, there are no relative payment weights displayed in the “Final CY 2019 Payment Weight” column for items and services with predetermined national payment amounts, such as separately payable drugs and biologicals. The “Final CY 2019 Payment” column displays the final CY 2019 national unadjusted ASC payment rates for all items and services. The final CY 2019 ASC payment rates listed in Addendum BB for separately payable drugs and biologicals are based on ASP data used for payment in physicians’ offices in October 2018.

Addendum EE provides the HCPCS codes and short descriptors for surgical procedures that are to be excluded from payment in ASCs for CY 2019.

XIII. Requirements for the Hospital Outpatient Quality Reporting (OQR) Program

A. Background

CMS seeks to promote higher quality and more efficient healthcare for Medicare beneficiaries. Consistent with these goals, CMS has implemented quality reporting programs for multiple care settings including the quality reporting program for hospital outpatient care, known as the Hospital Outpatient Quality Reporting (OQR) Program, formerly known as the Hospital Outpatient Quality Data Reporting Program (HOP QDRP). The Hospital OQR Program is generally aligned with the quality reporting program for hospital inpatient services known as the Hospital Inpatient Quality Reporting (IQR) Program (formerly known as the Reporting Hospital Quality Data for Annual Payment Update (RHQAPU) Program). In addition to the Hospital IQR and Hospital OQR Programs, CMS has implemented quality reporting programs as well as value-based purchasing programs for other care settings.

We refer readers to section IA.2. of this final rule with comment period where we discuss our new Meaningful Measures Initiative and our approach in evaluating quality program measures.

2. Statutory History of the Hospital OQR Program

We refer readers to the CY 2011 OPPS/ASC final rule with comment period (75 FR 72064 through 72065) for a detailed discussion of the statutory history of the Hospital OQR Program.

3. Regulatory History of the Hospital OQR Program

We refer readers to the CY 2008 through 2018 OPPS/ASC final rules with comment period (72 FR 66860 through 66875; 73 FR 68758 through 68779; 74 FR 60629 through 60656; 75 FR 72064 through 72116; 76 FR 74451 through 74462; 77 FR 68492; 78 FR 75090 through 75120; 79 FR 66940 through 66966; 80 FR 70502 through 70526; and 81 FR 79753 through 79797; 82 FR 59424 through 59445). We have also codified certain requirements under the Hospital OQR Program at 42 CFR 419.46.

4. Meaningful Measures Initiative

In the CY 2019 OPPS/ASC proposed rule, we proposed a number of new policies for the Hospital OQR Program (74 FR 37579). We developed these proposals after conducting an overall review of the program under our new
Meaningful Measures Initiative, which is discussed in more detail in section I.A.2. of this final rule with comment period. The proposals reflect our efforts to ensure that the Hospital OQR Program measure set continues to promote improved health outcomes for our beneficiaries while minimizing costs, which can consist of several different types of costs including, but not limited to: (1) Facility information collection burden and related cost and burden associated with the submitting/reporting of quality measures to CMS; (2) the facility cost associated with complying with other quality programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure, including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). These proposals also reflect our efforts to improve the usefulness of the data that we publicly report in the Hospital OQR Program. Our goal is to improve the usefulness and usability of CMS quality program data by streamlining how facilities are reporting and accessing data, while maintaining or improving consumer understanding of the data publicly reported on a Compare website. We believe this framework will allow hospitals and patients to continue to obtain meaningful information about HOPD performance and incentivize quality improvement while also streamlining the measure sets to reduce duplicative measures and program complexity so that the costs to hospitals associated with participating in this program do not outweigh the benefits of improving beneficiary care.

B. Hospital OQR Program Quality Measures

1. Considerations in the Selection of Hospital OQR Program Quality Measures

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74458 through 74460) for a detailed discussion of the priorities we consider for the Hospital OQR Program quality measure selection. In the CY 2019 OPPS/ASC proposed rule (83 FR 37176) we did not propose any changes to these policies.

2. Accounting for Social Risk Factors in the Hospital OQR Program

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425 through 59427), we discussed the importance of improving beneficiary outcomes including reducing health disparities. We also discussed our commitment to ensuring that medically complex patients, as well as those with social risk factors, receive excellent care. We discussed how studies show that social risk factors, such as being near or below the poverty level as determined by HHS, belonging to a racial or ethnic minority group, or living with a disability, can be associated with poor health outcomes and how some of this disparity is related to the quality of health care.105 Among our core objectives, we aim to improve health outcomes, attain health equity for all beneficiaries, and ensure that complex patients as well as those with social risk factors receive excellent care. Within this context, reports by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the National Academy of Medicine have examined the influence of social risk factors in CMS value-based purchasing programs.106 As we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425), ASPE’s report to Congress found that, in the context of value-based purchasing programs, dual eligibility was the most powerful predictor of poor health care outcomes among those social risk factors that they examined and tested. In addition, as we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59425), the National Quality Forum (NQF) undertook a 2-year trial period in which certain new measures and measures undergoing maintenance review have been assessed to determine if risk adjustment for social risk factors is appropriate for these measures.107 The trial period ended in April 2017 and a final report is available at: http://www.qualityforum.org/SES_Trial_Period.aspx. The trial concluded that “measures with a conceptual basis for adjustment generally did not demonstrate an empirical relationship” between social risk factors and the outcomes measured. This discrepancy may be explained in part by the methods used for adjustment and the limited availability of robust data on social risk factors. NQF has extended the socioeconomic status (SES) trial,108 allowing further examination of social risk factors in outcome measures.

In the FY 2018 and CY 2018 proposed rules for our quality reporting and value-based purchasing programs, we solicited feedback on which social risk factors provide the most valuable information to stakeholders and the methodology for illuminating differences in outcomes rates among patient groups within a hospital or facility that would also allow for a comparison of those differences, or disparities, across facilities. Feedback we received through our quality reporting programs included encouraging CMS to explore whether factors that could be used to stratify or risk adjust the measures (beyond dual eligibility); considering the full range of differences in patients’ backgrounds that might affect outcomes; exploring risk adjustment approaches; and offering careful consideration of what type of information display would be most useful to the public. We also sought public comment on confidential reporting and future public reporting of some of our measures stratified by patient dual eligibility. In general, commenters noted that stratified measures could serve as tools for hospitals to identify gaps in outcomes for different groups of patients, improve the quality of health care for all patients, and empower beneficiaries and other consumers to make informed decisions about health care. Commenters encouraged us to stratify measures by other social risk factors such as age, income, and educational attainment.

With regard to value-based purchasing programs, commenters also cautioned to balance fair and equitable payment while avoiding payment penalties that mask health disparities or discourage the provision of care to more medically complex patients. Commenters also noted that value-based purchasing program measure selection, domain


weighting, performance scoring, and payment methodology must account for social risk.

As a next step, CMS is considering options to reduce health disparities among patient groups within and across health care settings by increasing the transparency of disparities as shown by quality measures. We also are considering how this work applies to other CMS quality programs in the future. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38403 through 38409) for more details, where we discuss the potential stratification of certain Hospital IQR Program outcome measures. Furthermore, we continue to consider options to address equity and disparities in our value-based purchasing programs.

We plan to continue working with ASPE, the public, and other key stakeholders on this important issue to identify policy solutions that achieve the goals of attaining health equity for all beneficiaries and minimizing unintended consequences.

While we did not specifically request comment on social risk factors in the CY 2019 proposed rule, we received several comments with respect to social risk factors. We thank commenters for sharing their views and their willingness to support the efforts of CMS and NQF on this important issue. We take this feedback seriously and will continue to review social risk factors on an on-going and continuous basis. In addition, we both welcome and appreciate stakeholder feedback as we continue our work on these issues.

3. Retention of Hospital OQR Program Measures Adopted in Previous Payment Determinations

We previously adopted a policy to retain measures from a previous year’s Hospital OQR Program measure set for subsequent years’ measure sets as proposed.

4. Removal of Quality Measures From the Hospital OQR Program Measure Set

In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60315), we finalized a process to use the regular rulemaking process to remove a measure for circumstances for which we do not believe that continued use of a measure raises specific patient safety concerns. In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we did not propose any changes to this policy; however, we proposed to codify this policy at 42 CFR 419.46(h)(3). We refer readers to section XIII.B.4.a. of this final rule with comment period for more details.

We did not receive any public comments and are finalizing our proposal to codify at 42 CFR 419.46(h)(3) our policy to use the regular rulemaking process to remove a measure for circumstances for which we do not believe that continued use of a measure raises specific patient safety concerns as proposed.

a. Considerations in Removing Quality Measures From the Hospital OQR Program

1. Immediate Removal

In the CY 2010 OPPS/ASC final rule with comment period (74 FR 60634 through 60635), we finalized a process for immediate retirement, which we later termed “removal,” of Hospital OQR Program measures, based on evidence that the continued use of the measure as specified raise patient safety concerns. In the CY 2019 OPPS/ASC proposed rule (83 FR 37177), we did not propose any changes to our policy to immediately remove measures as a result of patient safety concerns; however, we proposed to codify that policy at 42 CFR 419.46(h)(2). We did not receive any public comments and are finalizing our proposal to codify at 42 CFR 419.46(h)(2) our policy to immediately remove measures as a result of patient safety concerns as proposed.

2. Consideration Factors for Removing Measures

In the CY 2013 OPPS/ASC final rule with comment period, we finalized a set of factors for determining whether to remove measures from the Hospital OQR Program (77 FR 68472 through 68473). These factors are:

• Factor 1. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

• Factor 2. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

• Factor 3. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

• Factor 7. Collection or public reporting of a measure leads to negative unintended consequences such as patient harm.

In addition, we refer readers to the FY 2015 OPPS/ASC final rule with comment period where we finalized the criteria for determining when a measure is “topped out” (79 FR 66769). In that final rule with comment period, we finalized two criteria for determining when a measure is “topped out” under the Hospital OQR Program: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 66942).

The benefits of removing a measure from the Hospital OQR Program are assessed on a case-by-case basis (79 FR 66941 through 66942). In the proposed rule, we noted that, under this case-by-case approach, a measure will not be removed solely on the basis of meeting any specific factor. We also noted that in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967), a similar measure removal policy was finalized for the ASCQR Program.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37177 through 37178), we...
proposed: (1) Update measure removal Factor 7; (2) add a new removal Factor 8; and (3) codify our measure removal policies and factors at 42 CFR 419.46(h) effective upon finalization of the CY 2019 OPPS/ASC final rule and for subsequent years. We also provided clarification of our “topped-out” criteria.

(3) Update To Measure Removal Factor 7

As shown above, Factor 7 under the Hospital OQR Program states, “collection or public reporting of a measure leads to negative unintended consequences such as patient harm.” In contrast, under the ASCQR Program, Factor 7 reads as follows, “collection or public reporting of a measure leads to negative unintended consequences other than patient harm” (79 FR 66967). We believe the wording in the ASCQR Program is more appropriate because measures causing patient harm would be removed immediately, outside of the program, whereas under the Hospital OQR Program, a measure could remain in the program for subsequent years. We also proposed this same removal factor for the ASCQR Program.

Response: Several commenters supported CMS’ proposal to update measure removal Factor 7 to read, “collection or public reporting of a measure leads to negative unintended consequences other than patient harm” to align with the ASCQR Program.

(4) New Measure Removal Factor 8

In the CY 2019 OPPS/ASC proposed rule (83 FR 37178 through 37179), we proposed to adopt an additional factor to consider when evaluating measures for removal from the Hospital OQR Program measure set:

- **Factor 8.** The costs associated with a measure outweigh the benefit of its continued use in the program.

As we discuss in section I.A.2. of the proposed rule and this final rule with comment period with respect to our new Meaningful Measures Initiative, we are engaging in efforts to ensure that the Hospital OQR Program measure set continues to promote improved health outcomes for beneficiaries while minimizing the overall costs associated with the program. We believe these costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. We have identified several different types of costs, including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other Federal and State regulations (if applicable). For example, it may be needlessly costly and/or of limited benefit to retain or maintain a measure which our analyses show no longer meaningfully supports program objectives (for example, informing beneficiary choice or payment scoring). It may also be costly for health care providers to track confidential feedback, preview reports, and publicly report information on a measure where we use the measure in more than one program. CMS may also have to expend unnecessary resources to maintain the specifications for the measure, as well as the tools needed to collect, validate, analyze, and publicly report the measure data. Furthermore, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

In weighing the costs against the benefits, we evaluate the benefits of the measure, but, we assess the benefits through the framework of our Meaningful Measures Initiative, as we discussed in section I.A.2. of the proposed rule and this final rule with comment period. One key aspect of patient benefits is assessing the improved beneficiary health outcomes if a measure is retained in our measure set. We believe that these benefits are multifaceted and are illustrated through the Meaningful Measures framework’s 6 domains and 19 areas. For example, we assessed the Healthcare Worker Influenza Vaccination and patient Influenza Vaccination measures categorized in the Quality Priority “Promote Effective Prevention and Treatment of Chronic Disease” in the meaningful measure area of “Preventive Care” across multiple CMS programs, and considered: Patient outcomes, such as mortality and hospitalizations associated with influenza; CMS measure performance in a program; and other available and reported influenza process measures, such as population influenza vaccination coverage.

When these costs outweigh the evidence supporting the benefits to patients with the continued use of a measure in the Hospital OQR Program, we believe it may be appropriate to remove the measure from the program. Although we recognize that one of the main goals of the Hospital OQR Program is to improve beneficiary outcomes by incentivizing health care facilities to focus on specific care issues and making public data related to those issues, we also recognize that those goals can have limited utility where, for example, the publicly reported data (including percentage payment adjustment data) is of limited use because it cannot be easily interpreted by beneficiaries, and used to inform their choice of facility.

In these cases, removing the measure from the Hospital OQR Program may better accommodate the costs of program administration and compliance without sacrificing improved health outcomes and beneficiary choice.

We proposed that we would remove measures based on this factor assessing costs versus benefits on a case-by-case basis. We might, for example, decide to retain a measure that is burdensome for health care facilities to report if we conclude that the benefit to beneficiaries justifies the reporting burden. Our goal is to move the program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures and continuing to incentivize improvement in the quality of care provided to patients.

We refer readers to section XIII.B.4.b. of the proposed rule (83 FR 37179 through 37186), where we proposed to remove two measures based on this proposed measure removal factor. In the proposed rule, we noted that we also proposed this same removal factor for the ASCQR Program in section XIV.B.3.b. of the proposed rule (83 FR 37195 through 37196), as well as for other quality reporting and value-based purchasing programs for FY 2019 including: The Hospital Value-Based Purchasing (VBP) Program (78 FR 20409), the Hospital OQR Program (83 FR 20472); the PPS-exempt Cancer...
Hospital Quality Reporting (PCHQR) Program (83 FR 20501 through 20502); the Long-Term Care Hospital Quality Reporting Program (LTCH QRP) (83 FR 20512); the Hospice Quality Reporting Program (HQRQ) (83 FR 20956); the Inpatient Rehabilitation Facility Quality Reporting Program (IRF QRP) (83 FR 21000); the Skilled Nursing Facility Quality Reporting Program (SNF QRP) (83 FR 21082); and the Inpatient Psychiatric Facilities Quality Reporting (IPFQQR) Program (83 FR 21118).

We invited public comment on our proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, beginning with the effective date of the CY 2010 OPPS/ASC final rule with comment period and for subsequent years.

Comment: Several commenters supported CMS’ proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweighing, but not limited to, its continued use in the program. A few commenters noted that this removal factor will help CMS to remove unnecessary cost and burden from the Hospital OQR Program and allow providers of care to focus on improving quality through innovation. Commenters also praised CMS for aligning this and other removal factors across quality reporting programs.

Response: We thank the commenters for their support.

Comment: A few commenters opposed CMS’ proposal to add a new measure removal Factor 8. A few commenters requested clarification on the types of costs that CMS will consider and requested transparency in the process of evaluation in the costs and benefits of measures. One commenter expressed concern that the costs described under measure removal Factor 8 are not defined. One commenter noted that there are costs associated with changing measures to facilities, providers, and measure developers. Another commenter expressed concern that CMS may deem a measure too costly to implement, while providers and patients may continue to find it meaningful. Commenters also recommended direct and indirect costs that CMS may consider in evaluating measures under measure removal Factor 8. These costs included those associated with: (1) Measures that require data collection from multiple data sources, rather than just one; (2) contracting with vendors; (3) tracking performance and investing in resources for quality improvement.

One commenter stated it opposed the new factor unless costs and benefits are defined as only costs and benefits to beneficiaries and the public.

Response: As noted in the proposed rule (83 FR 37176), we have defined costs, for the purpose of evaluating measures under proposed measure removal Factor 8, as including but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). This was not intended to be a complete list of the potential factors to consider in evaluating measures. In addition, as we apply this measure removal factor in future rulemaking, we will describe our rationale for the removal of a measure and will include the costs and benefits we considered.

We thank commenters for their suggestions regarding additional costs to consider. We will use this feedback as well as input from all stakeholders as we apply measure removal Factor 8 in future rulemaking.

Response: We believe that various stakeholders may have different perspectives on how to define costs as well as benefits. Because of these challenges, we intend to evaluate each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program.

Comment: A few commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Some commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Comment: A few commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Some commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Some commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Some commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the Hospital OQR Program. Some commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.
measure should be potentially removed from the Hospital OQR Program measure set. In addition, we note that in this final rule with comment period, we are not finalizing our proposals to remove two measures under Factor 8: OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients, and OP–31: Cataracts—Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery. This is discussed in more detail further below.

After consideration of the public comments we received, we are finalizing our proposal to adopt measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the Hospital OQR Program beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, as proposed.

As a result of the finalization of our proposals to update measure removal Factor 7 and add new removal Factor 8 as proposed, the new measure removal factors list for the Hospital OQR Program consists of the following:

- **Factor 1.** Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped out”) measures.
- **Factor 2.** Performance or improvement on a measure does not result in better patient outcomes.
- **Factor 3.** A measure does not align with current clinical guidelines or practice.
- **Factor 4.** The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic.
- **Factor 5.** The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic.
- **Factor 6.** The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.
- **Factor 7.** Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.
- **Factor 8.** The costs associated with a measure outweigh the benefit of its continued use in the program.

(5) Codification at 42 CFR 419.46(h)(2) and (3)

In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we proposed to codify our measure removal policies, including proposals made in the proposed rule, if finalized, at 42 CFR 419.46(h)(2) and (3).

We did not receive any public comments and are finalizing our proposal to codify our measure removal policies, at 42 CFR 419.46(h)(2) and (3) as proposed.

(6) Clarification of Removal Factor 1: “Topped-Out” Measures

As noted above, we refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66769), where we finalized the criteria for determining when a measure is “topped-out.” In that final rule with comment period, we finalized two criteria for determining when a measure is “topped out” under the Hospital OQR Program: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation (TCOV) is less than or equal to 0.10 (79 FR 66942).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37179), we clarified our process for calculating the truncated coefficient of variation (TCOV), particularly for two of the measures (OP–11 and OP–14) proposed for removal from the Hospital OQR Program. In accordance with our finalized methodology (79 FR 66942), we determine the truncated coefficient of variation (TCOV) by calculating the truncated standard deviation (SD) divided by the truncated mean. As discussed above, our finalized removal criteria state that to be considered “topped-out,” a measure must have a truncated TCOV of less than 0.10. We utilize the TCOV because it is generally a good measure of variability and provides a relative methodology for comparing different types of measures.

Unlike the majority of the measures, for which a higher rate (indicating a higher proportion of a desired event) is the preferred outcome, some measures—in particular, OP–11 and OP–14—assess the rate of rare, undesired events for which a lower rate is preferred. For example, OP–11 assesses the use of both a contrast and non-contrast CT Thorax study at the same time, which is not recommended, as no clinical guidelines or peer-reviewed literature supports such CT Thorax “combined studies.” However, when determining the TCOV for a measure assessing rare, undesired events, the mean—or average rate of event occurrence—is very low, and the result is a TCOV that increases rapidly and approaches infinity as the proportion of rare events declines. In the proposed rule, we noted that the SD, the variability statistic, is the same in magnitude for measures assessing rare and non-rare events.

In the proposed rule, we proposed to remove two measures that assess the rate of rare, undesired events for which a lower rate is preferred—OP–11 and OP–14—and refer readers to section XIII.B.4.b.(2)(c) of the proposed rule and this final rule with comment period, where these proposals are discussed in detail. Because by design these measures have maintained very low rates of rare, undesired events (indicating the preferred outcomes), we utilized the mean of non-adverse events in our calculation of the TCOV. For example, for OP–11, to calculate the TCOV, we divide the SD by the average rate of patients not receiving both contrast and non-contrast abdominal CT (1.0 minus the rate of patients receiving both), rather than the rate of those receiving both types of CT. Utilizing this methodology results in a TCOV that is comparable to that calculated for other measures and allows us to assess rare-event measures by still generally using our previously finalized topped-out criteria.

b. Removal of Quality Measures From the Hospital OQR Program Measure Set

In the CY 2019 OPPS/ASC proposed rule (83 FR 37179 through 37186), we proposed to remove a total of 10 measures from the Hospital OQR Program measure set across the CY 2020 and CY 2021 payment determinations. Specifically, beginning with the CY 2020 payment determination, we proposed to remove (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431); and beginning with the CY 2021 payment determination, we proposed to remove—(2) OP–5: Median Time to ECG (NQF #0289); (3) OP 31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536); (4) OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658); (5) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interventions for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use (NQF #0659); (6) OP–9: Mammography Follow-up Rates (no NQF number); (7) OP–11: Thorax Computed Tomography

---

112 Rose-Hulman Institute of Technology. Denominator approaching zero. Available at: https://www.rose-hulman.edu/media/89584/lclimitsguide.pdf
(CT)—Use of Contrast Material (NQF #0513); (8) OP–12: The Ability for Providers with HIT (Health Information Technology) to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data (NQF endorsement removed); (9) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT (no NQF number); and (10) OP–17: Tracking Clinical Results between Visits (NQF endorsement removed). We proposed to remove these measures under the following removal factors: Proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program; measure removal Factor 3, a measure does not align with current clinical guidelines or practice; measure removal Factor 1, measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures); and measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes.

These proposed measure-specific removals are discussed in detail further below. We also received several general comments regarding these proposals as a whole and are discussing those first.

Comment: Many commenters supported CMS’ proposals to remove 10 measures from the Hospital OQR Program measure set. Some noted that the proposals will reduce burden, simplify hospital reporting, and reduce duplication. Several commenters suggested that CMS remove all 10 measures beginning with CY 2020, rather than delaying removal of nine measures until CY 2021. Commenters agreed with CMS’ rationale for removals and noted that topped-out or not beneficial measures should be removed as soon as possible.

Response: We thank the commenters for their support. Data collection and reporting for the CY 2020 payment determination has already begun for all nine of the measures proposed for removal. Specifically, as finalized in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519 through 70520), data collection began with Q2, (April 1) of 2018. Thus, by the effective date of this final rule with comment period, hospitals will have already reported almost three quarters of data for these measures. In consideration of hospitals’ efforts already exerted, we are finalizing removal of these measures starting with the next proximate payment determination.

Comment: One commenter opposed all of CMS’ proposals to remove measures from the Hospital OQR Program, citing its belief that consumers should be offered more quality information, rather than less, that can be used in selecting facilities. Another commenter recommended that CMS maintain the existing measure set and, instead of removing measures, work to reduce provider burden through alignment across programs.

Response: We thank the commenters for their feedback and note our agreement that consumers should be provided with as much valuable quality information as possible. As described in the proposed rule, we proposed to remove these measures because the costs associated with a measure outweigh the benefit of its continued use in the program; the measure does not align with current clinical guidelines or practice, measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures); or because performance or improvement on a measure does not result in better patient outcomes. We have identified these and other measure removal factors specifically to ensure that the data provided to consumers is meaningful and valuable. We do not believe it is beneficial to maintain program measures indefinitely. However, we agree that burden should be reduced through program alignment and will continue to seek opportunities to do this. In the CY 2019 OPPS/ASC proposed rule, we proposed several policies to align with the ASCQR Program, including updating our measure removal factors and removing OP–27 and ASC–8, OP–29 and ASC–9, OP–30 and ASC–10, and OP–31 and ASC–11, and we are finalizing several of these aligned proposals in this final rule with comment period.

Comment: One commenter recommended that CMS consider the impact of the proposed removal of OP–5, OP–14, OP–27, OP–29, and OP–30 on the Hospital Compare overall hospital ratings.

Response: Although these measure removals will reduce the number of outpatient measures in the Hospital Overall Star Ratings, a representative measure set remains and includes OP–32: 7-day visit rate after colonoscopy, OP–4: Aspirin on arrival, OP–22: Patient Left Without Being Seen, OP–23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Inpatient Acute Stroke Patients who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival, OP–33: External Beam Radiotherapy for Bone Metastases, OP–3: Median Time to Transfer to Another Facility for Acute Coronary Intervention, and OP–18: Median Time from Emergency Department (ED) Arrival to ED Departure for Discharged ED Patients. Additional measures, including surgery and chemotherapy measures, may be considered for adoption in future years. (We refer readers to our web page at: https://www.medicare.gov/hospitalcompare/About/Hospital-overall-ratings.html for a discussion of Hospital Compare overall hospital ratings.)

(1) Measure Removal for the CY 2020 Payment Determination and Subsequent Years—Removal of OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431)

For the CY 2020 payment determination and subsequent years, we proposed to remove one NHSN measure under proposed measure removal Factor 8, the costs associated with this measure outweigh the benefit of its continued use in the program.

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099), where we adopted OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 2016 payment determination and for subsequent years. This process-of-care measure, also a National Healthcare Safety Network (NHSN) measure, assesses the percentage of healthcare personnel who have been immunized for influenza during the flu season. We initially adopted this measure based on our recognition that influenza immunization is an important public health issue and vital component to preventing healthcare associated infections. We believe that the measure addresses this public health concern by assessing influenza vaccination in the HOPD among health care personnel (HCP), who can serve as vectors for influenza transmission.

In the proposed rule, we proposed to remove OP–27, beginning with the CY 2020 payment determination under our proposed measure removal Factor 8 because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program.

The information collection burden for the Influenza Vaccination Coverage Among Healthcare Personnel measure is less than for measures that require chart-abstraction of patient data because the influenza vaccine among healthcare personnel can be calculated through review of records maintained in
In our assessment, we also considered that the vast majority (99.7 percent) of Hospital OQR Program eligible hospitals already report this measure in the Hospital IQR Program for workers providing any services to inpatient care. The Hospital IQR Program measure includes the vast majority of all hospital personnel since many workers in outpatient departments provide services to both inpatient and outpatient departments (adopted at 76 FR 51631 through 51633). These workers include most emergency department clinicians, specialists such as pharmacists and imaging professionals, and custodians and other support staff working across the hospital.

We continue to believe that the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) measure provides the benefit of protecting patients against influenza. However, we believe that these benefits are offset by other efforts to reduce influenza infection among patients, such as numerous healthcare employer requirements for health care personnel to be vaccinated against influenza.\textsuperscript{114,115} We also expect that a portion of MIPS-eligible clinicians nationwide will report on the Preventive Care and Screening: Influenza Immunization measure through the Quality Payment Program (QPP).\textsuperscript{116} Although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure. We remain responsive to the public health concern of influenza infection within the Medicare FFS population by collecting data on rates of influenza immunization among patients.\textsuperscript{117} Thus, the public health concern of influenza immunization is addressed via these other efforts to track influenza vaccination. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. In addition, as we discussed in section XIII.B.4.a of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

We wish to minimize the level of cost of our programs for participating facilities, as discussed under the Meaningful Measures Initiative, described in section I.A.2. of the proposed rule and this final rule with comment period. In our assessment of the Hospital OQR Program measure set, we prioritized measures that align with this Initiative’s framework as the most important to the Hospital OQR Program’s population. Our assessment concluded that while the OP–27 measure continues to provide benefits, these benefits are diminished by other factors and are outweighed by the costs and burdens of reporting this chart-abstracted measure.

For these reasons, we proposed to remove OP–27: NHSN Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the Hospital OQR Program beginning with the CY 2020 payment determination and for subsequent years. In the proposed rule, we noted that if proposed measure removal Factor 8 is not finalized, removal of this measure would also not be finalized. We also noted that a similar measure was also proposed for removal from the ASCQR Program in section XIV.B.3.c. of the proposed rule and the IPFQR Program in the FY 2019 IPF PPS proposed rule (83 FR 21104).

\textbf{Comment:} Several commenters supported CMS’ proposal to remove OP–27 from the Hospital OQR Program measure set, and noted that the proposal will reduce burden and costs to hospitals and that levels of vaccination of health care employees is already very high.

\textbf{Response:} We thank the commenters for their support regarding the burden associated with the OP–27 measure.

\textbf{Comment:} Several commenters opposed CMS’ proposal to remove OP–27 from the Hospital OQR Program. A few commenters expressed concern that influenza is a critical public health issue and that influenza vaccination coverage of healthcare workers helps create a safe environment for patients, visitors, and employees. A few commenters expressed concern that removal of OP–27 would result in lower vaccination rates among healthcare workers. A few commenters noted that the Medicare population may be more susceptible to vaccine preventable illnesses such as influenza.

\textbf{Response:} We thank these commenters for their input. We agree that influenza vaccination for both patients and healthcare personnel is important in the outpatient hospital setting, as well as other healthcare systems and because facilities have fewer healthcare personnel than patients. As such, OP–27 does not require review of as many records. However, this measure does still pose information collection burden on facilities due to the requirement to identify personnel who have been vaccinated against influenza and for those not vaccinated, the reason why.

Furthermore, as we stated in section XIII.B.4.a. of the proposed rule and this final rule with comment period, costs are multi-faceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. For example, it may be costly for health care providers to maintain general administrative knowledge to report these measures. In addition, CMS must expend resources in maintaining information collection systems, analyzing reported data, and providing public reporting of the collected information.

In our analysis of the Hospital OQR Program measure set, we recognized that some facilities face challenges with respect to the administrative requirements of the NHSN in their reporting of the Influenza Vaccination Coverage Among Healthcare Personnel measure. These administrative requirements (which are unique to NHSN) include annually completing NHSN system user authentication. Enrolling in NHSN is a five-step process that the Centers for Disease Control and Prevention (CDC) estimates takes an average of 263 minutes per facility.\textsuperscript{113}

Another factor that some facilities face challenges with respect to the administrative requirements of the NHSN is their contact information. The vast majority (99.7 percent) of Hospital OQR Program eligible hospitals already report this measure in the Hospital IQR Program for workers providing any services to inpatient care. The Hospital IQR Program measure includes the vast majority of all hospital personnel since many workers in outpatient departments provide services to both inpatient and outpatient departments. This measure requires the system security administrator of participating facilities to re-consent electronically, ensure that contact information is kept current, and other efforts to track influenza vaccination.

We continue to believe that the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) measure provides the benefit of protecting patients against influenza. However, we believe that these benefits are offset by other efforts to reduce influenza infection among patients, such as numerous healthcare employer requirements for health care personnel to be vaccinated against influenza.\textsuperscript{114,115} We also expect that a portion of MIPS-eligible clinicians nationwide will report on the Preventive Care and Screening: Influenza Immunization measure through the Quality Payment Program (QPP).\textsuperscript{116} Although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure. We remain responsive to the public health concern of influenza infection within the Medicare FFS population by collecting data on rates of influenza immunization among patients.\textsuperscript{117} Thus, the public health concern of influenza immunization is addressed via these other efforts to track influenza vaccination. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. In addition, as we discussed in section XIII.B.4.a of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

We wish to minimize the level of cost of our programs for participating facilities, as discussed under the Meaningful Measures Initiative, described in section I.A.2. of the proposed rule and this final rule with comment period. In our assessment of the Hospital OQR Program measure set, we prioritized measures that align with this Initiative’s framework as the most important to the Hospital OQR Program’s population. Our assessment concluded that while the OP–27 measure continues to provide benefits, these benefits are diminished by other factors and are outweighed by the costs and burdens of reporting this chart-abstracted measure.

For these reasons, we proposed to remove OP–27: NHSN Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the Hospital OQR Program beginning with the CY 2020 payment determination and for subsequent years. In the proposed rule, we noted that if proposed measure removal Factor 8 is not finalized, removal of this measure would also not be finalized. We also noted that a similar measure was also proposed for removal from the ASCQR Program in section XIV.B.3.c. of the proposed rule and the IPFQR Program in the FY 2019 IPF PPS proposed rule (83 FR 21104).

\textbf{Comment:} Several commenters supported CMS’ proposal to remove OP–27 from the Hospital OQR Program measure set, and noted that the proposal will reduce burden and costs to hospitals and that levels of vaccination of health care employees is already very high.

\textbf{Response:} We thank the commenters for their support regarding the burden associated with the OP–27 measure.

\textbf{Comment:} Several commenters opposed CMS’ proposal to remove OP–27 from the Hospital OQR Program. A few commenters expressed concern that influenza is a critical public health issue and that influenza vaccination coverage of healthcare workers helps create a safe environment for patients, visitors, and employees. A few commenters expressed concern that removal of OP–27 would result in lower vaccination rates among healthcare workers. A few commenters noted that the Medicare population may be more susceptible to vaccine preventable illnesses such as influenza.

\textbf{Response:} We thank these commenters for their input. We agree that influenza vaccination for both patients and healthcare personnel is important in the outpatient hospital setting, as well as other healthcare systems and because facilities have fewer healthcare personnel than patients. As such, OP–27 does not require review of as many records. However, this measure does still pose information collection burden on facilities due to the requirement to identify personnel who have been vaccinated against influenza and for those not vaccinated, the reason why.
settings, and we believe that these two activities are both intended to address the public health concern of reducing influenza infection.

However, while we agree that Medicare beneficiaries may have additional risk of contracting influenza, as noted in our proposal, we believe the effects of removing this measure from the Hospital QQR Program are mitigated as the issue is addressed by other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers. Because of this, we do not believe that retaining this measure would result in lower rates of vaccination coverage among healthcare personnel. Further, we have retained the measure in the Hospital IQR Program (83 FR 41579), thus requiring reporting in the short-term, acute care hospital setting. In addition, we believe that the burden of this measure on hospitals outweighs the limited benefit of addressing this topic again under the Hospital OQR Program in addition to the many other vaccination initiatives.

Comment: A few commenters stated that OP–27 plays a critical role in the CMS Quality Strategy and the National Quality Strategy in terms of immunization efforts. A few commenters suggested that removal of the measure would create greater inconsistency across quality reporting programs.

Response: We agree that influenza is a critical public health issue that is part of the CMS Quality Strategy and the National Quality Strategy. Through the Meaningful Measures Initiative, it is our goal to ensure that we are addressing high-impact measure areas that safeguard public health while minimizing the level of burden for providers and suppliers. We continue to believe in the importance of influenza vaccination coverage for health care workers, particularly in acute care settings, and have retained this measure in the Hospital IQR Program (83 FR 41579) in order to address this concern. As we noted above, the burden of reporting this measure is greater for outpatient hospitals compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system is due to this one measure; whereas hospitals paid under IPPS, participating in the Hospital IQR Program, the HAC Reduction Program and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one. However, we note that, beyond the Hospital OQR Program, HOPDs may independently choose to voluntarily report data to NHSN on vaccination rates using the NHSN Healthcare Personnel Safety Component.

Comment: One commenter stated that the cost associated with mitigating an influenza outbreak outweighs the cost of retaining OP–27 in the Hospital OQR Program.

Response: As we noted above, we have retained the measure in the Hospital IQR Program (83 FR 41579) in order to address concerns about influenza as a public health issue. In addition, as noted above, we believe the effects of removing this measure from the Hospital OQR Program are mitigated as the topic is addressed by other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers. As a result, we do not believe removing this measure from the Hospital OQR Program will result in lower rates of vaccination coverage among healthcare personnel in the HOPD setting or increase the risk of an outbreak.

After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–27: NHSN Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the Hospital OQR Program beginning with the CY 2020 payment determination and for subsequent years.

(2) Measure Removals for the CY 2021 Payment Determination and Subsequent Years

In the CY 2019 OPPS/ASC proposed rule (83 FR 37181 through 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove: Four measures under proposed measure removal Factor 8; one measure under measure removal Factor 3; two measures under removal Factor 1; and two measures under measure removal Factor 2.


In the proposed rule, we proposed to remove four measures under measure removal Factor 8, which is being finalized in this final rule with

118 CDC. Influenza Vaccination Information for Health Care Workers. Available at: https://www.cdc.gov/flu/healthcareworkers.htm.
119 CDC. Influenza Vaccination Coverage Among Health Care Personnel—United States, 2013–14 Influenza Season. Available at: https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6337a1.htm.

120 This measure was formerly called “ED–AMI–4—Median Time to Electrocardiogram (ECG)” in the cited Federal Register.
removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities, especially when taking into consideration that, although this measure is not topped-out, we have come to the conclusion that the benefit of this measure is limited. Based on our analysis of data submitted by 1,995 hospitals from Quarter 3 in 2016 through Quarter 2 in 2017 the variation in average measure performance between hospitals is minimal, with a difference in median time to ECG of less than two minutes between the 75th and 90th percentile hospitals. Furthermore, the difference between the 25th and 75th percentile, distinguishing between high and low performers, is only 5.5 minutes. Given clinical guidelines recommend that ECG be obtained within 10 minutes of arrival to the emergency department (ED), we do not believe this difference is clinically significant and further indicates that variations are not sufficiently large to inform beneficiary decision-making to justify the costs of collecting the data. These data are demonstrated in the table below.

### Differences in Performance for OP-5: Median Wait Time to ECG

<table>
<thead>
<tr>
<th>Period</th>
<th>Number of Hospitals</th>
<th>25th Percentile</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016 Q3 - 2017 Q2</td>
<td>1,995</td>
<td>11.0 minutes</td>
<td>5.5 minutes</td>
<td>3.8 minutes</td>
</tr>
</tbody>
</table>

We believe that the minimal variation in hospital performance does not help beneficiaries to make informed care decisions, since distinguishing meaningful differences in hospital performance on this measure is difficult. As such, the measure benefit is limited, and no longer meaningfully supports program objectives of informing beneficiary choice.

Thus, we believe that costs and burdens to both facilities and CMS such as program oversight, measure maintenance, and public display, associated with keeping this measure in the program outweigh the limited benefit associated with the measure’s continued use. Therefore, we proposed to remove OP–5: Median Time to ECG from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years.

**Comment:** Many commenters supported CMS’ proposal to remove OP–5. One commenter stated that the burden of collecting data for this chart-abstracted measure exceeds the value. Many other commenters praised CMS’ measure removals in general due to the resulting burden reduction.

**Response:** We thank the commenters for their support.

**Comment:** A few commenters recommended retaining OP–5. One commenter noted that ECG findings are important in managing acute coronary symptoms and affect patient morbidity. This commenter also noted that it is not overly burdensome to report the measure. Another commenter recommended that the measure be retained and revised so that patients admitted for observation or inpatient care are included.

**Response:** We thank commenters for this feedback. We agree that ECG findings are important, but our assessment indicates that there is minimal variation in hospital performance on this measure, and therefore, the opportunity to improve the management and patient morbidity associated with acute coronary symptoms is severely limited. In addition, we disagree that the measure is not burdensome to report overall, as it requires chart-abstractation. Many commenters supported removal and cited burden reduction as a benefit of this proposal. As a result, we believe it is appropriate to remove this measure and we do not intend to retain or revise it.

After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–5: Median Time to ECG from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years.

- **Proposal To Remove OP–29:** Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099 through 75100) noting that performing colonoscopy too frequently increases patients’ exposure to procedural harm. However, we noted concern in the proposed rule that the costs of this measure outweigh the benefit of its continued use in the program.

Chart-abstractation process measure assesses the “[p]ercentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report.” (78 FR 75099). This measure aims to assess whether average risk patients with normal colonoscopies receive a recommendation to receive a repeat colonoscopy in an interval that is less than the recommended amount of 10 years.

In the proposed rule, we proposed to remove OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2014 OPPS/ASC final rule with comment period (78 FR 75099 through 75100) noting that performing colonoscopy too frequently increases patients’ exposure to procedural harm. However, we noted concern in the proposed rule that the costs of this measure outweigh the benefit of its continued use in the program.

Chart-abstractation requires facilities to select a sample population, access historical records from several current and historic clinical data quarters, and

---

121 Diercks et al. 2006. Door-to-ECG time in patients with chest pain presenting to the ED. AJEM.
interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. We noted in the proposed rule that removing OP–29 would reduce the burden and cost to facilities associated with collection of information and reporting on their performance associated with the measure.

However, we also acknowledged that we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures that are relevant in the clinical condition and highly correlated in performance across measures. In the proposed rule, we noted another colonoscopy-related measure required in the Hospital QQR Program, OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539), which measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within 7 days of an outpatient colonoscopy procedure (79 FR 66949). This claims-based outcomes measure does not require chart-abstractation, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted OP–32, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66949). Furthermore, in the proposed rule, we noted our belief that the potential benefits of keeping OP–29 in the program are mitigated by the existence of the same measure (Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients) 122 for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we noted that the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. In the proposed rule, we noted that although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.123 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area.

Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chart-abstracted measure from the Hospital QQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, we noted that beneficiaries may find it confusing to see public reporting on the same measure in different programs. Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the Hospital QQR Program that provides valuable data for the same procedure, and the existence of the same measure in another CMS program, we noted in the proposed rule that the burdens and costs associated with this measure outweigh the limited benefit to beneficiaries. As a result, we proposed to remove OP–29: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure in the ASCQR Program in section XIV.B.3.c. of the proposed rule.

Comment: Several commenters opposed CMS’ proposal to remove OP–29 from the Hospital QQR Program. A few commenters expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that pose significant costs. One commenter believed that solely retaining the measure in MIPS is insufficient because the measure is voluntary in that program. A few commenters stated that OP–29 and OP–32 assess distinct and different aspects of colonoscopies, because OP–32 focuses on coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that OP–29 and OP–32 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. Some commenters recommended retaining OP–29 to achieve a holistic approach to measuring the quality of care in this clinical area. One commenter asserted that OP–29 is not overly burdensome to collect and report. Some commenters disagreed with CMS’ assessment that the costs of the measure outweigh the benefits.

Response: Although MIPS-eligible clinicians may voluntarily select measures from a list of options, in drafting our proposal, we believed that MIPS reporting would mitigate the impact of removing this measure and provide some meaningful data in this clinical area. After considering the commenters’ views, however, we acknowledge that although a similar measure is available in the QPP, OP–29 provides valuable information to beneficiaries specifically about the outpatient hospital setting, where high volumes of colonoscopies are performed. We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue due to many studies that document inappropriate use.124 125 126 One study

---

122 QPP Measure Selection: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients. Available at: https://qpp.cms.gov/mips/quality-measures.

123 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586).

124 Sheffield et al. 2013. Potentially Inappropriate Screening Colonoscopy in Medicare Patients:
showed high rates of inappropriate colonoscopies performed in older adult populations: 10 percent in adults aged 70–75, 39 percent in adults aged 76–85, and 25 percent in adults aged 86.\textsuperscript{127} Thus, we believe that OP–29 is a critical measure for the Hospital OQR Program because there is demonstrated substantial overuse of surveillance colonoscopies among low-risk patients,\textsuperscript{128} with research showing that colonoscopies are often recommended at shorter intervals than are advised by guidelines among patients with normal colorectal screening results.\textsuperscript{129} We believe it is especially important to assess this topic due to the high-volume of these procedures that occur in the outpatient setting.

Furthermore, while OP–29 and OP–32 assess the topic of colonoscopies generally, we acknowledge that they assess distinct clinical areas. OP–32 tracks adverse patient outcomes that result in unplanned hospital visits, whereas, OP–29 provides information about colonoscopies occurring at inappropriate intervals that may increase costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. While OP–32 provides vital data about patient outcomes after colonoscopies, OP–29 focuses on adherence to guideline recommendations for screening colonoscopy follow-up intervals, as noted by NQF’s evaluation report.\textsuperscript{130}

Despite the costs and burdens of chart-abstraction or the presence of other measures assessing a similar clinical topic, after considering incoming comments and reevaluating our data, we now believe OP–29 is a more critical measure for the Hospital OQR Program than initially perceived in the proposed rule. Specifically, as discussed above, upon reviewing the measure set as a whole, we now believe that OP–29 assesses a distinct clinical area not addressed by OP–32. Further, although we noted that OP–29 requires the burden of chart-abstraction to report, we believe this measure is significantly less burdensome than OP–30 due to the significant burden of obtaining patient histories required for that measure. We also appreciate commenters’ feedback that OP–29 is not overly burdensome to report. Because this measure tracks the number of patients who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their colonoscopy report, we believe it provides important information to beneficiaries on the avoidance of inappropriate endoscopies/colonoscopies. OP–29 evaluates overutilization that can lead to the overuse of resources and unnecessary risks to beneficiaries from possible procedural complications and harms.

Accordingly, after considering the public comments we received and upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the Hospital OQR Program.

In section I.A.2. of the proposed and this final rule with comment period, we describe our Meaningful Measures Initiative that is intended to reduce costs and minimize burden. We believe that while removing this chart-abstracted measure from the Hospital OQR Program would reduce program complexity, retaining it provides pertinent information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. Therefore, we are not finalizing our proposal to remove this measure. We believe retaining this measure is responsive to those comments as it is a valuable process measure and assesses a distinct clinical area.

\textbf{Comment:} A few commenters stated that OP–29 should be retained to promote program alignment across outpatient settings and allow for comparisons between facility types. \textbf{Response:} We have considered program alignment by adding and removing measures in tandem for the ASCQR and Hospital OQR Programs, such as ASC–9, Endoscopy/ Polypl Surveilance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients. As noted above, we adopted OP–29 into the Hospital OQR Program because we believe it is important for HOPDs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. As stated above, we are not finalizing our proposal to remove OP–29. We are similarly retaining the corresponding measure (ASC–9) in the ASCQR Program in section XIV.B.3.c. of this final rule with comment period.

\textbf{Comment:} One commenter did not support CMS’ proposal to remove OP–29 because it is included in the Core Quality Measures Collaborative (CQMC) Gastroenterology Core Set and is widely used in the private sector.

\textbf{Response:} The CMS CQMC identifies core sets of quality measures that payers have committed to using for reporting as soon as feasible.\textsuperscript{131} The guiding principles used by the Collaborative in developing the core measure sets are that they be meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost. Its goal is to establish broadly agreed upon core measure sets that could be harmonized across both commercial and government payers.\textsuperscript{132} We agree that the inclusion of OP–29 in the CQMC Gastroenterology Core Set speaks to its clinical value. However, although we are retaining OP–29 for the reasons described in this section, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the Hospital OQR Program.

\textbf{Comment:} One commenter recommended that CMS retain the measure and explore how to automate tracking of the information to reduce the resource-intensive use of chart-abstraction data.

\textbf{Response:} We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2. of this final rule with comment period, our Meaningful Measures Initiative prioritizes the least burdensome measure sets for our quality reporting programs, and we will continue to evaluate the Hospital OQR Program measure set through this framework. We continually seek opportunities to reduce


\textsuperscript{132} Ibid.
the reporting burden of our programs but note that collecting data for OP–29 still currently requires chart-abstractation. Comment: Many commenters supported CMS’ proposal to remove OP–29, noting that the proposal reduces burden and duplication between programs. A few commenters noted that the measure was developed to assess provider, rather than facility-level, performance.

Response: We thank the commenters for their support. As noted in our proposal above, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use. While this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099). Further, we believe that for HOPDs to be active partners in avoiding inappropriate use and ensuring that patients at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, after considering the public comments we received and upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the program as this measure assesses a unique and clinically important topic area not covered otherwise addressed by the Hospital OQR Program measure set.

After consideration of the public comments we received, we are not finalizing our proposal to remove OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our removal policies. We note that we also are not finalizing our proposal to remove ASC–9 under the ASCQR Program, and we refer readers to section XIV.B.3.c. of this final rule with comment period for more information.

• Removal of OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients With a History of Adenomatous Polyps—Avoidance of Inappropriate Use

We refer readers to CY 2014 OPPS/ASC final rule with comment period (78 FR 75102) where we adopted OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use (NQF #0659) beginning with the CY 2016 payment determination. This chart-abstracted process measure assesses the percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colon polyp in previous colonoscopy findings, who had a follow-up interval of three or more years since their last colonoscopy documented in the colonoscopy report. In the proposed rule, we proposed to remove OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75102) noting that colonoscopy screening for high risk patients is recommended based on risk factors and one such factor is a history of adenomatous polyps. The frequency of colonoscopy screening varies depending on the size and amount of polyps found, with the general recommendation of a 3-year follow-up. We stated that this measure is appropriate for the measurement of quality of care furnished by hospital outpatient departments because colonoscopy screening is commonly performed in these settings (78 FR 75102). However, we now believe that the costs of this measure outweigh the benefit of its continued use in the program.

Chart-abstractation requires facilities to select a sample population, access historical records from several clinical data quarters past, and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. Removing OP–30 would reduce the burden and cost to facilities associated with collection of information and reviewing their data and performance associated with the measure. However, we do not believe the use of chart-abstracted data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures. Another colonoscopy-related measure required in the Hospital OQR Program, OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within 7 days of an outpatient colonoscopy procedure (79 FR 66949). This claims-based outcome measure does not require chart-abstractation, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted OP–32, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66949). Furthermore, the potential benefits of keeping OP–30 in the program are mitigated by the existence of the same measure for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we believe the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP because we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, HOPD providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.133 The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area.

Furthermore, we seek to align our quality reporting work with the Patients

133CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under these methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 33886).
Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chart-abstracted measure from the Hospital OQR Program would reduce program complexity. In addition, as we discussed in section XIII.B.4.a. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in OQR that provides valuable data for the same procedure, and the existence of the same measure in the MIPS program, we believe that the burdens and costs associated with manual chart abstraction outweigh the limited benefit to beneficiaries of receiving this information. As a result, we proposed to remove OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure in the ASCQR Program in section XIV.B.3.c. of the proposed rule.

Comment: Many commenters supported CMS’ proposal to remove OP–30. A few commenters noted that the measure is burdensome and costly to report. In part due to the volume of cases that must be reviewed to identify patients that meet the inclusion and exclusion criteria. Some commenters agreed that the cost of the measure outweighs the benefits due to data collection challenges that are specific to OP–30, due to the extensive patient histories required and because data may need to be obtained from different settings.

Response: We thank the commenters for their support. In addition to the burden of chart-abstraction, we agree with the commenter that pointed out the unique burden of OP–30, which requires that facilities conduct extensive patient histories and contact other facilities in order to obtain documentation of a history of adenomatous polyps. Thus, the costs and burdens are higher for this measure than for the other colonoscopy measure considered for removal, OP–29, which requires less information from patients and does not require historical documentation. We thank the commenter for its feedback on the burden associated with identifying patients meeting the inclusion and exclusion criteria for this measure. We are finalizing our proposal to remove OP–30.

Comment: One commenter noted that the measure specifications for OP–30 will be updated soon and recommended that CMS retain the measure until new guidelines are available. A few commenters disagreed with CMS’ assessment that the cost of the measure outweighs the benefit, and one commenter recommended that CMS try to automate tracking of data needed for the measure to reduce its burden.

Response: We understand that the measure steward is planning to update OP–30; however, because these updates will not eliminate the need to collect patient histories, we do not believe such updates will lessen burden. Due to the burden of data collection for this measure, which includes taking extensive patient histories, we believe the costs outweigh the benefits and, therefore, we do not believe it is appropriate to retain the measure. We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2 of this final rule with comment period, our Meaningful Measures Initiative prioritizes burden reduction in our quality reporting programs, and we will continue to evaluate the Hospital OQR Program measure set through this framework. We continually seek opportunities to reduce the reporting burden of our programs, but note that currently, collecting data for OP–30 still requires chart-abstractation.

Comment: Several commenters noted that OP–30 was developed and tested as a provider-level measure and they did not believe it is appropriate for the hospital setting. One commenter stated that this measure is already being reported through the MIPS (formerly PQRS) and that MIPS is the appropriate program because OP–30 is a provider-level measure. Another commenter stated that duplicate reporting in CMS’ quality reporting programs has caused unnecessary provider burden without adding new information to the pool of quality data available to the public. Another commenter noted that relying on MIPS reporting of this measure is inadequate, as MIPS is a voluntary measure in that program.

Response: We adopted OP–30 into the Hospital OQR Program because we believe it is important for HOPDs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. And, while this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099). As noted in our proposal, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use.

A primary goal of our Meaningful Measures Initiative is to reduce provider burden through the deduplication of measures across quality reporting programs. As discussed above, after considering comments and reevaluating our measure sets as a whole, we are not finalizing our proposal to remove OP–29 in order to retain a measure assessing inappropriate use of endoscopies/colonoscopies in the Hospital OQR Program. We believe there may be a measurement gap if both OP–29 and OP–30 are removed and because of the unique burden associated with OP–30, we are finalizing its removal while maintaining OP–29. Removing OP–30 while retaining OP–29 best enables us to assess this important clinical area while ensuring that the costs of measure do not outweigh the benefits. Thus, due in part to the duplication of this measure through MIPS in the QPP and the additional burden to hospitals of obtaining patient records, we are finalizing our proposal to remove OP–30 from the Hospital OQR Program measure set beginning with the CY 2021 payment determination, as proposed.

Comment: A few commenters opposed CMS’ proposal to remove OP–30 from the Hospital OQR Program. One commenter noted that OP–30 is a cost measure and helps avoid inappropriate use or missed opportunities to screen patients who could result in significant harm to beneficiaries. One commenter

134 OP–30 Measure Information Form. Available at: http://www.qualitynet.org/dcs/ContentServer?c=
Page&pagename=qnetPublic%2FPage%2FSpecsManualTemplate&cid=1228778612884.
expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that poses significant costs.

Response: We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue. Measuring the inappropriate use of colonoscopy screenings is critical to preventing the waste of resources and potential patient harm. In part for this reason, we are retaining OP–29 in the Hospital OQR Program measure set and will continue to require reporting on appropriate follow-up intervals for normal risk patients. We believe that retaining OP–29 in the Hospital OQR Program enables us to address concerns regarding patient harm from unnecessary colonoscopy screenings. Further, due to the unique documentation burden specifically for OP–30, we believe it adds undue burden especially in comparison to OP–29.

After considering stakeholder comments, reevaluating our measure sets as a whole, and balancing the clinical value of measures with the costs, we believe it is appropriate to retain OP–29 while finalizing our proposal to remove OP–30.

Comment: One commenter did not support CMS’ proposal to remove OP–30 because it is included in the CQMC Gastroenterology Core Set and is widely used in the private sector.

Response: The CMS CQMC Gastroenterology Core Set is a set of measures identified as being meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost and is intended for use by payers who are part of CQMC. Because of this, we believe beneficiaries will continue to receive this data to help them make health care decisions. We agree that this measure is valuable to many stakeholders and support its continued reporting through other quality reporting programs and in the private sector. However, due to the measure’s requirement to obtain historical patient records, we believe that this measure adds undue burden to HOPDs. In addition, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the Hospital OQR Program.

Comment: A few commenters stated that OP–30 and OP–32 assess distinct aspects of colonoscopies, because OP–32 focuses on care coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that OP–30 and OP–32 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively.

Response: We thank the commenters for their feedback. We agree that OP–30 and OP–32 assess distinct clinical areas but do assess the topic of colonoscopies generally. While OP–32 tracks adverse patient outcomes that result in unplanned hospital visits, OP–30 provides information about colonoscopies occurring at inappropriate intervals for beneficiaries that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. However, we believe OP–30 should be removed because it is uniquely burdensome, as described in a previous response. After considering stakeholder comments, reevaluating our measure sets as a whole, and balancing the clinical value of measures with the costs, we believe it is appropriate to remove OP–30. We note that our retention of OP–29 allows us to continue to address inappropriate use of colonoscopy screenings.

After consideration of the public comments we received, we are finalizing our proposal to remove OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years. We refer readers to section XIV.B.3.c. of this final rule with comment period where we are removing a similar measure from the ASCQR Program.

Proposal To Remove OP–31: Cataracts—Improvement in Patient’s Visual Function Within 90 Days Following Cataract Surgery

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75103) where we adopted OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) beginning with the CY 2016 payment determination and subsequent years. This measure assesses the rate of patients 18 years and older (with a diagnosis of uncomplicated cataract) in a sample who had improvement in visual function achieved within 90 days following surgery based on completing both pre-operative and post-operative visual function survey.

Since the adoption of this measure, we came to believe that it can be operationally difficult for facilities to collect and report the measure (79 FR 66947). Specifically, we were concerned that the results of the survey used to assess the pre-operative and post-operative visual function of the patient may not be shared across clinicians and facilities, making it difficult for facilities to have knowledge of the visual function of the patient before and after surgery (79 FR 66947). We were also concerned about the surveys used to assess visual function; the measure allows for the use of any validated survey and results may be inconsistent should clinicians use different surveys (79 FR 66947). Therefore, on December 31, 2013, we issued guidance stating that we would delay data collection for OP–31 for 3 months (data collection would commence with April 1, 2014 encounters) for the CY 2016 payment determination (https://www.qualitynet.org/docs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1226772854917). We issued additional guidance on April 2, 2014, stating that we would further delay the implementation of OP–31 for an additional nine months, until January 1, 2015 for the CY 2016 payment determination, due to continued concerns (https://www.qualitynet.org/docs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228773786593). As a result of these concerns, in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66948), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years.

In the proposed rule, we proposed to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 and for subsequent years under our proposed measure removal Factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. We originally adopted OP–31 because we believe facilities should be a partner in care with physicians and other clinicians using their facility and that this measure would provide an opportunity to do so (79 FR 66947).

However, in light of the history of complications and upon reviewing this measure within our Meaningful Measures framework, we have concluded that it is overly burdensome for facilities to report this measure due...
to the difficulty of tracking care that occurs outside of the HOPD setting.

In order to report on this measure to CMS, a facility would need to obtain the visual function assessment results from the accompanying ophthalmologist and ensure that the assessment utilized is validated for the population for which it is being used. If the assessment is not able to be used or is not available, the facility would then need to administer the survey directly and ensure that the same visual function assessment tool is utilized preoperatively and postoperatively. There is no simple, preexisting means for information sharing between ophthalmologists and facilities, so a facility would need to obtain assessment results from each individual patient’s ophthalmologist both preoperatively and postoperatively. The high administrative costs of the technical tracking of this information presents an undue cost, and also burden associated with submission and reporting of OP–31 to CMS, especially for small facilities with limited staffing capacity.

Furthermore, this measure currently provides limited benefits. Since making the measure voluntary, only 59,136 facilities have reported this measure to CMS, compared to approximately 4,798 total facilities for all other measures, resulting in only 1.2 percent of facilities reporting. Consequently, we have been unable to uniformly offer pertinent information to beneficiaries on how the measure assesses facility performance. This reinforces comments made in the CY 2015 OPPS/ASC final rule with comment period in which commenters expressed concern that the incomplete display of data associated with voluntary reporting is confusing and not meaningful to beneficiaries and other consumers (79 FR 66947). Furthermore, commenters feared that the display of data from some hospitals, but not others, would lead some patients to conclude that some hospitals are more committed to improving cataract surgery. As described in section I.A.2. of the proposed rule and this final rule with comment period, we strive to ensure that beneficiaries are empowered to make decisions about their health care using information from data-driven insights. Because of the lack of sufficient data, this measure may be difficult for beneficiaries to interpret or use to aid in their choice of where to obtain care; thus, the benefits of this measure are limited.

Thus, we stated that we believed the high technical and administrative costs of this measure, coupled with the high technical and administrative burden, outweigh the limited benefit associated with the measure’s continued use in the Hospital OQR Program. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, above, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believed that removing this measure from the Hospital OQR Program will reduce program burdens, including complexity. Therefore, we proposed to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and for subsequent years. In the proposed rule, we noted that we also proposed to remove a similar measure under the ASCQR Program in section XIV.B.3.c. of the proposed rule.

Comment: A few commenters opposed all of CMS’ proposals to remove measuring OP–31. Response: In response to these comments requesting that measures, including OP–31, be retained, we reevaluated our measures and data. We found that a core group of facilities (between 52 and 66 for the CY 2017 through CY 2019 payment determinations) report on this voluntary measure. Although only a subset of hospitals voluntarily report data for this measure, we believe this measure is considered very meaningful by those that do report; a subset of reporting hospitals report consistently (11 hospitals submitted consistently for the CY 2017 through CY 2019 payment determinations). Because this subset of hospitals has consistently reported this measure we are able to make the data publicly available year after year—in this case, for the CYs 2017, 2018, and 2019 payment determinations. We believe providing data on this voluntary measure is still helpful for the public because it shows how a HOPD performs over time and in comparison to other HOPDs even if compared to a small group of HOPDs.

Furthermore, this is the only measure in the Hospital OQR Program measure set that deals with cataract surgery, which is commonly performed in the HOPD setting. If it is removed, the program will have a gap in coverage for this clinical area. As a result, we now believe that this measure maintains coverage in an important clinical area in the Hospital OQR Program and meaningful information can be provided to consumers regarding those facilities. In addition, when this measure was made voluntary in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66947 through 66948), commenters expressed support, indicating that some stakeholders value the measure.

Furthermore, we have reassessed our evaluation that the costs of this measure outweigh the benefits. Due to the voluntary nature of the measure, we believe that it is inherently not more burdensome than valuable. Because hospitals are not required to submit data, those that do not have the capacity to report, do not have to, thus creating no extra burden. Those that do report, do so voluntarily and have continued to report over the years—specifically since the CY 2015 reporting period—despite any burdens. Because of this, we believe the measure is meaningful to the core group of facilities that do consistently report.

After consideration of public comments and reassessing our analysis, we are not finalizing our proposal to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies.

Comment: Many commenters supported CMS’ proposal to remove OP–31. A few commenters noted that data collection for this measure is difficult as it requires following up with clinical settings outside of the hospital. Another commenter supported removal and noted that the measure is meant for physician level-use, rather than facility-level reporting. One commenter questioned the validity of the measure and noted that it allows providers to use different surveys to collect measure information.

Response: We thank the commenters for their support. As noted in the proposed rule, we agree that data collection for this measure may be difficult, and as a result in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66948), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. While this measure was initially developed at the physician level, it has been field-tested in the HOPD facility setting by the measure stewards (78 FR 75099).
In addition, we believe it is important for HOPDs to be active partners in care with physicians and other clinicians using their facility and this measure is an opportunity for hospitals to demonstrate this capability if they choose to report data. Further, as noted above, we no longer believe that the costs of this measure outweigh the benefits, as the measure is meaningful to the core group of outpatient hospitals that do consistently report and can provide valuable data to consumers on those specific facilities. While data collection for this measure can be difficult, those facilities that choose to report do so because they have systems in place to data from ophthalmologists’ medical records. We agree that as a voluntary measure, only a subset of hospitals report on the measure, but note it is a meaningful measure to beneficiaries given that our analyses show that a consistent group of facilities report data on this measure. So, while data is not available for all facilities, the data that is available is meaningful. In addition, this measure has been appropriately validated for the population for which it is being used, even acknowledging that various survey methods can be used.138

This same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about this important outcome for beneficiaries.

After consideration of the public comments we received and reassessing our analysis, we are not finalizing our proposal to remove OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2020 payment determination and for subsequent years. We are also retaining a similar measure in the ASCQR Program (ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery) in section XIV.B.3.b. of this final rule with comment period. (b) Measure Removal Under Removal Factor 3: OP–9: Mammography Follow-Up Rates

We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766) where we adopted OP–9: Mammography Follow-Up Rates beginning with the CY 2010 payment determination. This claims-based measure assesses the percentage of patients with mammography screening studies that are followed by a diagnostic mammography, ultrasound, or MRI of the breast in an outpatient or office setting within 45 days. In the proposed rule (83 FR 37184 through 37185), we proposed to remove this measure under measure removal Factor 3, a measure does not align with current clinical guidelines or practice.

An examination of the measure specifications139 shows that recent changes in clinical practice are not incorporated into the measure calculation. Since development of this measure in 2008, advancements in imaging technology and clinical practice for mammography warrant updating the measure’s specifications to align with current clinical practice guidelines and peer-reviewed literature. Specifically, findings from the annual Literature Reviews and Environmental Scans conducted by the measure developer suggest that there is additional clinical benefit in performing adjuvant digital breast tomosynthesis (DBT) concomitant with full-field digital mammography (FFDM) or conventional mammography (currently included in the measure denominator), especially in women with dense breast tissue.140 141 142

In addition, in 2016, the American College of Radiology (ACR) updated its Breast Cancer Screening Appropriateness Criteria® to include DBT.143 The ACR notes that DBT can better detect potential false-positive findings without the need for recall. Furthermore, the cancer detection rate is increased with use of DBT compared with traditional mammography alone.144 A 2014 study published in the Journal of the American College of Radiology assessed the utilization of DBT among physician members of the Society of Breast Imaging and found that 30 percent of respondents reported using DBT concurrent with traditional mammography.145 With the update of the ACR clinical practice guidelines (that is, the Breast Cancer Screening Appropriateness Criteria)® to include DBT, use of this technology is expected to increase.

As currently specified, the measure does not adequately capture this shift in clinical practice. Thus, we believe this measure as specified does not align with current clinical guidelines or practice, and we proposed to remove OP–9: Mammography Follow-up Rates from the program for the CY 2021 payment determination and subsequent years. We intend to investigate respecification of this measure and consider it for adoption to the program through future rulemaking. Specifically, we will consider ways to capture a broader, more comprehensive spectrum of mammography services including adding diagnostic digital breast tomosynthesis. In the proposed rule, we noted that, in crafting our proposal, we considered removing this measure beginning with the CY 2020 payment determination, but decided on proposing to delay removal until the CY 2021 payment determination and subsequent years to be sensitive to facilities’ planning and operational procedures given that data collection for this measure begins during CY 2018 for the CY 2020 payment determination.

* * *

Comment: Many commenters supported CMS’ proposal to remove OP–9 from the Hospital QPP Program measure set and noted that the measure does not align with clinical guidelines. One commenter noted that the measure is meant for physician-level use, rather than facility-level reporting.

Response: We thank the commenters for their support. We note that while the measure was developed for physician-level use, as we stated when adopting the measure, it has been tested and was determined to be appropriate for the Hospital QPP Program by the consensus-based development process that meets the statutory requirement for adoption of a measure (73 FR 68765).


144 Ibid.

After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–9: Mammography Follow-up Rates from the program for the CY 2021 payment determination and subsequent years.

(c) Measure Removals Under Removal Factor 1: OP–11 and OP–14

In the proposed rule (83 FR 37185 through 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove OP–11 and OP–14 under removal Factor 1, measure performance among providers is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made. The Hospital OQR Program previously finalized two criteria for determining when a measure is “topped-out”: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation is less than or equal to 0.10 (79 FR 66968 through 66969). We refer readers to section XIII.B.4.a.(6) of the proposed rule, where we clarified and discussed how we calculate the TCOV for measures that assess the rate of rare, undesired events for which a lower rate is preferred such as OP–11 and OP–14.

For each of these measures, we believe that removal from the Hospital OQR Program measure set is appropriate as there is little room for improvement. In addition, as discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believe that removing these measures from the Hospital OQR Program will reduce program burden, costs, and complexity. As such, we believe the burden associated with reporting these measures outweighs the benefits of keeping them in the Hospital OQR Program.

Each measure is discussed in more detail below. In the proposed rule, we also noted that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but decided on proposing to delay removal until the CY 2021 payment determination and subsequent years to be sensitive to providers’ planning and operational procedures given that data collection for the measures begins during CY 2018 for the CY 2020 payment determination.

• Removal of OP–11: Thorax CT Use of Contrast Material

We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766) where we adopted OP–11: Thorax CT Use of Contrast Material (NQF #0513) beginning with the CY 2010 payment determination. This claims-based measure assesses the percentage of thorax studies that are performed with and without contrast material out of all thorax studies performed. Based on our analysis of Hospital OQR Program measure data, we have determined that this measure meets our measure removal Factor 1. These analyses are captured in the table below.

<table>
<thead>
<tr>
<th>Encounters</th>
<th>Number of Hospitals</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
<th>Truncated COV</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2012</td>
<td>867</td>
<td>96.9</td>
<td>98.4</td>
<td>0.081</td>
</tr>
<tr>
<td>CY 2013</td>
<td>869</td>
<td>97.1</td>
<td>98.5</td>
<td>0.074</td>
</tr>
<tr>
<td>CY 2014</td>
<td>796</td>
<td>97.2</td>
<td>98.4</td>
<td>0.065</td>
</tr>
<tr>
<td>CY 2015</td>
<td>711</td>
<td>97.4</td>
<td>98.5</td>
<td>0.054</td>
</tr>
</tbody>
</table>

As displayed in the table above, there is a statistically indistinguishable difference in hospital performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2012.

• Removal of OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT

We refer readers to the CY 2010 OPPS/ASC final rule with comment period (75 FR 72082) where we adopted OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT beginning with the CY 2012 payment determination and for subsequent years. This claims-based measure assesses the extent to which patients with a headache who have a brain CT also have a sinus CT performed on the same date at the same facility.

Based on our analysis of Hospital OQR Program measure data, we have determined that this measure meets our measure removal Factor 1. These analyses are captured in the table below.
for quality improvement. and that the measures have limited use on our proposals to remove: (1) OP–11: Thorax CT Use of Contrast Material, and (2) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment determination and subsequent years as discussed above.

Comment: Many commenters supported CMS’ proposals to remove OP–11 and OP–14, noting agreement that the proposals will reduce burden and that the measures have limited use for quality improvement.

Response: We thank the commenters for their support. We agree that these topped-out measures have limited value.

Comment: A few commenters opposed CMS’ proposals to remove OP–11 and OP–14. One commenter expressed concern that measures should not be removed from the program based solely on topped-out status. This commenter recommended that CMS ensure the measure is topped-out for a number of years, evaluate whether there are unintended consequences of removal, and continue monitoring performance on topped-out safety measures. Another commenter expressed concern that variation in measure performance exists between high and low performing States.

Response: We thank the commenters for their feedback and note that we would consider re-proposing these measures for the Hospital OQR Program in the future if data and research indicate that performance in this area has declined, thus mitigating any potential unintended consequences of measure removal. In the meantime, however, we believe it is appropriate to remove these topped-out measures from the Hospital OQR Program, as we believe these measures have limited ability to encourage quality improvement or provide beneficiaries with information on differences in quality across hospitals.

We have previously finalized our policy to consider measures for removal if they meet topped-out status (79 FR 66769) and accordingly, we disagree with commenters that topped-out status is not sufficient grounds for measure removal. In addition, “topped-out” status is only one of many factors we consider in removing measures. We consider the removal of each topped-out measure on a case-by-case basis, as appropriate, and determine whether a clinical or other quality improvement need for the measure justifies the retention of a topped-out measure that otherwise meets our criteria. We also note that the measures have been topped-out for four years. However, if it becomes evident that performance on this measure topic declines over time, we will consider re-introducing this or similar measures and will do so through the rulemaking process. While slight variation may exist in measure performance, our analyses demonstrate that this variation is statistically indistinguishable.

The Hospital OQR Program has finalized the “topped-out” methodology to evaluate variation in performance among HOPDs (79 FR 66769), in line with other quality reporting and value-based purchasing programs including the ASCQR (79 FR 66968), Hospital IQR (80 FR 49641 through 49643), Hospital VBP (79 FR 50055), IPFQR (82 FR 38463 through 38465), and PCHQR (81 FR 57182 through 57183) Programs. Our topped-out methodology does not evaluate variation at the State level, but rather at the level of individual ASCs. Our analyses demonstrate that the variation in performance among HOPDs for these measures is statistically indistinguishable. As shown in the tables above, hospitals performing at the 90th vs. 75th percentile have a rate of 97.4 percent for OP–11 and a rate of 98.8 percent for OP–14. After consideration of the public comments we received, we are finalizing our proposals, as proposed, to remove: (1) OP–11: Thorax CT Use of Contrast Material, and (2) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment determination and subsequent years.

(d) Measure Removals Under Measure Removal Factor 2: OP–12 and OP–17

In the proposed rule (83 FR 37186), for the CY 2021 payment determination and subsequent years, we proposed to remove two measures under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes: OP–12 and OP–17. The proposals are discussed in more detail below. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measure Initiative is intended to reduce costs and minimize burden. We believe that removing these measures from the Hospital OQR Program will reduce program burden, costs, and complexity. In addition, we noted that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but decided on proposing to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for this measure begins during CY 2018 for the CY 2020 payment determination.

• Removal of OP–12: The Ability for Providers With HIT To Receive Laboratory Data Electronically Directly Into Their Qualified/Certified EHR System as Discrete Searchable Data

We refer readers to CY 2011 OPPS/ASC final rule with comment period (75 FR 72076) where we adopted OP–12: The Ability for Providers With HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data

<table>
<thead>
<tr>
<th>Encounters</th>
<th>Number of Hospitals</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
<th>Truncated COV</th>
</tr>
</thead>
<tbody>
<tr>
<td>CY 2012</td>
<td>1,478</td>
<td>97.8</td>
<td>98.3</td>
<td>0.012</td>
</tr>
<tr>
<td>CY 2013</td>
<td>1,939</td>
<td>97.7</td>
<td>98.2</td>
<td>0.010</td>
</tr>
<tr>
<td>CY 2014</td>
<td>2,023</td>
<td>97.6</td>
<td>98.2</td>
<td>0.011</td>
</tr>
<tr>
<td>CY 2015</td>
<td>1,101</td>
<td>98.5</td>
<td>98.8</td>
<td>0.007</td>
</tr>
</tbody>
</table>

As displayed in the table above, there is a statistically indistinguishable difference in hospital performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2012.

Therefore, we invited public comment on our proposals to remove: (1) OP–11: Thorax CT Use of Contrast Material, and (2) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT measure for the CY 2021 payment determination and subsequent years as discussed above.
beginning with the CY 2012 payment determination. This web-based measure assesses the extent to which a provider uses an Office of the National Coordinator for Health Information Technology (ONC) certified electronic health record (EHR) system that incorporates an electronic data interchange with one or more laboratories allowing for direct electronic transmission of laboratory data in the EHR as discrete searchable data elements. In the proposed rule, we proposed to remove OP–12 beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes.

OP–12 is a process measure that tracks the transmittal of data but does not directly assess quality or patient outcomes. In the CY 2011 OPPS/ASC final rule with comment period (75 FR 72075), commenters expressed concern that the measure only assesses HIT functionality and does not assess the quality of care provided. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to reduce burden associated with payment policy, quality measures, documentation requirements, conditions of participation, and health information technology. As also discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to utilize measures that are “outcome-based where possible.” We do not believe OP–12 adds to these goals. In fact, we believe that provider performance in the measure is not an indicator for patient outcomes and continued collection provides little benefit.

Therefore, we proposed to remove OP–12 from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years.

Comment: Many commenters supported CMS’ proposal to remove OP–12. One commenter noted that the measure does not directly assess quality of care or patient outcomes.

Response: We thank the commenters for their support.

Comment: A few commenters opposed CMS’ proposal to remove OP–12. One commenter requested that CMS revise the measure so that it assesses quality of care in addition to HIT functionality. Another commenter recognized the value of removing OP–12 from the program but recommended that CMS continue to promote interoperability in the outpatient hospital setting.

Response: We thank the commenters for their feedback. We note that as a structural measure, OP–12 is limited in evaluating whether or not a provider uses an ONC-certified EHR system, and does not provide data on patient outcomes. We agree that a measure assessing the impact of EHR use on quality would be valuable and we intend to identify and consider other measures that assess interoperability and care quality for future inclusion in the program as appropriate measures become available. Due to this measure’s limitations as a structural measure, we do not believe it is possible to revise the measure in order to assess patient outcomes or quality of care directly. Due to the limitations of OP–12, we believe it is appropriate to remove this measure from the Hospital OQR Program.

After consideration of the public comments we received, we are finalizing our proposal, as proposed to remove OP–12 beginning with the CY 2021 payment determination and for subsequent years.

• Removal of OP–17: Tracking Clinical Results Between Visits

We refer readers to CY 2011 OPPS/ASC final rule with comment period (75 FR 72085) where we adopted OP–17: Tracking Clinical Results between Visits beginning with the CY 2013 payment determination. This web-based measure assesses the extent to which a provider uses a certified/qualified EHR system to track pending laboratory tests, diagnostic studies (including common preventive screenings), or patient referrals. In the proposed rule, we proposed to remove OP–17 beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 2, performance or improvement on a measure does not result in better patient outcomes.

OP–17 is a process measure that tabulates only the ability for transmittal of data but does not directly assess quality or patient outcomes. In the CY 2011 OPPS/ASC final rule with comment period (75 FR 72075), commenters expressed concern that the measure only assesses HIT functionality and does not assess the quality of care provided. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to reduce burden associated with payment policy, quality measures, documentation requirements, conditions of participation, and health information technology. As also discussed in section I.A.2. of the proposed rule and this final rule with comment period, one of the goals of our Meaningful Measures Initiative is to utilize measures that “outcome-based where possible.” We do not believe OP–17 supports this goal. In fact, we believe that provider performance in the measure does not improve patient outcomes and continued collection provides little benefit. Therefore, we proposed to remove OP–17 from the Hospital OQR Program beginning with the CY 2021 payment determination and for subsequent years.

Comment: Many commenters supported CMS’ proposal to remove OP–17. A few commenters noted that the measure does not directly assess quality of care or patient outcomes.

Response: We thank the commenters for their support.

Comment: A few commenters opposed CMS’ proposal to remove OP–17. One commenter noted that the ability to transfer electronic records can hasten diagnosis and treatment and reduce service duplication. Another commenter recognized the value of removing OP–17 from the ASCQR Program, but recommended that CMS continue to promote interoperability in the outpatient hospital setting.

Response: We thank the commenters for their feedback. We note that as a structural measure, OP–17 is limited in evaluating whether or not a provider uses an ONC certified EHR system to track laboratory tests, diagnostic studies, or patient referrals but does not provide information of the impact on outcomes such as diagnosis and treatment. We intend to identify and consider other measures that assess interoperability and care quality for future inclusion in the program as appropriate measures become available. Due to the limitation of OP–17 as a structural measure, we do not believe it is possible to revise it to assess patient outcomes or quality of care directly. Due to the limitations of OP–17, we believe it is appropriate to remove this measure from the Hospital OQR Program.

After consideration of the public comments we received, we are finalizing our proposal, as proposed, to remove OP–17 beginning with the CY 2021 payment determination and for subsequent years.
The tables below summarize the Hospital OQR Program measure sets as finalized in this final rule with comment period for the CY 2020 and 2021 payment determinations and subsequent years (including previously adopted measures and excluding measures removed in this final rule with comment period).

<table>
<thead>
<tr>
<th>NQF #</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>0288</td>
<td>OP-2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival</td>
</tr>
<tr>
<td>0290</td>
<td>OP-3: Median Time to Transfer to Another Facility for Acute Coronary Intervention</td>
</tr>
<tr>
<td>0289</td>
<td>OP-5: Median Time to ECG†</td>
</tr>
<tr>
<td>0514</td>
<td>OP-8: MRI Lumbar Spine for Low Back Pain</td>
</tr>
<tr>
<td>None</td>
<td>OP-9: Mammography Follow-up Rates</td>
</tr>
<tr>
<td>None</td>
<td>OP-10: Abdomen CT – Use of Contrast Material</td>
</tr>
<tr>
<td>0513</td>
<td>OP-11: Thorax CT – Use of Contrast Material</td>
</tr>
<tr>
<td>None</td>
<td>OP-12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into their ONC-Certified EHR System as Discrete Searchable Data</td>
</tr>
<tr>
<td>0669</td>
<td>OP-13: Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low-Risk Surgery</td>
</tr>
<tr>
<td>None</td>
<td>OP-14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus Computed Tomography (CT)</td>
</tr>
<tr>
<td>0491</td>
<td>OP-17: Tracking Clinical Results between Visits†</td>
</tr>
<tr>
<td>0496</td>
<td>OP-18: Median Time from ED Arrival to ED Departure for Discharged ED Patients</td>
</tr>
<tr>
<td>0499</td>
<td>OP-22: Left Without Being Seen†</td>
</tr>
<tr>
<td>0661</td>
<td>OP-23: Head CT or MRI Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke who Received Head CT or MRI Scan Interpretation Within 45 minutes of ED Arrival</td>
</tr>
<tr>
<td>0658</td>
<td>OP-29: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients*</td>
</tr>
<tr>
<td>0659</td>
<td>OP-30: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use*</td>
</tr>
<tr>
<td>1536</td>
<td>OP-31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery**</td>
</tr>
<tr>
<td>2539</td>
<td>OP-32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy</td>
</tr>
<tr>
<td>1822</td>
<td>OP-33: External Beam Radiotherapy for Bone Metastases</td>
</tr>
<tr>
<td>None</td>
<td>OP-35: Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy</td>
</tr>
<tr>
<td>2687</td>
<td>OP-36: Hospital Visits after Hospital Outpatient Surgery</td>
</tr>
<tr>
<td>None</td>
<td>OP-37a: OAS CAHPS – About Facilities and Staff***</td>
</tr>
<tr>
<td>None</td>
<td>OP-37b: OAS CAHPS – Communication About Procedure***</td>
</tr>
<tr>
<td>None</td>
<td>OP-37c: OAS CAHPS – Preparation for Discharge and Recovery***</td>
</tr>
<tr>
<td>None</td>
<td>OP-37d: OAS CAHPS – Overall Rating of Facility***</td>
</tr>
<tr>
<td>NQF #</td>
<td>Measure Name</td>
</tr>
<tr>
<td>-------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>None</td>
<td>OP-37e: OAS CAHPS – Recommendation of Facility***</td>
</tr>
</tbody>
</table>

† We note that NQF endorsement for this measure was removed.

* OP-26: Procedure categories and corresponding HCPCS codes are located at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1196289981244.

** We note that measure name was revised to reflect NQF title.

*** Measure voluntarily collected as set forth in section XIII.D.3.b. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66946 through 66947).

**** Measure reporting delayed beginning with CY 2018 reporting and for subsequent years as discussed in section XIII.B.5. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59432 through 59433).
6. Hospital OQR Program Measures and Topics for Future Consideration

In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we requested public comment on future measure topics for the Hospital OQR Program. We seek to develop a comprehensive set of quality measures to be available for widespread use for informed decision-making and quality improvement in the hospital outpatient setting. The current measure set for the Hospital OQR Program includes measures that assess process of care, imaging efficiency patterns, care transitions, ED throughput efficiency, Health Information Technology (health IT) use, care coordination, and patient safety. Measures are of various types, including those of process, structure, outcome, and efficiency. Through future rulemaking, we intend to propose new measures that help us further our goal of achieving better health care and improved health for Medicare beneficiaries who receive health care in hospital outpatient settings, while...
aligning quality measures across the Medicare program to the extent possible.

We are moving towards greater use of outcome measures and away from use of clinical process measures across our Medicare quality reporting and value-based purchasing programs. We invited public comments on possible measure topics for future consideration in the Hospital OQR Program. We specifically requested comment on any outcome measures that would be useful to add to as well as any process measures that should be eliminated from the Hospital OQR Program.

Comment: Several commenters recommended measure topics for future consideration in the Hospital OQR Program. Commenters’ recommendations included: (1) Antibiotic-use related measures to assess inappropriate prescribing; (2) a focus on clinical and population based outcome measures; (3) cancer care measures including two measures related to radiation therapy for both post-breast conserving surgery (NQF 0219) and post-mastectomy (MASTRT); (4) psychiatric care and behavioral health measures; (5) measures identified as meaningful to providers as well patients and their families; (6) rural health measures; (7) measures assessing access to care; (8) measures assessing substance abuse; (9) management of chronic conditions; (10) measures that promote advance care planning and shared-decision making; (11) surgical site infections (SSIs) and medication-related measures such as the Ambulatory Breast Procedure Surgical Site Infection (SSI) Outcome Measure (NQF #3025) measure; (12) measures using the same unit of analysis that allow comparison between hospitals and ASCs; and, (13) adult immunization measures. Several commenters also supported outcome measures but noted the value of process measures for addressing topics where there is insufficient evidence or standardized data to assess an outcome. One commenter also recommended that CMS consider the recommendations of the 2018 National Quality Forum (NQF) Report titled, “A Core Set of Rural-Relevant Measures and Measuring and Improving Access to Care: 2018 Recommendations from the MAP Rural Health Workgroup.” Another commenter encouraged CMS to recognize composite measures, especially for surgical care, that span across phases of care.

Response: We thank the commenters for their recommendations and suggestions and agree that there are additional high priority topic measurement areas that may be appropriate for the Hospital OQR Program. We will consider the suggested topics for future rulemaking and intend to work with stakeholders as we continue to develop the Hospital OQR Program measure set. We thank the commenters for their views and will consider them as we develop future Hospital OQR Program measures and topics.

7. Maintenance of Technical Specifications for Quality Measures

CMS maintains technical specifications for previously adopted Hospital OQR Program measures. These specifications are updated as we modify the Hospital OQR Program measure set. The manuals that contain specifications for the previously adopted measures can be found on the QualityNet website at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier2&cid=1196289961244. In the proposed rule, we proposed to change the frequency of the Hospital OQR Program Specifications Manual release beginning with CY 2019 and for subsequent years and we refer readers to section XIII.D.2. of the proposed rule and this final rule with comment period for more details.

8. Public Display of Quality Measures

We refer readers to the CY 2014 and CY 2017 OPPS/ASC final rules with comment period (78 FR 75092 and 81 FR 79791 respectively) for our previously finalized policies regarding public display of quality measures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we did not propose any changes to our previously finalized public display policies.

C. Administrative Requirements

1. QualityNet Account and Security Administrator

The previously finalized QualityNet security administrator requirements, including setting up a QualityNet account and the associated timeframes, are described in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109). In that final rule with comment period, we codified these procedural requirements at 42 CFR 419.46(a). In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we did not propose any changes to our requirements for the QualityNet account and security administrator.

2. Requirements Regarding Participation Status

In the CY 2019 OPPS/ASC proposed rule (83 FR 37188), we proposed to update our requirements related to the Notice of Participation (NOP) form.

a. Background

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519) for requirements for participation and withdrawal from the Hospital OQR Program. We also codified these procedural requirements at 42 CFR 419.46(a) and (b).

b. Removal of the Notice of Participation (NOP) Form Requirement

We finalized in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109) that participation in the Hospital OQR Program requires that hospitals must: (1) Register on the QualityNet website before beginning to report data; (2) identify and register a QualityNet security administrator; and (3) complete and submit an online participation form, the Notice of Participation (NOP) form, available at the QualityNet website if this form has not been previously completed, if a hospital has previously withdrawn, or if the hospital acquires a new CMS Certification Number (CCN). In addition, in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75108 through 75109), we finalized the requirement that hospitals must submit the NOP form by July 31 of the calendar year prior to the affected annual payment update.

If a hospital has a Medicare acceptance date before January 1 of the year prior to the affected annual payment update, the hospital must complete and submit to CMS a completed Hospital OQR Notice of Participation Form by July 31 of the calendar year prior to the affected annual payment update.

If a hospital has a Medicare acceptance date on or after January 1 of the year prior to the affected annual payment update, the hospital must complete and submit to CMS a completed Hospital OQR Notice of Participation Form by no later than 180 days from the date identified as its Medicare acceptance date.

In the proposed rule (83 FR 37188), beginning with the CY 2018 reporting period/CY 2020 payment determination, we proposed to remove submission of the NOP form as a requirement for the Hospital OQR Program. After reevaluating program requirements, we have concluded that this form does not provide CMS with any unique information, and as such, we believe it is unnecessarily burdensome for
hospitals to complete and submit. In place of the NOP form, we proposed that submission of any Hospital OQR Program data would indicate a hospital’s status as a participant in the program. This includes submitting just one data element. That is, hospitals would no longer be required to submit the NOP form as was previously required. Instead, hospitals would need to do the following to be a participant in the Hospital OQR Program: (1) Register on the QualityNet website before beginning to report data; (2) identify and register a QualityNet security administrator; and (3) submit data. We also proposed to update 42 CFR 419.46(a) to reflect these changes.

Comment: A few commenters supported CMS’ proposal to remove the NOP as a requirement for the Hospital OQR Program.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposals, as proposed, to no longer require hospitals to submit the NOP form, and update 42 CFR 419.46(a) to reflect these changes.

D. Form, Manner, and Timing of Data Submitted for the Hospital OQR Program

1. Hospital OQR Program Annual Payment Determinations

In the CY 2014 OPPS/ASC final rule with comment period (78 FR 75110 through 75111) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70519 through 70520), we specified our data submission deadlines. We also codified our submission requirements at 42 CFR 419.46(c).

We refer readers to the CY 2016 OPPS/ASC final rule with comment period (80 FR 70359 through 70520), where we finalized our proposal to shift the quarters upon which the Hospital OQR Program payment determinations are based, beginning with the CY 2018 payment determination. The finalized deadlines for the CY 2020 payment determination and subsequent years are illustrated in the table below.

### CY 2020 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>Patient Encounter Quarter</th>
<th>Clinical Data Submission Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2 2018 (April 1 - June 30)</td>
<td>11/1/2018</td>
</tr>
<tr>
<td>Q3 2018 (July 1 – September 30)</td>
<td>2/1/2019</td>
</tr>
<tr>
<td>Q4 2018 (October 1 - December 31)</td>
<td>5/1/2019</td>
</tr>
<tr>
<td>Q1 2019 (January 1 - March 31)</td>
<td>8/1/2019</td>
</tr>
</tbody>
</table>

In the CY 2018 OPPS/ASC final rule with comment period, we finalized a policy to align the initial data submission timeline for all hospitals that did not participate in the previous year’s Hospital OQR Program and made conforming revisions at 42 CFR 419.46(c)(3). In the CY 2019 OPPS/ASC proposed rule (83 FR 37188 through 37189), we did not propose any changes to these policies.

2. Change to the Frequency of Hospital Outpatient Quality Reporting Specifications Manual Release Beginning With CY 2019 and for Subsequent Years

In the CY 2019 OPPS/ASC proposed rule (83 FR 37189), we proposed to change the frequency of the Hospital Outpatient Quality Reporting Specifications Manual release beginning with CY 2019 and for subsequent years. In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68766 through 68767), we established a subregulatory process for making updates to the measures we have adopted for the Hospital OQR Program. As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 75091), we believe that a measure can be updated through this subregulatory process provided it is a nonsubstantive change. We expect to continue to make the determination of what constitutes a substantive versus a nonsubstantive change on a case-by-case basis. Examples of nonsubstantive changes to measures might include updated diagnosis or procedure codes, medication updates for categories of medications, broadening of age ranges, and exclusions for a measure (such as the addition of a hospice exclusion to the 30-day mortality measures). We believe that nonsubstantive changes may include updates to measures based upon changes to guidelines upon which the measures are based.

For a history of our policies regarding maintenance of technical specifications for quality measures, we refer readers to the CY 2010 OPPS/ASC final rule with comment period (74 FR 60631), the CY 2011 OPPS/ASC final rule with comment period (75 FR 72069), and the CY 2013 OPPS/ASC final rule with comment period (77 FR 68469 through 68470). In the proposed rule, we noted that we will continue to use rulemaking to adopt substantive updates to measures we have adopted for the Hospital OQR Program. We believe that this policy adequately balances our need to incorporate nonsubstantive updates to Hospital OQR Program measures in the most expeditious manner possible, while preserving the public’s ability to comment on updates that so fundamentally change an endorsed measure that it is no longer the same measure that we originally adopted. We also noted that the NQF process incorporates an opportunity for public comment and engagement in the measure maintenance process.

As stated in CY 2014 OPPS/ASC final rule with comment period (78 FR 75091), under current policy, technical specifications for the Hospital OQR Program measures are listed in the Hospital Outpatient Quality Reporting Specifications Manual, which is posted on the CMS QualityNet website at: http://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnePublic%2FPage%2FSpecsManualTemplate&cid=1228772438492. We maintain the technical specifications for the measures by updating this Hospital Outpatient Quality Reporting Specifications Manual and including detailed instructions and calculation algorithms. In some cases where the specifications are available elsewhere, we may include links to websites hosting technical specifications. These resources are for hospitals to use when...
collecting and submitting data on required measures. We revise the Hospital Outpatient Quality Reporting Specifications Manual so that it clearly identifies the updates and provide links to where additional information on the updates can be found. We provide sufficient lead time for facilities to implement the changes where changes to the data collection systems would be necessary. We generally release the Hospital Outpatient Quality Reporting Specifications Manual every six months and release addenda as necessary. This release schedule provides at least three months of advance notice for nonsubstantive changes such as changes to ICD–10, CPT, NUBC, and HCPCS codes, and at least six months of advance notice for changes to data elements that would require significant systems changes (78 FR 75091).

However, we believe that unnecessarily releasing two manuals a year has the potential to cause confusion for Hospital OQR Program participants. Therefore, in the proposed rule, we proposed to update the frequency with which we release Hospital Outpatient Quality Reporting Specifications Manuals, such that instead of every 6 months, we would release Specifications Manuals every six to 12 months beginning with CY 2019 and for subsequent years. Under this proposal, we would release a Hospital Outpatient Quality Reporting Specifications Manual (Specifications Manual) one to two times per calendar year, depending on the need for an updated release and consideration of our policy to provide at least six months’ notice for substantive changes.

**Comment:** Several commenters supported CMS’ proposal to release the Specifications Manual less frequently than every six months. However, a few commenters noted that ad hoc timing for release of the Specifications Manual may be confusing and recommended that CMS release the Specifications Manual once annually. One commenter requested that CMS notify hospitals and vendors about whether or not there will be an update on a 6-month schedule, even if the Specifications Manual is only released every 12 months.

**Response:** We thank the commenters for their support. We clarify that under our proposal, we would release a full manual once or twice a year, depending on need, as well as any addenda as necessary. Addenda would include discrete updates and do not constitute full manual releases. We acknowledge that ad hoc specifications manual releases could be confusing. After considering public comments and in an effort to provide greater consistency, we are modifying our proposal that we would release a Hospital Outpatient Quality Reporting Specifications Manual one to two times per calendar year; instead, we are finalizing that we will release a full manual once every 12 months and release any addenda as necessary. This reduces manual releases from one to two times per year as proposed, to consistently only once a year. Specifications manuals and addenda will be provided via QualityNet.

After consideration of the public comments we received, we are finalizing a modification of our proposal, beginning with CY 2019 and for subsequent years, to release Specifications Manuals every six to 12 months, such that we will instead release a manual once every 12 months and release addenda as necessary.

3. Requirements for Chart-Abstracted Measures Where Patient-Level Data Are Submitted Directly to CMS for the CY 2020 Payment Determination and Subsequent Years

We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68481 through 68484) for a discussion of the form, manner, and timing for data submission requirements of chart-abstracted measures for the CY 2014 payment determination and subsequent years. In the CY 2019 OPPS/ASC proposed rule (83 FR 37189), we did not propose any changes to our policies regarding the submission of chart-abstracted measure data where patient-level data are submitted directly to CMS. We note that, in section XIII.B.4.b.(2)[a] of this final rule with comment period, we are finalizing our proposal to remove OP–5: Median Time to ECG for the CY 2021 payment determination and subsequent years. Therefore, the following previously finalized Hospital OQR Program chart-abstracted measures will require patient-level data to be submitted for the CY 2021 payment determination and subsequent years:

- OP–2: Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival (NQF #0288);
- OP–3: Median Time to Transfer to Another Facility for Acute Coronary Intervention (NQF #0290);
- OP–18: Median Time from ED Arrival to ED Departure for Discharged ED Patients (NQF #0496); and
- OP–23: Head CT Scan Results for Acute Ischemic Stroke or Hemorrhagic Stroke Patients who Received Head CT Scan Interpretation Within 45 Minutes of ED Arrival (NQF #0661).

4. Claims-Based Measure Data Requirements for the CY 2020 Payment Determination and Subsequent Years

In the CY 2019 OPPS/ASC proposed rule (83 FR 37189 through 37191), we proposed to extend the reporting period 146 for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy.

**a. General**

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75111 through 75112) for a discussion of the general claims-based measure data submission requirements for the CY 2015 payment determination and subsequent years. In the proposed rule, we did not propose changes to our general requirements for claims-based measure data but refer readers to the section below for discussion regarding our proposal specific to OP–32.

We note that, in section XIII.B.4.b. of the proposed rule, we proposed to remove OP–9: Mammography Follow-up Rates, OP–11: Thorax CT Use of Contrast Material, and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT for the CY 2021 payment determination and subsequent years. As discussed in section XIII.B.4.b. of this final rule with comment period, we are finalizing the removals of all of these measures as proposed. Accordingly, the following previously finalized Hospital OQR Program claims-based measures will be required for the CY 2021 payment determination and subsequent years:

- OP–8: MRI Lumbar Spine for Low Back Pain (NQF #0514);
- OP–10: Abdomen CT—Use of Contrast Material;
- OP–13: Cardiac Imaging for Preoperative Risk Assessment for Non-Cardiac, Low Risk Surgery (NQF #0669);
- OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539);
- OP–35: Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy; and
- OP–36: Hospital Visits after Hospital Outpatient Surgery (NQF #2687).

146 We note that we previously referred to these reporting periods as “collection periods” (for example, 82 FR 59440); we now use the term “reporting period” in order to align the Hospital OQR Program terminology with the terminology we use in other CMS quality reporting and pay for performance (value-based purchasing) programs.
b. Extension of the Reporting Period for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate After Outpatient Colonoscopy

In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66949), we finalized the adoption of OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy into the Hospital OQR Program for the CY 2018 payment determination and subsequent years, with public display to begin on or after December 1, 2017. This measure is calculated with data obtained from paid Medicare FFS claims (79 FR 66950). For this reason, facilities are not required to submit any additional information. In that final rule with comment period, we also finalized the reporting period for measure calculation as claims data from two calendar years prior to the payment determination year. Specifically, for the CY 2018 payment determination, we stated we would use paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate measure results (79 FR 66955). We finalized a 1-year reporting period, as it adequately balanced competing interests of measure reliability and timeliness for payment determination purposes and explained that we would continue to assess this during the dry run (79 FR 66955).

We noted we would complete a dry run of the measure in 2015 using three or four years of data, and, from the results of this dry run, we would review the appropriate volume cutoff for facilities to ensure statistical reliability in reporting the measure score (79 FR 66953). Our analyses of the 2015 dry run using data from July 2011 through June 2014 showed that a reporting period of one year had moderate to high reliability for measure calculation. Specifically, using data from July 2013 through June 2014, we calculated facility-level reliability estimates as the ratio of true variance to observed variance.147 Consistent with the original measure specifications as described in the 2014 technical report,148 this calculation was performed combining the measure results for HOPDs and ASCs. We found that for a facility with median case size, the reliability estimate was high (over 0.90), but the minimum reliability estimate for facilities with 30 cases (the minimum case size chosen for public reporting) was only moderate (that is, between 0.40 and 0.60).149

However, after the 2015 dry run, CMS calculated the HOPD and ASC scores separately to compare similar types of providers to each other. During subsequent analysis of the 1-year period July 2013 through June 2014, we confirmed that a 1-year reporting period with separate calculations for HOPDs and ASCs was sufficient but did result in lower reliability and decreased precision compared to these measures calculated from longer reporting periods (two or three years). Based on analyses conducted using data from July 2013 through June 2014 (1-year reporting period) and 2017 measure specifications,150 we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs. Using a 2-year reporting period (data from July 2012–June 2014), we found that median facility-level reliability was 0.81 for ASCs and 0.67 for HOPDs. When the reporting period was extended to three years (using data from July 2011 through June 2014), we found that median facility-level reliability was higher for both ASCs and HOPDs: 0.87 for ASCs and 0.75 for HOPDs. These results indicate that a larger portion of the included facilities have scores measured with higher reliability when three years of data are used rather than one year of data.

Using three years of data, compared to just one year, is estimated to increase the number of HOPDs with eligible cases for OP–32 by 5 percent, adding approximately 235 additional facilities to the measure calculation. Facilities reporting the measure would increase their sample sizes and, in turn, increase the precision and reliability of their measure scores. Thus, we believe extending the reporting period to three years from one year for purposes of increasing reliability would be beneficial for providing better information to beneficiaries regarding the quality of care associated with low-risk outpatient colonoscopy procedures. In crafting our proposal, we considered extending the reporting period to two years beginning with the CY 2020 payment determinations and subsequent years, but decided on proposing three years instead, because a higher level of reliability is achieved with a 3-year reporting period compared to two years.

Therefore, we proposed to change the reporting period for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination (which would use claims data from January 1, 2016 through December 31, 2018) and for subsequent years. Under this proposal, the annual reporting requirements for facilities would not change, because this is a claims-based measure. However, with a 3-year reporting period, the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus 2 prior years of data (CYs 2016 and 2017). In the proposed rule, we noted that since implementation of this measure began with the CY 2018 payment determination, we have already used paid Medicare fee-for-service claims from January 1, 2016 to December 31, 2016 to calculate measure scores, which have been previously previewed by facilities and publicly displayed. In crafting our proposal, we also considered timeliness related to payment determinations and public display. Because we would utilize data already collected to supplement current data, our proposal to use three years of data would not disrupt payment determinations or public display. We refer readers to the table below for example reporting periods and public display dates corresponding to the CY 2020, CY 2021, and CY 2022 payment determinations:

---

148 Additional methodology details and information obtained from public comments for measure development are available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Measure-Methodology.html under “Hospital Outpatient Colonoscopy.”
150 Current and past measure specifications are available at: https://www.qualitynet.org/docs/ContentServer/?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1228775214597.
We refer readers to section XIV.D.4.b. of the proposed rule, where we discussed a similar proposal under the ASCQR Program.

**Comment:** Several commenters supported CMS’ proposal to extend the reporting period for OP–32. A few commenters supported a 3-year reporting period, noting that the extension will mirror the Alternative Payment Model (APM) being presented by ACEP to the Payment Model Technical Advisory Committee (PTAC) and urged CMS to seek stakeholder feedback on developing a methodology and releasing a methodology report for public review and comment.

**Response:** We thank the commenters for their support for extending the reporting period for OP–32. Regarding the request to release a methodology report, we note that a methodology already exists. We publish annual updates and measure specifications reports, which is a description of the measure updates and measure results from reevaluation and includes detailed measure specifications.151 This report describes the measure methodology for a given reporting period. We encourage stakeholders to submit comments on the measure’s methodology via the Outpatient and ASC Question and Answer tool, https://cmsocsq.custhelp.com/.

**Comment:** One commenter provided general feedback on the measure not specifically related to the proposed extension of the reporting period for OP–32. This commenter suggested the measure methodology be updated to exclude diagnosis codes and/or procedures that are obviously indicative of an unforeseen and/or unrelated event.

**Response:** We measure all-cause hospital visits to encourage OPDs and ASCs to minimize all types of risks that may lead to the need for a hospital visit after a colonoscopy. Measuring only hospital visits that are potentially related to a colonoscopy, such as gastrointestinal bleeding, would limit the measure’s impact on quality improvement efforts. Measuring all-cause patient outcomes encourages facilities to minimize the risk of a broad range of outcomes, including the risk of dehydration, pain, dizziness, and urinary retention. These are common problems that may be related or unrelated to a recent colonoscopy. We have structured the measure so that OPDs and ASCs that most effectively minimize patient risk of these outcomes will perform better.

We refer readers to section XIV.D.4.b. of this final rule with comment period, where we are finalizing a similar policy under the ASCQR Program.

**5. Data Submission Requirements for the OP–37a–e:**

We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79792 through 79794) for a discussion of the previously finalized requirements related to survey administration and vendors for the OAS CAHPS Survey-based measures. In addition, we refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59432 through 59433), where we finalized a policy to delay implementation of the OP–37a–e OAS CAHPS Survey-based measures beginning with the CY 2020 payment determination (2018 reporting period) until further action in future rulemaking. In the CY 2019 OPPS/ASC proposed rule (83 FR 37191), we did not propose any changes to the previously finalized requirements related to survey administration and vendors for the OAS CAHPS Survey-based measures.

We refer readers to the CY 2014 OPPS/ASC final rule with comment

<table>
<thead>
<tr>
<th></th>
<th>CY 2020 Payment determination</th>
<th>CY 2021 Payment determination</th>
<th>CY 2022 Payment determination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public display</td>
<td>January 2020</td>
<td>January 2021</td>
<td>January 2022</td>
</tr>
</tbody>
</table>

Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP–17: Tracking Clinical Results between Visits; OP–29: Endoscopy/Polypl Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; OP–30: Endoscopy/Polypl Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use; and OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and subsequent years.

In section XIII.B.4.b.(2) of this final rule with comment period, we are finalizing the removal of OP–30 as proposed. However, as discussed in section XIII.B.4.b.(2)(a) of this final rule with comment period, we are not finalizing the removal of OP–29 or OP–31. Accordingly, the following web-based quality measures will require data to be submitted via a web-based tool for the CY 2021 payment determination and subsequent years:

- OP–22: Left Without Being Seen (NQF #0499) (via CMS’ QualityNet website);
- OP–29: Endoscopy/Polypl Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658) (via CMS’ QualityNet website);
- OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) (via CMS’ QualityNet website);
- OP–33: External Beam Radiotherapy (EBRT) for Bone Metastases (NQF #1822) (via CMS’ QualityNet website).

Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP–17: Tracking Clinical Results between Visits; OP–29: Endoscopy/Polypl Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; OP–30: Endoscopy/Polypl Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use; and OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination and subsequent years.

We refer readers to the CY 2013 OPPS/ASC proposed rule (83 FR 37191, 37192) for a complete discussion of our extraordinary circumstances exception (ECE) process under the Hospital OQR Program. In the CY 2019 OPPS/ASC proposed rule (83 FR 37192), we did not propose any changes to our ECE policy.

10. Hospital OQR Program Reconsideration and Appeals Procedures for the CY 2020 Payment Determination and Subsequent Years

We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68489), the CY 2014 OPPS/ASC final rule with comment period (78 FR 75119 through 75120), the CY 2015 OPPS/ASC final rule with comment period (79 FR 66966), and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70524), the CY 2018 OPPS/ASC final rule with comment period (82 FR 59441 through 59443), and 42 CFR 419.46(e) for our policies regarding reconsideration and appeals procedures. In the CY 2019 OPPS/ASC proposed rule (83 FR 37192), we did not propose any changes to our reconsideration and appeals procedures.

E. Payment Reduction for Hospitals That Fail To Meet the Hospital OQR Program Requirements for the CY 2019 Payment Determination

1. Background

Section 1833(t)(17) of the Act, which applies to subsection (d) hospitals (as defined under section 1886(d)(1)(B) of the Act), states that a hospital that fails to report data required to be submitted on measures selected by the Secretary, in
the form and manner, and at a time, specified by the Secretary will incur a 2.0 percentage point reduction to their Outpatient Department (OPD) fee schedule increase factor; that is, the annual payment update factor. Section 1833(t)(17)(A)(ii) of the Act specifies that any reduction applies only to the payment year involved and will not be taken into account in computing the applicable OPD fee schedule increase factor for a subsequent year.

The application of a reduced OPD fee schedule increase factor results in reduced national unadjusted payment rates that apply to certain outpatient items and services provided by hospitals that are required to report outpatient quality data in order to receive the full payment update factor and that fail to meet the Hospital QQR Program requirements. Hospitals that meet the reporting requirements receive the full OPPS payment update without the reduction. For a more detailed discussion of how this payment reduction was initially implemented, we refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68769 through 68772).

The national unadjusted payment rates for many services paid under the OPPS equal the product of the OPPS conversion factor and the scaled relative payment weight for the APC to which the service is assigned. The OPPS conversion factor, which is updated annually by the OPD fee schedule increase factor, is used to calculate the OPPS payment rate for services with the following status indicators (listed in Addendum B to this final rule with comment period, which is available via the internet on the CMS website): “J1”, “J2”, “P”, “Q1”, “Q2”, “Q3”, “R”, “S”, “T”, “V”, or “U”. In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79796), we clarified that the reporting ratio does not apply to codes with status indicator “Q4” because services and procedures coded with status indicator “Q4” are either packaged or paid through the Clinical Laboratory Fee Schedule and are never paid separately through the OPPS. Payment for all services assigned to these status indicators will be subject to the reduction of the national unadjusted payment rates for hospitals that fail to meet Hospital QQR Program requirements, with the exception of services assigned to New Technology APCs with assigned status indicator “S” or “T”. We refer readers to the CY 2009 OPPS/ASC final rule with comment period (73 FR 68770 through 68771) for a discussion of this policy.

The OPD fee schedule increase factor is an input into the OPPS conversion factor, which is used to calculate OPPS payment rates. To reduce the OPD fee schedule increase factor for hospitals that fail to meet reporting requirements, we calculate two conversion factors—a full market basket conversion factor (that is, the full conversion factor), and a reduced market basket conversion factor (that is, the reduced conversion factor). We then calculate a reduction ratio by dividing the reduced conversion factor by the full conversion factor. We refer to this reduction ratio as the “reporting ratio” to indicate that it applies to payment for hospitals that fail to meet their reporting requirements. Applying this reporting ratio to the OPPS payment amounts results in reduced national unadjusted payment rates that are mathematically equivalent to the reduced national unadjusted payment rates that would result if we multiplied the scaled OPPS relative payment weights by the reduced conversion factor. For example, to determine the reduced national unadjusted payment rates that applied to hospitals that failed to meet their quality reporting requirements for the CY 2010 OPPS, we multiplied the full national unadjusted payment rate found in Addendum B of the CY 2010 OPPS/ASC final rule with comment period by the CY 2010 OPPS final reporting ratio of 0.980 (74 FR 60642).

In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68771 through 68772), we established a policy that the Medicare beneficiary’s minimum unadjusted copayment and national unadjusted copayment for a service to which a reduced national unadjusted payment rate applies would equal each product of the reporting ratio and the national unadjusted copayment or the minimum unadjusted copayment, as applicable, for the service. Under this policy, we apply the reporting ratio to both the minimum unadjusted copayment and national unadjusted copayment for services provided by hospitals that receive the payment reduction for failure to meet the Hospital QQR Program reporting requirements. The reduction to the national unadjusted and minimum unadjusted copayments is calculated according to §419.41 of our regulations, prior to any adjustment for a hospital’s failure to meet the quality reporting standards according to §419.43(h). Beneficiaries and secondary payers thereby share in the reduction of payments to these hospitals.

In the CY 2009 OPPS/ASC final rule with comment period (73 FR 68772), we established the policy that all other applicable adjustments to the OPPS national unadjusted payment rates apply when the OPD fee schedule increase factor is reduced for hospitals that fail to meet the requirements of the Hospital QQR Program. For example, the following standard adjustments apply to the reduced national unadjusted payment rates: The wage index adjustment; the multiple procedure adjustment; the interrupted procedure adjustment; the rural sole community hospital adjustment; and the adjustment for devices furnished with full or partial credit or without cost. Similarly, OPPS outlier payments made for high cost and complex procedures will continue to be made when outlier criteria are met. For hospitals that fail to meet the quality data reporting requirements, the hospitals’ costs are compared to the reduced payments for purposes of outlier eligibility and payment calculation. We established this policy in the OPPS beginning in the CY 2010 OPPS/ASC final rule with comment period (74 FR 60642). For a complete discussion of the OPPS outlier calculation and eligibility criteria, we refer readers to section II.G. of this final rule with comment period.

2. Reporting Ratio Application and Associated Adjustment Policy for CY 2019

In the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we proposed to continue our established policy of applying the reduction of the OPD fee schedule increase factor through the use of a reporting ratio for those hospitals that fail to meet the Hospital QQR Program requirements for the full CY 2019 annual payment update factor. For the CY 2019 OPPS, the proposed reporting ratio was 0.980, calculated by dividing the proposed reduced conversion factor of 77.955 by the proposed full conversion factor of 79.546. We proposed to continue to apply the reporting ratio to all services calculated using the OPPS conversion factor. For the CY 2019 OPPS, we proposed to apply the reporting ratio, when applicable, to all HCPSC codes to which we have proposed status indicator assignments of “J1”, “J2”, “P”, “Q1”, “Q2”, “Q3”, “R”, “S”, “T”, “V”, or “U” (other than New Technology APCs to which we have proposed status indicator assignment of “S” and “T”). We proposed to continue to exclude services paid under New Technology APCs. We proposed to continue to apply the reporting ratio to the national unadjusted payment rates and the minimum unadjusted and national unadjusted copayment rates of all applicable services for those hospitals that fail to meet the Hospital QQR...
Program reporting requirements. We also proposed to continue to apply all other applicable standard adjustments to the OPPS national unadjusted payment rates for hospitals that fail to meet the requirements of the Hospital OQR Program. Similarly, we proposed to continue to calculate OPPS outlier eligibility and outlier payment based on the reduced payment rates for those hospitals that fail to meet the reporting requirements.

We did not receive any public comments on these proposals. For the CY 2019 OPPS, the final reporting ratio is 0.980, calculated by dividing the final reduced conversion factor of 77.900 by the final full conversion factor of 79.490. We also are finalizing the remainder of our proposals regarding the payment reduction for hospitals that fail to meet the Hospital OQR Program requirements for CY 2019 payment determination without modification.

**XIV. Requirements for the Ambulatory Surgical Center Quality Reporting (ASCQR) Program**

A. Background

1. Overview

We refer readers to section XIII.A.1. of the proposed rule for a general overview of our quality reporting programs and to section I.A.2. of the proposed rule and this final rule with comment period for a discussion of our new Meaningful Measures Initiative.

2. Statutory History of the ASCQR Program

We refer readers to section XIV.K.1. of the CY 2012 OPPS/ASC final rule with comment period (76 FR 74492 through 74494) for a detailed discussion of the statutory history of the ASCQR Program.

3. Regulatory History of the ASCQR Program

We seek to promote higher quality and more efficient health care for beneficiaries. This effort is supported by the adoption of widely-agreed-upon quality measures. We have worked with relevant stakeholders to define measures of quality in almost every healthcare setting and currently measure some aspect of care for almost all Medicare beneficiaries. These measures assess structural aspects of care, clinical processes, patient experiences with care, and outcomes. We have implemented quality measure reporting programs for multiple settings of care. To measure the quality of ASC services and to make such information publicly available, we implemented the ASCQR Program. We refer readers to section XV.A.3. of the CY 2014 OPPS/ASC final rule with comment period (78 FR 75122), section XIV. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66966 through 66987), section XIV. of the CY 2016 OPPS/ASC final rule with comment period (80 FR 70526 through 70538), section XIV. of the CY 2017 OPPS/ASC final rule with comment period (81 FR 79797 through 79826) and section XIV. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59476) for an overview of the regulatory history of the ASCQR Program.

4. Meaningful Measures Initiative

In the proposed rule, we proposed a number of new policies for the ASCQR Program. We developed these proposals after conducting an overall review of the Program under our new Meaningful Measures Initiative, which is discussed in more detail in section I.A.2. of the proposed rule and this final rule with comment period. The proposals reflected our efforts to ensure that the ASCQR Program measure set continues to promote improved health outcomes for our beneficiaries while minimizing costs, which can consist of several different types of costs, including, but not limited to: (1) Facility information collection burden and related cost and burden associated with the submitting/reporting of quality measures to CMS; (2) the facility cost associated with complying with other quality programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure, including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). These proposals also reflected our efforts to improve the usefulness of the data that we publicly report in the ASCQR Program. Our goal is to improve the usefulness and usability of CMS quality program data by streamlining how facilities are reporting and accessing data, while maintaining or improving consumer understanding of the data publicly reported on a Compare website. We believe this framework will allow ASCs and patients to continue to obtain meaningful information about ASC performance and incentivize quality improvement while also streamlining the measure sets to reduce duplicative and program complexity so that the costs to ASCs associated with participating in this program do not outweigh the benefits of improving beneficiary care.

**B. ASCQR Program Quality Measures**

1. Considerations in the Selection of ASCQR Program Quality Measures

We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 68493 through 68494) for a detailed discussion of the priorities we consider for ASCQR Program quality measure selection. In the CY 2019 OPPS/ASC proposed rule (83 FR 37193), we did not propose any changes to these policies.

2. Accounting for Social Risk Factors in the ASCQR Program

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59447), we discussed the importance of improving beneficiary outcomes including reducing health disparities. We also discussed our commitment to ensuring that medically complex patients, as well as those with social risk factors, receive excellent care. We discussed how studies show that social risk factors, such as being near or below the poverty level as determined by HHS, belonging to a racial or ethnic minority group, or living with a disability, can be associated with poor health outcomes and how some of this disparity is related to the quality of health care. Among our core objectives, we aim to improve health outcomes, attain health equity for all beneficiaries, and ensure that complex patients as well as those with social risk factors receive excellent care. Within this context, reports by the Office of the Assistant Secretary for Planning and Evaluation (ASPE) and the National Academy of Medicine have examined the influence of social risk factors in CMS value-based purchasing programs. As we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59445 through 59447), ASPE’s report to Congress found that, in the context of value-based
purchasing programs, dual eligibility was the most powerful predictor of poor health care outcomes among those social risk factors that they examined and tested. In addition, as we noted in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59446), the National Quality Forum (NQF) undertook a 2-year trial period in which certain new measures and measures undergoing maintenance review have been assessed to determine if risk adjustment for social risk factors is appropriate for these measures. The trial period ended in April 2017 and a final report is available at: http://www.qualityforum.org/SES_Trial_Period.aspx. The trial concluded that “measures with a conceptual basis for adjustment generally did not demonstrate an empirical relationship” between social risk factors and the outcomes measured. This discrepancy may be explained in part by the methods used for adjustment and the limited availability of robust data on social risk factors. NQF is now undertaking an extension of the socioeconomic status (SES) trial, allowing further examination of social risk factors in outcome measures.

In the FY 2018 and CY 2018 proposed rules for our quality reporting and value-based purchasing programs, we solicited feedback on which social risk factors provide the most valuable information to stakeholders and the methodology for illuminating differences in outcomes rates among patient groups within and across healthcare settings by increasing the transparency of disparities as shown by quality measures. We also are considering how this work applies to other CMS quality programs in the future. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38403 through 38409) for more details, where we discuss the potential stratification of certain Hospital Inpatient Quality Reporting Program outcome measures. Furthermore, we continue to consider options to address equity and disparities in our value-based purchasing programs.

We plan to continue working with ASPE, the public, and other key stakeholders on this important issue to identify policy solutions that achieve the goals of attaining health equity for all patients, and empower beneficiaries and other consumers to make informed decisions about health care. Commenters encouraged us to stratify measures by other social risk factors such as age, income, and educational attainment. With regard to value-based purchasing programs, commenters also cautioned to balance fair and equitable payment while avoiding payment penalties that mask health disparities or discourage the provision of care to more medically complex patients. Commenters also noted that value-based payment program measure selection, domain weighting, performance scoring, and payment methodology must account for social risk.

As a next step, CMS is considering options to reduce health disparities among patient groups within and across healthcare settings by increasing the transparency of disparities as shown by quality measures. We also are considering how this work applies to other CMS quality programs in the future. We refer readers to the FY 2018 IPPS/LTCH PPS final rule (82 FR 38403 through 38409) for more details, where we discuss the potential stratification of certain Hospital Inpatient Quality Reporting Program outcome measures. Furthermore, we continue to consider options to address equity and disparities in our value-based purchasing programs.

We plan to continue working with ASPE, the public, and other key stakeholders on this important issue to identify policy solutions that achieve the goals of attaining health equity for all beneficiaries and minimizing unintended consequences.

3. Policies for Retention and Removal of Quality Measures From the ASCQR Program

a. Retention of Previously Adopted ASCQR Program Measures

We previously adopted a policy that quality measures adopted for an ASCQR Program measure set for a previous payment determination year be retained in the ASCQR Program for measure sets for subsequent payment determination years, except when they are removed, suspended, or replaced as indicated (76 FR 74494 and 74504; 77 FR 68494 through 68495; 78 FR 75122; and 79 FR 66967 through 66969). In the CY 2019 OPPS/ASC proposed rule (83 FR 37194), we did not propose any changes to this policy.

b. Removal Factors for ASCQR Program Measures

(1) Previously Finalized Policy

We refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967 through 66969) and 42 CFR 416.320 for a detailed discussion of the process for removing adopted measures from the ASCQR Program. In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967 through 66969), we finalized the ASCQR Program measure removal factors156 for determining whether to remove ASCQR Program measures as follows:

• Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures).

• Factor 2. Availability of alternative measures with a stronger relationship to patient outcomes.

• Factor 3. A measure does not align with current clinical guidelines or practice.

• Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic.

• Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic.

• Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

• Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

In that final rule with comment period, we stated that the benefits of removing a measure from the ASCQR Program will be assessed on a case-by-case basis (79 FR 66969). Under this case-by-case approach, a measure will not be removed solely on the basis of meeting any specific factor. We noted that in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68472 through 68473), similar measure removal factors were finalized for the Hospital QOR Program.


156 We note that we previously referred to these factors as “criteria” (for example, 82 FR 59474 through 59475); we now use the term “factors” in order to align the ASCQR Program terminology with the terminology we use in other CMS quality reporting and pay for performance (value-based purchasing) programs.
and (3) update 42 CFR 416.320(c) to better reflect our measure removal policies. We also made one clarification to measure removal Factor 1. These items are discussed in detail below.

(2) Removal of Factor 2

In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to remove the ASCQR Program’s measure removal Factor 2, availability of alternative measures with a stronger relationship to patient outcomes. We received comments in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66967) remarking on the duplicative nature of the ASCQR Program’s measure removal Factor 2, availability of alternative measures with a stronger relationship to patient outcomes, with measure removal Factor 6, the availability of a measure that is more strongly associated with desired patient outcomes for the particular topic. In that final rule with comment period, we stated that “criterion (2) applies when there is more than one alternative measure with a stronger relationship to patient outcomes that is available, and criterion (6) applies where there is only one measure that is strongly and specifically associated with desired patient outcomes for the particular topic that is available” (79 FR 66967). Since reevaluating those comments, we have now come to agree that ASCQR measure removal Factor 2 is repetitive with Factor 6. Therefore, we proposed to remove Factor 2, “availability of alternative measures with a stronger relationship to patient outcomes,” beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period. We invited public comment on our proposal as discussed above.

Comment: One commenter supported CMS’ proposal to remove measure removal Factor 2, noting its repetitive nature with removal Factor 6.

Response: We thank the commenter for its support.

After consideration of the public comments we received, we are finalizing our proposal to remove measure removal Factor 2, “availability of alternative measures with a stronger relationship to patient outcomes,” from the ASCQR Program beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, as proposed.

(3) Addition of Two New Measure Removal Factors

(a) Measure Removal Factor 2

We want the ASCQR Program measure removal factors to be fully aligned with the Hospital OQR Program to provide consistency across these two outpatient setting quality reporting programs. We believe it is important to evaluate the appropriateness of measures across programs using similar standards. In evaluating the two programs’ removal factors, we became aware that the Hospital OQR Program includes one factor not currently in the ASCQR Program. The Hospital OQR Program’s second measure removal factor specifies “performance or improvement on a measure does not result in better patient outcomes” (75 FR 50185).

Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to add “performance or improvement on a measure does not result in better patient outcomes” as the new removal Factor 2 for the ASCQR Program (replacing the previously adopted factor removed above). We believe that this factor is applicable in evaluating the ASCQR Program quality measures for removal because we have found it useful for evaluating measures in the Hospital OQR Program, which also evaluates the outpatient setting. In the proposed rule, we also noted that this proposed factor is already included in the Hospital IQR (80 FR 49641 through 49642), the PCHQR (82 FR 38461), the LTCH QRP (77 FR 53614 through 53615), and the IPFQR (82 FR 38463) Programs. We proposed to add a new removal factor to the ASCQR Program: “performance or improvement on a measure does not result in better patient outcomes” beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period. We invited public comments on our proposal, as discussed above.

Comment: A few commenters supported CMS’ proposal to add a new measure removal Factor 2, noting it would align the ASCQR and Hospital OQR Programs and provide consistency for evaluating measures across quality reporting programs.

Response: We thank the commenters for their support.

After consideration of the public comments we received, we are finalizing our proposal to add a new removal factor to the ASCQR Program, “performance or improvement on a measure does not result in better patient outcomes” beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period, as proposed.

(b) New Measure Removal Factor 8

In the CY 2019 OPPS/ASC proposed rule (83 FR 37195), we proposed to adopt an additional factor to consider when evaluating measures for removal from the ASCQR Program measure set:

- Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

As we discuss in section I.A.2. of the proposed rule and this final rule with comment period with respect to our new Meaningful Measures Initiative, we are engaging in efforts to ensure that the ASCQR Program measure set continues to promote improved health outcomes for beneficiaries while minimizing the overall costs associated with the program. We believe these costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. We have identified several different types of costs, including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). For example, it may be needlessly costly and/or of limited benefit to retain or maintain a measure which our analyses show no longer meaningfully supports program objectives (for example, informing beneficiary choice or payment scoring). It may also be costly for ASCs to track confidential feedback, preview reports, and publicly reported information on a measure where we use the measure in more than one program. CMS may also have to expend unnecessary resources to maintain the specifications for the measure, as well as the tools needed to collect, validate, analyze, and publicly report the measure data. Furthermore, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

In weighing the costs against the benefits, we evaluate the benefits of the measure as a whole, but in particular, we assess the benefits through the framework of our Meaningful Measures Initiative, as we discussed in section I.A.2. of the proposed rule and this final rule with comment period. One key aspect of patient benefits is assessing the improved beneficiary health...
outcomes if a measure is retained in our measure set. We believe that these benefits are multifaceted and are illustrated through the Meaningful Measures framework’s 6 domains and 19 areas. For example, we assessed the Healthcare Worker Influenza Vaccination and patient Influenza Vaccination measures categorized in the Quality Priority “Promote Effective Prevention and Treatment of Chronic Disease” in the meaningful measure area of “Preventive Care” across multiple CMS programs, and considered: Patient outcomes, such as mortality and hospitalizations associated with influenza; CMS measure performance in a program; and other available and reported influenza process measures, such as population influenza vaccination coverage.

When these costs outweigh the evidence supporting the benefits to patients with the continued use of a measure in the ASCQR Program, we believe it may be appropriate to remove the measure from the Program. Although we recognize that one of the main goals of the ASCQR Program is to improve beneficiary outcomes by incentivizing health care facilities to focus on specific care issues and making public data related to those issues, we also recognize that those goals can have limited utility where, for example, the publicly reported data (including percentage payment adjustment data) is of limited use because it cannot be easily interpreted by beneficiaries and used to inform their choice of facility. In these cases, removing the measure from the ASCQR Program may better accommodate the costs of program administration and compliance without sacrificing improved health outcomes and beneficiary choice.

We proposed that we would remove measures based on this factor assessing costs versus benefits on a case-by-case basis. We might, for example, decide to retain a measure that is burdensome for ASCs to report if we conclude that the benefit to beneficiaries justifies the reporting burden. Our goal is to move the program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures and continuing to incentivize improvement in the quality of care provided to patients.

We invited public comment on our proposal to adopt an additional measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, beginning with the effective date of the CY 2019 OPPS/ASC final rule with comment period and for subsequent years.

We referred readers to section XIV.B.3.c. of the proposed rule, where we proposed to remove four measures based on this proposed measure removal factor. We noted that we had also proposed this same measure removal factor for the Hospital OQR Program in section XIII.B.4.a.4.(4) of the proposed rule, as well as for other quality reporting and value-based purchasing programs for FY 2019 including: the Hospital VBP Program (83 FR 41442), the Hospital IQR Program (83 FR 41544); the PCHQR Program (83 FR 41609 through 41610); the LTCH QRP (83 FR 41625 through 41627); the HQR (83 FR 41625 through 41627); the IFR QRP (83 FR 38556 through 38557); the SNF QRP (83 FR 39267 through 39269); and the IPFQR Program (83 FR 38591 through 38593).

Comment: Several commenters supported CMS’ proposal to add measure removal Factor 8, and noted that it will allow CMS to reduce cost and burden, promote alignment of measure removal criteria across quality reporting programs and the Meaningful Measures Initiative, and allow providers to focus on improving care.

Response: We thank the commenters for their support.

Comment: A few commenters opposed CMS’ proposal to add measure removal Factor 8. A few commenters requested clarification on the types of costs that CMS will consider and requested transparency in the process of evaluation in the costs and benefits of measures. One commenter expressed concern that the costs described under measure removal Factor 8 are not defined. One commenter noted the costs with changing measures to facilities, providers, and measure developers. Another commenter expressed concern that CMS may deem a measure too costly to implement, while providers and patients may continue to find it meaningful. Commenters also recommended direct and indirect costs that CMS may consider in evaluating measures under measure removal Factor 8. These costs included those associated with: (1) Measures that require data collection from multiple data sources, rather than just one; (2) contracting with vendors; (3) tracking performance and investing in resources for quality improvement. One commenter stated it would oppose the new factor unless costs and benefits are defined as only costs and benefits to beneficiaries and the public.

Response: As noted in the proposed rule (83 FR 37193), we have defined costs, for the purpose of evaluating measures under measure removal Factor 8, as including, but not limited to: (1) Facility information collection burden and related costs and burden associated with the submission/reporting of quality measures to CMS; (2) the facility cost associated with complying with other programmatic requirements; (3) the facility cost associated with participating in multiple quality programs, and tracking multiple similar or duplicative measures within or across those programs; (4) the CMS cost associated with the program oversight of the measure including measure maintenance and public display; and (5) the facility cost associated with compliance with other federal and/or State regulations (if applicable). This was not intended to be a complete list of the potential factors to consider in evaluating measures. In addition, as we apply this measure removal factor in future rulemaking, we will describe our rationale for the removal of a measure and will include the costs and benefits we considered.

We thank commenters for their suggestions regarding additional costs to consider. We will use this feedback, as well as input from all stakeholders, as we apply measure removal Factor 8 in future rulemaking.

With respect to the commenter that suggested that costs and benefits should be defined as only costs and benefits to beneficiaries and the public, we believe that various stakeholders may have different perspectives on how to define costs as well as benefits. Because of these challenges, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: Patients, caregivers, patient and family advocates, providers, provider associations, healthcare researchers, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the ASCQR Program. However, we intend to evaluate while a measure’s use in the ASCQR Program may benefit many entities, the primary benefit is to patients and their caregivers through incentivizing high-quality care and providing publicly reported data regarding the quality of care available. We note that we intend to assess the costs and benefits to program stakeholders, including but not limited to, those listed in the proposed rule. Therefore, we intend to consider the benefits, especially those to patients and their families, when evaluating measures under this measure removal factor. As noted above, we have offered
a definition of costs. However, this was not intended to be a complete list of the potential factors to consider in evaluating measures and we intend to consider additional examples of cost described in public comment, including the costs and benefits to beneficiaries and the public, as recommended above.

Comment: A few commenters recommended that CMS seek input from hospitals, physicians, and other stakeholders when evaluating the costs and benefits of quality reporting.

Response: We thank the commenters for their feedback and note that we will consider stakeholder input when evaluating both the costs of quality reporting as well as the benefits of collecting and reporting quality data. As stated above, we intend to evaluate costs and benefits for each measure on a case-by-case basis, while considering input from a variety of stakeholders, including, but not limited to: patients, caregivers, patient and family advocates, providers, provider associations, healthcare purchasers, data vendors, and other stakeholders with insight into the direct and indirect benefits and costs (financial and otherwise) of maintaining any specific measure in the ASCQR Program.

Comment: A few commenters recommended that CMS consider measure sets as a whole and the consistency of quality reporting program measure sets. Another commenter recommended that when a measure is removed under Factor 8 that it should be replaced by a measure that is easier to implement and aimed at improving care within the same measure domain to avoid gaps in the measure set. One commenter further recommended that measure sets should include actionable process measures that contribute to the outcomes being measured.

Response: We intend to continue to develop a robust measure set for the ASCQR Program and appreciate the commenters’ feedback. We consider the measure set as a whole, the types of measures in the measure set, and the consistency throughout quality reporting programs, among other things, when assessing measures in the ASCQR Program. We continually seek ways to improve the ASCQR Program measure set, including through identification of more efficient means of capturing data. Retaining a strong measure set that addresses critical quality issues is one benefit that we would consider in evaluating whether a measure should be potentially removed from the ASCQR Program measure set. In addition, we note that in this final rule with comment period, as discussed in more detail further below, we are not finalizing our proposals below to remove two measures (ASC–9 and ASC–11) under Factor 8 in part to maintain a more balanced and cohesive ASCQR Program measure set.

After consideration of the public comments we received, we are finalizing our proposal to adopt measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the ASCQR Program beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, as proposed.

As a result of the finalization of our proposals to remove one and add two new removal factors as proposed, the new measure removal factors list for the ASCQR Program consists of the following:

Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures).

Factor 2. Performance or improvement on a measure does not result in better patient outcomes.

Factor 3. A measure does not align with current clinical guidelines or practice.

Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic.

Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic.

Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic.

Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm.

Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37196), we did not propose any changes to this policy; however, we clarified our process for calculating the truncated coefficient of variation (TCOV) by using the mean, or average rate of event occurrence, is very low and the result is a TCOV that increases rapidly and approaches infinity as the proportion of rare events declines. We note that the SD, the variability statistic, is the same in magnitude for measures assessing rare and non-rare events.

In the proposed rule, we proposed to remove a number of measures that assess the rate of rare, undesired events for which a lower rate is preferred—ASC–1, ASC–2, ASC–3, and ASC–4—assess the rate of rare, undesired events for which a lower rate is preferred. For example, ASC–1 assesses the occurrence of patient burns, a patient safety issue. However, when determining the TCOV for a measure assessing rare, undesired events, the mean, or average rate of event occurrence, is very low and the result is a TCOV that increases rapidly and approaches infinity as the proportion of rare events declines. We note that the SD, the variability statistic, is the same in magnitude for measures assessing rare and non-rare events.

In the proposed rule, we proposed to remove a number of measures that assess the rate of rare, undesired events for which a lower rate is preferred—ASC–1, ASC–2, ASC–3, and ASC–4—and referred readers to section XIV.B.3.c. of the proposed rule where these proposed measure removals are discussed in detail. Because by design

these measures have maintained very low rates (indicating the preferred outcome), we utilized the mean of non-adverse events in our calculation of the TCOV. For example, for ASC–1, to calculate the TCOV we divide the SD by the average rate of patients not receiving burns (1 minus the rate of patients receiving burns) rather than the rate of patients receiving burns. Utilizing this methodology results in a TCOV that is comparable to that calculated for other measures and allows us to assess rare-event measures by still generally using our previously finalized topped-out criteria.

c. Removal of Quality Measures From the ASCQR Program Measure Set

In the CY 2019 OPPS/ASC proposed rule (83 FR 37197 through 37202), we proposed to remove a total of eight measures from the ASCQR Program measure set across the CY 2020 and CY 2021 payment determinations.

Specifically, beginning with the CY 2020 payment determination, we proposed to remove: (1) ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431); and beginning with the CY 2021 payment determination, we proposed to remove: (2) ASC–1: Patient Burn (NQF #0263); (3) ASC–2: Patient Fall (NQF #0266); (4) ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant (NQF #0267); (5) ASC–4: All-Cause Hospital Transfer/Admission (NQF #0265); (6) ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0658); (7) ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use (NQF #0659); and (8) ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536). We proposed to remove these measures under the following measure removal factors: Factor 1—measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures); and Factor 8—the costs associated with a measure outweigh the benefit of its continued use in the program.

We are finalizing the removal of two measures out of the eight measure removals we proposed. The proposed measure-specific removals are discussed in detail further below. However, because several general comments regarding all eight proposals as a whole, we are discussing those first.

Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program measure set. Some of these commenters noted that the proposals will reduce burden, simplify facility reporting, and reduce duplication. One commenter suggested that CMS remove all eight measures beginning with CY 2020, rather than delaying removal of seven measures until CY 2021. Some commenters agreed with CMS’ rationale for removals and noted that topped-out or not beneficial measures should be removed as soon as possible.

Response: We thank the commenters for their support for our proposed measure removals. However, data collection and reporting for the CY 2020 payment determination already began in January 2018 for all eight of the measures proposed for removal. Thus, by the effective date of this final rule with comment period, facilities will have already collected 11 months of data for the CY 2020 payment determination. In consideration of facilities’ efforts already exerted, we are finalizing removal of these measures starting with the next proximate payment determination.

Comment: One commenter opposed CMS’ proposal to remove measures from the ASCQR Program, citing its belief that consumers should be offered more quality information, rather than less, that can be used in selecting facilities. Another commenter recommended that CMS maintain the existing measure set and work to reduce provider burden through alignment across programs instead.

Response: We thank the commenters for their feedback and note our agreement that consumers should be provided with as much valuable quality information as possible. As described in the proposed rule, we proposed to remove some measures because the costs associated with a measure outweigh the benefit of its continued use in the program and measure performance among facilities is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (“topped-out” measures). We have identified these and other measure removal factors specifically to ensure that the data provided to consumers is meaningful and valuable. We do not believe it is beneficial to maintain program measures indefinitely.

However, we agree that burden should be reduced through program alignment and will continue to seek opportunities to do this. In the final rule, we proposed several policies to align with the Hospital OQR Program including updating our measure removal factors and removing OP–27 and ASC–8, OP–29 and ASC–9, OP–30 and ASC–10, and OP–31 and ASC–11, and we are finalizing several of these aligned proposals in this final rule with comment period.

(1) Measure Removal for the CY 2020 Payment Determination and Subsequent Years—ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel

For the CY 2020 payment determination and subsequent years, we proposed to remove one NHSN measure under proposed measure removal Factor 8, the costs associated with this measure outweigh the benefit of its continued use in the program.

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74510), where we adopted ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431), beginning with the CY 2016 payment determination and for subsequent years. This process of care measure, also a National Healthcare Safety Network (NHSN) measure, assesses the percentage of healthcare personnel who have been immunized for influenza during the flu season. We initially adopted this measure based on our recognition that influenza immunization is an important public health issue and vital component to preventing healthcare associated infections. We believe that the measure addresses this public health concern by assessing influenza vaccination in the ASC among healthcare personnel (HCP), who can serve as vectors for influenza transmission.

In the proposed rule, we proposed to remove ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel beginning with the CY 2020 payment determination under proposed measure removal Factor 8, because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program.

The information collection burden for the Influenza Vaccination Coverage Among Healthcare Personnel measure is less than for measures that require chart abstraction of patient data because influenza vaccination among health care personnel can be calculated through review of records maintained in administrative systems and because facilities have fewer health care personnel than patients. As such, ASC–8 does not require review of as many records. However, this measure does still pose information collection burden on facilities due to the requirement to identify personnel who have been
vaccinated against influenza and for those not vaccinated, the reason why. Furthermore, as we stated in section XIV.B.3.b. of the proposed rule, costs are multifaceted and include not only the burden associated with reporting, but also the costs associated with implementing and maintaining the program. For example, it may be costly for health care providers to maintain general administrative knowledge to report these measures. In addition, CMS must expend resources in maintaining information collection systems, analyzing reported data, and providing public reporting of the collected information.

In our analysis of the ASCQR Program measure set, we recognized that some ASCs face challenges with respect to the administrative requirements of the NHSN in their reporting of the Influenza Vaccination Coverage Among Healthcare Personnel measure. These administrative requirements (which are unique to NHSN) include annually completing a system user authentication. Enrolling in NHSN is a five-step process that the CDC estimates takes an average of 263 minutes per ASC. Furthermore, submission via NHSN requires the system security administrator of participating facilities to re-consent electronically, ensure that contact information is kept current, ensure that the ASC has an active facility administrator account, keep Secure Access Management Service (SAMS) credentials active by logging in approximately every two (2) months and changing the password, create a monthly reporting plan, and ensure the ASC’s CCN information is up-to-date.

Unlike short-term acute care hospitals which participate in other quality programs, such as the Hospital IQR and HAC Reduction Programs, ASCs are only required to participate in NHSN to submit data for this one measure. This may unduly disadvantage smaller ASCs, specifically those that are not part of larger hospital systems, because these ASCs do not have NHSN access for other quality reporting or value-based payment programs. It is our goal to ensure that the ASCQR Program is equitable to all ASCs and this measure may disproportionately affect small, independent ASCs. Especially for these small, independent ASCs, the incremental costs of this measure, as compared to other measures in the ASCQR Program measure set, are significant because of the requirements imposed by NHSN participation.

We continue to believe that the Influenza Vaccination Coverage Among Healthcare Personnel measure provides the benefit of protecting ASC patients against influenza. However, we believe that these benefits are offset by other efforts to reduce influenza infection among ASC patients, such as numerous healthcare employer requirements for healthcare personnel to be vaccinated against influenza. We also expect that a portion of MIPS-eligible clinicians nationwide will report on the Preventive Care and Screening: Influenza Immunization measure (NQF #0041) through the Quality Payment Program (QPP). Although MIPS-eligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure. CMS remains responsive to the public health concern of influenza infection within the Medicare FFS population by collecting data on rates of influenza immunization among patients. Thus, the public health concern is addressed via these other efforts to track influenza vaccination. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

We wish to minimize the level of cost of our programs for participating facilities, as discussed under the Meaningful Measures Initiative described in section I.A.2. of the proposed rule and this final rule with comment period. In our assessment of the ASCQR Program measure set, we prioritized measures that align with this Framework as the most important to the ASC population. Our assessment concluded that while the Influenza Vaccination Coverage Among Healthcare Personnel measure continues to provide benefits, these benefits are diminished by other factors and are outweighed by the costs and burdens of reporting this measure.

For these reasons, we proposed to remove ASC–8: Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) from the ASCQR Program beginning with the CY 2020 payment determination and for subsequent years because the costs associated with the measure outweigh the benefit of its continued use in the program. We noted that if proposed measure removal Factor 8 is not finalized, removal of this measure would also not be finalized. We also noted that a similar measure was also proposed for removal from the Hospital OQR Program in section XIII.B.4.b.(1) of the proposed rule and the IPFQR Program in the FY 2019 IPF PPS proposed rule (83 FR 21104). We invited public comments on our proposal to remove ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel from the ASCQR Program beginning with the CY 2020 payment determination under measure removal Factor 8, because we have concluded that the costs associated with this measure outweigh the benefit of its continued use in the program, as discussed above.

Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Many commenters specifically supported CMS’ proposal to remove ASC–8 because the costs of the measure outweigh its continued use in the ASCQR Program. One commenter remarked that while immunization is a critical component of preventing influenza transmission, that many employer-based programs and requirements already promote vaccination. Another commenter noted that many ASCs may fail to receive the APU due to failing to submit data related to ASC–8.

Response: We thank the commenters for their support.

Comment: A few commenters noted that the NHSN website is very burdensome and it is difficult for ASCs to keep their accounts active when it utilized only once per year. One commenter noted that keeping such accounts active may be particularly difficult for ASCs that are not part of a hospital system. A few commenters recommended that the measure could be redeveloped and submitted via QualityNet in the future.

Response: We thank the commenters for their support and agree that ASCs face an undue burden from registering for their support.

Comment: A few commenters noted that the NHSN website is very burdensome and it is difficult for ASCs to keep their accounts active when it utilized only once per year. One commenter noted that keeping such accounts active may be particularly difficult for ASCs that are not part of a hospital system. A few commenters recommended that the measure could be redeveloped and submitted via QualityNet in the future.

Response: We thank the commenters for their support and agree that ASCs face an undue burden from registering
healthcare safety measures. We will continue to assess the ASCQR Program measure set and will consider future measures, including the potential for a re-developed measure submitted via QualityNet that addresses influenza vaccinations for healthcare workers, as part of our goal to maintain a robust measure set.

Comment: One commenter stated that although the process to register on NHSN is tedious, that it is not impossible and that reporting on the site is easy. Another commenter noted that the burden to submit the measure via NHSN is minimal once the data is collected and that having ASCs participate in NHSN reporting will provide benefit as new measures are developed in partnership with the CDC.

Response: We thank the commenters for their input. We remain concerned that the burden of reporting this measure is greater for ASCs compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system for ASCs, especially independent or freestanding ASCs, is due to this one measure; whereas hospitals paid under the IPPS, participating in the Hospital IQR Program, the HAC Reduction Program and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one. However, we note that, beyond the ASCQR Program, hospitals may independently choose to voluntarily report data to NHSN on vaccination rates using the NHSN Healthcare Personnel Safety Component.

Comment: Several commenters opposed CMS’ proposal to remove ASC–8 from the ASCQR Program. A few commenters expressed concern that influenza is a critical public health issue and that influenza vaccination coverage of healthcare workers helps create a safe environment for patients, visitors, and employees. A few commenters expressed concern that removal of ASC–8 would result in lower vaccination rates among healthcare workers. A few commenters noted that the Medicare population may be more susceptible to vaccine preventable illnesses such as influenza.

Response: We agree that influenza vaccination for both patients and healthcare personnel is important in the ASC setting, as well as other healthcare settings, and we believe that these two activities help both intend to address the public health concern of reducing influenza infection. However, while we agree that Medicare beneficiaries may have additional risk of contracting influenza, as noted in our proposal, we believe the effects of removing this measure from the ASCQR Program are mitigated as the issue is addressed in other initiatives such as State laws and employer programs that require influenza vaccination of healthcare workers. Because of this, we do not believe that retaining this measure would result in lower rates of vaccination coverage among healthcare personnel. Further, we have retained the measure in the Hospital IQR Program (83 FR 41579), thus, requiring reporting in the short-term, acute care hospital setting. In addition, we believe that the burden of this measure on ASCs, especially independent or freestanding ASCs, outweighs the limited benefit of addressing this topic again under the ASCQR Program in addition to the many other vaccination initiatives.

Comment: A few commenters stated that ASC–8 plays a critical role in the CMS Quality Strategy and the National Quality Strategy in terms of immunization efforts. A few commenters stated that removal of the measure would create greater inconsistency across quality reporting programs.

Response: We agree that influenza is a critical public health issue that is part of the CMS Quality Strategy and the National Quality Strategy. Through our Meaningful Measures Initiative, it is our goal to ensure that we are addressing high-impact measure areas that safeguard public health while minimizing the level of burden for providers and suppliers. We continue to believe in the importance of influenza vaccination coverage for healthcare workers, particularly in acute care settings, and have retained this measure in the Hospital IQR Program (83 FR 41579) in order to address this concern.

As we noted above, the burden of reporting this measure is greater for ASCs compared to the relative burden for hospitals participating in the Hospital IQR and HAC Reduction Programs. The entire burden of registering for and maintaining access to the CDC’s NHSN system for ASCs, especially independent or freestanding ASCs, is due to this one measure; whereas, hospitals paid under the IPPS, participating in the Hospital IQR Program, the HAC Reduction Program, and the Hospital VBP Program, for example, must register and maintain NHSN access for several healthcare safety measures, not just one.

Comment: One commenter stated that the cost associated with mitigating an influenza outbreak outweighs the cost of retaining ASC–8 in the ASCQR Program.

Response: As noted above, because this issue is addressed in other initiatives at the State-level and through employers, we do not believe it would result in lower rates of vaccination coverage among healthcare personnel in ASCs or increase the risk of an outbreak.

After consideration of the public comments we received, we are finalizing our proposal to remove ASC–8 from the ASCQR Program beginning with the CY 2020 payment determination, as proposed.

(2) Measure Removals for the CY 2021 Payment Determination and Subsequent Years

For the CY 2021 payment determination and subsequent years, we proposed to remove: (1) Four claims-based measures under measure removal Factor 1, “topped-out” status; as well as (2) two chart-abstraction measures and (3) one web-based tool measure under proposed measure removal Factor 8.

(a) Proposals To Remove Measures Under Removal Factor 1: ASC–1, ASC–2, ASC–3, and ASC–4

In the proposed rule, beginning with the CY 2021 payment determination and subsequent years, we proposed to remove ASC–1, ASC–2, ASC–3, and ASC–4 under measure removal Factor 1, measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made. The ASCQR Program previously finalized two criteria for determining when a measure is “topped-out”: (1) When there is statistically indistinguishable performance at the 75th and 90th percentiles of national facility performance; and (2) when the measure’s truncated coefficient of variation is less than or equal to 0.10 (79 FR 66968 through 66969). In the proposed rule, we referred readers to section XIV.B.3.b of the proposed rule, where we clarified and discussed how we calculate the TCOV for measures that assess the rate of rare, undesired events for which a lower rate is preferred, such as ASC–1, ASC–2, ASC–3, and ASC–4.
For each of these measures, we stated that we believed that removal from the ASCQR Program measure set is appropriate as there is little room for improvement. In addition, removal would alleviate the maintenance costs and administrative burden to ASCs associated with retaining the measures. As such, we stated that we believed the burden associated with reporting these measures outweighs the benefits of keeping them in the program.

We also note that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination, but opted to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for the measures begins during CY 2018 for the CY 2020 payment determination. Each measure is discussed in more detail further below. However, because we received several general comments regarding these proposals as a whole, we are discussing those first.

Due to public comments, we have reevaluated our data. In the proposed rule, we believed that the measures’ performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made and that the measures met the criteria for being topped-out. However, we have reviewed many studies, in addition to the public comments we received, that show the importance of measuring and reporting the data for these measures, as discussed in each proposal below.

Therefore, we have now come to believe that these measures may be more valuable to stakeholders than we initially perceived in the proposed rule. We agree that it is important to continue to monitor these types of events considering the potential negative impacts to patients’ morbidity and mortality, in order to continue to prevent their occurrence and ensure that they remain rare. We acknowledge that these measures provide critical data to beneficiaries and further transparency for care provided in the ASC setting that would be useful in choosing an ASC for care, and that these measures are valuable to the ASC community. Despite little room for improvement, these measures provide beneficiaries and ASCs with vital information about patient burns, patient falls, wrong site, wrong side, wrong patient, wrong procedure, wrong implant events, and hospital transfers/admissions that take place in the ASC setting and we believe it would be important to keep them in the program at this time in order to continue to detect and prevent these events. Further, we acknowledge that having measures that apply to all ASCs provides beneficiaries with the most comprehensive patient safety data to use when making decisions about a site of care. ASC–1, ASC–2, ASC–3, and ASC–4 are measures for which all ASCs, regardless of specialty area, can submit data in contrast to other measures, such as ASC–14: Unplanned Anterior Vitrectomy, which would only apply to ASCs where specialty-specific procedures are performed, such as ophthalmology procedures in the case of ASC–14. Therefore, we are not finalizing our proposals to remove ASC–1, ASC–2, ASC–3, and ASC–4. These measures will remain in the program under our measure retention policies, unless we take future action under our measure removal policies.

Comment: A few commenters who opposed the removal of these measures were also concerned about the data submitted for them. One commenter expressed concern that only 50 percent of claims are required to have QDCs and questioned how some ASCs are able to report that no errors occurred in their facilities. Another commenter was concerned about the proportion of ASCs that had missing data for these measures, noting that the missing data would affect their eligibility to receive the APU, but does not impact their status as a Medicare provider. Another commenter was concerned about under-reporting and recommended that CMS conduct data validation studies and empirical analyses of these measures, particularly for ASC–1, ASC–2, and ASC–3. This commenter also recommended that the denominator for ASC–1, ASC–2, and ASC–3 should only include cases that present risk for the adverse event as utilizing an amplified denominator would provide a false reading of lower rates. A few commenters who supported the removal of these measures suggested that the measure be redrafted and submitted via QualityNet in the future. One commenter suggested that revising the data submission method in this way could capture data from all payers. One commenter noted that ASC–1, ASC–2, and ASC–3 specifically should include all patients in the denominator. A few commenters who opposed CMS’ proposals to remove the measures stated that the measures could be redeveloped for all payers and could be reported via QualityNet in order to further reduce burden and ensure data is posted publicly for accountability and for quality improvement. A few commenters recommended that the measures could be included as part of
a composite measure that encompasses the various phases of care.

Response: The ASCQR Program is a quality reporting program for which ASCs must meet program requirements including the submission of quality measure data, else they are subject to a two percent reduction in their annual payment update. As a quality reporting program, the data collected is publicly reported in order to aide beneficiaries in choosing sites of care. Our regulations at 42 CFR part 416 detail the requirements that determine a facility’s eligibility to participate as a Medicare supplier of ambulatory surgical services. We will continue to assess our measure set in light of stakeholder concerns and within the framework of our Meaningful Measures Initiative.

Currently, ASCs are only able to report adverse events for Medicare fee-for-service beneficiaries and that adverse events that have occurred to patients with other payers are not reflected in the currently reported data. As such, it is possible for an ASC to report zero adverse events via the ASCQR Program because no adverse events occurred to Medicare FFS beneficiaries within the reporting period. In addition, we thank the commenters for their suggestions regarding redeveloping the measure to capture all payers and to submit via QualityNet to reduce burden. We note that because the data for these measures are currently collected via Medicare FFS claims, as specified in the Specifications Manual, we are unable to include data from other payers for which Medicare does not receive FFS claims.

We thank the commenters for their feedback and note that we are also concerned about some of the data submitted for these measures. In the FY 2013 IPPS/LTCH PPS final rule (77 FR 53641), we finalized our policy that the minimum threshold for successful reporting be that at least 50 percent of claims meeting measure specifications contain QDCs. At that time, we believed that 50 percent was a reasonable minimum threshold for the initial implementation years of the ASCQR Program, because ASCs were not yet familiar with how to report quality data under the ASCQR Program and because many ASCs are relatively small and may have needed more time to set up reporting systems. We stated in that final rule that we intended to propose to increase this percentage for subsequent years’ payment determinations as ASCs become more familiar with reporting requirements for the ASCQR Program. We have assessed this reporting threshold annually and have found that over 78 percent of reporting ASCs report data for at least 90 percent of eligible claims. However, we believe that the current data submission method for these measures may impact the completeness and accuracy of the data due to the inability of ASCs to correct the QDC codes that are used to calculate these measures from Medicare FFS claims. Currently, a facility that identifies an erroneous or missing QDC code is unable to correct or add a QDC code if the claim has already been submitted to Medicare. We believe that revising the data submission method for the measures, such as via QualityNet, would address this issue and allow facilities to correct any data submissions errors, resulting in more complete and accurate data. Further, we will conduct additional empirical analyses to identify any other potential issues with the data submitted for these measures. We refer readers to section XIV.B.6 of this final rule with comment period, where we discuss public comments received about the potential future validation of ASCQR Program measures.

We are committed to work with stakeholders to ensure the ASCQR Program measure set does not place an inappropriate amount of burden on facilities while addressing and providing information about these types of patient safety, adverse, rare events to patients and other consumers. As such, while we will retain ASC–1, ASC–2, ASC–3, and ASC–4 in the program as discussed above, after considering public comments and reevaluating our concerns about data submission, we will also suspend their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the data submission method for the measures. In other words, starting with the CY 2021 payment determination, facilities would not be required to submit data for these four measures as part of ASCQR Program requirements although the measures would remain in the ASCQR Program measure set. As we develop future revisions for the data collected for these measures, we will take into consideration other data submission methods that may allow for the reporting of adverse events across payers and will consider commenters’ feedback toward the future updates to the measures.

Comment: A few commenters noted that it would be beneficial to also have these measures included in the Hospital OQR Program in order to provide patients with more meaningful data to compare sites of service.

Response: We thank the commenters for their feedback. We will take this into consideration for the future.

Comment: One commenter stated that the NQF endorsement of these measures was removed because they were allowed to lapse by the measure steward, not because they failed the endorsement maintenance process, and noted that the ASCQR Program did not provide this as a rationale for removing the measures. The commenter noted that all of these measures have ongoing support from the ASC community.

Response: NQF endorsement, or lack thereof, does not automatically qualify or disqualify a measure for removal from the ASCQR Program. We thank the commenter for its comment as ASC stakeholder feedback is important, and we will weigh the benefits of support of the ASC community in our consideration of our proposals to ensuring that the ASCQR Program has a robust and responsive measure set.

 Proposal To Remove ASC–1: Patient Burn

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74497 through 74498) where we adopted ASC–1: Patient Burn beginning with the CY 2014 payment determination (NQF #0263). This claims-based outcome measure assesses the percentage of ASC admissions experiencing a burn prior to discharge.

Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–1 measure meets our measure removal Factor 1. These analyses are captured in the table below.

As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles, and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0263) was removed on May 24, 2016.

Comment: One commenter specifically opposed the removal of ASC–1, noting that it measures rare, isolated events and that it is valuable to monitor for consumers as a burn measure.

Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74497), we adopted this measure for ASCs because they serve surgical patients who may face the risk of burns during ambulatory surgical procedures and because we agree monitoring patient burns is valuable to patients and other stakeholders. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient burns due to the large number of surgeries performed in the outpatient setting because patient burns are serious reportable events in healthcare, and because of patient burns are preventable.

We note that we are not finalizing our proposal to remove ASC–1 as discussed in the section above.

Proposal To Remove ASC–2: Patient Fall

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498) where we adopted ASC–2: Patient Fall beginning with the CY 2014 payment determination. This NQF-endorsed (NQF #0266), claims-based measure assesses the percentage of ASC admissions experiencing a fall in the ASC.

Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–2 measure meets our measure removal Factor 1.

Comment: One commenter specifically opposed the removal of ASC–2, noting that ASC–2 measures rare, isolated events and that it is valuable to monitor for consumers as a patient fall measure.

Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498), we adopted this measure for ASCs because falls, particularly in the elderly, can cause injury and loss of functional status, because the use of anxiolytics, sedatives, and anesthetic agents may put patients undergoing outpatient surgery at increased risk for falls, and because falls in healthcare settings can be prevented through the assessment of risk, care planning, and patient monitoring. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient burns due to the large number of surgeries performed in the outpatient setting, because patient falls are serious reportable events in healthcare, and because of patient falls are preventable.

As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013.

Comment: One commenter specifically opposed the removal of ASC–2, noting that ASC–2 measures rare, isolated events and that it is valuable to monitor for consumers as a patient fall measure.

Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498), we adopted this measure for ASCs because they serve surgical patients who may face the risk of burns during ambulatory surgical procedures and because we agree monitoring patient burns is valuable to patients and other stakeholders. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient burns due to the large number of surgeries performed in the outpatient setting because patient burns are serious reportable events in healthcare, and because of patient burns are preventable.

We note that we are not finalizing our proposal to remove ASC–1 as discussed in the section above.

<table>
<thead>
<tr>
<th>Encounters</th>
<th>Number of ASCs</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
<th>Truncated COV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1-Q4 2013</td>
<td>4,768</td>
<td>100.00</td>
<td>100.00</td>
<td>0.023</td>
</tr>
<tr>
<td>Q1-Q4 2014</td>
<td>4,794</td>
<td>100.00</td>
<td>100.00</td>
<td>0.015</td>
</tr>
<tr>
<td>Q1-Q4 2015</td>
<td>4,783</td>
<td>100.00</td>
<td>100.00</td>
<td>0.011</td>
</tr>
<tr>
<td>Q1-Q4 2016</td>
<td>4,788</td>
<td>100.00</td>
<td>100.00</td>
<td>0.010</td>
</tr>
<tr>
<td>Q1-Q4 2017</td>
<td>4,814</td>
<td>100.00</td>
<td>100.00</td>
<td>0.008</td>
</tr>
</tbody>
</table>


of these concerns, we agree that monitoring patient falls is valuable to patients and other stakeholders. We note that we are not finalizing our proposal to remove ASC–2 as discussed in the previous section.

- Proposal To Remove ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498 through 74499) where we adopted ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant beginning with the CY 2014 payment determination (NQF #0267). This claims-based outcome measure assesses the percentage of ASC admissions experiencing a wrong site, wrong side, wrong patient, wrong procedure, or wrong implant.

Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–3 measure meets our measure removal Factor 1. These analyses are captured in the table below.

### ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant Topped-Out Analysis

<table>
<thead>
<tr>
<th>Encounters</th>
<th>Number of ASCs</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
<th>Truncated COV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1-Q4 2013</td>
<td>4,769</td>
<td>100.00</td>
<td>100.00</td>
<td>0.000</td>
</tr>
<tr>
<td>Q1-Q4 2014</td>
<td>4,793</td>
<td>100.00</td>
<td>100.00</td>
<td>0.000</td>
</tr>
<tr>
<td>Q1-Q4 2015</td>
<td>4,781</td>
<td>100.00</td>
<td>100.00</td>
<td>0.000</td>
</tr>
<tr>
<td>Q1-Q4 2016</td>
<td>4,787</td>
<td>100.00</td>
<td>100.00</td>
<td>0.000</td>
</tr>
<tr>
<td>Q1-Q4 2017</td>
<td>4,815</td>
<td>100.00</td>
<td>100.00</td>
<td>0.000</td>
</tr>
</tbody>
</table>

As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0267) was removed on May 24, 2016.174

Comment: One commenter specifically opposed the removal of ASC–3, noting that although wrong site surgery is infrequent, it is an egregious error. The commenter was concerned that removing the measure would imply that it is no longer important to providers and also noted their belief that because ASCs tend to have more rapid patient turnover that may make them prone to “never events” such as wrong site surgeries.

Response: We thank the commenter for its feedback. While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74498 through 74499), we adopted this measure for ASCs because surgeries and procedures performed on the wrong site/side, and wrong patient can result in significant impact on patients, including complications, serious disability or death. We also stated that while the prevalence of such serious errors may be rare, such events are considered serious reportable events. Further, we have reviewed numerous studies demonstrating the high impact of monitoring wrong site, wrong side, wrong patient, wrong procedure, wrong implant procedures and surgeries due to the large number of surgeries performed in the outpatient setting.175 because these types of errors are serious reportable events in healthcare176 and because of these errors are preventable.177 178 Because of this, we agree that it is important to monitor this measure in ASCs, which perform a large volume of outpatient surgeries every year. We note that we are not finalizing our proposal to remove ASC–3 as discussed in the previous section.

- Proposal To Remove ASC–4: All-Cause Hospital Transfer/Admission

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74499) where we adopted ASC–4: All-Cause Hospital Transfer/Admission beginning with the CY 2014 payment determination (NQF #0265). This claims-based outcome measure assesses the rate of ASC admissions requiring a hospital transfer or hospital admission upon discharge from the ASC.

Based on our analysis of ASCQR Program measure data for CYs 2013 to 2017 encounters, the ASC–4 measure meets our measure removal Factor 1. These analyses are captured in the table below.

### ASC-4: All Cause Hospital Transfer/Admission Topped-Out Analysis

<table>
<thead>
<tr>
<th>Encounters</th>
<th>Number of ASCs</th>
<th>75th Percentile</th>
<th>90th Percentile</th>
<th>Truncated COV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1-Q4 2013</td>
<td>4,768</td>
<td>100.00</td>
<td>100.00</td>
<td>0.059</td>
</tr>
<tr>
<td>Q1-Q4 2014</td>
<td>4,793</td>
<td>100.00</td>
<td>100.00</td>
<td>0.050</td>
</tr>
<tr>
<td>Q1-Q4 2015</td>
<td>4,781</td>
<td>100.00</td>
<td>100.00</td>
<td>0.041</td>
</tr>
<tr>
<td>Q1-Q4 2016</td>
<td>4,787</td>
<td>100.00</td>
<td>100.00</td>
<td>0.040</td>
</tr>
<tr>
<td>Q1-Q4 2017</td>
<td>4,814</td>
<td>100.00</td>
<td>100.00</td>
<td>0.037</td>
</tr>
</tbody>
</table>

As displayed in the analysis above, there is no distinguishable difference in ASC performance between the 75th and 90th percentiles and the truncated coefficient of variation has been below 0.10 since 2013. In the proposed rule, we also noted that NQF endorsement of this measure (NQF #0265) was removed on February 4, 2016.

**Comment:** One commenter specifically supported the inclusion of ASC–4 in the ASCQR Program, noting that it believed that the issues surrounding transfers to hospitals, although infrequent, are significant. The commenter noted that it believed that ASCs can only function safely if there is a hospital available to care for patients with unanticipated problems, noting that there can be an unclear and competitive relationship between the ASC and the hospital.

**Response:** While the measure is topped-out, we acknowledge that it is still valuable. In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74499), we adopted this measure for ASCs because the transfer or admission of a surgical patient from an outpatient setting to an acute care setting can be an indication of a complication, serious medical error, or other unplanned negative patient outcome. We also stated that while acute intervention may be necessary in these circumstances, a high rate of such incidents may indicate suboptimal practices or patient selection criteria. Further, we have reviewed numerous studies demonstrating the high impact of monitoring patient transfers and admissions due to the large number of surgeries performed in the outpatient setting, and because facilities can take steps to prevent and reduce these types of events. On this basis, we agree that the issue of patient transfers to hospitals within the ASC setting are significant adverse events to beneficiaries and ASC stakeholders, even if infrequent. Currently, 42 CFR 416.41(b)(9)(i) and (ii) requires ASCs to have a written transfer agreement with a hospital that meets certain Medicare requirements or ensure all physicians performing surgery in the ASC have admitting privileges in a hospital that meets certain Medicare requirements. A written transfer agreement and physician admitting privileges are intended to ensure there is a relationship between the ASC and the hospital that would serve the patient in the event of a medical emergency. We note that changes to these requirements were proposed in the Medicare and Medicaid Programs: Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction proposed rule (83 FR 47686) due to the difficulty of obtaining these agreements.

Over the past 5 years, we have heard from the largest ASC trade association and multiple ASCs that we need to address the widespread issue of the growing number of hospitals that are declining to work with ASCs (either by declining to sign a transfer agreement or by declining to allow admitting privileges to the hospital by physicians who work in ASCs) due to competition between hospital outpatient surgery departments and ASCs. We have continually worked with the ASCs and hospitals directly to resolve this requirement issue. However, we are aware that several facilities have not been able to reach a positive outcome. On September 20, 2018, we issued a proposed rule in the Federal Register titled “Medicare and Medicaid Programs: Regulatory Provisions To Promote Program Efficiency, Transparency, and Burden Reduction” (83 FR 47686 through 47762). In that proposed rule (83 FR 47693 through 47694), we discussed proposals regarding ASC transfer agreements and admitting privileges. We noted that we have seen no evidence of negative patient outcomes due to a lack of such transfer agreements and admitting privileges, and research reports published by the ASC Quality Collaborative indicate the national hospital transfer rate from an ASC to a hospital for care is about 1.25 per 1,000 ASC admissions (https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/ASCQuality-Reporting/index.html). As we also noted in that proposed rule, ASCs are already required to have personnel trained and available for emergency response when there is a patient in the ASC, and the ASC is expected to provide initial stabilizing treatment until the patient is transferred. Finally, we noted that the current requirement dates back to 1982, when ASCs were a newly emerging medical care option and there was reasonable concern as to needed emergency care being available. As we noted above, we are not finalizing our proposal to remove ASC–4 as discussed in the section above.

**Comment:** One commenter recommended that ASC–4 only includes data for Medicare patients and the potential for this to skew the data and misrepresent the facility’s transfer rate, and recommended that CMS collect data for all cases regardless of payer type. The commenter was also concerned that by only reporting Medicare data for the measure, that it may create a disincentive for facilities to transfer a Medicare patient because it would raise their transfer rate. Another commenter recommended that CMS expand ASC–4 to include patients who visit a hospital for an inpatient admission or emergency department visit in the days following their ASC procedure.

---

Response: We do not believe that the ASC–4 measure, as specified in the ASCQR Program Specifications Manual, 184 would create a disincentive for facilities to transfer a Medicare patient to a hospital because both the denominator, and the numerator as noted by the commenter, is comprised of all Medicare FFS beneficiaries that have been admitted to the ASC. We also note, that because ASC–4 is a claims-based measure, it is only able to assess transfer rates for Medicare FFS beneficiaries for which claims are received by CMS. We agree that measuring hospital visits after ASC procedures may be a valuable metric to Medicare beneficiaries and the public due to concerns about patient harm or complications. As such, we have already incorporated multiple measures assessing this area by adopting ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (79 FR 66970), ASC–17: Hospital Visits After Orthopedic Ambulatory Surgical Center Procedures (82 FR 59454), and ASC–18: Hospital Visits After Urology Ambulatory Surgical Center Procedures (82 FR 59463) into the ASCQR Program measure set. We will continue to evaluate the ASCQR Program measure set to ensure it is robust and responsive to beneficiary needs and thank the commenter for the feedback. We note that we are not finalizing our proposal to remove ASC–4 as discussed in the previous section.

(b) Measure Removals Under Removal Factor 8: ASC–9, ASC–10, and ASC–11

In the proposed rule, we proposed to remove three measures (ASC–9, ASC–10, and ASC–11) under proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program, for the CY 2021 payment determination and subsequent years. In the proposed rule, we noted that if proposed measure removal Factor 8 is not finalized, removal of these measures would also not be finalized. The proposals are discussed in more detail below. We note that in crafting our proposals, we considered removing these measures beginning with the CY 2020 payment determination but opted to delay removal until the CY 2021 payment determination to be sensitive to facilities’ planning and operational procedures given that data collection for these measures begins during CY 2018 for the CY 2020 payment determination.

• Proposal To Remove ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75127 through 75128) where we adopted ASC–9: Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients (NQF #0659) beginning with the CY 2016 payment determination. This chart-abstracted process measure assesses the “[p]ercentage of patients aged 50 years and older receiving a screening colonoscopy without biopsy or polypectomy who had a recommended follow-up interval of at least ten (10) years for repeat colonoscopy documented in their colonoscopy report.” (78 FR 75127).

This measure assesses whether average risk patients with normal colonoscopies receive a recommendation to receive a repeat colonoscopy in an interval that is less than the recommended amount of ten (10) years. In the proposed rule, we proposed to remove ASC–9: Endoscopy/Polyp Surveillance Follow-Up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and for subsequent years under our measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program. We adopted ASC–9: Endoscopy/Polyp Surveillance Follow-Up Interval for Normal Colonoscopy in Average Risk Patients in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75127 through 75128) noting that performing colonoscopy too frequently increases patients’ exposure to procedural harm. However, we noted concern in the proposed rule that the costs of this measure outweigh the benefit of its continued use in the program.

Chart-abstractation requires facilities to select a sample population, access historical records from several current and historic clinical data quarters and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. We noted in the proposed rule that removing ASC–9 would reduce the burden and cost to facilities associated with collection of information and reviewing their data and performance associated with the measure.

However, we also acknowledged that we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities, especially when taking into consideration the availability of other CMS quality measures that are relevant in the clinical condition and highly correlated in performance across measures. In the proposed rule we noted another colonoscopy-related measure required in the ASCQR Program, ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) which measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within seven (7) days of an outpatient colonoscopy procedure (79 FR 66970). This claims-based outcome measure does not require chart-abstractation, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted ASC–12, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66970). Furthermore, in the proposed rule we noted our belief that the potential benefits of keeping ASC–9 in the program are mitigated by the existence of the same measure (Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients) 185 for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we noted that the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible will


have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts. The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area.

Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and those that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chart-abstracted measure from the ASCQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, we noted that beneficiaries may find it confusing to see public reporting on the same measure in different programs.

Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the ASCQR Program that provides valuable data for the same procedure, and the existence of the same measure in another CMS program, we noted in the proposed rule that the burdens and costs associated with this measure outweigh the limited benefit to beneficiaries. As a result, we proposed to remove ASC–9: Endoscopy/Polyph Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients in section XIII.B.4.b. of the proposed rule. Comment: Several commenters opposed CMS’ proposal to remove ASC–9 from the ASCQR Program. A few commenters expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that pose significant costs. One commenter suggested that solely retaining the measure in MIPS is insufficient because the measure is voluntary in that program. A few commenters stated that ASC–9 and ASC–12 assess distinct and different aspects of colonoscopies, because ASC–12 focuses on coordination and does not evaluate the interval between colonoscopies or the appropriate use of care. One commenter noted that ASC–9 and ASC–12 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively. These commenters recommended retaining ASC–9 to achieve a holistic approach to measuring the quality of care in this clinical area. One commenter noted that ASC–9 is not overly burdensome to collect and report. Some commenters disagreed with CMS’ assessment that the costs of the measure outweigh the benefit.

Response: Although MIPS-eligible clinicians may voluntarily select measures from a list of options, we believe that MIPS reporting would provide some meaningful data in this clinical area. While we proposed to remove this measure because we believed the costs associated with a measure outweigh the benefit of its continued use in the program, after reviewing public comments, we reevaluated our data and analysis. We acknowledge that adherence to clinical guidelines for colonoscopy screening intervals is an important issue due to studies that document inappropriate use. One study showed high rates of inappropriate colonoscopies performed in older adult populations: 10 percent in adults aged 70–75; 39 percent in adults aged 76–85; and 25 percent in adults aged ≥86. We believe that ASC–9 is a critical measure for the ASCQR Program because there is demonstrated substantial overuse of surveillance colonoscopies among low-risk patients, with research showing that colonoscopies are often recommended at shorter intervals than are advised by guidelines among patients with normal colonoscopy results. We believe it is especially important to assess this topic due to the high-volume of these procedures that occur in the outpatient setting.

Furthermore, while ASC–9 and ASC–12 assess the topic of colonoscopies generally, we acknowledge that they assess distinct clinical areas. ASC–12 tracks adverse patient outcomes that result in unplanned hospital visits; ASC–9 provides information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative. While ASC–12 provides vital data about patient outcomes after colonoscopies, ASC–9 focuses on adherence to guideline recommendations for screening colonoscopy follow-up intervals, as noted by NQF’s evaluation report. Upon reviewing the measure set as a whole, we now believe that ASC–9 assesses a distinct clinical area not addressed by ASC–12 and as a result, there may be a measurement gap if both ASC–9 and ASC–10 are removed. Further, although we noted that ASC–9 requires the burden of chart-abstraction to report, we believe it is significantly less burdensome than ASC–10 due to the significant burden of obtaining patient histories required for that measure. We also appreciate commenters’ feedback that ASC–9 is not overly burdensome to report. Because this measure tracks the number of beneficiaries who had a recommended follow-up interval of at least 10 years for repeat colonoscopy documented in their chart.

186 CMS finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payable under those methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 53586).


193 NQF #0658 Endoscopy/Polyph Surveillance: Appropriate follow-up interval for normal colonoscopy in average risk patients. Date Submitted: Jul 09, 2012 National Quality Form, Stage 1 Comment Submission and Evaluation Worksheet 1.0.
colonoscopy report, we believe it provides important information to beneficiaries on the avoidance of inappropriate endoscopies/colonoscopies. ASC–9 evaluates overutilization that can lead to the overuse of resources and unnecessary risks to beneficiaries from possible procedural complications and harms.

In section I.A.2. of the proposed rule and this final rule with comment period, we describe our Meaningful Measures Initiative that is intended to reduce costs and minimize burden. We believe that although removing this chart-abstracted measure from the ASCQR Program would reduce program complexity, retaining it provides pertinent information about colonoscopies occurring at inappropriate intervals that may contribute to increased costs to beneficiaries and to CMS, a priority of our Meaningful Measures Initiative.

Despite the costs and burdens of chart-abstraction or the presence of otherwise using a similar clinical topic, after considering incoming comments and reevaluating our data, we now believe ASC–9 is a more critical measure for the ASCQR Program than we initially perceived in the proposed rule. Accordingly, upon further review of the benefits of the measure, we no longer believe that the costs associated with this measure outweigh the benefit of its continued use in the program. Therefore, we are not finalizing our proposal to remove this measure. This measure will remain in the program under our measure retention policies, unless we take future action under our measure removal policies.

Comment: A few commenters stated that CMS should retain ASC–9 in order to promote program alignment across outpatient settings and allow for comparisons between facility types.

Response: We have considered program alignment by adding and removing measures in tandem for the ASCQR and Hospital OQR Programs so that measures may be compared across facility types, such as ASC–9/OP–29: Endoscopy/Polypl Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients. As noted above, we adopted ASC–9 into the ASCQR Program because we believe it is important for ASCs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their facilities are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, after considering the public comments we received, we are not finalizing our proposal to remove ASC–9. We are similarly retaining the corresponding measure (OP–29) in the Hospital OQR Program in section XIII.B.4.h. of this final rule with comment period.

Comment: One commenter did not support CMS’ proposal to remove ASC–9 because it is included in the CMS Core Quality Measures Collaborative (CQMC) Gastroenterology Core Set and is widely used in the private sector.

Response: The CMS CQMC identifies core sets of quality measures that payers have committed to using for reporting as soon as feasible.194 The guiding principles used by the Collaborative in developing the core measure sets are that they be meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost. The goal is to establish broadly agreed upon core measure sets that could be harmonized across both commercial and government payers.195 We agree that the inclusion of ASC–9 in the CMS CQMC Gastroenterology Core Set speaks to its clinical value. However, although we are retaining ASC–9 for the reasons discussed in this section, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the ASCQR Program.

Comment: One commenter recommended that CMS retain ASC–9 and explore how to automate tracking of the information to reduce the resource-intensive use of chart-abstracted data. Another commenter recommended that CMS retain the measure because it could be useful for validation, as it is a chart-abstracted measure.

Response: We thank the commenter for the suggestion regarding automated data submission and will take this into consideration for the future. As discussed in section I.A.2. of this final rule with comment period, our Meaningful Measures Initiative prioritizes burden reduction in our quality reporting programs, and we will continue to evaluate the ASCQR Program measure set through this framework. We continually seek opportunities to reduce the reporting burden of our programs, but note that collecting data for ASC–9 still currently requires chart-abstractation.

In section XIV.B.6. of this final rule with comment period, we discuss public comments we received on the possible future validation of ASCQR Program measures and will include this comment in our consideration of that...
rule with comment period for more information.

- Removal of ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients With a History of Adenomatous Polyps—Avoidance of Inappropriate Use

We refer readers to CY 2014 OPPS/ASC final rule with comment period (78 FR 75128) where we adopted ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use (NQF #0659) beginning with the CY 2016 payment determination. This chart-abstracted process measure assesses the percentage of patients aged 18 years and older receiving a surveillance colonoscopy, with a history of a prior colonic polyp in previous colonoscopy findings, who had a follow-up interval of 3 or more years since their last colonoscopy documented in the colonoscopy report.

In the proposed rule, we proposed to remove ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use beginning with the CY 2021 payment determination and for subsequent years under our proposed measure removal Factor 8, the costs associated with a measure outweigh the benefit of its continued use in the program.

We adopted ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75128) noting that colonoscopy screening for high risk patients is recommended based on risk factors, and one such factor is a history of adenomatous polyps. The frequency of colonoscopy screening varies depending on the size and amount of polyps found, with the general recommendation of a 3-year follow-up. We stated that this measure is appropriate for the measurement of quality of care furnished by ASCs, because colonoscopy screening is commonly performed in these settings (78 FR 75128). However, we now believe that the costs of this measure outweigh the benefit of its continued use in the program.

Chart-abstraction requires facilities to select a sample population, access historical records from several clinical data quarters past, and interpret that patient data. This process is typically more time and resource-consuming than for other measure types. In addition to submission of manually chart-abstracted data, we take all burden and costs into account when evaluating a measure. Removing ASC–10 would reduce the burden and cost to facilities associated with collection of information and reporting on their performance associated with the measure.

However, we do not believe the use of chart-abstracted measure data alone is sufficient justification for removal of a measure under proposed measure removal Factor 8. The costs of collection and submission of chart-abstracted measure data is burdensome for facilities especially when taking into consideration the availability of other CMS quality measures. Another colonoscopy-related measure required in the ASCQR Program, ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy (NQF #2539) measures all-cause, unplanned hospital visits (admissions, observation stays, and emergency department visits) within seven (7) days of an outpatient colonoscopy procedure (79 FR 66970).

This claims-based outcome measure does not require chart-abstraction, and similarly contributes data on quality of care related to colonoscopy procedures, although the measure does not specifically track processes such as follow-up intervals. When we adopted ASC–12, we believed this measure would reduce adverse patient outcomes associated with preparation for colonoscopy, the procedure itself, and follow-up care by capturing and making more visible to facilities and patients all unplanned hospital visits following the procedure (79 FR 66970). Furthermore, the potential benefits of keeping ASC–10 in the ASCQR Program are mitigated by the existence of the same measure (Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use)\(^\text{196}\) for gastroenterologists in the Merit-Based Incentive Payment System (MIPS) for the 2019 performance period in the QPP (82 FR 30292). Thus, we believe the issue of preventing harm to patients from colonoscopy procedures that are performed too frequently is adequately addressed through MIPS in the QPP, because we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS. Although MIPS-eligible clinicians may voluntarily select measures from a list of options, ASC providers that are MIPS-eligible will have the opportunity to continue collecting information for the measure without being penalized if they determine there is value for various quality improvement efforts.\(^\text{197}\) The availability of this measure in another CMS program demonstrates CMS’ continued commitment to this measure area.

Furthermore, we seek to align our quality reporting work with the Patients Over Paperwork and the Meaningful Measures Initiatives described in section I.A.2. of the proposed rule and this final rule with comment period. The purpose of this effort is to hold providers accountable for only the measures that are most important to patients and clinicians and that are focused on patient outcomes in particular, because outcome measures evaluate the actual results of care. As described in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden, and we believe that removing this chart-abstracted measure from the ASCQR Program would reduce program complexity. In addition, as we discussed in section XIV.B.3.b. of the proposed rule, where we proposed to adopt measure removal Factor 8, beneficiaries may find it confusing to see public reporting on the same measure in different programs.

Therefore, due to the combination of factors of the costs of collecting data for this chart-abstracted measure, the preference for an outcomes measure in the ASCQR Program that provides valuable data for the same procedure, and the existence of the same measure in the MIPS program, we believe that the burdens and costs associated with manual chart abstraction outweigh the limited benefit to beneficiaries of receiving this information. As a result, we proposed to remove ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use nationwide to provide meaningful data to CMS. Although we finalized that services furnished by an eligible clinician that are payable under the ASC, HHA, Hospice, or HOPD methodology will not be subject to the MIPS payments adjustments, but eligible clinicians payables under these methodologies may have the option to still voluntarily report on applicable measures and the data reported will not be used to determine future eligibility (82 FR 33866).

Comment: Many commenters supported all of CMS’ proposals to remove measures from the ASCQR Program. Several commenters specifically supported CMS’ proposal to remove ASC–10 from the ASCQR Program because the costs outweigh the benefits of retaining it in the ASCQR Program. One commenter noted that unless the reporting facility was the site of the patient’s previous procedure, the reporting facility would not have the data necessary from their medical records and would need to obtain it from other providers, including the date of the procedure, and the number types, and locations of any polyps found. One commenter recommended that CMS remove ASC–10 beginning with the CY 2020 payment determination, so that facilities may shift resources dedicated to operationalizing the measure sooner.

Response: We thank the commenters for their support. In addition to the burden of chart-abstraction, we acknowledge the unique burden of ASC–10, which requires that facilities conduct extensive patient histories and contact other facilities in order to obtain documentation of a history of adenomatous polyps. Thus, the costs and burdens are higher for this measure than for the other colonoscopy measure considered for removal, ASC–9, which requires less information from patients and does not require historical documentation.

Comment: Several commenters noted that ASC–10 was developed and tested as a provider-level measure and they do not believe it is appropriate for the ASC setting. One commenter stated that this measure is already being reported through the MIPS (formerly PQRS) and that MIPS is the appropriate program because ASC–10 is a provider-level measure. Another commenter stated that duplicate reporting in CMS’ quality reporting programs has caused unnecessary provider burden without adding new information to the pool of quality data available to the public.

Response: We adopted ASC–10 into the ASCQR Program because we believe it is important for ASCs to be active partners in avoiding inappropriate use and ensuring that beneficiaries at their ASCs are referred for follow-up care at appropriate intervals in alignment with current guidelines. In addition, as noted when we assessed this measure (78 FR 75125), it was specified for the ASC setting and field tested at the ASC setting level by the measure steward. As noted in our proposal, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about avoiding inappropriate use.

As discussed above, we are retaining ASC–9 in order to retain a measure assessing inappropriate use of endoscopies/colonoscopies in the ASCQR Program. After reconsideration, we believe there may be a measurement gap if both ASC–9 and ASC–10 are removed and because of the unique burden associated with ASC–10, we are finalizing our removal of this measure but retaining ASC–9. A primary goal of our Meaningful Measures Initiative is to reduce provider burden through the deduplication of measures across quality reporting programs. Thus, due in part to the duplication of this measure through MIPS in the QPP and the additional burden to ASCs of obtaining patient records, we believe ASC–10 is the more appropriate measure to be removed from the ASCQR Program measure set. Removing ASC–10 while retaining ASC–9 best enables us to assess this important clinical area while ensuring that the costs of measure do not outweigh the benefits.

Comment: A few commenters opposed CMS’ proposal to remove ASC–10 from the ASCQR Program. One commenter noted that ASC–10 is a cost measure and helps avoid inappropriate use or missed opportunities to screen patients that could result in significant harm to beneficiaries. One commenter expressed concern that physicians may not follow the recommended guidelines for colonoscopy screenings and noted that there is a potential for patient harm from unnecessary colonoscopy screenings that poses significant costs.

Response: We agree that adherence to clinical guidelines for colonoscopy screening intervals is an important issue. Measuring the inappropriate use of colonoscopy screenings is critical to preventing the waste of resources and potential patient harm. In part for this reason, we are retaining ASC–9 in the ASCQR Program measure set and will continue to require reporting on appropriate follow-up intervals for normal risk patients. We believe that retaining ASC–9 in the ASCQR Program enables us to address concerns regarding patient harm from unnecessary colonoscopy screenings. Further, due to the documentation burden specifically for ASC–10, we believe it adds undue burden to ASCs, particularly small ASCs and those that do not have EHRs and is more burdensome than ASC–9. After review of public comments we received, we reevaluated our data and our measure set as a whole. To balance the clinical value of measures with the costs, we believe it is appropriate to retain ASC–9 while finalizing our proposal to remove ASC–10.

Comment: One commenter did not support CMS’ proposal to remove ASC–10 because it is included in the CMS CQMC Gastroenterology Core Set and is widely used in the private sector.

Response: The CMS CQMC Gastroenterology Core Set is a set of measures identified as being meaningful to patients, consumers, and physicians, while reducing variability in measure selection, collection burden, and cost and is intended for use by payers who are part of the CQMC. Because of this, we believe beneficiaries will continue to receive this data to help them make health care decisions. We agree that this measure is valuable to many stakeholders and support its continued reporting through other quality reporting programs and in the private sector. However, due to the measure’s requirement to obtain historical patient records, we believe that this measure adds undue burden to ASCs, particularly small ASCs and those that do not have EHRs. In addition, we note that the inclusion of measures in the CQMC Core Sets does not necessitate retention in the ASCQR Program.

Comment: A few commenters stated that ASC–10 and ASC–12 assess distinct different aspects of colonoscopies, because ASC–12 focuses on care coordination and does not evaluate the interval between colonoscopies occurring at the appropriate use of care. One commenter notes that ASC–10 and ASC–12 fall into different Meaningful Measures categories, Preventable Healthcare Harm and Admissions and Readmissions, respectively.

Response: We thank the commenters for their feedback. We agree that ASC–10 and ASC–12 assess distinct clinical areas, but do assess the topic of colonoscopies generally. While ASC–12 tracks adverse patient outcomes that result in unplanned hospital visits, ASC–10 provides information about colonoscopies occurring at inappropriate intervals for beneficiaries that may contribute to increased costs to beneficiaries and to CMS, a priority of
our Meaningful Measures Initiative. However, we believe ASC–10 should be removed because it is uniquely burdensome, as described above, and because our retention of ASC–9 allows us to continue to address inappropriate use of colonoscopy screening.

After consideration of the public comments we received, we are finalizing our proposal to remove ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years, as proposed. We refer readers to section XIII.B.4.b. of this final rule with comment period where we are removing a similar measure from the Hospital OQR Program.

• Proposal To Remove ASC–11: Cataracts: Improvement in Patient’s Visual Function Within 90 Days Following Cataract Surgery

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75129) where we adopted ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NQF #1536) beginning with the CY 2016 payment determination. This measure assesses the rate of patients 18 years and older (with a diagnosis of uncomplicated cataract) in a sample who had improvement in visual function achieved within 90 days following cataract surgery based on completing both a preoperative and postoperative visual function survey. Since the adoption of this measure, we came to believe that it can be operationally difficult for ASCs to collect and report the measure (79 FR 66984). Specifically, we were concerned that the results of the survey used to assess the preoperative and post-operative visual function of the patient may not be shared across clinicians and facilities, making it difficult for ASCs to have knowledge of the visual function of the patient before and after surgery (79 FR 66984). We were also concerned about the surveys used to assess visual function; the measure allows for the use of any validated survey and results may be inconsistent should clinicians use different surveys (79 FR 66984).

Therefore, on December 31, 2013, we issued guidance stating that we would delay data collection for ASC–11 for three (3) months (data collection would commence with April 1, 2014 encounters) for the CY 2016 payment determination. We issued additional guidance on April 2, 2014, stating that we would further delay the implementation of ASC–11 for an additional 9 months, until January 1, 2015 for the CY 2016 payment determination, due to continued concerns (https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier3&cid=1228772879036). As a result of these concerns, in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years.

In the proposed rule, we proposed to remove ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2021 payment determination under proposed measure removal Factor 8, the costs associated with the measure outweigh the benefit of its continued use in the program. We originally adopted ASC–11 because we believe ASCs should be a partner in care with physicians and other clinicians using their facility and that this measure would provide an opportunity to do so (79 FR 66984). However, in light of the history of complications and upon reviewing this measure within our Meaningful Measures framework, we have concluded that it is overly burdensome for ASCs to report this measure due to the difficulty of tracking care that occurs outside of the ASC setting.

In order to report on this measure to CMS, a facility would need to obtain the visual function assessment results from the appropriate ophthalmologist and ensure that the assessment utilized is validated for the population for which it is being used. If the assessment is not able to be used or is not available, the ASC would then need to administer the survey directly and ensure that the same visual function assessment tool is utilized preoperatively and postoperatively. There is no simple, preexisting means for information sharing between ophthalmologists and ASCs, so an ASC would need to obtain assessment results from each individual patient’s ophthalmologist both preoperatively and postoperatively. The high administrative costs of the technical tracking of this information presents an undue cost, and also burden associated with submission and reporting of ASC–11 to CMS, especially for small ASCs with limited staffing capacity.

Furthermore, this measure currently provides limited benefits. Since making the measure voluntary, only 118 ASCs have reported this measure to CMS, compared to approximately 5,121 total ASCs for all other measures, resulting in only 2.3 percent of ASC reporting. Consequently, we have been unable to uniformly offer pertinent information to beneficiaries on how the measure assesses ASC performance. This reinforces comments made in the CY 2015 OPPS/ASC final rule with comment period, in which commenters expressed concern that the voluntary reporting of this measure would result in incomplete data that may be confusing to beneficiaries and other consumers (79 FR 66984). As we state in section I.A.2. of the proposed rule and this final rule with comment period, we strive to ensure that beneficiaries are empowered to make decisions about their healthcare using information from data-driven insights. Because of the lack of sufficient data, this measure may be difficult for beneficiaries to interpret or use to aid in their choice of where to obtain care; thus, the benefits of this measure are limited.

Therefore, we stated that we believed the high technical and administrative costs of this measure outweigh the limited benefit associated with its continued use in the ASCQR Program. As discussed in section I.A.2. of the proposed rule and this final rule with comment period, our Meaningful Measures Initiative is intended to reduce costs and minimize burden. We believed that removing this measure from the ASCQR Program will reduce program burden, costs, and complexity. As a result, we proposed to remove ASC–11 beginning with the CY 2021 payment determination and for subsequent years. We also proposed to remove a similar measure under the Hospital OQR Program in section XIII.B.4.b. of the proposed rule.

Comment: A few commenters opposed all of CMS’ proposals to remove measures, including ASC–11.

Response: In response to the commenters who requested that measures, including ASC–11, be retained, we reevaluated our measures and data. We found that a core group of ASCs (between 107 and 137 for each year between the CY 2017 through CY 2019 payment determinations) report on this voluntary measure. Although only a subset of ASCs voluntarily report this measure, we believe it is considered
very meaningful by those ASCs that do report because these facilities do so consistently (38 ASCs submitted consistently for the CY 2017 through CY 2019 payment determinations). Because this subset of ASCs has consistently reported this measure we are able to make the data publicly available year after year—in this case, for the CYs 2017, 2018, and 2019 payment determinations. We think providing data on this voluntary measure is still helpful for the public because it shows how an ASC performs over time and in comparison to other ASCs even if compared to a small group of ASCs.

Furthermore, this is the only measure in the ASCQR Program measure set that deals with cataract surgery, which is commonly performed in the ASC setting. If it is removed, the program will have a gap in coverage for this clinical area. As a result, we now believe that meaningful information can be provided to consumers regarding those facilities. In addition, when this measure was made voluntary in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984) commenters stated that the measure would promote and improve care coordination among providers.

Furthermore, we have reassessed our evaluation that the costs of this measure outweigh the benefits. Due to the voluntary nature of the measure, we believe that it is inherently not more burdensome than valuable. Because ASCs are not required to submit data, those that do not have the capacity to report, do not have to, thus creating no extra burden. Those that do report, do so voluntarily and have continued to report over the years—specifically since the CY 2015 reporting period—despite any burdens. Because of this, we believe the measure is meaningful to the core group of facilities that do consistently report.

Therefore, we are not finalizing our proposal to remove ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2020 payment determination, so that ASCs may shift resources dedicated to operationalizing the measure sooner. Response: We thank the commenters for their support. As noted in the proposed rule, we agree that data collection for this measure may be difficult, and as a result in the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985), we finalized our proposal to allow voluntary data collection and reporting of this measure beginning with the CY 2017 payment determination and for subsequent years. However, we believe ASCs should be a partner in care with physicians and other clinicians using their facility and this measure is an opportunity for hospitals to demonstrate this capability if they choose to report it. In addition, as noted above, we no longer believe that the costs of this measure outweigh the benefits, as the measure is meaningful. Further, while data collection for this measure can be difficult, those facilities that choose to report do so year after year despite any burdens.

Comment: Several commenters noted that the measure was endorsed by the NQF as a physician-level, rather than facility-level, measure and that therefore it was never intended for the ASC setting. A few commenters noted that the measure is included in the MIPS (formerly PQRS Program) as a clinician-level measure and is therefore redundant in the ASC setting. One commenter noted that as a voluntary measure, ASC–11 did not have widespread participation and therefore had minimal impact on the care of patients.

Response: As we noted when we adopted this measure (78 FR 75125), it was specified for the ASC setting and field tested at the ASC facility setting level by the measure steward. We believe it is important for ASCs to be active partners in ensuring improvement in patients’ visual function following cataract surgeries. As commenters correctly noted, this same measure is available through MIPS in the QPP and, although MIPS-eligible clinicians may voluntarily select measures from a list of options, and we expect a portion of MIPS-eligible clinicians reporting on the measure nationwide to provide meaningful data to CMS about this important outcome for beneficiaries. We agree that as a voluntary measure that only a subset of ASCs participating in the ASCQR Program reported on the measure, but note it is a meaningful measure to beneficiaries given that our analyses show that a consistent group of facilities report data on this measure. So, while data is not available for all facilities, the data that is available is meaningful.

After consideration of the public comments we received, we are not finalizing our proposal to remove ASC–11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery from the ASCQR Program beginning with the CY 2021 payment determination and for subsequent years. We also note that we are retaining a similar measure under the Hospital OQR Program, OP–31: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery in section XIII.B.4.b.(2)(a) of this final rule with comment period.

4. ASCQR Program Quality Measures Adopted in Previous Rulemaking

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59470) for the previously finalized ASCQR Program measure set for the CY 2020 payment determination and subsequent years.

5. Summary of ASCQR Program Quality Measure Sets Finalized for the CY 2020, CY 2021, and CY 2022 Payment Determinations

In the CY 2019 OPPS/ASC proposed rule, we did not propose any new measures for the ASCQR Program. The tables below summarize the ASCQR Program measure sets as finalized in this final rule with comment period for the CY 2020, 2021, and 2022 payment determinations (including previously adopted measures and measures finalized for removal in this final rule with comment period). We note that the tables reflect that we are finalizing our proposal to change the reporting period for one previously adopted measure, ASC–12, and we refer readers to section

---

201 Hospital Compare ASCQR: https://www.medicare.gov/hospitalcompare/asccqr.html.
### Finalized ASCQR Program Measure Set for the CY 2020 Payment Determination and Subsequent Years

<table>
<thead>
<tr>
<th>ASC #</th>
<th>NQF #</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASC-1</td>
<td>0263^</td>
<td>Patient Burn</td>
</tr>
<tr>
<td>ASC-2</td>
<td>0266</td>
<td>Patient Fall</td>
</tr>
<tr>
<td>ASC-3</td>
<td>0267^</td>
<td>Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant</td>
</tr>
<tr>
<td>ASC-4</td>
<td>0265^</td>
<td>All-Cause Hospital Transfer/Admission</td>
</tr>
<tr>
<td>ASC-9</td>
<td>0658</td>
<td>Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</td>
</tr>
<tr>
<td>ASC-10</td>
<td>0659</td>
<td>Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps-Avoidance of Inappropriate Use</td>
</tr>
<tr>
<td>ASC-11</td>
<td>1536</td>
<td>Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery*</td>
</tr>
<tr>
<td>ASC-12</td>
<td>2539</td>
<td>Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy</td>
</tr>
<tr>
<td>ASC-13</td>
<td>None</td>
<td>Normothermia Outcome</td>
</tr>
<tr>
<td>ASC-14</td>
<td>None</td>
<td>Unplanned Anterior Vitrectomy</td>
</tr>
<tr>
<td>ASC-15a</td>
<td>None</td>
<td>OAS CAHPS – About Facilities and Staff**</td>
</tr>
<tr>
<td>ASC-15b</td>
<td>None</td>
<td>OAS CAHPS – Communication About Procedure**</td>
</tr>
<tr>
<td>ASC-15c</td>
<td>None</td>
<td>OAS CAHPS – Preparation for Discharge and Recovery**</td>
</tr>
<tr>
<td>ASC-15d</td>
<td>None</td>
<td>OAS CAHPS – Overall Rating of Facility**</td>
</tr>
<tr>
<td>ASC-15e</td>
<td>None</td>
<td>OAS CAHPS – Recommendation of Facility**</td>
</tr>
</tbody>
</table>

^ NQF endorsement was removed.

* Measure voluntarily collected effective beginning with the CY 2017 payment determination as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985).

** Measure finalized for delay in reporting beginning with the CY 2020 payment determination (CY 2018 data collection) until further action in future rulemaking as discussed in section XIV.B.4. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59450 through 59451).
<table>
<thead>
<tr>
<th>ASC #</th>
<th>NQF #</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASC-1</td>
<td>0263†</td>
<td>Patient Burn*</td>
</tr>
<tr>
<td>ASC-2</td>
<td>0266</td>
<td>Patient Fall*</td>
</tr>
<tr>
<td>ASC-3</td>
<td>0267†</td>
<td>Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant*</td>
</tr>
<tr>
<td>ASC-4</td>
<td>0265†</td>
<td>All-Cause Hospital Transfer/Admission*</td>
</tr>
<tr>
<td>ASC-9</td>
<td>0658</td>
<td>Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</td>
</tr>
<tr>
<td>ASC-11</td>
<td>1536</td>
<td>Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery**</td>
</tr>
<tr>
<td>ASC-12</td>
<td>2539</td>
<td>Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy</td>
</tr>
<tr>
<td>ASC-13</td>
<td>None</td>
<td>Normothermia Outcome</td>
</tr>
<tr>
<td>ASC-14</td>
<td>None</td>
<td>Unplanned Anterior Vitrectomy</td>
</tr>
<tr>
<td>ASC-15a</td>
<td>None</td>
<td>OAS CAHPS – About Facilities and Staff***</td>
</tr>
<tr>
<td>ASC-15b</td>
<td>None</td>
<td>OAS CAHPS – Communication About Procedure***</td>
</tr>
<tr>
<td>ASC-15c</td>
<td>None</td>
<td>OAS CAHPS – Preparation for Discharge and Recovery***</td>
</tr>
<tr>
<td>ASC-15d</td>
<td>None</td>
<td>OAS CAHPS – Overall Rating of Facility***</td>
</tr>
<tr>
<td>ASC-15e</td>
<td>None</td>
<td>OAS CAHPS – Recommendation of Facility***</td>
</tr>
</tbody>
</table>

† NQF endorsement was removed.

* Measure finalized for suspension in reporting beginning with the CY 2021 payment determination (CY 2019 data collection) until further action in future rulemaking as discussed in section XIV.B.3.c.(2)(a) of this final rule with comment period.

** Measure voluntarily collected effective beginning with the CY 2017 payment determination as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985).

*** Measure finalized for delay in reporting beginning with the CY 2020 payment determination (CY 2018 data collection) until further action in future rulemaking as discussed in section XIV.B.4. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59450 through 59451).
6. ASCQR Program Measures and Topics for Future Consideration: Possible Future Validation of ASCQR Program Measures

In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we requested public comment on the possible future validation of ASCQR Program measures. There is currently no validation of ASCQR measure data, and we believe ASCs may benefit from the opportunity to better understand their data and examine potential discrepancies. We believe the ASCQR Program may similarly benefit from the opportunity to produce a more reliable estimate of whether an ASC’s submitted data have been abstracted correctly and provide more statistically reliable estimates of the quality of care delivered in each selected ASC as well as at the national level. We believe the Hospital OQR Program validation policy could be a good model for the ASCQR Program and are requesting comment on the validation methodology and identifying one measure with which to start.

The Hospital OQR Program requires validation of its chart-abstrated measures. We refer readers to the CY 2013 OPPS/ASC final rule with comment period (77 FR 66984 through 66985) and the CY 2015 OPPS/ASC final rule with comment period (79 FR 69064 through 69065) for a discussion of finalized policies regarding Hospital OQR Program validation requirements, which are also codified at 42 CFR 419.46(e). Under the Hospital OQR Program, CMS selects a random sample of 450 hospitals and an additional 50 hospitals based on the following criteria: (1) The hospital failing of the validation requirement that applies to the previous year’s payment determination; or (2) the hospital having an outlier value for a measure based on data that it submits. An “outlier value” is defined as a measure value that is greater than 5 standard deviations from the mean of the measure values for other hospitals, and indicates a poor score. Then, CMS or its contractor provides written requests to the randomly selected hospitals by requesting

<table>
<thead>
<tr>
<th>ASC #</th>
<th>NQF #</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASC-1</td>
<td>0263†</td>
<td>Patient Burn*</td>
</tr>
<tr>
<td>ASC-2</td>
<td>0266</td>
<td>Patient Fall*</td>
</tr>
<tr>
<td>ASC-3</td>
<td>0267†</td>
<td>Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant*</td>
</tr>
<tr>
<td>ASC-4</td>
<td>0265†</td>
<td>All-Cause Hospital Transfer/Admission*</td>
</tr>
<tr>
<td>ASC-9</td>
<td>0658</td>
<td>Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients</td>
</tr>
<tr>
<td>ASC-11</td>
<td>1536</td>
<td>Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery**</td>
</tr>
<tr>
<td>ASC-12</td>
<td>2539</td>
<td>Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy</td>
</tr>
<tr>
<td>ASC-13</td>
<td>None</td>
<td>Normothermia Outcome</td>
</tr>
<tr>
<td>ASC-14</td>
<td>None</td>
<td>Unplanned Anterior Vitrectomy</td>
</tr>
<tr>
<td>ASC-15a</td>
<td>None</td>
<td>OAS CAHPS – About Facilities and Staff***</td>
</tr>
<tr>
<td>ASC-15b</td>
<td>None</td>
<td>OAS CAHPS – Communication About Procedure***</td>
</tr>
<tr>
<td>ASC-15c</td>
<td>None</td>
<td>OAS CAHPS – Preparation for Discharge and Recovery***</td>
</tr>
<tr>
<td>ASC-15d</td>
<td>None</td>
<td>OAS CAHPS – Overall Rating of Facility***</td>
</tr>
<tr>
<td>ASC-15e</td>
<td>None</td>
<td>OAS CAHPS – Recommendation of Facility***</td>
</tr>
<tr>
<td>ASC-17</td>
<td>None</td>
<td>Hospital Visits after Orthopedic Ambulatory Surgical Center Procedures</td>
</tr>
<tr>
<td>ASC-18</td>
<td>None</td>
<td>Hospital Visits after Urology Ambulatory Surgical Center Procedures</td>
</tr>
</tbody>
</table>

† NQF endorsement was removed.
* Measure finalized for suspension in reporting beginning with the CY 2021 payment determination (CY 2019 data collection) until further action in future rulemaking as discussed in section XIV.B.3.c.(2)(a) of this final rule with comment period.
** Measure voluntarily collected effective beginning with the CY 2017 payment determination as set forth in section XIV.E.3.c. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66984 through 66985).
*** Measure finalized for delay in reporting beginning with the CY 2020 payment determination (CY 2018 data collection) until further action in future rulemaking as discussed in section XIV.B.4. of the CY 2018 OPPS/ASC final rule with comment period (82 FR 59450 through 59451).
supporting medical record documentation used for purposes of data submission under the program. The hospital must submit the supporting medical record documentation within 45 days of the date written in the request. A hospital meets the validation requirement with respect to a calendar year if it achieves at least a 75 percent reliability score, as determined by CMS.

Specifically, for the ASCQR Program, we are interested in the validation of chart-abstracted measures. We believe it would be beneficial to start with validation of just one measure, such as ASC–13: Normothermia Outcome, prior to expanding to more measures. ASC–13: Normothermia Outcome was finalized in the 2017 OPPS/ASC final rule with comment period (81 FR 79798 through 79801) and assesses the percentage of patients having surgical procedures under general or neuraxial anesthesia of 60 minutes or more in duration who are normothermic within 15 minutes of arrival in the post-anesthesia care unit. We also considered starting with ASC–14: Unplanned Anterior Vitrectomy instead, which was finalized in the 2017 OPPS/ASC final rule with comment period (81 FR 79801 through 79803) and assesses the percentage of cataract surgery patients who have an unplanned anterior vitrectomy. However, we believe ASC–13 would be the most feasible measure for validation because it assesses surgical cases and would have a larger population of cases from which to sample. ASC–14, which assesses rare, unplanned events that are less common, would have a smaller population of cases from which to sample.

Therefore, we invited public comment on the possible future validation of ASCQR Program measures. We specifically request comment on whether Hospital OQR Program's validation policies could be an appropriate model for the ASCQR Program, the possible ASC sample size, sampling methodology, number of cases to sample, validation score methodology, and reduced annual payment updates for facilities that do not pass validation requirements. We also requested comment on possibly starting with only one measure, specifically ASC–13, before expanding to more measures.

Comment: A few commenters supported the possible validation of ASCQR Program data through a program similar to Hospital OQR Program validation. These commenters noted that this would further align the programs and provide accountability for the accuracy of reporting.

Response: We thank the commenters for their support.

Comment: One commenter opposed validation of ASCQR Program measures, citing the cost and burden to providers and CMS. This commenter recommended that CMS instead invest in ways to receive timelier and meaningful data related to patient quality and safety. One commenter was concerned about the burden to ASCs of the validation process due to the low level of EHR adoption among ASCs as compared to hospital outpatient departments, noting that the majority of ASCs may need to submit paper records.

Response: We thank the commenters for their feedback regarding additional program impact of validation for the ASCQR Program. As noted above, we will take facility burden into consideration regarding the selection of measures for the potential future validation of ASCQR Program measures.

Comment: One commenter was concerned that the sample size of ASCs at or around 500, comparable to Hospital OQR Program, would represent a significantly larger percentage of ASCs reporting chart-abstracted measures under the ASCQR Program than under the Hospital OQR Program. The commenter recommended that a smaller number of ASCs be selected for validation, perhaps based on the percentage of HOPDs selected for validation under the Hospital OQR Program. Another commenter stated that a similar random sample to the Hospital OQR Program (450 ASCs) could be utilized, as well as an additional number of ASCs with outlier values. One commenter was concerned about ASCs that fail to record adverse events and recommended that CMS develop additional sampling criteria based on selecting ASCs that have a “good score” outlier rate.

Response: We thank the commenters for their suggestions regarding sampling for any validation scheme considered for the ASCQR Program and will take these into consideration as we move forward.

Comment: A few commenters supported beginning validation with only one measure, with one noting it would allow participants time to understand the program and its implications for payment. Some commenters supported using ASC–13 as an initial measure for validation within the ASCQR Program, with a few commenters noting it is an important and prescient measure for outpatient settings.

Response: We thank the commenters for their feedback supporting validation for the ASCQR Program and the possible use of ASC–13 for this purpose. We agree that it is most feasible to begin potential future validation of measures in the ASCQR Program with a single measure.

Comment: A few commenters expressed concern about using ASC–13 as an initial measure for validation within the ASCQR Program. One commenter noted their belief that ASC–13 is not indicative of care at an ASC. Another commenter expressed concern that ASC–13 is reported as a sample chart-abstracted web-based metric and that patient-level information is not submitted by ASCs. One commenter was concerned about incongruent definitions of normothermia among quality reporting programs and recommended that if discrepancies are found during the validation process that anesthesia professionals be held harmless. Another commenter stated that ASC–14 would be a better initial measure for validation, noting that cases requiring general or neuraxial anesthesia are less common than cataract surgery and would likely have a smaller population of cases from which to sample.

Response: We thank the commenters for their feedback and will further examine ASC–13 and ASC–14 case volumes, appropriate methods of validation of aggregated web-based metrics, and normothermia definitions among quality reporting programs.

Comment: A commenter noted that not all ASCs report data for ASC–13 and ASC–14 due to not performing cases involving general/neuraxial anesthesia of 60 minutes or more in duration (ASC–13) and/or cataract surgery (ASC–14), and noted their concern that ASCs that do report these measures would bear more burden and be required to meet a higher threshold for retaining their APU. The commenter recommended only selecting measures for validation that are applicable to all ASCs. Another commenter recommended that all measures should be validated, with the prioritization for ASC–1, ASC–2, and ASC–3 in order to study closely the occurrence of adverse events. A commenter recommended that the ASCQR Program implement validation only when more manually abstracted measures are added to the program, noting that implementing a validation process for a small number of measures is burdensome and may yield only limited value to CMS.

Response: We thank the commenters for their feedback regarding alternate measures to consider for validation within the ASCQR Program. We agree that the percentage of ASCs actually reporting on a measure is an important
consideration in choosing measures for validation. We will investigate the feasibility of validating ASC–1, ASC–2, and ASC–3. We will further assess the potential burden impact of the potential future validation of any ASCQR Program measures. We note that one of the goals of our Meaningful Measures Initiative is to move the ASCQR Program forward in the least burdensome manner possible, while maintaining a parsimonious set of meaningful quality measures. 

Comment: One commenter was concerned that ASCs submit aggregated web-based data on an annual basis and that sampling is allowed for the submission of ASC–13 data without patient identifying information. The commenter recommended that CMS consider selection bias if ASC–13 data is validated.

Response: We thank the commenter for its feedback and agree that there is a potential for selection bias if the aggregated web-based data for ASC–13 is validated. We will take this potential for selection bias into consideration as we craft future policy.

We thank the commenters for their views and will take them into consideration as we determine future policy regarding validation in the ASCQR Program.

7. Maintenance of Technical Specifications for Quality Measures

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74513 through 74514), where we finalized our proposal to follow the same process for updating the ASCQR Program measures that we adopted for the Hospital OQR Program measures, including the subregulatory process for updating adopted measures. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68496 through 68497), the CY 2014 OPPS/ASC final rule (78 FR 75131), and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66981), we provided additional clarification regarding the ASCQR Program policy in the context of the previously finalized Hospital OQR Program policy, including the processes for addressing nonsubstantive and substantive changes to adopted measures. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70531), we provided clarification regarding our decision to not display the technical specifications for the ASCQR Program on the CMS website, but stated that we will continue to display the technical specifications for the ASCQR Program on the QualityNet website. In addition, our policies regarding the maintenance of technical specifications for the ASCQR Program are codified at 42 CFR 416.325. In the CY 2019 OPPS/ASC proposed rule (83 FR 37204), we did not propose any changes to our policies regarding the maintenance of technical specifications for the ASCQR Program.

8. Public Reporting of ASCQR Program Data

In the CY 2012 OPPS/ASC final rule with comment period (76 FR 74514 through 74515), we finalized a policy to make data that an ASC submitted for the ASCQR Program publicly available on a CMS website after providing an ASC an opportunity to review the data to be made public. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70531 through 70533), we finalized our policy to publicly display data by the National Provider Identifier (NPI) when the data are submitted by the NPI and to publicly display data by the CCN when the data are submitted by the CCN. In addition, we codified our policies regarding the public reporting of ASCQR Program data at 42 CFR 416.315 (80 FR 70533). In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79819 through 79820), we formalized our current public display practices regarding timing of public display and the preview period by finalizing our proposals to: Publicly display data on the Hospital Compare website, or other CMS website as soon as practicable after measure data have been submitted to CMS; to generally provide ASCs with approximately 30 days to review their data before publicly reporting the data; and to announce the timeframes for each preview period starting with the CY 2018 payment determination on a CMS website and/or on our applicable listservs. In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59455 through 59470), we discussed specific public reporting policies associated with two measures beginning with the CY 2022 payment determination: ASC–17: Hospital Visits after Orthopedic Ambulatory Surgical Center Procedures, and ASC–18: Hospital Visits after Urology Ambulatory Surgical Center Procedures.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37204 through 37205), we did not propose any changes to our public reporting policies.

C. Administrative Requirements

1. Requirements Regarding QualityNet Account and Security Administrator

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75132 through 75133) for a detailed discussion of the QualityNet security administrator requirements, including setting up a QualityNet account, and the associated timelines, for the CY 2014 payment determination and subsequent years. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70533), we codified the administrative requirements regarding maintenance of a QualityNet account and security administrator for the ASCQR Program at 42 CFR 416.310(c)(1)(i). In the CY 2018 OPPS/ASC final rule (82 FR 59473), we finalized expanded submission via the CMS online tool to also allow for batch data submission and made corresponding changes to the 42 CFR 416.310(c)(1)(i). In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies.

2. Requirements Regarding Participation Status

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75133 through 75135) for a complete discussion of the participation status requirements for the CY 2014 payment determination and subsequent years. In the CY 2016 OPPS/ASC final rule with comment period (80 FR 70533 and 70534), we codified these requirements regarding participation status for the ASCQR Program at 42 CFR 416.305. In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies.

D. Form, Manner, and Timing of Data Submitted for the ASCQR Program

1. Requirements Regarding Data Processing and Collection Periods for Claims-Based Measures Using Quality Data Codes (QDCs)

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (78 FR 75135) for a complete summary of the data processing and collection periods for claims-based measures using QDCs for the ASCQR Program at 42 CFR 416.310(a)(1) and (2).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these requirements. However, in the proposed rule we noted that in section XIV.B.3.c. of the proposed rule, beginning with the CY 2021 payment determination and for subsequent years, we proposed to
remove all four claims-based measures currently using QDCs:

- ASC–1: Patient Burn;
- ASC–2: Patient Fall;
- ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and
- ASC–4: Hospital Transfer/Acquisition.

We are not finalizing our proposals to remove ASC–1, ASC–2, ASC–3, and ASC–4 as described further in section XIV.B.3.c. of this final rule with comment period, and are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. However, we did not propose any changes to our requirements regarding data processing and collection periods for these types of measures. These requirements will apply to any future claims-based measures using QDCs adopted in the program.

2. Minimum Threshold, Minimum Case Volume, and Data Completeness for Claims-Based Measures Using QDCs

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59472) (and the previous rulemakings cited therein), as well as 42 CFR 416.310(a)(3) and 42 CFR 416.305(c) for our policies about minimum threshold, minimum case volume, and data completeness for claims-based measures using QDCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies.

3. Requirements for Data Submitted via an Online Data Submission Tool

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59472) (and the previous rulemakings cited therein) as well as 42 CFR 416.310(c) for our policies about minimum threshold, minimum case volume, and data completeness for claims-based measures using QDCs. In the CY 2019 OPPS/ASC proposed rule (83 FR 37205), we did not propose any changes to these policies.

a. Requirements for Data Submitted via a Non-CMS Online Data Submission Tool

We refer readers to the CY 2014 OPPS/ASC final rule with comment period (79 FR 75139 through 75140) and the CY 2015 OPPS/ASC final rule with comment period (79 FR 66985 through 66986) for our requirements regarding data submitted via a non-CMS online data submission tool (that is, the CDC NHSN website). We codified our existing policies regarding the data collection time periods for measures involving online data submission and the deadline for data submission via a non-CMS online data submission tool at 42 CFR 416.310(c)(2).

Currently, we only have one measure (ASC–8: Influenza Vaccination Coverage among Healthcare Personnel) that is submitted via a non-CMS online data submission tool. In the proposed rule, we noted that we proposed this measure for removal for the CY 2020 payment determination and subsequent years in section XIV.B.3.c. of the proposed rule. Because we are finalizing the removal of ASC–8 as proposed, no measures submitted via a non-CMS online data submission tool will remain in the ASCQR Program beginning with the CY 2020 payment determination. However, we did not propose any changes to our non-CMS online data submission tool reporting requirements; these requirements would apply to any future non-CMS online data submission tool measures adopted in the program.

b. Requirements for Data Submitted via a CMS Online Data Submission Tool

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59473) (and the previous rulemakings cited therein) and 42 CFR 416.310(c)(1) for our requirements regarding data submitted via a CMS online data submission tool. We are currently using the QualityNet website as our CMS online data submission tool: https://www.qualitynet.org/dcs/ContentServer?c=Page&pагename=Qnet Public%2FPage%2FQnet Homepage&cid=1120143435383. We note that in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59473), we finalized expanded submission via the CMS online tool to also allow for batch data submission and made corresponding changes to the 42 CFR 416.310(c)(1)(i).

In the CY 2019 OPPS/ASC proposed rule (83 FR 37205 through 37206), we did not propose any changes to this policy. However, in the proposed rule we noted that in sections XIV.B.3.c. of the proposed rule, we proposed to remove three measures collected via a non-CMS online data submission tool—ASC–9: Endoscopy/Polyposis Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients, ASC–10: Endoscopy/Polyposis Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use, and ASC–11: Cataracts: Improvement in Patients’ Visual Function within 90 Days Following Cataract Surgery—beginning with the CY 2021 payment determination.

Because we are finalizing ASC–10 for removal as proposed and are not finalizing our proposals to remove ASC–9 and ASC–11 in the ASCQR Program measure set (these measures will remain in the program), the following measures will require data to be submitted via a CMS online data submission tool for the CY 2021 payment determination and subsequent years:

- ASC–9: Endoscopy/Polyposis Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients
- ASC–11: Cataracts: Improvement in Patients’ Visual Function within 90 Days Following Cataract Surgery
- ASC–13: Normothermia Outcome
- ASC–14: Unplanned Anterior Vitrectomy

4. Requirements for Non-QDC Based, Claims-Based Measure Data

In the CY 2019 OPPS/ASC proposed rule (83 FR 37206 through 37207), we did not propose any changes to our requirements for non-QDC based, claims-based measures. However, in the proposed rule we proposed to change the reporting period for the previously adopted measure, ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy. This proposal is discussed in more detail further below.

a. General

We refer readers to the CY 2015 OPPS/ASC final rule with comment period (79 FR 66985) and the CY 2016 OPPS/ASC final rule with comment period (80 FR 70536) for our previously adopted policies regarding data processing and reporting periods for claims-based measures for the CY 2018 payment determination and subsequent years. In addition, in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70536), we codified these policies at 42 CFR 416.310(b). In the proposed rule, we did not propose any changes to these policies. We note that the non-QDC, claims-based measures in the program are as follows:

- CY 2020 payment determination and subsequent years: ASC–12: Facility 7-Day Risk Standardized Hospital Visit Rate after Outpatient Colonoscopy (79 FR 66970 through 66978)
• ASC–17: Hospital Visits after Orthopedic Ambulatory Surgical Center Procedures (82 FR 59455 through 59470)

• ASC–18: Hospital Visits after Urology Ambulatory Surgical Center Procedures (82 FR 59455 through 59470)

b. Extension of the Reporting Period for ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate After Outpatient Colonoscopy

In the CY 2015 OPPS/ASC final rule with comment period (79 FR 66970 through 66978), we finalized the adoption of ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy into the ASCQR Program for the CY 2018 payment determination and subsequent years, with public display to begin on or after December 1, 2017. This measure is calculated with data obtained from paid Medicare FFS claims (79 FR 66978). For this reason, facilities are not required to submit any additional information. In that final rule with comment period, we also finalized the reporting period for measure calculation as claims data from two calendar years prior to the payment determination year. Specifically, for the CY 2018 payment determination, we stated we would use paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate measure results (79 FR 66985). We finalized a 1-year reporting period as it adequately balanced competing interests of measure reliability and timeliness for payment determination purposes, and explained that we would continue to assess this during the dry run (79 FR 66973).

We noted we would complete a dry run of the measure in 2015 using three or four years of data, and, from the results of this dry run, we would review the appropriate volume cutoff for facilities to ensure statistical reliability in reporting the measure score (79 FR 66974). Our analyses of the 2015 dry run using data from July 2011 through June 2014 showed that a reporting period of one year had moderate to high reliability for measure calculation. Specifically, using data from July 2013 through June 2014, we calculated facility-level reliability estimates as the ratio of true variance to observed variance.203 Consistent with the original measure specifications as described in the 2014 technical report,204 this calculation was performed combining the measure results for HOPDs and ASCs. We found that for a facility with median case size, the reliability estimate was high (over 0.90), but the minimum reliability estimate for facilities with 30 cases (the minimum case size chosen for public reporting) was only moderate (that is, between 0.40 and 0.60).205

However, after the 2015 dry run, CMS calculated the HOPD and ASC scores separately to compare similar types of facilities to each other. During subsequent analysis of the 1-year reporting period of July 2013 through June 2014, we confirmed that a 1-year reporting period with separate calculations for HOPDs and ASCs was sufficient, but did result in lower reliability and decreased precision, compared to results calculated with longer reporting periods (two or three years). Based on analyses conducted using data from July 2013 through June 2014 (1-year reporting period) and 2017 measure specifications,206 we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs. Using a 2-year reporting period (data from July 2012–June 2014), we found that median facility-level reliability was 0.81 for ASCs and 0.67 for HOPDs.

When the reporting period was extended to three years (using data from July 2011 through June 2014), we found that median facility-level reliability was higher for both ASCs and HOPDs: 0.87 for ASCs and 0.75 for HOPDs. These results indicate that a larger portion of the included facilities have scores measured with higher reliability when three years of data are used rather than one year of data.

Using three years of data, compared to just one year, is estimated to increase the number of ASCs with eligible cases for ASC–12 by 10 percent, adding approximately 235 additional ASCs to the measure calculation. ASCs reporting the measure would increase their sample sizes and, in turn, increase the precision and reliability of their measure scores. Thus, we believe extending the reporting period to three years from one year for purposes of increasing reliability would be beneficial for providing better information to beneficiaries regarding the quality of care associated with low-risk outpatient colonoscopy procedures. In crafting our proposal, we considered extending the reporting period to two years beginning with the CY 2020 payment determinations and subsequent years, but decided on proposing three years instead, because a higher level of reliability is achieved with a 3-year reporting period compared to two years.

Therefore, in the CY 2019 OPPS/ASC proposed rule (83 FR 37206 through 37207), we proposed to change the reporting period for ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination (which would use claims data from January 1, 2016 through December 31, 2018) and for subsequent years. Under this proposal, the annual reporting requirements for ASCs would not change because this is a claims-based measure. However, with a 3-year reporting period, the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus two prior years of data (CYs 2016 and 2017). In the proposed rule, we noted that since implementation of this measure began with the CY 2018 payment determination, we have already used paid Medicare FFS claims from January 1, 2016 to December 31, 2016 to calculate the measure scores, which have been previously previewed by ASCs and publicly displayed. In crafting our proposal, we also considered timeliness related to payment determinations and public display. Because we would utilize data already collected to supplement current data, our proposal to use three years of data would not disrupt payment determinations or public display. We refer readers to the table below for example reporting periods and public display dates corresponding to the CY 2020, CY 2021, and CY 2022 payment determinations:

---


204 Additional methodology details and information obtained from public comments for measure development are available at: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInitiatives/Measure-Methodology.html under “Hospital Outpatient Colonoscopy.”


206 Current and past measure specifications are available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pagename=QnetPublic%2FPage%2FQnetTier3&cid=1229775214597.
We refer readers to section XIII.D.4.b. of the proposed rule, where we discussed a similar proposal under the Hospital OQR Program.

Comment: Several commenters supported the proposed extension of the reporting period for ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy. A few commenters supported a 3-year reporting period, noting that the reliability of measure data intended for public reporting and accountability is important and urged CMS to seek stakeholder feedback on developing a methodology and release a methodology report for public review and comment. 

Response: We thank the commenters for their support for extending the reporting period for ASC–12. Regarding the request to release a methodology report, we publish an annual update and measures specifications report, which is a description of the measure updates and measure results from reevaluation and includes detailed measure specifications. This report describes the measure methodology for a given reporting period. CMS encourages stakeholders to submit comments on the measure’s methodology via the Outpatient and ASC Question and Answer tool, https://cms-ocsq.custhelp.com/.

Comment: One commenter stated that in order to make the measure data as reliable as possible, CMS should increase the minimum case volume threshold from less than thirty cases to less than one hundred cases.

Response: While it is true that a higher minimum case count would result in a higher minimum reliability, we must balance the goal of adequate reliability with the goal of providing measure performance information on as many facilities as possible. The minimum case count of 30 was set during the dry run of the measure and resulted in a minimum reliability estimate that was “moderate” for those facilities meeting the requirement. While the measure now calculates score for ASCs and OPDs separately, increasing the number years used for the measure should increase reliability for facilities meeting this minimum case count. We must balance the goal of adequate reliability with the goal of providing timely measure information that can inform quality improvement efforts. A 3-year reporting period improves the reliability of the measure and increases the number of facilities that meet the minimum case count.

Comment: A few commenters supported a 2-year reporting period, stating that priority interest should be giving beneficiaries critical information they can use today and two years of data typically yields the best mix of reliability and predicting performance today.

Response: We chose to propose a 3-year reporting period for the colonoscopy measure because using three years of data would increase the number of facilities meeting minimum case count requirements and increase the overall reliability of each facility measure score by increasing sample sizes. We balance the goal of adequate reliability with the goal of providing timely measure information that can inform quality improvement efforts. A 3-year reporting period substantially improves the reliability of the measure, as described above. Using a 1-year reporting period, we found that the median facility-level reliability was 0.74 for ASCs and 0.51 for HOPDs, and for a 2-year reporting period 0.81 for ASCs and 0.67 for HOPDs. However, the median facility-level reliability was highest for both ASCs and HOPDs using a 3-year reporting period: 0.87 for ASCs and 0.75 for HOPDs. In addition, we note that using a 3-year reporting period does not affect the timeliness of our ability to report on this measure, as the data being used has already been collected. Specifically, we note that the most current year of data would be supplemented by the addition of two prior years. For example, for the CY 2020 payment determination, we would use a reporting period of CY 2018 data plus two prior years of data (CYs 2016 and 2017).

Comment: Several commenters provided general feedback on the measure. A few noted that the data reported for the two measures (ASC–12 and OP–32) reflects fundamental claim and billing policy differences—such as the CMS three-day payment window—between the two settings (ASCs and HOPDs) that preclude valid comparisons, and the two measures should be clearly distinguished. A few commenters noted that the all-cause ED visit outcome is too broad and is not giving any specific information about the quality of care given at an endoscopy center, and that the measure does not help the consumer make distinctions among ASCs.

Response: We thank commenters for their feedback on the measure. The commenter is correct that there are differences between the ASC and HOPD colonoscopy measures (ASC–12 and OP–32) that specifically relate to billing differences between the two settings. For example, for outpatient (HOPD) colonoscopies that occur in the three calendar days preceding the date of a beneficiary’s inpatient admission, the facility claim is bundled with the inpatient claim, and therefore would not be identified using only outpatient facility claims. Therefore, for OP–32, cases subject to the 3-day payment window are identified with a matching algorithm that uses inpatient and physician (Medicare Part B) claims to attribute the colonoscopy procedure to the appropriate outpatient facility (HOPD). We also calculate the measure scores separately for ASCs and HOPDs; HOPDs are only compared to other HOPDs, and ASCs to other ASCs, therefore the difference in methodology does not affect the overall evaluation of ASCs or HOPDs within each measure’s calculation. Furthermore, we note that ASC–12 and OP–32 performance data are presented separately on Hospital Compare. In the future, we intend to update publicly available resource materials to clarify that ASC–12 and OP–32 are calculated separately using

207 Measure Methodology. Colonoscopy measure. Available at: https://www.qualitynet.org/dcs/ContentServer?c=Page&pageName=QnetPublic%2FPage%2FQnetTier3&cid=1228775197506.
different benchmarks and should not be compared.

In addition, we measure all-cause hospital visits (including Emergency department visits) to encourage OPDs and ASCs to minimize all types of risks that may lead to hospital visits after a colonoscopy. Measuring only hospital visits that are narrow procedural complications of colonoscopy, such as gastrointestinal bleeding, would limit the measure’s impact on quality improvement efforts and miss events such as dehydration, pain, dizziness, and urinary retention that are often related to the colonoscopy or the preparation for the colonoscopy and present to the ED. From the patient’s perspective, these events reflect the quality of care for the full episode of care. Measuring all-cause patient outcomes encourages facilities and their clinicians minimizes the risk of a broad range of outcomes. We have structured the measure so that OPDs and ASCs that most effectively minimize patient risk of these outcomes will perform better.

While we employ a conservative approach to categorizing facility performance relative to the national rate, the distribution of measure scores for both ASC–12 and OP–32 demonstrate meaningful variation. This variation provides valuable information to facilities about their performance and the possibility for reducing complications following low risk colonoscopies. Using claims from January 1, 2016 through December 31, 2016, we characterize the degree of variability by calculating the median odds ratio (MOR). The median odds ratio represents the median increase in odds of a hospital visit if a procedure on a single patient was performed at a higher risk facility compared to a lower risk facility. Both median odds ratios indicate the impact of quality on the outcome rate is substantial at both ASCs and HOPDs.

- For HOPDs, a value of 1.23 indicates that a patient has a 23 percent increase in the odds of a hospital visit if the same procedure was performed at a higher risk HOPD compared to a lower risk HOPD.
- For ASCs, a value of 1.19 indicates that a patient has a 19 percent increase in the odds of a hospital visit if the same procedure was performed at higher risk ASC compared to a lower risk ASC.

After consideration of the public comments we received, we are finalizing our proposal to change the reporting period for ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate Risk Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination and for subsequent years, as proposed. We refer readers to section XIII.D.4.b. of this final rule with comment period, where we are finalizing a similar policy under the Hospital OQR Program.

5. Requirements for Data Submission for ASC–15a–e: Outpatient and Ambulatory Surgical Center Assessment of Healthcare Providers and Systems (OAS CAHPS) Survey-Based Measures

We refer readers to the CY 2017 OPPS/ASC final rule with comment period (81 FR 79822 through 79824) for our previously finalized policies regarding survey administration and vendor requirements for the CY 2020 payment determination and subsequent years. In addition, we codified these policies at 42 CFR 416.310(e). However, in the CY 2018 OPPS/ASC final rule with comment period (82 FR 59450 through 59451), we delayed implementation of the ASC–15a–e: OAS CAHPS Survey-based measures beginning with the CY 2020 payment determination (CY 2018 data submission) until further action in future rulemaking, and we refer readers to that discussion for more details. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to this policy.

6. Extraordinary Circumstances Exception (ECE) Process for the CY 2020 Payment Determination and Subsequent Years

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59474 through 59475) (and the previous rulemakings cited therein) and 42 CFR 416.310(d) for the ASCQR Program’s policies for extraordinary circumstance exceptions (ECE) requests.

In the CY 2018 OPPS/ASC final rule with comment period (82 FR 59474 through 59475), we: (1) Changed the name of this policy from “extraordinary circumstances extensions or exemption” to “extraordinary circumstances exceptions” for the ASCQR Program, beginning January 1, 2018, and (2) revised 42 CFR 416.3(d) of our regulations to reflect this change. We also clarified that we will strive to complete our review of each request within 90 days of receipt. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to these policies.

7. ASCQR Program Reconsideration Procedures

We refer readers to the CY 2016 OPPS/ASC final rule with comment period (82 FR 59475) (and the previous rulemakings cited therein) and 42 CFR 416.330 for the ASCQR Program’s reconsideration policy. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), we did not propose any changes to this policy.

E. Payment Reduction for ASCs That Fail To Meet the ASCQR Program Requirements

1. Statutory Background

We refer readers to section XVI.D.1. of the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499) for a detailed discussion of the statutory background regarding payment reductions for ASCs that fail to meet the ASCQR Program requirements.

2. Policy Regarding Reduction to the ASC Payment Rates for ASCs That Fail To Meet the ASCQR Program Requirements for a Payment Determination Year

The national unadjusted payment rates for many services paid under the ASC payment system equal the product of the ASC conversion factor and the scaled relative payment weight for the APC to which the service is assigned. For CY 2019, the ASC conversion factor we are finalizing is equal to the conversion factor calculated for the previous year updated by the multifactor productivity (MFP)-adjusted hospital market basket update factor. The MFP adjustment is set forth in section 1833(i)(2)(D)(v) of the Act. The MFP-adjusted hospital market basket update is the annual update for the ASC payment system for an interim 5-year period (CY 2019 through CY 2023). As discussed in the CY 2011 OPPS/ASC final rule with comment period (75 FR 72062), if the CPI–U update factor is a negative number, the CPI–U update factor would be held to zero. In the CY 2019 OPPS/ASC proposed rule (83 FR 37207), consistent with past practice, in the event the percentage change in the hospital market basket for a year is negative, we proposed to hold the hospital market basket update factor for the ASC payment system to zero. Under the ASCQR Program in accordance with section 1833(i)(7)(A) of the Act and as discussed in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499), any annual increase shall be reduced by 2.0 percentage points for ASCs that fail to meet the reporting requirements of the ASCQR Program. This reduction applied beginning with the CY 2014 payment rates (77 FR 68500). For a complete discussion of the calculation of the ASC conversion factor and our proposal to update the ASC payment rates using the inpatient hospital market basket update for CYs
In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68499 through 68500), in order to implement the requirement to reduce the annual update for ASCs that fail to meet the ASCQR Program requirements, we finalized our proposal that we would calculate two conversion factors: A full update conversion factor and an ASCQR Program reduced update conversion factor. We finalized our proposal to calculate the reduced national unadjusted payment rates using the ASCQR Program reduced update conversion factor that would apply to ASCs that fail to meet their quarterly reporting requirements for that calendar year payment determination. We finalized our proposal that application of the 2.0 percentage point reduction to the annual update may result in the update to the ASC payment system being less than zero prior to the application of the MFP adjustment.

The ASC conversion factor is used to calculate the ASC payment rate for services with the following payment indicators (listed in Addenda AA and BB to the proposed rule, which are available via the internet on the CMS website): “A2”, “G2”, “P2”, “R2” and “Z2”. As well as the service portion of device-intensive procedures identified by “J8” (77 FR 68500). We finalized our proposal that payment for all services assigned the payment indicators listed above would be subject to the reduction of the national unadjusted payment rates for applicable ASCs using the ASCQR Program reduced update conversion factor (77 FR 68500).

The conversion factor is not used to calculate the ASC payment rates for separable separately payable services that are assigned status indicators other than payment indicators “A2”, “G2”, “J8”, “P2”, “R2” and “Z2.” These services include separable separately payable drugs and biologicals, pass-through devices that are contractor-priced, brachytherapy sources that are paid based on the OPPS payment rates, and certain office-based procedures, radiology services and diagnostic tests where payment is based on the PFS nonfacility PE RVU-based amount, and a few other specific services that receive cost-based payment (77 FR 68500). As a result, we also finalized our proposal that the ASC payment rates for these services would not be reduced for failure to meet the ASCQR Program requirements because the payment rates for these services are not calculated using the ASC conversion factor and, therefore, not affected by reductions to the annual update (77 FR 68500).

Office-based surgical procedures (generally those performed more than 50 percent of the time in physicians’ offices) and separately paid radiology services (excluding covered ancillary radiology services involving certain nuclear medicine procedures or involving the use of contrast agents) are paid at the lesser of the PFS nonfacility PE RVU-based amounts or the amount calculated under the standard ASC ratesetting methodology. Similarly, in section XII.D.2.b. of the CY 2015 OPPS/ASC final rule with comment period (79 FR 66933 through 66934), we finalized our proposal that payment for certain diagnostic test codes within the medical range of CPT codes for which separate payment is allowed under the OPPS and when they are integral to covered ASC surgical procedures will be at the lesser of the PFS nonfacility PE RVU-based (or technical component) amount or the rate calculated according to the standard ASC ratesetting methodology. In the CY 2013 OPPS/ASC final rule with comment period (77 FR 68500), we finalized our proposal that the standard ASC ratesetting methodology for this type of comparison would use the ASC conversion factor that has been calculated using the full ASC update adjusted for productivity. This is necessary so that the resulting ASC payment indicator, based on the comparison, assigned to these procedures or services is consistent for each HCPCS code, regardless of whether payment is based on the full update conversion factor or the reduced update conversion factor.

For ASCs that receive the reduced ASC payment for failure to meet the ASCQR Program requirements, we believe that it is both equitable and appropriate that a reduction in the payment for a service should result in proportionately reduced coinsurance liability for beneficiaries (77 FR 68500). Therefore, in the CY 2013 OPPS/ASC final rule with comment period (77 FR 68500), we finalized our proposal that the Medicare beneficiary’s national unadjusted coinsurance for a service to which a reduced national unadjusted payment rate applies will be based on the reduced national unadjusted payment rate.

In that final rule with comment period, we finalized our proposal that all other applicable adjustments to the ASC national unadjusted payment rates would apply in those cases when the annual update is reduced for ASCs that fail to meet the requirements of the ASCQR Program (77 FR 68500). For example, the following standard adjustments would apply to the reduced national unadjusted payment rates: The wage index adjustment; the multiple procedure adjustment; the interrupted procedure adjustment; and the adjustment for devices furnished with full or partial credit or without cost (77 FR 68500). We believe that these adjustments continue to be equally applicable to payment for ASCs that do not meet the ASCQR Program requirements (77 FR 68500).

In the CY 2015, CY 2016, CY 2017, and CY 2018 OPPS/ASC final rules with comment period (79 FR 66982; 80 FR 70537 through 70538; 81 FR 79825 through 79826; and 82 FR 59475 through 59476, respectively), we did not make any other changes to these policies. We did not propose any changes to these existing policies for CY 2019 in the CY 2019 OPPS/ASC proposed rule (83 FR 37207 through 37208).

We did not receive any public comments on our proposal that, in the event the percentage change in the hospital market basket for a year is negative, we would hold the hospital market basket update factor for the ASC payment system to zero. We also did not receive any public comments on our existing policies for all other applicable adjustments to the ASC national unadjusted payment rates discussed earlier. Therefore, we are finalizing our proposal without modification and continuing the existing policies for CY 2019.

XV. Comments Received in Response To Requests for Information (RFIs) Included in the CY 2019 OPPS/ASC Proposed Rule

In the CY 2019 OPPS/ASC proposed rule (83 FR 37207 through 37217), we included three requests for information (RFIs). We stated in the proposed rule that the RFIs were issued solely for information and planning purposes; none of the RFIs constituted a Request for Proposal (RFP), application proposal abstract, or quotation. In addition, we stated that the RFIs did not commit the U.S. Government to contract for any supplies or services or make a grant award. Further, we stated that CMS was not seeking proposals through these RFIs and would not accept unsolicited proposals. Responders were advised that the U.S. Government will not pay for any information or administrative costs incurred in response to these RFIs; all costs associated with responding to these RFIs would be solely at the interested party’s expense. In addition, we stated in the proposed rule that failing to respond to either RFI would not
information as part of our price transparency initiatives. We received over 90 timely pieces of correspondence on this RFI. We appreciate the input provided by commenters.

C. Comments Received in Response To Request for Information on Leveraging the Authority for the Competitive Acquisition Program (CAP) for Part B Drugs and Biologicals for a Potential CMS Innovation Center Model

In the CY 2019 OPPS/ASC proposed rule (83 FR 37212 through 37217), we included a Request for Information (RFI) related to leveraging the authority for the Competitive Acquisition Program (CAP) for Part B drugs and biologicals for a potential CMS Innovation Center Model. We received approximately 80 timely pieces of correspondence on this RFI. We appreciate the input provided by commenters.

XVI. Additional Hospital Inpatient Quality Reporting (IQR) Program Policies

A. Background

We refer readers to the FY 2010 IPPS/LTC PPS final rule (74 FR 43860 through 43861) and the FY 2011 IPPS/LTC PPS final rule (75 FR 50180 through 50181) for detailed discussions of the history of the Hospital IQR Program, including the statutory history, and to the FY 2015 IPPS/LTC PPS final rule (79 FR 50217 through 50249), the FY 2016 IPPS/LTC PPS final rule (80 FR 49660 through 49692), the FY 2017 IPPS/LTC PPS final rule (81 FR 57148 through 57150), and the FY 2018 IPPS/LTC PPS final rule (82 FR 38323 through 38411) for the measures and program policies we have adopted for the Hospital IQR Program through the FY 2020 payment determination and subsequent years. In addition to the proposed and finalized policies discussed in this section, we also refer readers to the FY 2019 IPPS/LTC PPS final rule (83 FR 41537 through 41609) for a full discussion of the Hospital IQR Program and its policies.

B. Update to the HCAHPS Survey Measure (NQF #0166) for the FY 2021 Payment Determination and Subsequent Years

1. Background of the HCAHPS Survey in the Hospital IQR Program

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37211), CMS partnered with the Agency for Healthcare Research and Quality (AHRQ) to develop the Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) patient experience of care survey (NQF #0166). The HCAHPS Survey in the Hospital IQR Program (at the time called the Reporting Hospital Quality Data Annual Payment Update Program, or RHQDAUP) in the CY 2007 OPPS final rule with comment period (71 FR 68202 through 68204) beginning with the FY 2008 payment determination and for subsequent years. We refer readers to the FY 2010 IPPS/LTC PPS final rule (74 FR 43882), the FY 2011 IPPS/LTC PPS final rule (75 FR 50220 through 50224), the FY 2012 IPPS/LTC PPS final rule (76 FR 51641 through 51643), the FY 2013 IPPS/LTC PPS final rule (77 FR 53537 through 53538), the FY 2014 IPPS/LTC PPS final rule (78 FR 50819 through 50820), and the FY 2018 IPPS/LTC PPS final rule (82 FR 38328 to 38342) for details on previously-adopted HCAHPS Survey requirements.

The HCAHPS Survey (OMB control number 0938–0981) is the first national, standardized, publicly reported survey of patients’ experience of hospital care. It asks discharged patients and their families questions about their recent hospital stay. The HCAHPS Survey is administered to a random sample of adult patients who receive medical, surgical, or maternity care between 48 hours and 6 weeks (42 calendar days) after discharge and is not restricted to Medicare beneficiaries. Hospitals must survey patients throughout each month of the year. The HCAHPS Survey is available in official English, Spanish, Chinese, Russian, Vietnamese, and Portuguese versions. The HCAHPS Survey and its protocols for sampling, data collection and coding, and data submission can be found in the current HCAHPS Quality Assurance Guidelines, which is available on the official HCAHPS website at: http://www.hcahpsonline.org/en/quality-assurance/. AHRQ carried out a rigorous scientific process to develop and test the HCAHPS Survey instrument. This process entailed multiple steps, including: a public call for measures; literature reviews; cognitive interviews; consumer focus groups; multiple opportunities for additional stakeholder

210 The HCAHPS measure also includes the NQF-endorsed Care Transition Measure (CTM–3) (NQF #0228), which we added in the FY 2013 IPPS/LTC PPS final rule (77 FR 53513 through 53516). We added the Communication About Pain composite measure in the FY 2016 IPPS/LTC PPS final rule (38328 through 38342), and stated that we would seek NQF endorsement for this measure.

211 We refer readers to the FY 2018 IPPS/LTC PPS final rule (62 FR 38328 to 38342, 38309) and to the official HCAHPS website at: http://www.hcahpsonline.org for details on HCAHPS requirements.
input: a 3-State pilot test; small-scale field tests; and notice-and-comment rulemaking. In May 2005, the HCAHPS Survey was first endorsed by the NQF.213

In the FY 2018 IPPS/LTCH PPS final rule (82 FR 38328 through 38342), out of an abundance of caution, in the face of a nationwide epidemic of opioid overprescription, we finalized a refinement to the HCAHPS Survey measure as used in the Hospital IQR Program by removing the previously adopted pain management questions and Incorporating new Communication About Pain questions beginning with patients discharged in January 2018, for the FY 2020 payment determination and subsequent years.214 These three survey questions within the HCAHPS Survey, collectively known as the Communication About Pain questions,215 address how providers communicate with patients about pain. These questions are as follows:216

- HP1: “During this hospital stay, did you have any pain?”
  - Yes
  - No → If No, Go to Question

- HP2: “During this hospital stay, how often did hospital staff talk with you about how much pain you had?”
  - Never
  - Sometimes
  - Usually
  - Always

- HP3: “During this hospital stay, how often did hospital staff talk with you about how to treat your pain?”
  - Never
  - Sometimes
  - Usually
  - Always

In addition, we finalized public reporting on the Communication About Pain questions, such that hospita performance data on those questions would be publicly reported on the Hospital Compare website beginning October 2020, using CY 2019 data. We also stated that we would provide performance results based on CY 2018 data on the Communication About Pain questions to hospitals in confidential preview reports, upon the availability of four quarters of data, as early as July 2019. We believed implementing the Communication About Pain questions as soon as feasible was necessary to address any perceived conflict between appropriate management of opioid use and patient satisfaction by relieving any potential pressure physicians may feel to overprescribe opioids (82 FR 38333).

2. Updates to the HCAHPS Survey: Removal of Communication About Pain Questions

As discussed in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), since we finalized the Communication About Pain questions, we have received feedback that some stakeholders are concerned that, although the revised questions focus on communications with patients about their pain and treatment of that pain, rather than how well their pain was controlled, the questions still could potentially impose pressure on hospital staff to prescribe more opioids in order to achieve higher scores on the HCAHPS Survey. In addition, in its final report, the President’s Commission on Combating Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS Pain Management questions in order to ensure providers are not incentivized to offer opioids to raise their HCAHPS Survey score.217

Other potential factors outside the control of CMS quality program requirements may contribute to the perception of a link between the Communication About Pain questions and opioid prescribing practices, including: misuse of the HCAHPS Survey (such as using it for outpatient emergency room care instead of inpatient care, or using it for determining individual physician performance); failure to recognize that the HCAHPS Survey excludes certain populations from the sampling frame (such as those with a primary substance use disorder diagnosis); and the addition of supplemental pain-related survey questions by the hospital that are not formally part of the HCAHPS Survey or otherwise required by CMS.

Because some hospitals have identified patient experience of care as a potential source of competitive advantage, we have heard from stakeholders that some hospitals may be disaggregating their raw HCAHPS Survey data to compare, assess, and incentivize individual physicians, nurses, and other hospital staff. Some hospitals also may be using the HCAHPS Survey to assess their emergency and outpatient departments. To be clear, the HCAHPS Survey was never designed or intended to be used in these ways.218 In our HCAHPS Quality Assurance Guidelines,219 which sets forth current survey administration protocols, we strongly discourage the unofficial use of HCAHPS scores for comparisons within hospitals, such as for comparisons of particular wards, floors, and individual staff hospital members. The standardization of HCAHPS Survey administration and data collection methodologies is also emphasized during the required introductory and annual update trainings for hospitals/survey vendors.

As we stated in the CY 2019 OPPS/ASC proposed rule, we continue to believe that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers. It is important to reiterate that the HCAHPS Survey does not specify any particular type of pain control method. The revised questions focus entirely on communication about pain with patients and do not refer to, recommend, or imply that any particular type of treatment is appropriate (82 FR 38333). In addition, appropriate pain management includes communication with patients about pain-related issues, setting expectations about pain, shared decision-making, proper prescription practices, and alternative treatments for pain management.

Although we are not aware of any scientific studies that support an association between scores on the prior or current iterations of the Communication About Pain questions and opioid prescribing practices, out of an abundance of caution and to avoid any potential unintended consequences, in the CY 2019 OPPS/ASC proposed rule (83 FR 37218), we proposed to update the HCAHPS Survey by removing the Communication About Pain questions effective with January 2020.


214 In the CY 2017 OPPS/ASC final rule with comment period (81 FR 79855 through 79862), the Hospital VBP Program removed the Pain Management dimension of the HCAHPS Survey in the Patient and Caregiver-Centered Experience of Care/Care Coordination domain of the Hospital VBP Program beginning with the FY 2018 program year. Under the Hospital VBP Program, payment adjustments are tied to hospitals’ performance on the measures that are used to calculate each hospital’s Total Performance Score.


216 We note that in the CY 2019 OPPS/ASC proposed rule, we inadvertently omitted the “If No, Go to Question” phrase that accompanies the “No” response option for the first question. We have added the language above to reflect the full question.


2022 discharges, for the FY 2024 payment determination and subsequent years. This proposal would reduce the overall length of the HCAHPS Survey from 32 to 29 questions, and the final four quarters of reported Communication About Pain data (comprising data from the first, second, third, and fourth quarters 2021) would be publicly reported on Hospital Compare in October 2022 and then subsequently discontinued. As stated above, in its final report, the President’s Commission on Combating Drug Addiction and the Opioid Crisis recommended removal of the HCAHPS Pain Management Survey questions in order to ensure providers are not incentivized to offer opioids to raise their HCAHPS Survey score.220

In proposing removal of the Communication About Pain questions, we did not propose to change how performance scores are calculated for the remaining questions on the HCAHPS Survey. The Hospital IQR Program is a quality data reporting program; payments to hospitals will not be affected so long as hospitals timely submit data on required measures and meet all other program requirements. We stated in the proposed rule that we would continue to use the remaining 29 questions of the HCAHPS Survey to assess patients’ experience of care, and would continue to publicly report hospital scores on those questions in order to ensure patients and consumers have access to these data while making decisions about their care. Patients and providers can continue to review data from responses to the remaining 29 questions of the HCAHPS Survey on the Hospital Compare website.

In crafting our proposal, we considered whether the Communication About Pain questions should be retained in both the HCAHPS Survey and the Hospital IQR Program but with a further delay in public reporting. For example, instead of public reporting starting in October 2020 as previously finalized, we could have proposed to delay public reporting of the Communication About Pain questions until October 2021. We stated we were interested in feedback on whether the Communication About Pain questions should be retained in both the HCAHPS Survey and the Hospital IQR Program but with a further delay in public reporting. Delay in public reporting would allow further time to engage a broad range of stakeholders and assess their feedback regarding use of the Communication About Pain questions in the HCAHPS Survey and the Hospital IQR Program and to assess the impact of the new Communication About Pain questions. However, we chose to propose to remove the Communication About Pain questions as discussed above instead, so providers would not perceive that there are incentives for prescribing opioids to increase HCAHPS Survey scores.

In crafting our proposal, we also considered proposing earlier removal of the Communication About Pain questions from the HCAHPS Survey effective as early as January 2020 discharges, for the FY 2022 payment determination and subsequent years. However, we stated that removing the questions effective with January 2020 discharges would not allow sufficient time to make necessary updates to the data collection tools, including the CMS data submission warehouse and associated reporting tools, as well as to update the HCAHPS Survey administration protocols and the survey tool itself. In addition, our proposal to make these updates effective later, with January 2022 discharges, would allow time to assess the potential impact of using the Communication About Pain questions while monitoring unintended consequences. It would also allow time for empirical testing for any potential effect the removal of the Communication About Pain questions might have on responses to the remaining non-pain related survey items.

We invited public comment on our proposal as discussed above and whether the questions should be removed from the HCAHPS Survey and Hospital IQR Program. We stated that we were particularly interested in receiving feedback on any potential implications on patient care related to removing these questions. We also expressed interest in receiving feedback from stakeholders on: (1) The importance of receiving feedback from patients related to communication about pain management and the importance of publicly reporting this information for use both by patients in healthcare decision-making and by hospitals in focusing their quality improvement efforts; (2) additional analyses demonstrating a relationship between the use of pain questions in patient surveys and prescribing behavior, including unpublished data, if available; (3) input from clinicians and other providers concerning whether it would be valuable for CMS to issue guidance suggesting that hospitals do not administer any surveys with pain-related questions, including wording hospital-specific supplemental items to the HCAHPS Survey, as well as the potential implementation of a third party quality assurance program to assure that hospitals are not misusing survey data by creating pressure on individual clinicians to provide inappropriate clinical care; (4) information from clinicians and other providers concerning instances of hospital administrators using results from the HCAHPS Survey to compare individual clinician performance directly to other clinicians at the same facility or institution and examples where, as a result, clinicians have felt pressured to prescribe opioids inappropriately (in terms of either quantity or appropriateness for particular patients); (5) suggestions for other measures that would capture facets of pain management and related patient education, for instance, collecting data about a hospital’s pain management plan, and provide that information back to consumers; and (6) how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks of opioid use and about non-opioid pain management alternatives.

Comment: A number of commenters responded to CMS’ request for feedback regarding potential misuse of the HCAHPS Survey and its impact on provider decision-making. Commenters indicated the Communication About Pain questions in the HCAHPS Survey unduly influence providers’ decision-making by encouraging providers to focus on improving patient satisfaction scores regarding pain management. One commenter indicated this influence is significant enough to compel providers to prescribe opioids to patients showing signs of drug-seeking behavior. Other commenters expressed concern that some hospitals use disaggregated survey results to assess individual clinician performance, with some hospitals tying these disaggregated survey results to individual compensation.

Response: We thank the commenters for their feedback. We also reiterate that the HCAHPS Survey was never intended to be used to assess the performance of individual clinicians or provider groups within a hospital. The HCAHPS Survey is designed to evaluate the performance of a hospital as a whole, not individuals or groups within the larger hospital setting.221

---


its use for evaluating or incentivizing individual providers or groups within the hospital is contrary to the survey’s design and policy aim.

During annual survey vendor training for HCAHPS and in the HCAHPS Quality Assurance Guidelines, we clearly state the purpose and the proper use of HCAHPS data: Official HCAHPS Survey scores are published on the Hospital Compare website. CMS emphasizes that HCAHPS scores are designed and intended for use at the hospital level for the comparison of hospitals (designated by their CMS Certification Number) to each other. CMS does not review or endorse the use of HCAHPS scores for comparisons within hospitals, such as comparison of HCAHPS scores associated with a particular ward, floor, individual staff member, etc. to others. Such comparisons are unreliable unless adequate sample sizes are collected at the ward, floor, or individual staff member level. In addition, since HCAHPS questions inquire about broad categories of hospital staff (such as doctors in general and nurses in general rather than specific individuals), HCAHPS is not appropriate for comparing or assessing individual hospital staff members. Using HCAHPS scores to compare or assess individual staff members is inappropriate and is strongly discouraged by CMS.

Comment: The majority of commenters supported CMS’ proposal to remove the Communication About Pain questions from the HCAHPS Survey. A number of commenters who supported removal of the Communication About Pain questions also recommended CMS remove the questions earlier than proposed. Several commenters specifically recommended that CMS remove these questions immediately, asserting that the severity and urgency of the opioid crisis justifies immediate termination of the questions. One commenter recommended immediate removal of the Communication About Pain questions due to concerns that the subjective nature of the HCAHPS Survey, and the Communication About Pain questions, may not accurately represent hospital performance.

Other commenters recommended that CMS remove the Communication About Pain questions as feasible, with one commenter specifically recommending removal effective with January 2020 discharges, due to the potential unintended consequences associated with continued use of the questions. These commenters further recommended that CMS first remove the Communication About Pain questions, then evaluate alternate methods of determining the impacts of removal and the value of collecting pain management data, rather than delaying removal in order to collect more data.

Response: We thank the commenters for their feedback and their support of our proposal to remove the Communication About Pain questions from the HCAHPS Survey. We believe that removing the Communication About Pain questions from the HCAHPS Survey will address potential confusion about the appropriate use of the HCAHPS Survey, is responsive to concerns regarding the public health issues arising from the opioid epidemic, and addresses the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis.

In addition, Section 6104 of the Substance Use—Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act (SUPPORT for Patients and Communities Act) (Pub. L. 115–271) enacted on October 24, 2018, prohibits HCAHPS Surveys conducted on or after January 1, 2020 from including questions about communication by hospital staff with an individual about such individual’s pain, unless such questions take into account, as applicable, whether an individual experiencing pain was informed about risks associated with the use of opioids and about non-opioid alternatives for the treatment of pain. Section 6104 of the SUPPORT for Patients and Communities Act also states that the Secretary shall not include any measures based on the pain communication questions on the HCAHPS Survey in 2018 or 2019 on the Hospital Compare website and in the Hospital Value-Based Purchasing (VBP) Program.

We proposed to remove the Communication About Pain questions beginning with January 2022 discharges for the FY 2024 payment determination in an effort to avoid imposing undue burden on providers or their survey vendors to make necessary updates to surveys and data collection tools while also providing us additional time to assess the potential impact of using these questions in the HCAHPS Survey and the impact removal may have on responses to subsequent survey items (83 FR 37218 through 37220). Based on the stakeholder comments supporting removal of these questions, particularly those who requested we remove them immediately or as soon as possible, we assessed the feasibility of removing the questions as soon as operationally possible.

Upon further review of the operational timelines for making necessary updates to the HCAHPS Survey administration protocols, including conducting associated training of survey vendors and hospitals, and making updates to the CMS data submission warehouse and associated reporting tools, we found that it would be operationally feasible to remove the Communication About Pain questions earlier than we proposed. Furthermore, because the SUPPORT for Patients and Communities Act prohibits use of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020, it is appropriate to remove these questions from the HCAHPS Survey sooner than proposed—effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. We also note that removing these questions effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years is responsive to commenters who recommended that we remove the Communication About Pain questions immediately or as soon as possible. Although we are removing the Communication About Pain questions, we will continue to consider the value of collecting data that relates to pain management. We will examine the effect of the absence of the Communication About Pain items on subsequent survey items once these items have been removed.

Therefore, in response to stakeholder feedback, to comply with the requirements of the SUPPORT for Patients and Communities Act, and upon further review of the operational considerations involved in removing the Communication About Pain questions, we are finalizing a modification to our proposal and will remove the questions effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years.

Comment: A few commenters also recommended that CMS remove the Communication About Pain questions from public reporting. One commenter further recommended that CMS not publicly report performance data on the Communication About Pain questions until further research on the impact and utility of the questions is performed. Another commenter recommended that while the Communication About Pain questions remain in the HCAHPS Survey, CMS should remove them from
the scoring calculation to minimize potential adverse consequences.

Response: We appreciate the commenters’ feedback regarding public reporting of the Communication About Pain questions. Due in part to stakeholder input urging us to remove the Communication About Pain questions immediately or as soon as possible, as discussed above, we have assessed the operational considerations and are finalizing a modification to our proposal to remove the questions effective with October 2019 discharges, which is the earliest we can feasibility implement removal of the Communication About Pain questions.

We are finalizing a modification of our public display proposal that we publicly reporting the Communication about Pain questions on Hospital Compare until October 2022 (comprising data from the first, second, third, and fourth quarters 2021) and then subsequently discontinue public reporting. Instead, we are finalizing that we will no longer collect four quarters of CY 2019 Communication About Pain questions data; stakeholders’ recommendations that we not publicly report the Communication About Pain data at all because: We will no longer collect four quarters of CY 2019 Communication About Pain questions data; stakeholders’ recommendations that we not publicly report the Communication About Pain data at all in order to avoid exacerbating any possible link between these questions and inappropriate prescribing practices; and the requirements of the SUPPORT for Patients and Communities Act, which prohibit publicly reporting on Hospital Compare any measures based on the Communication About Pain questions appearing in the HCAHPS Survey in 2018 or 2019. Not publicly reporting the data collected from the Communication About Pain questions also aligns with our efforts to mitigate any potential tie between the Communication About Pain questions and inappropriate opioid prescribing practices.

We note that in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38342), we finalized a delay in public reporting, such that hospital performance data on the refined Communication About Pain composite measure questions would not be publicly reported on the Hospital Compare website until October of CY 2020, using CY 2019 data. We stated that we would provide performance results, based on CY 2018 data on the refined Communication About Pain composite measure questions to hospitals in confidential preview reports, upon the availability of four quarters of data. We stated that we anticipated that these confidential preview reports would be available as early as July 2019. The effect of the modified policy we are finalizing in this final rule with comment period is that Communication About Pain data from the final CY 2019 reporting period (which would consist of three quarters of data, 1st quarter through 3rd quarter 2019) will also not be publicly reported.

However, we still plan to provide performance results based on these data to hospitals in confidential preview reports upon the availability of four quarters of CY 2018 data, as early as July 2019. Updated confidential reports will be provided on a quarterly basis with the availability of each new calendar quarter of data. The last confidential preview report containing the Communication About Pain questions data will reflect data from the fourth quarter of 2018 (October 1, 2018) through the third quarter of 2019 (September 30, 2019). We also note that the data collected from these questions will not be scored for purposes of CMS payments to hospitals, because the Hospital IQR Program is a pay-for-reporting, performance-based quality program and these questions are not part of the Hospital VBP Program.

Comment: Many commenters supported CMS’ proposal to remove the current Communication About Pain questions from the HCAHPS Survey beginning with January 2022 discharges for the FY 2024 payment determination and subsequent years. Many commenters supported removing the Communication About Pain questions based on concerns about unintended consequences of their continued use, specifically that the questions may incentivize or pressure clinicians into inappropriately prescribing opioids. Some commenters asserted that removing these questions from the HCAHPS Survey would allow providers to address patients’ pain in a safer manner, avoid inadvertently fostering an environment that could potentially promote the inappropriate use of opioids, and change perceptions about pain management. One commenter noted the Communication About Pain questions may also disincentivize the use of alternative methods of pain management in an effort to address patients’ pain in the most efficient manner (that is, prescription of opioids). Another commenter specifically cited agreement with the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis in supporting removal of the Communication About Pain questions. Several commenters supported removal of the Communication About Pain questions because the commenters believe pain is subjective and is therefore, difficult to measure using a standardized set of survey questions. A number of other commenters supported removal of these questions due to their concern the questions correlate pain treatment with patient satisfaction, thereby creating unrealistic patient expectations regarding pain management. These commenters also expressed concern the questions contribute to an environment in which patients expect to be pain free, whereas the goal of pain therapy should be to appropriately manage, not eliminate, pain. One commenter specifically supported removal of these questions because the commenter believed the questions elevate pain too highly as a factor in patient satisfaction and, thereby, in hospital reimbursement.

Another commenter supported removing the Communication About Pain questions because the commenter believed the approach to pain management is too complicated and unclear to be assessed using survey questions.

Response: We thank the commenters for their support. We are not aware of any scientific studies that support an association between scores on the Communication About Pain questions and opioid prescribing practices. In addition, we continue to believe that many factors outside the control of our quality program requirements may contribute to the perception of a link between the Communication About Pain questions and opioid prescribing practices, that pain management is an appropriate part of routine care that hospitals should manage and that pain management is an important concern for patients, their families, and their caregivers. Furthermore, we continue to believe the HCAHPS Survey is a valid and reliable measure of hospital quality that encourages hospitals to assess and improve patient experience. However, we believe that removing the Communication About Pain questions from the HCAHPS Survey will address potential concerns about the appropriate use of the HCAHPS Survey, is responsive to concerns regarding the public health issues arising from the opioid epidemic, and addresses both the recommendation of the President’s Commission on Combating Drug Addiction and the Opioid Crisis and the prohibitions in the SUPPORT for Patients and Communities Act.

Comment: A few commenters encouraged CMS to remove the Communication About Pain questions from both payment programs (for example, the Hospital VBP Program) and public reporting programs (for...
example, the Hospital IQR Program) given the concern about unintended consequences. One commenter stated that the Communication About Pain questions and related bonus payments led to an overuse of opioids and that removing the questions is important to addressing the current opioid crisis.

Response: To be clear, the Communication About Pain questions in the HCAHPS Survey are only used in the Hospital IQR Program. While the Hospital VBP Program uses HCAHPS Survey data to score the Patient and Community Engagement domain, it does not include the Pain Management dimension of the HCAHPS Survey—the predecessor of the current Communication About Pain questions. This dimension was removed from the Hospital VBP Program in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79855 through 79862) beginning with the FY 2018 program year. The Hospital VBP Program also does not use the current Communication About Pain questions. In addition, the Hospital IQR Program is a pay-for-reporting quality program, as opposed to a pay-for-performance quality program, and does not award incentive payments of any kind, including based on performance.

Comment: Several commenters acknowledged the lack of scientific evidence demonstrating an impact of the Communication About Pain questions on providers’ prescribing practices, but supported removal of the questions out of an abundance of caution. One commenter noted that CMS programs can significantly influence trends in the opioid epidemic and agreed it was prudent, despite the lack of scientific evidence, to remove the Communication About Pain questions until a better understanding of the link between the questions and prescribing practices is reached. Another commenter acknowledged the value of patient satisfaction surveys but expressed concern about tying these surveys to publicly reported hospital ratings and accountability, and therefore, supported removal of the Communication About Pain questions from the HCAHPS Survey. Other commenters stated that the questions are only tenuously linked to improved quality of care, and that the questions are of limited value in their current state.

Response: We thank the commenters for their support. As noted above, we are not aware of any scientific studies that support an association between scores on the Communication About Pain questions and opioid prescribing practices. However, we believe that removing these questions from the HCAHPS Survey will address potential confusion about the appropriate use of the HCAHPS Survey, and is responsive to concerns regarding the public health concerns about the opioid epidemic as well as the provisions of the SUPPORT for Patients and Communities Act.

Comment: A few commenters supported removal of the Communication About Pain questions due to concerns regarding the wording and focus of the questions. One commenter expressed its belief the questions focus on the frequency of communication about pain management rather than the quality or impact of this communication on the patient’s expectations and understanding about pain, while another commenter expressed concern that the questions fail to address population-specific challenges and variations in pain treatment regimens due to physician preference, patient behavior, or health care facility practices. A third commenter stated its belief the questions do not allow for nuanced discussion of pain management and patient expectations. Another commenter asserted that the Communication About Pain questions create patient expectations that hospital personnel should always discuss pain and its treatment with patients, which the commenter believes can encourage inappropriate prescribing and unrealistic expectations. This commenter further asserted that the wording of the questions encourages providers to overemphasize pain when it may not be an issue for a particular patient.

Response: We thank the commenters for their support of our proposal to remove the Communication About Pain questions from the HCAHPS Survey. We continue to believe the HCAHPS Survey as a whole, and the Communication About Pain questions, are valid and reliable measures of hospital quality that encourage hospitals to assess and improve patient experience. Further, we recognize that our programs may have an influence over trends in the opioid epidemic, which underscores our decision to remove the Communication About Pain questions from the HCAHPS Survey earlier than originally proposed. We believe that removing the Communication About Pain questions from the HCAHPS Survey out of an abundance of caution and to comply with the provisions of the SUPPORT for Patients and Communities Act will address potential confusion about the appropriate use of the HCAHPS Survey, and is responsive to concerns regarding the public health issues arising from the opioid epidemic.

Comment: A few commenters also noted the lack of National Quality Forum (NQF) endorsement as a reason to remove the Communication About Pain questions from the HCAHPS Survey and recommended that regardless of whether the questions are removed, CMS should submit the Communication About Pain questions for NQF endorsement.

Response: We note that, while the Hospital IQR Program is not statutorily limited to only using NQF-endorsed measures, we consider NQF endorsement status when evaluating measures for adoption into the measure set. While the Communication About Pain questions are not currently NQF endorsed, because we are removing the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program, we do not believe it prudent to submit the questions for NQF endorsement at this time. However, we will take commenters’ feedback and recommendations into account as we continue to assess whether and how the Hospital IQR Program should assess communications about pain management. We note, however, that the HCAHPS Survey, in its entirety, is in fact NQF-endorsed (NQF #0166).224

Comment: A few commenters supported removal of the Communication About Pain questions because the commenters believe that it is inappropriate to tie pain management to hospital reimbursement. One commenter supported removal of the Communication About Pain questions because the commenter believed that incentivizing providers to base care on patient satisfaction increases healthcare costs. Another commenter expressed its belief that decreasing the incentive to prescribe opioids for pain management


224 HCAHPS measure description and history, including NQF endorsement status, available at: https://www.qualityforum.org/QPS/6166/.
could reduce healthcare costs because opioid use can lead to a cascade of negative health effects that can increase lengths of stay and healthcare costs. Other commenters supported removal of the Communication About Pain questions because they believe it will help to reduce administrative burden and costs associated with data collection and reporting.

Response: As noted above, we continue to believe the HCAHPS Survey and Communication About Pain questions are reliable measures of hospital quality that encourage hospitals to assess and improve patient experience, and that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers. We believe the HCAHPS Survey is appropriate for use in CMS quality programs for public display of quality measurement data and tying hospital performance to Medicare reimbursement. However, out of an abundance of caution, and in the face of a nationwide epidemic of opioid overprescription, we believe that removal of the Communication About Pain questions from the HCAHPS Survey is warranted in order to resolve any perceived conflict between appropriate management of opioid use and patient satisfaction. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020.

Comment: Many commenters did not support removal of the Communication About Pain questions based on concerns that removal of the questions may minimize the importance of appropriate communication about pain management in the hospital setting. Specifically, a number of commenters stated that pain management is a critical part of routine patient care on which hospitals should focus and an important concern for patients, their families, and their caregivers, and expressed concern that removing the Communication About Pain questions may result in potential negative consequences for both patients and providers. We remain concerned, however, about the potential negative consequences resulting from retaining the Communication About Pain questions in the HCAHPS Survey, including confusion regarding the appropriate use of the questions. We believe these concerns, coupled with the severity and urgency of the nationwide opioid epidemic, warrant removing the Communication About Pain questions to relieve any potential pressure clinicians may feel to prescribe opioids in order to achieve higher scores on the HCAHPS Survey. By removing the Communication About Pain questions from the HCAHPS Survey, the Survey neither encourages nor discourages clinicians from communicating with their patients about their pain and how best to manage their pain as appropriate for the particular patient.

In addition, we disagree with commenters’ assertions that removal of the Communication About Pain questions might lead hospitals and providers to place less importance on communication about pain management, or might lead to a negative impact on appropriate pain treatment, including treatment for pain associated with complex chronic and end-of-life illnesses. As a number of commenters noted, pain management is an appropriate part of routine patient care upon which hospitals should focus and an important concern for patients, their families, and their caregivers, and we do not believe removal of the Communication About Pain questions will necessarily result in hospitals no longer focusing on maintaining a high level of performance. Rather, we remain confident that hospitals will continue to focus on appropriate pain management, including communicating with their patients about pain, as part of their commitment to the patient experience and ongoing quality improvement efforts. In addition, as one commenter noted, engaging patients in treatment decisions about their pain management is required under the enhanced pain assessment and management requirements, applicable to all Joint Commission-accredited hospitals, effective January 1, 2018.226

With respect to commenters’ requests that we not overlook the need to measure and evaluate the role of appropriate communication about pain management during a hospital stay, including legitimate pain management using opioids in addition to other pain management methods, we reiterate that we remain dedicated to improving the quality of care provided to patients, including patients’ experience in receiving care, and continue to consider the appropriate management of pain and communication between patients and their providers regarding pain as important aspects of care quality. As previously stated, we believe that removing the Communication About Pain questions will relieve any potential undue pressure on clinicians to prescribe opioids in order to achieve high patient satisfaction scores. We also believe that removing any such potential pressure on clinicians to prescribe opioids will ensure that providers can use their best judgment regarding pain management methods most appropriate for their patients, which may include non-opioid

---

225 More information about The Joint Commission’s new and revised pain assessment and management standards effective January 1, 2018 is available at: https://www.jointcommission.org/joint_commission_enhances_pain_assessment_and_management_requirements_for_accredited_hospitals.  
226 Ibid. The enhanced standards require that the hospital involves patients in the pain management treatment planning process through the following: Developing realistic expectations and measurable goals that are understood by the patient for the degree, duration, and reduction of pain; discussing the objectives used to evaluate treatment progress (for example, relief of pain and improved physical and psychosocial function); and providing education on pain management, treatment options, and safe use of opioid and non-opioid medications when prescribed. The enhanced standards also require, among other things, the hospital to analyze data collected on pain assessment and pain management to identify areas that need change to increase safety and quality for patients.
management methods. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020.

Finally, we disagree with commenters’ assertion that removing the Communication About Pain questions is tantamount to CMS’ refusal to acknowledge, or avoiding, the legitimate pain management needs of patients. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), we solicited feedback regarding suggestions for other measures that would capture facets of pain management and related patient education, for instance, for collecting data about a hospital’s pain management plan and providing that information back to consumers, and how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks of opioid use and about non-opioid pain management alternatives.

Numerous commenters responded to our requests for feedback, and we summarize these responses later in this discussion. We will take commenters’ suggestions into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement.

Comment: A number of commenters did not support removal of the Communication About Pain questions due to the lack of empirical evidence that the questions influence providers to prescribe opiates or demonstrating a link between patient experience scores and opiate prescribing. One commenter further asserted that the Communication About Pain survey questions do not put pressure on providers to prescribe opioids, but rather encourage providers to communicate about and address pain using multiple treatment methods.

Response: As previously stated, we are unaware of any empirical evidence demonstrating that failing to prescribe opioids lowers a hospital’s HCAHPS Survey scores. While we intended for the Communication About Pain questions to encourage providers to communicate with patients about pain management-related issues, including non-opioid pain management therapies (82 FR 38330), out of an abundance of caution, and in the face of a nationwide epidemic of opioid overprescription, we believe that removal of the Communication About Pain questions is warranted to resolve any perceived conflict between appropriate management of opioid use and patient satisfaction. Moreover, because the SUPPORT for Patients and Communities Act prohibits the inclusion of such questions in HCAHPS Surveys conducted on or after January 1, 2020, removal of the Communication About Pain questions is required. We believe that removing these questions will resolve any potential confusion by ensuring providers can use their best judgment in appropriately managing patients’ pain without any potential undue pressure stemming from fear of negative feedback on the HCAHPS Survey. We note that hospitals will continue to be required to administer the HCAHPS Survey comprised of the remaining 29 questions to eligible patients, and that hospital performance on HCAHPS Survey measures based on the remaining questions will continue to be publicly reported on Hospital Compare.

Comment: Some commenters opposed removal of the Communication About Pain questions because hospitals rely on the data for quality and performance improvement purposes. A few commenters asserted historical HCAHPS Survey data is one of the most effective tools hospitals have to improve patient experience of care. Some commenters noted that hospitals rely on HCAHPS Survey data to inform their quality and performance improvement efforts, including data from the Communication About Pain questions to assess how well they are discussing pain and communicating issues about pain management to patients. A few commenters noted that removal of the questions would force hospitals to rely on their vendors for any pain communication composite calculations or benchmarks for internal assessment purposes, as opposed to the national and State averages provided by CMS under the HCAHPS Survey. These commenters recommended that CMS furnish providers with important care experience metrics by making current pain communication scores, along with national and State benchmarks, available through confidential preview reports, from October 2019 onward. Commenters further requested CMS include these scores in CMS data files for providers’ benchmarking and analysis.

Response: We appreciate commenters’ feedback about their concerns, experiences using HCAHPS Survey data, and recommendations. We acknowledge that removal of the Communication About Pain questions will eliminate our ability to calculate State and national averages, but we believe the importance of removing any perceived pressure of opioid overprescribing justifies removal of the questions during the national opioid epidemic. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. As described above, we will provide each hospital with feedback on its own performance in confidential preview reports starting with four quarters of CY 2018 Communication About Pain question data, and then on a rolling four-quarter basis through the final quarter of CY 2019 Communication About Pain question data (that is, the 3rd quarter of 2019). These confidential reports will include State and national averages for the reporting periods when this measure is collected.

Comment: A number of commenters recommended that CMS retain the Communication About Pain questions in order to further investigate the relationship between these questions and opiate prescribing patterns, asserting that continuing data collection would enable CMS to make a data-driven decision to retain or remove the questions based on available evidence. A few commenters questioned removal of the Communication About Pain questions based on concerns that the Communication About Pain questions were only recently implemented in January 2018. These commenters recommended that CMS retain the Communication About Pain questions in order to engage a broad range of stakeholders and assess their feedback regarding the use and impact of the Communication About Pain questions on opioid prescribing practices, hospital quality improvement efforts, and patient care. Other commenters recommended convening Technical Expert Panels and a pilot study to better assess the implications of removing the pain questions on patient care before removing the Communication About Pain questions.

Response: We thank commenters for their recommendations to postpone removal of the Communication About Pain questions until additional analyses can be performed. While we agree delaying removal of these questions would increase the amount of data available to potentially assess the questions’ effect on physician prescription practices and the link between patient experience scores and opiate prescribing, we believe concerns regarding the potential negative consequences of retaining the questions and public health concerns about the epidemic outweigh the benefits of additional data collection. We believe the importance of removing any
perceived pressure of opioid overprescribing justifies removal of the questions during the national opioid epidemic. Moreover, the SUPPORT for Patients and Communities Act prohibits inclusion of the Communication About Pain questions in HCAHPS Surveys conducted on or after January 1, 2020. For these reasons, as discussed above, we are finalizing a modification of our proposal and are removing the Communication About Pain questions beginning with October 2019 discharges for the FY 2021 payment determination and subsequent years.

Comment: Many commenters who did not support removal of the Communication About Pain questions due to the importance of capturing pain management experience data also recommended that CMS delay public reporting on the questions beyond October 2020 to allow further time for additional assessment of the questions. A number of these commenters recommended that CMS continue to test the questions and delay public reporting until the questions are valid, reliable, and do not pose a risk of unintended consequences. A few commenters also supported delaying public reporting based on their concerns about the absence of any evidence demonstrating a relationship between the use of the Communication About Pain questions and opioid prescribing behavior.

Response: We thank commenters for their recommendations. We continue to believe the HCAHPS Survey as a whole, and the Communication About Pain questions, are valid and reliable measures of hospital quality that encourage hospitals to assess and improve patient experience. However, we believe that removing the Communication About Pain questions from the HCAHPS Survey during the national opioid epidemic will remove any perceived pressure of opioid overprescribing, and will address potential confusion about the appropriate use of the HCAHPS Survey. Therefore, as stated above, upon consideration of the comments received and public health concerns about the opioid epidemic, as well as to comply with the SUPPORT for Patients and Communities Act, we will not publicly report data collected from the Communication About Pain questions.

Comment: A number of commenters responded to CMS’ request for feedback in the proposed rule (83 FR 37220) regarding whether it would be valuable for CMS to issue guidance suggesting that hospitals do not administer any survey-related questions, including adding hospital-specific supplemental items to HCAHPS, as well as the potential implementation of a third-party quality assurance program to assure that hospitals are not misusing survey data by creating pressure on individual clinicians to provide inappropriate clinical care. A few commenters recommended that CMS consider issuing guidance to providers and hospitals regarding appropriate use of the HCAHPS Survey, specifically against the disaggregation of HCAHPS Survey data. These commenters stated their belief that clearer survey use guidance would mitigate inappropriate use of survey results, such as using disaggregated data to assess providers’ performance, to compare performance across providers or wards, and/or to influence provider performance by tying disaggregated survey results to individual clinician compensation. One commenter asserted that CMS guideline adherence works best when an HCAHPS Survey vendor provides hospitals and healthcare systems with clear communication and interpretation of those guidelines, and therefore recommended against implementation of an HCAHPS Survey-specific quality assurance program. This commenter recommended that CMS consider future implementation of a third-party quality assurance program for all CMS-mandated CAHPS surveys.

Other commenters recommended against CMS disallowing administration of supplemental pain management related questions alongside the HCAHPS Survey. These commenters noted pain remains one of the most important aspects of a patient’s experience of care, that hospitals rely on this survey-based information for research and evaluation regarding their quality and efficacy of care, and that disallowing these supplemental questions would effectively omit a critical care experience factor from hospitals’ quality improvement efforts.

Response: We thank the commenters for their feedback and will take these recommendations into consideration as we move forward with the HCAHPS Survey.

Comment: A number of commenters responded to CMS’ request for feedback regarding suggestions for other measures that would capture facets of pain management and related patient education, and that would provide that information back to consumers, as well as CMS’ request for feedback regarding how other measures could take into account provider-supplied information on appropriate pain management and whether patients are informed about the risks and use and about non-opioid pain management alternatives. Many commenters encouraged CMS to engage with stakeholders, including hospitals, clinicians, experts in pain management and palliative care, mesure developers, researchers, the NQF, and the Measure Applications Partnership (MAP) to explore a range of approaches to assessing how healthcare systems and hospitals are addressing pain management, including further revisions to the pain questions in HCAHPS Survey and the use of other measurement methods, including pain assessments that are more sensitive to beneficiaries’ needs.

Several commenters recommended that CMS engage in further research on the current version of the Communication About Pain questions, including assessing the potential tie between the questions and opioid prescribing practices. A few commenters provided specific recommendations for improving pain management assessment within the HCAHPS Survey. Some commenters recommended that CMS revise the current pain management questions to focus more on alternative pain management methods, such as ice packs and over-the-counter pain medication, and to better assess whether the patient was given sufficient guidance on how to manage pain post-discharge. Another commenter recommended that CMS develop new pain management questions focused on pain management processes and evidence-based standards of care rather than patient-reported outcomes. A third commenter recommended that CMS develop alternate questions assessing the role and behaviors of different clinicians in a patient’s pain management because the commenter believed these alternatives are more objective than the current Communication About Pain questions and would provide a better picture of the assessment and treatment undertaken by the clinician for the patient’s pain. Another commenter encouraged CMS to conduct additional research on pain-related survey questions and prescribing practices in emergency departments. One commenter recommended that CMS continue to collect the current Communication About Pain questions while evaluating potential new measures due to the importance of continuing to collect data on hospitals’ communication about pain management as a critical component of patient experience and because more time is needed to collect feedback on potential alternatives.

One commenter suggested CMS evaluate assessing communication about pain management within the context of specific care episodes because these
assessments could focus on the use of targeted pain management modalities, unlike the global HCAHPS Survey. This commenter further recommended that CMS focus on developing high-priority pain measures that can improve functional assessment scores with reduced opioid use. Another commenter recommended that CMS evaluate the use of patient-reported outcome measures to assess pain management and communication about pain because the commenter believed these types of measures would provide hospitals with valuable experience of care data relative to the investment required to update infrastructure and workflow investment. A third commenter expressed support for development of meaningful measures of pain management but urged caution about the potential for measures to create undue barriers to access to appropriate pain medication for patients suffering from chronic pain and therefore recommended that CMS strive to make measures more sensitive to patients’ disease state. Another commenter encouraged additional research and measure development specific to emergency department care and emergency nursing.

Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods. We will continue to consider unintended consequences of pain management assessment and we encourage hospitals to monitor the administration of opioids through programs that are tailored to the needs of the specific hospitals and patient populations. We do not anticipate that removing the Communication About Pain questions would impact the overall HCAHPS scores. We note that the data collected from the Communication About Pain questions will not be scored for purposes of CMS payments to hospitals, because the Hospital IQR Program is a pay-for-reporting not pay-for-performance quality program. Further, we note that the data from the Communication About Pain question will not be publicly reported. We believe that removing the Communication About Pain questions from the HCAHPS Survey out of an abundance of caution during the national opioid epidemic will help to address any potential confusion about the appropriate use of the HCAHPS Survey by relieving any potential pressure or undue influence on clinicians’ opioid prescribing practices. Commenters also recommended that CMS focus on mitigating any unintended consequences of pain management assessment before developing new measures, and further recommended against the adoption of measures that increase administrative burden and/or are not linked to improved outcomes. These commenters also recommended that CMS enable hospitals and physicians to monitor the administration of opioids and promote their evidence-based use through programs that are tailored to the needs of the hospital and its patient population. One commenter specifically recommended against development of pain management-specific measures because the commenter believes a set of measures designed to be applied universally would downplay critical factors that are necessary to create individualized pain management plans. One commenter requested a model of the impact of the removal of the Communication About Pain questions on overall HCAHPS scores and urged CMS to carefully balance the need to remove the questions with the need to retain an important component of patient experience.

Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods. We will continue to consider unintended consequences of pain management assessment and we encourage hospitals to monitor the administration of opioids through programs that are tailored to the needs of the specific hospitals and patient populations. We do not anticipate that removing the Communication About Pain questions would impact the overall HCAHPS scores.

Comment: A few commenters recommended that instead of removing the Communication About Pain questions, CMS consider incentivizing alternative pain management methods. Specifically, one commenter recommended that CMS consider alternate ways to ensure adequate patient awareness of non-opioid alternative treatments because the commenter believed that in the future there will be more ways to treat chronic and acute pain. Another commenter expressed the belief that there is a need for additional funding or other incentives to increase research supporting evidence-based practices around effective pain assessment and intervention and to develop operational guidelines and clinical practice standards for use in hospitals. A few commenters who supported both the importance of assessing patient experience, as well as of avoiding incentivizing inappropriate opioid prescribing, urged CMS to ensure that CMS does not adopt policies that could impede access to medication for patients who legitimately need opioids.

Response: We appreciate the feedback from commenters and will take these comments into consideration as we continue to consider how best to capture and assess facets of pain management through quality measurement, including the role of appropriate communication about pain during a hospital stay, informing patients about the risks associated with the use of opioids, and educating patients on non-opioid alternative pain management methods.

After consideration of the public comments we received, and as required by the SUPPORT for Patients and Communities Act, we are finalizing a modified version of our proposals regarding removal of the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing removing them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data from October 2020 until October 2022 and then subsequently discontinuing public reporting as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all.

XVII. Additional PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program Policies

A. Background

Section 1866(k)(1) of the Act requires that, for FY 2014 and each subsequent fiscal year, hospitals described in section 1886(d)(1)(B)(v) of the Act (referred to as “PPS-Exempt Cancer Hospitals” or “PCHs”) submit data to the Secretary in accordance with section 1866(k)(2) of the Act with respect to such fiscal year.
The PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program strives to put patients first by ensuring they, along with their clinicians, are empowered to make decisions about their own health care using data-driven insights that are increasingly aligned with meaningful quality measures. To this end, we support technology that reduces burden and allows clinicians to focus on providing high quality health care to their patients. We also support innovative approaches to improve the quality, accessibility, and affordability of care, while paying particular attention to improving clinicians’ and beneficiaries’ experiences when participating in CMS programs. In combination with other efforts across the Department of Health and Human Services (HHS), we believe the PCHQR Program incentivizes PCHs to improve their health care quality and value, while giving patients the tools and information needed to make the best decisions.

For additional background information, including previously finalized measures and other policies for the PCHQR Program, we refer readers to the following final rules: The FY 2013 IPPS/LTCH PPS final rule (77 FR 53556 through 53561); the FY 2014 IPPS/LTCH PPS final rule (76 FR 50838 through 50846); the FY 2015 IPPS/LTCH PPS final rule (79 FR 50277 through 50288); the FY 2016 IPPS/LTCH PPS final rule (80 FR 49713 through 49723); the FY 2017 IPPS/LTCH PPS final rule (81 FR 57182 through 57193); the FY 2018 IPPS/LTCH PPS final rule (82 FR 38411 through 38425); and the FY 2019 IPPS/LTCH PPS final rule (83 FR 41609 through 41624).

B. Retention of Two Safety Measures in the PCHQR Program

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41611 through 41616), we finalized the removal of four previously finalized measures and finalized one new quality measure for the FY 2021 program year and subsequent years. We also discussed our proposal in the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503) to remove two National Healthcare Safety Network (NHSN) chart-abstracted measures from the PCHQR Program beginning with the FY 2021 program year under proposed removal Factor 8, “the costs associated with the measure outweigh the benefit of its continued use in the program.”

The measures we had proposed to remove under this removal factor are:

- NHSN Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138);

We noted that we had first adopted the CAUTI and CLABSI measures for the FY 2014 program year in the FY 2013 IPPS/LTCH PPS final rule (77 FR 53557 through 53559), and we referred readers to that final rule for a detailed discussion of the measures. We also stated that we had proposed to remove these measures from the PCHQR Program based on our belief that removing these measures would reduce program costs and complexities associated with the use of these data by patients in decision-making. We also believed the costs, coupled with the high technical and administrative burden on PCHs associated with collecting and reporting this measure data, outweighed the benefits of the continued use of the CAUTI and CLABSI measures in the program. Further, we noted that it has become difficult to publicly report these measures due to the low volume of data produced and reported by the small number of facilities participating in the PCHQR Program and the corresponding lack of an appropriate methodology to publicly report these data.

We stated in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41613) that we had invited public comment on our proposals to remove the CAUTI and CLABSI measures from the PCHQR Program beginning with the FY 2021 program year. We also stated that we would defer making a final decision on the removal or retention of the CAUTI and CLABSI measures from the PCHQR Program in order to conduct additional data analyses to assess measure performance based on new information provided by the CDC which was not available at the time we had proposed the removal of these measures. Lastly, we stated that we wished to evaluate those data for trends that link positive improvements (that is, a decrease in the reporting burden and/or cost, and/or demonstrated feasibility for public reporting) to these measures. We also noted that we would reconcile the public comments we received in future rulemaking.

Comment: Many commenters supported the proposed removal of the CAUTI and CLABSI measures from the PCHQR Program. Commenters indicated that an appropriate statistical method to publicly report the data has not been identified and believed that these definitional and statistical issues may hamper the cancer hospitals’ ability to identify opportunities for internal performance improvement activities related to these measures. Commenters also noted that the low number of PCHs, the heterogeneous makeup of the hospitals, and the nationwide dispersion of the sites make it difficult to provide meaningful comparisons for consumers. Commenters supported CMS’ efforts in streamlining the PCHQR Program measure set, consistent with CMS’ commitment to using a smaller set of more meaningful measures and reducing paperwork and reporting burden on providers. Nevertheless, given the potential negative impact of health-care acquired infections (HAIs) in patients, particularly for the cancer patient population, commenters encouraged the CDC and CMS to continue to work collaboratively with professional societies to standardize definitions, reporting, and sharing of data to foster performance improvement in these areas.

Response: We thank the commenters for their support. We will continue to work collaboratively to standardize definitions, and to develop a sufficient reporting mechanism for quality metrics that assess the impact of HAIs on patients, particularly for the cancer patient population. However, for the reasons discussed in more detail below, we are not finalizing our proposals to remove the CAUTI and CLABSI measures from the PCHQR Program.

Comment: Some commenters did not support the proposed removal of the CAUTI and CLABSI measures from the PCHQR Program, asserting that the application of proposed removal Factor 8 was inadequate for measure removal because consumers’ needs have not been appropriately factored into the value assessment of the measures. Commenters specifically expressed concern that removing these measures might inappropriately deemphasize the importance of patient safety in quality care delivery. The commenters further questioned whether cost is the direct driving factor for the low volume of reporting on the CAUTI and CLABSI measures. Commenters also noted that because cancer hospitals will still be required to complete NHSN reporting for other measures, removal of the CAUTI and CLABSI measures would not necessarily lead to significant burden reduction. Lastly, commenters encouraged CMS to continue to work with the measures’ developer to consider alternative methodologies for publicly reporting the measure data.

Response: We thank the commenters for their feedback. We believe the primary benefit of a measure’s use in the PCHQR Program is to empower consumers through the provision of high quality care and providing publicly reported data
regarding the quality of care available for use in making decisions about their care. Therefore, we intend to consider the benefits, especially to patients and their families, when evaluating measures under measure removal Factor 8, which we finalized in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41609 through 41611). We emphasize that consumers’ needs and interests are factored into the value assessment of measures prior to any proposal to remove a measure from the PCHQR Program, and further note that we regularly solicit consumer feedback on the PCHQR Program via public comment periods and education and outreach activities, and that this feedback informs our policy development efforts.

At the time that we proposed to remove the CAUTI and CLABSI measures from the PCHQR Program, the available performance data did not enable us to assess PCH performance relative to oncology unit performance in other care settings. In addition, CDC’s previous analytic work used to develop the rebaselined predictive models had demonstrated that PCH status was not a significant predictor for either CAUTIs or CLABSIs. Since that time, we have conducted our own updated analyses regarding the continued use of the CAUTI and CLABSI measures in the PCHQR Program using updated CDC data. Although CDC had previously believed that oncology unit locations, including those in PCHs, had a higher incidence of infections than other types of units in acute care hospitals, CDC now believes, after controlling for location type, that oncology unit locations in PCHs do not have a higher incidence of infection than oncology units within other acute care hospitals. CDC’s updated analysis also produced a consistent finding that cancer hospital status was not a significant risk factor in any of the device-associated HAI risk models, including those used for CAUTI and CLABSI.227 We believe that these results indicate that reporting PCH CAUTI and CLABSI performance measure data is just as important as reporting acute care hospital CAUTI and CLABSI performance measure data.

We are aware that the CAUTI and CLABSI measures specifications were recently updated to use new standard infection ratio (SIR) calculations that can be applied to cancer hospitals, including PCHs. This SIR calculation method is different than the current CLABSI and CAUTI measure methodology, which provides raw location-stratified rates. We are also aware that there may be concern that the CAUTI and CLABSI data calculated under the current methodology may inaccurately appear to show lower performance among PCHs than the performance reported by acute care hospitals that are reporting CLABSI and CAUTI data under the newly updated methodology. We believe this recent update228 of the CAUTI and CLABSI measures addresses these concerns. Specifically, the updates include rates that are stratified by patient care locations within PCHs, and no predictive models or comparisons are used in these rate calculations. We intend to propose to adopt these updated versions of the CLABSI and CAUTI measures in future rulemaking but believe that, until that time, the importance of emphasizing patient safety in quality care delivery justifies retaining the current versions of the CLABSI and CAUTI measures in the PCHQR Program. Despite the fact that infection rates are not higher in the PCHs, we believe it is important to measure CLABSI and CAUTI in this setting. However, we will work closely with the CDC to update the assessed risk-adjusted versions of CAUTI and CLABSI, and evaluate the data provided in the form of SIRs for each PCH, for the purposes of future program implementation and public reporting.

After consideration of the public comments we received, and consideration of the most recent information provided by the CDC, we are not finalizing our proposals to remove the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–4/NQF #0138) and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–5/NQF #0139) from the PCHQR measures beginning with the FY 2021 program year. We agree with the conclusions drawn from the CDC’s data analyses, which demonstrate that reporting PCH CAUTI and CLABSI performance measure data is just as important as reporting acute care hospital CAUTI and CLABSI performance measure data. Further, we believe that these measures have the potential to provide beneficiaries with valuable information on PCH performance in avoiding hospital-acquired infections and improving patient safety. However, for the reasons discussed in section XVII.C.2. of this final rule with comment period, we are continuing to defer public reporting of these measure data.

We believe this approach most effectively balances the needs of the PCHQR Program and the importance of collecting patient safety data while taking into consideration the impact on the 11 PCHs of reporting raw data to CMS. We hope to introduce the refined CAUTI and CLABSI measures with adequate risk adjustment into the PCHQR Program in the near future. We note any such change will be made via rulemaking, and that we will solicit input from the Measures Application Partnership (MAP) to garner multi-stakeholder input on the updated versions prior to proposing to adopt these refined measures.

The table below summarizes the PCHQR Program measure set for the FY 2021 program year:

---


### FY 2021 PCHQR Program Measure Set

<table>
<thead>
<tr>
<th>Short Name</th>
<th>NQF Number</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Safety and Healthcare-Associated Infection (HAI)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAUTI</td>
<td>0138</td>
<td>National Healthcare Safety Network (NHSN) Catheter Associated Urinary Tract Infection (CAUTI) Outcome Measure</td>
</tr>
<tr>
<td>CLABSI</td>
<td>0139</td>
<td>National Healthcare Safety Network (NHSN) Central Line Associated Bloodstream Infection (CLABSI) Outcome Measure</td>
</tr>
<tr>
<td>Colon and Abdominal Hysterectomy SSI</td>
<td>0753</td>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes SSIs following Colon Surgery and Abdominal Hysterectomy Surgery]</td>
</tr>
<tr>
<td>CDI</td>
<td>1717</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset <em>Clostridium Difficile</em> Infection (CDI) Outcome Measure</td>
</tr>
<tr>
<td>MRSA</td>
<td>1716</td>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant <em>Staphylococcus Aureus</em> Bacteremia Outcome Measure</td>
</tr>
<tr>
<td>HCP</td>
<td>0431</td>
<td>National Healthcare Safety Network (NHSN) Influenza Vaccination Coverage Among Healthcare Personnel</td>
</tr>
<tr>
<td><strong>Clinical Process/Oncology Care Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N/A</td>
<td>0383</td>
<td>Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology</td>
</tr>
<tr>
<td>EOL-Chemo</td>
<td>0210</td>
<td>Proportion of Patients Who Died from Cancer Receiving Chemotherapy in the Last 14 Days of Life</td>
</tr>
<tr>
<td>EOL-Hospice</td>
<td>0215</td>
<td>Proportion of Patients Who Died from Cancer Not Admitted to Hospice</td>
</tr>
<tr>
<td><strong>Intermediate Clinical Outcome Measures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EOL-ICU</td>
<td>0213</td>
<td>Proportion of Patients Who Died from Cancer Admitted to the ICU in the Last 30 Days of Life</td>
</tr>
<tr>
<td>EOL-3DH</td>
<td>0216</td>
<td>Proportion of Patients Who Died from Cancer Admitted to Hospice for Less Than Three Days</td>
</tr>
<tr>
<td><strong>Patient Engagement/Experience of Care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCAHPS</td>
<td>0166</td>
<td>HCAHPS</td>
</tr>
<tr>
<td><strong>Clinical Effectiveness Measure</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EBRT</td>
<td>1822</td>
<td>External Beam Radiotherapy for Bone Metastases</td>
</tr>
</tbody>
</table>
**Claims Based Outcome Measures**

<table>
<thead>
<tr>
<th>Short Name</th>
<th>NQF Number</th>
<th>Measure Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
<td>N/A</td>
<td>Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy</td>
</tr>
<tr>
<td>N/A*</td>
<td>3188</td>
<td>30-Day Unplanned Readmissions for Cancer Patients</td>
</tr>
</tbody>
</table>

* Measure finalized for adoption for the FY 2021 program year and subsequent years.

---

**BILLING CODE 4120–01–C**

**C. Continued Deferment of Public Display of the NHSN Measures**

1. **Background**

   Under section 1866(k)(4) of the Act, we are required to establish procedures for making the data submitted under the PCHQR Program available to the public. Such procedures must ensure that a PCH has the opportunity to review the data that are to be made public with respect to the PCH prior to such data being made public. Section 1866(k)(4) of the Act also provides that the Secretary must report quality measures of process, structure, outcome, patients’ perspective on care, efficiency, and costs of care that relate to services furnished in such hospitals on the CMS website.


   In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41622), we indicated that all PCHs are reporting Colon and Abdominal Hysterectomy SSI, MRSA, CDI, and HCP data to the NHSN under the PCHQR Program. In 2016, the CDC announced that HAI data reported to NHSN for 2015 will be used as the new baseline, serving as a new “reference point” for comparing progress. The results of the rebaselining allow for year-to-year comparisons beginning with 2015 data; beginning with FY 2019, we will have more than 2 years of comparable data available for evaluation. We are currently still evaluating the data resulting from the rebaselining to properly assess trends. Therefore, in that final rule (83 FR 41622), we finalized a modification of our proposal to delay public reporting of data for the SSI, MRSA, CDI, and HCP measures until CY 2019. Based on stakeholder feedback, we finalized a policy to provide stakeholders with performance data as soon as practicable (that is, if useable data is available sooner than CY 2019, we will publicly report it on the Hospital Compare website via the next available Hospital Compare release).

   As discussed above, we are not finalizing our proposal to remove the CAUTI and CLABSI measures. However, we will continue to defer public reporting for the CAUTI and CLABSI measures. However, we will continue to defer public reporting for the CAUTI and CLABSI measures as indicated in the FY 2018 IPPS/LTCH PPS final rule (82 FR 38423). Based on our intent to propose to adopt the revised versions of the measures in the PCQHR Program in future rulemaking, we are continuing to evaluate the performance data for the updated versions of the CAUTI and CLABSI measures to draw conclusions about their statistical significance, in accordance with current risk adjustment methods defined by CDC. For these reasons, we are finalizing that we will provide stakeholders with performance data for the CAUTI and CLABSI measures as soon as practicable.

3. **Update on Public Display of the Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy Measure**

   In the FY 2017 IPPS/LTCH PPS final rule (81 FR 57187 through 57188), we stated that we would publicly report the risk-standardized admission rate (RSAR) and risk-standardized ED visit rate (RSEDR) for the Admissions and Emergency Department (ED) Visits for the Patients Receiving Outpatient Chemotherapy measure for all participating PCHs with 25 or more eligible patients per measurement period to maintain a reliability of at least 0.4 (as measured by the interclass correlation coefficient, (ICC)). We also noted that if a PCH did not meet the 25-eligible patient threshold, we would include a footnote on the Hospital Compare website indicating that the number of cases is too small to reliably measure that PCH’s rate, but that these patients and PCHs would still be included when calculating the national rates for both the RSAR and RSEDR. Lastly, we indicated that to prepare PCHs for public reporting, we would conduct a confidential national reporting (dry run) of measure results prior to public reporting.

   We recently completed the confidential national reporting (dry run) for this measure and are currently assessing the results to ensure data accuracy and completeness. We intend to propose a timeframe for public reporting of this measure in the FY 2020 IPPS/LTCH PPS proposed rule.

4. **Summary of Public Display Requirements for the FY 2021 Program Year**

   Our public display policies for the FY 2021 program year are shown in the following table:

---


Summary of Public Display Requirements

<table>
<thead>
<tr>
<th>Measures</th>
<th>Public Reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCAHPS (NQF #0166)</td>
<td>2016 and subsequent years</td>
</tr>
<tr>
<td>Oncology: Plan of Care for Pain – Medical Oncology and Radiation Oncology (NQF #0383)</td>
<td></td>
</tr>
<tr>
<td>External Beam Radiotherapy for Bone Metastases (EBRT) (NQF #1822)</td>
<td>2017 and subsequent years</td>
</tr>
<tr>
<td>American College of Surgeons – Centers for Disease Control and Prevention (ACS-CDC) Harmonized Procedure Specific Surgical Site Infection (SSI) Outcome Measure [currently includes SSIs following Colon Surgery and Abdominal Hysterectomy Surgery] (NQF #0753)</td>
<td>As soon as practicable</td>
</tr>
<tr>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus Bacteremia Outcome Measure (NQF #1716)</td>
<td></td>
</tr>
<tr>
<td>National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717)</td>
<td></td>
</tr>
<tr>
<td>National Healthcare Safety Network (NHSN) Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431)</td>
<td></td>
</tr>
<tr>
<td>CLABSI (NQF #0139)</td>
<td>Deferred</td>
</tr>
<tr>
<td>CAUTI (NQF #0138)</td>
<td></td>
</tr>
</tbody>
</table>

XVIII. Files Available to the Public via the Internet

The Addenda to the OPPS/ASC proposed rules and the final rules with comment period are published and available via the internet on the CMS website. In the CY 2019 OPPS/ASC proposed rule (83 FR 37220), for CY 2019, we proposed to change the format of the OPPS Addenda A, B, and C, by adding a column entitled "Copayment Capped at the Inpatient Deductible of $1,364.00" where we would flag, through use of an asterisk, those items and services with a copayment that is equal to or greater than the inpatient hospital deductible amount for any given year for which the copayment will be capped at the inpatient deductible amount.

To view the Addenda to this final rule with comment period pertaining to CY 2019 payments under the OPPS, we refer readers to the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Hospital-Outpatient-Regulations-and-Notices.html; select "1695–FC" from the list of regulations. All ASC Addenda to this final rule with comment period are contained in the zipped folders entitled “Addendum AA, BB, DD1, DD2, and EE.”

XIX. Collection of Information Requirements

A. Statutory Requirement for Solicitation of Comments

Under the Paperwork Reduction Act of 1995, we are required to provide 60-day notice in the Federal Register and solicit public comment before a collection of information requirement is submitted to the Office of Management and Budget (OMB) for review and approval. In order to fairly evaluate whether an information collection should be approved by OMB, section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 requires that we solicit comment on the following issues:

- The need for the information collection and its usefulness in carrying out the proper functions of our agency.
- The accuracy of our estimate of the information collection burden.
- The quality, utility, and clarity of the information to be collected.

“Copayment Capped at the Inpatient Deductible of $1,364.00” where we flag, through use of an asterisk, those items and services with a copayment that is equal to or greater than the inpatient hospital deductible amount for any given year for which the copayment will be capped at the inpatient deductible amount.

"1695–FC" from the list of regulations. All ASC Addenda to this final rule with comment period are contained in the zipped folders entitled “Addendum AA, BB, DD1, DD2, and EE.”
• Recommendations to minimize the information collection burden on the affected public, including automated collection techniques.

In the CY 2019 OPPS/ASC proposed rule (83 FR 37720), we solicited public comment on each of these issues for the following sections of this document that contain information collection requirements (ICRs).

B. ICRs for the Hospital OQR Program

1. Background

The Hospital OQR Program is generally aligned with the CMS quality reporting program for hospital inpatient services known as the Hospital IQR Program. We refer readers to the CY 2011 through CY 2018 OPPS/ASC final rules with comment periods (75 FR 72114 through 72119; 76 FR 74549 through 74554; 77 FR 68527 through 68532; 78 FR 75170 through 75172; 79 FR 67012 through 67015; 80 FR 70580 through 70582; 81 FR 79862 through 79863; and 82 FR 59476 through 59479) respectively) for detailed discussions of the Hospital OQR Program information collection requirements we have previously finalized. The information collection requirements associated with the Hospital OQR Program are currently approved under OMB control number 0938–1109. Below we discuss only the changes in burden that will result from the newly finalized policies in this final rule with comment period.

In section XIII.B.4.b. of the proposed rule, we proposed to remove a total of 10 measures. Specifically, beginning with the CY 2020 payment determination, we proposed to remove: (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel; and beginning with the CY 2021 payment determination, we proposed to remove: (2) OP–5: Median Time to ECG; (3) OP–9: Mammography Follow-up Rates; (4) OP–11: Thorax CT Use of Contrast Material; (5) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (6) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; (7) OP–17: Tracking Clinical Results between Visits; (8) OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; (9) OP–30: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use; and (10) OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. However, after consideration of public comments we received, in this final rule with comment period we are not finalizing our proposals to remove these two measures: OP–29: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery beginning with the CY 2021 payment determination. The reduction in burden associated with our finalized policies is discussed below in sections XIX.B.3. and 4. of this final rule with comment period.

In section XIII.D.2. of this final rule with comment period, we are finalizing our proposal to update the frequency with which we will release HOPD Specifications Manuals, with modification, such that instead of releasing the full manual once or twice a year, as proposed, we would release specifications manuals every 12 months beginning with CY 2019 and for subsequent years and release addenda (specific updates rather than full manual releases) as necessary. In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are finalizing our proposal to remove the Notice of Participation (NOP) Form Requirement for the Hospital OQR Program and to update 42 CFR 419.46(a) to reflect these policies. As discussed below, we do not expect these finalized policies to affect our collection of information burden estimates.

2. Update to the Frequency of Releasing Hospital Outpatient Quality Reporting Specifications Manuals Beginning With CY 2019 and for Subsequent Years

In section XIII.D.2. of this final rule with comment period, we are finalizing our proposal, with modification, to update the frequency with which we will release Hospital Outpatient Quality Reporting Specifications Manuals, with modification such that instead of releasing the full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. We anticipate that this change will reduce hospital confusion, as releasing fewer manuals per year reduces the need to review updates as frequently as was previously necessary. However, because this change does not affect Hospital OQR Program participation requirements or data reporting requirements, we do not expect a change in the information collection burden experienced by hospitals.

3. Estimated Burden of Hospital OQR Program Newly Finalized Policies for the CY 2020 Payment Determination and Subsequent Years

a. Removal of the Notice of Participation (NOP) Form Requirement

In section XIII.C.2.b. of this final rule with comment period, beginning with the CY 2020 payment determination, we are finalizing our proposal to remove the NOP form as a requirement. As a result, to be a participant in the Hospital OQR Program, hospitals will need to: (1) Register on the QualityNet website; (2) identify and register a QualityNet security administrator, and (3) submit data. In addition, we are finalizing our proposal to update 42 CFR 419.46(a) to reflect these policies. We have previously estimated in the CY 2014 OPPS/ASC final rule with comment period (78 FR 75171) that the burden associated with administrative requirements including completing program requirements, system requirements, and managing facility operations is 42 hours per hospital or 138,600 hours across 3,300 hospitals. We believe that removal of the NOP requirement will reduce administrative burden experienced by hospitals by only a nominal amount, as it is not required every year, but only at the start of a hospital’s participation. As a result, this finalized policy does not influence our information collection burden estimates.

b. Removal of OP–27 for the CY 2020 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposal to remove the OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) measure beginning with the CY 2020 payment determination and for subsequent years. The burden associated with OP–27, a National Healthcare Safety Network (NHSN) measure, is accounted for under a separate information collection request, OMB control number 0920–0666. Because burden associated with submitting data for this measure is captured under a separate OMB control number, we are not providing an estimate of the information collection burden associated with this measure for the Hospital OQR Program.
4. Estimated Burden of Hospital OQR Program Newly Finalized Policies for the CY 2021 Payment Determination and Subsequent Years

a. Removal of Chart-Abstracted Measures for the CY 2021 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposal to remove one chart-abstracted measure for the CY 2021 payment determination and subsequent years: OP–5: Median Time to ECG. With regard to chart-abstracted measures for which patient-level data is submitted directly to CMS, we have previously estimated it would take 2.9 minutes, or 0.049 hours, per measure to collect and submit the data for each submitted case (80 FR 70582). In addition, based on the most recent data, we estimate that 947 cases are reported per hospital for chart-abstracted measures. Therefore, we estimate that it will take approximately 46 hours (0.049 hours × 947 cases) to collect and report data for each chart-abstracted measure. Accordingly, we believe that the removal of this chart-abstracted measure for the CY 2021 payment determination will reduce burden by 151,800 hours (46 hours × 3,300 hospitals) and $5.6 million (151,800 hours × $36.58).

b. Removal of Measures Submitted Via a Web-Based Tool for the CY 2021 Payment Determination and Subsequent Years

While we proposed to remove five measures submitted via a web-based tool beginning with the CY 2021 payment determination and for subsequent years, in section XIII.B.4.b. of this final rule with comment period, we are only finalizing our proposals to remove three measures: (1) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (2) OP–17: Tracking Clinical Results between Visits; and (3) OP–30: Endoscopy/Polyph Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. In section XIII.B.4.b. of this final rule with comment period, we are not finalizing our proposals to remove the following web-based measures for the CY 2021 payment determination and subsequent years: OP–29: Endoscopy/Polyph Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. Therefore, we are revising the initially estimated burden reduction from the CY 2019 OPPS/ASC proposed rule.

As we stated in the CY 2016 OPPS/ASC final rule with comment period (80 FR 70582), we estimate that hospitals spend approximately 10 minutes, or 0.167 hours, per measure to report web-based measures. Accordingly, we believe that the removal of OP–12, OP–17, and OP–30 for the CY 2021 payment determination will reduce burden by 0.501 hours per hospital (3 measures × 0.167 hours per measure) and 1,653 hours (0.501 hours × 3,300 hospitals) across 3,300 hospitals. In addition, we estimate that OP–30 requires 25 additional minutes (0.417 hours) per case per measure to chart-abstract and that hospitals would each abstract 384 cases per year for this measure. This number is based on previous analysis (78 FR 75171) where we estimated that each of the approximately 3,300 responding hospitals will have a case volume adequate to support quarterly sample sizes of 96 cases, for a total of 384 cases (96 cases per quarter × 4 quarters) to be abstracted by each hospital annually. Therefore, we estimate an additional burden reduction of 528,422 hours (3,300 hospitals × 0.417 hours × 384 cases per measure) for all participating hospitals for OP–30. In total, we estimate a burden reduction of 530,075 hours (1,653 hours for web submission + 528,422 hours for chart-abstractation of OP–30) and $19.4 million (530,075 hours × $36.58) due to the removal of three web-based measures.

c. Removal of Claims-Based Measures for the CY 2021 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposals to remove three claims-based measures beginning with the CY 2021 payment determination: OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT. Claims-based measures are derived through analysis of administrative claims data and do not require additional effort or burden on hospitals. As a result, we do not expect these removals to affect collection of information burden for the CY 2021 payment determination.

In total for the CY 2021 payment determination, we expect the information collection burden will be reduced by 151,800 hours due to the removal of one chart-abstracted measure, and 530,075 hours due to the removal of three measures submitted via a web-based tool. In total, we estimate an information collection burden reduction of 681,875 hours (151,800 hours for the removal of one chart-abstracted measure + 530,075 hours for the removal of three web-based measures) and $24.9 million (681,875 hours × $36.58) for the CY 2021 payment determination.

C. ICRs for the ASCQR Program

1. Background

We refer readers to the CY 2012 OPPS/ASC final rule with comment period (76 FR 74554), the FY 2013 IPPS/ LTCH PPS final rule (77 FR 53672), and the CY 2013, CY 2014, CY 2015, CY 2016, CY 2017, and CY 2018 OPPS/ASC final rules with comment period (77 FR 68532 through 68533; 78 FR 75172 through 75174; 79 FR 67015 through 67016; 80 FR 70582 through 70584; 81 FR 79863 through 79865; and 82 FR 59479 through 59481, respectively) for detailed discussions of the ASCQR Program information collection requirements we have previously finalized. The information collection requirements associated with the ASCQR Program are currently approved under OMB control number 0938–1270. Below we discuss only the changes in burden that would result from the newly finalized provisions in this final rule with comment period.

While we proposed to remove eight measures, in section XIV.B.3.c. of this final rule with comment period, we are only finalizing the removal of two measures: One measure beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel, and one measure beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polyph Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. We expect these finalized policies will reduce the overall burden of reporting data for the ASCQR Program, as discussed below. In section XIV.B.3.c. of this final rule with comment period, we are not finalizing our proposal to remove ASC–9: Endoscopy/Polyph...
Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients beginning with the CY 2021 payment determination and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures.

2. Estimated Burden of ASCQR Program Newly Finalized Policy Beginning With CY 2020 Payment Determination and Subsequent Years: Removal of ASC–8

In section XIV.B.3.c. of this final rule with comment period, we are finalizing the removal of one measure beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel. Data for ASC–8 are submitted via a non-CMS online data submission tool, to the NHSN. However, we note that the information collection burden associated with ASC–8, a NHSN measure, is accounted for under a separate information collection request, OMB control number 0920–0666. As such, we are not providing an estimate of the information collection burden associated with this measure under the ASCQR Program OMB control number.

3. Estimated Burden of ASCQR Program Newly Finalized Measure Removals for the CY 2021 Payment Determination

While we proposed to remove seven measures beginning with the CY 2021 payment determination, in section XIV.B.3.c. of this final rule with comment period, we are only finalizing our proposal to remove one measure: ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. In section XIV.B.3.c. of this final rule with comment period we are not finalizing our proposals to remove ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn: ASC–2: Patient Fall: ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures.

The reduction in information collection burden associated with these requirements is available for review and comment under OMB control number 0938–1270.

D. ICRs for the Update to the HCAHPS Survey Measure in the Hospital IQR Program

As described in section XVI. of this final rule with comment period, we are finalizing a modified version of our proposals regarding the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing to remove them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data in October 2022 and then subsequently discontinuing as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all.

While we anticipate that the removal of these questions will reduce the burden associated with reporting this measure, as further discussed below, the burden estimate for the Hospital IQR Program excludes the burden associated with the HCAHPS Survey measure, which is submitted under a separate information collection request and approved under OMB control number 0938–0981. For discussion of the burden estimate specifically for the HCAHPS Survey, including use of the Communication About Pain questions, we refer readers to the notice published in the Federal Register on Information Collection for the National Implementation of the Hospital CAHPS Survey (83 FR 21296 through 21297). We note that a revised information collection request under OMB control number 0938–0981 will be submitted to OMB based on the update to the HCAHPS Survey in accordance with this final rule with comment period.

As noted above, the removal of the Communication About Pain questions does not change the estimated burden for the Hospital IQR Program under the program’s OMB control number 0938–1022. However, we believe that overall cost and burden will change slightly for hospitals and HCAHPS Survey respondents. Under HCAHPS Survey
OMB control number 0938–0981, it is estimated that the average cost and hour burdens for hospitals are $4,000 and 1 hour per hospital for HCAHPS data collection activities. Because these estimates include administrative activities and overhead costs, we believe our removal of the Communication About Pain questions from the HCAHPS Survey will not reduce these estimates of hospital burden or will only nominally and temporarily increase the average cost and hour burdens associated with the removal of these questions from the survey, given the need to adjust the survey instrument and instructional materials and, therefore, marginally reduce the burden due to the shortening of the survey instrument.

Under HCAHPS Survey OMB control number 0938–0981, the average time for a respondent to answer the 32 question survey is estimated at 8 minutes, which we estimate to be 0.25 minutes per question (8 minutes/32 questions = 0.25 minutes per question). In addition, under this OMB control number, the number of respondents is estimated at 3,104,200 respondents. In this final rule with comment period, we are finalizing a modified version of our proposal to remove 3 questions, which we estimate would reduce the time burden by 0.75 minutes (0.25 minutes per question × 3 questions), or 0.0125 hours (0.75 minutes/60 minutes) per respondent. We anticipate a total hourly burden reduction for respondents of 38,803 hours (0.0125 hours × 3,104,200 respondents). Further, under OMB control number 0938–0981, the cost of respondent time is based on the average hourly earnings of $26.71 per hour as reported by the U.S. Bureau of Labor Statistics final January 2018 estimates available on the website at: https://www.bls.gov/eag/eag.us.htm. We anticipate a total cost reduction for respondents associated with the proposal to remove the three Communication About Pain questions of $1,036,428 (38,803 total hours × respondent earnings estimate of $26.71 per hour) for the FY 2021 payment determination.

**E. ICRs for PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program for the FY 2021 Program Year**

In the FY 2019 IPPS/LTCH PPS proposed rule (83 FR 20503), we proposed to remove two NHSN measures, Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138) and Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/NQF #0139), from the PCHQR Program beginning with the FY 2021 program year. In section VII.B.3.b.(2) of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41613), we indicated that we would take final action regarding our proposals to remove the CAUTI and CLABSI measures in a future 2018 final rule. In section XVII. of this final rule with comment period, after consideration of the public comments received, and consideration of the most recent information provided by the CDC, we are not finalizing our proposals to remove the CAUTI and CLABSI measures. We note that this CDC information was not available at the time when we proposed the removal of these measures from the PCHQR Program.

In the FY 2019 IPPS/LTCH PPS final rule (83 FR 41695) we reconciled the burden estimates associated with the NHSN measures (CLABSI, CAUTI, CDI, HCP, MRSA and Colon and Abdominal Hysterectomy SSI) included in the PCHQR Program, which were formerly accounted for under both the PCHQR Program’s estimates OMB control number 0938–1175 and the CDC’s estimates under OMB control number 0920–0666. Because the CDC maintains the NHSN system used to collect this data and captures the burden associated with this data collection under its estimates in OMB control number 0920–0666, we removed the duplicative burden estimate from the PCHQR Program’s OMB Control Number, 0938–1175. As a result, there is no change in burden under the PCHQR Program associated with not finalizing removal of the CLABSI and CAUTI measures.

In summary, our decisions not to remove the CAUTI and CLABSI measures in the PCHQR Program for FY 2021 program year and subsequent years does not change the information collection estimates for the PCHQR Program. We refer readers to section XIV.B.4 of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41694 through 41695) for more detail on the information collection calculations for the finalized policies in the PCHQR Program.

**F. Total Reduction in Burden Hours and in Costs**

Below is a chart reflecting the total burden and associated costs for the provisions included in this final rule with comment period.
XX. Response to Comments

Because of the large number of public comments we normally receive on Federal Register documents, we are not able to acknowledge or respond to them individually. We will consider all comments we receive by the date and time specified in the DATES section of this final rule with comment period, and, when we proceed with a subsequent document(s), we will respond to those comments in the preamble to that document.

XXI. Economic Analyses

A. Statement of Need

This final rule with comment period is necessary to make updates to the Medicare hospital OPPS rates. It is necessary to make changes to the payment policies and rates for outpatient services furnished by hospitals and CMHCs in CY 2019. We are required under section 1833(t)(3)(C)(ii) of the Act to update annually the OPPS conversion factor used to determine the payment rates for APCs. We also are required under section 1833(t)(9)(A) of the Act to review, not less often than annually, and revise the groups, the relative payment weights, and the wage and other adjustments described in section 1833(t)(2) of the Act. We must review the clinical integrity of payment groups and relative payment weights at least annually. We are revising the APC relative payment weights using claims data for services furnished on and after January 1, 2017, through and including December 31, 2017, and processed through June 30, 2018, and updated cost report information.

We note that we are finalizing our proposal to control unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at off-campus PBDs at an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate). The site-specific PFS payment rate for clinic visits furnished in excepted off-campus PBDs is the OPPS rate reduced to the amount paid for clinic visits furnished by nonexcepted off-campus PBDs under the PFS, which is 40 percent of the OPPS rate. We expect that, by removing the payment differential, we will control unnecessary volume increases both in terms of the number of covered outpatient services furnished and the costs of those services. We are implementing this policy with a 2-year phase-in. In CY 2019, the payment reduction will be transitioned by applying 50 percent of the total reduction in payment that would apply if these off-campus PBDs were paid the site-specific PFS payment rate for the clinic visit service. In other words, these excepted off-campus PBDs will be paid 70 percent of the OPPS rate for the clinic visit service in CY 2019. In CY 2020, we will complete the transition to paying the PFS-equivalent amount for clinic visits furnished in excepted off-campus PBDs. In other words, these excepted off-campus PBDs will be paid 40 percent of the OPPS rate for the clinic visit service in CY 2020.

This final rule with comment period also is necessary to make updates to the ASC payment rates for CY 2019, enabling CMS to make changes to payment policies and payment rates for covered surgical procedures and covered ancillary services that are performed in an ASC in CY 2019. Because ASC payment rates are based on the OPPS relative payment weights for most of the procedures performed in ASCs, the ASC payment rates are updated annually to reflect annual changes to the OPPS relative payment weights. In addition, we are required under section 1833(i)(1) of the Act to review and update the list of surgical procedures that can be performed in an ASC, not less frequently than every 2 years.

For CYs 2019 through 2023, we are finalizing our proposal to update the ASC payment system rates using the hospital market basket update instead of the CPI–U. We believe that this finalized proposal could stabilize the differential between OPPS payments and ASC payments, given that the CPI–U has been generally lower than the hospital market basket, and encourage the

<table>
<thead>
<tr>
<th>Information Collection Requests</th>
<th>Burden Hours Increase/Decrease (-)*</th>
<th>Cost (+/-)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital Outpatient Quality Reporting Program</td>
<td>- 681,875</td>
<td>- $24.9 million</td>
</tr>
<tr>
<td>Ambulatory Surgical Center Quality Reporting Program</td>
<td>- 62,008</td>
<td>- $2.3 million</td>
</tr>
<tr>
<td>Hospital Inpatient Reporting Program – Update to the HCAHPS Survey Measure¹</td>
<td>- 38,803 hours</td>
<td>- $1 million</td>
</tr>
<tr>
<td>PPS-Exempt Center Hospital Quality Reporting Program – Additional Policies²</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>- 782,686 hours</td>
<td>- $28.2 million</td>
</tr>
</tbody>
</table>

* Numbers rounded.

¹ We note that the burden estimate for the Hospital IQR Program excludes the burden associated with the HCAHPS Survey measure, which is submitted under a separate information collection request and approved under OMB control number 0938–0981.

² There is no change in burden associated with not finalizing removal of the CLABSI and CAUTI measures from the PCHQR Program.

---

Federal Register / Vol. 83, No. 225 / Wednesday, November 21, 2018 / Rules and Regulations 59159
B. Overall Impact for Provisions of This Final Rule With Comment Period

We have examined the impacts of this final rule with comment period, as required by Executive Order 12866 on Regulatory Planning and Review (September 30, 1993), Executive Order 13563 on Improving Regulation and Regulatory Review (January 18, 2011), the Regulatory Flexibility Act (RFA) (September 19, 1980, Pub. L. 96–354), section 1102(b) of the Social Security Act, section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) (March 22, 1995, Pub. L. 104–4), Executive Order 13132 on Federalism (August 4, 1999), the Congressional Review Act (5 U.S.C. 804(2)), and Executive Order 13771 on Reducing Regulation and Controlling Regulatory Costs (January 30, 2017). This section of this final rule with comment period contains the impact and other economic analyses for the provisions we are finalizing for CY 2019.

Executive Orders 12866 and 13563 direct agencies to assess all costs and benefits of available regulatory alternatives and, if regulation is necessary, to select regulatory approaches that maximize net benefits (including potential economic, environmental, public health and safety effects, distributive impacts, and equity). Executive Order 13563 emphasizes the importance of quantifying both costs and benefits, of reducing costs, of harmonizing rules, and of promoting flexibility. This final rule with comment period has been designated as an economically significant rule under section 3(f)(1) of Executive Order 12866 and a major rule under the Congressional Review Act. Accordingly, this final rule with comment period has been reviewed by the Office of Management and Budget. We have prepared a regulatory impact analysis that, to the best of our ability, presents the costs and benefits of the provisions of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37224), we solicited public comments on the regulatory impact analysis in the proposed rule, and we address any public comments we received in this final rule with comment period, as appropriate.

We estimate that the total increase in Federal government expenditures under the OPPS for CY 2019, compared to CY 2018, due only to the changes to the OPPS included in this final rule with comment period, will be approximately $440 million. Taking into account our estimated changes in enrollment, utilization, and case-mix for CY 2019, we estimate that the OPPS expenditures, including beneficiary cost-sharing, for CY 2019 will be approximately $74.1 billion; approximately $5.8 billion higher than estimated OPPS expenditures in CY 2018. We note that these spending estimates include the final CY 2019 final policy to control for unnecessary increases in the volume of covered outpatient department services by paying for clinic visits furnished at accepted off-campus PBPs at a rate that will be 70 percent of the OPPS rate for a clinic visit service. Because the provisions of the OPPS are part of a final rule that is economically significant, as measured by the threshold of an additional $100 million in expenditures in 1 year, we have prepared this regulatory impact analysis that, to the best of our ability, presents its costs and benefits. Table 62 of this final rule with comment period displays the distributional impact of the CY 2019 changes in OPPS payment to various groups of hospitals and for CMHCs. We estimate that the update to the wage indexes, the continuation of a State wage adjustment for CY 2019, and the implementation of the program to control unnecessary increases in the volume of outpatient services as described in section X.B. of this final rule with comment period, due in addition to the application of the OPD fee schedule increase factor after all adjustments required by sections 1833(t)(3)(F), 1833(t)(3)(G), and 1833(t)(17) of the Act, will increase total estimated OPPS payments by 0.6 percent.

We estimate the total increase (from changes to the ASC provisions in this final rule with comment period as well as from enrollment, utilization, and case-mix changes) in Medicare expenditures (not including beneficiary cost-sharing) under the ASC payment system for CY 2019 compared to CY 2018 to be approximately $200 million. Because the provisions for the ASC payment system are part of a final rule that is economically significant, as measured by the $100 million threshold, we have prepared a regulatory impact analysis of the changes to the ASC payment system that, to the best of our ability, presents the costs and benefits of this portion of this final rule with comment period. Tables 63 and 64 of this final rule with comment period display the redistributive impact of the CY 2019 changes regarding ASC payments, grouped by specialty area and then grouped by procedures with the greatest ASC expenditures, respectively.

C. Detailed Economic Analyses

1. Estimated Effects of OPPS Changes in This Final Rule With Comment Period

a. Limitations of Our Analysis

The distributional impacts presented here are the projected effects of the CY 2019 policy changes on various hospital groups. We post on the CMS website our hospital-specific estimated payments for CY 2019 with the other supporting documentation for this final rule with comment period. To view the hospital-specific estimates, we refer readers to the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/index.html. At the website, select “regulations and notices” from the left side of the page and then select “CMS-1695-FC” from the list of regulations and notices. The hospital-specific file layout and the
hospital-specific file are listed with the other supporting documentation for this final rule with comment period. We show hospital-specific data only for hospitals whose claims were used for modeling the impacts shown in Table 62 below. We do not show hospital-specific impacts for hospitals whose claims we were unable to use. We refer readers to section II.A. of this final rule with comment period for a discussion of the hospitals whose claims we do not use for ratesetting and impact purposes.

We estimate the effects of the individual policy changes by estimating payments per service, while holding all other payment policies constant. We use the best data available, but do not attempt to predict behavioral responses to our policy changes in order to isolate the effects associated with specific policies or updates, but any policy that changes payment could have a behavioral response. In addition, we have not made adjustments for future changes in variables, such as service volume, service-mix, or number of encounters.

b. Estimated Effects of the Finalized Proposal To Control for Unnecessary Increases in the Volume of Outpatient Services

In section X.B. of this final rule with comment period, we discuss our CY 2019 finalized proposal to control for unnecessary increases in the volume of outpatient department services by paying for clinic visits furnished at an off-campus PBD at an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate).

Specifically, we are finalizing our proposal to pay for HCPCS code G0463 (Hospital outpatient clinic visit for assessment and management of a patient) when billed with modifier “PO” at an amount equal to the site-specific PFS payment rate for nonexcepted items and services furnished by a nonexcepted off-campus PBD (the PFS payment rate), with a 2-year transition period. For a discussion of the PFS payment amount for outpatient clinic visits furnished at nonexcepted off-campus PBDs, we refer readers to the CY 2018 PFS final rule with comment period discussion (82 FR 53023 through 53024), as well as the CY 2019 PFS final rule.

To develop an estimated impact of this policy, we began with CY 2017 outpatient claims data used in ratesetting for the CY 2019 OPPS. We then flagged all claim lines for HCPCS code G0463 that contained modifier “PO” because the presence of this modifier indicates that such claims were billed for services furnished by an off-campus department of a hospital paid under the OPPS. Next, we excluded those that were billed as a component of C–APC 8011 (Comprehensive Observation Services) or packaged into another C–APC because in those instances OPPS payment is made for a broader package of services. We then simulated payment for the remaining claim lines as if they were paid at the PFS-equivalent rate. An estimate of the policy that includes the effects of estimated changes in enrollment, utilization, and case-mix based on the FY 2019 President’s budget approximates the estimated decrease in total payment under the OPPS at $380 million, with Medicare OPPS payments decreasing by $300 million and beneficiary copayments decreasing by $80 million in CY 2019. This estimate is utilized for the accounting statement displayed in Table 65 of this final rule with comment period because the impact of this CY 2019 policy, which is not budget neutral, is combined with the impact of the OPD update, which is also not budget neutral, to estimate changes in Medicare spending under the OPPS as a result of the changes in this final rule with comment period. The estimated decrease in payment due to this policy is not as great as in the proposed rule because we are proposing to transition the application of this policy over 2 years.

We note that our estimates may differ from the actual effect of the policy due to offsetting factors, such as changes in provider behavior. We note that, by removing this payment differential that may influence site-of-service decision-making, we anticipate an associated decrease in the volume of clinic visits provided in the excepted off-campus PBD setting. In the proposed rule, we reminded readers that this estimate could change in this final rule with comment period based on a number of factors such as the availability of updated data, changes in the final payment policy, and/or the method of assessing the payment impact in the final rule with comment period. This estimate changed due to the final policy of establishing a 2-year phase-in. As discussed in more detail in section X.B. of the proposed rule, we sought public comment on both our proposed payment policy for clinic visits furnished at off-campus PBDs as well as how to apply methods for controlling overutilization of services more broadly. We refer readers to section X.B. of this final rule with comment period for our discussion of the public comments we received.

c. Estimated Effects of Finalized Proposal To Apply the 340B Drug Payment Policy to Nonexcepted Off-Campus Departments of Hospitals

In section X.C. of this final rule with comment period, we discuss the proposal we are finalizing to pay average sales price (ASP) minus 22.5 percent under the PFS for separately payable 340B-acquired drugs furnished by nonexcepted, off-campus PBDs beginning in CY 2019. This is consistent with the payment methodology adopted in CY 2018 for 340B-acquired drugs furnished in hospital departments paid under the OPPS.

To develop an estimated impact of this finalized proposal, we began with CY 2017 outpatient claims data used in ratesetting for the CY 2019 OPPS. We then flagged all claim lines that contained modifier “PN” because the presence of this modifier indicates that such claims were billed for services furnished by a nonexcepted off-campus department of a hospital paid under the PFS. We further subset this population by identifying 340B hospitals that billed for status indicator “K” drugs or biologics (that is, nonpass-through, separately payable drugs) because such drugs may have been subject to the 340B discount. We found 117 unique nonexcepted-off-campus PBDs associated with 340B hospitals billed for status indicator “K” drugs. Their “K” billing represents approximately $183 million in Medicare payments (including beneficiary copayments) based on a payment rate of ASP+6 percent. Based on our adjustment, for CY 2019, we estimate that the Medicare Program and beneficiaries will save approximately $491.1 million, under the PFS. This estimate represents an upper bound of potential savings under the PFS for this policy change and does not include adjustments for beneficiary enrollment, case-mix, or potential offsetting behaviors. We noted in the proposed rule that the estimated effect of the proposed policy could change in this final rule with comment period based on a number of factors such as the availability of updated data, changes in the final payment policy, and/or the method of assessing the payment impact in the final rule.

d. Estimated Effects of OPPS Changes on Hospitals

Table 62 below shows the estimated impact of this final rule with comment period on hospitals. Historically, the first line of the impact table, which estimates the change in payments to all
facilities, has always included cancer and children’s hospitals, which are held harmless to their pre-BBA amount. We also include CMHCs in the first line that includes all providers. We include a second line for all hospitals, excluding permanently held harmless hospitals and CMHCs.

We present separate impacts for CMHCs in Table 62, and we discuss them separately below, because CMHCs are paid only for partial hospitalization services under the OPPS and are a different provider type from hospitals. In CY 2019, we are paying CMHCs for partial hospitalization services under APC 5853 (Partial Hospitalization for CMHCs), and we are paying hospitals for partial hospitalization services under APC 5863 (Partial Hospitalization for Hospital-Based PHPs).

The estimated increase in the total payments made under the OPPS is determined largely by the increase to the conversion factor under the statutory methodology. The distributional impacts presented do not include assumptions about changes in volume and service-mix. The conversion factor is updated annually by the OPD fee schedule increase factor, as discussed in detail in section II.B. of this final rule with comment period.

Section 1833(t)(O)(C)(iv) of the Act provides that the OPPS increases the OPD fee schedule increase factor is equal to the market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act, which we refer to as the IPPS market basket percentage increase. The IPPS market basket percentage increase for FY 2019 is 2.9 percent (83 FR 41395). Section 1833(t)(O)(C)(iv) of the Act reduces that 2.9 percent by the multifactor productivity adjustment described in section 1886(b)(3)(B)(xi)(II) of the Act, which is 0.8 percentage point for FY 2019 (which is also the MFP adjustment for FY 2019 in the FY 2019 IPPS/LTCN OPPS final rule (83 FR 41395)), and sections 1833(t)(O)(F)(ii) and 1833(t)(O)(F)(v) of the Act further reduce the market basket percentage increase by 0.75 percentage point, resulting in the OPD fee schedule increase factor of 1.35 percent. We are using the OPD fee schedule increase factor of 1.35 percent in the calculation of the CY 2019 OPPS conversion factor. Section 10324 of the Affordable Care Act, as amended by HCERA, further authorized additional expenditures outside budget neutrality for hospitals in certain frontier States that have a wage index less than 1.0000. The amount attributable to this frontier State wage index adjustment are incorporated in the CY 2019 estimates in Table 62 of this final rule with comment period.

To illustrate the impact of the CY 2019 changes, our analysis begins with a baseline simulation model that uses the CY 2018 relative payment weights, the FY 2018 final IPPS wage indexes that include reclassifications, and the final CY 2018 conversion factor. Table 62 shows the estimated redistribution of the increase or decrease in payments for CY 2019 over CY 2018 payments to hospitals and CMHCs as a result of the following factors: The impact of the APC reconfiguration and recalibration changes between CY 2018 and CY 2019 (Column 2); the wage indexes and the provider adjustments (Column 3); the combined impact of all of the changes described in the preceding columns plus the 1.35 percent OPD fee schedule increase factor update to the conversion factor (Column 4); the finalized off-campus PBD clinic visits payment policy (Column 5), and the estimated impact taking into account all payments for CY 2019 relative to all payments for CY 2018, including the impact of changes in estimated outlier payments, the frontier State wage adjustment, and changes to the pass-through payment estimate (Column 6).

We did not model an explicit budget neutrality adjustment for the rural adjustment for SCHs because we are maintaining the current adjustment percentage for CY 2019. Because the updates to the conversion factor (including the update of the OPD fee schedule increase factor), the estimated cost of the rural adjustment, and the estimated cost of projected pass-through payment for CY 2019 are applied uniformly across services, observed redistributions of payments in the impact table for hospitals largely depend on the mix of services furnished by a hospital (for example, how the APCs for the hospital’s most frequently furnished services will change), and the impact of the wage index changes on the hospital. However, total payments made under this system and the extent to which this final rule with comment period will redistribute money during implementation also will depend on changes in volume, practice patterns, and the mix of services billed between CY 2018 and CY 2019 by various groups of hospitals, which CMS cannot forecast.

Overall, we estimate that the rates for CY 2019 will increase Medicare OPPS payments by an estimated 0.6 percent. Removing payments to cancer and children’s hospitals because their payment rates have increased by the pre-OPPS ratio between payment and cost and removing payments to CMHCs results in an estimated 0.6 percent increase in Medicare payments to all other hospitals. These estimated payments will not significantly impact other providers.

Column 1: Total Number of Hospitals

The first line in Column 1 in Table 62 shows the total number of facilities (3,840), including designated cancer and children’s hospitals and CMHCs, for which we were able to use CY 2017 hospital outpatient and CMHC claims data to model CY 2018 and CY 2019 payments, by classes of hospitals, for CMHCs and for dedicated cancer hospitals. We excluded all hospitals and CMHCs for which we could not plausibly estimate CY 2018 or CY 2019 payment and entities that are not paid under the OPPS. The latter entities include CAHs, all-inclusive hospitals, and hospitals located in Guam, the U.S. Virgin Islands, Northern Mariana Islands, American Samoa, and the State of Maryland. This process is discussed in greater detail in section II.A. of this final rule with comment period. At this time, we are unable to calculate a DSH variable for hospitals that are not also paid under the IPPS because DSH payments are only made to hospitals paid under the IPPS. Hospitals for which we do not have a DSH variable are grouped separately and generally include freestanding psychiatric hospitals, rehabilitation hospitals, and long-term care hospitals. We show the total number of OPPS hospitals (3,727), excluding the hold-harmless cancer and children’s hospitals and CMHCs, on the second line of the table. We excluded cancer and children’s hospitals because section 1833(t)(7)(D) of the Act permanently holds harmless cancer hospitals and children’s hospitals to their “pre-BBA amount” as specified under the terms of the statute, and therefore, we removed them from our impact analyses. We show the isolated impact on the 46 CMHCs at the bottom of the impact table and discuss that impact separately below.

Column 2: APC Recalibration—All Changes

Column 2 shows the estimated effect of APC recalibration. Column 2 also reflects any changes in multiple procedure discount patterns or conditional packaging that occur as a result of the changes in the relative magnitude of payment weights. As a result of APC recalibration, we estimate that urban hospitals will experience no change, with the impact ranging from an increase of 0.4 percent to a decrease of 0.1 percent, depending on the number of beds. Rural hospitals will experience
an increase of 0.1 percent, with the impact ranging from a decrease of 0.3 percent to an increase of 0.4 percent, depending on the number of beds. Major teaching hospitals will experience no change.

Column 3: Wage Indexes and the Effect of the Provider Adjustments

Column 3 demonstrates the combined budget neutral impact of the APC recalibration; the updates for the wage indexes with the FY 2019 IPPS post-recalibration wage indexes; the rural adjustment; and the cancer hospital payment adjustment. We modeled the independent effect of the budget neutrality adjustments and the OPD fee schedule increase factor by using the relative payment weights and wage indexes for each year, and using a CY 2018 conversion factor that included the OPD fee schedule increase and a budget neutrality adjustment for differences in wage indexes.

Column 3 reflects the independent effects of the updated wage indexes, including the application of budget neutrality for the rural floor policy on a nationwide basis. This column excludes the effects of the frontier State wage index adjustment, which is not budget neutral and is included in Column 6. We did not model a budget neutrality adjustment for the rural adjustment for SCHs because we are continuing the rural payment adjustment of 7.1 percent to rural SCHs for CY 2019, as described in section II.E. of this final rule with comment period. We also did not model a budget neutrality adjustment for the cancer hospital payment adjustment because we are using a payment-to-cost ratio target for the cancer hospital payment adjustment in CY 2019 of 0.89, which is the same ratio that was reported for the CY 2018 OPPS/ASC final rule with comment period (82 FR 59266). We note that, in accordance with section 16002 of the 21st Century Cures Act, we are applying a budget neutrality factor calculated as if the cancer hospital adjustment target payment-to-cost ratio was 0.89, not the 0.88 target payment-to-cost ratio we are applying in section II.F. of this final rule with comment period.

We modeled the independent effect of updating the wage indexes by varying only the wage indexes, holding APC relative payment weights, service-mix, and the rural adjustment constant and using the CY 2019 scaled weights and a CY 2018 conversion factor that included a budget neutrality adjustment for the effect of the changes to the wage indexes between CY 2018 and CY 2019. The FY 2019 wage policy results in modest redistributions.

Column 4: All Budget Neutrality Changes Combined With the Market Basket Update

Column 4 demonstrates the combined impact of all of the changes previously described and the update to the conversion factor of 1.35 percent. Overall, these changes will increase payments to urban hospitals by 1.4 percent and to rural hospitals by 1.3 percent. Urban hospitals will receive an increase in line with the 1.4 percent overall increase for all facilities after the update is applied to the budget neutrality adjustments. The increase for classes of rural hospitals will be more variable with sole community hospitals receiving a 1.1 percent increase and other rural hospitals receiving an increase of 1.6 percent.

Column 5: Off-Campus PBD Visits Payment Policy

Column 5 displays the estimated effect of our finalized CY 2019 volume control method to pay for clinic visit HCPCS code G0463 ([Hospital outpatient clinic visit for assessment and management of a patient) when billed with modifier “PO” by an excepted off-campus PBD at a rate that will be 70 percent of the OPPS rate for a clinic visit service for CY 2019. We note that the numbers provided in this column isolate the estimated effect of this policy adjustment relative to the numerator of Column 4. Therefore, the numbers reported in Column 5 show how much of the difference between the estimates in Column 4 and the estimates in Column 6 are a result of the finalized off-campus PBD visits policy.

Column 6: All Changes for CY 2019

Column 6 depicts the full impact of the CY 2019 policies on each hospital group by including the effect of all changes for CY 2019 and comparing them to all estimated payments in CY 2018. Column 6 shows the combined budget neutral effects of Columns 2 through 3; the OPD fee schedule increase; the effect of the finalized off-campus PBD visits policy, the impact of the frontier State wage index adjustment; the impact of estimated OPPS outlier payments, as discussed in section II.G. of this final rule with comment period; the change in the Hospital OQR Program payment reduction for the small number of hospitals in our impact model that failed to meet the reporting requirements (discussed in section XIII. of this final rule with comment period); and the difference in total OPPS payments dedicated to transitional pass-through payments.

Of those hospitals that failed to meet the Hospital OQR Program reporting requirements for the full CY 2018 update (and assumed, for modeling purposes, to be the same number for CY 2019), we included 72 hospitals in our model because they had both CY 2017 claims data and recent cost report data. We estimate that the cumulative effect of all changes for CY 2019 will increase payments to all facilities by 0.6 percent for CY 2019. We modeled the independent effect of all changes in Column 6 using the final relative payment weights for CY 2018 and the relative payment weights for CY 2019. We used the final conversion factor for CY 2018 of $78.636 and the final CY 2019 conversion factor of $79.490 discussed in section II.B. of this final rule with comment period.

Column 6 contains simulated outlier payments for each year. We used the 1-year charge inflation factor used in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41722) of 4.3 percent (1.04338) to increase individual costs on the CY 2017 claims, and we used the most recent overall CCR in the October 2018 Outpatient Provider-Specific File (OPSF) to estimate outlier payments for CY 2018. Using the CY 2017 claims and a 4.3 percent charge inflation factor, we currently estimate that outlier payments for CY 2018, using a multiple threshold of 1.75 and a fixed-dollar threshold of $4,150, will be approximately 1.01 percent of total payments. The estimated current outlier payments of 0.1 percent are incorporated in the comparison in Column 6. We used the same set of claims and a charge inflation factor of 8.9 percent (1.08864) and the CCRs in the October 2018 OPSF, with an adjustment of 0.981397, to reflect relative changes in cost and charge inflation between CY 2017 and CY 2019, to model the CY 2019 outliers at 1.0 percent of estimated total payments using a multiple threshold of 1.75 and a fixed-dollar threshold of $4,825. The charge inflation and CCR inflation factors are discussed in detail in the FY 2019 IPPS/LTCH PPS final rule (83 FR 41722).

Overall, we estimate that facilities will experience an increase of 0.6 percent under this final rule with comment period in CY 2019 relative to total spending in CY 2018. This projected increase (shown in Column 6) of Table 62 reflects the 1.35 percent OPD fee schedule increase factor, minus 0.6 percent for the off-campus PBD visits policy, minus 0.10 percent for the change in the pass-through payment estimate between CY 2018 and CY 2019, plus a decrease of 0.01 percent for the difference in estimated outlier payments.
between CY 2018 (1.01 percent) and CY 2019 (1.00 percent). We estimate that the combined effect of all changes for CY 2019 will increase payments to urban hospitals by 0.7 percent. Overall, we estimate that rural hospitals will experience a 0.5 percent increase as a result of the combined effects of all the changes for CY 2019.

Among hospitals, by teaching status, we estimate that the impacts resulting from the combined effects of all changes will include an increase of 0.4 percent for major teaching hospitals and an increase of 0.9 percent for nonteaching hospitals. Minor teaching hospitals will experience an estimated increase of 0.5 percent.

In our analysis, we also have categorized hospitals by type of ownership. Based on this analysis, we estimate that voluntary hospitals will experience an increase of 0.6 percent, proprietary hospitals will experience an increase of 1.0 percent, and governmental hospitals will experience an increase of 0.5 percent.

BILLING CODE 4120–01–P
## TABLE 62.—ESTIMATED IMPACT OF THE CY 2019 CHANGES FOR THE HOSPITAL OUTPATIENT PROSPECTIVE PAYMENT SYSTEM

<table>
<thead>
<tr>
<th></th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>(4)</th>
<th>(5)</th>
<th>(6)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of Hospitals</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All Budget Neutral Changes (combined cols 2 and 3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>New Wage Index and Provider Adjustments</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Off-Campus Provider-Based Department Visits Policy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>All Changes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ALL FACILITIES *

<table>
<thead>
<tr>
<th></th>
<th>3,840</th>
<th>0.0</th>
<th>0.0</th>
<th>1.3</th>
<th>-0.6</th>
<th>0.6</th>
</tr>
</thead>
</table>

(excludes hospitals permanently held harmless and CMHCs)

### URBAN HOSPITALS

<table>
<thead>
<tr>
<th></th>
<th>2,938</th>
<th>0.0</th>
<th>0.0</th>
<th>1.4</th>
<th>-0.6</th>
<th>0.7</th>
</tr>
</thead>
<tbody>
<tr>
<td>LARGE URBAN (GT 1 MILL.)</td>
<td>1,542</td>
<td>0.1</td>
<td>-0.1</td>
<td>1.3</td>
<td>-0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>OTHER URBAN (LE 1 MILL.)</td>
<td>1,396</td>
<td>0.0</td>
<td>0.1</td>
<td>1.5</td>
<td>-0.7</td>
<td>0.6</td>
</tr>
</tbody>
</table>

### RURAL HOSPITALS

<table>
<thead>
<tr>
<th></th>
<th>789</th>
<th>0.1</th>
<th>-0.2</th>
<th>1.3</th>
<th>-0.6</th>
<th>0.5</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOLE COMMUNITY</td>
<td>370</td>
<td>-0.1</td>
<td>-0.2</td>
<td>1.1</td>
<td>-0.7</td>
<td>0.2</td>
</tr>
<tr>
<td>OTHER RURAL</td>
<td>419</td>
<td>0.4</td>
<td>-0.1</td>
<td>1.6</td>
<td>-0.6</td>
<td>0.9</td>
</tr>
</tbody>
</table>

### BEDS (URBAN)

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 99 BEDS</td>
<td>1,018</td>
<td>0.4</td>
<td>-0.1</td>
<td>1.6</td>
<td>-0.4</td>
<td>1.1</td>
</tr>
<tr>
<td>100-199 BEDS</td>
<td>846</td>
<td>0.1</td>
<td>-0.1</td>
<td>1.4</td>
<td>-0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>200-299 BEDS</td>
<td>468</td>
<td>0.0</td>
<td>0.1</td>
<td>1.5</td>
<td>-0.5</td>
<td>0.9</td>
</tr>
<tr>
<td>300-499 BEDS</td>
<td>390</td>
<td>-0.1</td>
<td>0.0</td>
<td>1.3</td>
<td>-0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>500+ BEDS</td>
<td>216</td>
<td>0.0</td>
<td>0.1</td>
<td>1.4</td>
<td>-0.8</td>
<td>0.5</td>
</tr>
</tbody>
</table>

### BEDS (RURAL)

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0 - 49 BEDS</td>
<td>328</td>
<td>0.4</td>
<td>0.0</td>
<td>1.7</td>
<td>-0.2</td>
<td>1.3</td>
</tr>
<tr>
<td>50-100 BEDS</td>
<td>288</td>
<td>0.2</td>
<td>-0.1</td>
<td>1.4</td>
<td>-0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>101-149 BEDS</td>
<td>89</td>
<td>0.2</td>
<td>-0.2</td>
<td>1.3</td>
<td>-0.5</td>
<td>0.7</td>
</tr>
<tr>
<td>150-199 BEDS</td>
<td>47</td>
<td>0.1</td>
<td>-0.4</td>
<td>1.1</td>
<td>-1.1</td>
<td>-0.1</td>
</tr>
<tr>
<td>200+ BEDS</td>
<td>37</td>
<td>-0.3</td>
<td>-0.3</td>
<td>0.7</td>
<td>-0.5</td>
<td>0.1</td>
</tr>
</tbody>
</table>

### REGION (URBAN)

<p>| | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW ENGLAND</td>
<td>143</td>
<td>0.2</td>
<td>1.7</td>
<td>3.3</td>
<td>-1.0</td>
<td>2.1</td>
</tr>
<tr>
<td>MIDDLE ATLANTIC</td>
<td>336</td>
<td>0.0</td>
<td>-0.2</td>
<td>1.1</td>
<td>-0.4</td>
<td>0.6</td>
</tr>
<tr>
<td>SOUTH ATLANTIC</td>
<td>469</td>
<td>0.0</td>
<td>-0.4</td>
<td>1.0</td>
<td>-0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Region (Rural)</td>
<td>Number of Hospitals</td>
<td>APC Recalibration (all changes)</td>
<td>New Wage Index and Provider Adjustments</td>
<td>All Budget Neutral Changes (combined cols 2 and 3) with Market Basket Update</td>
<td>Off-Campus Provider-Based Department Visits Policy</td>
<td>All Changes</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------</td>
<td>---------------------------------</td>
<td>------------------------------------------</td>
<td>-------------------------------------------------</td>
<td>------------------------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>EAST NORTH CENT.</td>
<td>469</td>
<td>0.0</td>
<td>-0.3</td>
<td>1.0</td>
<td>-0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>EAST SOUTH CENT.</td>
<td>178</td>
<td>0.0</td>
<td>-0.2</td>
<td>1.2</td>
<td>-0.2</td>
<td>0.9</td>
</tr>
<tr>
<td>WEST NORTH CENT.</td>
<td>182</td>
<td>-0.2</td>
<td>-0.2</td>
<td>1.0</td>
<td>-0.6</td>
<td>0.1</td>
</tr>
<tr>
<td>WEST SOUTH CENT.</td>
<td>517</td>
<td>0.1</td>
<td>0.0</td>
<td>1.4</td>
<td>-0.5</td>
<td>0.8</td>
</tr>
<tr>
<td>MOUNTAIN</td>
<td>214</td>
<td>0.0</td>
<td>0.2</td>
<td>1.5</td>
<td>-0.6</td>
<td>0.8</td>
</tr>
<tr>
<td>PACIFIC</td>
<td>384</td>
<td>0.1</td>
<td>0.5</td>
<td>1.9</td>
<td>-0.6</td>
<td>1.1</td>
</tr>
<tr>
<td>PUERTO RICO</td>
<td>46</td>
<td>-0.6</td>
<td>-1.2</td>
<td>-0.4</td>
<td>0.0</td>
<td>-0.4</td>
</tr>
<tr>
<td>REGION (RURAL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEW ENGLAND</td>
<td>21</td>
<td>-0.1</td>
<td>-0.7</td>
<td>0.5</td>
<td>-2.0</td>
<td>-1.6</td>
</tr>
<tr>
<td>MIDDLE ATLANTIC</td>
<td>54</td>
<td>0.2</td>
<td>0.1</td>
<td>1.6</td>
<td>-1.0</td>
<td>0.5</td>
</tr>
<tr>
<td>SOUTH ATLANTIC</td>
<td>122</td>
<td>0.1</td>
<td>-0.2</td>
<td>1.3</td>
<td>-0.2</td>
<td>1.0</td>
</tr>
<tr>
<td>EAST NORTH CENT.</td>
<td>120</td>
<td>0.3</td>
<td>-0.2</td>
<td>1.5</td>
<td>-0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>EAST SOUTH CENT.</td>
<td>152</td>
<td>0.1</td>
<td>0.1</td>
<td>1.5</td>
<td>-0.3</td>
<td>1.1</td>
</tr>
<tr>
<td>WEST NORTH CENT.</td>
<td>95</td>
<td>-0.2</td>
<td>-0.2</td>
<td>1.0</td>
<td>-0.8</td>
<td>-0.2</td>
</tr>
<tr>
<td>WEST SOUTH CENT.</td>
<td>151</td>
<td>0.5</td>
<td>0.2</td>
<td>2.0</td>
<td>-0.3</td>
<td>1.6</td>
</tr>
<tr>
<td>MOUNTAIN</td>
<td>51</td>
<td>-0.2</td>
<td>-0.6</td>
<td>0.5</td>
<td>-0.2</td>
<td>0.9</td>
</tr>
<tr>
<td>PACIFIC</td>
<td>23</td>
<td>0.1</td>
<td>-0.4</td>
<td>1.1</td>
<td>-1.0</td>
<td>-0.1</td>
</tr>
<tr>
<td>TEACHING STATUS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NON-TEACHING</td>
<td>2,599</td>
<td>0.1</td>
<td>-0.1</td>
<td>1.4</td>
<td>-0.4</td>
<td>0.9</td>
</tr>
<tr>
<td>MINOR</td>
<td>776</td>
<td>0.0</td>
<td>0.0</td>
<td>1.3</td>
<td>-0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>MAJOR</td>
<td>352</td>
<td>0.0</td>
<td>0.1</td>
<td>1.5</td>
<td>-0.9</td>
<td>0.4</td>
</tr>
<tr>
<td>DSH PATIENT PERCENT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>11</td>
<td>-0.8</td>
<td>-0.5</td>
<td>0.1</td>
<td>0.0</td>
<td>0.2</td>
</tr>
<tr>
<td>GT 0 - 0.10</td>
<td>265</td>
<td>0.1</td>
<td>-0.2</td>
<td>1.3</td>
<td>-0.4</td>
<td>0.8</td>
</tr>
<tr>
<td>0.10 - 0.16</td>
<td>241</td>
<td>0.0</td>
<td>-0.1</td>
<td>1.2</td>
<td>-0.4</td>
<td>0.7</td>
</tr>
<tr>
<td>0.16 - 0.23</td>
<td>575</td>
<td>-0.1</td>
<td>-0.2</td>
<td>1.0</td>
<td>-0.6</td>
<td>0.3</td>
</tr>
<tr>
<td>0.23 - 0.35</td>
<td>1,113</td>
<td>0.1</td>
<td>0.0</td>
<td>1.4</td>
<td>-0.7</td>
<td>0.6</td>
</tr>
<tr>
<td>GE 0.35</td>
<td>953</td>
<td>0.1</td>
<td>0.1</td>
<td>1.6</td>
<td>-0.6</td>
<td>0.8</td>
</tr>
</tbody>
</table>
### Unformatted Text:

The last line of Table 62 demonstrates the isolated impact on CMHCs, which furnish only partial hospitalization services under the OPPS. In CY 2018, CMHCs are paid under APC 5853 (Partial Hospitalization (3 or more services) for CMHCs). We modeled the impact of this APC policy assuming CMHCs will continue to provide the same number of days of PHP care as seen in the CY 2017 claims used for ratesetting in this final rule with comment period. We excluded days with 1 or 2 services because our policy only pays a per diem rate for partial hospitalization when 3 or more qualifying services are provided to the beneficiary. We estimate that CMHCs will experience an overall 15.1 percent decrease in payments from CY 2018 (shown in Column 6). We note that this includes the trimming methodology described in section VIII.B. of this final rule with comment period.

### Table:

<table>
<thead>
<tr>
<th></th>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>(4)</th>
<th>(5)</th>
<th>(6)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DSH NOT AVAILABLE</strong></td>
<td>569</td>
<td>2.5</td>
<td>0.0</td>
<td>3.9</td>
<td>-0.3</td>
<td>3.4</td>
</tr>
<tr>
<td><strong>URBAN TEACHING/DSH</strong></td>
<td>1,013</td>
<td>0.0</td>
<td>0.1</td>
<td>1.4</td>
<td>-0.7</td>
<td>0.5</td>
</tr>
<tr>
<td><strong>NO TEACHING/DSH</strong></td>
<td>1,369</td>
<td>0.1</td>
<td>0.0</td>
<td>1.4</td>
<td>-0.4</td>
<td>0.9</td>
</tr>
<tr>
<td><strong>NO TEACHING/NO DSH</strong></td>
<td>10</td>
<td>1.2</td>
<td>-1.0</td>
<td>1.5</td>
<td>0.0</td>
<td>1.3</td>
</tr>
<tr>
<td><strong>DSH NOT AVAILABLE</strong></td>
<td>545</td>
<td>2.5</td>
<td>0.0</td>
<td>3.9</td>
<td>-0.3</td>
<td>3.4</td>
</tr>
<tr>
<td><strong>TYPE OF OWNERSHIP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>VOLUNTARY</strong></td>
<td>1,977</td>
<td>0.0</td>
<td>0.0</td>
<td>1.4</td>
<td>-0.7</td>
<td>0.6</td>
</tr>
<tr>
<td><strong>PROPRIETARY</strong></td>
<td>1,281</td>
<td>0.1</td>
<td>0.0</td>
<td>1.4</td>
<td>-0.2</td>
<td>1.0</td>
</tr>
<tr>
<td><strong>GOVERNMENT</strong></td>
<td>469</td>
<td>0.0</td>
<td>0.1</td>
<td>1.4</td>
<td>-0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>CMHCs</td>
<td>46</td>
<td>-16.8</td>
<td>0.7</td>
<td>-15.0</td>
<td>0.0</td>
<td>-15.1</td>
</tr>
</tbody>
</table>

#### Notes:

- Column (1) shows total hospitals and/or CMHCs.
- Column (2) includes all CY 2019 OPPS policies and compares those to the CY 2018 OPPS.
- Column (3) shows the budget neutral impact of updating the wage index by applying the FY 2019 hospital inpatient wage index. The rural SCH adjustment continues our current policy of 7.1 percent so the budget neutrality factor is 1. The budget neutrality adjustment for the cancer hospital adjustment is 1 because in CY 2019 the target payment-to-cost ratio is the same as it was in CY 2018 (0.88).
- Column (4) shows the impact of all budget neutrality adjustments and the addition of the 1.35 percent OPD fee schedule update factor (2.9 percent reduced by 0.8 percentage point for the productivity adjustment and further reduced by 0.75 percentage point as required by law).
- Column (5) shows the additional impact of the policy to pay clinic visits for nonexcepted providers under the otherwise applicable payment system. We note that we are applying a 2-year phase-in so the amount of the reduction will be 50 percent of the difference in CY 2019 (or payment at 70 percent of the OPPS rate).
- Column (6) shows the additional adjustments to the conversion factor resulting from the frontier adjustment, a change in the pass-through estimate, and adding estimated outlier payments.
- * These 3,840 providers include children and cancer hospitals, which are held harmless to pre-BBA amounts, and CMHCs.
- ** Complete DSH numbers are not available for providers that are not paid under IPPS, including rehabilitation, psychiatric, and long-term care hospitals.
Column 3 shows that the estimated impact of adopting the FY 2019 wage index values will result in an increase of 0.7 percent to CMHCs. Column 4 shows that combining this OPD fee schedule increase factor, along with changes in APC policy for CY 2019 and the FY 2019 wage index updates, will result in an estimated decrease of 15.0 percent. Column 5 shows that the off-campus PBD clinic visits payment policy has no effect on CMHCs. Column 6 shows that adding the changes in outlier and pass-through payments will result in a total 15.1 percent decrease in payment for CMHCs. This reflects all changes to CMHCs for CY 2019.

f. Estimated Effect of OPPS Changes on Beneficiaries

For services for which the beneficiary pays a copayment of 20 percent of the payment rate, the beneficiary’s payment will increase for services for which the OPPS payments will rise and will decrease for services for which the OPPS payments will fall. For further discussion on the calculation of the national unadjusted copayments and minimum unadjusted copayments, we refer readers to section III.I of this final rule with comment period. In all cases, section 1833(t)(8)(C)(i) of the Act limits beneficiary liability for copayment for a procedure performed in a year to the hospital inpatient deductible for the applicable year.

We estimate that the aggregate beneficiary coinsurance percentage will be 18.5 percent for all services paid under the OPPS in CY 2019. The estimated aggregate beneficiary coinsurance reflects general system adjustments, including the CY 2019 comprehensive APC payment policy discussed in section II.A.2.b. of this final rule with comment period. The aggregate coinsurance percentage reflects changes that we have made for the CY 2019 OPPS. Total estimated copayments over total estimated payments results in 18.6 percent. Under the C–APC payment methodology, the copayment is based on the claim level for the C–APC payment line level. Because outpatient copayment is capped at the inpatient deductible, this can lead to an aggregate cost-sharing below 20 percent.

g. Estimated Effects of OPPS Changes on Other Providers

The relative payment weights and payment amounts established under the OPPS affect the payments made to ASCs, as discussed in section XII. of this final rule with comment period. We do not anticipate that any types of providers or suppliers other than hospitals, CMHCs, and ASCs will be affected by the changes in this final rule with comment period. However, we are interested in exploring how these Medicare changes may affect others in the health care marketplace.

h. Estimated Effects of OPPS Changes on the Medicare and Medicaid Programs

The effect on the Medicare program is expected to be an increase of $440 million in program payments for OPPS services furnished in CY 2019. The effect on the Medicare program is expected to be limited to copayments that Medicare may make on behalf of Medicare recipients who are also Medicare beneficiaries. We estimate that the changes in this final rule with comment period will increase these Medicare beneficiary payments by approximately $35 million in CY 2019. Currently, there are approximately 10 million dual-eligible beneficiaries, which represents approximately one third of Part B FFS beneficiaries. The impact on Medicaid was determined by taking one-third of the beneficiary cost-sharing impact. The national average split of Medicaid payments is 57 percent Federal payments and 43 percent State payments. Therefore, for the estimated $35 million Medicaid increase, approximately $20 million would be from the Federal Government and $15 million would be from State government.

i. Alternative OPPS Policies Considered

Alternatives to the OPPS changes we are making and the reasons for our selected alternatives are discussed throughout this final rule with comment period.

• Alternatives Considered for the Method to Control for Unnecessary Increases in the Volume of Outpatient Services

We refer readers to sections II.A.3.b. and XII.D.3. of the proposed rule and this final rule with comment period for a discussion of our policy to assign any skin substitute product that was assigned to the high cost group in CY 2018 to the high cost group in CY 2019, regardless of whether the product’s mean unit cost (MUC) or the product’s per day cost (PDC) exceeds below the overall CY 2019 MUC or PDC threshold. We will continue to assign products that exceed either the overall CY 2019 MUC or PDC threshold to the high cost group. We also considered, but did not propose, reinstating our methodology from CY 2017 and assigning skin substitutes to the high cost group based on whether an individual product’s MUC or PDC exceeded the overall CY 2019 MUC or PDC threshold based on calculations done for either the proposed rule or the final rule with comment period.

• Alternatives Considered for the Methodology for Payment for Non-Opioid Pain Management Treatments

We refer readers to sections II.A.3.b. and XII.D.3. of the proposed rule and this final rule with comment period for a discussion of our change in the packaging policy for certain drugs when administered in the ASC setting and policy provide separate payment for non-opioid pain management drugs that function as a supply when used in a surgical procedure when the procedure is performed in an ASC. In those sections of the proposed rule, we also solicited comments on whether we should pay separately for other non-opioid treatments for pain under the OPPS and the ASC payment system. We discuss the comments we received in those sections of this final rule with comment period. In the proposed rule, we also considered and solicited comments on an alternative policy that would use our equitable adjustment authority under section 1833(t)(2)[E] of the Act to establish an incentive payment for non-opioid alternatives that would apply to drugs and devices under
the OPPS that are not currently separately paid, are supported by evidence that demonstrates such drugs and devices are effective at treating acute or chronic pain, and would result in decreased use of prescription opioid drugs and any associated opioid addiction, when furnished in the outpatient setting. We discuss the comments we received in those sections of this final rule with comment period.

2. Estimated Effects of CY 2019 ASC Payment System Changes in This Final Rule With Comment Period

Most ASC payment rates are calculated by multiplying the ASC conversion factor by the ASC relative payment weight. As discussed fully in section XII. of this final rule with comment period, we are setting the CY 2019 ASC relative payment weights by scaling the CY 2019 OPPS relative payment weights by the ASC scalar of 0.8792. The estimated effects of the updated relative payment weights on payment rates are varied and are reflected in the estimated payments displayed in Tables 63 and 64 below.

Beginning in CY 2011, section 3401 of the Affordable Care Act requires that the annual update to the ASC payment system (which will be the hospital market basket for CY 2019) after application of any quality reporting reduction be reduced by a productivity adjustment. The Affordable Care Act defines the productivity adjustment to be equal to the 10-year moving average of changes in annual economy-wide private nonfarm business multifactor productivity (MFP) (as projected by the Secretary for the 10-year period, ending with the applicable fiscal year, year, cost reporting period, or other annual period). For ASCs that fail to meet their quality reporting requirements, the CY 2019 payment determinations will be based on the application of a 2.0 percentage point reduction to the annual update factor, which will be the hospital market basket for CY 2019. We calculated the CY 2019 ASC conversion factor by adjusting the CY 2018 ASC conversion factor by 1.0004 to account for changes in the pre-floor and pre-reclassified hospital wage indexes between CY 2018 and CY 2019 and by applying the CY 2019 MFP-adjusted hospital market basket update factor of 2.1 percent (hospital market basket update of 2.9 percent minus a projected productivity adjustment of 0.8 percentage point). The CY 2019 ASC conversion factor is $46.555 for ASCs that successfully meet the quality reporting requirements.

a. Limitations of Our Analysis

Presented here are the projected effects of the changes for CY 2019 on Medicare payment to ASCs. A key limitation of our analysis is our inability to predict changes in ASC service-mix between CY 2017 and CY 2019 with precision. We believe the net effect on Medicare expenditures resulting from the CY 2019 changes will be small in the aggregate for all ASCs. However, such changes may have differential effects across surgical specialty groups, as ASCs continue to adjust to the payment rates based on the policies of the revised ASC payment system. We are unable to accurately project such changes at a disaggregated level. Clearly, individual ASCs will experience changes in payment that differ from the aggregated estimated impacts presented below.

b. Estimated Effects of ASC Payment System Policies on ASCs

Some ASCs are multispeciality facilities that perform a wide range of surgical procedures from excision of lesions to hernia repair to cataract extraction; others focus on a single specialty and perform only a limited range of surgical procedures, such as eye, digestive system, or orthopedic procedures. The combined effect on an individual ASC of the update to the CY 2019 payments will depend on a number of factors, including, but not limited to, the mix of services the ASC provides, the volume of specific services provided by the ASC, the percentage of its patients who are Medicare beneficiaries, and the extent to which an ASC provides different services in the coming year. The following discussion presents tables that display estimates of the impact of the CY 2019 updates to the ASC payment system on Medicare payments to ASCs, assuming the same mix of services, as reflected in our CY 2017 claims data. Table 63 depicts the estimated aggregate percent change in payment by surgical specialty or ancillary items and services group by comparing estimated CY 2018 payments to estimated CY 2019 payments, and Table 64 shows a comparison of estimated CY 2018 payments to estimated CY 2019 payments for procedures that we estimate will receive the most Medicare payment in CY 2018. In Table 63, we have aggregated the surgical HCPCS codes by specialty group, grouped all HCPCS codes for covered ancillary items and services into a single group, and then estimated the effect on aggregate payment for surgical specialty and ancillary items and services groups. The groups are sorted for display in descending order by estimated Medicare program payment to ASCs. The following is an explanation of the information presented in Table 63.

- Column 1—Surgical Specialty or Ancillary Items and Services Group indicates the surgical specialty into which ASC procedures are grouped and the ancillary items and services group which includes all HCPCS codes for covered ancillary items and services. To group surgical procedures by surgical specialty, we used the CPT code range definitions and Level II HCPCS codes and Category III CPT codes, as appropriate, to account for all surgical procedures to which the Medicare program payments are attributed.

- Column 2—Estimated CY 2018 ASC Payments were calculated using CY 2017 OPPS utilization data (the most recent full year of ASC utilization) and CY 2018 ASC payment rates. The surgical specialty and ancillary items and services groups are displayed in descending order based on estimated CY 2018 ASC payments.

- Column 3—Estimated CY 2019 Percent Change is the aggregate percentage increase or decrease in Medicare program payment to ASCs for each surgical specialty or ancillary items and services group that are attributable to updates to ASC payment rates for CY 2019 compared to CY 2018. As shown in Table 63, for the six specialty groups that account for the most ASC utilization and spending, we estimate that the update to ASC payment rates for CY 2019 will result in a 1-percent decrease in aggregate payment amounts for eye and ocular adnexa procedures, a 3-percent increase in aggregate payment amounts for nervous system procedures, 3-percent increase in aggregate payment amounts for digestive system procedures, 3-percent increase in aggregate payment amounts for musculoskeletal system procedures, a 1-percent increase in aggregate payment amounts for genitourinary system procedures, and a 1-percent decrease in aggregate payment amounts for integumentary system procedures. We note that these changes can be a result of different factors, including updated data, payment weight changes, and changes in policy. In general, spending in each of these categories of services is increasing due to the 2.1 percent payment rate update. After the payment rate update is accounted for, aggregate payment increases or decreases for a category of services can be higher or lower than a 2.1 percent increase, depending on if payment weights in the OPPS APCs that correspond to the applicable services...
increased or decreased or if the most recent data show an increase or a decrease in the volume of services performed in an ASC for a category. For example, we estimate a 1-percent decrease in aggregate eye and ocular adnexa procedure payments due to a reduction in hospital reported costs for the primary payment grouping for this category under the OPPS. This lowers the payment weights for eye and ocular adnexa procedure payments and, overall, offsets the 2.1 percent ASC rate update for these procedures. For estimated changes for selected procedures, we refer readers to Table 64 provided later in this section.

Also displayed in Table 63 is a separate estimate of Medicare ASC payments for the group of separately payable covered ancillary items and services. The payment estimates for the covered surgical procedures include the costs of packaged ancillary items and services. We estimate that aggregate payments for these items and services will increase by 79 percent for CY 2019. This is largely attributed to the introduction of utilization data for HCPCS code C9447 (Inj, phenylephrine ketorolac), Omidria®, and HCPCS code Q4172 (Puraply or puraply am), a high-cost skin substitute.

### Table 63.—Estimated Impact of the CY 2019 Update to the ASC Payment System on Aggregate CY 2019 Medicare Program Payments by Surgical Specialty or Ancillary Items and Services Group

<table>
<thead>
<tr>
<th>Surgical Specialty Group</th>
<th>Estimated CY 2018 ASC Payments (in Millions)</th>
<th>Estimated CY 2019 Percent Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>$4,772</td>
<td>2</td>
</tr>
<tr>
<td>Eye and ocular adnexa</td>
<td>$1,737</td>
<td>-1</td>
</tr>
<tr>
<td>Nervous system</td>
<td>$993</td>
<td>3</td>
</tr>
<tr>
<td>Digestive system</td>
<td>$873</td>
<td>3</td>
</tr>
<tr>
<td>Musculoskeletal system</td>
<td>$574</td>
<td>3</td>
</tr>
<tr>
<td>Genitourinary system</td>
<td>$188</td>
<td>1</td>
</tr>
<tr>
<td>Integumentary system</td>
<td>$145</td>
<td>-1</td>
</tr>
<tr>
<td>Ancillary items and services</td>
<td>$64</td>
<td>79</td>
</tr>
</tbody>
</table>

Table 64 below shows the estimated impact of the updates to the revised ASC payment system on aggregate ASC payments for selected surgical procedures during CY 2019. The table displays 30 of the procedures receiving the greatest estimated CY 2018 aggregate Medicare payments to ASCs. The HCPCS codes are sorted in descending order by estimated CY 2018 program payment.

- Column 1—CPT/HCPCS code.
- Column 2—Short Descriptor of the HCPCS code.
- Column 3—Estimated CY 2018 ASC Payments were calculated using CY 2017 ASC utilization (the most recent full year of ASC utilization) and the CY 2018 ASC payment rates. The estimated CY 2018 payments are expressed in millions of dollars.
- Column 4—Estimated CY 2019 Percent Change reflects the percent differences between the estimated ASC payment for CY 2018 and the estimated payment for CY 2019 based on the update.
We estimate that the CY 2019 update to the ASC payment system will be generally positive (that is, result in lower cost-sharing) for beneficiaries with respect to the new procedures we are adding to the ASC list of covered surgical procedures, the existing covered surgical procedures we reviewed as safe to perform in an ASC, and for those surgical procedures we are designating as office-based for CY 2019. For example, using 2017 utilization data and CY 2019 OPPS and ASC payment rates, we estimate that if 5 percent of

<table>
<thead>
<tr>
<th>CPT/HCPCS Code (1)</th>
<th>Short Descriptor (2)</th>
<th>Estimated CY 2018 ASC Payment (in millions) (3)</th>
<th>Estimated CY 2019 Percent Change (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>66984</td>
<td>Cataract surg w/iol 1 stage</td>
<td>$1,206</td>
<td>-2</td>
</tr>
<tr>
<td>45380</td>
<td>Colonoscopy and biopsy</td>
<td>$228</td>
<td>4</td>
</tr>
<tr>
<td>63685</td>
<td>Instr/redo spine n generator</td>
<td>$221</td>
<td>-1</td>
</tr>
<tr>
<td>43239</td>
<td>Egd biopsy single/multiple</td>
<td>$180</td>
<td>1</td>
</tr>
<tr>
<td>63650</td>
<td>Implant neuroelectrodes</td>
<td>$166</td>
<td>-3</td>
</tr>
<tr>
<td>45385</td>
<td>Colonoscopy w/lesion removal</td>
<td>$156</td>
<td>4</td>
</tr>
<tr>
<td>64483</td>
<td>Inj foramen epidural l/s</td>
<td>$101</td>
<td>13</td>
</tr>
<tr>
<td>01911</td>
<td>Insert ant segment drain int</td>
<td>$96</td>
<td>4</td>
</tr>
<tr>
<td>66982</td>
<td>Cataract surgery complex</td>
<td>$89</td>
<td>-2</td>
</tr>
<tr>
<td>64635</td>
<td>Destroy lumb/sac facet jnt</td>
<td>$75</td>
<td>-1</td>
</tr>
<tr>
<td>66821</td>
<td>After cataract laser surgery</td>
<td>$69</td>
<td>1</td>
</tr>
<tr>
<td>29827</td>
<td>Arthrosoc rotator cuff repr</td>
<td>$65</td>
<td>1</td>
</tr>
<tr>
<td>64493</td>
<td>Inj paravert f jnt l/s 1 lev</td>
<td>$63</td>
<td>13</td>
</tr>
<tr>
<td>62323</td>
<td>Njx interlaminar lmbr/sac</td>
<td>$53</td>
<td>9</td>
</tr>
<tr>
<td>64590</td>
<td>Instr/reo pn/gastr stimul</td>
<td>$51</td>
<td>3</td>
</tr>
<tr>
<td>G0105</td>
<td>Colorectal scrn; hi risk ind</td>
<td>$47</td>
<td>4</td>
</tr>
<tr>
<td>G0121</td>
<td>Colon ca scrn not hi rsk ind</td>
<td>$42</td>
<td>4</td>
</tr>
<tr>
<td>45378</td>
<td>Diagnostic colonoscopy</td>
<td>$41</td>
<td>4</td>
</tr>
<tr>
<td>64721</td>
<td>Carpal tunnel surgery</td>
<td>$34</td>
<td>-1</td>
</tr>
<tr>
<td>15823</td>
<td>Revision of upper eyelid</td>
<td>$33</td>
<td>-2</td>
</tr>
<tr>
<td>29881</td>
<td>Knee arthroscopy/surgery</td>
<td>$29</td>
<td>-2</td>
</tr>
<tr>
<td>C9740</td>
<td>Cysto impl 4 or more</td>
<td>$28</td>
<td>2</td>
</tr>
<tr>
<td>64561</td>
<td>Implant neuroelectrodes</td>
<td>$26</td>
<td>-2</td>
</tr>
<tr>
<td>67042</td>
<td>Vif for macular hole</td>
<td>$26</td>
<td>0</td>
</tr>
<tr>
<td>29880</td>
<td>Knee arthroscopy/surgery</td>
<td>$25</td>
<td>-2</td>
</tr>
<tr>
<td>26055</td>
<td>Incise finger tendon sheath</td>
<td>$25</td>
<td>-4</td>
</tr>
<tr>
<td>28285</td>
<td>Repair of hammertoe</td>
<td>$24</td>
<td>-2</td>
</tr>
<tr>
<td>63655</td>
<td>Implant neuroelectrodes</td>
<td>$24</td>
<td>5</td>
</tr>
<tr>
<td>52000</td>
<td>Cystoscopy</td>
<td>$23</td>
<td>-2</td>
</tr>
<tr>
<td>G0260</td>
<td>Inj for sacroiliac jt anesth</td>
<td>$22</td>
<td>9</td>
</tr>
</tbody>
</table>
cardiac catheterization procedures migrate from the hospital outpatient setting to the ASC setting as a result of this policy. Medicare payments will be reduced by approximately $36 million in CY 2019 and total beneficiary copayments will decline by approximately $14 million in CY 2019. First, other than certain preventive services where coinsurance and the Part B deductible is waived to comply with sections 1833(a)(1) and (b) of the Act, the ASC coinsurance rate for all procedures is 20 percent. This contrasts with procedures performed in HOPDs under the OPPS, where the beneficiary is responsible for copayments that range from 20 percent to 40 percent of the procedure payment (other than for certain preventive services), although the majority of HOPD procedures have a 20-percent copayment. Second, in almost all cases, the ASC payment rates under the ASC payment system are lower than payment rates for the same procedures under the OPPS. Therefore, the beneficiary coinsurance amount under the ASC payment system will almost always be less than the OPPS copayment amount for the same services. (The only exceptions will be if the ASC coinsurance amount exceeds the inpatient deductible. The statute requires that copayment amounts under the OPPS not exceed the inpatient deductible.) Beneficiary coinsurance for services migrating from physicians’ offices to ASCs may decrease or increase under the revised ASC payment system, depending on the particular service and the relative payment amounts under the MPFS compared to the ASC. While the ASC payment system bases most of its payment rates on hospital cost data used to set OPPS relative payment weights, services that are performed a majority of the time in a physician office are generally paid the lesser of the ASC amount according to the standard ASC rate setting methodology or at the nonfacility practice expense based amount payable under the PFS. Because of this fact, we do not believe that the increase in ASC payment rates that will result from this policy will cause any significant migration of services from the physician office setting to the ASC setting. For those additional procedures that we are designating as office-based in CY 2019, the beneficiary coinsurance amount under the ASC payment system generally will be no greater than the beneficiary coinsurance under the PFS because the coinsurance under both payment systems generally is 20 percent (except for certain preventive services where the coinsurance is waived under both payment systems).

d. Alternative ASC Payment Policies Considered

Alternatives to the ASC changes we are making and the reasons for our selected alternatives are discussed throughout this final rule with comment period.

• Alternatives Considered for the CY 2019 ASC Rate Update

As discussed in section XII. of this final rule with comment period, for CY 2019 through CY 2023 (5 years total), in response to stakeholder concerns regarding the application of CPI–U to update ASC payment rates, we are updating ASC payment rates using the hospital market basket and revising our regulations under 42 CFR 416.171(a), which address the annual update to the ASC conversion factor, to reflect this policy.

As an alternative proposal, we considered whether to continue applying the CPI–U as the update factor. If we were to update ASC payment rates for CY 2019 with an update factor based on CPI–U, the update would have been 1.8 percent (the 2.6 percentage point CPI–U less the 0.8 percentage point MFP adjustment). This update factor would have resulted in increased payments to ASCs in CY 2019 of approximately $60 million, compared to the increased payments to ASCs in CY 2019 of approximately $80 million as a result of the 2.1 percent update based on the hospital market basket.

3. Accounting Statements and Tables

As required by OMB Circular A–4 (available on the Office of Management and Budget website at: https://www.whitehouse.gov/omb/circulars_a004_a-4), we have prepared accounting statements to illustrate the impacts of the OPPS and ASC changes in this final rule with comment period. The first accounting statement, Table 65 below, illustrates the classification of expenditures for the CY 2019 estimated hospital OPPS incurred benefit impacts associated with the CY 2019 OPD fee schedule increase. This $440 million in additional Medicare spending estimate includes the $740 million in additional Medicare spending associated with updating the CY 2018 OPPS payment rates by the hospital market basket update for CY 2019, offset by the $300 million in Medicare savings associated with the finalized policy to pay for clinic visits furnished at off-campus PBDs at a PFS-equivalent rate. In addition, we estimate that OPPS changes in this final rule with comment period will increase copayments that Medicaid may make on behalf of Medicaid recipients who are also Medicare beneficiaries by approximately $35 million in CY 2019.

The second accounting statement, Table 66 below illustrates the classification of expenditures associated with the 2.1 percent CY 2019 update to the ASC payment system, based on the provisions of this final rule with comment period and the baseline spending estimates for ASCs. Both tables classify most estimated impacts as transfers.

TABLE 65.—ACCOUNTING STATEMENT: CY 2019 ESTIMATED HOSPITAL OPPS TRANSFERS FROM CY 2018 TO CY 2019 ASSOCIATED WITH THE CY 2019 HOSPITAL OUTPATIENT OPD FEE SCHEDULE INCREASE

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$440 million</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to outpatient hospitals and other providers who receive payment under the hospital OPPS</td>
</tr>
<tr>
<td>Total</td>
<td>$440 million</td>
</tr>
</tbody>
</table>

BILING CODE 4120-01-P
4. Effects of Changes in Requirements for the Hospital OQR Program

a. Background

We refer readers to the CY 2018 OPPS/ASC final rule with comment period (82 FR 59492 through 59494), for the previously estimated effects of changes to the Hospital OQR Program for the CY 2018, CY 2019, and CY 2020 payment determinations. Of the approximately 3,300 hospitals that met eligibility requirements for the CY 2018 payment determination, we determined that 36 hospitals did not meet the requirements to receive the full OPD fee schedule increase factor. Many of these hospitals (18 of the 36), chose not to participate in the Hospital OQR Program for the CY 2018 payment determination. In the proposed rule, we did not propose to add any quality measures to the Hospital OQR Program measure set for the CY 2020 or CY 2021 payment determinations, and, in this final rule with comment period we are finalizing our proposals to remove eight measures from the program measure set; we are not finalizing our proposals to remove two measures, as discussed in section XIII.B.4.b. of this final rule with comment period. We do not believe that the finalized policies will increase the number of hospitals that do not receive a full annual payment update for the CY 2020 or CY 2021 payment determinations.

In section XIII.B.4.b. of this final rule with comment period, we are finalizing our proposals to remove a total of eight measures. Specifically, beginning with the CY 2020 payment determination, we are finalizing the removal of: (1) OP–27: Influenza Vaccination Coverage Among Healthcare Personnel; and beginning with the CY 2021 payment determination, we are removing: (2) OP–5: Median Time to ECG; (3) OP–9: Mammography Follow-up Rates; (4) OP–11: Thorax CT Use of Contrast Material; (5) OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; (6) OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT; (7) OP–17: Tracking Clinical Results between Visits; and (8) OP–30: Endoscopy/Polypl Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. However, we are not finalizing our proposals to remove two measures: OP–29: Endoscopy/Polypl Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery for the CY 2021 payment determination and subsequent years. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 32734 through 32736). The reduction in burden associated with our finalized policies is discussed below.

In section XIII.B.4.a. of this final rule with comment period, beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, we are updating one removal factor and adding one removal factor. We are also codifying our measure removal policies and factors at 42 CFR 419.46(b) effective upon finalization of this CY 2019 OPPS/ASC final rule with comment period and for subsequent years. In addition, in section XIII.C.2. of this final rule with comment period, we are updating the frequency with which we will release Hospital Outpatient Quality Reporting Specifications Manuals, such that instead of releasing the full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are removing the Notice of Participation (NOP) form as a requirement for the Hospital OQR Program and updating 42 CFR 419.46(a)(3) to reflect this policy.

Finally, in section XIII.D.4.b. of this final rule with comment period, we are changing the data reporting period for OP–32: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination. As discussed below, we do not expect these policies to affect our burden estimates. However, as further explained in section XIX.B. of this final rule with comment period, we believe that there will be an overall decrease in the estimated information collection burden for hospitals due to the other finalized policies. We refer readers to section XIX.B. of this final rule with comment period.

**TABLE 66.—ACCOUNTING STATEMENT: CLASSIFICATION OF ESTIMATED TRANSFERS FROM CY 2018 TO CY 2019 AS A RESULT OF THE CY 2019 UPDATE TO THE ASC PAYMENT SYSTEM**

<table>
<thead>
<tr>
<th>Category</th>
<th>Transfers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annualized Monetized Transfers</td>
<td>$80 million</td>
</tr>
<tr>
<td>From Whom to Whom</td>
<td>Federal Government to Medicare Providers and Suppliers</td>
</tr>
<tr>
<td>Total</td>
<td>$80 million</td>
</tr>
</tbody>
</table>

**TABLE 67.—ESTIMATED COSTS, COST SAVINGS, AND BENEFITS**

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>Costs</th>
<th>Cost Savings</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICR Burden Savings</td>
<td>$28.2 million*</td>
<td></td>
</tr>
<tr>
<td>Regulatory Familiarization</td>
<td>$2.6 million*</td>
<td></td>
</tr>
</tbody>
</table>

*The annual estimates are in 2017 year dollars.

** Regulatory familiarization costs occur upfront only.
period for a summary of our information collection burden estimate calculations. The effects of these proposals are discussed in more detail further below.

b. Estimated Effects of Hospital OQR Program Beginning With the Effective Date of This CY 2019 OPPS/ASC Final Rule With Comment Period

In section XIII.B.4.a. of this final rule with comment period, we are: (1) Updating measure removal Factor 7; (2) adding one new removal factor; and (3) codifying our removal factors policy at 42 CFR 419.46(h). We do not expect a change in the information collection burden or other costs experienced by hospitals because these changes do not affect Hospital OQR Program participation requirements or data reporting requirements.

c. Update to the Frequency of Releasing the Hospital Outpatient Quality Reporting Specifications Manual Beginning With CY 2019 and for Subsequent Years

In section XIII.D.2. of this final rule with comment period, we are finalizing with modification our proposal to update the frequency with which we will release a Hospital Outpatient Quality Reporting Specifications Manual such that instead of releasing a full manual once or twice each year, as proposed, we will release the Specifications Manuals once every 12 months and release addenda as necessary, beginning with CY 2019 and for subsequent years. We anticipate that this change will reduce hospital confusion, as potentially releasing fewer manuals per year reduces the need to review updates as frequently as was previously necessary. However, because this change does not affect Hospital OQR Program participation requirements or data reporting requirements, we do not estimate a change in our calculation of the information collection burden experienced by hospitals.

d. Estimated Effects of Hospital OQR Program Finalized Proposals for the CY 2020 Payment Determination and Subsequent Years

(1) Removal of the Notice of Participation (NOP) Form Requirement

In section XIII.C.2. of this final rule with comment period, beginning with the CY 2020 payment determination, we are removing the NOP form as a requirement. As a result, to be a participant in the Hospital OQR Program, hospitals will need to: (1) Register on the QualityNet website, (2) identify and register a QualityNet security administrator, and (3) submit data. In addition, we are updating 42 CFR 419.46(a) to reflect these policies. We believe that the finalized policy to remove the NOP will reduce administrative burden experienced by hospitals by only a nominal amount. As a result, this finalized policy does not influence our information collection burden estimates. We refer readers to section XIX.B. of this final rule with comment period, where our burden calculations for the Hospital OQR Program are discussed in detail. In addition, we anticipate that this finalized proposal will reduce the possibility of hospitals failing to meet Hospital OQR Program requirements due to a failure to submit the NOP.

(2) Extension of the Reporting Period for OP–32: Facility 7-Day Risk-Standardized Hospital Visit Rate After Outpatient Colonoscopy

In section XIII.D.4.b. of this final rule with comment period, we are increasing the data reporting period for OP–32: Facility Seven-Day Risk-Standardized Hospital Visit Rate After Outpatient Colonoscopy from one year to three years beginning with the CY 2020 payment determination. We expect this policy to increase the reliability of OP–32 data allowing better information to be publicly reported. However, the policy does not change our data reporting requirements, such that hospitals will be required to continue reporting claims data that are used to calculate this measure. Therefore, we do not expect a change in the information collection burden experienced by hospitals.

(3) Removal of OP–27 for the CY 2020 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are removing OP–27: Influenza Vaccination Coverage Among Healthcare Personnel (NQF #0431) beginning with the CY 2020 payment determination and for subsequent years. The burden associated with OP–27, a NHSN measure, is accounted for under a separate Paperwork Reduction Act Package, OMB control number 0920–0666. Because burden associated with submitting data for this measure is captured under a separate OMB control number, we are not providing an estimate of the information collection burden associated with this measure for the Hospital OQR Program. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with this proposal stemming from no longer having to review and track program requirements associated with this measure.

e. Estimated Effects of Hospital OQR Program Proposals for the CY 2021 Payment Determination and Subsequent Years

(1) Removal of Chart-Abstracted Measures for the CY 2021 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are removing OP–5: Median Time to ECG, a chart-abstracted measure, for the CY 2021 payment determination and subsequent years. We believe that the removal of this chart-abstracted measure for the CY 2021 payment determination will reduce collection of information burden by 151,800 hours and $5.6 million (151,800 hours $36,580), as discussed in section XIX.B. of this final rule with comment period. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with this proposal stemming from no longer having to review and track program requirements associated with this measure.

(2) Removal of Measures Submitted via a Web-Based Tool for the CY 2021 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, while we proposed to remove five measures, we are only finalizing the removal of three measures submitted via a web-based tool beginning with the CY 2021 payment determination and for subsequent years: OP–12: The Ability for Providers with HIT to Receive Laboratory Data Electronically Directly into Their Qualified/Certified EHR System as Discrete Searchable Data; OP–17: Tracking Clinical Results between Visits; and OP–30: Endoscopy/Polyph Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. We are not finalizing the removal of OP–29: Endoscopy/Polyph Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients; and OP–31: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37234 through 32736). As discussed in section XIX.B. of this final rule with comment period, we anticipate a burden
reduction of 530,075 hours and $19.4 million associated with the removal of OP–12, OP–17, and OP–30 for the CY 2021 payment determination. Aside from burden associated with information collection however, we also anticipate that hospitals will experience a general burden and cost reduction associated with these measure removals stemming from no longer having to implement, review, track, and maintain program requirements associated with these measures.

(3) Removal of Claims-Based Measures for the CY 2021 Payment Determination and Subsequent Years

In section XIII.B.4.b. of this final rule with comment period, we are removing three claims-based measures beginning with the CY 2021 payment determination: OP–9: Mammography Follow-up Rates; OP–11: Thorax CT Use of Contrast Material; and OP–14: Simultaneous Use of Brain Computed Tomography (CT) and Sinus CT. These claims-based measures are calculated using only data already reported to the Medicare program for payment purposes, therefore, we do not believe removing these measures will affect the information collection burden on hospitals. Nonetheless, we anticipate that hospitals will experience a general burden reduction associated with these proposals stemming from no longer having to review and track various associated program requirements.

In total for the CY 2021 payment determination, we expect information collection burden will be reduced by 151,800 hours due to our removal of one chart-abstracted measure, and 530,075 hours due to our removal of three measures submitted via a web-based tool. In total, we estimate an information collection burden reduction of 681,875 hours (151,800 hours for the removal of one chart-abstracted measure + 530,075 hours for the removal of three web-based measures) and $24.9 million (681,875 hours × $36.58) for the CY 2021 payment determination.

5. Effects of Requirements for the ASCQR Program

a. Background

In section XIV. of this final rule with comment period, we discuss our adopted policies affecting the ASCQR Program. For the CY 2018 payment determination, of the 6,683 ASCs that met eligibility requirements for the ASCQR Program, 233 ASCs did not meet the requirements to receive the full annual payment update. We note that, in the CY 2017 OPPS/ASC final rule with comment period (81 FR 79874), we used the CY 2016 payment determination numbers as a baseline, and estimated that approximately 200 ASCs will not receive the full annual payment update in CY 2019 due to failure to meet the ASCQR Program requirements (CY 2017 and CY 2018 payment determination information were not yet available). In the proposed rule, we did not propose to add any new quality measures to the ASCQR Program measure set for the CY 2020 payment determination and subsequent determinations, and we do not believe that the other measures we previously adopted will cause any additional ASCs to fail to meet the ASCQR Program requirements. Therefore, we do not believe that our finalized proposals will increase the number of ASCs that do not receive a full annual payment update for the CY 2020 payment determination. Below we discuss only the effects that will result from the newly finalized provisions in this final rule with comment period.

In section XIV.B.3.c. of this final rule with comment period, we are removing one measure beginning with the CY 2020 payment determination (ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel) and removing one measure beginning with the CY 2021 payment determination (ASC–10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use). We expect these measure removals will reduce the overall burden of reporting data for the ASCQR Program, as discussed further below. In section XIV.B.3.c. of this final rule with comment period, we are not finalizing our proposals to remove ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures. Therefore, we are revising the estimated burden changes found in the CY 2019 OPPS/ASC proposed rule (83 FR 37236) and ASC–9: Endoscopy/Polyp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. In addition, we are not finalizing our proposals to remove ASC–1: Patient Burn; ASC–2: Patient Fall; ASC–3: Wrong Site, Wrong Side, Wrong Patient, Wrong Procedure, Wrong Implant; and ASC–4: All-Cause Hospital Transfer/Admission, but are instead retaining the measures in the ASCQR Program and suspending their data collection beginning with the CY 2019 reporting period/CY 2021 payment determination until further action in rulemaking with the goal of updating the measures.

b. Estimated Effects of ASCQR Program Newly Finalized Policies Beginning With the Effective Date of This CY 2019 OPPS/ASC Final Rule With Comment Period

In section XIV.B.3.a. of this final rule with comment period, we are, beginning with the effective date of this CY 2019 OPPS/ASC final rule with comment period, removing one measure removal factor, adding two new measure removal factors, and updating 42 CFR 416.320(c) to better reflect our measure removal policies; we are also:

(1) Extension of the Reporting Period for ASC–12: Facility 7-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy

In section XIV.D.4.b. of this final rule with comment period, we are extending the data reporting period for ASC–12: Facility Seven-Day Risk-Standardized Hospital Visit Rate after Outpatient Colonoscopy from two years beginning with the CY 2020 payment determination. We expect this newly finalized policy to increase the
reliability of ASC–12 data allowing better information to be publicly reported. However, the policy does not change our data reporting requirements, because ASC–12 is a claims-based measure that is calculated based on claims data that facilities already submit to CMS. Therefore, we do not expect a change in the information collection burden or other costs experienced by ASCs.

(2) Removal of ASC–8 for the CY 2020 Payment Determination and Subsequent Years

In section XIV.B.3.c. of this final rule with comment period, we are removing one measure from the ASCQR Program measure set beginning with the CY 2020 payment determination, ASC–8: Influenza Vaccination Coverage Among Healthcare Personnel. As discussed in section XIX.C.3.b. of this final rule with comment period, the information collection burden associated with ASC–8, a NHSN measure, is accounted for under a separate information collection request, OMB control number 0920–0666. As such, we are not providing an estimate of the information collection burden associated with this measure under the ASCQR Program control number. Aside from burden associated with information collection however, we anticipate that facilities will experience a general burden and cost reduction associated with this proposal stemming from no longer having to review and track program requirements associated with this measure.

d. Estimated Effects of ASCQR Program Newly Finalized Policies for the CY 2021 Payment Determination and Subsequent Years: Removal of One Chart-Abstracted Measure for the CY 2021 Payment Determination and Subsequent Years

In section XIV.B.3.c. of this final rule with comment period, we proposed to remove seven measures; we are finalizing the removal of only one measure from the ASCQR Program measure set beginning with the CY 2021 payment determination: ASC–10: Endoscopy/Polymp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps—Avoidance of Inappropriate Use. We are not finalizing the removal of ASC–9: Endoscopy/Polymp Surveillance Follow-up Interval for Normal Colonoscopy in Average Risk Patients and ASC–11: Cataracts—Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery. As discussed in section XIX.C.4.b. of this final rule with comment period, we believe the removal of ASC–10 will result in a burden reduction for ASCs. For ASC–10, we estimate the total annualized burden reduction to be 62,008 hours and $2,268,244 (3,937 ASCs x 15.75 hours x $36.58 per hour). Aside from burden associated with information collection however, we anticipate that facilities will experience a general burden and cost reduction associated with these removals stemming from no longer having to review and track program requirements associated with this measure.

Therefore, as noted in section XIX.C.4. of this final rule with comment period, we believe the removal of a total of one measure (ASC–10) from the ASCQR measure set beginning with the CY 2021 payment determination will result in a total annual reduction in information collection burden of 62,008 hours and $2,268,244.

D. Effects of the Update to the HCAHPS Survey Measure in the Hospital IQR Program

As discussed in section XVI. of this final rule with comment period, we are finalizing a modified version of our proposal regarding the Communication About Pain questions from the HCAHPS Survey in the Hospital IQR Program. Instead of removing the questions effective with January 2022 discharges, for the FY 2024 payment determination and subsequent years as proposed, we are finalizing to remove them effective with October 2019 discharges, for the FY 2021 payment determination and subsequent years. In addition, instead of publicly reporting the data in October 2022 and then subsequently discontinuing as proposed, we are finalizing that we will not publicly report the data collected from the Communication About Pain questions at all. We anticipate that the removal of these questions will result in only a nominal and temporary increase on the information collection burden on providers associated with adjusting the survey instrument and instructional materials, and a burden decrease for survey respondents. We note that the burden estimate for the Hospital IQR Program under the program’s OMB control number 0938–1022 excludes the burden associated with the HCAHPS Survey measure, which is submitted under a separate information collection request and approved under OMB control number 0938–0981. We address the anticipated information collection burden reduction in section XVIII.D. of this final rule with comment period.

E. Effects of Requirements for the PPS-Exempt Cancer Hospital Quality Reporting (PCHQR) Program

As described in section XVII.B. of this final rule with comment period, we are not finalizing our proposals made in the FY 2019 IPPS/LTCH PPS final rule (83 FR 20503) to remove two chart-abstracted, NHSN measures, the Catheter-Associated Urinary Tract Infection (CAUTI) Outcome Measure (PCH–5/NQF #0138) and the Central Line-Associated Bloodstream Infection (CLABSI) Outcome Measure (PCH–4/ NQF #0139) from the PCHQR Program beginning with the FY 2021 program year.

We estimate that not finalizing our proposals to remove the CAUTI and CLABSI measures will result in no changes to our previously finalized burden estimates under the PCHQR Program. We refer readers to section XIX.E. of this final rule with comment period for a discussion of the information collection estimates for the CAUTI and CLABSI measures. We refer readers to section XIV.B.4. of the preamble of the FY 2019 IPPS/LTCH PPS final rule (83 FR 41694 through 41695) and Appendix A, section I.L. of that final rule (83 FR 41772) for more regarding our previously finalized information collection and burden estimates under the PCHQR Program.
F. Regulatory Review Costs

If regulations impose administrative costs on private entities, such as the time needed to read and interpret a rule, we should estimate the cost associated with regulatory review. Due to the uncertainty involved with accurately quantifying the number of entities that will review a rule, we assumed that the number of commenters on the CY 2019 OPPS/ASC proposed rule (2,994) will be the number of reviewers of this final rule with comment period. We acknowledge that this assumption may underestimate or overstate the costs of reviewing this final rule with comment period. It is possible that not all commenters will review this final rule with comment period in detail, and it is also possible that some reviewers will choose not to comment on this final rule with comment period. Nonetheless, we believe that the number of commenters on the CY 2019 OPPS/ASC proposed rule will be a fair estimate of the number of reviewers of this final rule with comment period. In the CY 2019 OPPS/ASC proposed rule (83 FR 37237), we welcomed any comments on the approach in estimating the number of entities that will review the proposed rule. We also recognize that different types of entities are, in many cases, affected by mutually exclusive sections of the proposed rule and this final rule with comment period, and, therefore, for the purposes of our estimate, we assumed that each reviewer reads approximately 50 percent of the rule. In the proposed rule, we sought public comments. We did not receive any public comments specific to our solicitation.

Using the wage information from the BLS for medical and health service managers (Code 11–9111), we estimated that the cost of reviewing this rule is $107.38 per hour, including overhead and fringe benefits (https://www.bls.gov/oes/current/oes_nat.htm). Assuming an average reading speed, we estimate that it will take approximately 8 hours for the staff to review half of this final rule with comment period. For each facility that reviewed this final rule with comment period, the estimated cost is $859.04 (8 hours × $107.38). Therefore, we estimated that the total cost of reviewing this final rule with comment period is $2,571,966 ($859.04 × 2,994 reviewers).

G. Regulatory Flexibility Act (RFA) Analysis

The RFA requires agencies to analyze options for regulatory relief of small entities, if a rule has a significant impact on a substantial number of small entities. For purposes of the RFA, we estimate that most hospitals, ASCs and CMHCs are small entities as that term is used in the RFA. For purposes of the RFA, most hospitals are considered small businesses according to the Small Business Administration’s size standards with total revenues of $38.5 million or less in any single year or by the hospital’s not-for-profit status. Most ASCs and most CMHCs are considered small businesses with total revenues of $15 million or less in any single year. For details, we refer readers to the Small Business Administration’s “Table of Size Standards” at: http://www.sba.gov/content/table-small-business-size-standards.

In addition, section 1102(b) of the Act requires us to prepare a regulatory impact analysis if a rule may have a significant impact on the operations of a substantial number of small rural hospitals. This analysis must conform to the provisions of section 603 of the RFA. For purposes of section 1102(b) of the Act, we define a small rural hospital as a not-for-profit hospital that is located outside of a metropolitan statistical area and has 100 or fewer beds. We estimate that this final rule with comment period will increase payments to small rural hospitals by less than 3 percent; therefore, it should not have a significant impact on approximately 616 small rural hospitals.

The analysis above, together with the remainder of this preamble, provides a regulatory flexibility analysis and a regulatory impact analysis.

H. Unfunded Mandates Reform Act Analysis

Section 202 of the Unfunded Mandates Reform Act of 1995 (UMRA) also requires that agencies assess anticipated costs and benefits before issuing any rule whose mandates require spending in any 1 year of $100 million in 1995 dollars, updated annually for inflation. That threshold level is currently approximately $150 million. This final rule with comment period does not mandate any requirements for State, local, or tribal governments, or for the private sector.

I. Reducing Regulation and Controlling Regulatory Costs

Executive Order 13771, titled Reducing Regulation and Controlling Regulatory Costs, was issued on January 30, 2017. It has been determined that this final rule with comment period, will be a deregulatory action for the purposes of Executive Order 13771. We estimate that this final rule with comment period will generate $22.52 million in annualized cost savings at a 7-percent discount rate, discounted relative to 2016, over a perpetual time horizon.

J. Conclusion

The changes we are making in this final rule with comment period will affect all classes of hospitals paid under the OPPS and will affect both CMHCs and ASCs. We estimate that most classes of hospitals paid under the OPPS will experience a modest increase or a minimal decrease in payment for services furnished under the OPPS in CY 2019. Table 62 demonstrates the estimated distributional impact of the OPPS budget neutrality requirements that will result in a 0.6 percent increase in payments for all services paid under the OPPS in CY 2019, after considering all of the changes to APC reconfiguration and recalibration, as well as the OPD fee schedule increase factor, wage index changes, including the frontier State wage index adjustment, estimated payment for outliers, the finalized off-campus provider-based department clinic visits payment policy, and changes to the pass-through payment estimate. However, some classes of providers that are paid under the OPPS will experience more significant gains or losses in OPPS payments in CY 2019.

The updates to the ASC payment system for CY 2019 will affect each of the approximately 5,500 ASCs currently approved for participation in the Medicare program. The effect on an individual ASC will depend on its mix of patients, the proportion of the ASC’s patients who are Medicare beneficiaries, the degree to which the payments for the procedures offered by the ASC are changed under the ASC payment system, and the extent to which the ASC provides a different set of procedures in the coming year. Table 63 demonstrates the estimated distributional impact among ASC surgical specialties of the MFP-adjusted hospital market basket update factor of 2.1 percent for CY 2019.

XXII. Federalism Analysis

Executive Order 13132 establishes certain requirements that an agency must meet when it promulgates a proposed rule (and subsequent final rule) that imposes substantial direct costs on State and local governments, preempts State law, or otherwise has Federalism implications. We have examined the OPPS and ASC provisions included in this final rule with comment period in accordance with Executive Order 13132. Federalism, and have determined that this final rule will not have a substantial direct effect on State, local or tribal governments, preempt State
law, or otherwise have a Federalism implication. As reflected in Table 62 of this final rule with comment period, we estimate that OPPS payments to governmental hospitals (including State and local governmental hospitals) will increase by 0.5 percent under this final rule with comment period. While we do not know the number of ASCs or CMHCs with government ownership, we anticipate that it is small. The analyses we have provided in this section of this final rule with comment period, in conjunction with the remainder of this document, demonstrate that this final rule with comment period is consistent with the regulatory philosophy and principles identified in Executive Order 12866, the RFA, and section 1102(b) of the Act.

This final rule with comment period will affect payments to a substantial number of small rural hospitals and a small number of rural ASCs, as well as other classes of hospitals, CMHCs, and ASCs, and some effects may be significant.

List of Subjects
42 CFR Parts 416
Health facilities, Health professions, Medicare, Reporting and recordkeeping requirements.
42 CFR Parts 419
Hospitals, Medicare, Reporting and recordkeeping requirements.

For reasons stated in the preamble of this document, the Centers for Medicare & Medicaid Services is amending 42 CFR chapter IV as set forth below:

PART 416—AMBULATORY SURGICAL SERVICES

1. The authority citation for part 416 is revised to read as follows:

Authority: 42 U.S.C. 273, 1302, 1320b–8, and 1395hh.

2. Section 416.164 is amended—

a. By revising paragraph (a)(4);

b. In paragraph (b)(5), by removing the period and adding in its place “; and”;

and
c. By adding paragraph (b)(6).

The revision and addition read as follows:

§ 416.164 Scope of ASC services.

(a) * * *

(4) Drugs and biologicals for which separate payment is not allowed under the hospital outpatient prospective payment system (OPPS), with the exception of non-opioid pain management drugs that function as a supply when used in a surgical procedure.

(b) * * *

(6) Non-opioid pain management drugs that function as a supply when used in a surgical procedure.

* * * * *

3. Section 416.171 is amended by revising paragraphs (a)(2) and (b)(1) and (2) to read as follows:

§ 416.171 Determination of payment rates for ASC services.

(a) * * *

(2) Conversion factor for CY 2009 and subsequent calendar years. The conversion factor for a calendar year is equal to the conversion factor calculated for the previous year, updated as follows:

(i) For CY 2009, the update is equal to zero percent.

(ii) For CY 2010 through CY 2018, the update is the Consumer Price Index for All Urban Consumers (U.S. city average) as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved.

(iii) For CY 2019 through CY 2023, the update is the hospital inpatient market basket percentage increase applicable under section 1886(b)(3)(B)(iii) of the Act.

(iv) For CY 2024 and subsequent years, the update is the Consumer Price Index for All Urban Consumers (U.S. city average) as estimated by the Secretary for the 12-month period ending with the midpoint of the year involved.

(v) For CY 2014 through CY 2018, the Consumer Price Index for All Urban Consumers update determined under paragraph (a)(2)(iii) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year.

(vi) For CY 2019 through CY 2023, the hospital inpatient market basket update determined under paragraph (a)(2)(iii) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year.

(vii) For CY 2024 and subsequent years, the Consumer Price Index for All Urban Consumers update determined under paragraph (a)(2)(iii) of this section is reduced by 2.0 percentage points for an ASC that fails to meet the standards for reporting of ASC quality measures as established by the Secretary for the corresponding calendar year.

(viii)(A) For CY 2011 through CY 2018, the Consumer Price Index for All Urban Consumers determined under paragraph (a)(2)(ii) of this section, after application of any reduction under paragraph (a)(2)(iv) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xii)(II) of the Act.

(B) For CY 2019 through CY 2023, the hospital inpatient market basket update determined under paragraph (a)(2)(iii) of this section, after application of any reduction under paragraph (a)(2)(vi) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xii)(II) of the Act.

(C) For CY 2024 and subsequent years, the Consumer Price Index for All Urban Consumers determined under paragraph (a)(2)(iv) of this section, after application of any reduction under paragraph (a)(2)(vii) of this section, is reduced by the productivity adjustment described in section 1886(b)(3)(B)(xii)(II) of the Act.

(D) The application of the provisions of paragraph (a)(2)(vii)(A), (B), or (C) of this section may result in the update being less than zero percent for a year, and may result in payment rates for a year being less than the payment rates for the preceding year.

(b) * * *

(1) Covered ancillary services specified in § 416.164(b), with the exception of radiology services and certain diagnostic tests as provided in § 416.164(b)(5) and non-opioid pain management drugs that function as a supply when used in a surgical procedure as provided in § 416.164(b)(6).

(2) The device portion of device-intensive procedures, which are procedures that—

(i) Involve implantable devices assigned a CPT or HCPCS code;

(ii) Utilize devices (including single-use devices) that must be surgically inserted or implanted; and

(iii) Have a HCPCS code-level device offset of greater than 30 percent when calculated according to the standard OPPS ASC ratesetting methodology.

* * * * *

4. Section 416.320 is amended by revising paragraph (c) to read as follows:

§ 416.320 Retention and removal of quality measures under the ASCQR Program.

* * * * *

(c) Removal of quality measures—(1) General rule for the removal of quality measures. Unless a measure raises specific safety concerns as set forth in paragraph (b) of this section, CMS will use the regular rulemaking process to remove, suspend, or replace quality measures in the ASCQR Program to allow for public comment.

(2) Factors for consideration of removal of quality measures. CMS will
weigh whether to remove measures based on the following factors:

(i) Factor 1. Measure performance among ASCs is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made (topped-out measures);

(ii) Factor 2. Performance or improvement on a measure does not result in better patient outcomes;

(iii) Factor 3. A measure does not align with current clinical guidelines or practice;

(iv) Factor 4. The availability of a more broadly applicable (across settings, populations, or conditions) measure for the topic;

(v) Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic;

(vi) Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic;

(vii) Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm; and

(viii) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

(3) Criteria to determine topped-out measures. For the purposes of the ASCQR Program, a measure is considered to be topped-out under paragraph (c)(2)(i) of this section when it meets both of the following criteria:

(i) Statistically indistinguishable performance at the 75th and 90th percentiles (defined as when the difference between the 75th and 90th percentiles for an ASC’s measure is within two times the standard error of the full data set); and

(ii) A truncated coefficient of variation less than or equal to 0.10.

(4) Application of measure removal factors. The benefits of removing a measure from the ASCQR Program will be assessed on a case-by-case basis. A measure will not be removed solely on the basis of meeting any specific factor or criterion.

PART 419—PROSPECTIVE PAYMENT SYSTEM FOR HOSPITAL OUTPATIENT DEPARTMENT SERVICES

§ 419.32 Calculation of prospective payment rates for hospital outpatient services.

* * * * *

(b) * * *

(1) * * *

(iv) * * *

(B) * * *

(10) For calendar year 2019, a multifactor productivity adjustment (as determined by CMS) and 0.75 percentage point.

* * * * *

7. Section 419.46 is amended by revising paragraphs (a)(1) through (3) and adding paragraph (h) to read as follows:

§ 419.46 Participation, data submission, and validation requirements under the Hospital Outpatient Quality Reporting (OQR) Program.

(a) * * *

(1) Register on the QualityNet website before beginning to report data;

(2) Identify and register a QualityNet security administrator as part of the registration process under paragraph (a)(1) of this section; and

(3) Submit at least one data element.

* * * * *

(h) Retention and removal of quality measures under the Hospital OQR Program—(1) General rule for the retention of quality measures. Quality measures adopted for the Hospital OQR Program measure set for a previous payment determination year are retained for use in subsequent payment determination years, except when they are removed, suspended, or replaced as set forth in paragraphs (h)(2) and (3) of this section.

(2) Immediate measure removal. For cases in which CMS believes that the continued use of a measure as specified raises patient safety concerns, CMS will immediately remove a quality measure from the Hospital OQR Program and will promptly notify hospitals and the public of the removal of the measure and the reasons for its removal through the Hospital OQR Program ListServ and the QualityNet website.

(3) Measure removal, suspension, or replacement through the rulemaking process. Unless a measure raises specific safety concerns as set forth in paragraph (h)(2) of this section, CMS will use the regular rulemaking process to remove, suspend, or replace quality measures in the Hospital OQR Program to allow for public comment.

(i) Factors for consideration of removal of quality measures. CMS will weigh whether to remove measures based on the following factors:

(A) Factor 1. Measure performance among hospitals is so high and unvarying that meaningful distinctions and improvements in performance can no longer be made ("topped out" measures);

(B) Factor 2. Performance or improvement on a measure does not result in better patient outcomes;

(C) Factor 3. A measure does not align with current clinical guidelines or practice;

(D) Factor 4. The availability of a measure that is more broadly applicable (across settings, populations, or conditions) measure for the topic;

(E) Factor 5. The availability of a measure that is more proximal in time to desired patient outcomes for the particular topic;

(F) Factor 6. The availability of a measure that is more strongly associated with desired patient outcomes for the particular topic;

(G) Factor 7. Collection or public reporting of a measure leads to negative unintended consequences other than patient harm; and

(H) Factor 8. The costs associated with a measure outweigh the benefit of its continued use in the program.

(ii) Criteria to determine topped-out measures. For the purposes of the Hospital OQR Program, a measure is considered to be topped-out under paragraph (h)(3)(i)(A) of this section when it meets both of the following criteria:

(A) Statistically indistinguishable performance at the 75th and 90th percentiles (defined as when the difference between the 75th and 90th percentiles for a hospital’s measure is within two times the standard error of the full data set); and

(B) A truncated coefficient of variation less than or equal to 0.10.

(iii) Application of measure removal factors. The benefits of removing a measure from the Hospital OQR Program will be assessed on a case-by-case basis. Under this case-by-case approach, a measure will not be removed solely on the basis of meeting any specific factor.

Dated: October 26, 2018.

Seema Verma,
Administrator, Centers for Medicare and Medicaid Services.


Alex M. Azar II,
Secretary, Department of Health and Human Services.

[FR Doc. 2018–24243 Filed 11–2–18; 8:45 am]

BILLING CODE 4120–01–P